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Valvular structural and functional defects account for millions of defects in human 
births, and their effects can be immediately life threatening or cause more subtle cell 
and/or matrix changes that can lead to functional defects later in life. Nearly all study 
of mechanical action on cellular function focuses on the “normal and pathological” 
adult age. This neglects key stages in the functional life cycle of tissues where 
remodeling is most active yet, controlled, early development. Until the basic 
interactions between cells and their microenvironment are understood in this context, 
our ability to understand congenital malformation and manipulate these phenomena 
remains limited.  The objective of this thesis was to understand the role of mechanics 
combined with biology during the developmental process of valvulogenesis.  This 
thesis demonstrates that valve interstitial cells respond to mechanical strain and 
directionality by regulating cellular proliferation, differentiation, and matrix remodeling.  
Using a novel bioreactor and in-vivo perturbation studies, we found that mechanical 
stretch directly inhibits myofibroblastic activation in mitral valve progenitor cells 
through a RhoA dependent mechanism.  Consequently, Rac1 expression is promoted 
matrix condensation, as typically seen in mature quiescent leaflets.  In post-natal 
valve maturation, we determined that tissue stretch correlates with tissue 
 biomechanics and underlying cellular deformation.  However, in pathological 
conditions such as Marfan Syndrome, tissue stretch becomes decoupled with cellular 
deformation by an unknown mechanism.  Lastly, we modeled the molecular 
mechanisms of early cushion development applying systems biology model of 
ordinary differential equations.  In addition to predicting and confirming a new 
heterogeneous phenotype, we concluded with 3 other possible hypotheses, which are 
included in the discussion.  The biological and computer models developed in this 
thesis can be used in future experiments to explore the combined biological and 
mechanical regulation of multi-scale valve formation.  My hope is that the results 
presented in this thesis will eventually be useful for developing efficient strategies to 
control tissue adaptation and remodeling as well as accelerate the construction of 
cardiovascular tissue replacements. 
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CHAPTER 1 
INTRODUCTION TO VALVULOGENESIS 
 
 
1.1: Valvular Morphogenesis 
Initiation of Valvular Morphogenesis - Valvulogenesis is a complex process involving the 
formation and morphogenesis of both the atrioventricular and semilunar valves.  The early 
embryonic heart is a single myocardial tube lined with endocardial cells.  During the looping 
process, simultaneous valve formation initiates by deposition of hyaluronan-rich gelatinous 
matrix, called cardiac jelly, forming swellings, which project into the lumen.  At the onset of 
Hamburger and Hamilton (HH14-, E9.0 in mouse), a process called EMT (epithelial-
mesenchymal transition) takes place in which endocardial cells lining the cushions rapidly 
differentiate towards a mesenchymal phenotype.  This process is associated with 
downregulation of cell-cell contacts, such as E-cadherin and PECAM1, the acquisition of cell-
matrix adhesions, and cytoskeleton rearrangement [1].  Loss of tight junctions in EMT is 
concomitant with the acquisition of a spindle shaped morphology and migratory/invasive 
phenotype. The invasiveness of the mesenchymal phenotype is critical, as these cells dive into 
the hyaluronan-rich cardiac jelly, degrade the underlying matrix, and deposit newly synthesized 
collagen I, II, III, versican, and other proteoglycans [2].  These newly populated mesenchymal 
swellings are called “cushions” due to their soft visual appearance while stitched to the 
myocardial wall.  These cushions are formed in pairs that oppose each other during the cardiac 
cycle to act as primitive valves by maintaining unidirectional blood flow [3].  One pair of cushions 
develops in the atrioventricular (AV) canal, while the set (proximal and distal) develops in the 
outflow tract (OFT).  The processes by which the AV and outflow cushions remodel into thin 
fibrous leaflets are discussed below.  
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Atrioventricular Valve Remodeling - By HH26 (E12.5 in mouse), the AV cushions fuse together 
at the midline along a superior/inferior axis, dividing the canal into the right and left conduits.  
Even before fusing, the expansion of the cushions creates a “dog-bone” shape of the ventricular 
inlet that begins to divert blood flow around the cushions, potentially contributing to their 
eventual fusion [4].  From the left and right lateral aspects of this fused central cushion mass 
evolves the septal leaflets of the left and right AV valves.  At about the same time as central 
cushion fusion, new cushions begin to form from the left and right lateral walls, which will 
eventually form the mural AV leaflets.  The process by which the AV leaflets  form is thought to 
involve a process of proliferation, extension, condensation, and delamination [5] (Figure 1.1).  
Briefly, a subendocardial portion of the AV cushion expands and extends along the myocardial 
substrate, which is mediated in part by a fibroblast growth factor 4 (FGF4) section by the 
endocardium [6].  These cells form a progressive-like zone and begin to differentiate further 
towards a fibroblastic phenotype [7].  This zone of differentiated cells condenses the cushion 
matrix into a thinner and more fibrous tissue consisting of a subendocardial surface, which is 
largely positive for laminin, while the ventricular side is predominately collagen III.  Furthermore, 
fenestrations between the myocardial wall and valve tissue begin to form, possibly due to 
expansion of the ventricular cavities or changes in hemodynamic loading [8].  Upon further 
delamination, residual contacts between the valve tissue and myocardium form the site of newly 
developing papillary muscles. This creates mesenchymal tissue strands that develop into the 
tendinous chords of the AV valves.  By HH36 full delamination from the myocardial wall occurs 
and the distinct tri-layer structure (atrialis/spongiosa, fibrosa, and ventricularis) with a largely 
organized lamellar network of elastin and newly formed collagen (I,II,III,V,VI) [9].   
 
Semilunar Valve Morphogenesis - Similar to AV valves in terms of mesenchymal transformation 
and formation of the tri-layered valve structure, semilunar valves become excavated from the 
aortic side inward.  Between HH17 and HH26 (E10–E12), the conal and truncal cushion pairs of 
3 
 
the outflow tract become invaded and populated by activated endocardially derived cells.  The 
aorticopulmonary (AP) septum spirals through the out flow tract lumen with a counterclockwise 
rotation so that the right portion of the semilunar ring is derived from the original left side of the 
primitive outflow tract [10, 11].  The splitting of the parietal and septal distal truncal cushions by 
the AP septum, combined with the intercalated cushions of the distal outflow tract creates the 
six cushions required for the formation of the semilunar valves which is completed by HH34 
(E14.5).  The tissue on the arterial side becomes a more condensed, fibrous matrix as the small 
depression continues to deepen, sculpting the leaflet cusps. By HH39–40, the leaflets begin to 
appear trilaminar in nature, with an elastin–collagen lamellar structure forming at the ventricular 
surface. By HH45, fibrous tissue is seen radiating from the attachment of the valve cusps into 
the aortic wall from the base to the level of the commissures, creating an anchoring ring of fibro-
cartilaginous tissue around the sinuses [12].     
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Figure 1.1 – Summary diagram illustrating heart and valve morphogenesis with respect to embryonic 
chick, mouse, and human staging. 
 
 
 
 
1.2: Model Systems to Study Valve Development 
Generating suitable quantitative data is essential for developing a model with predictive 
capability.  In vivo experimental and/or genetic perturbations of animal models, coupled with 
well-controlled in vitro analyses, have been vital to understanding mechanisms of cell and tissue 
level morphogenesis.  Technology capable of generating large amounts of data across multiple 
experimental scales is relatively straightforward to apply; however, the technology that can be 
applied is dependent on the animal model.  As a result, investigators often combine data from 
multiple animal models when performing computational studies [13].  A discussion of different 
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animal models as well as appropriate corresponding experimental assays essential for 
connecting molecular and morphogenetic aspects of cardiac development proceeds below.  
 
Zebrafish - Employed in research since the 1970’s, the zebrafish (Danio rerio) is small, can be 
cultured inexpensively, and can produce up to 200 eggs per week as an adult.  The zebrafish 
embryo is transparent, develops rapidly, and grows externally from the mother, which allows for 
ease in experimental manipulation and observation [14]  Zebrafish have a unique ability to 
develop in the absence of a functioning heart for at least 5 days post fertilization, since sufficient 
oxygen is obtained by diffusion [15].  Its genome has been fully sequenced, and zebrafish eggs 
have been found to tolerate microinjection and DNA delivery very well.  Genetic manipulation 
via morpholinos and transgenics is among the simplest to perform of all vertebrate models [16, 
17].  Furthermore, whole genome genetics and phenotype screens from mutagenesis agents 
can be filtered using a high throughput format [18, 19].  While the genetic and molecular 
process of myocardial formation of the zebrafish broadly parallels that of the human, the 
zebrafish only possesses a two-chambered, essentially right-sided heart.  In addition, zebrafish 
valves do not develop through endocardial-mesenchymal transition (EMT) as in larger, higher 
order models [20].  Instead, the valves fold inward to create a thin, bilayerd tissue without 
mesenchyme until much later [21].  Likewise, there are also differences in outflow tract/aortic 
arch morphogenesis compared to human morphogenesis [22].  The embryonic zebrafish heart 
is only a few hundred microns in length when fully grown, which limits non-genetic experimental 
inquiry and/or tissue isolation. 
 
Amphibian - Amphibians, such as the African clawed frog (Xenopus laevis) and the eastern 
newt (Notophthalmus viridescens), have a three-chambered heart containing two atria, a single 
shared ventricle, and a shared outflow tract with a spiral shaped valve that helps partition 
relatively unmixed flow to the lungs and the rest of the body [23].  Amphibian eggs can be 
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cultured very easily, but mesodermal cells are pigmented, limiting in vivo optical analysis during 
heart development stages.  Morpholinos can also be developed and employed in frog 
embryogenesis similar to zebrafish hearts [24].  Frog embryos were used to show that cardiac 
laterality extends to the cellular level, with heterotaxic chambers and valves populated by cells 
from both sides [25].  Fewer studies have been conducted with the newt model, but recent 
findings show adult newt ventricular regeneration is similar to that of zebrafish suggesting it will 
become a more common model choice for heart development as its genome is clarified [26].   
 
Avian - Avian models such as the chick (gallus gallus) and quail (Coturnix) are well 
characterized and long applied in experimental embryogenesis ranging from cell isolation to in-
vivo perturbation models. Within two to three days, chick embryos gastrulate, neurulate, and 
fold into three-dimensional (3-D) animals with beating hearts, somites, and complex nervous 
systems. Complete cardiac morphogenesis in the avian model occurs from approximately 2.5-
10 days, which is slower compared to other small animal models and enables investigation of 
highly time sensitive transient features of morphogenesis such as septation and outflow tract 
morphogenesis [5]. Such rapid development is an advantage for experimental design and timely 
data collection.  The anatomy of the chick heart closely parallels that of the human heart.  In 
particular, the left ventricle, atrioventricular valves, and outflow tract valves are similar in shape, 
matrix composition, and cellularity.  The principle differences between chick and human are that 
the right AV valve develops into a muscular flap valve in the right AV junction and the aorta 
arises from the right fourth aortic arch instead of the left [27].  Chick embryos can be cultured in 
ovo or removed from the eggshell [28] making them semi-transparent and of sufficient size to 
enable microscope guided experimentation [29, 30].  These experiments include microsurgery, 
tissue ablation, transplantation chimeras, local gene delivery, and biochemical delivery via 
soaked materials [31, 32].  Experiments using the avian model have generated significant 
insight into the contributions of local cell populations to tissue morphogenesis and physical 
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function.  Although genetic manipulation is more technically challenging and time consuming in 
the avian embryo, some transgenics are available for study [33].  
 
Drosophila - The fly (Drosophila melanogaster) is one of the most intensively studied organisms 
in biology and has served as a model system for the investigation of cardiac development.  
The Drosophila heart (also called the dorsal vessel) is an organ for hemolymph circulation that 
resembles the vertebrate heart at its transient linear tube stage. Dorsal vessel morphogenesis 
shares several similarities with early events of vertebrate heart development.  In particular, 
cardiac progenitors are derived from laterally positioned mesoderm, being specified through the 
use of conserved cellular induction pathways and downstream transcriptional effectors [34].  At 
these early stages of heart development, the drosophila has been an attractive system for the 
study of cardiogenesis due to its relatively simple structure and the productive use 
of Drosophila genetic approaches [35].  Genetic analyses have identified and/or confirmed 
hundreds of important intracellular transducers, which provide large gene regulatory networks 
essential for mapping the underlying cardiac specification [36].  Currently, projects such as the 
Berkeley Drosophila Genome are in the middle of a sustained effort to define the expression 
patterns of all predicted genes in the genome [37].  This information will be critical in identifying 
what genes contribute to the cardiac phenotype.   
 
Rat -The rat (Rattus norvegicus) has been used extensively in cardiac research, although 
studies focusing on embryonic development have been limited.  This is largely due to the 
abundance of genetic models available in mice and the overall economic cost.  The majority of 
investigations focus on later stage pathogenesis of cardiovascular disease and/or the effects of 
drug intervention [38].  In general, the rat embryo, fetus, and postnatal morphologies correlate 
with both mouse and human development, and nearly all the features (external and internal) of 
the embryonic chick [39].  This provides an excellent morphological and chronological model for 
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all stages of cardiac development.  A major advantage of the rat is the relative ease with which 
surgical techniques can be performed when necessary for some disease or treatment models 
[40].  In many cases, measurement of relevant circulatory, biochemical, and hemodynamics 
parameters have been largely optimized for understanding cardiac function.  
 
Mouse - Mice (Mus musculus) are the mammalian animal model of choice for cardiac 
developmental genetics.  The mouse has a relatively fast gestation cycle, many pups per litter, 
and relatively short post-natal development compared to other mammals.  Nearly every genetic 
tool developed has reagents available for the mouse.  Mice tolerate oocyte injections very well, 
and their embryonic stem cells receive DNA easily.  Unlike the other animal models, mice have 
a placental circulation and a fully four chambered heart with correct laterality, similar to humans 
[41].  However, the chordae of the murine AV valves are far less prominent than the pronounced 
tendinous chords of the human heart valves and heart beat frequency during development is 6-
8 fold higher [27].  The cellularity and matrix striation of mouse valves are significantly less 
prominent than in humans or avians, in part because of their small size.  Mouse embryos are 
difficult to culture outside of the mother, precluding experimentation except during the earliest 
stages of cardiogenesis [42].  Quantifying mouse heart physiology has also been challenging 
because of its size and speed with investigators normally relying on approximations from the 
dorsal aorta.    
 
The largest integrated database of genetic, genomic, and phenotypic data has been generated 
for the laboratory mouse and compiled by the Mouse Genome Database (MGD) [43].  Reporter 
genes, such as lacZ or GFP, provide a sensitive method of detecting and following gene 
expression trends during morphogenesis.  Mutant mouse transgenesis, either to overexpress or 
knock out specific genes, is an indispensable component of current research [44, 45].  Tissue-
specific promoter targeting constructs, especially when combined with conditional expression 
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systems such as Cre/Lox, has permitted spatial and temporal mapping of gene mapping and 
perturbation through manipulation [46-48].   
 
Overall, each animal system has advantages and limitations to studying cardiogenesis, and no 
one model yet captures all components.  A key challenge with a multi-scale approach is 
merging and analyzing data acquired from multiple animal models, especially in situations 
where the morphogenetic processes are known to be different (Table 1.1).   
 
 
Table 1.1 - Summary of advantages and disadvantages of using animal models to study embryonic valve 
development. 
 
In-Vitro Experimentation - In vitro culture systems enable well-controlled investigation of 
fundamental molecular, cellular, and tissue level responses in isolation from other tissues.  
These experiments require the ability to isolate pure tissue segments that can either be 
explanted directly or digested to obtain cells.  Genetic manipulation of cells and tissues, 
including overexpression and knockdown, is achieved through a variety of methods including 
electroporation, viral delivery, or lipid carriers [49-51].  The vast majority of genetic manipulation 
studies have used isolated cells cultured on artificial plastic substrates.  The physical properties 
of the cellular microenvironment (e.g. stiffness) can have profound effects on cell phenotype 
[52].  Tunable soft culture substrates have been developed to overcome these limitations, most 
notably polyacrylamide and polydimethylsulfone (PDMS) gels [53].  These materials can be 
further functionalized via microfabrication and selective polymerization techniques to exhibit 
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gradients in stiffness, adhesion ligands, growth factors, and even gene plasmid concentration 
[54].  While microfabrication and selective polymerization approaches enable high throughput 
screening of the effects of the different gradient paramters on cell phenotype, these model 
systems remain inherently two dimensional (2D).  Three dimensional (3D) culture models can 
be created using tissue engineering techniques, mainly with aqueous hydrogels created from 
natural extracellular components, which include collagen, fibrin, alginate, and hyaluronic acid 
[55].  The addition of hybridizing biopolymers and synthetic polymers can enhance the range of 
possible material properties [56].  One of the first examples of a tissue engineering approach 
used a collagen hydrogel to study embryonic heart valve formation.  Runyan and Markwald et 
al. isolated avian AV canals (chick HH14- or mouse embryos E8.5) and then explanted onto the 
surface of a collagen gel surface [57].  It has since become a staple assay to study 3D matrix 
interactions in developmental biology.  
 
Genomics and epigenomics - The emerging epigenomic changes and the interactions between 
cis-acting elements and protein factors may play a central role in gene regulation [58]. To 
understand the crosstalk between DNA and protein on a genome-wide scale, techniques like 
ChIP-seq take the appraoch of combining chromatin immunoprecipitation with microarray 
technology [59, 60].  This high throughput strategy helps screen the targets of critical 
transcription factors and profile the genome-wide distribution of histone modifications, which will 
enable the feasibility of conducting large-scale studies, such as the Human Epigenome Project 
[61].  Many variations of the CHIP technology have been implemented such as the presence of 
DNA methylation (MeDIPchip) or DNA methylation based on the hypersensitivity to DNaseI 
cleavage (DNase-chip) [62, 63].  Other applications include the analysis of sequence variations 
by genotyping microarrays, copy number variations (Array-CGH), or RNA profiling (mRNA, 
microRNA).  A custom-made, cardiovascular-based cDNA microarray, termed the CardioChip, 
was created to characterize gene expression in end-stage cardiomyopathies relative to gene 
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expression associated with heart function [64].  Even more recent, NGS technology (Next 
Generation Sequencing) has revolutionized the genomic and transcriptomic approaches to 
biology reducing the sequencing cost and significantly increasing the throughput [65].  It is 
expected that NGS will become more important in the study of inherited and complex 
cardiovascular diseases (CVDs) [66].  However, the NGS approach to the genetics of CVDs 
represents a territory, which has not been widely investigated. 
 
These approaches have been useful for characterizing expression profiles in developmental, 
normal, and diseased conditions [67].  For example Chen et al. and colleagues found that 
Csx/Nkx2-5-deficient hearts were hypertrabeculated and noncompacted at birth.  At adulthood, 
the mice exhibited progressive heart failure characterized by chamber dilatation with extensive 
trabecular formation [68, 69] (It is important to note though that mice lacking this supposedly 
essential identifier of cardiac phenotype still produced a functioning heart, emphasizing the fact 
that perfect "markers" aren't necessarily functionally essential).  Upon microarray analysis, 
aberrant expression was revealed in a number of genes including the potential downstream 
targets, such as bone morphogenic protein-10 (BMP-10).  A similar approach was used to 
understand the existence of regulatory pathways active in developing AV valves and bone 
progenitor cells.  Overall, MC3T3 cells (pre-osteoblasts) were significantly more similar to late 
stage valves (E17.5), supporting the hypothesis that valve maturation involves the expression of 
many genes also expressed in osteoblast differentiation [70].  
 
1.3: Embryonic Valve Biology 
Initiation of EMT - Efforts to investigate the mechanisms of epithelial to mesenchymal transition 
and cushion formation have been greatly facilitated by the use of a three-dimensional collagen 
gel explants.  In this system, AV canals (chick or mouse embryos) are isolated and then 
explanted onto the collagen gel surface.  The endocardium of the AV canal adheres to the 
12 
 
surface, from which a subset of these cells undergoes the mesenchymal transformation and 
invades the underlying matrix.  Interestingly, EMT does not take place if the myocardium is 
removed directly after the endocardium has been attached to the collagen gel surface (HH14- or 
E9.0).  This suggests that the AV myocardium has a unique capacity to secrete specific signals 
for EMT [71].  After these landmark observational studies, the focus shifted to understand the 
makeup of the myocardial inductive signal for EMT in AV canal endocardial cells.  Through 
segmental patterning, it was found that myocardial cells express BMP2 in a manner consistent 
with the segmental pattern of cushion formation.  Using these AV explants in mice, Sugi et al. 
showed that BMP2 was sufficient to induce EMT in mouse AV canal cultures in the absence of 
AV myocardium [72]. Furthermore, treatment of AV cultures with Noggin, a BMP inhibitor, 
prevented mesenchymal cell formation in untreated cultures, and also prevented BMP2 induced 
EMT in AV cultures with intact AV myocardium (Figure 1.2).   
 
Interestingly, BMP2 treatments of AV explants resulted in increased TGFβ2 protein levels [72].  
This is particularly important because antagonists to TGFβ2 and TGFβ3 show that they play 
distinct but complementary roles in regulating the initial transformation events in chick.  
Endocardial TGFβ2 expression is required for cell separation and hypertrophy, while TGFβ3 
signaling is required for mesenchymal transformation and migration [73]. TGFβ3 induces 
expression of MMP-2 and MT-MMP, which digest the collagen IV endocardial matrix, permitting 
invasion [74].  At the onset of EMT in chick cardiogenesis, TGFβ3 is expressed in transforming 
endothelial and invading mesenchymal cells, while BMP2 is expressed in the subjacent 
myocardium.  To restrict this entire process to the cushion forming region in the lumen, 
endocardial Notch1 signals repress myocardial BMP2 through the Hey1 transcription factor [75].  
Furthermore, chick AV explants experiments have investigated the combinatory role of both 
TGFβ3 and BMP2.  In summary, it was found that (1) myocardial derived inductive signals 
upregulate the expression of AV endothelial TGFβ3 at the onset of EMT, (2) TGFβ3 needs to be 
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expressed by these endothelial cells to trigger the initial phenotypic changes of EMT, and (3) 
myocardial BMP2 acts synergistically with TGFβ3 in the initiation of EMT [76].   
 
 
Figure 1.2 – Summary diagram illustrating the results from bioassays to assess the role of BMP2 and 
BMP signaling using AV cushion mesenchymal cell aggregates cultured on 3D-collagen gels. Exogenous 
BMP2 or caBMPR1B treatments induced mesenchymal cell migration and expression of periostin, Twist 
and Id1, while a BMP antagonist, Noggin, or dnBMPR1B treatment inhibited BMP2 promoted cell 
migration and expression of periostin, Twist and Id1. Phospho-Smad 1/5/8 expression was induced by 
BMP2 or caBMPR1B treatments but reduced by Noggin or dnBMPR1B treatments.  Inai, K., et al., BMP-2 
induces cell migration and periostin expression during atrioventricular valvulogenesis. Dev Biol, 2008. 
315(2): p. 383-96. 
 
 
Cushion Maturation - In the chick, the early EMT phase occurs between Hamburger and 
Hamilton (HH) stage 14 through 25, while the later phase of valvular maturation occurs from 
HH25 onward (even after birth). During this remodeling, the cushion mesenchyme transitions 
from an activated myofibroblast (a-smooth muscle actin, MMP-2 positive, highly proliferative) to 
a more quiescent fibroblast (a-SMA, MMP-2 negative, sparsely mitotic) [77]. The molecular and 
cellular regulation of this process is far less understood than EMT, but mutant mouse models 
and in-vitro experimentation have determined important roles for a number of signaling 
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pathways [78-80].  Disruption of these pathways leads to either hypoplastic (thinned, rigid, 
sparsely populated) or hyperplastic (swollen, weak, densely populated) valves that lead to late 
embryonic and/or postnatal lethality through valvular stenosis or insufficiency.   
 
VEGFA: In vivo and in vitro experiments suggest that low level endocardial expression of 
vascular endothelial growth factor alpha (VEGFA) is required to permit EMT [81], but higher 
doses (~3 fold) inhibits this process [82]. VEGFA action through its receptor Flk-1 and 
transcription factor NFATc1 is required for cushion extension and condensation into leaflets, as 
well as for proliferation of valvular endothelial cells that line the cushions [79, 83].  Thus, 
persistent low levels of VEGFA result in hyperplastic valves while premature elevation of 
VEGFA results in hypoplastic valves. TGFβ:  Transforming growth factor beta (TGFβ) 
stimulates proliferation and migration through its receptor (TBRII/III) complexing with Alk1 or 
Alk2 (which also interact with BMP receptors) and activating the smad1/5 transduction pathway, 
but inhibits of proliferation and migration through receptor complexing with Alk5 and activation of 
smad2/3 [84, 85].  Both TGFβ2 and TGFβ3 are strong inducers of migration, compaction, and 
differentiation towards a fibroblastic phenotype through positive expression of alpha-SMA and 
vimentin in mice and avian models, respectively [86].  BMP: Bone morphogenetic protein (BMP) 
activates transcription of AV mesenchymal genes through its receptor (TBRI/II) and 
phosphorylation of smad 1/5/8 [87].  Type I BMP receptors, BMPR1A (Alk3), BMPR1B (Alk6), 
and Alk2 have all been localized in AV cushion mesenchyme in stage-24 chick embryos.   AV 
explant experiments applying exogenous BMP2 or caBMPR1B (Alk6) treatments significantly 
promoted expression of an extracellular matrix (ECM) proteins [88].  Similar to cartilage 
development, BMP2 is sufficient to induce SOX9 and aggrecan expression through pSMAD 1/5, 
which has been confirmed in a number of assays using prefused endocardial cushions [80, 89].  
FGF: Fibroblastic growth factor (FGF2) signals to the nucleus by binding to the FGFR and 
activating multiple signaling pathways, namely phosphorylated MAPK (dpERK).  FGF2 has also 
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been localized throughout the leaflet (and chorade), and increases during maturation.  Similar to 
limb and tendon development, FGF is sufficient to drive scleraxis (SCX) and tenomodulin 
(TNMD) expression through dpERK, which has also been confirmed in a number of assays 
using avian cushions [90, 91].   RhoA: Ras homolog gene family, member A (RhoA) is a small 
GTPase protein known to regulate the actin cytoskeleton and the formation of stress fibers.  It is 
activated when bound to the GTP-bound form of Rho GTPase and phosphorylates a LIM 
kinase, which in turn inhibits actin-depolymerizing activity.  RhoA can also directly signal to the 
transcription factor serum response factor (SRF) which drives myofibroblastic activation and 
alpha smooth muscle actin production.  Studies have shown that the RhoA pathway is 
necessary for endocardial cell transformation, proliferation, and migration during cushion 
formation [92, 93].      
 
1.4: Transcriptional Regulation of Valve Formation 
The role of growth factors directing the differentiation of mesenchymal valve progenitor cells and 
maturation into elongated heart valves with highly organized ECM remains widely unknown.  
Recent work by Chakraborty et al. conducted gene expression profiling analysis of murine 
E12.5 AV endocardial cushions compared with E17.5.  They hypothesized that existence of 
shared regulatory pathways active in developing AV valves and bone progenitor cells.  Overall, 
MC3T3 cells (pre-osteoblasts) were significantly more similar to E17.5 valves than to E12.5 
cushions, supporting the hypothesis that valve maturation involves the expression of many 
genes also expressed in osteoblasts.  Several transcription factors characteristic of 
mesenchymal and osteoblast precursor cells, including Twist1, Sox9, Tbx20, and Msx1/Msx2, 
are predominant in E12.5 cushion [70].  Interestingly, the roles of growth and key transcription 
factors identified within these microarrays have been widely studied in developing valves.   
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Sox9 - Sox9 is thought to be a master regulator required for endocardial cushion cell lineage 
expansion, as well as differentiation associated with cartilage progenitor cells [94, 95].  In both 
chick and mouse, Sox9 is expressed within the endocardial cushions and remodeling leaflets.  
BMP2 activates expression of Sox9 and the cartilage differentiation marker Col2a1, which has 
been observed in cultured avian endocardial cushion cells [96].  Upon gene knockout of Sox9 in 
mice, embryonic lethality occurs between E11.5 and E12.5 with hypoplastic endocardial 
cushions.  It is thought that loss of Sox9 inhibits EMT after delamination and initial migration, but 
before definitive mesenchymal transformation [97].  Upon targeted loss of Sox9 with Col2a1Cre 
in the remodeling valve, decreased expression of cartilage-associated proteins Col2a1 occurs. 
In adult mice, heterozygous loss of Sox9 in Col2a1Cre results in thickened valve leaflets and 
calcification characteristic of valve disease [95]. This suggests that that a relationship between 
BMP and Sox9 has a critical role in endocardial cushion formation and valve remodeling.   
 
Msx1/Msx2 - Expression of the Msx1 and Msx2 homeobox genes have been shown to be co-
coordinately regulated with the BMP2 and BMP4 ligands in a variety of developing tissues.  It 
known that that both Msx1 and Msx2 are crucial downstream effectors of BMP signaling in 
endocardial cushion.  Upon mouse knockout, Msx1 and Msx2 single homozygous mutant mice 
exhibited normal valve formation, while hypoplastic AV cushions and malformed AV valves were 
evident in the double Msx1 and Msx2 homozygous mutant mouse.  These results support 
redundant functions for Msx1 and Msx2 during AV valve morphogenesis. In the Msx1/2 mutant 
embryos, endocardial expression of Notch1, BMP2/ 4, and NFATc1 is reduced, and patterning 
of the AVC myocardium also is abnormal, leading to compromised EMT [98].  In addition, loss of 
both Msx1 and Msx2 were also found to affect secondary heart field and neural crest anomalies 
related to defects in cell proliferation and migration [99].  Taken together, combined Msx1 and 
Msx2 mutations lead to a spectrum of cardiac malformations including double outlet right 
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ventricle (DORV), pulmonary stenosis, atrial and ventricular septal defects, and hypoplastic 
ventricle [100].   
 
Twist1 - Endocardial cushion expression of Twist1 is induced by BMP2 in both chicken and 
mouse embryos.  During valve morphogenesis, Twist1 is expressed throughout the endocardial 
cushions of the AVC and OFT, and expression is down-regulated in the remodeling valves [80].  
Shelton et al. performed gain and loss of function studies in avian endocardial cushion cell 
cultures to demonstrate that Twist1 promotes cell proliferation and migration, while increasing 
the expression of periostin and MMP-2 [101].  Twist1 activity was examined in transgenic mice 
with persistent expression in the developing valves. Persistent Twist1 expression leads to 
increased valve cell proliferation, increased expression of Tbx20, and increased ECM gene 
expression, characteristic of early valve progenitors. Among the ECM genes predominant in the 
endocardial cushions, Col2a1 was identified as a direct transcriptional target of Twist1.  
Increased Twist1 expression also leads to dysregulation of fibrillar collagen and periostin 
expression, as well as enlarged hypercellular valve leaflets prior to birth [102].    
 
Tbx20 - Tbx20 is thought to maintain BMP2 expression localized to the AVC region.  Tbx20 is 
strongly expressed in the myocardium of the AVC in both mouse and chick [103, 104].  Mice 
lacking Tbx20 in the AVC myocardium fail to form the AVC constriction, and EMT is severely 
perturbed.   Furthermore, downstream genes, such as Twist1, Sox9, and Msx1, involved in the 
EMT initiation were found nearly absent.  Upon re-expression of BMP2 in the AVC myocardium, 
BMP2 substantially rescues the EMT defects resulting from the lack of Tbx20, suggesting BMP2 
is one of the key downstream targets of Tbx20 in AVC development [105].  Furthermore, Tbx20 
gain and loss of function studies performed in chicken AVC explants were found to increase cell 
proliferation and migration while repressing ECM maturation. Tbx20 promotes expression of the 
ECM remodeling enzymes, MMP9 and MMP13, while repressing expression of the chondroitin 
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sulfate proteoglycans, aggrecan, and versican [106]. Overall, Tbx20 has essential roles in 
regulating AVC development that coordinate early cushion formation.   
 
1.5: Biomechanics and Mechanobiology Atrioventricular Valvulogenesis 
Virtually unexplored is how mechanical signals regulate valvulogenesis.  The primitive heart is 
formed within 48 hours of development and resembles a single tube surrounded by 
myocardium.  At these early stages, the tube acts as a suction pump to regulate blood flow 
[107].  During diastolic loading, expansion of the tube pulls fluid into the tube and throughout the 
embryo.  The heart then undergoes a complex folding to form a four chambered organ in 
response to the increased hemodynamic demands.  This folding is critical to sustain the total 
energy needed through systolic loading and pulsatile fluid flow [108].   During cardiac 
morphogenesis, cardiac jelly swellings appear in the AV canal and OT and are critical for 
maintaining unidirectional blood flow during pulsatile contractions.  Both theoretical and 
biological tissue models, suggest the duration of valve growth and function is dependent upon 
blood hemodynamics.  Hemodynamic metrics of the embryonic heart (e.g. cardiac output, 
systolic blood pressure, and heart rate) [109-113] increase monotonically with developmental 
stage.   
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Table 1.2 – Summary of pressures within the developing heart and across the valve regions shown for 
human, chick, and mouse models.  Adapted from [109, 114, 115]. 
 
 
Developing valves are unique in that they are always under significant mechanical force during 
the cardiac cyclic.  During systolic loading, the valve opens and the surface facing the passing 
blood is exposed to significant wall shear stress (WSS), while the opposing side experiences 
disturbed blood flow and eddy formation.  During diastole, the valve is closed and blood 
pressure imposes a force normal on the leaflet preventing retro-grade blood flow with distinct 
orthogonal mechanical tissue response, and highly anisotropic ECM.  At stages HH14-HH25, 
the magnitude of wall shear stress is greatest in the inner curvatures and sites of lumen 
constrictions, corresponding to the site of cushion and OFT formation [4].  Recent studies have 
even found that high unidirectional shear stress promote cushion extension in the direction of 
flow in contrast to recirculating flows, which encourages the pre-valvular sculpting process 
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[116].  One could speculate that shear induced mechanisms are important factors for 
remodeling of the developing AV valves based upon the correlation of WSS and valve 
formation.  A number of studies have supported shear sensitivity to directly regulate valve 
mechanobiology.  Balachandran et al. found in-vitro that shear strain is critical for driving the 
epithelial-mesenchymal transition process through direct regulation of the TGFβ1 morphogen, 
and was both magnitude and directional dependent [117].  Other studies in-vivo have found that 
the mechanosensitive gene kruppel-like factor-2 (KFL2) will result in AV valve dysgenesis in 
zebrafish knockouts [118].  In avian models, venous clipping induced an increased in shear 
stress resulted in augmented KLF2 levels and abnormal valve development [119].   
 
During later stages of formation (HH36, HH42), the AV valve condenses and elongate to thin 
leaflet like structures capable of withstanding remarkable hemodynamic loads [5].  During 
diastolic loading, resident valve cells are thought to be exposed by cyclic deformation [120] and 
studies have shown that embryonic cushions alter their structural composition in strengthening 
to maintain unidirectional flow amidst increasing hemodynamic loading [3, 107, 109, 113, 121].  
However, the role of mechanical strain on embryonic valvular mesenchymal cells is almost 
completely unknown.  Rhia et al. found that murine embryonic mesenchymal progenitor cell 
differentiated towards fibroblasts like-phenotype through positive expression of smooth muscle 
α-actin at both the protein and gene expression level in response to cyclic strain.  As a positive 
control, TGFβ was added and found to have synergistic effects with cyclic strain on alpha-SMA 
mRNA expression [122].  Several studies have shown that adult valvular interstitial cells (VIC) 
regulate their phenotype based on the mechanical strain [123, 124]. VIC are normally 
fibroblastic-like cells (vimentin positive, α-smooth muscle actin negative, MMP-2 negative) but 
become activated (α-SMA, MMP-2 positive) in various disease [125] and  remodeling conditions 
[126, 127].  This has been associated with elevated TGFβ and BMP signaling [128, 129].  
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1.6: Relevance and Significance: Congenital Defects, Stem Cells, and Tissue 
Engineering. 
Congenital heart defects (CHD) affect 1-2% of all Americans and are significant contributor to 
heart valve disease [130].  Valvular structural and functional defects account for 20-30% of all 
defects in live human births, and their effects can be immediately life threatening or cause more 
subtle cell and/or matrix changes that can lead to functional defects later in life [131].  The 
embryonic heart grows and develops to adapt to ventricular geometry and function to optimize 
efficiency.  The valves are critical for maintaining unidirectional blood flow and pressure within 
the developing heart chambers.  It would be unsurprising that many of the defects within the 
heart and valves arise from alterations of the normal hemodynamic environment.   It has been 
suggested by Goerttlet et al. that deviations from normal heart development, is a result of 
displaced blood-streams [132].  However, distinctions between gene and hemodynamic related 
abnormalities are not that well defined.  Genetics allow do not provide the full picture, as roughly 
only 10-15 percent of the left ventricular outflow malformations are linked to chromosomal 
abnormalities.  While genetic mutations explain a significant portion of congenital heart defects, 
mutating a single gene rarely copies a human cardiac phenotype [133].  Alternatively, an 
alternative hypothesis is that mechanical perturbation through blood flow is a key regulator of 
normal and abnormal phenotypes may be likely.  
 
Bicuspid aortic valve disease is the most frequent congenital anomaly of the heart.  It is 
commonly associated with aortic valve stenosis and regurgitation, though symptoms largely 
exacerbate later in life, despite the abnormal valve formation.  In BAV, patients possess a valve 
of limited mobility, as the free edge is rounded and of unequal size.  Excessive length of one 
leaflet results in abnormal contact which in turn leads to abnormal function.  Later in life, the 
valve will become thickened, diffuse, and calcified [134].   Recent analysis involving families 
with BAV found that overrepresentation of NOTCH1 missense variants among patients with 
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bicuspid aortic valves and thoracic aortic aneurysms [135].  This suggests that mutations of the 
gene directly effects valve formation and dysfunctional morphogenesis.  While this provides an 
important explanation, large calcific deposits are unusual before the age of thirty, and very 
prevelant thereafter.  Interestingly, BAV patients without signficant stenosis or regurgitation 
were found to have larger annulus, aortic sinus, and proximal ascending aorta when compared 
to normal valves [136].    The peak aortic velocity and systolic wall velocity were also found 
higher in these BAV patients, implying these regions are subjected to increased stress levels 
[137].     
 
Perturbations in ECM expression (elastin, collagen, and proteoglycans) can also lead to cardiac 
defects.  For example, mutations in FBN1 (an extracellular glycoprotein of the ECM that acts to 
maintain tissue elasticity of the valve leaflets and aortic wall by linking smooth muscle cells to 
adjacent elastin fibrils) have been observed in patients with Marfan syndrome (MFS) [138].  
Targeted deletion of Fbn1 in mice phenocopies the defects observed in Marfan syndrome 
indicative of a causal relationship between FBN1mutations and valve malformation [139].  
These mice have upregulated TGF-β signaling, mitral valve prolapse and die shortly after birth 
due to aortic dissection caused by weakening of the aortic wall [140]. In humans, mutations in 
the TGF-β receptors, TGFBR1 and TGFBR have been associated with both Marfan and Loeys-
Dietz syndromes.  Interestingly, reduced expression of FBN1in the aorta of patients with BAVs 
was also reported [141].  
 
Hypoplastic left heart syndrome (HLHS) is marked by severe underdevelopment of the left 
ventricle and patients born with HLHS continue to have some of the highest mortality rates 
within the first year among all infants with congenital heart defects [142].  To date, no single 
mutation or chromosomal abnormalities has been identified as the culprit.  Cardiac defects 
associated with HLHS also include valve hypoplascia, hypoplastic aorta, and coarctation of the 
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aorta.  The underdeveloped tissues are thought to be the result of underdeveloped blood flow 
from the left ventricle and outflow tract during development [143].  In HLHS, almost 50 percent 
of patients have malformed valves, suggesting that alterations in the site of the primordial mitral 
valve may induce HLHS [144].  Harh et al. was one of the first to investigate this hypothesis by 
placing a nylon device in the left AV canal to reduce blood flow and hemodynamic loading.  It 
was found that this greatly reduced the left ventricle size and the developing AV valve resulted 
in a thickened hypoplastic valve.  Others have also mechanically induced HLHS through ligation 
techniques, which have been shown to display altered ventricular filling patterns, epicardial 
strain patterns, and reduced AV inflow velocity [145].  The increasing amount of information 
regarding HLHS adds credence to the paradigm that altered hemodynamic loading in 
development results in both altered heart formation and dysfunctional valves.       
 
HVD is particularly devastating for children, as the current therapy of prosthetic valve 
replacement necessitates multiple open heart surgeries to accommodate growth and requires 
debilitating anti-coagulant therapy [146].  Living heart valve replacements created through tissue 
engineering have the potential to alleviate these concerns with the potential for growth and an 
anticoagulant endothelial surface, but efforts to date have had limited success due to persistent 
transvalvular pressure gradients and cell-mediated leaflet thickening and contraction [147]. 
Because native valvular cells are not accessible as a source for these devices, other autologous 
cell sources are necessary. A study by Sutherland et al. used bone marrow derived 
mesenchymal stem cells (MSC) to populate polymeric valve-like scaffolds, and showed that this 
population could recapitulate both endothelial and fibroblastic like cells, which in turn secreted 
and organized a fibrillar matrix somewhat similar to native valves (though the valves were still 
mechanically insufficient) [148].  A separate study by Visconti et al injected clonal populations of 
MSC into lethally irradiated mice and found that a subset of these cells were recruited to heart 
valve leaflets, and were phenotypically indistinct from the native cells [149]. These studies 
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suggest that bone marrow derived stem cells can differentiate into valvular specific phenotypes 
if exposed to valvular specific mechanical stimulation regimens.  
 
Embryonic cushion mesenchyme is also pluripotent, capable of differentiating into bone, 
cartilage, and even cardiac muscle, yet normally forms fibroblastic cells [150]. The mechanism 
that directs this fibroblastic regulation is not known, but by association may be the normal stage 
specific valvular mechanical stimulation regimen. Indeed, altered tissue stress distributions and 
hemodynamic loading are implicated in a variety of adult valvular diseases, which also present 
osteochondral cell phenotypes. Therefore, determining the relationships between stage specific 
valvular mechanical environments and valvulogenic molecular regulation may not only help to 
delineate causes of CHD and motivate mechanically based repair schemes, but begin to 
establish a developmentally based “road map” to direct the differentiation of precursor/stem 
cells into valvular specific phenotypes, a critical unmet need. 
 
1.7: Objective of this Research 
The control of planar connective tissue assembly and remodeling is important target for 
bioengineering.  Tissue biomechanical function is driven by local cellular responses to 
environmental stimuli. These may include mechanical cues, including secreting and/or 
degrading extracellular matrix proteins, releasing soluble growth factors, and reorganizing cell-
cell/cell-matrix adhesive interactions.  Nearly all study of mechanical action on cellular function 
focuses on the “normal and pathological” adult age.  This neglects key stages in the functional 
life cycle of tissues where remodeling is most active yet, controlled: “embryonic development”.  
Until the basic interactions between cells and their microenvironment are understood in this 
context, our ability to manipulate these phenomena remains limited.  The overall goal of my 
thesis therefore, is to identify key mechanosensitive signaling networks, which underlie heart 
valve maturation and remodeling across the development continuum.  My guiding hypothesis is 
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that mechanical loading and subsequent strain fields play a large role in directing resident 
mesenchymal differentiation.  By using a developmentally focused approach, I hope my 
research will inform efficient strategies for control tissue adaptation and remodeling as well as 
accelerate the construction of cardiovascular tissue replacements.  To achieve this, several 
research goals were set, and the results of each are presented and discussed in separate 
chapter.  They are summarized as follows: 
 
Goal 1:  Optimize the Isolation and Culture of Pure Populations of Avian Progenitor Mitral Valve 
Cells.  Native embryonic mitral valve cells are not easily obtained and cannot be obtained 
commercially.  Therefore, techniques and methods to isolate and culture these cells within an 
avian animal model were tested and optimized.  Typical results in both 2-D and 3-D are 
presented, and a discussion regarding limitations and assumptions are presented in Chapter 2.  
 
Goal 2:  Develop and Implement a Bioreactor for Understanding the Role of Strain Magnitude 
and Directionality in Valve Development. Valves are subjected to a constant barrage of 
mechanical forces while maintaining unidirectional blood flow.  Mechanical stretch has been 
identified as one of the central regulators of interstitial cell development and homeostasis.  
However, understanding the mechano-biological response of VIC to both strain magnitude and 
directionality is technically challenging.  We therefore developed a strain bioreactor and applied 
physiological anisotropic stretch profiles to adult VIC.  Cell proliferation, matrix remodeling, and 
differentiation markers were assessed and discussed in Chapter 3.      
 
Goal 3: Determine the role of Mechanical Stretch and Hemodynamic Loading on Embryonic 
Valve Differentiation and Morphogenesis.  The mechanisms by which sustained cyclic loading 
directs the cellular response to coordinate embryonic valve morphogenesis and function are not 
known, but central to leaflet maturation. We explored how mechanosensitive small GTPases 
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RhoA and Rac1 participate in atrioventricular valve morphogenesis and remodeling.  Using a 
combination of in-vitro and in-vivo methods, we found that cyclic loading regulates a switch from 
RhoA to Rac1 which drives cell quiescence while simultaneously condensing the ECM.  The 
results and discussion are presented in Chapter 4.     
 
Goal 4:  Determine the Relationship between Post-natal Biomechanics and Cellular Deformation 
in Normal and Genetic Mutant Murine Mitral Valve Leaflets.  Changes in local cell-matrix 
deformation relationships may be an important metric for determining mechanisms of normal 
and pathological tissue remodeling in valves, as in aging or genetic mutation.  Therefore, a 
novel testing device was constructed to quantify global biomechanical and local cell-matrix 
relationships in FBN1 mutant murine mitral valves.  We found that local cell and matrix 
kinematics are decoupled to different degrees correlating with magnitude of global valve tissue 
stretch which are presented and discussed in Chapter 5.   
 
Goal 5: Generate and Analyze Mechanistic Model to Predict Signaling “BottleNecks” During 
Valve Development.   It is well appreciated that a systems level approach may be an essential 
resource to accelerate information generation concerning the functional relationships across 
multiple length scales and structural development.  Computer simulations modeling valve 
development is a great opportunity as the underlying cell signaling and morphogenesis is 
extremely controlled and consistent.  Hence, we generated a model to understand the 
differentiation states during the epithelial to mesenchymal transformation found in early cushion 
development.  The effectives and feasibility of our model was tested in adult epithelial cells and 
the results are presented and discussed in Chapter 7.      
 
Goal 6:  Develop Multidisciplinary Inquiry Based Learning Activities Using Engineering 
Frameworks used in Secondary Education.  Embryonic development offers a unique 
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perspective on the function of many biological processes and their heightened sensitivity to 
environmental factors.  I developed a hands-on lesson to investigate the effects of prostaglandin 
E1 (PGE1) on the morphogenesis of chick neo-vasculature.  PGE1 is applied to shell-less (ex-
ovo) cultured chick embryos, which are highly accessible and intrinsically spawn inquiry. The 
student activities mirror the scientific research process and the results are presented and 
discussed in Chapter 8.   
 
The significance and consequences of these studies are presented in Chapter 9, followed by a 
concluding summary in Chapter 10. 
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Chapter 2 
Isolation and Culture of Embryonic Valve Progenitor Cells 
 
 
2.1: Introduction 
Proper formation and function of embryonic heart valves is critical for developmental 
progression. The early embryonic heart is a U-shaped tube of endocardium surrounded by 
myocardium. The myocardium secretes cardiac jelly, a hyaluronan-rich gelatinous matrix, into 
the atrioventricular (AV) junction and outflow tract (OFT) lumen. At stage HH14 valvulogenesis 
begins when a subset of endocardial cells receive signals from the myocardium, undergo 
endocardial to mesenchymal transformation (EMT), and invade the cardiac jelly. At stage HH25 
the valvular cushions are fully mesenchymalized, and it is this mesenchyme that eventually 
forms the valvular and septal apparatus of the heart. Understanding the mechanisms that 
initiate and modulate the process of EMT and cell differentiation are important because of their 
connection to serious congenital heart defects. In this study we present methods to isolate pre-
EMT endocardial and post-EMT mesenchymal cells, which are the two different cell phenotypes 
of the prevalvular cushion. Pre-EMT endocardial cells can be cultured with or without the 
myocardium. Post-EMT AV cushion mesenchymal cells can be cultured inside mechanically 
constrained or stress-free collagen gels. These 3D in vitro models mimic key valvular 
morphogenic events and are useful for deconstructing the mechanisms of early and late stage 
valvulogenesis.  
 
2.2: Protocol Preparation 
1.) Preparation 
1.1) Incubate fertile quail or chicken eggs to stage 14- (about 2 days) or 25 (about 4.5 
days) at 60% humidity and 37oC.  
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1.2)  Prepare sterile Earl’s Balanced Salt Solution (EBSS) 
1.2.1) Add 100 mL 10X EBSS to 600 mL 18 MΩ water 
1.2.2.) Add 2.2 g sodium bicarbonate 
1.2.3.) Adjust the pH of the solution to 7.2 
1.2.4.) Bring the solution up to 1000 mL 
1.2.5.) Sterilize the solution by passing through a 0.2 μm filter 
 
 1.3) Prepare sterile M199 culture medium. 
  1.3.1.) Add 1 package of M199 powder to 700 mL 18 MΩ water. 
  1.3.2.) Add 2.2 g sodium bicarbonate 
  1.3.3.) Adjust the pH of the solution to 7.2. 
  1.3.4.) Add 10 mL (1%) Penicillin-Streptomycin 
  1.3.5.) Bring the solution up to 1000 mL 
  1.3.6) Sterilize the solution by passing through a 0.2 μm filter 
1.3.7.) Add 1 mL sterile 100X Insulin-Transferrin-Selenium-G supplement 
  1.3.8) Add 10 mL (1%) sterile chicken serum 
 
1.4) Prepare three dimensional collagen gels at a collagen concentration of 1.5 mg/mL. 
Previous work in our lab has shown that a collagen concentration of more than 1.5 
mg/mL provides a matrix that is too biomechanically stiff for the cells to move through. 
Collagen gel concentrations lower than 1.5 mg/mL have so few collagen fibers that the 
cell clump can shred the fibers locally, producing an island of cells. 
1.4.1) Add the following ice-cold reagents to a sterile 15 mL centrifuge tube in 
order 
 3X M199: Volume = total volume necessary / 3 
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 Sterile 18 MΩ water: Volume = total volume necessary – (M199 
volume + chicken serum volume + 0.1 M NaOH volume + collagen 
volume) 
 Sterile chicken serum: Volume = total volume necessary * 0.01 
 Rat tail collagen I: Volume = (collagen gel concentration * total 
volume necessary) / collagen stock concentration 
 Sterile 0.1 M NaOH: Volume = collagen volume * 0.2 
Note: The amount of water, 0.1 M NaOH, and collagen added will vary 
depending on the concentration of the collagen stock solution. 
1.4.2.) Mix the collagen solution well with a sterile pipette. 
1.4.3.) Immediately transfer 0.3 mL of the collagen solution into 1.9 cm2 growth 
area wells. This is enough collagen solution to completely cover the well and to 
provid
is necessary for cell invasion studies.  
1.4.4.) Allow the collagen solution to gel for at least 1 hour at 37oC, 5% CO2, and 
100% humidity.  
 
 
2.3: Pre-EMT endocardial cell isolation and culture 
2.) Pre-EMT cell isolation and culture 
 2.1.) Embryo isolation 
2.1.1.) Place one inch long piece of laboratory tape over the larger end of the 
egg. This is where the air cell is located. The tape stabilizes the fragile quail egg 
shell.  
2.1.2.) Gently puncture the taped area of the egg in the air cell with the tip of 
sterilized curved scissors. 
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2.1.3.) Cut a hole in the taped portion of the egg that is large enough to allow the 
yolk to pass through. Start the hole at the puncture and cut outward in a spiral 
shape. Make sure to cut through the outer membrane, but avoid piercing the 
yolk.  
2.1.4.) When the hole in the shell is complete, visualize the quail embryo. The 
embryo is normally located on the top side of the yolk. 
2.1.5.) Begin to pour the yolk through the hole cut in the egg with one hand. Hold 
a #55 tweezer in the other hand. As the embryo exits the egg on the top side of 
the yolk, gently slide the #55 tweezers under the embryo and remove it from the 
yolk.  
Note: For chicken eggs, the embryo isolation involves cracking the chicken egg 
on a sharp, clean surface and breaking the egg into a 100 mm petri dish. The 
embryo should be located on the top side of the yolk. Gently slide #55 tweezers 
under the embryo and remove it from the yolk. 
2.1.6.) Place the embryo into a 100 mm petri dish containing sterile, ice-cold 
EBSS. 
 
2.2.) Stage the embryos according to the criteria of Hamburger and Hamilton1. Embryos 
at stage 14- are past stage 13, but not yet at stage 14, with 20-21 somites and a tail bud. 
A key characteristic of stage 14- embryos is the head angle, which is slightly greater than 
90º to the body. 
 
2.3.) Remove the hearts from quail embryos at stage 14- with #55 tweezers by cutting 
transversely where the AV canal and OFT make contact with the thoracic wall. Place the 
hearts together on one side of the petri dish. 
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2.4.) Collect the isolated hearts with a sterile transfer pipette and place them into a new 
100 mm petri dish filled with sterile, ice-cold EBSS. 
 
2.5.) Cut the OFTs and AV canals transversely from the ventricles with #55 tweezers. 
 
2.6.) Section the remaining AV canals and/or outflow tracts (OFTs) longitudinally. 
 
2.7.) Set a pipette to a volume of 20 uL. Use this pipette to aspirate six longitudinally-cut 
AV canals and OFTs.  
 
2.8.) Expel the AV canals and OFTs onto the collagen gel. Aspirate any excess EBSS 
from the surface of the gel. 
 
2.9.) Use #55 tweezers to orient the explants so they are flat and so the lumen side 
faces the collagen gel. Try not to puncture the collagen gel with the tweezers. 
 
2.10.) After 2 hours at 37oC and 5% CO2, remove the myocardium from the explants with 
#55 tweezers. The endocardial cells should be left behind on the surface of the collagen 
gel. Alternatively, the myocardium can be left on the explant. With the myocardium 
removed, the endocardial cells with not undergo EMT without intervention. With the 
myocardium present a subset of endocardial cells will transform into mesenchyme, but 
the degree of transformation can be modulated with external factors.  
Note: Even if the myocardium will be left on, the explant must be allowed at least 2 hours 
to attach to the gel before medium is added.   
 
2.11.) Add 0.4 mL M199 medium to each well containing explants. 
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2.12.) Culture the cells at 37oC, 5% CO2, and 100% humidity.  
 
2.4: Post-EMT AV cushion mesenchymal cell isolation and culture 
3.) Post-EMT cell isolation and culture 
3.1.) Crack the chicken egg on a sharp, clean surface and break the egg into a 100 mm 
petri dish. The embryo should be located on the top side of the yolk. Pick up the embryo 
with #5 tweezers by grabbing the membranes surrounding the embryo and place the 
embryo into a 100 mm petri dish filled with sterile, ice-cold EBSS. 
 
3.2.)  Stage the embryos according to the criteria of Hamburger and Hamilton1. Features 
of a stage 25 embryo include distinct elbow and knee joints and slight eye pigmentation. 
  
3.3.)  Isolate the hearts from all HH25 embryos and place the hearts together on one 
side of the petri dish.  
 
3.4.) Collect the isolated hearts with a sterile transfer pipette and place them into a new 
100 mm petri dish filled with sterile, ice-cold EBSS. 
 
3.5.) Isolate the AV region from all hearts at once. Place the AVs together on one side of 
the petri dish. Gently agitate the AV region to remove all blood, which can affect cell 
viability.  
 
3.6.) Collect the isolated AVs with a sterile transfer pipette and place them into a new 
100 mm petri dish filled with sterile, ice-cold EBSS. 
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3.7.) Sequentially isolate the cushions from the AV.  Make sure there is no myocardium 
present on the AV cushions.  
 
3.8.) Collect the isolated cushions with a sterile transfer pipette and place them into a 
sterile 15 mL centrifuge tube. 
 
3.9.) Spin the cushions to the bottom of the centrifuge tube at 15 x g for 3 minutes. 
 
3.10.) Use a sterile 1000 mL tip to remove as much of the EBSS supernatant as possible 
without disturbing the cushions. 
 
3.11.) Add 1 mL of 0.25% Trypsin-EDTA that has been pre-warmed to 37oC. Allow the 
cushions to incubate in trypsin until they are completely dissolved, which is normally 
about 3-5 minutes. 
 
3.12.) Add 100 μL of chicken serum to the centrifuge tube to quench the trypsin.   
 
3.13.) Pellet the cells at 160 x g for 5 minutes. Remove the supernatant with a sterile, 
1000 μL tip. 
 
3.14.) Resuspend the cells in 2 mL of M199 medium and mix by pipetting.  Take 10 μL of 
the cell suspension to count on a hemocytometer and determine the total number of 
cells that have been isolated. 
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3.15.) Determine how many collagen gels will be made based on the number of cells 
isolated. Cells need to be plated at a density of 2 × 105 cells/mL with a 250 μL gel 
volume. 
 
3.16.) Pellet the cells at 160 x g for 5 minutes. Remove the supernatant with a sterile, 
1000 μL tip. 
 
3.17.) Using the protocol listed above, add 3X M199, water, chicken serum, collagen, 
and 0.1 M NaOH, in that order, to the cell pellet. Mix by gentle pipetting. 
 
3.18.) Add 250 uL to each 1.9 cm2 growth area well.  
 
3.19.) Allow the collagen solution to gel for at least 1 hour at 37oC, 5% CO2, and 100% 
humidity. 
 
3.20.) Add 0.4 mL of culture media and incubate overnight. 
 
3.21.) To continue culturing the gels in stress-free conditions, liberate the gels from the 
sides of the culture well using a sterile 200 ul pipet tip. Mechanically constrained cultures 
are gels that remain attached to the sides of the culture well.  
 
 
2.5: Representative Results 
4. Results 
4.1.) An HH14- quail embryo (Figure 2.1 left) and an HH25 chicken embryo (Figure 2.1 
right) are shown here. A key characteristic of stage 14- embryos is the head angle. At 
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stage 14- the head is at slightly greater than 90º angle to the body.  Features of a stage 
25 embryo include distinct elbow and knee joints and slight eye pigmentation. 
 
 
Figure 2.1 – Representative images of avian embryo at stage 14- (left) and HH25 (right).  
 
4.2.) The HH14- valve endocardial explants are shown after 2 hours of culture with the 
myocardium present (Figure 2.2 left) or removed (Figure 2.2 right). 
 
Figure 2.2 – Representative images of endocardial explants at stage 14- with myocardium (left) and 
without myocardium (right).  
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4.3.) In HH14- valve endocardial explants with the myocardium present many of the cells 
undergo endocardial to mesenchymal transformation and have a spindle-shaped, 
mesenchymal phenotype after 48 hours of culture (Figure 2.3 left). When the 
myocardium is removed all of the cells maintain a cobblestone-shaped, endocardial 
phenotype after 48 hours in culture (Figure 2.3 right). 
 
Figure 2.3 – Representative images of endocardial explants at stage HH14- after 48 hours with 
myocardium (left) and without myocardium (right). 
 
4.4) HH25 valve mesenchymal cells in a collagen gel are rounded immediately after 
seeding (Figure 2.4).  After 48 hours of culture in a constrained collagen gel the HH25 
mesenchymal cells are beginning to spread (Figure 2.4 left). HH25 cells in a stress-free 
collagen gel 7 days after seeding and 6 days after liberation have compacted the gel to 
approximately 50% of the original area (Figure 2.4 right). 
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Figure 2.4 – Representative images endocardial cells at HH25 within a collagen hydrogel immediately 
after seeding (left) and after 48 hours in culture (right).  
 
2.6: Discussion 
The method for isolating endocardial cells from stage HH14- hearts originally developed by 
Runyan and Markwald provides a controlled, in vitro environment to study the factors that 
initiate and modulate embryonic EMT [1]. HH14- endocardial explants cultured without 
myocardium will not undergo EMT without biomechanical or biochemical intervention. If the 
myocardium is left on the explant it will signal a subset of endocardial cells to undergo 
mesenchymal transformation, but external factors may regulate this process. Isolating 
embryonic progenitor mesenchymal cells from HH25 AV valve cushion using the method 
described by Butcher et al. provides an opportunity to determine what signals drive 
differentiation toward mature valvular interstitial cells [2]. Culturing the cells in mechanically 
stressed or stress-free conditions allows the researcher to probe biomechanical stimuli, and 
factors added to the culture medium can provide biochemical signals. In vitro models that help 
to decipher mechanisms affecting EMT, cell differentiation, and structural remodeling can be 
used to better understand the causes of congenital heart defects and could help determine 
ways to drive stem cells toward mature valve cell phenotypes for tissue engineering applications 
[3]. 
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Table 2. 1- Specific reagents and equipment:  
Name of the reagent Company Catalogue number Comments  
Extra fine Bonn 
scissors, curved 
Fine Science Tools 14085-08 
 
Dumont tweezers #55 
World Precision 
Instruments, Inc. 
14099 
Purchasing tweezers 
from fine science has 
also been done. 
Dumont tweezers #5 
World Precision 
Instruments, Inc. 
14098 
 
Sterile transfer 
pipettes 
Samco Scientific  2041S 
 
4-well culture plates Nunc  176740  
Sterile disposable 
filter units, PES 0.2um 
pore membrane 
Nalgene              566-0020 
 
Sterile 15 mL 
centrifuge tubes 
Corning 430828 
 
Sterile petri dishes,   
100 mm x 15 mm 
VWR International 25384-342 
 
Laboratory tape VWR International 89097-920  
Rat-tail collagen I BD Biosciences 354236 
Stock concentration 
should be at least 
4mg/ml. 
10X Earl’s Balanced 
Salt Solution 
Quality Biological, Inc. 119-064-131 
We have the protocol 
to now make the 
solution in the lab. 
M199 powder Invitrogen 31100-035 
Gibco can also be 
used. 
Penicillin-
Streptomycin 
Invitrogen 15140-122 
 
Insulin-Transferrin-
Selenium-G 
Invitrogen 41400-045 
Use 1ml per 1Liter.  
Each bottle makes 10 
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supplement (100X) Liters (.1%). 
Chicken serum Invitrogen 16110-082 
Use 5% chick serum 
for HH25 cells. 
0.25% Trypsin-EDTA Invitrogen 25200-056  
Sodium bicarbonate Sigma-Aldrich S5761  
Sodium hydroxide 
solution, 1.0 N 
Sigma-Aldrich S2770 
 
Fertile quail eggs 
(Coturnix coturnix) 
Lake Cumberland 
Game Bird Farm 
  
Fertile chicken eggs 
(Gallus gallus) 
Cornell University 
Poultry Farm 
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CHAPTER 3 
DEVELOPMENT OF IN-VITRO BIOREACTOR TO TEST EFFECTS OF MECHANICAL 
STRAIN ON VALVULAR INTERSTITIAL CELLS 
 
 
3.1: Summary 
Many planar connective tissues exhibit complex anisotropic matrix fiber arrangements that are 
critical to their biomechanical function.  This organized structure is created and modified by 
resident fibroblasts in response to mechanical forces in their environment.  The directionality of 
applied strain fields change dramatically during development, aging, and disease, but the 
specific effect of strain direction on matrix remodeling is less clear.  Current mechanobiological 
inquiry of planar tissues is limited to equibiaxial or uniaxial stretch, which inadequately simulate 
many in vivo environments.  In this study, we implement a novel bioreactor system to 
demonstrate the unique effect of controlled anisotropic strain on fibroblast behavior in 3D 
engineered tissue environments, using aortic valve interstitial fibroblast cells (VIC) as a model 
system.  Cell seeded 3D collagen hydrogels were subjected to cyclic anisotropic strain profiles 
maintained at constant areal strain magnitude for up to 96 hours at 1Hz.  Increasing anisotropy 
of biaxial strain resulted in increased cellular orientation and collagen fiber alignment along the 
principal directions of strain and cell orientation was found to precede fiber reorganization.  
Cellular proliferation and apoptosis were both significantly enhanced under increasing biaxial 
strain anisotropy (P < 0.05).  While cyclic strain reduced both vimentin and alpha-smooth 
muscle actin compared to unstrained controls, vimentin and alpha-smooth muscle actin 
expression increased with strain anisotropy and correlated with direction (P < 0.05).  
Collectively, these results suggest that strain field anisotropy is an independent regulator of 
fibroblast cell phenotype, turnover, and matrix reorganization, which may inform normal and 
pathological remodeling in soft tissues.   
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Figure 3.1 – Valvular interstitial cells rapidly reorient orthogonally with biaxial anisotropic strain, 
while modulating directional levels of ACTA2.  (A) Orientation of valvular interstitial cells (f-actin, 
green) align without a preferred direction during isotropic strain (DNA, blue).  (B) During anisotropic strain, 
cellular orientation aligns with respect to the principal directions of strain. (C) A larger degree of ACTA2 
expression (green) occurs perpendicular to the first principal strain direction (DNA-red). 
 
 
3.2: Introduction 
Planar connective tissues such as the diaphragm, pericardium, and valve leaflets perform 
critical biomechanical functions under cyclic mechanical loading [1, 2].  These tissues have 
evolved complex multidirectional collagenous fiber orientations that result in anisotropic 
mechanical properties ideally suited to their local microenvironment.  Resident tissue fibroblasts 
continuously repair and remodel their tissue microenvironment in response to these mechanical 
cues, including secreting and/or degrading extracellular matrix proteins, releasing soluble 
growth factors, and reorganizing cell-cell/cell-matrix adhesive interactions [3, 4].  Fibroblasts 
transition between a quiescent synthetic phenotype, characterized by homeostatic matrix 
turnover, to activated contractile myofibroblasts that change the underlying matrix mechanics 
and/or composition depending on the remodeling state of the tissue [5].  For example, during 
wound closure and fibrosis/scar formation, myofibroblasts elevate expression of contractile 
proteins and generate traction forces that create mechanical tension to pull matrix fibers 
together [6].  Heart valve leaflets are exposed to arguably the most demanding mechanical 
environment in the body, yet interstitial fibroblasts thrive and mediate significant matrix turnover 
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[7, 8].  Mechanical microenvironmental cues therefore provide strong inductive signals 
regulating tissue homeostasis and remodeling, but how they mediate healthy instead of 
pathological tissue remodeling remains poorly understood.   
 
Mechanistic understanding of fibroblast mediated tissue remodeling has advanced considerably 
with the aid of engineered tissue models that enable testing of molecular, cellular, and tissue 
scale mechanisms within a well defined, repeatable, and physiologically relevant 
microenvironment [9].  Fibroblasts in anchored 3D hydrogels develop mechanical tension 
leading to increased expression of contractile proteins, enhanced matrix synthesis, and release 
of growth factors such as transforming growth factor-beta (TGFβ), while fibroblasts in free-
floating unstressed gels remain quiescent [10].  More recently, bioreactors have been 
developed to apply specific mechanical strain parameters uniformly to a specimens as to isolate 
the underlying signaling mechanisms [11].  For example, cyclic stretching of fibroblasts in vitro 
induces cytoskeleton rearrangement [12], focal adhesion clustering [13], and downstream 
intracellular signaling cascades leading to cell and matrix fiber reorganization [14].  While the 
effects of strain magnitude and frequency have been studied for some time, the unique 
signaling from strain directionality is much less known.  Cyclic uniaxial (one direction) stretch 
induced TGFβ1, collagen III and fibronectin gene expression in cardiac fibroblasts.  Equiaxial 
(isotropic) strain, however, induced divergent responses in extracellular matrix (ECM) mRNA 
levels [15].  Fibroblasts have also been shown to align perpendicular to the direction of principal 
strain, while no-preferred direction occurs during equiaxial strain [16].  Given that planar tissues 
experience multi-axial strain patterns in vivo and exhibit anisotropic biomechanical properties 
rather than either of the above extremes [17], it is therefore critically important to understand 
how biaxial strain anisotropy independently affects molecular signaling, fibroblast phenotype, 
and matrix remodeling behavior 
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While biaxial and even triaxial stretches have been applied to tissues in cylindrical 
configurations, such as blood vessels [18], a similar device for planar 3D engineered tissues 
has not been developed.  Well-defined anisotropic biaxial strain fields have to date only been 
applied to planar cultures on 2D substrates [19].  Biaxial (radial and circumferential) tensile 
strains can be applied in 2D using a vacuum-pressure (Flexcell) system, but strain magnitude 
varies in-homogeneously with distance from the center of the membrane [20].  Tan et al. also 
generated static heterogeneous anisotropic biaxial micro-strain patterns through multi-spoke 
and microgroove array patterned 2D substrates [21].  We previously showed that smooth 
muscle cells exposed to homogeneous equiaxial stretch in 3D culture dedifferentiate to 
synthetic myofibroblasts [22].  Studies with valve fibroblasts in 3D culture have shown 
heterogeneous changes in cell phenotype and matrix synthesis, but these could not be directly 
related to specific strain profiles [23].   
 
The objective of this study, therefore, was to test how biaxial strain anisotropy independently 
controls fibroblast cell phenotype and matrix remodeling in 3D environments.  We developed 
and implemented a novel cyclic biaxial strain bioreactor with controllable homogeneous strain 
field anisotropy for engineered tissue hydrogels.  We hypothesized that valvular interstitial cells 
(VIC) would align with respect to the principal directions of strain and rapidly remodel the 
underlying matrix to mirror this alignment pattern. We first determined the temporal changes in 
cell and matrix fiber reorganization with strain anisotropy, followed by quantification of cell 
proliferation, apoptosis, and fibroblast phenotype. 
 
3.3: Materials and Methods 
3.3.1: Bioreactor Design and Optimization 
Our challenge was to create a bioreactor test system that enabled 1) fabrication and stable 
anchoring of 3D hydrogels and 3) applied controlled multiaxial mechanical stimulation without 
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having to disturb the tissue.  We hypothesized that if elliptically shaped 3D hydrogels were 
stretched uniformly along their outer perimeters, then the internal strain field would be 
homogeneous but biaxial.  To evaluate this, finite element simulations (FEA, ANSYS Inc.) were 
first conducted to optimize geometric parameters for the bioreactor system.  20,000 prismatic 
rectangular elements were used with large strain hyperelastic (Mooney-Rivlin, modulus = 1 
MPa) material properties performed on quarter-symmetric circular sections of silicone slab and 
platen.  Both elliptical and circular slabs and/or platens were tested, with radii between 0.5 and 
2 inches.  Platen/cassette hole diameter ratios were varied between 0.5 and 0.9.  Slab thickness 
was varied from 2-6 mm, with well depth ratios ranging from 0.5 to 0.9.  Finally, well centroid 
within the slab was translated radially from concentric to 75% of the platen radius.  Design 
optimization criteria were to1) maximize the number of samples testable within one cassette 
well, 2) maximize the size of samples testable, 3) maximize the depth of the PDMS wells, 4) 
maximize the possible applied strain magnitude, and 5) minimize the stress developed in the 
PDMS. 
 
To fabricate these different hydrogel 3D geometries, we developed thick elastomeric slabs 
instead of commonly used thin membranes (described below), which were secured between two 
circular aluminum flanges of a cassette (Figure 3.2A).  Each cassette contained four cylindrical 
holes (where the slabs were exposed) positioned concentrically over Teflon lined platens.  
Negative molds were machined from polycarbonate such that small wells would be present 
within the silicone slab spanning the cassette holes above the platens (Figure 3.2B).  Molds 
were designed with ellipsoidal wells of major/minor axis ratios (hereafter X and Y respectively) 
of 1:1, 2:1, and 4:1.  Beveled edges were machined within the ellipse to ensure uniform vertical 
strain fields through the well edges and to secure a compression spring (Lee Spring) for 
anchoring hydrogels.  Polydimethylsiloxane (PDMS Sylgard 184, Dow Corning) was formed at a 
concentration of 20:1, degassed, poured into the negative molds, and solidified at 70°C for 12 
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hours.  Slabs were then released from the molds, mounted within the aluminum cassettes, and 
autoclaved before use (Figure 3.2C).  The stage was constrained to vertical motion using shafts 
with linear bearings. A rotary stepper motor (34Y, Anaheim Automation) drove vertical 
translation through a screw-pinion gear assembly (Figure 3.2D).  Limit switches were mounted 
on either side of the translation stage to prevent overstrain and semi-automate calibration.  A 
cold plate (CP12, Lytron) was placed underneath the stepper motor for heat transfer. Strain 
magnitude and frequency waveforms were applied to the motor via a controller module and 
custom software (DPN10601, Anaheim Automation). 
 
Figure 3.2 – Design of the anisotropic biaxial strain (ABS) bioreactor.  (A) Conceptual schematic 
showing a cross-sectional view of a constrained collagen construct embedded in a silicone slab and 
loaded within an aluminum cassette.  (B) An inverted polycarbonate negative mold with machined circular 
and elliptical wells used for constructing the silicone slab with embedded wells.  (C) An expanded view of 
the elliptical well containing elliptical compression springs.  (D) Macroscopic view of the bioreactor 
containing 4 cassettes and 16 independent wells. 
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3.3.2: Construction of Cassettes  
To create the silicon membranes used for straining the hydrogels, a negative mold within 3/8” 
piece of polycarbonate was constructed.  The polycarbonate was machined to form wells at a 
depth of 3mm, at various biaxial eccentricities.   In terms of major to minor axis (x vs. y), 
ellipsoidal wells were generated at 1:1, 2:1, and 4:1 geometries.  A bevel was also machined 
within the ellipse for securing the compression springs.  Polydimethylsiloxane (Sylgard 184, 
Dow Corning, Midland, MI) was combined at a concentration of 20:1 respectively, and degassed 
prior to use.  The silicon was poured into the negative molds and let solidify at 70°C for 12 
hours.  The silicon molds were then released from the polycarbonate, mounted within the 
cassettes, and autoclaved.  The sterilized compression springs were then placed in the wells 
and covered with a petri dish lid (150mm).  
 
3.3.3: FEA Analysis 
Throughout the design of the bioreactor, a finite element model was used to optimize shapes 
and ensure homogeneous anisotropic strain patterns.  Various well diameters, aspect ratios, 
silicon membrane depths, cassette sizes, magnitudes of strain, and frequency were all 
considered.  The silicon membranes were modeled as a hyperelastic material using a Mooney-
Rivlin two-parameter model with invariant coefficients of 0.55 and 0.14 MPa.  The membranes 
were first generated within the plane function as 2D triangular elements.   The geometry of 
membrane measured 25mm in radius and the platen was 20mm in radius with a filet radius of 
1mm.  Contact analysis using a sliding boundary condition was used for the intersection 
between the membrane and platen, assuming a   coefficient of friction of 0.06 (Castrol, Braycote 
803).  For all simulations, the displacement was applied to the edge of the membrane.  All finite 
element simulations were completed through ANSYS.IN 
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3.3.4: Cell Isolation  
Adult PAVIC were isolated by a collagenase digestion method as previously described[24].  
Briefly, aortic valve leaflets were obtained from a local abattoir and placed on cold Dulbecco’s 
phosphate buffered saline (Invitrogen) for transport.  The surface of the leaflets was partially 
digested in (600U/ml, Worthington) collagenase solution with Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Gibco) for 5-10 minutes after which the endothelial layer was sheared off with 
a cotton swab.  The remaining leaflet was then incubated for 12-18 hours in collagenase 
solution and homogenized with a serological pipette.  Cells were then plated on tissue culture 
plastic, and maintained with DMEM (Gibco) supplemented with 10% fetal bovine serum (Gibco) 
and 1% penicillin/streptomycin (Gibco).  Cultures were fed every two days and split at 
confluency.  Cultures used for experiments were between passages 4 and 6. 
 
3.3.5: 3D Hydrogel Formation 
Three-dimensional (3D) hydrogel constructs were created using a modified procedure from that 
previously described[25].  Porcine aortic valve interstitial cells (PAVIC) were used as a 
representative planar tissue fibroblast source.  A suspension of 400,000 cells/ml porcine aortic 
valvular interstitial cells (PAVIC) were used in 3x DMEM with 10% FBS (Gibco), 2 mg/ml type I 
collagen (BD), and 0.1 M NaOH to neutralize the solution.  3D cultures with 1:1, 2:1, and 4:1 
aspect ratio were pre-loaded 300 steps below center of platen.  This was done to shift the 
calibration curve to the linear portion of the graph and increase the size of the well.  Once pre-
loaded, wells were filled with different volumes of gels depending on the geometry (ratio of 
major to minor axis).  For the 1:1, 2:1, 4:1, and control wells, 100µl, 125µl, 150µl, and 125µl 
respectively of gel was inoculated into the wells containing the compression springs, which 
solidified after 60 minutes.  After 60 min, 18 ml of media was added to the reservoir.  The 
hydrogels were allowed to compact around the springs over a 24 hr period after which a 20% 
area strain (250 step size, 2mm) was applied to all the constructs at 1Hz.  This seeded 
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compaction process is similar to Garvin et al. such that fibroblasts suspended in collagen gels 
will compact around an anchor and form a stable construct [26].  Static cultures served as 
controls and both mechanically anchored and unanchored hydrogels were used.  The 
unanchored controls were lifted from the well after 24 hr to allow free compaction of the gels.  
All materials were sterilized via autoclaving before use.  The system was housed in a standard 
tissue culture incubator, maintained at 37°C and 5% CO2 throughout the culture period. 
 
3.3.6: Strain Field Calibration 
Marker fields (40µm glass beads) were placed along the well bottom, gel surface, and at the 
compression spring attachment points (Figure 3.3).  The stage was translated to different 
depths, and marker positions within multiple wells were imaged and digitally recorded using 
ImageJ.  Assuming uniform deformation within small groups of three points, the local normal 
and shear strain field could be described by a system of equations as previously described [22] 
(see Supplementary Methods for more details).    Comparing multiple marker groups 
determined strain field homogeneity.  At least three independent point groups were compared 
per well and experimental condition for calibration.  For frequency response mapping, linear 
acceleration/deceleration-time commands of increasing magnitude and shorter time intervals 
were sent to the stepper motor, creating sinusoidal stage motion patterns.  Peak sustainable 
frequencies were recorded for each applied strain magnitude (equiaxial configuration). 
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Figure 3.3 – Calibration of anisotropic strain fields.  (A) 40 µm glass beads were placed within the 
collagen hydrogel and tracked from the undeformed to the (B) deformed configuration.  Virtual triangles 
created with bead centroids as vertexes were used to quantitatively monitor tissue deformation and to 
assess the uniformity of the strain field (inset). 
 
 
Strain Calibration Equations  
These patterns related the undeformed (unstrained) configuration and the deformed (strained) 
configuration by position [27], namely: 
 
          , Equation (1) 
 
where x is the deformed coordinates, and X  is the undeformed coordinates. F is a deformation 
gradient tensor for the plane of interest, either membrane or construct surface: 
 
    
   
   
  Equation (2) 
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By solving the system of equations in Eq. (1) relating the observed deformed and undeformed 
configurations of triangular bead/mark positions, the coefficients of F were obtained. These 
were then was used to obtain finite (Green’s) strain components: 
 
     (     )   Equation (3) 
 
where I is the identity tensor. Finite strain was then transformed into area strain by the following 
formula:  
 
    =      = (      )
   (      )
   ,   Equation (4) 
 
3.3.7: Anisotropic Strain of 3D Tissue Constructs  
The device used to impose anisotropic strain is a modified version of the system described in 
detail by Butcher et al [22].  The system consists of four aluminium cassettes which are placed 
on a movable stage, and clamped concentrically over a rigid aluminium cylindrical mandrel lined 
with Teflon.  A stepper motor (34Y, Anaheim Automation) was used to drive the movable stage 
down over the rigid mandrel deforming the silicon membrane at a specific magnitude and 
frequency.  Limit switches were mounted on either side of the movable stage so that any 
unwanted movement would be controlled.   These modifications only require one calibration of 
the wells and re-zeroing is recognized by the limit switches.  A cooling system was also 
implemented to control the temperature from the stepper motor to the surrounding metal.  A cold 
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plate (CP12, Lytron) was mounted below the stepper motor connected to a stand up freezer 
contained cold water.  The cold water from the freezer was pumped to the cold plate and 
returned the heated water from the stepper motor.  The magnitude and frequency of the stepper 
motor was controlled through a controller (DPN10601, Anaheim Automation) and various 
waveforms could be applied depending on the duration of current applied. 
 
3.3.8: Quantification of Cell and Matrix Architecture 
We quantified changes in cell orientation and matrix fiber reorganization at 48 and 96 hours via 
multiphoton microscopy.  Image stacks of the collagen hydrogels were taken from the central 
region of each well at 5-µm vertical steps.  Z-stacks encompassed at least 80% of the gel 
thickness in each sample, but were limited by the penetration depth of laser microscopy and 
slight differences in hydrogel compaction.  Cell orientation angle distributions within each gels (0 
degrees representing the X direction) were determined using f-actin staining (Sigma) and 
quantified from maximum intensity projections images using ImageJ as previously described 
[28].  We manually traced the shape of hundreds of cells across multiple sections for each 
sample, and organized them within a histogram to enable comparison with the fiber alignment 
data.  Alignment angle distributions from each gel were normalized to the most common 
alignment angle, which was assigned a value of 1.  Simultaneously, collagen fibril alignment 
angle distributions were captured using second harmonic generation (SHG) imaging using a 
custom-built nonlinear laser scanning microscope employing 1040-nm, 1-MHz, 300-fs pulses 
from a Yb-fiber chirped pulse amplifier (FCPA μJewel D-400, IMRA America, Inc.) as previously 
described [29].  Galvanometric mirrors were use to scan laser pulses in a raster pattern. The 
laser scanning and data acquisition were controlled by MPSCOPE software [30]. SHG signal 
was detected using a bandpass filter centered at 517 nm with 65-nm bandwidth.  Images were 
acquired using a 0.95-numerical aperture, 20x water immersion objective (Carl Zeiss Inc., 
Thornwood, NY) at 10 µm section spacing.  Similar to the cellular orientation quantification, fiber 
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angle distributions within gels (0 degrees representing the X direction) were determined using 
central region z-stacks and the maximum intensity projections images processed using ImageJ.  
ECM fibers were analyzed in total using an alignment algorithm (adapted from Bowles et al. 
2010)  that assessed second harmonic generation autofluorescence [31].   We observed no 
variation in histogram profiles with relative z-axis position, and therefore pooled all the data into 
single histograms for each construct.   
 
3.3.9: Proliferation and Apoptosis Assays 
5-bromo-2’-deoxyuridine (BrdU) incorporation was used to detect proliferating cells.  BrdU 
labeling reagent (Invitrogen) was added to the culture media 12 hours prior to experiment 
termination (48 hours).  Hydrogel constructs were fixed and targeted with a monoclonal Anti-
BrdU Alexa Fluor 488 conjugate (PRB-1, Invitrogen).  Total DNA was counterstained using a 
DRAQ-5 (Biostatus) far red nuclear dye.  TUNEL (Apo-Brdu TUNEL assay kit, Invitrogen) was 
used to detect apoptotic cells.  48 hour stretch and control hydrogels were fixed and stained for 
disrupted DNA targeted by incorporation of terminal deoxynucleotidyl transferase (Tdts) and 5-
Bromo-2’-deoxyuridine 5’-triphosphate (BrdUTPs).  Monoclonal Ani-BrdU Alexa Fluor 488 
conjugate was used to target the fragmented DNA and a propidium iodide counter stain was 
used to determine total cellular DNA.  Positive fluorescent areas for each cell were measured 
using ImageJ and normalized by cell nuclei. 
 
3.3.10: VIC Phenotype 
Alpha smooth muscle actin (gene name ACTA2, marker of myofibroblastic phenotype) and 
vimentin protein expression (VIM, indicative of quiescent fibroblast phenotype) were compared 
across strain conditions at 48 hours using quantitative real-time PCR (RT-PCR, see 
supplemental methods) and immunohistochemistry.  Antibody staining was performed as 
previously described [22].  Image Z-stacks (10 µm intervals) were taken with laser confocal 
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microscopy (TCS or Leica LSM510) at fixed gain, offset, and averaging settings.  Each label 
occupied a different fluorescence channel, and excitation lasers were sequentially activated to 
negate signal bleed.  Z-stacks were taken at 5-10µm sections and converted into maximum 
projections.  Positive fluorescent areas for each color were measured using ImageJ and 
normalized by cell nuclei.  Data was related as percentage of cells with cytoskeletal signal and 
compared across conditions. 
 
3.3.11: RT-PCR 
To determine gene expression changes, the hydrogel construct was isolated from the center of 
each well.  Using a Qiagen total RNA purification kit (Qiagen, Valencia, CA), RNA was reverse 
transcribed to cDNA using the SuperScript III RT-PCR kit with oligo(dT) primer (Invitrogen).  
Sufficient quality RNA was determined by an absorbance ratio A
260
/A
280 
of 1.8 – 2.1, while the 
quantity of RNA was determined by measuring the absorbance at 260nm (A
260
). Primers were 
designed to detect 18S, alpha-smooth muscle actin, and vimentin in cDNA clones:  18S (R–
AATGGGGTTCAACGGGTTAC, F-TAGAGGGACAAGTGGCGTTC, Amplicon 92bp, Accession 
DQ437859.1), VIM (F–GTACCGGAGACAGGTGCAGT, R– TTCCACGGCAAAGTTCTCTT, 
Amplicon 69bp, Accession XM_00213072.1), ACTA2 (F–CAGCCAGGATGTGTGAAGAA, R-
TCACCCCCTGATGTCTAGGA, Amplicon 104bp, Accession NM_001164650.1 ).  Real time 
PCR was performed on all samples using SYBR Green PCR master mix (Applied Biosystems, 
Carlsbad, CA) and a MiniOpticon Real-Time PCR Detection System (Biorad, Hercules, CA).  
Amplification cycle thresholds were normalized to those from 18S and melt curves compared 
across samples.  Stable expression of 18S was observed across all mechanically stimulated 
conditions and GAPDH was used as a secondary housekeeping gene to verify expression level. 
 
3.3.12: Collagen Gel Immunofluorescence  
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Fixed samples on collagen gels were washed for 15 minutes on a rocker 3 times with PBS, 
permeabilized with 0.2% Triton-X 100 (VWR International, Radnor, PA) for 10 minutes, and 
washed another 3 times with PBS. For the phenotype studies, samples were incubated 
overnight at 4oC in a 1% BSA (Rockland Immunochemicals, Inc., Gilbertsville, PA) blocking 
solution followed by another 4oC overnight incubation with mouse anti-human vimentin (VIM) 
1:100 (Invitrogen) and rabbit anti-human α-SMA 1:100 (Spring Bioscience).  For the orientation 
studies, samples were incubated with phalloidin (Invitrogen).  After 3 washes for 15 minutes with 
PBS, samples were exposed to Alexa Fluor® 488 or 568 conjugated (Invitrogen), species 
specific secondary antibodies at 1:100 in 1% BSA for 2 hours at room temperature. Three more 
washes with PBS for 15 minutes were followed by incubation with either DRAQ5 far red nuclear 
stain (Enzo Life Sciences, Plymouth Meeting, PA) at 1:1000 or Hoechst (Invitrogen) at 1:10000.  
Samples were washed once more with 18Mohm water and stored in 18mohm water at 40C. 
Images were taken with a Leica TCS SP2 laser scanning spectral confocal microscope (Leica-
Microsystems, Bannockburn, IL).  ACTA2 and VIM was measured by creating a region of 
interest across the entire image.  Total intensity of F-actin (green) and VIM (blue) was 
quantified.  These values were then normalized by total nuclei within the image.  All image and 
processing settings were consistent throughout. 
 
Statistics 
At least 6 samples per time point and treatment condition were used in each endpoint assay for 
statistical analysis.  One-way ANOVA with Tukey’s modified post-hoc tests were used to 
compare differences between means and data was transformed when necessary to obtain 
equal sample variances.  For proliferation/apoptosis studies, statistical tests were implemented 
across treatment conditions and results are expressed as mean ± standard error.  For 
gene/protein expression studies, statistical tests compared individual genes across treatment 
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conditions and results are expressed as mean ± standard deviation.  P < 0.05 denoted 
statistical significance.   
  
3.4: Results 
3.4.1: Design and Optimization of the Anisotropic Biaxial Strain (ABS) Bioreactor 
3D collagen gels could be anchored within cyclically deforming wells through compression 
springs whose lengths were adjusted to press fit inside the outer edge of the well and were 
secured with a 60 degree beveled edge.  Preliminary finite element simulations determined that 
the major and minor axis lengths of an ellipsoidal well shape could independently control XX 
and YY strain magnitudes (Figure 3.4).  Thus, by varying the eccentricity of the elliptical well, 
the biaxial strain profiles scaled with the major to minor axis ratio.  Further simulations were 
done to characterize well placement within the PDMS slab and dependence upon equiaxial well 
diameter.  Using a 1:1 geometric ratio, we found that deviations in the placement of the well, up 
to 60% (25mm) along the platen radius, did not significantly affect strain magnitude (Figure 
3.4B).  It was also determined that the strain magnitude inversely correlated with well diameter, 
such that a reduction of 20% to 10% radial strain occurred when increasing well diameter from 
2mm to 8mm (Figure 3.4C).  Finally, parametric optimization through finite element simulations 
predicted that for 50 cm diameter cassette holes and 6 mm wells, a silicone slab of 3/8” 
thickness with 3 mm deep wells, achieved a uniform 50% strain during 1 cm of stage translation.  
In this configuration, 4 holes could be fabricated in each cassette, and 4 cassettes could be 
secured on the translating stage.  For these experiments, however, one well was created at the 
center of each cassette hole. 
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Figure 3.4 – Mechanically anchored and unanchored hydrogels regulate ACTA2 expression levels 
at 48 hours.  Mechanically anchored hydrogels elevate ACTA2 and expression levels (2.87 fold ± 0.13) 
compared to unanchored hydrogels, while VIM expression is unchanged.  Gene expression was 
measured via real-time PCR and normalized to 18S. Error bars show ±SD, n ≥ 6.  Asterisks signify 
statistical differences according to a Student’s t-test (p ≤ 0.05). 
 
We next compared our FEA simulations against measured strains of 3D tissues within different 
elliptical well geometries.  Stretching a 1:1 axis ratio well to strains exceeding 25% ± 0.6% 
resulted in no significant differences between Exx and Eyy (Figure 3.5A).  Conversely, a 2:1 
geometry created homogeneous biaxial strain fields of at least 20% ± 1.8% in the Exx and 42% ± 
2.1% in the Eyy directions, with negligible shear strain.  The applied Exx/Eyy strain ratio was 
consistently 2:1 regardless of applied strain magnitude or loading cycle (Figure 3.5B).  
Stretching 4:1 axis ratio gels introduced strains exceeding 9.1% ± 1.1% in the Exx and 39% ± 
1.2% in the Eyy, with a nearly consistent 4:1 magnitude ratio (Figure 3.5C).  Experimental results 
confirmed FEA predicted nonlinear increases in applied biaxial strain magnitudes with stage 
65 
 
translation.  For all gel ratios, shear strain Exy varied between 0 ± 1.5% at the maximum loaded 
conditions and can be considered not statistically different from zero strain.  We next 
determined the maximum stable strain magnitude as a function of frequency (Figure 3.5D).  For 
equiaxial profiles, a maximum strain of 27%, 18%, 12%, 8%, and 5% was achieved at 1Hz, 2Hz, 
3Hz, 4Hz, and 5Hz, respectively.  Peak biaxial strain magnitudes in the YY direction were higher 
at each frequency, but proportional to the area strain during equiaxial loading.  Collectively, 
these results establish and validate a unique and versatile high-throughput anisotropic biaxial 
strain bioreactor system for planar 3D tissue cultures.   
`  
Figure 3.5 – Calibrated strain fields overlaid with FEA simulations.  (A) 1:1 axis ratio circular well 
introduced an equiaxial strain field with minimal shear captured by FEA simulations.  (B) 2:1 ellipsoidal 
well introduced a biaxial strain field captured by the FEA simulations.  (C) 4:1 ellipsoidal well introduced a 
biaxial strain field that was slightly overestimated by the FEA simulations.  (D) Strain vs. frequency curves 
for the 1:1 geometry indicates the ability to generate large deformations at high frequencies.  Error bars 
show ± SD.  N≥ 6 samples for each geometry and strain magnitude condition. 
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3.4.2: Biaxial Strain Anisotropy Regulates Cellular Apoptosis and Proliferation 
VIC seeded 3D collagen hydrogel constructs were strained at 20% area strain, with varying 
biaxial anisotropies at 1Hz, and static cultures served as controls.  To verify that our bioreactor 
was able to maintain viable cells for at least 96 hours, we performed a live/dead (green/red) 
assay on the hydrogel constructs. The percentage of live cells in the 1:1 (89% ± 1.3%) and 4:1 
(86% ± 0.9%) geometries decreased with anisotropy compared to the percentage in anchored 
controls (91% ± 0.9%), but were consistently above 85% viability (Figure 3.6A-E).  At 48 hrs, the 
number of apoptotic cells (yellow) in the 2:1 (8.5% ± 0.3%) and 4:1 (9.6% ± 0.5%) geometries 
increased relative to anchored controls (5% ± 0.2%) (Figure 3.6F-J).  This result suggests that 
cell death is largely driven by strain induced apoptosis rather than bioreactor cytotoxicity.  An 
increase in cell proliferation was also visually apparent for the mechanically stimulated 
conditions at 48 hrs.  Using BrdU labeling, we found that with increasing biaxial anisotropy, the 
number of proliferative cells (green) in the 1:1 (26% ± 1.9%),  2:1 (34% ± 1.4%), and 4:1 (37% ± 
1.1%) geometries statistically increased relative to anchored controls (16%, ± 1%) (Figure 3.6K-
O).  These findings suggest biaxial strain anisotropy enhances both cell proliferation and 
apoptosis, suggestive of an actively remodeling microenvironment.    
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Figure 3.6 – Apoptosis and proliferation correlate with increasing biaxial anisotropy at 48hr.  (A-D)  
Live/Dead assay reveals an increasing amount of dead cells with increasing biaxial anisotropy (live-
green, dead-red).  (E) Quantification of dead cells as a percentage of total cells.  (F-I) Apo-BrdU assay 
reveals an increasing amount of apoptotic cells with increasing biaxial anisotropy (apoptotic-yellow, DNA-
red).  (J) Quantification of apoptotic cells as a percentage of total cells.  (K-N) BrdU labeling assay reveals 
an increasing amount of proliferative cells with increasing biaxial anisotropy (proliferative-green, DNA-
blue).  (O) Quantification of proliferative cells as a percentage of total cells. Error bars show ± SE, N ≥ 6 
samples per test condition.  ANOVA with Tukey’s post hoc testing determined statistical significance at p 
≤ 0.05 thresholds.  Bars that do not share letters are significantly different from each other. 
 
 
3.4.3: Cell and Matrix Fibers Rapidly Reorient Orthogonally with Cyclic Strain Anisotropy 
At 48 hours, significantly more f-actin labeled cells were found in cyclically stretched compared 
to the statically anchored controls, which partly reflects both increased matrix compaction and 
proliferation (Figure 3.7A-D).  Static controls and 1:1 equiaxial strain revealed random 
orientations of cells denoted by the cytoskeletal (f-actin) filaments (Figure 3.7E-F). Normalized 
cell and matrix alignment index distribution curves indicate that orientation along the major X (0 
degrees) and minor Y (90 degrees) axes was maintained throughout a 0.3-0.8 range (Figure 
3.7M-N).  In contrast, the 2:1 and 4:1 geometries revealed a cross hatched network of cells 
aligning along the major and minor axes with greater cross-alignment in the 4:1 geometry 
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(Figure 3.7G-H).  Normalized alignment curves indicate that alignment along the major and 
minor axes ranged from 0.90-0.95 and 0.50-0.40, respectively, while the 45 degree orientation 
dropped to a lower fraction of 0.1-0.2 (Figure 3.7O-P).  Second harmonic generation imaging of 
collagen fibrils showed a lack of fibril alignment regardless of strained condition (Figure 3.7I–L, 
M-P).   
 
 
Figure 3.7 – Cell and matrix fibers rapidly reorient orthogonally with cyclic strain anisotropy at 48 
hours.  (A-D)  Macroscopic view of collagen gels compacted within elliptical compression springs.  (E-H)  
Orientation of AVIC associated with the anisotropic strain profiles (f-actin-green).  (I-L)  Orientation of 
collagen fibrils associated with anisotropic strain profiles (SHG imaging).  (M-P)  Representative 
alignment curves indicate orientation of VIC and coincide with respect to the principal directions of strain 
while minimal collagen fibril alignment has occurred. 
 
 
At 96 hours, static controls and 1:1 cyclic equiaxial strain revealed random orientations of cells 
denoted by the cytoskeletal (f-actin) filaments (Figure 3.8A-B, E-F). Normalized cell and matrix 
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alignment index distribution curves indicate that orientation along the major X (0 degrees) and 
minor Y (90 degrees) axes was maintained throughout a 0.4-0.8 range (Figure 3.8M-N).  In 
contrast, the 2:1 and 4:1 geometries revealed a cross hatched network of cells aligning along 
the major and minor axes with greater cross-alignment in the 4:1 geometry (Figure 3.8G-H).  
Normalized alignment curves indicate that alignment along the major and minor axes ranged 
from 0.85-0.95 and 0.55-0.35, respectively, while the 45 degree orientation dropped to a lower 
fraction of 0.1-0.2 (Figure 3.8O-P).  Likewise, second harmonic generation imaging of collagen 
fibrils showed a similar trend such that increasing degrees of fibril alignment occurred with 
increasing anisotropic strain (Figure 3.8I–L, M-P).  Taken together, VIC rapidly re-oriented 
within 48 hours of cyclic strain and maintained orientation through 96 hours.  Extracellular matrix 
architecture, on the other hand, was poorly aligned at 48 hours regardless of the applied strain 
field as determined by SHG, suggesting that cell orientation precedes fiber alignment.  
Collectively, these results demonstrate that applied cyclic biaxial strain anisotropy drives rapid 
VIC cell orientation and matrix fiber alignment in a temporally regulated manner, with cell 
reorientation leading extracellular matrix remodeling. 
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Figure 3.8 – Cell and matrix fibers rapidly reorient orthogonally with cyclic strain anisotropy at 
96hr.  (A-D)  Macroscopic view of collagen gels compacted within elliptical compression springs.  (E-H)  
Orientation of AVIC associated with the anisotropic strain profiles (f-actin-green).  (I-L)  Orientation of 
collagen fibrils associated with anisotropic strain profiles (SHG imaging).  (M-P)  Representative 
alignment curves indicate orientation of both VIC and collagen fibrils coincide and align with respect to the 
principal directions of strain.  However, a larger degree cellular orientation and fiber alignment occurs 
perpendicular to the first principal strain direction (Y). 
 
 
3.4.4: Valve Interstitial Cell Phenotype is Modulated by Biaxial Strain Anisotropy 
Alpha-smooth muscle actin (ACTA2) is a key cytoskeletal filament involved in many 
myofibroblastic phenotype behaviors.  Within unanchored 3D hydrogel cultures (free floating), 
VIC express low amounts of ACTA2.  However, when cultured under anchored conditions 
(mechanically constrained), ACTA2 gene expression increased (2.87 ± 0.13 of control), 
indicating that tissue stress enhances myofibroblastic differentiation (Figure 3.9).   
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Figure 3.9 – Mechanically anchored and unanchored hydrogels regulate ACTA2 expression levels 
at 48 hours.  Mechanically anchored hydrogels elevate ACTA2 and expression levels (2.87 fold ± 0.13) 
compared to unanchored hydrogels, while VIM expression is unchanged.  Gene expression was 
measured via real-time PCR and normalized to 18S. Error bars show ±SD, n ≥ 6.  Asterisks signify 
statistical differences according to a Student’s t-test (p ≤ 0.05). 
 
After 48 hours of stretch at either the 1:1 or 2:1 geometries, ACTA2 gene expression was 
significantly downregulated with respect to anchored unstrained controls (expression 0.27-0.32 
± 0.05 fold of anchored control, no difference between).  Stretch at the 4:1 geometry nearly 
doubled the amount of ACTA2 expression compared to equiaxial strain, but still less than half of 
the static anchored condition (0.47 ± 0.04 of control).  Vimentin (VIM) expression was 
insensitive to unanchored vs. anchored conditions, but was significantly downregulated within 
the 1:1 or 2:1 geometries (0.62 ± 0.07 and 0.59 ± 0.13 respectively, no difference between).  
Stretch at the 4:1 geometry significantly increased VIM expression (1.13 ± 0.18 fold), recovering 
to control expression levels (Figure 3.10A).  These same trends were confirmed at the protein 
level via immunofluorescence (Figure 3.9-F).  ACTA2 protein was downregulated significantly 
under equiaxial strain (0.61 ± 0.07) and slightly increased with the 4:1 geometry (0.76 ± 0.05).  
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VIM was downregulated with equiaxial strain (0.76 ± 0.08) and then returned toward unstrained 
control levels with the 4:1 geometry (0.87 ± 0.06) (Figure 3.10G).  Interestingly, a 
preponderance of cells oriented parallel to the gel major axis (thus perpendicular to the greater 
strain direction) expressed ACTA2 protein in the 4:1 geometry (Figure 3.10F).  Together, this 
suggests that cyclic strain anisotropy independently contributes to VIC fibroblast-myofibroblast 
differentiation tendencies.  Equibiaxial to mildly anisotropic stretch decreases ACTA2 and VIM 
gene and protein expression, while more dramatic strain anisotropy increases both ACTA2 and 
VIM expression.   
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Figure 3.10 – Biaxial strain anisotropy modulates fibroblast cell phenotype at 48hr.  (A) Gene 
expression was measured via real-time PCR, normalized to 18S, and expressed relative to unstretched 
anchored gel controls.  ACTA2 gene expression decreased in all strain conditions, while VIM gene 
expression returned to control levels with 4:1 biaxial directionality.  (B-F)  ACTA2 (green) and VIM (blue) 
protein expression were measured via immunofluorescence with DNA (red) counterstain.  (G) 
Quantification of total fluorescence was normalized to cell number and compared relative to unstretched 
control gels.  (F) Although ACTA2 expression reduces with cyclic stretch, cells orienting perpendicular to 
the major axis of stretch expressed increased ACTA2 in the 4:1 geometry.  Error bars show ± SD, N ≥ 6 
samples per strain geometry and protein.  Bars that do not share letters are significantly different from 
each other as determined by one-way ANOVA with Tukey’s post hoc (p ≤ 0.05). 
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3.5: Discussion 
Anisotropic Strain in Vivo and in Vitro – Many planar connective tissues exhibit heterogeneous 
matrix fiber orientations that dictate anisotropic biomechanical properties which are critical for 
proper function.  As an example, aortic heart valve cusps are very compliant in the radial 
direction but stiff in the circumferential direction, which greatly assists in efficient coaptation and 
rapid opening during the cardiac cycle.  Simultaneous mechanical testing and collagen fiber 
distribution profiling demonstrates that anisotropic fiber splay and reorientation is a key 
contributor to physiological valve function [32, 33].  In altered loading environments, such as in 
hypertension or congenital malformation (e.g. bicuspid aortic valve), local cell and matrix 
architecture is modified with an increased risk of tissue degeneration [34] [35-37].  Greater 
understanding of how strain field anisotropy controls fibroblast cell phenotype and matrix 
remodeling has been challenging to study in vivo due to the confounding complexity of multiple 
interrelated biological signals and inherent tissue variability.  Applying anisotropic strains within 
well-controlled 3D culture systems has been limited by 1) an inability to prescribe strain 
magnitudes in orthogonal directions independently, and 2) difficulties in anchoring 3D 
engineered tissues within bioreactors without compromising the homogeneity and consistency 
(over time) of the applied strain. Pneumatic actuator based elastomeric substrate deformation is 
commonly applied but rate-limited by the compressibility of air, rarely exceeding 1.5 Hz for 
physiological soft tissue strains.  Alternatively, mechanical cams require constant adjustment 
and repeat calibration [20, 38].  Biaxial stretching of hydrogels was recently performed by 
molding hydrogel constructs in a cross pattern within a rotating cam [39].  However, the applied 
strain field was inhomogeneous and difficult to monitor over time.  Furthermore, hydrogels can 
be adhered to elastomeric substrates via adhesive proteins, but the magnitudes of strain 
applicable are limited [22].  The design presented in this study overcomes these limitations by 1) 
prescribing strain anisotropy through eccentricity of the culture well geometry, and 2) providing 
uniform and stable construct attachment via compression springs.  We were able to apply 
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homogeneous large deformation strain profiles (>30%) at high frequencies (3Hz) to engineered 
3D tissues for at least 96 hours, significantly broadening the scope of 3D in vitro 
mechanobiological inquiry available.  
 
Anisotropic Mechanoregulation of VIC Phenotype – Fibroblast transition between quiescent to 
activated myofibroblasts is controlled in part by the local mechanical environment.  In the case 
of aortic valves, interstitial cells are largely quiescent fibroblasts in healthy tissue, but can 
become activated myofibroblasts and even osteoblasts in disease states [40-42].  Taylor et al. 
defines the quiescent valve fibroblast phenotype as one that maintains ECM composition and 
collagen maturity [43].  When VIC become activated myofibroblasts, they significantly 
upregulate contractile filaments including ACTA2, exhibit increased traction forces and 
migratory behavior, and secrete matrix proteins as well as their proteases and inhibitors.  These 
factors all lead to dramatic changes in matrix composition and structural organization [40, 43].  
Grinnell et al. and colleagues have used free floating (stress-free) and anchored (stressed) 
collagen hydrogels to show that matrix tension induces a myofibroblastic differentiation of 
fibroblasts from a variety of sources [6, 44, 45].   We previously found that VIC cultured in 2-D 
flasks expressed nearly double the amount of ACTA2 when compared to seeded within floating 
3-D collagen gels, supporting this concept [24].  Similarly, we here find that mechanically 
anchored VIC in 3D culture expressed ACTA2 nearly 3 fold higher than unstressed controls 
(Fig. S4).  Taken together, these results suggest that VIC in anchored 3D collagen gels provide 
a simple positive-control model of myofibroblast like differentiation.   
 
Fibroblast-myofibroblast transitions of VIC in the context of cyclic stretch, however, are more 
complex.  Merryman et al. showed that cyclic uniaxial stretch of porcine aortic valve leaflets for 
7-14 days produced a slight increase in ACTA2 gene expression, but a marked increase with 
exogenous TGFβ1 administration [46].  Thayer et al. found that increased ACTA2 expression 
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due to cyclic stretch could be relieved with combined loading with cyclic pressure [47].  Our 
findings here, using VIC in 3D hydrogel culture, show that ACTA2 expression is also 
independently regulated by the anisotropy of applied cyclic strain.  Cyclic equiaxial strain 
decreases ACTA2 expression, suggesting fibroblast-like tendencies, but strong directional 
biaxial strain re-elevates ACTA2 toward the stressed myofibroblastic control condition.  We 
further found that ACTA2 expression was directly related to the degree of cell alignment, which 
occurred perpendicular to the first principal axis of stretch.  Vimentin, commonly employed as a 
marker for fibroblasts, is an intermediate filament expressed by mesenchymal cells and 
responsible for cytoskeletal integrity, but not expressed exclusively by fibroblasts [48]. We found 
vimentin expression changed similarly with ACTA2 under cyclic stretch, but there was no 
change between anchored and free-floating 3D gels, nor we did not notice a directionally 
dependent expression tendency like we did with ACTA2.   Therefore, we are confident that 
vimentin was a reasonable choice as a fibroblast marker for this system, and focus our 
interpretations on ACTA2 and other behaviors. 
 
Our results here demonstrate that the complete picture of fibroblast “quiescence” and 
“activation” should also include cell phenotype and turnover characteristics.  Schnieder & Deck 
et al. used autoradiographic labeling in rats to demonstrate that normal cell and matrix turnover 
in a variety of fibroblast-populated tissues are not identical.  In fact, valve leaflets exhibited 
naturally elevated proliferation, matrix synthesis, and degradation rates indicative of a 
continuous but homeostatic remodeling environment [7]. Considering that the native healthy 
valve contains relatively few myofibroblasts, this suggests that phenotype “quiescence” may still 
present dynamic matrix remodeling behavior. Our studies here suggest that one factor that can 
potentiate this is mechanical forces, specifically anisotropic cyclic stretch.  Cyclic biaxial strain 
induced both VIC proliferation and apoptosis, suggesting a high degree of turnover, while 
equiaxial strain exhibited significantly less.  Furthermore, equiaxial strain had very little effect on 
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matrix fiber reorganization, while cyclic anisotropic strain resulted in significantly aligned matrix 
fibers.  Following this trend, equibiaxial stretch reduced ACTA2 expression, while anisotropic 
strain elevates it.  Taken together, these results suggest that cyclic equiaxial strain promotes a 
tendency towards a quiescent fibroblastic phenotype, and increasing strain anisotropy supports 
a tendency towards an active myofibroblastic differentiation.  We note that all these studies 
were performed at the same overall magnitude of area strain and frequency.  While not the 
focus of this study, we believe that these responses are likely further altered by strain 
magnitude and frequency [49].  It appears that matrix remodeling lags changes in cell response 
to anisotropic strain, but the underlying cause is not yet known.  Without live cells, however, no 
matrix fiber alignment occurs in any strain pattern (data not shown), suggesting that this 
remodeling is an active cell-mediated response to the applied strain field.  Future studies 
considering altered matrix synthesis, degradation, or matrix fibril diameter, may help reveal the 
time dependent remodeling tendencies and clarify the extent of differentiation.   
 
Accelerated Tissue Engineering via Strain Anisotropy - Modern tissue engineering approaches 
for load bearing tissues have sought to mimic or restore the native biological and biomechanical 
characteristics of replaced tissue, among them biomimetic material anisotropy [50]. Fiber 
reinforced scaffolds, whether electrospun, nonwoven, or woven mesh designs with 
biodegradable materials have been employed to create directionally dependent material 
behaviors [51].  Alternatively, biological polymers such as collagen and fibrin can be 
mechanically stimulated to evolve material heterogeneity [52, 53].  Whether this anisotropy 
needs to be included at the outset or evolved over time is still debated.  Many bioreactors 
designed for whole tissues expose local regions to anisotropic strain fields, but these are difficult 
to quantify and challenging to relate directly to local cell differentiation and matrix remodeling 
[54].  Alternatively, anisotropic mechanical conditioning of 3D engineered tissue sheets could 
accelerate the formation of desired structural architecture and tissue biomechanics prior to 
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forming more complex tissue shapes [55].  Furthermore, our results suggest it may be possible 
to direct stem/progenitor cells towards multiple distinct phenotypes through strain anisotropy, 
which has a potential advantage in that these cells will also be self-organized in their 
environmental context.  It is not yet known how cells in defined 3D matrix architectures interpret 
both time and directionally varying anisotropic strain fields, but our findings suggest that each 
component may contribute to accelerated matrix remodeling and cell differentiation.  
 
 
In conclusion, we developed and implemented a novel bioreactor to investigate the relationship 
between anisotropic strain, cell differentiation, and matrix remodeling in 3D culture.  Our findings 
demonstrate that applied cyclic biaxial strain anisotropy induces time dependent VIC orientation 
and collagen fiber alignment, which occurs at 48 hours and 96 hours, respectively.  During this 
process, ACTA2 expression was directly related to the degree of cell alignment and occurred 
perpendicular to the principal axes of loading.  These findings suggest biaxial strain anisotropy, 
independent of magnitude or frequency, is a potent regulator of rapid matrix reorganization and 
VIC phenotype.  Controlling strain anisotropy in vivo or in vitro may be a potent means of 
directing adaptive tissue remodeling. 
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CHAPTER 4 
RHOA AND RAC1 PLAY DISTINCT AND ESSENTIAL ROLES IN THE MECHANICAL 
REGULATION OF EMBRYONIC VALVE MORPHOGENESIS 
 
 
4.1: Summary 
Embryonic valves rapidly evolve from disorganized globular “cushions” to highly organized thin 
fibrous leaflets.  These multi-scale interactions occur within a demanding hemodynamic 
environment and are essential to maintain unidirectional flow. The mechanisms by which 
mechanical forces direct cellular response to coordinate this cycle of morphogenesis and 
function are not known. In this study, we determined how mechanosensitive small GTPases 
RhoA and Rac1 coordinate atrioventricular valve (AV) differentiation and morphogenesis.  RhoA 
activity is elevated during early cushion formation, but decreases considerably over 
development.  In contrast, active Rac1 increases as cushions mature into valves. Using gain 
and loss of function assays, we determined that the RhoA-SRF pathway was essential for a 
myofibroblastic contractile phenotype in early cushion formation, but was surprisingly insufficient 
to drive matrix condensation during valve maturation.  Interestingly, sustained cyclic stretch was 
a potent inhibitor of RhoA, and inactivation resulted in favor of Rac1 signaling. The Rac1-p38 
pathway was necessary and sufficient to cause directed matrix condensation through cell 
polarization, leading to enhanced stress fiber alignment and adhesion necessary for valvular 
remodeling.  Finally, we used partial atrial ligation experiments to show that altered cyclic 
mechanical loading in vivo augmented or restricted cushion growth directly through potentiation 
of RhoA and Rac1 activity. Together, these results demonstrate that mechanical signaling is 
essential to coordinate a transition from RhoA to Rac1 based signaling, to produce a thin 
organized leaflet with a quiescent phenotype.  
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4.2: Introduction  
Congenital valve abnormalities affect 1-2% of all live births and predispose the tissue to early 
failure [1].  It is thought that the majority of valve defects occur during the maturation stage.  
Despite the significant public health and clinical burden posed by valve abnormalities, a basic 
understanding of the mechanisms orchestrating valve formation has to yet to be achieved.  
Valvulogenesis occurs under a continuous barrage of fluid shear stress and mechanical strain. 
The increasing hemodynamic loads and extension of the valves into the flow field suggests that 
these forces play a critical role [2].  Central to valve morphogenesis, embryonic globular 
“cushions” condense, and remodel into thin fibrous leaflets.  This provides the necessary 
biomechanical structure for maintaining efficient unidirectional blood flow [3].  Interestingly, 
during this extensive remodeling process, residing progenitor valve cells are thought to evolve 
toward a quiescent phenotype [4].  While the importance of transitioning to a quiescent 
phenotype during development is still under investigation, numerous reports in adult diseased 
conditions have indicated that chronic myofibroblastic activation leads a thick and disorganized 
extracellular matrix (ECM) valve structure with inadequate biomechanical function [5, 6].  There 
is a substantial gap in understanding the phenotype transition with respect to ECM remodeling 
during development and the need is clear.  Revealing the cellular mechanisms underlying this 
multi-scale process during development will shed light on the “normal” controlled process of 
valve maturation and function.  This is may prove a necessity for developing regenerative 
strategies to combat dysfunctional tissue states, such as congenital defects or adult valve 
disease. 
 
Hemodynamic loading within embryonic valve tissue can occur at the surface due to shear flow, 
or through internal constituents called tissue stretch (mechanical strain).  Both forces are 
important during valve development, but the influence of each can change dramatically 
depending on the developmental stage.  During early valve formation (HH25), the influence of 
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shear flow has been well established.  For example, computational modeling using native tissue 
geometries and measured fluid velocities demonstrated that regions associated with early valve 
formation were among the highest for shear flows [7].  Likewise, in developing zebrafish, Vermot 
et al. found that reversing flows is important to initiate endocardial ring formation through 
activation of KLF2, necessary for normal valvulogenesis [8].  However, only at later stages 
(HH36, HH40, and beyond) does the valve primordia transition to a thin leaflet architecture 
capable of withstanding remarkable hemodynamic loads [3].  The fact that morphological 
change with increased transvalvular pressure suggest that resident valve cells are heavily 
influenced by cyclic mechanical strain [9].  The post-EMT valvular remodeling process has been 
difficult to understand because tissue strain cannot be as easily measured as shear flow.  
Likewise, resident cells reside within a 3D matrix, rather than a 2D substrate typically seen with 
endothelial layers.   
 
Microsurgical experimental approaches have enabled the study of mechanical signaling in the 
post-EMT maturation process.  Sedmera and colleagues employed partial left atrial ligation 
(LAL) to reduce ventricular preload in avian embryos [10]. They observed that this global 
hemodynamic change caused the AV valve primordia to remain thickened and not progress 
towards a thin fibrous leaflet [11]. Conversely, banding of the right atrium increased ventricular 
preload, and observations suggested an acceleration of valve condensation, though few details 
were reported [12].  The shared mechanisms responsible for accelerating or retarding valvular 
remodeling are not known, but strong candidates include the small GTPase proteins Rho and 
Rac.  These proteins have been widely established as mechanosensitive, and are capable of 
regulating cellular differentiation and ECM remodeling through a spatial balance of expression 
[13]. Recent studies in-vitro has shown that the RhoA pathway is necessary for endocardial cell 
transformation, proliferation, and migration during cushion formation [14, 15].  Likewise, 
extracted cushions implanted within a pulsatile flow system were found to enhance fibrous ECM 
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accumulation and tissue stiffening through RhoA activation [16].  These results confirm the 
relationship between hemodynamics and small GTPase proteins, but to the extent are unknown.      
 
The objective of this study was to understand how resident valvular interstitial cell (VIC) 
quiescence is achieved in conjunction with condensing and remodeling the ECM.  Initial 
examination revealed a marked transition from RhoA to Rac1 dependent signaling during early 
to late cushion/valve morphogenesis (HH25, HH36, and HH40).  Using in-vitro gain and loss of 
function assays, we determined that cyclic mechanical strain in-vitro inhibited myofibroblastic 
activation by decreasing RhoA-GTP levels, and in turn promoted the Rac1 signaling pathway.  
Elevated Rac1 activity resulted in strong cell polarization, stress fiber alignment, and adhesion, 
which is critical for enhanced matrix condensation.  These effects were further confirmed in-vivo 
using ligation experiments to modulate side specific hemodynamic load.  We found that specific 
alterations to hemodynamic inflow augmented either RhoA or Rac1 activity, which in turn 
retarded or accelerated valve morphogenesis. 
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4.3: Materials and Methods. 
4.3.1: Avian Valve Cell Progenitor Isolation and Culture 
AV cushions (HH25) or left AV leaflets (HH36 or HH40) were dissected from the myocardium of 
embryonic chick hearts and digested via trypsin (0.025%, Invitrogen) to obtain valve progenitor 
cells as previously described [17] and used directly in experiments (without passaging). Cells 
were pelleted via centrifugation and re-suspended within a neutralized collagen hydrogel (1.5 
mg/mL) solution at a density of 400,000 cells/ml.  Approximately 150 uL of gel was inoculated 
into culture wells, which solidified after 60 min. Cells were cultured in a base medium consisting 
of M199 (Invitrogen) supplemented with 5% chick serum (Hyclone), 250 mg/mL insulin, 25 
ug/mL transferrin, and 250 ug/mL selenium (ITS; Sigma), and 1% penicillin/ streptomycin as 
previously established for valve mesenchyme [14]. 
 
4.3.2: Static and Cyclic Stress Experiments  
A subset of collagen gels were formed around rings of compression springs as previously 
described [18], creating a mechanically anchored (MA) culture condition [19]. Alternatively, gels 
were released after 24 hours of culture so that the gel created a free floating culture condition 
(FF).  Each resulted in either a mechanically stressed or stress-free condition during cell 
compaction, respectively [20, 21]. A custom designed bioreactor was implemented to apply 
cyclic stretch to aqueous hydrogels as previously described [18]. Gels were cultured around 
similar compression springs over a 24 hr period, after which 20% cyclic equiaxial strain (area 
strain) (225 step size, 2mm) was applied at 2.1Hz, which approximated in vivo embryonic valve 
cyclic strain profiles (STIM) [22]. Experiments were conducted at both short (<60 minutes) and 
longer (up to 48 hr) term intervals.  In total three conditions were used, MA (static mechanically 
anchored stressed gels), FF (static stress free floating gels), and STIM (dynamic mechanically 
anchored strained gels).   
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4.3.3: RhoA/Rac1 Gain and Loss of Function Assays 
To test the effect of specific activation or inhibition of RhoA or Rac1 in different environments , 
mesenchyme was electroporated with plasmids encoding for constitutively active RhoA (CA-
RhoA, Q63L), CA-Rac1 (Q61L), dominant negative RhoA (DN-RhoA, T19N), or DN-Rac1 
(T17N) using the Neon transfection system (Invitrogen, Carlsbad, CA) as previously described 
[23]. Cells were then embedded into collagen constructs and further cultured in 5% serum, 
antibiotic-free M199 for up to 48 hr after initial compaction. For inhibitor experiments, cells were 
embedded into collagen gels and cultured in 5% serum, 1% penicillin/streptomycin, and treated 
with small molecule inhibitors specific to p38 (SB203580, 10 uM, Cell Signaling), SRF (CCG-
1423, 20 uM, Millipore), or ROCK (Y-27632, 10 μM, Cell Signaling) for up to 48 hr after initial 
compaction. 
 
4.3.4: Measuring RhoA and Rac1 Activity 
RhoA and Rac1 activity was measured using GLISA activation assay kits from Cytoskeleton 
according to the manufacturer’s instructions.  Cell extracts were added to 96-well plate coated 
with GST fusion of Rho binding domain. After incubation with shaking at 4°C for 30 minutes, the 
plate was washed 3 times with washing buffer (Cytoskeleton) before addition of antigen 
presenting buffer. The captured GTP-bound Rho GTPases were incubated with their 
corresponding anti-Rho GTPase antibodies. The GTPase-antibody conjugates were detected 
with horseradish peroxidase (HRP)–conjugated secondary antibody and quantiﬁed using an 
Epoch Microplate Spectrophotometer (Biotek). 
 . 
4.3.5: Phenotype Assessment 
Cell phenotype was assessed at both the gene and protein level (primers and proteins are 
included in the supplement).  Briefly, gene expression was measured by extracting RNA using a 
Qiagen total RNA purification kit (Qiagen, Valencia, CA) and reverse transcribed to cDNA using 
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the SuperScript III RT-PCR kit with oligo(dT) primer (Invitrogen).  Samples were amplified using 
the SYBR Green PCR system (Biorad, Hercules, CA) on a Biorad CFX96 cycler.  For 
visualization of proteins, collagen constructs were fixed in 4% PFA overnight at 4C. Cells were 
incubated overnight with the appropriate primary/secondary antibodies, washed, and nuclear 
counterstained for subsequent confocal imaging.  To quantify protein expression, cells were 
trypsinzed from the collagen constructs, fixed with 4% PFA for 10 min and then preserved in 
50% methanol/PBS.  Cells were further washed and incubated with appropriate 
primary/secondary antibodies and scanned using a Coulter Epics XL-MCL Flow Cytometer 
(Coulter).  Adhesion testing and scratch methods are also included in the supplement. 
 
4.3.6: In-Vivo Atrial Ligation Experiments 
Fertilized White Leghorn chicken eggs were incubated in a 38°C forced-draft incubator to 
Hamburger-Hamilton (HH) stage 21 (3.5 days, Hamburger and Hamilton). The embryo was 
cultured in an ex-ovo platform previously described.  Briefly, an overhand knot of 10–0 nylon 
suture loop was placed across either the right or left atrium and tightened, partially constricting 
the left or right AV oriﬁce respectively. This diverted flow from the constricted inlet towards the 
untreated inlet, decreasing hemodynamic load on the one side and increasing it on the other 
[10, 12].   At D7 and D10, hearts and/or left AV valves were analyzed using RT-PCR, 
immunohistochemistry, and micro-ct.     
 
Statistics.  Statistical analysis was done using SAS and/or JMP software using a One-way or 
Two-way ANOVA w/ Tukey’s Post Hoc.  Sample size and significance are labeled within each 
figure legend.  
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4.4: Results 
4.4.1: RhoA and Rac1 pathway expression patterns diverge in the AV valve region during 
morphogenesis.  Native expression profiles in the developing left AV valve (HH25, HH36, and 
HH40) were evaluated using qPCR, ELISA, and immunofluorescence (whole mount) on freshly 
isolated tissue.  We found that the relative gene and protein expression of alpha-smooth muscle 
actin (ACTA2), serum response factor (SRF), and active RhoA (RhoA-GTP) all decreased 
exponentially during development, while vimentin (VIM) remained unchanged.  SRF nuclear 
localization was also found to significantly decrease as measured through co-localization with 
cell nuclei (Figure 4.1A-C).  Conversely, active Rac1 (Rac1-GTP) and β1 integrin expression 
significantly increased.  Phospho-PAK1 expression, indicative of the active Rac1 pathway, was 
also elevated exclusively in later stage AV valves (Figure 4.1D-F). These results support that 
RhoA activity dominates early AV cushion formation, but abates in favor of activated Rac1 
during leaflet maturation.  This divergence was concomitant with a transition from activated 
myofibroblast-like cushion mesenchyme in early AV cushions towards more quiescent 
fibroblasts in remodeled valves. 
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Figure 4.1 –  Native expression profiles in the developing left AV valve reveal the divergence of RhoA 
and Rac1 pathways.  (A) Protein expression of RhoA-GTP was quantified using GLISA and samples were 
normalized to total RhoA.  (B) Gene expression of ACTA2 and Vimentin (inset) was quantified using real-
time PCR.  (C) Whole-mount immunofluorescence for RhoA-red, RhoA-GTP-green (top row), ACTA2-red, 
Vimentin-green (middle row), and SRF-green (bottom row).  (D) Protein expression of Rac1-GTP was 
quantified using GLISA and samples were normalized to total protein.  (E) Gene expression for β1 
integrin was quantified using real-time PCR.  (F) Whole-mount immunofluorescence for Rac1-GTP, F-
actin-green (top row), phospho-Pak1-green (middle row), and β1 integrin-green (bottom row).  All 
samples were counterstained for nuclei using Draq5-blue.  Scale bars represent 100um (C,F). N≥ 8, One-
way ANOVA w/ Tukey’s Post Hoc.   Different letters indicate statistical significance P < 0.05.  
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4.4.2: Matrix condensation capacity of AV valve mesenchyme increases during 
development.  We isolated HH25, HH36, and HH40 left AV leaflets and optically measured 
thickness at the midpoint.   We found that leaflets at later stages of maturation had a significant 
decrease in thickness (Figure 4.2A).  This led us to believe that a decrease in leaflet thickness 
may be a function of the matrix condensation capacity in later stage valve cells.   We then 
freshly isolated AV leaflets at HH25, HH36, and HH40 and embedded the valve progenitor cells 
into collagen hydrogels.  After 24 hr, constructs were released and compaction area was 
measured during the next five days (Figure 4.2B).  We found that matrix compaction was 
dependent on leaflet stage, and significantly increased during valve development (Figure 4.2C).  
Together, these results suggest that the decreased thickness of valve leaflets is due to the 
increased matrix condensation levels, as shown in later stage (HH36, HH40) valve cells. 
 
 
Figure 4.2 – Native embryonic left AV valve thickness decreases and correlates with matrix condensation 
potential.  (A) Left AV valve tissue was isolated from H25, HH36, and HH40 avian embryos and thickness 
was determined by optical measurements.  (B) AV progenitor cells were isolated and subjected to 3D 
collagen hydrogel compaction cultures.  (C) Matrix condensation was quantified by measuring current 
area and normalized to initial area (A/Ao) during a 5 day period.  Note the significance in compaction at 
later stages (HH36,HH40). N≥ 6, One-way ANOVA w/ Tukey’s Post Hoc.   Different letters indicate 
statistical significance P < 0.05. 
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4.4.3: ECM content increases in collagen/GAG ratio and valve becomes highly organized 
during AV valve development.  HH25 mitral cushions contained equal proportions of 
collagens and glycosaminoglycans (GAGs), with more collagen located near the annular 
attachment region.  At HH36, mitral leaflets were significantly more compacted at both the 
annular attachment and mid-zone regions.  At HH40, mitral leaflets became even thinner and 
more organized in cross-section.  The GAG/collagen architecture was starting to establish the 
tri-laminar structure typically found in post-natal mitral valves.  The fractional ratio of collagen to 
GAG was quantified and increased significantly at all stages during development (Figure S4.1).     
 
4.4.4: Myofibroblastic activation is mitigated by cyclic mechanical stretch in AV 
progenitor cells.  Because RhoA has been previously shown to be a mechanosenstive protein, 
we speculated that a relationship might exist between mechanical stretch and RhoA [13, 16].  
We freshly isolated HH40 leaflets, and embedded the progenitor cells into our previously 
described 3D bioreactors.  Mechanically anchored (MA) and free-floating (FF) gels were also 
seeded.  These control conditions are indicative of positive and negative controls for 
myofibroblastic activation, respectively (Figure 4.3A) [18, 21, 24].  Cells were stimulated at 20% 
area strain, at 2.1hz, for up to 48 hr.  Gene expression of ACTA2 and SRF decreased after 12 
hr, and was not significantly different from free-floating gels at 24, 48 hr (Figure 4.3B).  At 48 hr, 
we confirmed these results using flow cytometry (Figure 4.3C).   
 
To assess the dynamics of RhoA during mechanical strain, we performed a time dependent 
assay using GLISA to determine RhoA activity.  STIM RhoA-GTP levels increased initially (0-3 
hr), and then decreased to CTRL-FF levels thereafter, when compared to CTRL-MA gels 
(Figure 4.3D).  Additionally we found a strong correlation between RhoA-GTP and matrix 
tension within the CTRL-MA gels by measuring compaction force using micro spring 
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transducers (Figure S4.2).  These findings were confirmed via immunofluorescence at the 48 hr 
time-point.  We also showed that SRF nuclear localization was mitigated by mechanical stretch 
(Figure 4.3E).  Together, these results indicate that sustained cyclic stretch is a potent inhibitor 
of myofibroblastic activation, and RhoA-GTP levels correlate with underlying cell-matrix tension.   
 
 
Figure 4.3 – Mechanical stretch mitigates myofibroblastic activation in HH40 AV progenitor cells.  (A) 
Cells were isolated from left AV valve tissue and seeded into our previously described bioreactor.  Free 
floating (FF-liberated after 24 hr) and mechanically anchored (MA-confined compaction) gels were used 
as control conditions.  Cells were allowed to compact for 24 hr and stimulated at 20% area strain at 2.1hz 
(average frequency during development) in a time dependent manner (STIM).  (B) After mechanical 
stretch, gene expression for SRF and ACTA2 was measured using real-time PCR at 12, 24, and 48 hr.  
(C) Flow cytometry was used to quantify the protein expression of ACTA2 between MA-CTRL and STIM 
conditions. (D) Dynamic protein expression of RhoA-GTP was quantified using GLISA for MA-CTRL, FF-
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CTRL, and STIM conditions. (E) Immunofluorescence for ACTA2-green (top row), RhoA-GTP-green, 
RhoA-Red (middle row), and SRF-green (bottom row) was conducted on fixed collagen constructs at 48 
hr for CTRL-MA, CTRL-FF, and STIM conditions.  (F) Nuclear localization of SRF was quantified using 
metamorph co-localization software.  All samples were counterstained for nuclei using Draq5-blue.  Scale 
bars represent 50um (A) and 20um (E) . N≥ 6, One-way ANOVA w/ Tukey’s Post Hoc.   Different letters 
indicate statistical significance P < 0.05. 
 
          
We next determined the role of mechanical stretch on myofibroblastic activation for different 
stages of development.  We found that mechanical strain decreased SRF and ACTA2 
expression at both the gene and protein levels in a stage-dependent manner.  Together, these 
results indicate that mechanical stretch regulates cell quiescence in AV leaflets, especially at 
later stages of valve development.  Lastly, because nuclear localization of SRF expression 
directly correlated with ACTA2 expression, and is a known regulator of the ACTA2 gene, we 
speculated that SRF was necessary to promote ACTA2 expression [25].  Using MA-CTRL 
conditions, the SRF pathway was inhibited by supplementing with a SRF pathway inhibitor 
(CCG-1423).  Inhibition of the SRF pathway at 48 hr resulted in a quiescent phenotype at both 
the gene and protein level (Figure S4.3). 
 
4.4.5: ACTA2 and SRF expression are directly controlled by RhoA Activity.  To determine 
the relationship between RhoA and myofibroblastic activation, we performed gain- and loss-of-
function experiments using CA- and DN-RhoA (Figure S4.4).  Using FF gels (indicative of 
quiescent phenotype), transfection with CA-RhoA was found to increase myofibroblastic activity 
comparable to CTRL-MA gels, as shown through increased ACTA2, SRF, and CyclinB2 
(proliferation marker) expression (Figure 4.4A,C).  Conversely, using MA gels (indicative of 
myofibroblastic phenotype), transfection with DN-RhoA was found to inhibit myofibroblastic 
activity comparable to CTRL-FF gels, as shown through decreased ACTA2, SRF, and CyclinB2 
expression at 48 hr (Figure 4.4B,D).   
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Additionally, we directly perturbed the role of RhoA during simulated conditions. Because 
mechanical stimulation was found to inhibit myofibroblastic activation, we hypothesized that 
elevated RhoA activity would block the effects in strained cells.  We thus transfected HH40 AV 
mesenchyme with CA-RhoA and even after mechanical stimulation, myofibroblastic activation 
was non-significant from CTRL-MA gels at 48 hr (Figure 4.4E,F). Together, these results 
confirm the role of RhoA in regulating myofibroblastic activation through increased tension 
(stress-build up), while sustained cyclic mechanical strain inhibits this process.     
     
 
Figure 4.4 – Myofibroblastic activation in HH40 AV progenitor cells is dependent on RhoA activity.   (A-B) 
Gene expression of ACTA2, VIM, SRF, and CyclinB2 were quantified using RT-PCR and compared to 
CTRL-MA or CTRL-FF conditions.  Note the similarity between CA-RhoA-FF and CTRL-MA vs. DN-
RhoA-MA and CTRL-FF. (C-D) Visualization of SRF-green (left column), ACTA2-green (middle column), 
RhoA-GTP-green, and RhoA-Red (right column) by immunofluorescence on the fixed collagen constructs.  
(E) Transfected CA-RhoA cells were stretched for 48 hr at 2.1hz.  Gene expression of ACTA2 and SRF 
was quantified using RT-PCR.  Flow cytometry quantified ACTA2 expression in MA-CTRL, STIM, and 
CA-RhoA-STIM conditions (10000 cells).  All samples were counterstained for nuclei using Draq5-blue.  
Scale bars represent 10um (C-D). N≥ 8, Two-way ANOVA w/ Tukey’s Post Hoc.   Different letters indicate 
statistical significance P <0 .05. 
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4.4.6: Rac1-p38 pathway drives matrix condensation in AV valve progenitor cells. We next 
sought to determine whether RhoA or Rac1 was important for mediating cushion matrix 
condensation at 48 hr.  We determined that RhoA activity (via CA-RhoA or DN-RhoA 
transfection, respectively) resulted in no significant change in compaction potential as compared 
to control conditions (Figure 4.5A). However, elevated Rac1 activity (via CA-Rac1 transfection) 
dramatically enhanced compaction, while suppressed Rac1 activity (via DN-Rac1 transfection) 
inhibited this process. Interestingly, the combination of CA-Rac1 with DN-RhoA inhibited 
compaction similar to controls, suggesting that basal levels of RhoA activity are still required for 
matrix condensation to proceed (Figure 4.5B). CA-Rac1 combined with p38 MAP kinase 
inhibition (via SB203580) significantly reduced compaction levels similar to control (Figure 
4.5C).  These results together determine that matrix condensation by AV cushion mesenchyme 
is dominated via the Rac1-p38 pathway. 
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Figure 4.5 – Compaction potential of HH40 AV progenitor cells is dependent upon Rac1 via p38. (A-C) 
HH40 cells were isolated from left AV valve tissue and immediately transfected with CA-RhoA, DN-RhoA, 
CA-Rac1, DN-Rac1 (Neon Transfection system) and/or chemical inhibitors.  Cells were then embedded 
into collagen hydrogels and allowed to compact for 24 hr. Hydrogel compaction was measured by current 
area over initial area (A/Ao), and determined at the end of 48 hr. N≥ 6, One-way ANOVA w/ Tukey’s Post 
Hoc.  Asterisks indicate statistical significance at P < 0.05.  
 
 
 
4.4.7: Rac1 promotes matrix condensation through increased adhesion and polarity, but 
independent of myofibroblast behavior.  To determine the mechanism through which Rac1 
enhances matrix condensation, we performed gain and loss of function experiments using CA- 
and DN- mutants of Rac1.  CA-Rac1 was found to increase myofibroblastic activity and integrin 
expression as measured through increased ACTA2, SRF, and β1 integrin gene expression in 
MA conditions (Figure 4.6A,C).  Conversely, DN-Rac1 had no effect on myofibroblastic 
activation, but significantly decreased β1 integrin gene expression in FF conditions at 48 hr 
(Figure 4.6B).  This indicates that Rac1 drives integrin expression independent of static 
mechanical tension.  To test whether increased integrin expression effected adhesion, cells 
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were seeded in well plates and exposed to an orbital shaker at >500rpm for 15 seconds at 
intervals of 30 min.  CA-Rac1 was found to increase the percentage of adherent cells in a time 
dependent manner compared to control, while DN-Rac1 had the opposite effect (Figure 4.6D,E).  
We next quantified a number of subcellular macromolecules that mediates the regulatory effects 
of cell anchorage on ECM adhesion.  After 24 hr, transfection with CA-Rac1 increased the 
number of focal complexes at the leading edge of lamellipodium by measuring co-localization 
intensity of vinculin and F-actin along the periphery.  Moreover, the distribution angle of F-actin 
and subsequent stress fibers was highly aligned indicating a polarized cell. DN-Rac1 had the 
opposite effect (Figure 4.6F,G).  Lastly, CA-Rac1 resulted in a decreased migration potential as 
shown through a scratch assay (Figure S4.5).  These results indicate that Rac1 increases both 
the number of integrin binding sites and focal complexes leading to enhanced cell polarity and 
adhesion, but reduced cell migration.      
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Figure 4.6 – Rac1 promotes matrix condensation through increased adhesion and polarity, but 
independent of myofibroblast behavior in HH40 AV progenitor cells. (A-B) Gene expression for ACTA2, 
Vim, SRF, and β1 integrin was quantified using RT-PCR in both CTRL-MA and CTRL-FF conditions (note 
myofibroblastic activation is dependent upon MA conditions).  (C) Immunofluorescence for ACTA2-red 
and β1 integrin-green of the control (left column), CA-Rac1 (middle column), and DN-Rac1 conditions 
(right column row) on the fixed collagen constructs.  (D) An adhesion test was performed on tissue culture 
plastic and the extent of spreading was visualized through immunofluorescence for β1 integrin-red and F-
actin-green of DN-Rac1 (top row), control (middle row), and CA-Rac1 conditions (bottom row).  (E) The 
percentage of adherent cells was quantified at each time interval after application of the orbital shaker.  
(F) At 24 hr, the extent of F-actin alignment and focal complexes were quantified for each condition.  (G) 
Focal complexes and F-actin alignment were visualized using immunofluorescence (note the distribution 
angle of F-actin and subsequent stress fibers alignment within CA-Rac1).  All samples were 
counterstained for nuclei using Draq5-blue.  Scale bars represent 20um.  N≥ 6, One-way ANOVA w/ 
Tukey’s Post Hoc.  Asterisks indicate statistical significance at P < 0.05.  
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4.4.8: In vivo perturbation of AV valve mechanical environment confirms the divergent 
roles of RhoA and Rac1 in valvular morphogenesis.  To determine the importance of 
sustained mechanical loading on valvulogenesis in-vivo, we performed partial atrial ligation 
experiments on ex-ovo cultured chick embryos [10, 12].  Left atrial ligation (LAL) shunted 
hemodynamic flow into the right side of the AV canal, while right atrial ligation (RAL) diverted 
hemodynamic flow into the left side of the AV canal (Figure 4.7A).  As a result of the altered 
hemodynamic loading, LAL had reduced collagen along the attachment zone, and extensive 
GAGs were present throughout the leaflet with a noticeable reduction in the fibrosa layer.  
Conversely, the RAL had increased collagen along the attachment zone and throughout the 
midzone of the leaflets.  The collagen to GAG fractional ratio in the RAL was s ignificantly more 
than the LAL, and normal leaflets suggesting a more mature leaflet in the RAL conditions 
(Figure S4.6).  Using micro-CT, the functional consequence of these procedures was found to 
alter both leaflet size and left ventricular volume.  RAL were found to have significantly 
increased leaflet area and left-ventricular volume as compared to control.  Conversely, LAL had 
significantly decreased leaflet area and left-ventricular volume as compared to control (Figure 
4.7B).  Together, LAL procedures resulted in a significantly underdeveloped valve, with reduced 
functional characteristics.  RAL had the opposite effect. 
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Figure 4.7 – Hemodynamic perturbation in-vivo confirms divergence of RhoA/Rac1 pathways during AV 
valve development.  (A) Atriums of the heart were ligated using suture material between 4-5 days.  Micro-
CT was used to measure both the change in size of ventricular chambers, but also left AV valve geometry 
(ultrasound also confirmed a significant decrease in time averaged velocity and cardiac output) at D7.  
H&E histology stain of the heart and left AV valve structures for the control, LAL, and RAL conditions.  (B) 
Real-time PCR for SRF, ACTA2, VIM, and β1 integrin gene expression at D7.  (E) Immunohistochemistry 
for SRF, ACTA2, RhoA-GTP, Rac1-GTP, and β1 integrin of resident valve cells at D7 of wild-type (top 
row), left atrial ligation (middle row), and right atrial ligation conditions (bottom row).  (F) RALs (right atrial 
ligation) at D10 were analyzed.  H&E histology was conducted on both the left AV valve and ventricular 
chamber structures. (G) Real-time PCR for ACTA2, VIM, and β1 integrin gene expression at D10. (H) 
Immunohistochemistry staining of ACTA2, RhoA-GTP, and Rac1-GTP in resident valve cells for wild-type 
(top row), left atrial ligation (middle row), and right atrial ligation conditions (bottom row).  All samples 
were counterstained for nuclei using Draq5-blue.  Scale bars represent 300um (A,F) and 40um (E,H).  N≥ 
8, One-way ANOVA w/ Tukey’s Post Hoc.  Asterisks indicate statistical significance at P < 0.05.  
 
 
 
 
As anticipated, reduced hemodynamic load in the LAL was found to enhance myofibroblastic 
activation in the left AV valve mesenchyme.  ACTA2 and SRF gene expression was significantly 
elevated compared to sham controls, while RAL had the opposite effect at D7 (Figure 4.7C,D).  
β1 integrin gene expression also increased in the RAL conditions.  Using 
immunohistochemistry, nuclear localization of SRF and increased RhoA-GTP activity was 
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clearly evident in the left AV valve of LAL treated embryos, while Rac1-GTP activity was 
decreased relative to sham controls.  Conversely, RAL treat embryos resulted in a loss of SRF 
nuclear localization and decreased Rho-GTP activity, while Rac1-GTP activity was significantly 
elevated (Figure 4.7E).  We further analyzed D10 embryos within the RAL conditions (LAL have 
significant lethality at D8 as previously reported [10]) to assess late stage morphogenesis 
(Figure 4.7F).  ACTA2 expression and SRF nuclear localization significantly decreased and 
correlated with RhoA-GTP activity, while Rac1-GTP activity increased (Figure 4.7G,H).  
Furthermore, the left AV valve in the RAL treated embryos had increased in collagen/GAG 
content relative to sham controls. Together, these results confirm the importance of RhoA and 
Rac1 activity in regulating proper cell phenotype and valve morphogenesis through mechanical 
load.  We summarized our results as illustrated in the cartoon (Figure 4.8). 
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Figure 4.8 – Summary of phenotypic changes associated with cyclic stretch during valve maturation.  (A) 
Early valve tissue resembles a globular “cushion” consisting of high GAG/collagen ratio.  Resident 
mesenchyme cells are highly myofibroblastic as indicated by positive expression for ACTA2 and RhoA-
GTP.   During valve maturation, the resident cells become Rac1 positive, and transition to a highly 
polarized but quiescent valvular phenotype.  The valve morphology changes to a thin fibrous leaflet 
consisting of a high collagen/GAG ratio.  (B) Underlying this process, sustained cyclic stretch is necessary 
for directing valvular phenotype through a RhoA/Rac1 divergence “switch”.  At early stages, the resident 
cells activate the RhoA pathway and nuclear localization of SRF to enhance smooth muscle actin, 
collagen production, and proliferation.  At later stages, significant collagen is produced and promotion of 
the Rac1-p38 pathway leads to enhanced ECM adhesion and cell polarization necessary for matrix 
condensation. Concurrently, the RhoA pathway is “switched” off by sustained cyclic stretch and cell 
quiescence is maintained. 
 
 104 
 
4.5: Discussion 
Embryonic valve primordia deform considerably as they withstand increasing hemodynamic 
loads while transitioning from thick endocardial cushions to thin fibrous leaflets [26, 27].  
Previous studies altering intracardiac flows in vivo report a high incidence of valvular 
malformation [11, 28, 29].  Similarly, genetic mutant animal models with malformed valves 
experience a changed hemodynamic environment [30, 31].  While the importance of flow in the 
initiation of valve formation is well recognized, how mechanical signals participate in the 
transition from cushion to fibrous leaflet is poorly understood [32-34].  Morphogenic processes 
involve adhesion, migration, and matrix remodeling behaviors, which are all impossible without 
mechanosensitive action and reaction [35, 36]. Furthermore, as morphogenesis and ECM 
remodeling subsides, active myofibroblasts transition to quiescence for maintaining tissue 
homeostasis [37].  In this study, we clarify how mechanical signaling orchestrates endocardial 
cushion condensation into thin fibrous leaflets, while simultaneously establishing fibroblastic 
quiescence.  Using gain and loss of function assays, we identify RhoA and Rac1 as key 
participants in mechanical regulation of embryonic valve remodeling.  Mechanical tension 
promotes RhoA mediated cell migration essential for early cushion formation, but RhoA activity 
subsides as cushions condense into leaflets.  Rac1 activity in contrast was necessary and 
sufficient to mediate condensation and reduction of myofibroblastic phenotype. Interestingly, 
cyclic mechanical stretch in-vitro inhibited myofibroblastic activation by decreasing RhoA-GTP 
levels and promoted Rac1 signaling. Rac1 activity resulted in strong cell polarization, stress 
fiber alignment, and adhesion, which in turn is necessary for enhanced matrix condensation.  
These effects were further confirmed in-vivo using ligation experiments to regulate side specific 
hemodynamic load.  These results establish the importance of mechanical load on regulating 
valve progenitor differentiation and matrix condensation through coordinated RhoA/Rac1 
signaling.  
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Valvular interstitial cells are predominantly quiescent ﬁbroblasts in healthy postnatal tissue, but 
exhibit activated myoﬁbroblastic behavior during embryonic remodeling or disease states [6, 
38]. When VICs become activated myoﬁbroblasts, they signiﬁcantly up-regulate contractile 
ﬁlaments (including ACTA2), exhibit increased matrix turnover, and are highly proliferative. 
These factors all lead to dramatic changes in matrix composition and structural organization [4, 
39]. Grinnell et al. and colleagues developed a now classic ﬂoating (stress-free) and 
mechanically anchored (stressed) hydrogel 3D culture system to study mechanoregulation of 
matrix remodeling adapted herein. They determined that fibroblasts within mechanically 
stressed environments generate cell tension and become activated myofibroblasts, while cells in 
stress-free free floating gels do not (negative control) [19, 40].  We previously confirmed a 
similar behavior of postnatal VICs in these model systems [18]. The mechanisms underlying this 
mechanosensation are incompletely understood, but involve at least in part cytoskeletal tension 
and RhoA signaling [41, 42]. In our system, we found that mechanical tension increases in 
mechanically anchored hydrogels (measured via spring transducers) and monotonically 
correlates with RhoA activity during a 72 hr period. Concurrently, SRF nuclear localization 
ensues, where it can directly bind the promoter region of ACTA2 to drive myofibroblastic 
differentiation [43].  We confirmed the requirement of RhoA activation by measuring 
myofibroblastic activation of valvular progenitors in stress-free (floating) gels with CA-RhoA 
conditions, which express ACTA2 and SRF similar to the stressed (mechanically anchored) 
condition. 
  
The functional consequence of the transition from activated myofibroblast to quiescent fibroblast 
is incompletely understood, but corresponds with the remodeling of homogenous GAG rich 
cushion matrix at HH25 to an organized trilaminar leaflet structure consisting of collagen, 
elastin, and GAGs at HH40 [44, 45].  We found that disruption of this process in the form of 
sustained myofibroblastic activation restricts valve condensation and development of striated 
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architecture, which is confirmed by observations in valves with chronically activated interstitial 
cells [4, 37].   As demonstrated both in-vitro and in-vivo, sustained cyclic loading is a key 
mechanism for abating myofibroblastic activity by suppressing RhoA activity.  How and why 
diseased postnatal valves persist in myofibroblastic activation in the presence of cyclic stretch is 
not fully ascertained, but is likely due to the combinatorial involvement of altered biochemical 
(e.g. TGFβ) and mechanical (e.q. cytoskeletal tension) conditions.  Our findings support 
however, that decreasing RhoA activity is a potential mechanism for alleviating myofibroblastic 
activation of VIC in a remodeling valve. 
 
While the extent of cell deformation during valve maturation is unknown, it is well documented 
that valve primordia increase their motion as they elongate [8], and tissue stretch undoubtedly 
occurs in proportion to the transvalvular pressure the valves experience [46, 47].  
Simultaneously, tissue stiffness increases during development [22, 48].  Interestingly, we 
recently found that resident valve cell deformation and tissue stiffness are functionally 
connected, and cells in stiffer ECM environments are more sensitive to tissue stretch [49].  
Given the fact that both transvalvular pressure and tissue stiffness increases during 
development; we speculate that sustained cyclic deformation may be more critical for 
maintaining a quiescent cell at later stages, possibly through tensional homeostasis  [50].  
Additionally, because cell-matrix interactions change during valve development (i.e. increase 
beta1 integrin) the sensitivity (stage independent effects) of deformation may be a function of 
the resident cells’ ability to form stable ECM connections, possibly through increased adhesion, 
cell polarization, and alignment.   
 
Our results further identify the p38-Rac1 pathway as necessary and sufficient for matrix 
condensation by valve progenitors. This was initially surprising, as the RhoA pathway is a well-
established driver of stress fiber formation and contractility [41, 51].  However, Parsons et al. 
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recently demonstrated that constitutively active-Rac1 drives the formation of adhesions along 
the ventral surface of the cell body, which move toward those at the tip and result in contraction-
like shortening and matrix compression at the base of lamellipodia [52]. Both the magnitude and 
direction of the adhesion motions correlate strongly with nearby matrix displacements indicating 
the importance of cell polarity for force generation [53].  Additionally, fibroblast-specific deletion 
of Rac1 in mouse resulted in delayed cutaneous wound closure, with reduced collagen 
production and matrix compaction [54].  Consistent with these results, we determined that 
colocalization of actin fibers and vinculin along the cell periphery depended on Rac1 activity.  
Actin stress fibers were highly aligned within the cells only when Rac1 was active, indicating 
strong polarization and contraction [55].  Importantly, CA-RhoA or DN-RhoA did not affect matrix 
condensation.  However, CA-Rac1 combined with DN-RhoA completely blocked matrix 
condensation, suggesting that basal levels of RhoA are still needed to maintain cell contractility 
and traction force. We therefore conclude that Rac1 enhances cell polarization and adhesion to 
coordinate actin stress fiber alignment and directionally for RhoA mediated contractility.  This 
explains at least in part the inverse relationship between matrix condensation and 
myofibroblastic differentiation during valve maturation that leads to thin mature quiescent 
valves.   
 
Clinically, Rac1 signaling defects have been implicated in Noonan Syndrome.  About 10%–15% 
of individuals with NS have mutations in son of sevenless 1 (SOS1), which encodes a RAS and 
RAC guanine nucleotide exchange factor (GEF) [56].  Interestingly, a retrospective study of 136 
patients with Noonan Syndrome and cardiac heart defects found that 15% of these individuals 
had anomalies of the atrioventricular canal, and a subset with severe mitral defects [57].  
Recently, mice with the Noonan Syndrome-associated Sos1E846K gain-of-function mutation 
were found to have hyperactive Rac1 activity, leading to extensive cardiac and valve defects 
[58].  While the direct mechanism by which Sos1-Rac1 leads to cardiac defects is still unclear, a 
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potentially deleterious combination of altered mechanical and genetic signaling cannot be 
overlooked.  Patients with Noonan syndrome and mitral defects often have elevated blood 
pressure, as measured by peak-to-peak gradient and Doppler mean gradient, leading to sub-
aortic stenosis and accessory fibrous mitral valve tissue [57].  Our results indicate that 
hemodynamic loading contributes to Rac1 activity, and reduced mechanical loading cause’s 
dysfunctional adhesion and cell polarization, leading to immature matrix remodeling.  In 
corroboration with previous studies, genetic mutations of Rac1 were found to result in abnormal 
ECM remodeling in-vitro and in-vivo [54, 59].  The mechanisms were found to include impaired 
adhesion as well as reduced matrix condensation [60, 61].  Together, consideration of 
hemodynamic loading in concert with Rac1 signaling may inform mechanistic insights in mitral 
valve malformation and/or premature degeneration. 
 
In summary, these results establish that mechanical loading is essential for coordinating a 
transition from RhoA to Rac1 based signaling to produce a thin organized valve leaflet with a 
quiescent phenotype. Unbalanced RhoA/Rac1 signaling may therefore be an important 
predictor of abnormal valve morphogenesis.  Additionally, altered hemodynamic signaling can 
possibly be used to control RhoA/Rac1 signaling to rescue tissue fate.  These findings and 
innovative methodologies motivate and enable new mechanobiological hypotheses to link 
microenvironmental cues with genetic regulation for understanding tissue formation and 
remodeling. 
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CHAPTER 5 
 
MULTI-SCALE BIOMECHANICAL REMODELING IN AGING AND GENETIC MUTANT 
MURINE MITRAL VALVE LEAFLETS: INSIGHTS INTO MARFAN SYNDROME 
 
 
 
5.1: Summary 
Mitral valve degeneration is a key component of the pathophysiology of Marfan syndrome.  The 
biomechanical consequences of aging and genetic mutation in mitral valves are poorly 
understood because of limited tools to study this in mouse models.  Our aim was to determine 
the global biomechanical and local cell-matrix deformation relationships in the aging and Marfan 
related Fbn1 mutated murine mitral valve.  To conduct this investigation, a novel stretching 
apparatus and gripping method was implemented to directly quantify both global tissue 
biomechanics and local cellular deformation and matrix fiber realignment in murine mitral 
valves.  Excised mitral valve leaflets from wild-type and Fbn1 mutant mice from 2 weeks to 10 
months in age were tested in circumferential orientation under continuous laser optical imaging.  
Mouse mitral valves stiffen with age, correlating with increases in collagen fraction and matrix 
fiber alignment.  Fbn1 mutation resulted in significantly more compliant valves (modulus 1.34 ± 
0.12 vs. 2.51 ± 0.31 MPa, respectively, P<.01) at 4 months, corresponding with an increase in 
proportion of GAGs and decrease in elastin fraction.  Local cellular deformation and fiber 
alignment change linearly with global tissue stretch, and these slopes become more extreme 
with aging.  In comparison, Fbn1 mutated valves have decoupled cellular deformation and fiber 
alignment with tissue stretch.  Taken together, quantitative understanding of multi-scale murine 
planar tissue biomechanics is essential for establishing consequences of aging and genetic 
mutations.  Decoupling of local cell-matrix deformation kinematics with global tissue stretch may 
be an important mechanism of normal and pathological biomechanical remodeling in valves.  
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5.2: Introduction 
Marfan syndrome (MFS) is an autosomal-dominant systemic disorder of connective tissue, with 
an estimated prevalence of 1 in 5,000 individuals [1].   It is associated with mutations in Fbn1, 
encoding fibrillin-1, the principal component of extracellular microfibrils, leading to severe 
cardiovascular, ocular, and skeletal defects [2].  Of these consequences, mitral valve disease is 
one of the leading indications for surgery and causes of death in young children with MFS. 
Furthermore, mitral valve prolapse is widely prevalent, affecting 2.4% of individuals in a 
community-based survey [3].  Currently, no medical therapies exist to prevent valve disease in 
predisposed individuals [4].  Despite its significant public health and clinical burden, very little is 
known about the biomechanical remodeling of mitral valves with age or genetic mutations, 
which lie at the core of its pathophysiology. 
 
Mitral valves (MV) are fibrous leaflets whose primary function is to maintain unidirectional blood 
inflow into the left ventricle with each heartbeat [5].  Resident valve interstitial cells (VIC) repair 
and remodel the tissue to form a complex biomechanical structure capable of withstanding 
forces exerted by the surrounding blood and muscle walls [6].  MV tissue biomechanics is 
dictated in large part by local microstructure, which is comprised of stratified collagen and 
elastin dispersed with proteoglycans [7].  Myxomatous MV leaflets have increased production of 
collagens, particularly type III collagen, and glycosaminoglycans (GAGs) [8].  Some postulate 
that this may be the result of a leaflet response to repeated mechanical stress leading to MV 
dysfunction [9].  Sherratt et al. suggested that microfibrils, predominantly composed of fibrillin-1, 
act as stiff reinforcing filaments in elastic fibers, possibly limiting the extension of elastin and 
protecting these fibers from hemodynamic damage [10].  Breakdown of these microfibrils may 
also affect adjacent cell attachment, as an RGD sequence of fibrillin-1 has been reported to 
support cellular adhesion in vitro via integrin αvβ3 [11,12].  Still, the global and local 
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biomechanical consequences of human fibrillin-1 mutations in the mitral valve have not been 
fully elucidated. 
 
Mouse models are indispensible for understanding functional consequences of fibrillin-1 
mutations.  Ng et al. found that MV leaflets from mice with a heterozygous cysteine-substitution 
mutation in fibrillin-1 exhibit postnatally acquired alterations in architecture that correlate both 
temporally and spatially with increased cell proliferation, decreased apoptosis, and excess TGF-
β activation and signaling [13]. Mice homozygous for a hypomorphic Fbn1 allele (mgR) die 
between 3 and 6 months of age from aortic dissections.  This tissue mechanical failure is 
preceded by a series of secondary events that are spatially coincident including progressive 
elastic fiber degradation and disarray and aortic wall thickening due to excessive deposition of 
matrix elements including collagen and proteoglycans.  These findings suggest that cell 
mediated matrix remodeling leads to gross tissue biomechanical changes.  While molecular 
processes are easily studied in mice, no experimental devices exist for quantifying the 
biomechanical characteristics of these micro-scale planar soft tissues. 
 
In this study, we implement a novel method to quantify global biomechanical and local cell-
matrix relationships in small-scale planar tissues.  By stretching mouse mitral valves under 
confocal microscopy, tissue strain was quantified concurrently with underlying cellular 
deformation and fiber alignment.  We found that local cell and matrix kinematics are decoupled 
to different degrees correlating with magnitude of global valve tissue stretch.  This decoupling 
was correlated with transitions in the proportions of collagen and GAGs, whether with age or 
Fbn1 mutation.   
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5.3: Materials and Methods 
5.3.1: Device Fabrication and Biomechanical Testing 
 We designed and fabricated a device that miniaturized a classical uniaxial strip test.  Two 
challenges for very small, ultra compliant tissues are 1) measuring very small magnitude forces 
applied, and 2) securing the tissue to a member that can stretch without failure at the grips.  We 
addressed the first using classical Euler cantilever beam deflection mechanics.  Elastomeric 
posts (Polydimethylsiloxane, Sylgard184) were prepared by casting a 10:1 mix of base and 
curing agent in custom made negative molds and curing at 65oC for 6 hours.  The mold 
geometry (cross-section, depth) was adjusted to create posts with different force sensitivity and 
strain capacity.  Bending stiffness was calculated analytically with the measured deflection 
(Figure 5.1A-B), and measured force verified independently via mass balance as previously 
described (1).   
 
 
Figure 5.1 – Silicon post construction and calibration.  (A)  Elastomeric posts mounted on micro-
manipulation and deflection force measured via weight scale.  (B) Representative calibration curves for 
fixed aspect ratio of height to diameter (H/D) = 3 with varying diameters.  Euler beam theory (dashed line) 
predicts a linear increase in bending stiffness with diameter.  Post bending stiffness was measured for 3 
diameters and agrees with theory.  n = 6 (3 silicon batches), with data presented as mean± SD. 
 
Cylindrical posts with a diameter of 2mm and axial length of 6mm were used for mitral valve 
testing.  Once calibrated, the silicon posts were mounted on top of two L-shaped plastic beams 
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that traveled on linear rail guides.  A screw-driven wedge enabled equal and opposite co-linear 
displacement of the L-beams, and thus the cantilever posts, micron resolution (Fig. 5.2). Valve 
tissue was secured to the post top using filter paper and a high-viscosity cyanoacrylate (454 
Prism, Loctite).  The tissue was kept flat prior to mounting by first placing it on a glass coverslip 
and removing all excess liquid, then inverting it to contact the posts.  Once mounted, the entire 
system was placed on the stage of an upright confocal microscope (TCS SP2, Leica). 
 
 
 
Figure 5.2 – Meso-scale uniaxial tensile device.  (A)  Experimental stage controls the opposite co-
linear translation of two cylindrical elastomeric beams.  Tissue is mounted on the top surface of the posts 
using filter paper.  The assembly is fully submerged in a buffered saline bath, and able to be imaged 
continuously under an upright confocal system.  (B) Silicon post defection (v), post separation (s), and 
horizontal translation (d) were used for the biomechanical analysis.  (C)  Fabricated device implements a 
screw-driven wedge design for separation of the two linear rail guides at micro-meter resolution.  (D)  
Detailed view of the silicon-post setup located inside the water bath.  Distance between the posts is 
approximately 500 um. 
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5.3.2: Mitral Valve Isolation and Biomechanical Testing 
 Wildtype (Fbn1 +/+) and heterozygous ( C1039G/+Fbn1) knock-in mice between the ages of 2 
weeks and 10 months were used in this study, as that reflects a broad range of murine valve 
growth and development [15].  Details of the human Fbn1 knock-in mutation (C1039G/+) have 
been previously described [16].  Mutant mice were back-crossed into the C57BL/6J background 
for at least 10 generations.  All animal use was approved by the Cornell University and Johns 
Hopkins Institutional Animal Care and Use Committee (IACUC). For valve tissue isolation, mice 
were then anesthetized using anintraperitoneal injection of sodium pentobarbital (125 mg/kg) 
and verified via toe pinch.  Acranio-caudal incision was then made to expose the thoracic cavity, 
and the diaphragm severed.  The heart was then excised above the level of the aortic valve and 
perfused with ice-cold saline to wash away any blood from the chamber and valve regions.  
Mutant mouse hearts were prepared at Johns Hopkins, placed in a 15ml conical tube containing 
DMEM, 10% FBS, and 0.1% ITS, and shipped on ice the same day to Cornell.  Shipped mitral 
valve tissues were stained with Live-Dead to confirm greater than 90% cell viability (Figure 5.3.  
Tissues were tested immediately on arrival, which was within 24 hours after the initial isolation.  
 
Figure 5.3 – Live/dead stain on shipped 
C1039G/+
Fbn1 mitral valves.  (A) Visualization of Live/dead 
stain.  (B) Shipped FBN1 valves had over 90% viability upon arrival, similar to valves excised directly at 
our institution. Magnification, ×4 Scale bars: 500 μm.   Error bars show ±SD, n ≥ 3 valves per time point. 
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The anterior mitral valve leaflet was dissected from the annular wall and trimmed to a 
rectangular strip using micro-scissors.  The presence and architecture of cells and extracellular 
matrix were visualized using fluorescent vital dyes (5 µM CellTrackerRed CMPTX and 10 µM 5-
DTAF, respectively, both from Invitrogen).  Leaflets were then mounted to the posts in the 
atrialis-up configuration, immersed in a bath containing Dulbecco’s phosphate buffered saline 
(DPBS) and placed under an upright confocal (TCS SP2, Leica).  Zero-strain reference length 
was defined as the maximum length of tissue for which no post deflection was visible 
(representing a maximum tensile preload of 100 nN). Tissues were first preconditioned with 3 
cycles of approximately 10% strain, followed by a single quasi-static tensile test administered at 
25-micron displacement intervals.  At each test position, a macroscopic tissue view of the valve 
was taken at 10x magnification, and microscopic z-stacks of cells and fibers at 40x, both using 
confocal microscopy.  Simultaneously, post deflection was monitored using a digital SLR 
camera (D5000, Nikon) positioned at the side of the test system.   
 
5.3.3: Determination of Local Biomechanics 
Biomechanical parameters were quantified through image analysis performed using ImageJ 
(NIH).  Global tissue deformation was measured via tip-to tip post displacement, while local 
tissue deformation at each incremental stretch were measured at the midline zone by tracking 
virtual fiducial markers using confocal microscopy as previously described (2). Applied force 
was determined by comparing measured post-deflection against the calibration curve. Tissue 
width and thickness was measured at the initial state using confocal microscopy (10X and 40x 
z-stacks, respectively). First Piola-Kirchoff stress and stretch ratio-based strain data were 
generated and fit to a uniaxial exponential Fung model.  From this, an effective tissue modulus 
was determined using the two material coefficients (α,β) as previously described (3).  Local 
matrix fiber alignment and cell deformation was captured at each stretch interval using 40x 
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confocal z-stacks (Figure 5.4). Cell shape changes were traced manually, tracked over 
subsequent images, and quantified as a cell circularity index (CI = 4*Pi*(Area/Perimeter2)) as 
manually traced in ImageJ.  Fiber alignment along the axis of stretch was quantified as an 
alignment index (FAI) custom algorithm through MATLAB as previously described (4).  The 
Fourier Transform intensity was computed between 0o to 180o (angles with respect to 
horizontal) at 5o intervals and presented the results in the form of a histogram as a graphic 
display of alignment along a particular angle. The AI integrals were approximated as the sum of 
these 5o intervals.  This was directly compared to the summed angles ±10  o from the direction of 
stretch for a FAI.   
 
Figure 5.4 – Stretching mouse valves under continuous fluorescence imaging.  (A)  Post deflection 
used for measuring force generation.   (B)  Top view of post with attached tissue (center-outlined).  
Outline of post cross-section included as a reference (circles).  (C) Macro scale valve deformation at 10X 
under confocal microscropy (extracellular matrix-green, cells- red).  Stars denote post centroids.  (D)  
Valve thickness measured using confocal microscopy full thickness z-stacks (40 um in this image). 
 
5.3.4: Extracellular Matrix Composition.  Additional hearts were excised and fixed in 10% 
buffered formalin overnight, arranged in 1.5% agar prior to paraffin embedding, and slides were 
prepared using 7µm sections. Sections of paraffin-embedded tissue were prepared and stained 
with either Movat Pentachrome, Masson’s Trichrome, or Verhoff-van Gieson stain (VVG).  Mitral 
valves were examined at 4X magnification and compared to a 200µm calibration standard 
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included in each image.  Only sections in which the entire anterior leaflet was present were 
included in analyses. Colors representing different matrix constituents were separated in NIH 
ImageJ using an RGB or CMYK channel splitter and converted to grayscale images.  These 
areas were then thresholded, quantified, and normalized against the area of the entire valve 
leaflet to determine relative fractional composition as previously described (5) (Figure 5.5). 
 
 
Figure 5.5 – Digital quantification of ECM composition.  Serial sections of the mitral valves were 
stained with Movat’s Pentachrome to identify the relative amounts of cells, collagen, and 
glycosaminoglycans at each age. The relative contributions changed dramatically across the length of the 
valve, so the entire valve area was considered (dashed contour).  Colors were separated using an RGB 
or CMYK channel splitter.  Black and white thresholds were created in NIH ImageJ and used to determine 
the volume fractions of each contributor. 
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Statistics 
At least 6 independent valve specimens per time point and treatment condition were used 
during mechanical testing and samples from at least 3 independent valves were used for 
histochemical/morphologic analysis.  All results are expressed as mean ± standard deviation, 
unless otherwise stated.  One-way ANOVA with Tukey’s modified post-hoc tests were used to 
compare differences between means and data was transformed when necessary to obtain 
equal sample variances.  For Fbn1-mutant mice, Student’s t-tests compared single time point 
across treatment conditions.  P < 0.05 denoted statistical significance.  
 
 
5.4: Results  
5.4.1: Temporal biomechanical analysis of wild-type C57BL/6J mitral valves.  We tested 
circumferentially oriented mitral valve leaflet specimens from 2 week-, 3 week-, 4 month-, and 
10 month-old C57BL/6J mice, an interval during which significant physiological and 
morphological changes (valve thickness, mitral annulus, and blood pressure) have been 
observed [15].  As our objective was to compare local and global tissue deformations, tissues 
were stretched to a maximum of λ=1.6, which was sufficient to induce large cell shape changes 
but not cause fiber disruption or fracture.  Macroscopically, the planar valves deformed as a 
typical uniaxial strip, with necking in the central region (Figure 5.6A-D).  Microscopically, 
resident cells steadily changed shape from round to elliptical with stretch (Fig 5.6E-H), while 
matrix fibers progressively straightened and aligned to the loading direction (Fig. 5.6I-L).   
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Figure 5.6 – Macro and micro-scale tissue analysis.  (A-D)  Macro scale valve deformation at varying 
stretch ratios (λ) viewed at 10X under confocal microscopy (Green: 5-DTAF stained matrix fibers, Red: 
vital dye labeled cell bodies).  Stars denote centroid location of the cantilever posts.  (E-H)  Micro-scale 
cellular deformation of the same group of cells viewed during the same test at 40X under confocal 
microscopy.  Arrows denote tracked morphology of individual cells. (I-L) Micro-scale fiber alignment from 
the same region viewed during the same test at 40X under confocal microscopy.  Fiber un-crimping and 
alignment is clearly visible as stretch progresses left to right. 
 
Biomechanically, anterior leaflets at each age exhibited nonlinear elastic material responses 
(Figure 5.7A).  Valve leaflets significantly increased in stiffness with maturation (effective 
modulus of 1.04 ± 0.24MPa at 2 weeks to 2.88 ± 0.27MPa at 4 months, P<0.05), after which 
stiffness was maintained for the next 6 months of life (2.58 ± 0.28MPa at 10 months, not 
different from 4 months) (Figure 5.7B).  Quantification of local cell deformation revealed a linear 
reduction in circularity index (CI) with stretch (Figure 5.7C).  The slope of CI became 
increasingly negative over maturation (-0.11 ± 0.03 at 2 weeks to -0.32 ± 0.05 at 4 months, 
P<0.05), but leveled off at 10 months (-0.28 ± 0.4) (Figure 5.7 D).  From these data, we were 
able to visualize a correlation between the effective tissue modulus and slope of CI, which 
suggests that cellular deformation increases with both stretch and tissue stiffness.  Similarly, 5-
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DTAF labeled extracellular matrix fibers aligned linearly with stretch, and the degree of 
alignment significantly increased with tissue maturation (Figure 5.7E).  The slope of fiber 
alignment (FA) index increased from 0.46 ± 0.12 at 2 weeks to 0.93 ± 0.17 at 4 months 
(P<0.05).  In contrast to cell shape, FA slope decreased significantly at 10 months (0.58 ± 0.09), 
which suggests that older valves have a reduced capacity for fiber reorientation with stretch, 
reminiscent of immature valves (Figure 5.7 F).  Taken together, these results suggest that valve 
tissue microstructure is similarly sensitive to changes in deformation even at low strain and high 
stiffness zones.   
 
 
Figure 5.7 – Temporal biomechanical analysis of C57/B6J mitral valves.  (A)  Representative stress-
strain curves of mitral valves loaded in the circumferential direction (not to failure).  (B)  Stress-strain data 
were fit to an exponential Fung model, from which coefficients were used to determine effective modulus.  
(C)  Representative circularity index curves as defined by the ratio of 4*Pi*(Area/Perimeter
2
).  (D)  
Circularity-index curves were modeled as a linear fit and the negative slope was used for comparison.  (E)  
Representative fiber-alignment curves were defined by the Fourier-Transform of collagen alignment and 
summed within ten degrees of the image horizontal, which was parallel to the tissue and loading direction.  
(F)  Fiber-alignment data were fit to a linear model, the negative slope of which was used for comparison. 
Error bars show ±SD, n ≥ 6 for each condition.  Groups that do not share letters are significantly different 
from each other according to a one-way ANOVA with Tukey’s post hoc (p ≤ 0.05). 
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5.4.2: Age dependent changes in anterior mitral valve leaflet extracellular matrix 
composition in wild-type C57BL/6J mice.  Noticeable changes in structural organization 
occurred in mitral valves with age.  2-3 week old mitral leaflets contained equal proportions of 
collagens and GAGs, with more collagen located near the annular attachment region (Figure 
5.8A-B).  At 4 months, valves were significantly more compacted in both the annular attachment 
and mid-zone regions (Figure 5.8C).  At 10-12 months, valves became thicker, more irregular in 
cross-section, and a larger disorganization of GAG/collagen architecture near the annulus 
region (Figure 5.8D). The fractional ratio of collagen to GAG increased from 2 weeks to 4 
months (1.14 ± 0.78 to 2.94 ± 0.88, P<0.05), then tapered off in older valves (1.94 ± 0.89) 
(Figure 5.8E).  Taken together, these results suggest that mitral valve tissue biomechanics was 
related to the fractional ratio of collagen to GAGs.   
 
 
Figure 5.8 – Temporal histological examination of C57/B6J mitral valves.  (A)  2 week old murine 
mitral valves contain similar fractional amounts of collagen and GAGs, with the majority of collagen near 
the attachment zones but mostly undefined architecture (Movat’s stain: yellow/orange = collagen, 
green/blue = GAGs).  (B) More collagen relative to GAGs is present in 3 week old MV, with matrix 
stratification developing (Arrows).  (C)  At 4 months, murine mitral valves have nearly 3 times the amount 
of collagen to GAGs, are significantly more compact, and have well defined atrialis/fibrosa strata (Arrows). 
(D)  At 12 months, murine mitral valves have significantly less collagen to GAGs, with dramatically 
increased thickening and reduced structural organization.  (E) Digital quantification of matrix composition 
using color thresholding.  Data compared as the ratio of collagen to GAGs within each valve leaflet.  
Magnification, ×4. Scale bars: 200 μm.   Error bars show ±SD, n ≥ 3 valves per time point.  Bars that do 
not share any letters are significantly different according to a one-way ANOVA with Tukey’s post hoc (p ≤ 
0.05). 
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5.4.3: Increased compliance of C1039G/+Fbn1 mitral valves and its relationship to tissue 
microstructure. Transported +/+Fbn1 and C1039G/+Fbn1 valves had over 90% viability upon 
arrival, similar to valves excised and assessed without transportation.  As anticipated, 4 month 
old +/+Fbn1 valves responded nonlinearly when stretched, with an effective modulus that was 
not significantly different from those of our locally-housed mouse valves (2.51 ± 0.31MPa).  
C1039G/+Fbn1 valves, in contrast, had significantly reduced moduli (1.34 ± 0.12MPa, P<0.05) 
(Figure 5.9A-B).  At the microstructural level, we found a reduction in the negative slope of 
circularity index with C1039G/+Fbn1 mice relative to +/+Fbn1 (-0.23 ± 0.04 vs. -0.34 ± 0.04, P<0.05) 
(Figure 5.9C-D), suggesting that the fibrillin-1 mutation impairs local cell sensitivity to tissue 
stretch.   
 
 
 
 
Figure 5.9 – Biomechanical analysis of 
+/+
Fbn1 and 
C1039G/+
Fbn1 at 4 months.  (A)  Representative 
stress-strain responses of mitral valves loaded in the circumferential direction.  (B)  Stress-strain data 
were fit to an exponential Fung model, coefficients of which were used to determine effective modulus.  
(C)  Representative stretch induced cell shape changes responses defined by the circularity index (CI) = 
4*Pi*(Area/Perimeter
2
).  (D)  Circularity-index data were modeled as a linear fit, the negative slope of 
which was used for comparison.  Error bars show ±SD, n ≥ 6 valves per condition.   Asterisks signify 
statistical differences according to a Student’s t-test (p ≤ 0.05). 
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Likewise, fiber alignment with stretch is reduced in C1039G/+Fbn1 mitral valves in comparison to 
wildtype (0.36 ± 0.08 vs. 0.85 ± 0.12, P<0.05) (Figure 5.10).  This suggests that matrix fiber 
reorganization with stretch is also impaired in mitral valves of C1039G/+Fbn1 mice, which may 
explain in part their reduced global tissue stiffness.   
 
`  
Figure 5.10 – Fiber alignment analysis of 
+/+
Fbn1 and 
C1039G/+
Fbn1 at 4 months.  (A)  Representative 
fiber-alignment curve as defined by the Fourier-Transform. (B)  Fiber-alignment curves were modeled as 
a linear fit and the negative slope was used for comparison. Error bars show ±SD, n ≥ 6.  Asterisks signify 
statistical differences according to a Student’s t-test (p ≤ 0.05). 
 
5.4.4: Fractional composition of the extracellular matrix components in the C1039G/+Fbn1 
mitral valves.  The fraction of connective tissue was found significantly less in the C1039G/+Fbn1 
(0.51 ± 0.18) compared to the +/+Fbn1 leaflets (1 ± 0.28, P<0.05) (Figure 5.11A-C).  Less 
compacted collagen was present at the attachment zone, but extensive GAGs were present 
throughout the leaflet with a noticeable reduction in the fibrosa layer.  The collagen to GAG 
fractional ratio was significantly less in the C1039G/+Fbn1 (0.44 ± 0.26) compared to the +/+Fbn1 
(2.94 ± 0.84, P<0.05) (Figure 5.11D-F).  In contrast to the layer specific elastin present in 
wildtype valves, mutant valves contained significantly less fraction of elastin (0.75 ± 0.17 for 
C1039G/+ compared to 1 ± 0.07 for wildtype, P<0.05), which was less organized throughout the 
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leaflet (Figure 5.11G-I).  Collectively, these results indicate that decreased stiffness with Fbn1 
mutation correlates with a reduction in the amount of connective tissue fraction, elastin fraction, 
and collagen/GAG fractional ratio. 
 
 
Figure 5.11 – Differences between 
+/+
Fbn1 and 
C1039G/+
Fbn1 mitral valve matrix composition at 4 
months.  (A-B)  Masson’s Trichrome reveals a reduction in the fractional amount of connective tissue in 
the marfan mitral valve compared to wildtype.  (C) Digital quantification of the connective tissue 
composition using color thresholding, with blue regions denoting connective tissue. (D-F)  Movat’s stain 
reveals over 3-fold reduction in the fractional amount of collagen compared to GAGs in the Marfan mitral 
valve relative to the wildtype (yellow-collagen, blue-GAGs).  (G-I) Verhoeff’s–van Gieson (VVG) stain 
reveals a significant reduction in the fractional amount of elastin in the Marfan mitral valve compared to 
the wildtype (purple/black-elastin).  Magnification, ×4. Scale bars: 200 μm.  Error bars show ±SD, n ≥ 3 
valves per condition.  Asterisks denote statistical differences according to a Student’s t-test (p ≤ 0.05). 
 
 
5.5: Discussion 
Myxomatous degeneration of the MV with consequent valve prolapse and dysfunction is a 
common phenotype, affecting 2-3% of individuals in the general population [3].  Over the last 
decade, murine models have been indispensible for understanding many of the functional 
consequences of mutations in fibrillin-1 [13,21,22].  The bulk of these studies have established 
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the critical contribution of fibrillin-1 deficiency to disease progression through altered cell–matrix 
interactions and dysregulated TGFβ signaling.  To further evaluate the global biomechanical 
and local cell-matrix relationships, we developed a novel method to evaluate mouse MV 
architecture during loaded conditions.  We found that in the Fbn1 mutant mice, the effective 
modulus was less, which was supported by our histological analysis revealing a reduction in the 
amount of connective tissue fraction, elastin fraction, and collagen/GAG fractional ratio.  
Interestingly, both valve deformation and fiber alignment were significantly reduced, suggesting 
that MV cell-matrix interactions become progressively more decoupled.  Quantitative differences 
between local cell or matrix deformations and global tissue stretch may be an important 
contributor to pathological tissue remodeling in valves, whether originated by aging, mechanical, 
or genetic mutation contexts.   
 
The ability to investigate the integration of mechanics and genetics in small animal models 
across multiple length scales represents a powerful tool for quantifying functional consequences 
of sub-lethal mutations.  Historically, this has been particularly challenging due to the difficulty 
with attaching small tissues (0.2mm-2mm), measuring force ranges (10µN-10mN), and imaging 
of underlying microarchitecture.  Pipette aspiration has been a classic approach for measuring 
the mechanical properties of small tissues.  Butcher et al. used this method to measure the 
nonlinear pseudoelastic biomechanics of developing chick atrioventricular cushions while, 
Krishnamurthy et al., used a similar approach to measure the measure regional mechanical 
properties of mouse aortic valve tissue [20,23].  Others have used micro-indentation testing 
systems to determine the compressive and biphasic mechanical properties of cartilage in the 
small joints of the mouse using glass fibers [24].  More sophisticated devices have been 
designed to take advantage of the cylindrical geometry of soft tissues, such as blood vessels.   
Small caliber (50–5000 µm) blood vessels mounted on cannulaes provide a substrate for well-
controlled mechanical loads and multiaxial mechanical tests [25].  While these approaches 
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provide tremendous information in small model tissue biomechanics, quantification of the 
underlying cell deformation is necessary for understanding the mechanobiological 
consequences of tissues at physiological levels.  To overcome these limitations, a novel 
stretching apparatus and gripping method was implemented to directly quantify both global 
tissue biomechanics and local cellular deformation and matrix fiber realignment in murine mitral 
valves.    
 
The clinical manifestation of the MV when it is affected in MFS involves redundant prolongation 
of one or both leaflets, often accompanied by myxomatous thickening [26].  MV prolapse and 
regurgitation also commonly occur in related conditions.  A retrospective review and ultrasound 
based comparison of MV morphology at the time of MV surgery in MFS and myxomatous non-
syndromic MV disease reported that individuals with MFS presented at an earlier age (41 vs. 57 
years, respectively), and that the anterior MV leaflet was longer in MFS than in non-syndromic 
MV disease (40 vs. 33 mm, respectively) [27].  As with many phenotypic characteristics of MFS, 
the presence and severity of MV prolapse, thickening, and regurgitation often vary within 
families segregating the same Fbn1 gene mutation [28,29].  In mice, MV leaflets heterozygous 
or homozygous for a Fbn1 mutation were also shown to be both longer and thicker than in wild-
type littermates, and these differences correlated with increased TGFβ signaling and increased 
production of collagen.  Adult heterozygous mutant mice were also shown to have MV prolapse 
by high-resolution echocardiography [13].  Furthermore, in sheep with displaced papillary 
muscles (commonly used to replicate MV regurgitation), assessment of total mitral leaflet area 
by 3-D echo was found to increase with stretch, and was 2.8 times thicker than normal [30].  
While further investigation is needed, these findings suggest that adaptive mechanisms within 
the MV are connected to the in-vivo physiological loads within the MV.  In the case of the Fbn1 
mutation, increased leaflet length/thickness, annulus diameter, and transvalvular pressure all 
130 
 
govern the stress distribution within the MV (tissue deformation), which potentially leads to valve 
remodeling and aberrant function.   
 
Recent studies have investigated both the in-vitro and in-vivo dynamic deformation of the MV.  It 
was found that the MV anterior leaflet experiences large anisotropic strains, approaching stretch 
ratios of 1.2 in the circumferential and 1.4 in the radial direction at physiological levels [31].  
Furthermore, their observations also suggest that changes in left ventricular pressure and 
annular geometry result in altered effective leaflet stiffness, which may be an important factor in 
reducing leaflet stress [32].  From our studies, the decreased compliance of Fbn1 MV implies 
they may be subjected to increased strain at the same transvalvular pressures.  However, we 
find that the interstitial cells within Fbn1 valves do not deform to the same degree at the same 
strain.  These two datasets suggest there may exist a balance between excess loading and 
altered mechanosensitivity that can initiate or exacerbate pathological cell remodeling.   If the 
known differences in growth factor expression, particularly TGFβ, is additionally factored in, 
clearly uncovering the mechanobiological mechanism of MV dysfunction in MFS remains a 
major challenge.  The additional mechanical tools generated from this study enable important 
new hypotheses and avenues of research in this direction. 
 
Our histochemical analysis also revealed a large abundance of GAGs, which was not 
unexpected as myxomatous valves have been shown to contain more GAGs and PGs than 
normal [8,33].  In MV excised from human patients, myxomatous leaflets were found to have 3% 
more water content and 30% higher GAG concentrations than  normal mitral leaflets, which are 
thought to influence the hydration-related "floppy" nature of these tissues [34].  Biomechanical 
testing of myxomatous valves have also been shown physically and mechanically different from 
normal MV leaflets in human patients such that they are more extensible and less stiff  [35].  
These findings align closely with our results, which suggest that the functional consequence of 
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valve thickening, reduced fiber alignment, and abnormal matrix deposition ultimately leads to a 
reduction in tissue stiffness.  Upon substantial remodeling, the functional consequence of MV 
leaflets can ultimately result in prolapse and regurgitation [36].  Although several studies have 
reported disparate prevalence of MV prolapse among individuals with MFS, the biomechanical 
remodeling within the MV is substantial [37].  We suspect the underlying mechanobiological 
regulation of VIC is a critical component for understanding the long-term biomechanical and 
pathological consequences of MV disease in MFS. 
 
Interestingly, at the cellular level, we found that both collagen fiber alignment and overall cellular 
deformation were significantly reduced in the Fbn1 mutant leaflets.  Although the underlying 
mechanism is currently unknown, cellular deformation has been shown dependent upon integrin 
binding and traction force generation.  Numerous studies have shown that the degree of traction 
force is proportional to substrate stiffness, via integrins [38].  Strengthening of focal adhesions is 
thought to dominate on stiffer substrates as compared to soft substrates [39].  Bax et al., 
reported an RGD sequence of fibrillin-1 that supports cellular adhesion in vitro via integrin αvβ3.  
Using human dermal fibroblasts, fibrillin-1 protein fragments induced signaling events that led to 
cell spreading, altered cytoskeletal organization, and enhanced extracellular fibrillin-1 deposition 
[40].  Mutations in integrin binding also result in a unique human phenotype called “stiff skin 
syndrome (SSS)”.   Cultured dermal fibroblasts from patients with SSS showed dysregu lated 
amounts activated (phosphorylated) focal adhesion kinase (pFAK) [41].  Therefore, the 
increased GAG content, disorganized extracellular matrix, and/or altered integrin motifs may 
regulate traction force generation, and hence the ability to deform during mechanical load.   
   
Few studies have investigated the mechano-regulation of VIC in response to altered pressure or 
strain.  VIC isolated in vitro and mechanically strained at 10%, 14%, and 20% have also been 
shown to upregulate collagen synthesis by an increase in [3H]-proline incorporation in a strain 
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dependent manner [42].  Hence, collagen synthesis by VICs is dependent upon the degree and 
duration of stretch.  Furthermore, when pulmonary VICs were exposed to aortic pressure levels, 
as occurs following the Ross operation, collagen and sulfated glycosaminoglycan synthesis 
were increased significantly [43]. This demonstrates that VICs are capable of remodeling the 
ECM in response to changes in strain magnitude and/or the stress state of the tissue.  
Comparing our findings between age and Fbn1 mutation, we find a strong similarity between 
altered local cell-matrix kinematics and changes in matrix composition.  Interestingly, leaflet 
thickness, blood pressure, and MV annulus were also correlated [15,44,45].  This suggests that 
elevated blood pressure magnitudes (age dependent) and/or altered valve stress states may 
dictate the mechano-biological response, possibly through regulating ECM composition and 
hence, overall cellular deformation.   
 
Taken together, an important question previously unidentified and revealed by this study is 
whether these alterations in local cell-matrix interactions with stretch are a cause or 
consequence of valve tissue remodeling.  Three possible hypotheses into the mechanical 
etiologies of MFS valve dysfunction include 1) the interstitial cells experience a reduced 
mechanical force distribution in Fbn1 mutant vs. wild-type tissue, 2) cells in both cases 
experience the same loads but, the Fbn1 mutant interstitial cell is unable to sense it correctly 
(e.g. its mechanotransduction processes are tuned improperly), or 3) both cells sense the same 
loads but the Fbn1 mutant cells can’t respond appropriately, pathologically remodeling the 
matrix instead of augmenting/maintaining its mature organization.  Studies have shown that 
cytokines and growth factor signaling is altered in Fbn1 mutant valves, but it is yet unclear 
whether they are genetically prescribed or the consequence of the altered mechanobiological 
signaling (i.e. integrin binding or expression).  Further investigation systematically testing these 
different hypotheses is ongoing.  
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Our results provide a framework to explore a fibrillin-1 mutation leading to abnormal 
biomechanics/mechanobiology and clinical manifestations in MFS associated MV disease.  The 
most novel and unexpected finding is that not only are extracellular matrix components altered, 
but the response of VIC to stress is also changed, so that cells effectively sense less stretch in 
MFS during normal physiological loads.  This decoupling of local cell and matrix kinematics from 
global valve tissue stretch may have direct implications in the ability of VIC to maintain normal 
homeostatic cellular deformation.  Pathological changes in MV matrix composition and 
organization ensue, which in turn weakens the tissue.  These results support the potential for 
matrix stabilization techniques such as collagen crosslinking or radiofrequency ablation for 
maintaining mechanical performance and cell mechanobiology, and thereby delay pathological 
remodeling [46].   
 
The mouse MV is an extremely thin piece of tissue, with an average thickness in the mid region 
of ≈ 30-40µm (4-5 cells thick), compared to the ≈ 500-700µm thick human MV [47].  We 
therefore used confocal z-stacks to capture both collagen fibers and cells across the entire 
thickness.  With this method, we found that collagen fiber alignment and un-crimping occurred 
simultaneously across the valve, but potential thickness dependent inhomogeneities were not 
addressable.  We also measured the circularity index (CI) of cells rather than nuclear aspect 
ratios (NAR).  While CI is representative of cell morphology, cells were well spread in almost all 
cases, potentially limiting our sensitivity to deformation.  However, using the change in CI, we 
were able to ascertain significant differences in local cell behavior in association with both age 
and Fbn1 genotype. 
 
In conclusion, degenerative biomechanical remodeling of the MV is a key component of Marfan 
syndrome.  Through quantifying global biomechanical and local cell-matrix relationships in Fbn1 
mutant murine mitral valves, we found that local cell and matrix kinematics are decoupled to 
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different degrees correlating with magnitude of global valve tissue stretch.  Changes in local 
cell-matrix deformation relationships may be an important metric for determining mechanisms of 
normal and pathological tissue remodeling in valves, as in aging or genetic mutation.
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CHAPTER 6 
 
HIERARCHICAL APPROACHES FOR SYSTEMS MODELING DURING CARDIAC 
DEVELOPMENT 
 
 
6.1: Summary 
Ordered cardiac morphogenesis and function is essential for all vertebrate life.  The heart 
begins as a simple contractile tube, but quickly grows and morphs into a multi-chambered 
pumping organ, complete with valves, while maintaining regulation of blood flow and nutrient 
distribution.  Though not identical, cardiac morphogenesis shares many molecular and 
morphological processes across vertebrate species.  Quantitative data across multiple time and 
length scales have been gathered through decades of reductionist single variable analyses.  
These range from detailed molecular signaling pathways at the cellular levels to cardiac function 
at the tissue/organ levels.  However, none of these components act in true isolation from others, 
and each in turn exhibits short and long-range effects in both time and space.  Genetic 
expression networks may not just be shifted by the absence of a gene, but an entire signaling 
cascade left “on” or “off” depending on the condition.  Also taking into account local 
microenvironmental changes throughout development, it is apparent that a systems level 
approach is an essential resource to accelerate information generation concerning the 
functional relationships across multiple length scales (molecular data vs. physiological function) 
and structural development.  In this review, we discuss relevant in vivo and in vitro experimental 
approaches, compare different computational frameworks for systems modeling, and discuss 
the latest information about systems modeling of cardiac development.  Lastly, we conclude 
with some important future directions for cardiac systems modeling.    
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6.2: Background  
The first definitive organ to form in the embryo is the heart, whose morphogenesis, growth, and 
integrated function are essential to embryonic survival.  The embryonic heart begins as a 
spontaneously contractile tube with an outer muscular (myocardial) layer and an inner 
endothelial (endocardial) layer.  Myocardial and endocardial progenitor cells arise from bilateral 
populations of mesodermal cells close to the midbrain–hindbrain boundary [1]. Shortly before 
circulation is established, these mesodermal cells migrate medially to form a linear heart tube. 
This simple tube then undergoes complex morphogenetic movements that lead to the formation 
of a looped, multi-chambered organ complete with valves to regulate blood flow [2-4].  Though 
much research has highlighted roles of individual genes, the complex molecular networks that 
control this process are only beginning to be elucidated.  Recent evidence suggests that the 
cardiogenic transcriptome is dependent upon the combinatorial binding of “master” transcription 
factors Gata4, Mef2a, Nkx2.5, and Srf.  Together, these transcription factors have been targeted 
for regulation in over 1600 genes [5].  Only a small fraction of these genes have been 
investigated through the use of genetic mutant animal models, and filling this gap would 
consume significant time and resources Each mutation causes compensatory changes in 
signaling networks that may further confound understanding, especially in less pronounced 
phenotypes.  Genetic regulation is, however, only a fraction of the story.  Cells are highly 
sensitive to microenvironmental factors (e.g. physiological conditions such as oxygen content or 
pressure load) which affect molecular targets across multiple scales (e.g. transcript levels, 
protein modifications, histone interactions) which sometimes result in divergent effects [6, 7].  
Deciphering the complexity is even more challenging when considering how features change in 
time (across development) and space (region of the heart).  
 
140 
 
Systems biology implements a process to identify emergent static and dynamic properties to 
obtain, replicate, and predict biological phenomena.  The systems approach synthesizes 
experimental data into a computational model that not only simulates the previous data but can 
be used to predict previously untested interactions. These predictions in turn motivate further 
biological experiments; the results of which are used to then validate and improve the model [8, 
9].  First, one must identify the core architecture driving a cellular process.  A network is, 
technically speaking, a graph consisting of nodes connected by edges. In biological networks, 
nodes typically represent molecules like gene transcripts or proteins. Edges define the type of 
connection between nodes, e.g. interactions or relationships such as protein–protein 
interactions or transcription factor-DNA binding. Examples of biological networks are gene 
networks, transcription networks, protein–protein interaction networks, and metabolomic 
networks.  This architecture can be derived from a variety of sources, including primary 
literature and database websites.  Relationships describing the node interactions include purely 
empirical, statistical, or defined by continuous equations (e.g. reaction-diffusion).  Once the core 
architecture is in place, both high and low throughput, quantitative data from multiple single or 
small number factor, primary experiments are gathered.  The model is then trained against the 
primary data to determine preliminary coefficient subsets to mirror the data, such that the 
biological networks provide physiologically relevant information.  From the newly trained 
network, simulations can be conducted across possible parameter sets to prioritize and identify 
key regulatory nodes and recognize critical pathways through robustness analysis (Figure 
6A.1).  The predictions are then tested on follow-up biological experiments. These results can 
also be applied back to re-train the model to strengthen its specificity and predicative capacity. 
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Figure 6.1 – The objective of systems biology is to integrate low- and high-throughput data with predictive 
computer modeling to better understand the properties of networks and cell systems important to human 
health. To apply such an approach, one must identify the core architecture driving a cellular process 
through biological networks, gather both high and low throughput quantitative data from single factor 
experiments, train and validate the model for physiological relevance, and run simulations in order to 
prioritize wet experiments. 
 
 
Complex systems like the heart are composed of diverse elements constructed spatially and 
temporally in a hierarchical fashion [10].  Analyses of these multi-scale systems is likely most 
efficient by linking together different types of models that are ideal for particular scales.  It is 
impossible and impractical to model the organ and tissue levels in the same framework as at the 
molecular and cellular levels, because they are driven by completely different stimuli that result 
in different responses [11].  A systems approach is necessary to connect, inform, and predict 
the functional relationships that span these length scales (e.g. molecular data versus 
physiological function and structural development) [12].  A cardiac developmental systems 
model has the potential to accelerate the discovery of key regulatory aspects of heart 
development and predict testable hypotheses about cardiac function eventually motivating new 
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approaches for congenital malformations therapy.  Although the necessary framework capable 
of integrating such massive amounts of data is still in its infancy, recent systems approaches 
have shown promise for enabling the identification of critical signaling protein complexes and, 
moreover, for predicting tissue morphogenesis through multi-scale approaches.       
 
6.2.1: Computational resources for data integration and model implementation 
The progressive accumulation of enormous amounts of heterogeneous molecular response 
data has created a significant need to create databases that can organize, store, and rapidly 
retrieve pertinent information.  In this section we will discuss the organizational framework 
necessary to approach a systems level question: (1) integration of heterogeneous datasets from 
a wide spectrum of databases, (2) standardization of systems languages to facilitate data 
representation and interoperability, and (3) robust integrative software tools available for 
systems biology research. 
 
6.2.2: Availability of databases for integrating biological information  
The emergence of large-scale biological information has driven the development of global 
databases.  These databases are important for the future of systems biology, as they centralize 
quantitative and qualitative data, ranging from protein structures to signaling pathways.  
However, to fully take advantage of these databases (biological information in general), one 
would need to obtain repeatedly the information necessary to piece together the larger network, 
which is not at all practical [13, 14].  A comprehensive database which integrates not only “-
omics” datasets from experiments and literature, but also other information such as kinetic data 
and existing mathematical models is invaluable given the resources currently available to 
researchers [15-18].  There are many resources for integrated data analysis as reviewed by 
Joyce and Palsson [19, 20].  To name a few, HCNet [21], GEO database [22], and Cardiac 
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Integrated Database Management System (CIDMS) all contain information related to genetic 
regulation of heart development and function. 
 
6.2.3: Multi-scale standardization of system biology languages 
As previously mentioned, a major problem in systems biology is how to establish and maintain 
cohesion between data derived from multiple independent experiments using different cell 
sources with slightly different controls, doses, time-courses, and analysis methods.  Standards 
for the interpretation, handling, and dissemination of data should be given priority.  It is crucial 
that individual research groups be able to exchange their models and create publicly accessible 
data banks and software environments that function with a broad selection of tool sets.  There 
are many data exchange formats currently available to aid in the exchange of information such 
as MIAME for microarray experiments [23], PSI-MI for protein–protein interaction, BIOPAX for 
pathways, and MIRIAM for biochemical models [24]. SBML [25], CellML [26], and FieldML [27] 
are machine-readable formats and standard forms of information exchange between software 
tools that provide both spatially distinct qualitative and quantitative models of biochemical 
networks (Sauro and Bergmann 2008; Kohl 2011).  On the other hand, ontologies are well-
structured controlled platforms providing standard definitions and concepts, as they aid in 
facilitating semantic-level data integration.  Systems Biology Ontology (SBO) and Systems 
Biology Graphical Notation (SBGN) projects are also gaining popularity and have been initiated.  
For example, ontologies are important to define spatial domains at both the molecular and 
cellular levels (GO-MF-Gene Ontology Molecular Function, CBO-Cell behavior Ontology) while 
their function may be determined by the physics of biology and/or phenotype and traits (OPB-
Ontology of Physics for biology, PATO-Phenotype and Traits Ontology).  However, the XML 
based languages described above have been adopted as standards for representing biological 
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data despite the limitation in data interoperability.  There are multiple resources available that 
discuss the topics mentioned above in depth [28-30].   
 
6.2.4: Example approaches for multi-scale simulation of valvulogenesis 
Many examples illustrating a systematic approach could be taken from heart development, but 
for this purpose we will discuss heart valve morphogenesis, as it is a fundamentally important 
component of cardiac development and a process for which significant data exists 
characterizing the anatomical morphogenesis, microstructural remodeling, and molecular 
regulation [31] (Figure 6A.2).  Briefly, valvulogenesis initiates through a process called 
endocardial-to-mesenchymal transition (EMT) by which the endocardial lining in specific regions 
of the linear heart tube (in the atrioventricular canal and outflow tract segments) differentiate into 
a mesenchymal phenotype and invade into the gelatinous matrix underneath called the cardiac 
jelly.  EMT is characterized by loss of tight junctions, downregulation of cell-cell adhesive 
contacts (e.g. E-cadherin, PECAM1) upregulation of cell-matrix adhesions (integrins), and 
development of contractile cytoskeletal machinery [32]. Continued cellularization and expansion 
of these tissue regions creates apposing pairs of tissues dubbed “cushions” that act as primitive 
valves to maintain unidirectional blood flow[33] [34]. This cellular transformation of EMT has 
also been shown in other processes such as fibrosis and oncogenesis [35].   
 
The need for systems biology is becoming more apparent as the complexity of EMT (both 
spatial and temporal fashion) remains to be fully elucidated [36].  By applying a standardized 
strategy through XML based languages and systematic ontologies, centralization of ideas, 
resources, and strategies will be critical for continual advancement of predicting complex tissue 
formation such as valvulogenesis.  In Figure 6A.2 the different levels of spatial and temporal 
scales as they pertain to heart development and their associated modes of representation are 
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illustrated.  A signaling network within the cell may be represented using an ordinary differential 
equation (ODE) within a markup language, such as SBML, that enable the network to be 
interpreted by many different modeling platforms.  At the next level up, cell-cell interactions and 
their chemical signaling mechanisms can be represented by partial differential equations (PDEs) 
or Stochastic Petri Nets.  For larger cell networks at the growing tissue level, some form of 
agent based modeling (ABM) is likely to be used. When looking at the level of the developing 
heart and its structural components, a finite element (FE) approach or a multiphysics simulation 
can be used to understand the functional relationship between the different components of the 
heart from its walls, valves. and vessels.  
 
Figure 6.2 – Heart valve morphogenesis initiates through a process called epithelial-mesenchymal 
transition (EMT), in which endocardial cells loose cell-cell contacts (tight junctions), acquire cell-matrix 
adhesions, and undergo cytoskeleton rearrangement The modeling framework encompasses a wide 
range of spatial scales 10
-9
m (proteins) to 10
-3
m (the primitive heart tube), and temporal scales from 10
-6
s 
(molecular events) to 10
6
s (weeks of heart development).  Multiple XML languages (SBML, CellML, 
FieldML) and ontology’s are required for multi-scale modeling of this complex tissue formation during 
development.  Figure adapted from [37].  (PRO-Protein Ontology, ChEBI-Chemical Entities of Biological 
Interest, CL-Cell Type Ontology, FMA-Foundational Model of Anatomy, GO-CC-Gene Ontology Cellular 
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Component, GO-MF-Gene Ontology Molecular Function, CBO-Cell Behavior Ontology, OPB-Ontology of 
Physics for Biology, PATO-Phenotype and Trait Ontology, GO-BP-Gene Ontology Biological Process. 
 
 
 
6.2.5: Integrative software  
There are multiple software tools available to the research community used to facilitate 
integration of cardiac systems data.  The most useful programs (1) handle genome-size data 
sets, (2) integrate multiple data types obtained from systems measurements, (3) provide a way 
to map and model networks and pathways, and (4) contain a user friendly interface as well as 
visual display of both the data and models.  We focus on software tools that do not require the 
individual to have an extensive background in computer programming but still prove to be 
valuable resources for cell biologists.  Cytoscape, an open source bioinformatics computing 
environment, is used for integration, visualization, and query of biological networks [38, 39].  
NAViGaTOR, another open source network visualization package, is an alternative to 
Cytoscape and uses Open Graphics Library (openGL) to allow for quick generation of a model 
and for visualization of both 2D and 3D graphical views [40].  VisANT is a lightweight network 
visualization tool able to run as a browser-based applet or as a standalone Java program.  The 
name resolution feature of this tool maps all network nodes to gene names pairing the two 
proteins encoded by each gene simplifying the mapping feature; it is well designed with 
scalability concerns in mind [41].  Another open-source option is Pathway Assist.  The focus of 
this tool is an automated natural language processing-based information extraction system for 
protein-protein and gene-gene functional interactions.  Pathway Assist contains a built in 
database of protein interactions and cellular pathways [42].  CellDesigner is a structured 
diagram editor for drawing gene regulatory and biochemical networks stored in SBML for use in 
simulation packages [25, 43].  Through a graphical user interface, the dynamics of the network 
under defined input parameters can be observed [44].  Continuity 6 is a problem-solving 
environment for multi-scale modeling in bioengineering and physiology, especially cardiac 
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biomechanics, transport and electrophysiology, and it is distributed free for academic research 
[45]. 
 
6.2.6: Computational Modeling of Cardiac Development 
A particularly challenging aspect of understanding the development process of cardiac 
formation is the complexity of information at multiple spatial scales evolving in a dynamic 
manner; thus, a systems approach to understand the flow of information is critical.  As we move 
forward with cardiac model generation pertaining to cardiac development, there is considerable 
debate over the best strategy for biological simulation, whether it should be “bottom- up,” “top-
down” or some combination of the two [46, 47].  The consensus is that the approach be “middle-
out,” meaning that we start modeling at the level(s) at which there are rich biological data and 
then reach up and down to other levels [48].  In the case of the heart, we have benefited from 
the fact that multiple levels of quantitative data have been gathered ranging from detailed 
molecular signaling pathways at the cellular levels to complex 3D geometrical models of the 
whole organ [49, 50].  Connecting these structurally diverse and hierarchically spatial levels of 
interactions has been challenging.  We will now discuss current cardiac models involving 
molecular regulation of the cardiac transcriptome, morphogenesis, and function.     
 
6.2.7: Molecular Mechanisms Regulating the Cardiac Transcriptome 
 With the emergence of the human genome project and advancement of biotechniques, detailed 
signaling networks and systems models describing these networks have started to generate 
momentum.  Recently, a group sought to map the molecular patterns critical to cardiogenesis 
through interrogated gene expression in stem cells undergoing guided differentiation, while 
generating genomic paradigms responsible for confinement of pluripotency.  They found that 
examination of gene relationships revealed a non-stochastic network anchored by integrin, 
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WNT/β-catenin transforming growth factor β and vascular endothelial growth factor pathways, 
which were validated by manipulation of selected cascades that promoted or restrained 
cardiogenic yield.  Moreover, candidate genes within anchor pathways acted as nodes that 
organized correlated expression profiles into functional clusters which collectively orchestrated 
and secured an overall cardiogenic theme [51].  
 
Underlying these signaling pathways, a combination of key transcription factors was found to 
drive a wide range of gene expression essential for cardiac development [17, 52].  Using a 
custom Chip-chip analysis (promoter and enhancer sequenc) and cardiac myocte mRNA 
expression levels, it was found that the combinatorial contribution of Gata4, Mef2a, Nkx2.5, and 
Srf transcription factors was responsible for regulating the cardiac transcriptome.  Specifically, 
the 91 target genes were bound by all four factors, 121 target genes were bound by three and 
286 target genes were bound by two transcription factors, all targeting over 1600 genes.  
Surprisingly, Gata4 and Nkx2.5 had the lowest number of targets (345 for Gata4, 276 for 
Nkx2.5), but it was found that their co-binding to 143 genes made each transcription factor 
highly correlated [5] (Figure 6A.3).   
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Figure 6.3 – Transcription factor network showing a selection of cardiac relevant genes (nkx 2.5, srf, 
gata4, mef2a) bound in ChIP-chip and/or ChIP-seq, and significantly differentially expressed in RNAi 
knockdown experiments of the respective factor. Up- and downregulation of genes is depicted and 
occurrence of ChIP binding marked by color-coded circles.  Figure taken from [5]. 
 
 
Furthermore, histone modifications and microRNAs modulate the underlying functional 
consequence of these cardiac transcription factors.  Histone-3 acetylation was found to have a 
strong correlation with Srf- and Gata4- dependent gene activation.  Moreover, upon Srf 
knockdown, a large proportion of targets were found to regulate microRNAs (potentially explains 
up to 45% of indirect mRNA targets), which thus might represent an important intermediate 
layer of regulation. [5].  Interestingly, it was found that even these non-paralogous transcription 
factors can partially compensate each other’s function, as shown through RNAi knockdown 
experiments.  In addition, enzymatic complexes such as the Swi/Snf-like BAF complexes 
remodel chromatin to allow the transcriptional machinery access to heart-specific enhancers 
[53].  Through experimental observations, it was revealed that dynamic randomness of 
SWI/SNF occurs in the cis chromatin remodeling process.  By applying a stochastic model, a 
150 
 
recent group identified the physiological properties of the chromatin remodeling process through 
a system of parametric microevents.  Their simulations showed that SWI/SNF chromatin 
remodeling has low energy efficiency suggesting that the orchestrated chromatin remodeling 
makes few kilobase-pairs of the DNA accessible to the transcription machinery in a timely 
manner [54]. 
 
6.2.8: Cardiac Signaling Networks and Morphological Changes 
Connecting these underlying molecular networks driving cardiac tissue morphogenesis is 
important for understanding aberrations, which underlie a wide spectrum of human disorders 
including congenital cardiac defects.  A recent study sought to connect model human heart 
morphogenesis through dissecting the underlying functional signaling pathway.  Using detailed 
phenotype information from deleterious mutations in 255 genes with high-confidence 
experimental interactome data, systematic analysis of spatio-temporal protein networks driving 
cardiac development were revealed.  A striking temporal correlation between organ complexity 
and the number of discrete functional modules coordinating morphogenesis was found (Figure 
6A.4).  For example, abnormal myocardial trabeculae formation was found dependent upon 
core networks within the NOTCH, Focal Adhesion, and ERBB signaling pathways, while 
abnormal valve formation was found dependent upon core pathways within the ERBB, Retinoic 
Acid, and Neurotrophin signaling pathways. [55].   
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Figure 6.4 – Examples of four functional networks driving the development of different anatomical 
structures in the human heart. These four networks were constructed by analyzing the interaction 
patterns of four different sets of cardiac development (CD) proteins corresponding to the morphological 
groups ‘atrial septal defects,’ ‘abnormal atrioventricular valve morphology,’ ‘abnormal myocardial 
trabeculae morphology,’ and ‘abnormal outflow tract development’.  Centrally in the figure is a 
haematoxylin-eosin stained frontal section of the heart from a 37-day human embryo, where tissues 
affected by the four networks are marked.  Figure taken from [55]. 
 
 
A follow up study by Lage et al. explored the relationships between congenital heart disease 
(CHD) risk factors and responses using datasets from similar studies of CHD in humans and 
model organisms. They found that CHD risk factors functionally converge in protein networks 
driving the development of specific anatomical structures (e.g., outflow tract, ventricular septum, 
and atrial septum) which are malformed by CHD. This integrative analysis of CHD risk factors 
and responses suggests a complex pattern of functional interactions between genomic variation 
and environmental exposures that modulate critical biological systems during heart 
development [56]. 
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Interestingly, recapitulation of these critical signaling pathways were shown when murine 
embryos were exposed to high glucose, a condition known to induce cardiovascular defects in 
both animal models and humans.  Through a mass spectrometry-based proteomics approach, 
critical protein clusters were found differentially expressed in embryos with defects from those 
with normal cardiovascular development.  These protein clusters were mapped to 
adhesion/migration, differentiation, and insulin signaling pathways while correlating with 
increased protein levels observed in the amniotic fluid of human foetuses with CHD [57].   
 
Toenjes and colleagues used a similar approach to precisely describe the variety of heart 
malformations observed in the patients using an integrative approach combining cardiac gene 
regulatory networks based on correlated gene expression and optimized prediction of 
transcription factor binding sites.  From this combined approach, they were able to find genes 
that appeared to be specifically associated with certain phenotypes such as TOF-1-3 (Tetrology 
of Fallot), TGA (transposition of great arteries), or VSD (ventricular septal defect) [58].   
 
6.2.9: Modeling Cardiac Function  
A large number of models for cardiac function have been based proper physio-chemical or 
and/or biophysical principles that emphasize different levels of structural organization.  Contrary 
to signaling networks, cellular networks use physical properties or rules that approximate 
individual cells into large scale combinations forming systems [15].  These models are 
computationally tractable and informative since predictability using intrinsic physical properties 
has proven reliable.  For example, dynamic gap junction models coupled with cardiac cell 
models have proven insightful such that Ca2+ transients affect gap junction conductance during 
action potential propagation leading to potential arrhythmias [59-61].  Likewise, dynamics in 
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heart trabeculae with changing heart frequency (mechanical load increases during 
development) was found to support the hypothesis that mitochondrial matrix Ca2+ plays an 
important role in matching energy supply with mechanical demand in cardiac myocytes [62].  
Other systems have focused solely on the mechanical environment leading to proper heart tube 
function and formation.  For example, heart tube formation is driven by cytoskeletal contraction, 
as exposure to the myosin-II inhibitor blebbistatin arrested any shortening and also decreased 
both tissue stiffness (measured by microindentation) and mechanical tension (measured by 
cutting experiments)  Finite element simulations complementing these experiments suggest that 
the endoderm (not the mesoderm) is the primary contractile tissue layer during this process [63].  
 
Modeling the whole heart typically use more of a continuum approach such that these models 
attempt to explain the integrated function in terms of ventricular anatomy, the structure and 
material properties of myocardial tissue, and/or associated intra-cellular and extracellular 
conductivities of the tissue [64].  With the development of anatomically detailed models of 
ventricular geometry and associated muscle fiber architecture, models have been developed to 
incorporate cardiac electrical impulse propagation [65].  For example, physiologically based 
mathematical models of the ventricular cell, together with a realistic three-dimensional computer 
model of cardiac anatomy, predicted that dynamical instabilities remain a major cause of the 
wavebreak that drives fibrillation, even in an anatomically realistic heart [14].  Others have 
incorporated further model complexity by integrating continuum models of cardiac electrical 
impulse propagation and wall mechanics through finite element methods [66, 67].  These 
models have proven useful in understanding relationships between ventricular contraction and 
heart dilation, an important component of cardiac development [68]. 
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6.3: Limitations and Future Directions 
Cardiac development is inevitably multi-scalar and contains elements of a diverse nature 
constructed spatially in a hierarchical fashion.  To understand this process and the origins of 
congenital heart defects, an integrative approach is needed to connect a diverse range of 
biological information and computational frameworks within a spatial hierarchy.  However, some 
of the fundamental limitations with multi-scale analysis are biological uncertainties, lack of 
integrating the diverse modeling environments, and unimaginably large computational times [69, 
70].  To combat these limitations, most of the systems insight has been implemented through 
highly focused directed models such as cardiac transcriptome networks or protein-clusters 
correlating with tissue morphogenesis.  These have been extremely useful for understanding 
cardiac differentiation and connecting aberrant tissue morphogenesis to congenital heart defect.   
 
Modularity of conserved canonical biological frameworks may help bride these gaps [71].  
Having such units well defined provides for security in archiving, in model sharing and in ease of 
reproducibility and of selection in model construction. It also renders those units more 
accessible and independently modifiable.  We see such modularity approaches to combine 
functionally integrated cell systems models of cardiac metabolism, signal transduction, and 
excitation-contraction coupling interactions into multi-scale models of cardiac electromechanical 
interactions that include hierarchical structures (cells, tissue, organs) [72, 73]. 
 
Recently, a number of groups have already sought to undertake the challenging tasks of 
incorporating many of the above mentioned processes into multi-scale models [49, 67, 73].  
Through the generation of powerful software tools, integrating computational models for 
interpreting the functional or clinical significance is starting to be achieved.  Continuing on with 
this process, the need for open source web technologies and associated informatics 
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approaches (i.e. Continuity 6) are important for improvements in data sharing, integration, and 
mining.  This includes data representation (markup language, graphical), computational 
algorithms, and incorporating mechanical aspects such as FEA analyses packages.   
 
In whole, connecting the phenotype of cardiac formation with the underlying molecular 
regulation is a grand challenge.  Using both “top-down” and “bottom-up” approaches, insightful 
information regarding tissue morphogenesis and underlying transcription networks is being 
achieved [74].  As improvements within the field are made, investigations can begin to integrate 
the spatial hierarchy of cardiac development and to tackle difficult biological problems on 
unprecedented scales.  Hopefully, over time, we will fully understand the origins of genetic and 
environmental factors leading to the majority of CHD and devise strategies for novel therapeutic 
and, even more importantly, preventive approaches. 
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Chapter 7
Phenotypic heterogeneity in EMT is controlled by NFAT and phospho-Sp1
7.1: Summary
Identifying master molecular regulators of EMT is a key pursuit for their potential as diagnostic or
therapeutic targets. Though research has uncovered hundreds of genes that are involved in EMT,
almost all have been studied in isolation from one another. The ability to generate a large net-
work analysis of EMT has been suggested as an attractive approach due to the ability to rapidly
screen signaling networks. We formulated and analyzed a family of mechanistic models (1700
kinetic constants and 995 initial conditions) using a detailed molecular framework to describe the
induction of EMT through TGFβ isoforms. The models were trained and cross-validated to pre-
scribe biological significance using 41 different experimental data sets taken from literature from
DLD1 colon carcinoma, MDCKII, and A375 melanoma cell lines. To address parametric uncer-
tainty in ODE-based deterministic models, we implemented an ensemble approach using POET.
The ensemble of parameter sets allowed us to identify different operational paradigms within EMT
(sub-populations), which provide testable hypotheses into the possible transformational aspects of
cellular phenotype. After network analysis and experimental verification, our results suggest the
ability of both MCF10A and DLD1 to exhibit phenotypic heterogeneity based on the simultaneous
treatment of TGFβ2 and VEGFA. Underlying this heterogeneous phenotype, master regulatory
complexes were found to include both the NFAT and phospho-Sp1 transcription factors. Lastly, we
found that the extent of ductal branch formation during acini formation was dependent upon phe-
notype heterogeneity in MCF10A. Together, these results establish a predictive mechanistic model
of EMT susceptibility, and reveal a novel signaling axis between phospho-Sp1/NFAT for possibly
regulating carcinoma progression through an EMT vs. tubulogenesis response.
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7.2: Introduction
The molecular networks orchestrating the epithelial to mesenchymal transition (EMT) remain an
important area of investigation. Much promise has been focused on developing diagnostic or
therapeutic agents in hopes of controlling epithelial differentiation during pathological conditions
(1). Decades of work employing a reductionist approach has identified critical signaling pathways
controlling EMT, including MAPK, Smad, Wnt, and NFAT (2). Each of these pathways are respon-
sive to multiple ligands and display a high degree of cross-talk (3). For example, VEGF is critical
for tumor progression through angiogenesis, while TGFβ has both protective and transformative
roles, depending on the extent of disease progression (4, 5). However, the convergence of these
multiple signaling components to promote or inhibit phenotypic consequences during EMT is not
well understood. This is largely true because directly testing hundreds of variables is intractable
with a reductionist approach. On the other hand, a systems analysis of EMT is attractive because
of the ability to rapidly simulate virtual experiments involving a myriad of biological perturbations,
including those for which relevant reagents are not available (6).
Previous computational models investigating EMT signaling components have focused on the
effects of a single biological factor and/or simulations within a single cell. For example, Chung
et al., constructed an ordinary differential equation model using mass-action kinetics to investi-
gate the mechanisms associated with TGFβ receptor activation and Smad signaling. Their model
suggested that a reduction of functional TGFβ receptors in cancer cells may lead to attenuated
and delayed signaling responses via Smad2 (7). Similar work by Vilar et al. suggested that spe-
cific changes in receptor trafficking patterns can lead to phenotypes that favor tumor progression
(8). Although these models have provided useful information about receptor dynamics, complex
signaling networks like EMT contain interactions at other levels, including competing second mes-
sengers and transcriptional regulators. Furthermore, because these reactions occur with varying
initial conditions and unknown parameter values, significant differences may exist in the overall
response of the model. In order to address these additional levels of uncertainty, recent compu-
tational algorithms and statistical approaches have been developed for application of large scale
ODE modeling (9, 10).
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The objective of this study was to determine the extent of EMT in normal epithelial cells ex-
posed to pathological conditions by (1) implementing and subsequently interrogating a population
based model containing canonical EMT regulatory networks, and (2) verify our mechanistic tar-
gets using established cell lines with differing induction capacities for EMT. Toward this objective,
we modeled the core molecular interactions of EMT using mass-action kinetics within an ordinary
differential equation (ODE) framework. A population approach was used to estimate a family or
ensemble of EMT models that was consistent with the previous literature (11, 12). Using the newly
predicted operational paradigms, we sought to capture the role of phospho-Sp1 and NFAT on phe-
notype heterogeneity during TGFβ induced EMT in vitro via key marker expression profiles and
fate processes.
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7.3: Materials and Methods
7.3.1: Formulation and Analyses of the Model. The EMT model was formulated as a set of
coupled non-linear ordinary differential equations (ODEs). Equations were generated using UNI-
VERSAL from an SBML input file (available in the supplemental materials). UNIVERSAL is an
open source Objective-C/Java code generator, available at Google Code (http://code.google.com
/p/universal-code-generator). The model equations were solved using the LSODE routine in OC-
TAVE (v 3.0.5; www.octave.org) on an Apple workstation (Apple, Cupertino, CA; OS X v10.6.4) as
previously described (13). The model has 1756 unknown parameters (1700 kinetic constants and
56 non-zero initial conditions) which were not uniquely identifiable given the training data. Instead
of identifying a single best fit model, we estimated a population of likely models (each consistent
with the training data) using 41 data sets generated in DLD1 colon carcinoma, MDCKII, and A375
melanoma cells taken from Medici et al. (12). We used the Pareto Optimal Ensemble Technique
(POET) multiobjective optimization framework in combination with leave-one-out cross-validation
to estimate an ensemble (9). Robustness coefficients were calculated as shown previously (13).
Extended methods are included in appendix D.
7.3.2: Cell Culture DLD1 colon carcinoma, MCF10A, and HUVEC were acquired from the
American Tissue Culture Collection (Manassas, VA). Cells were grown in culture with RPMI 1640
medium with 10% fetal bovine serum and 1% penicillin/streptomycin for DLD1, EBM-2 supple-
mented with EGM-2, 5% fetal bovine serum, and 1% penicillin/streptomycin for HUVEC, or MGEM
2 supplemented with insulin, bovine pituitary extract, cholera toxin, hEGF, hydrocortisone, 5%
horse serum, and 1% penicillin/streptomycin for MCF10A. Cells were serum starved for 24 hours
and removed from all experimental conditions. Recombinant VEGFA165 was also removed from
culture medium prior to experimentation. Recombinant human TGFβ2 (R & D Systems, Min-
neapolis, MN) was added to the culture medium at a concentration of 10 ng/ml and recombinant
VEGFA165 at a concentration of (5ng/ml, 50ng/ml) for all relative experiments. NFAT inhibitor
(VIVIT peptide) (EMDBiosciences, Darmstadt, Germany), was added to the culture medium at a
concentration of 10µM for all relative experiments. Cells were passaged 1:3 or 1:4 every 3-6 d and
used between passages 4 and 8.
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7.3.3: RT-PCR RNA extractions were performed using a Qiagen total RNA purification kit (Qia-
gen, Valencia, CA) and RNA was reverse transcribed to cDNA using the SuperScript III RT-PCR kit
with oligo(dT) primer (Invitrogen). Sufficient quality RNA was determined by an absorbance ratio
A260/A280 of 1.8-2.1, while the quantity of RNA was determined by measuring the absorbance at
260nm (A260). Real-time PCR experiments were conducted using the SYBR Green PCR system
(Biorad, Hercules, CA) on a Biorad CFX96 cycler, with 40 cycles per sample. Cycling temperatures
were as follows: denaturing, 95C; annealing, 60C; and extension, 70C. Primers were designed to
detect GAPDH, ecadherin, vimentin, Slug, Sp1, and NFATc1 in cDNA clones: Sp1 (F-TTG AAA
AAG GAG TTG GTG GC, R-TGC TGG TTC TGT AAG TTG GG, Accession NG030361.1), NFATc1
(F-GCA TCA CAG GGA AGA CCG TGT C, R-GAA GTT CAA TGT CGG AGT TTC TGA G, Acces-
sion NG029226.1). GAPDH, ecadherin, vimentin, and Slug primers were taken from previously
published literature (Medici et al.) (12).
7.3.4: Antibody Staining Samples were fixed in 4% PFA overnight at 4C. Samples were then
washed for 15 minutes on a rocker 3 times with PBS, permeabilized with 0.2% Triton-X 100 (VWR
International, Radnor, PA) for 10 minutes, and washed another 3 times with PBS. Samples were
incubated overnight at 4C in a 1% BSA (Rockland Immunochemicals, Inc., Gilbertsville, PA) block-
ing solution followed by another 4C overnight incubation with either rabbit anti-human ecadherin
1:100 (Abcam, ab53033), mouse anti-human phospho-Sp1 1:100 (Abcam, ab37707), mouse anti-
human vimentin 1:100 (Invitrogen, V9), and rabbit anti-human NFATc1 (Santa Cruz, sc-7294)
1:100. After 3 washes for 15 minutes with PBS, samples were exposed to Alexa Fluor 488 or 568
conjugated (Invitrogen), species specific secondary antibodies at 1:100 in 1% BSA for 2 hours at
room temperature. Three more washes with PBS for 15 minutes were followed by incubation with
either DRAQ5 far red nuclear stain (Enzo Life Sciences, Plymouth Meeting, PA) at 1:1000.
7.3.5: FACS Flow cytometry for ecadherin 1:100 (Abcam) and vimentin 1:100 expressing cells
was performed. Briefly, cells were trypsinized, fixed with 4% PFA for 10 min and then preserved
in 50% methanol/PBS. Cells were kept in the -20C until antibody staining was preformed. Sam-
ples were divided into multiple aliquots in order to stain the proteins separately and compensate for
secondary antibody non-specific binding. Cells were incubated for 24 hr at 4 C in primary antibody
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diluted in either PBS (extracellular) or 0.2% saponin-PBS (intracellular). Cells were then washed
3 times with PBS and incubated with appropriate secondary antibodies and imaged using a Coul-
ter Epics XL-MCL Flow Cytometer (Coulter). All samples were compensated using appropriate
background subtraction and all samples were normalized using 7500 cells per flow condition.
7.3.6: Three-Dimensional Culture Assays For invasion/migration assays, cells were resus-
pended in culture media, and allowed to aggregate overnight in hanging drop culture (20µL;
20,000 cells). The spherical aggregates were placed on the surface of neutralized type I colla-
gen hydrogels (1.5mg/mL) and allowed to adhere for 2h before adding treatments. Cultures were
maintained for 72h, after which they were fixed in 4% PFA and slowly rehydrated using PBS. For
compaction assays, cells were pelleted via centrifugation and resuspended within a neutralized
collagen hydrogel (1.5mg/mL) solution at a density of 400,000 cells/mL. 250µL of gel was inocu-
lated into culture wells, which solidified after 60min. Treatments were then added within 800µL of
the culture medium without serum. Gels were liberated from the surfaces of the culture wells the
next day and cultured free floating for an additional 3-7 days, exchanging serum free media with
appropriate factors every 48hr.
7.3.7: Statistics Results are expressed as mean ± standard error, n≥6. Data was analyzed
with the GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA) and
SAS (Statistical Analysis Software, Cary, NC). A one-way ANOVA with Tukey’s post hoc was used
to compare differences between means and data was transformed when necessary to obtain equal
sample variances. Differences between means were considered significant at p≺0.05.
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7.4 Results
Model connectivity re-creates core architecture within EMT. The EMT network connectivity
(proteins, mRNA, and genes) was assembled from literature and on-line databases: String-8 (14),
NetworKIN (15), and TRANSFAC (16). The model interactome contained over 1700 interactions
and was not specific to a single cell line. Rather, we assembled canonical pathways involved in
EMT signaling and defaulted to human connectivity when possible. Using a canonical network
allowed us to explore general features of TGFβ induced EMT without cell line specific artifacts
(Figure 7.1). Briefly, induction of EMT occurs through the binding of extracellular TGFβ1/2 with
TGFβ surface receptors I/II (TGFβR-I/II) to initiate the assembly of an adapter complex, beginning
the downstream signaling program. Central to this process, autocrine production of TGFβ3 binds
to the TGFβR-I/II followed by the recruitment of activin receptor-like kinase 1 (ALK5) and TGFβ
surface receptor III (TGFβR-III) to form the activated receptor complex (17). Complex assembly
activates the serine/threonine kinase intracellular domain, leading to the recruitment and phos-
phorylation of both MAPK (Ras-Raf-Mek-Erk) and Smad partners (18). Downstream of the TGFβ
signaling, nuclear pSmad2/3-Smad4 proteins form transcriptional complexes with several genes
in the model, including lymphoid enhancer-binding factor 1 (LEF-1), nuclear factor of activated T-
cells (NFAT), and specificity protein 1 (Sp1). Simultaneously, ERK1/2-mediated phosphorylation of
the AP1 and Sp1 transcription factors can also regulate transcriptional complexes involving NFAT,
Slug, and Smads. The VEGFA, BMP, Wnt, and PI3K pathways are also included in the model.
The full model connectivity and inital conditions as a datafile are located in Appendix D.
7.4.1: Model population quantitatively captured key features of TGFβ induced EMT sig-
naling. EMT signaling was modeled using mass-action kinetics within an ordinary differential
equation (ODE) framework. This formulation is a common method to model biological pathways
(19, 20). The EMT model had 1756 unknown parameters (1700 kinetic constants and 56 non-zero
initial conditions) which were not uniquely identifiable given the training data and organized into
well mixed sub-compartments. Instead of identifying a single best fit model, we estimated a popu-
lation of likely models (each consistent with the training data) by minimizing the difference between
simulations and 41 data sets generated in DLD1 colon carcinoma, MDCKII, and A375 melanoma
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Figure 7. 1: Model population quantitatively captures TGFβ-induced EMT signaling. (A-I) The population was gen-
erated using POETs and trained using 11 different objective functions (41 data sets) taken from Medici et al. (12).
The model was able to effectively capture the simulated experiments 78% of the time. (J-L) The model populations
were also compared against untrained temporal data to measure the effectiveness as a pure prediction. The high pre-
dictability can be contributed to the leave-one-out cross validation scheme, objective functions with overlapping data,
and multi-objective optimization algorithm.
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cells by Medici et al. (12) using the Pareto Optimal Ensemble Technique (POETs) (Fig. T2).
Additionally, we used POETs in combination with leave-one-out cross validation to independently
calculate training and prediction error as previously described (9, 13).
POETs generated an ensemble of models which captured the multiple phases of EMT induc-
tion. Stimulation with TGFβ2 (10 a.u.) induced Snail expression, while the MEK inhibitor (U0126)
blocked Snail expression by inhibiting AP1 activation. Similar results were obtained for Slug con-
firming initial activation through the MAPK pathway. Over-expression of Snail or Slug in the ab-
sence of ecadherin indirectly induced TGFβ3 expression through the β-catenin/TCF4 complex.
Conversely, over-expression of ecadherin inhibited the TGFβ3 autocrine production by sequester-
ing cytosolic β-catenin, thereby blocking EMT. TGFβ3 signaled through through the Smad pathway
to regulate LEF1 expression and downstream target EMT genes. TGFβ3 (10 a.u.) in combination
with downstream inhibitors (DN-Smad4 and DN-LEF1) completely inhibited vimentin expression,
while elevating ecadherin expression (Figure 7.2). Taken together, our model was able to quanti-
tatively capture the signaling network previously revealed by Medici et al. (12). A complete listing
of all data used for training (including statistics) are included in appdendix D (Fig. T3).
The predictive power of the model ensemble was also tested against non-trained EMT data
(11). Our model was able to capture the dynamic gene expression levels of ecadherin, pSmad2,
and LEF1 within one-standard deviation (up to the 48 hr time-point) (Figure 7.2). In whole, 78%
of our training objectives were statistically significant (at a 95% confidence interval) compared to
the randomized parameter sets generated from the best-fit nominal set (starting point for the opti-
mization). The high predictability can be attributed to the leave-one-out cross validation scheme,
diverse objective functions, and robustness of the POETs algorithm. Further discussion of the
POET residuals and prediction statistics are included in the supplement (Fig. T3).
7.4.2: Simulated TGFβ2 induction revealed heterogeneity within themodel population through
NFAT and phospho-Sp1. After validating our model ensemble, we used robustness analysis to
generate falsifiable phenotypic predictions in response to different perturbations. Robustness co-
efficients with values > 1 (< 1) indicated a marker increased (decreased) compared to a base
168
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Figure 7. 2: Model population quantitatively captures TGFβ-induced EMT signaling. (A-I) The population was gen-
erated using POETs and trained using 11 different objective functions (41 data sets) taken from Medici et al. (12).
The model was able to effectively capture the simulated experiments 78% of the time. (J-L) The model populations
were also compared against untrained temporal data to measure the effectiveness as a pure prediction. The high pre-
dictability can be contributed to the leave-one-out cross validation scheme, objective functions with overlapping data,
and multi-objective optimization algorithm.
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state, while a value of 1 indicated approximately no change following a perturbation. Phenotypic
behavior of the entire 1091 parameter ensemble was interpreted using downstream markers vi-
mentin (mesenchymal) and ecadherin (epithelial) at 48 hrs as previously described (21).
Interestingly, POETs identified four subpopulations which responded differently to TGFβ2 in-
duction. Cells in subpopulation one (R1) had high levels of phospho-Sp1 was responsible for the
decreased ecadherin expression through Slug-mediated inhibition, and increased vimentin expres-
sion. In subpopulation two (R2), moderate levels of phospho-Sp1 (activated form) was responsible
for the increased vimentin expression. In subpopulation three (R3), elevated levels of phospho-
Sp1 and nuclear localization of NFAT (driven by AP1) were responsible for increased vimentin and
ecadherin expression. Lastly, in subpopulation four (R4) reduced levels of AP1, phospho-Sp1,
and NFAT (loss of ERK activity) were responsible for the lack of induction. In addition, by applying
flow analysis, we determined that these key transcription factors (phospho-Sp1 and NFAT) were
localized within the TGFβ2 and VEGFA pathways, respectively (Fig. S1). This lead use to hypoth-
esize that phospho-Sp1 and NFAT expression levels could be driven by VEGFA and/or TGFβ2
stimulation. Specifically, simultaneous VEGFA and TGFβ2 treatment would yield an atypical and
heterogeneous EMT response (similar to R3), at least in vitro (Figure 7.3).
7.4.3: Simulated TGFβ2 and VEGFA treatment recreated phenotype heterogeneity through
NFAT. To re-create the phentoype heterogeneity as found in region three (R3), we conducted
simulated treatments of TGFβ2 and/or VEGFA (as hypothesized above). Stimulation with VEGFA
(50 a.u.) maintained a population of epithelial (Q4-43.6%) compared to mesenchymal phenotype
(Q1-7.5%). Conversely, addition of TGFβ2 (10 a.u.) shifted the population from an epithelial
(Q4-5.5%) to mesenchymal (Q1-45.6%) phenotype. Interestingly, the combined effects of TGFβ2
and VEGFA were found to increase both ecadherin and vimentin levels (Q2-45.3%). To isolate
the effect of NFAT, NFAT dephosphorylation was inhibited across all conditions. NFAT inhibition
with TGFβ2 treatment resulted in a loss of all ecadherin positive sets (Q2-23.5%). Likewise,
NFAT inhibition with VEGFA treatment mitigated all ecadherin positive sets (Q2-19.1%). Lastly,
NFAT inhibition with TGFβ2 and VEGFA mitigated nearly all ecadherin expression, shifting the
population (Q2-27.3%) towards a mesenchymal phenotype (Q1-45.1%) (Figure 7.4).
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Figure 7. 3: TGFβ pertubation reveals phenotype heterogeneity within regional subpopulations of the model. Ro-
bustness coefficients were used to quantify the effect of initial condition perturbations after steady state across the
population of data sets. Coefficients with values > 1 (< 1) indicated a marker increased (decreased) compared to a
base state, while a value of 1 indicated approximately no change following a perturbation. Ecadherin and vimentin
robustness coefficients were used as phenotypic markers. (A) After TGFβ2 perturbation, we isolated 4 distinct pa-
rameter sets known to have phenotypically different behaviors. (B) Each region has been represented by a small
signaling network. From our analysis, we determined that the differences were a function of downstream transcription
factors (phospho-Sp1, and NFAT) within the TGFβ2 and VEGFA pathway, respectively. (C) We hypothesized that el-
evated phospho-Sp1 and NFAT levels could drive phenotype heterogeneity through simultaneous TGFβ2 and VEGFA
treatment, similar to region three (R3).
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We further quantified the protein levels using the raw values at 48 hrs for multiple targets
including ecadherin, vimentin, phospho-Sp1, nuclear NFAT, alpha-SMA, and Slug. Similar to our
robustness analysis, elevated ecadherin expression was dependent upon the addition of VEGFA,
while NFAT inhibition mitigated this effect. Taken together, high levels of phospho-Sp1 correlated
with vimentin expression, while NFAT was found critical for maintaining ecadherin expression,
although neither mutually exclusive.
7.4.4: Combined TGFβ2 and VEGFA treatment drives phenotypic heterogeneity in MCF10A
and DLD1. Our simulations (robustness analysis and combined perturbations) all support the
hypothesis that elevated expression levels of both NFAT and phospho-Sp1 is a master signaling
axis for driving EMT phenotype heterogeneity (positive ecadherin, positive vimentin). To vali-
date these results in vitro, we stimulated either quiescent epithelial/endothelial cells (MCFA10 and
HUVEC) or transformed epithelial cell lines (DLD1) with TGFβ2 and/or VEGFA. Treatment with
(10ng/ml) TGFβ2 increased Slug and vimentin, while ecadherin expression was inhibited at both
the gene and protein level at 48 hrs. Within DLD1, a similar response occurred, although vimentin
and ecadherin expression was more significant. Interestingly, HUVEC were not shown responsive
to EMT with TGFβ2 addition (Fig. S3). An increase in nuclear phospho-Sp1 during EMT induction
was also clearly evident, and quantified through nuclear co-localization (Figure 7.5). Morphologi-
cal changes were also verified, changing from a quiescent cobblestone structure to spread spindle
shaped. These results suggest TGFβ2 as a potent inducer of EMT and is cell type dependent.
Conversely, treatment with (50ng/ml) VEGFA increased both NFATc1 and ecadherin gene ex-
pression in MCF10A at both the gene and protein level at 48 hrs. In DLD1, a similar trend occurred
although the expression levels of NFATc1 and ecadherin was less significant. We also found that
NFATc1 nuclear localization significantly increased in both MCF10 and DLD1, while having no
effect on phospho-Sp1 levels (Figure 7.5). Hence, VEGFA is a potent inducer of NFAT activation.
Combining VEGFA (50ng/ml) with TGFβ2 (10ng/ml) treatment in MCF10A, ecadherin and vi-
mentin expression were significantly elevated at both the gene and protein level resulting in a
heterogeneous response. No change in Sp1 expression was observed, although NFATc1 expres-
172
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Figure 7. 4: Simulated TGFβ2 and VEGFA (known inducer of NFAT) combination re-creates phenotype heterogeneity
through NFAT and phospho-Sp1. Robustness coefficients were used to quantify the shift in population at 48 hr. (A-C)
Initial VEGFA (50 a.u.) treatment resulted in a popluation with enhanced epithelial (Q4) properties. This was contrary
to the addition of TGFβ2 (10 a.u.), which shifted the population towards a mesenchymal phenotype (Q1). Interestingly,
the combined effects of TGFβ2 and VEGFA was found to increase both ecadherin and vimentin levels, creating a het-
erogeneous population (Q2). (D-F) To isolate the effect of NFAT, we inhibited NFAT de-phosphorylation in combination
with VEGFA. This negated the increase in ecadherin expression and shifted the population towards a mesenchymal
phenotype (Q1,Q3). Likewise, combining NFAT inhibition with TGFβ mitigated all ecadherin expression (Q2) confirm-
ing their importance for population heterogeneity. Lastly, combination of TGFβ2, VEGFA, and NFAT inhibition nearly
mitigated all effects of VEGFA, shifting the heterogeneous population (Q2) towards a mesenchymal phenotype (Q1). In
whole, high levels of phospho-Sp1 correlated with vimentin expression, while NFAT was found largely responsible for
maintaining ecadherin expression, although neither mutually exclusive.
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sion was shown to increase. DLD1 underwent a similar response as NFATc1, Slug, and vimentin
all significantly increased, while maintaining ecadherin levels (Fig. S3). Nuclear co-localization
of both NFATc1 and phospho-Sp1 was also apparent, especially within the MCF10A (Figure 7.5).
Taken together, these results suggest that combined VEGFA and TGFβ2 treatment promote phe-
notype heterogeneity.
7.4.5: Ecadherin expression is dependent upon NFAT. To establish the role of NFAT during
EMT heterogeneity, we applied a VIVIT peptide to inhibit NFAT dephosphorylation (22). Treatment
with VEGFA (50ng/ml) and VIVIT (10µM) in MCF10A resulted in significantly reduced ecadherin
levels. However, treatment with TGFβ2 and VIVIT had little effect on EMT induction capacity. VIVIT
in combination with TGFβ2 and VEGFA resulted in almost complete inhibition of ecadherin, while
increasing Slug and vimenti nlevels. These findings were confirmed via immunofluorescence,
as NFAT was shown to inhibit ecadherin expression in all three cases (Figure 7.5). Nuclear co-
localization of NFAT in all three cases was mitigated (as expected), while phospho-Sp1 increased
in both TGFβ conditions (Fig. S4).
Quantitative flow cytometry confirmed these results. Control cells maintained high ecadherin
and low vimentin levels (Q1-99.5%). Comparable to our simulations, we found that upon TGFβ2
treatment, MCF10A cells shifted from an epithelial to mesenchymal phenotype (Q1-33.4%, Q4-
42.8%). Combined TGFβ2 and VEGFA treatment increased vimentin levels (Q1-42.1%, Q2-
52.3%), while positively effecting ecadherin levels (compared to TGFβ2 alone). NFAT was also
found critical for maintaining these ecadherin levels (Q1-37.3%, Q4-29.0%). Together, these re-
sults suggests that NFAT are critical for regulating ecadherin expression during phenotype hetero-
geneity in MCF10A, but to a lesser extent in DLD1 (Fig. S4).
7.4.6: Ductal branching during acini formation is dependent upon phenotype heterogeneity
in MCF10A. To determine the functional consequences of phenotype heterogeneity, we applied
previously developed 3D in-vitro models of invasion, migration, compaction, and tubulogenesis
(23). MCF10A and DLD1 were formed into spheroids overnight and explanted to a collagen gel
for 72 hours. Within MCF10A, TGFβ2 significantly enhanced invasive and compaction proper-
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Figure 7. 5: Simultaneous TGFβ2 and VEGFA treatment induced phenotype heterogeneity and is dependent upon
NFAT activity in-vitro. (A) In MCF10A, treatment with (10ng/ml) TGFβ2 increased Slug and vimentin, while ecadherin
expression was inhibited at both the gene and protein level at 48 hrs. Conversely, VEGFA alone increased both NFATc1
and ecadherin gene expression. Simultaneous TGFβ2 (10ng/ml) and VEGFA (50ng/ml) treatment increased Slug,
NFATc1, and vimentin expression, while also increasing ecadherin levels via qPCR. (B-C) Immunofluorescence con-
firmed these results and nuclear co-localization of both phospho-Sp1 and NFAT were found dependent upon TGFβ2
and VEGFA, respectively. (D) To isolate the effect of NFAT, treatment of VEGFA (50ng/ml) and VIVIT (10µM) reduced
ecadherin expression at 48hrs (control-dashed line). Similarly, combined TGFβ2, VEGFA and VIVIT treatment in-
creased Slug and vimentin expression, while inhibiting ecadherin levels via qPCR. (E) These findings were confirmed
via immunofluorescence as the VIVIT peptide inhibited ecadherin and nuclear localization of NFATc1 in all three cases.
(F) Quantitative flow cytometry also confirmed this trend. Similar experiments in DLD1 followed a similar trend (supple-
ment). Magnification, 40x. Scale bars: 50µm. C=Control, T=TGFβ2 , V=VEGFA, VI= NFAT inhibitor (VIVIT). Asterisks
signify statistical differences from each other according to a one-way ANOVA with Tukey’s post hoc (p≺0.05).
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ties, while VEGFA promoted migration. Mediating these effects, combined TGFβ2 and VEGFA
significantly increased migration, while limiting the compaction potential. NFAT was found to be
an important target of VEGFA, as the VIVIT peptide mitigated migration during VEGFA alone.
Likewise, VIVIT in combination with VEGFA and TGFβ2 significantly decreased migration, while
increasing invasion and compaction (Figure 7.6). DLD1 cells followed a similar trend to MCF10A,
although the degree of migration, invasion, and compaction was less.
After analyzing compaction assays at 7 days, we measured cell morphology (circularity index),
and was found to correlate overall with both invasion and compaction. TGFβ2 treatment resulted
in an irregular and spindle shaped morphology, while VEGFA promoted round quiescent cells.
Combined VEGFA and TGFβ2 promoted a hybrid morphology, while NFAT inhibition (VIVIT) sig-
nificantly reduced the circularity index, similar to TGFβ2 treatment. The formation of tubular struc-
tures (acini) was also found to increase in size and number upon VEGFA treatment. However,
the number of tubular branches relative to total acini was significantly increased upon combined
TGFβ2 and VEGFA. These results indicate that simultaneous VEGFA and TGFβ2 treatment (hy-
brid phenotype) regulates acini and ductal branch formation, and is dependent upon NFAT activity
(Figure 7.6). No tubular structures were identified within the DLD1 constructs during the 7 day
tubulogenesis endpoints.
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Figure 7. 6: Ductal branching is dependent upon phenotype heterogeneity within MCF10A in 3-D culture. MCF10A
and DLD1 were formed into spheroids overnight and explanted to a collagen gel for 72 hrs. For compaction and tubular
assays, cells were embedded into collagen gels for 72 hrs, and the extent of tubulogenesis was measured at 7 days. (A-
D) Within MCF10A, TGFβ2 (10ng/ml) enhanced invasion and contractile properties while, VEGFA (50ng/ml) promoted
increased migration. TGFβ2 with VEGFA significantly increased migration, while limiting with compaction. VIVIT (10µM)
in combination with VEGFA and TGFβ2 decreased migration and compaction, while increasing invasion. (D) Likewise,
cell morphology (circularity index) correlated with both invasion and compaction in MCF10A. (E-F) The size of tubular
structures (acini) also increased significantly upon addition of VEGFA, while the number of ductal branches was most
significant upon simultaneous TGFβ2 and VEGFA treatment (Red-Ecadherin, Green-Factin, Blue-Nuclear). DLD1 cells
followed a similar trend, although the degree of migration, invasion, and compaction was less significant. In addition,
no tubular structures were identified during the 7 day tubulogenesis endpoints. Scale bars: 500µm, 1000µm, 250µm,
and 80µm, respectively. C=Control, T=TGFβ2 , V=VEGFA, VI= NFAT inhibitor (VIVIT). Asterisks signify statistical
differences from each other according to a one-way ANOVA with Tukey’s post hoc (p≺0.05).
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7.5: Discussion
We formulated and analyzed a family of mechanistic models using a detailed molecular framework,
which describes the induction of EMT. The models were trained and cross-validated to prescribe
biological significance using experimental data sets taken from literature. To address parametric
uncertainty in ODE-based deterministic models, we implemented an ensemble approach using
POETs. The ensemble of parameter sets allowed us to identify different operational paradigms
within EMT (sub-populations), which provide testable hypotheses into the possible transforma-
tional aspects of cellular phenotype. Our results suggest the ability of both MCF10A and DLD1
to exhibit phenotypic heterogeneity based on the combined treatment of TGFβ2 and VEGFA and
master regulatory complexes included both the NFAT and Sp1 transcription factors. Lastly using
3D cultures, we found that the extent of ductal branching in MCF10A was dependent upon pheno-
type heterogeneity. Together, these results establish a predictive mechanistic model of EMT, and
suggest pathogenetic phenotype outcomes of EMT through an NFAT/phospho-Sp1 signaling axis.
Classically, ODEs and mass-action kinetics are common frameworks for modeling biological
pathways (19, 20, 24). However, the use of ODEs for large scale deterministic modeling has been
limited. This is largely because structural and parametric uncertainty associated with this type of
modeling can be substantial. Furthermore, the availability of computational algorithms capable
of handling such an approach are few. We have addressed both of these ODE shortcomings by
including well-mixed compartments to account for spatially localized species and processes and
have considered an ensemble of models in our analysis to coarse-grain population phenomena.
Regardless of model formulation, each model class requires the identification of a large number
of unknown model parameters. While computationally complex, multi-objective optimization is an
important tool to address qualitative conflicts in training data that arise from experimental error or
cell line artifacts (25, 26). To minimize the parametric uncertainty associated with large scale de-
terministic networks, population based techniques can robustly capture model predictions through
an ensemble of parameter sets (10).
Pathological conditions leading to tumor progression have revealed a plethora of microenvi-
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ronmental factors, including soluble factors VEGF and TGFβ. VEGFA has been shown critical for
tumor progression via angiogenesis, while TGFβ is thought to have both protective and transfor-
mative roles, depending on the extent of disease progression (4, 5). In the context of EMT, the
combined role of both VEGFA and TGFβ has yet to be understood. Recent evidence both in vitro
and in vivo have identified the ability of epithelial cells to obtain heterogeneous phenotypes, rather
than the classical mesenchymal transition (2, 27). For example, studies exploring the levels of
EMT markers in cancerous human epithelial cell lines were found to contain a spectrum of expres-
sion profiles, such that both ecadherin and vimentin positive cells were found (28). Furthermore,
Zajchowski et al., speculated that these expression profiles were important for maintaining ep-
ithelial properties, while allowing other characteristics such as proliferation and migration (29). A
fundamental question often discussed is whether phenotype heterogeneity reflects the plasticity of
normal cells responding to pathological conditions. Our results suggest that hybrid phenotypes are
clearly evident and one possibility is through combined treatment of two growth factors commonly
localized in the tumor microenvironment, VEGFA and TGFβ.
Underlying the convergence of TGFβ2 and VEGFA signaling pathways, our model identified
key transcription factors (Sp1 and NFAT) critical for regulating ecadherin and vimentin expres-
sion. Specifically, we showed in vitro that NFAT expression and nuclear localization was critical
for ecadherin expression during phenoype heterogeneity. Recent studies have suggested the
importance of nuclear factor of activated T cells (NFAT) as a key transcription factors involved
in cell growth, survival, invasion, angiogenesis and cancer (30). For example, proliferation and
anchorage-independent growth of pancreatic tumor cells is dependent on calcineurin activity and
NFATc1, which induces MYC transcription and is consistent with high levels of nuclear NFATc1 in
pancreatic cancers (31). Likewise, our results found that VEGFA was a potent inducer of NFATc1
expression and may be required for epithelial cell polarization and tubulogenesis. Although NFAT
isoforms were not specifically addressed in our work, our simulations suggest that NFAT is capable
of mediating EMT (subset of population). Experimentally, we found that ecadherin expression lev-
els are dependent upon NFAT dephosphorylation in response to simultaneous VEGFA and TGFβ2
treatment. These results suggest that NFAT (possibly NFATc1) plays a critical role in maintaining
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cell-cell contacts, even during partial EMT.
The ability of epithelial cells to reproduce a tissue-like organization when grown inside a 3D
extracellular matrix (ECM) has been widely applied for understanding tubular formation processes.
MCF10A cells have been previously shown to form structures that closely resemble acini (multi-
lobed cluster of cells) (32). Underlying this process, it is thought that a cellular response rem-
iniscent of a partial epithelial mesenchymal transition ensues, stimulating further branching and
formation of acini. It has been speculated that this well controlled process of tubulogenesis might
be co-opted as a mechanism for tumour cells to break away from a primary lesion and invade
through the stroma (33). However, because the EMT-like process is transient, clusters of tumor
cells can reform at a high rate, possibly explaining why invasive human carcinomas are frequently
observed to be collections of cells with varying degrees of gland-like differentiation. Based on our
results, we show that that heterogeneous phenotype during EMT, is important for underlying cellu-
lar migration and invasion leading to tubular branching. However, a salient feature of partial EMT
is the retention of cell-cell contacts in which cells possess migratory properties, but do not com-
pletely break away from their neighbors. By quantifying cell morphology, we were able to conclude
that cells within this hybrid phenotype still maintain properties of epithelial cells, in comparison
to a fully differentiated mesenchymal state. This might explain why fibroblastoid morphology, an
important feature of traditional EMT, is not commonly observed in human carcinomas (34).
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CHAPTER 8 
MULTIDISCIPLINARY INQUIRY BASED LEARNING USING AN EX-OVO CHICKEN 
CULTURE PLATFORM TO INVESTIGATE NEO-ANGIOGENESIS IN DEVELOPMENT 
 
 
 
8.1: Summary 
Embryonic development offers a unique perspective on the function of many biological 
processes and their heightened sensitivity to environmental factors.  This hands-on lesson 
investigates the effects of prostaglandin E1 (PGE1) on the morphogenesis of chick vasculature.  
PGE1 is applied to shell-less (ex-ovo) cultured chick embryos, which are highly accessible and 
intrinsically spawn inquiry. The student activities mirror the scientific research process, including 
review of the scientific literature, hypothesis formation, experimental design, interpretation of 
data, and re-evaluation of initial hypothesis.  This exercise supports instruction on 
developmental biology, biophysics, animal research, and experimental design, and is motivated 
by a clinically relevant health issue.  
 
8.2: Introduction 
The cardiovascular system is a critical supplier of nutrients and oxygen for vertebrate 
development and homeostasis.  During embryonic development, vasculature is formed by both 
vasculogenesis and angiogenesis.  Vasculogenesis, which consists of de novo vessel formation 
from angioblasts, provides the nascent vascular network, particularly during early embryonic life. 
Angiogenesis, which refers to expansion of a pre-existing vascular bed through sprouting, 
bridging and intussusceptive growth, intervenes mostly during later stages of embryogenesis.  
Recent experimental studies have demonstrated that Prostaglandin E1 (PGE1) can contribute 
to embryonic induction of neo-angiogenesis (Ribatti and Djonov 2011).   
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Prostaglandins are a family of chemical messengers which are involved in local signaling within 
tissues and are a group of lipid compounds that are derived enzymatically from fatty acids.  
Specifically, every prostaglandin contains 20 carbon atoms, including a 5- ring and signals 
through a wide array of G-protein coupled receptors (Amano, Hayashi et al. 2003). The effects 
of the signal are highly dependent upon both the specific type of prostaglandin as well as the 
properties of the target tissue cells.  For instance, the same prostaglandin may have different 
effects when acting upon the endothelial cells of the gastrointestinal tract than on the 
vasculature of inflamed tissue (Jabbour and Sales 2004).  In the developing chick embryo, 
PGE1 has been shown a potent inducer of neo-angiogenesis which is important for developing 
the chorioallantoic membrane (CAM) (Dohle, Pasa et al. 2009).   
 
The chicken embryo chorioallantoic membrane (CAM) assay has been a model for studying 
neovascularization since the early 1970’s when it was adapted by Folkmann et al (Gimbrone, 
Cotran et al. 1974).  While there have been many variations developed over the years, the basic 
assay is performed by implanting a membrane or filter paper containing the compound of 
interest on the chick embryo CAM through an ex-ovo platform.  The subsequent incubation 
period ranges from 1-3 days, depending on the compound, after which time angiogenesis can 
be quantified via image analysis.  The CAM assay is quick, technically simple, and inexpensive 
making it suitable for a classroom activity.  
 
The ex-ovo culture is an intrinsically inquiry based classroom activity as the natural response of 
students is to ask, “What will happen to the chick embryo?”  The high school lesson engages 
this enthusiasm by exploring the role of PGE1 on the developing chick vasculature.  The 
teaching activities include an interactive background of PGE1 scientific literature, hypothesis 
driven experiments, hands-on ex-ovo culture with PGE1 treated embryos, systematic 
measurement of growth, and interpretation of data in the context of the reviewed literature.  This 
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exercise supports instruction in developmental biology, molecular signaling, animal research, 
experimental design, and is motivated by a clinically relevant health issue using current 
scientific research. 
 
8.3: Preparing for the Study  
8.3.1: Materials and Methods 
 Fertilized white Leghorn chicken eggs (local poultry farm)          
 Egg Incubator & Rocker (HovaBator, GQF Mfg.  $60-$100) 
 Cling Wrap    
 70% ethanol       
 Rubber bands (#16, 2.5 in)         
 Rubber gloves  & Safety Glasses          
 9 oz plastic cups (Dia. 3in)          
 100 mm diameter Petri dish    
 Whatman Filter Paper Size 3 
 1.5 ml centrifuge tubes  (optional) 
 Forceps 
 Prostaglandin E1 (Cayman Chemicals 13010 $15) 
 USB Microscope Veho VMS-100 (~$70) or alternative large working distance scope 
 
Safety: Prostaglandin E1 should be handled with gloves and safety glasses 
Preparation of Incubator and Chick Embryos 
Fertilized white Leghorn chicken eggs should be obtained from your local poultry farms.  These 
fertilized embryos can be stored in a cooler maintained at 13 ◦C (55 ◦F) for up to 3-4 days until 
ready for use.  Prior to the start of your activity, clean out incubator with soap and water to 
188 
 
remove contaminates.  Dilute bleach or 70% ethanol may be used to sterilize incubator.  Line 
base of incubator with aluminum foil for easy clean up and place thermometer inside.  Pre-heat 
incubator to 37 ◦C (99 ◦F), and let stand 1 hour to confirm constancy of temperature.  Place eggs 
blunt side up in incubator and turn on rocker to chick start incubation (day 0).  Include a ¾ filled 
9 oz cup of water inside incubator to maintain humidity.  
 
8.3.2: Ex-ovo Culture of Chick Embryos 
After 72 hours (day 3), prepare hammocks for ex-ovo culture (Figure 1).  Fill ¾ of 9 oz plastic 
cups with warm water.  Cut about 20 x 20 cm (8 x 8 in) square of cling wrap and place loosely 
inside the cups.  Cling wrap should be in contact with water and form loose hammock. Secure 
cling wrap to cup with a rubber band (Figure 7.1A).  Spray the plastic wrap with 70% ethanol to 
prevent contamination.  Remove eggs from incubator after 72 hours of incubation.  Sterilize 
eggs by spraying surface with 70% ethanol.  Lay the eggs horizontally on egg carton for 1-2 
minutes to allow the embryo to rotate (Figure 7.1B).  Using a sharp edge (like the edge of a 
metal bucket or a glass beaker), tap the egg gently until there is a small dent on the underside 
of the egg (Figure 7.1C).  Put thumbs in opposite sides of the dent and open the shell directly 
above hammock (Figure 7.1D).  The entire yolk, egg white, and embryo should fall into the 
hammock softly (Figure 7.1E).  If the embryo is not on top side of yolk, gently rotate egg yolk 
with fingers (using gloves).  Place a 100 mm diameter Petri dish on top of the cup to seal the 
embryo.  Transfer the embryo back into the incubator set at 37°C with water cup to maintain 
humidity (Figure 7.1F).  Observe embryos as long as you would like or directed by the activity.  
We recommend that the students perform the ex-ovo culture under close supervision of an 
instructor or teaching aid. 
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Figure 8.1 – Step-by-step ex-ovo culture technique.  A) Prepare hammocks in plastic cups, B) Lay eggs 
on blunt side to prep for cracking, C) Use sharp edge to create narrow crack on center of egg, D) 
Carefully open egg shell directly above hammock and cup E) Rotate embryo to top side of egg yolk, F) 
Place in incubator at to 37 
◦
C (99 
◦
F) 
 
 
8.3.3: Motivate Study and Discuss Background 
Before investigating the effect of PGE1 on the embryonic chick, it is important to motivate this 
study.  Using the information outlined in the introduction and below, attempt to connect the 
importance of neo-angiogenesis with the students experience or perceptions of the issue.  We 
found this was best done through a brief, but interactive large group discussion.  In addition, we 
recommend discussing normal embryonic development, particularly pertaining to chick 
development (Hamburger and Hamilton embryo atlas images provided in the supplement and/or 
online at www.butcherlab.com ).  
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Sufficient background information is needed to further place neo-angiogenesis context and 
facilitate the students’ hypothesis formation.  The students were given excerpts from 
introduction sections of scientific and medical journal articles to analyze.  Field-specific literature 
was paraphrased to increase the readability of the excerpts.  With each excerpt we included a 
series of questions which assessed reading comprehension and the acquisition of scientific 
concepts.  Though reading technical literature can be difficult for students, completion of the 
exercise empowered the students and broke down the false notion that scientific research can 
only be understood by scientists.  The exercise is similar to scientific reading comprehension 
questions on many standardized tests.  It may also be used as a graded activity, which provides 
early feedback for both student and teacher on the progress of the project. We recommend 
small groups of two or three students, preferably with a range of ability, for this exercise.  An 
initial read-through as a large group can remove any class wide gaps in understanding.   
         
8.3.4: Background Information Excerpt Example 
Read the excerpt from (Ribatti and Djonov 2011) and answer the following questions. 
 
“Angiogenesis is an important process by which new blood vessels are formed, both in health 
and disease.   Starting with the hypothesis of Judah Folkman (1933-2008) that tumor growth is 
angiogenesis dependent, this area of research has a solid scientific foundation. More than 30 
years ago, Folkman found a revolutionary new way to think about cancer. He postulated that in 
order to survive and grow, tumors require blood vessels and that by cutting off the blood supply; 
a cancer could be starved into remission. Several clinical studies have shown a positive 
correlation between the number of vessels in the tumor, metastasis formation and prognosis. 
The genetic instability of tumor cells permits the occurrence of multiple genetic alterations that 
facilitate tumor progression and metastasis, and cell clones with diverse biological 
aggressiveness may coexist within the same tumor. These two properties allow tumors to 
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acquire resistance to cytotoxic agents. Inhibiting angiogenesis is a major area of therapeutic 
development for the treatment of cancer. Whereas conventional chemotherapy, radiotherapy 
and immunotherapy are directed against tumor cells, antiangiogenic therapy is aimed at the 
vasculature of a tumor and will either cause total tumor regression or keep tumors in a state of 
dormancy. Even though numerous compounds inhibit angiogenesis, few of them have proved 
effective in vivo, and only a couple of agents have been able to induce tumor regression.” 
 
Table 8.1 - Background Questions to Help with Hypothesis Generation    
Q#1) List the stages of chick embryonic development and illustrate normal morphology.  
Q#2) What are prostaglandins and how do they signal to cells? 
Q#3) Are the effects of prostaglandins tissue or cell type specific? 
Q#4) What role does angiogenesis play in development? 
Q#5) What does this excerpt indicate about the role of angiogenesis in cancer? 
Q#6) Why would scientists target molecules which induced neo-angiogenesis in cancer?  
 
8.3.5: Experimental Design 
After reading the background material and discussing it as a class, divide the students into 
groups of 3-4 to prepare for experiment.  Ask each group to formulate and record a hypothesis 
on what will happen when PGE1 is applied to the vasculature network of the ex-ovo cultured 
embryo as compared to a normal embryo.  Remind the students to develop a testable 
hypothesis, considering ahead of time which metrics they will use to evaluate the hypothesis.  In 
this module, embryo, the number of vascular branches was the morphological parameter used 
to compare between treatments (Figure 7.2).  Other measurement ideas include CAM width, 
anterior vein thickness, or radius of vasculature.  
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8.3.6: Example Hypothesis & Proposed Metrics 
We hypothesis that PGE1 administered to the embryo will create a localized neo-angiogenesis. 
We will use “number of vascular branches” as metric of vascular growth. 
 
Figure 8.2 – Image of chick embryo in ex-ovo culture at 4.5 days of incubation. 
 
 
Control experiments are an essential component to any well designed scientific study.  Spend a 
brief, but intentional time explaining the types and purpose of controls with the students.  Solicit 
their assistance in identifying the most appropriate controls for this study.  We recommend two 
controls, an untreated group (standard control) and a filter paper with PBS (phospho-buffered 
saline) only (sham control).  The standard control will provide the benchmark of normal 
development to compare with PGE1 treated, and the sham control to verify that the effects 
observed are not due to the filter paper or PBS.  
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8.4: Conducting the Investigation  
8.4.1: Environment Perturbation Study - Addition of PGE1 
From previous dose dependent and temporal responses, we have determined that a PGE1 
concentration of 1mg/ml at applied at day 8 of incubation induces morphological changes by 
day 10 of incubation.  We recommend that the teacher mix and administer the PGE1 treatment 
to the embryo.  Cut the Whatman filter paper into 2-5 mm diameter punches or strips.  Dilute 
1mg of PGE1 in 1ml of PBS in a 1.5ml tube.  Place the filter paper sections in the 1.5ml tube 
and let soak for 30 minutes.  Using forceps, remove filter paper from PGE1 solution and place 
on the ex-ovo culture.  We suggest placement of the filter paper on the right side of the embryo, 
within the vasculature (Figure 7.3).   Capture images of the embryo and vasculature sequentially 
at day 8, day 9, and, day 10 using the USB-microscope (Veho VMS-100, Figure 7.3 and 7.4).  
Measure the predetermined metrics of vascular branches from these images using open source 
software ImageJ (NIH, http://rsbweb.nih.gov/ij/). Simple instructions for ImageJ are available at 
http://climb.bme.cornell.edu/embryo.php. Hand measurement using a caliper or ruler is a viable 
alternative. Finally, record the measurements in tables for each metric (Figure 5).   
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Figure 8.3 – Experimental design consists of soaking filter paper in different concentrations of 
prostaglandin E1 (PGE1) and placing it on the embryonic vasculature.  Following several days of 
incubation, a USB-microscope can capture the downstream effects on development. 
 
 
8.4.2: Analysis & Interpretation of PGE1 Treatment Results   
An essential part of the scientific process, and often the most challenging, is to quantitatively 
analyze and correctly interpret the data.  To assist with this task, we recommend the students 
plot the data, either digitally or by hand, for each output measured (Figure 7.4).  Instruct the 
students to use the data to confirm or deny their initial hypothesis.  If the hypothesis is 
confirmed, the students must prepare a series of arguments from the data to support their claim.  
If the hypothesis fails, the students must generate a new hypothesis based on the results of the 
study.  It is also important to consider the implications of these results in a broader context.  For 
instance, ask the students how these results might relate to wound healing or cancerous 
tumors. 
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Figure 8.4 – PGE1 perturbation study data set.  Array of ex-ovo chick images across treatment and over 
time.  Treatment resulted in neo-angiogenesis over a three day period starting at day 8.  Scale bar 
indicates 5 mm. 
 
 
8.4.3: Example Data Analysis & Interpretation Worksheet 
Using the generated tables, line graphs, and previous understanding of embryonic development 
and PGE1, work through the following questions as you analyze the data (Figure 7.5). 
 
 Q#1) Compare the number of vasculature branches between the control and PGE1 
treatments.  Did the addition of PGE1 increase or decrease vasculature?  
o While the control and treated embryos had roughly the same number of 
vasculature branches, by day 10 the number of vasculature branches within the 
(1mg/ml) PGE1 treatment increased 2.8 times than the control.  These results 
suggest that PGE1 has a positive effect on vasculature within the embryo. 
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 Q#2) Are the sham results different from the control?  What do the sham results indicate 
about our method of treatment?  
o The sham results do not appear to be significantly different from the control.  This 
indicates that the defects were not induced by the filter paper or PBS, but instead 
can be wholly attributed to the addition of PGE1. 
 
 Q#3) Approximate the growth rate of each treatment by determining the slope of the “tip-
to-tail” curves.  Which condition had the fastest growth rate? Is the rate linear?  
o Control Sham – 0.25 branches/day, PGE1 1mg/ml – 4 branches/day.  The 
control embryo had the slowest growth rate and the 1mg/ml PGE1 treatment had 
the fastest.  The PGE1 growth rate was roughly 16 times as fast as the control 
treatment.  This result agrees with the conclusion in question #1, that PGE1 
increased the number of vasculature branches within the embryo. 
o Growth rate is exponential for the PGE1.  This suggests that the embryo needs 
time to respond to the PGE1 and may involve a positive feedback system. 
 
 Q#4) From our data, we see that PGE1 treatment effected the local development of the 
embryos vasculature.  Do you think any effect will occur globally?  
o PGE1 is saturated in filter paper and is applied over a small area away from the 
embryo.  However, it is placed within the blood vessel bed.  This particular 
placement on a vessel may facilitate the spread, and uptake, of PGE1 in the 
embryo body.  This emphasizes the substantial role the circulatory system plays 
in nutrient consumption and trafficking, demonstrating how even local 
concentrations of agents can have global consequences due to rapid transport 
throughout the developing embryo.  
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 Q#5) Explain why tumors need blood vessels and why my PGE1 be an important 
molecule underlying cancer spreading. 
o Tumors need oxygen to rapidly grow and thrive.  By creating neo-angiogenesis, 
vasculature can be formed to supply these important nutrients.  PGE1 may be 
up-regulated in cases of cancer since it has been shown a potent inducer of 
vessel formation within the developing embryo. 
 
 
Figure 8.5 – Quantifying the number of vascular branches for PGE1 perturbation study using open 
source software (ImageJ) provided by the NIH. 
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8.5: Discussion  
The embryo provides a unique lens through which to study general (cell activity, organ systems) 
and development specific (cell differentiation, morphogenesis) processes in biology and 
physics.  Watching the embryo induces fundamental questioning of why some structures 
develop first vs. later on, how the embryo is feeding itself, and how processes change with 
growth.  Even if just a biology classroom, the effects of physics such as diffusion, transport, and 
mechanical forces can be incorporated into our lesson framework.  Instructional versatility 
enables the breadth of content to be appropriately scaled to student ability or knowledge base.  
For instance, observation, measurement, and prediction of normal development may be 
sufficient for middle school biology students, while the PGE1 perturbation model may be more 
appropriate for upper level high school students.  In the following, we present further 
background information and ethical issues with animal research to extend the applicability of 
this lesson (Figure 7.6). 
 
 
Figure 8.6 – Engagment of students during the ex-ovo chick culture and analysis of experimental results.  
 
199 
 
Metabolic and Molecular Aspects of Study – Mechanism of Action 
Prostaglandin E1 activates several signal transduction pathways that have been implicated in 
carcinogenesis. For example, PGE1 mediated activation of E prostanoid receptors (G protein 
couple receptors, GPCR) leads to enhanced adenylate cyclase activity and cyclic adenosine 
monophosphate production (cAMPs). This in turn activates protein kinase A/cyclic adenosine 
monophosphate response element binding protein (PKA).  Upon activation, nuclear transcription 
factor CREB can bind to the promoter of vascular endothelial growth factor (VEGFA) to drive 
neo-angiogenesis and blood vessel assembly (Figure 7.7, adapted from (Mann, Backlund et al. 
2005).  PGE2 and PGE3 also signal through similar signaling cascades, however, their effects 
may be quite different depending on cell and tissue type.  
 
Figure 8.7 – Metabolic and molecular pathway advanced student classrooms) describing the mechanism 
through which PGE1 regulates gene regulation. 
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Bioethics of Animal Research  
Using live embryos within the classroom will inevitably spark a conversation about humane 
treatment and ethics.  We feel this is an extremely important aspect, and should not be 
overlooked.  From a purely regulatory standpoint, all use of vertebrate animals in research, 
teaching and testing is regulated by the Institutional Animal Care and Use Committee (IACUC, 
http://www.iacuc.org/).  Chick embryos younger than embryonic day 15 (E15) are assumed to 
be unable to experience pain, because of limited neural development.  It is recommended that 
E14 or younger embryos be euthanized by hypothermia, typically by placing the eggs in a 
−20°C freezer.  Chick embryos from E15 to pre-hatching should be euthanized by decapitation, 
anesthetic agents or another rapid and humane method.  Studies using embryos within three 
days of hatching or hatchlings must be reviewed by the normal IACUC procedure for vertebrate 
animals.  In our experiments, embryos will be euthanized at day 7, which is only 1/3 of the way 
through its 3 week hatching cycle.  Therefore, the embryos cannot experience pain and are 
exempt from any IACUC protocols.  This however, will not limit conversation about the ethics of 
animal research within the classroom.  We encourage teachers to lead a classroom discussion 
on the role of animals in scientific research, and use this time effectively to discuss humane 
treatment and ethics.  From our experience, the level of concern and opinions will vary from 
class to class.  It is imperative to gage student sensitivity in a considerate and objective manner 
before conducting the experiments. Resources for animal research ethics can be found on the 
web: www.ethics.org.  
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Table 8.2 - Addressing the National Science Education Standards  
Standard Value of this Activity 
Teachers should successfully 
convey unifying concepts of 
science. 
Students will successfully design, conduct, report and evaluate 
the effects of PGE1 on embryonic development.  Using 
mathematics, students will process and report data to 
understand the origin of congenital defects through 
environmental factors. 
Teachers should engage 
students in various methods and 
active learning through scientific 
inquiry.  
During our investigation, we implement multiple methods of 
inquiry leading to scientific knowledge.  Students determine the 
effects of PGE1 on embryonic development that require them to 
develop concepts and relationships from their observations, 
data, and inferences in a scientific manner 
Teachers should organize safe 
and effective learning 
environments that promote the 
success of students and the 
welfare of all living things 
Students will treat all living organisms used in the classroom or 
found in the field in a safe, humane, and ethical manner and 
respect legal restrictions on their collection, keeping, and use.  
Classroom discussions on using animals for experimental 
systems have been highlighted.  
Teachers should create a 
community of diverse learners 
who construct meaning from their 
science experiences for further 
exploration and learning. 
The experiments have been organized to engage students in a 
collaborative learning environment.  In addition, technological 
tools such as (NIH) Image J, allow students to collect, process 
data, and facilitate the learning of science.  
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CHAPTER 9 
DISCUSSION  
 
 
9.1 Congenital Valve Malformations and Treatment 
As presented in Chapter 1, the clinical incidence of congenital heart disease is approximately 
1% of all births, with 20-30% directly related to valves in the US [1].  This statistic 
underestimates the true incidence of congenital valve defects, as a significant portion of these 
defects are not diagnosed until adulthood [2].  The most common is human bicuspid aortic 
valve, where the valve forms only two leaflets instead of three.  Although it may function 
normally during development, during later stages of life BAV is prone to disease such as 
calcification and aortic stenosis [3].  Specific abnormalities in valve structural proteins present at 
birth can also contribute to valve dysfunction and disease later in life, making the distinction 
between congenital and acquired valve disease unclear [4].  Marfan syndrome is an example 
where dysfunctional expression of the fibrillin-1 gene leads to a wide spectrum of clinical 
phenotypes, including valve regurgitation, thickening, and prolapse.  The current treatment for 
heart valve defects is replacement, and approximately 95,000 valve replacement surgeries are 
performed in the United States annually [5]. The majority of aortic valves that are replaced at 
any age have congenital malformations, including BAV, further supporting developmental 
origins of adult valve dysfunction and disease [6].  This clinical data demonstrates a serious 
problem of valve related disease and its etiologies.  
 
Ongoing studies have been directed toward identifying genetic components responsible for 
congenital valve malformation and disease [7].  Genetic syndromes including Williams, Marfan, 
Trisomy 21, Alagille, Turner, and Noonan are all examples where valve malformation are 
prevelant [8-10].  Mitral valve prolapse is not traditionally considered a congenital malformation, 
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however it is heritable and be diagnosed at birth [11].   Likewise, heart malformations such as 
tetralogy of Fallot, hypoplastic left heart syndrome, or Ebsteins’s anamoly have a strong 
presence of valve related defects [12].  Several gene loci have been associated valve defects, 
such as Notch1 in BAV, filamin-A in MVP, and fibrillin-1 in MFS [13-15].   
 
While congenital valve malformation and disease may have a genetic component, other factors 
are likely to be involved.  In many cases, nonsyndromic valve malformations are idiopathic and 
the origins are unknown.  However, evidence over the last decade has suggested the 
importance of hemodynamics during valve development.  For example, in zebrafish and chick, 
altered blood flow lead to dysfunctional leaflet morphogenesis [16].  The molecular mechanisms 
through which hemodynamics regulates valve maturation is poorly understood, especially at 
later stages of development.  Interestingly, the genetic association of BAV with hypoplastic left 
heart syndrome suggests that normal valve hemodynamics is required for ventricular chamber 
morphogenesis [17].  Additionally, there is increasing evidence that the coordinated function of 
the myocardium and valves is necessary for normal prenatal heart development [18].  This 
creates a complicated situation such that the congenital heart malformations likely lie at the 
multi-scale interface of genetics and mechanics. 
 
Currently, the treatment options for congenital valve defects are limited.  In most cases, total 
replacements of the valve are done using mechanical valves.  However, this is expensive and 
extremely evasive.  Additionally, as the patient grows, multiple heart surgeries need to be 
conducted in order to accommodate for the increased size of the heart and aortic vessel.  
Current diagnostic tools for valve dysfunction rely on echocardiography and while the fetus is in 
the developing womb, there is not much that can be done.  While a therapy is needed in these 
situations, applying a strategy to understand the mechanistic development of these 
abnormalities may be an effective research path [19].  That way, diagnostic tools and targeted 
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therapies can be developed for these underlying causes, effectively removing the need for any 
kind of prosthetic valvular replacement.   
 
The paradigm for biological research in the 20th century was the use of animal models.  While 
having the advantage of systemic circulation and immune response these models are 
expensive, require long development times, and often offer little mechanistic data.  While animal 
models are need evaluate preclinical safety and confirm efficacy of drugs/devices, other 
technologies such as tissue engineering and in-vitro bioreactors are needed to understand 
cellular action in response to biological and physiological cues.  Experimental research over the 
last 20-30 years has been developing along these lines.  Tissue engineering has now been 
useful generating 3D constructs to more effectively model and capture the native environment.  
Likewise, bioreactors are important for applying controlled physiological stimulation such as 
electrical, chemical, or mechanical.  Together, by utilizing combined approaches with animal 
models, tissue engineering [20], and in-vitro bioreactors [21, 22] we may begin to better 
understand the biological and mechanical factors which drive the embryonic valve 
morphogenesis and related congenital malformations.    
    
9.2: Embryonic Valve Mechanics and Biology 
Valve leaflets are critical for maintaining unidirectional blood flow during embryonic 
development.  These tissues have evolved complex multidirectional collagenous fiber 
orientations that result in anisotropic mechanical properties ideally suited to their local 
microenvironment.  Underlying this process, resident tissue fibroblasts continuously repair and 
remodel their tissue microenvironment in response to these mechanical cues, including 
secreting and/or degrading extracellular matrix proteins, releasing soluble growth factors, and 
reorganizing cell-cell/cell-matrix adhesive interaction.  Developing leaflets are exposed to 
arguably the most demanding mechanical environment in the body, yet interstitial fibroblasts 
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thrive and mediate significant matrix turnover [19, 23].  Cyclic loading my therefore provide 
strong inductive signals towards resident valve cells for regulating tissue formation and 
homeostasis [24].   However, deciphering the role of cyclic stretch on valve phenotype 
combined with tissue remodeling presents a situation that is both technically challenging and 
theoretically difficult; some have even suggested it as a “moving” target [24]. 
 
We are beginning to understand more about embryonic valve biology and the effects of 
mechanical cues on their behavior.  Techniques to isolate and culture these cells have only 
recently been developed, and to date use of these cells in tissue engineered constructs (i.e. 
collagen hydrogel) are becoming a more popular method to study cellular phenomenons.  In 
Chapter 2 of this work, detailed protocols were developed to isolate pure populations of avian 
progenitor endocardial cells [25].  These cells were characterized through functional assays and 
compare favorably to other reports in the literature.  The avian endocardial cells were used as 
the model cell source to determine biological response to mechanical forces and the effects in 
3-D culture, the results of which are discussed in Chapter 5.  However, before these cells could 
be used for that application, we developed and implemented a bioreactor capable of applying 
homogeneous strain field anisotropy within engineered tissue hydrogels as presented in 
Chapter 3.  This platform was essential to enable testing of molecular, cellular, and tissue scale 
mechanisms within a well-defined, repeatable, and physiologically relevant microenvironment 
[26]. 
 
A central theme throughout this thesis was to understand the role of mechanical stretch on 
valvular differentiation combined with multi-scale tissue morphogenesis.  However, deciphering 
the role of mechanical stretch during valve formation is extremely complicated due to changes 
in magnitude, duration, and frequency during valvular morphogenesis.  Additionally, as pointed 
out in Chapter 6, residing valvular interstitial cell-matrix kinematics can vary in normal and 
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pathological conditions [27].  This leads to differences in the extent of both cell and tissue 
deformation.   These dynamic conditions make experimental testing a difficult challenge and 
while it is not feasible to test every condition (nor would anyone want to), insight and clever 
design is needed.  The purpose of this chapter is then to combine some of the results of 
different chapters to provide future direction into the biological responses of resident valve 
interstitial cells.  Two prominent themes developed, and they are addressed in the following 
paragraphs.  First expanding the definition of embryonic valve phenotype and second, 
understanding the role of anisotropic strain. 
 
9.2.1: Expanding and Describing the Embryonic Valve Cell Phenotype 
As demonstrated in Chapter 3 and Chapter 4, sustained cyclic stretch was a potent inhibitor of 
valvular myofibroblastic differentiation in a stage independent manner.  The mechanism was 
found that stretch directly mitigates RhoA-GTP levels to inactivate SRF (serum response factor) 
and hence, downstream smooth muscle actin [28].  Although the regulation of a myofibroblastic 
to quiescent phenotype is critical for valve formation, regulation of these factors alone does not 
fully describe the phenotype which is seen during leaflet formation.  We and others suspect that 
both FGF and BMP pathways play a large role in driving the mesenchymal-transformation 
through Sox9 and Scx transcription factors [29, 30].  Using IHC and real-time PCR, we found 
that the FGF and BMP pathways dramatically diverge during AV valve formation (Figure 8.1).   
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Interestingly, Sox9 is thought to be a master regulator required for endocardial cushion cell 
lineage expansion, as well as differentiation associated with cartilage progenitor cells [31, 32].  
In both chick and mouse, Sox9 is expressed within the endocardial cushions and remodeling 
leaflets.  BMP2 activates expression of Sox9 and the cartilage differentiation marker Col2a1, 
which has been observed in cultured avian endocardial cushion cells [30].  Upon gene knockout 
of Sox9 in mice, embryonic lethality occurs between E11.5 and E12.5 with hypoplastic 
endocardial cushions.  It is thought that loss of Sox9 inhibits EMT after delamination and initial 
migration, but before definitive mesenchymal transformation [33].  Upon targeted loss of Sox9 
with Col2a1Cre in the remodeling valve, decreased expression of cartilage-associated proteins 
Col2a1 occurs. In adult mice, heterozygous loss of Sox9 in Col2a1Cre results in thickened valve 
leaflets and calcification characteristic of valve disease [32].   
 
 
 
Figure 9.1 - Native expression profiles in the developing AV valve reveal the divergence 
of the BMP/FGF.  Avian embryonic left mitral valve tissue (AV) was harvested at HH25, 
HH36, and HH42, and subjected to whole mount (IF) analysis.  
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Furthermore, recent results demonstrate a new interaction that directly links ROCK to increased 
cartilage matrix production via activation of SOX9 in response to mechanical and growth factor 
stimulation.  It was found that ROCK can directly phosphorylate SOX9 at Ser181 leading to 
enhanced transcription [34].  As stated previously, the activity of RhoA and Rho kinase (ROCK) 
has profound effects on the actin cytoskeleton, and these effects are instrumental in determining 
the phenotype and differentiation of vavlular interstitial cells [35].  This begs the question, is 
RhoA a master regulator of both myofibroblastic differentiation and fibroblast transformation?  
Furthermore, if mechanical strain inhibits RhoA-GTP levels, does it also effect Sox9 
expression?  While we were not able to directly answer this question, we conducted a few 
preliminary tests to evaluate the potential of this hypothesis.  
 
Resident valve cells isolated from HH25, HH36, and HH42 avian leaflets were exposed to 20% 
area strain  at 2.1 Hz (approximating a range between the in vivo HH23-HH36 AV valves [36]) 
for 24 hours with static cultures as controls.  In vitro mechanical stimulation resulted in 
significant (P<0.05, normalized to 18S) differences in SOX9, COL2A1, relative to control 
(mechanically constrained).  These results indicated that mechanical stimulation can modulate 
the transcription factors and ECM markers of progenitor AV cells.  At early staging (HH25, 
HH36) mechanical strain mitigates levels of SOX9 expression (and COL2A1) (Figure 8.2).   
   
 
 
 
 
 
 
Figure 9.2 – Equiaxial strain regulates Sox9 and Col2a1 expression in a stage 
independent manner. 
.  
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Conversely, at later stages (HH42) mechanical strain mitigates levels of SOX9 expression (and 
COL2A1) (Figure 8.2).  While these preliminary experiments confirm the mechno-sensitivity of 
Sox9, expression is stage dependent effect.  This is contrary to what has been shown with 
myofibroblastic differentiation.  This suggests that although RhoA may regulate Sox9 inhibition, 
it does not fully explain why Sox9 expression increases at early stages (mesenchymal) and 
decrease at later stages (fibroblast) upon mechanical strain.  Further experiments investigating 
the mechanism   of this switch will be extremely important for understanding the complete 
picture of mesenchymal-fibroblast phenotype change, with respect to mechanical strain.   
 
As a final thought, Sox9 has been shown to regulate expression of the LEF1 gene by interacting 
with the bcatenin pathway [37].  This is particularly interesting because the bcatenin/LEF1 
pathway can directly regulate myofibroblastic differentiation through alpha-SMA expression [38].  
Bcatenin has been shown elevated within the developing cushions, especially when the 
progenitor valve cells are of strong mesenchymal phenotype (HH25) [39].  Recently, a study 
LEF1 was found essential for valve endocardial cell proliferation and extracellular matrix 
development, but is not required for initiation of EMT [40]. While the role of bcatenin and LEF1 
in valve maturation remains under investigation, the relative levels of bcatenin may help to 
explain why Sox9 expression increases at early stages (mesenchymal), but then decreases at 
later stages (fibroblast) upon mechanical strain.  For example, myofibroblastic differentiation 
may have to precede the fibroblast transition in order to free up cytosolic Sox9 levels from the 
beta-catenin complex.  This is because Sox9 is a potent inhibitor of bcatenin via the 
ubiquitination/proteasome pathway [38].  Once myofibroblastic transformation is complete, Sox9 
inhibition may occur via integrin transduction and downstream cytoskeletal rearrangement.  
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9.2.2: Role of Strain Directionality in Embryonic Valves 
Valve leaflets experience cyclic strain every cardiac cycle. Replicating these strain patterns in 
controlled in vitro test beds has been challenging because physiological profiles are highly 
anisotropic and heterogeneous [41]. The vast majority of studies have focused on modulating 
the magnitude and frequency of cyclic strain.  However, these aspects do not change as much 
in vivo compared to the stretch directionality in the developing valve [42].  In Chapter 3, we 
implemented a novel bioreactor to investigate the relationship between anisotropic strain, cell 
differentiation, and matrix remodeling in 3D culture.  Our findings demonstrated that applied 
cyclic biaxial strain anisotropy induces time dependent VIC orientation and collagen fiber 
alignment.  During this process, ACTA2 expression was directly related to the degree of cell 
alignment and expression occurred perpendicular to the principal axes of loading.  These 
findings suggest biaxial strain anisotropy, independent of magnitude or frequency is a potent 
regulator of rapid matrix reorganization and VIC phenotype.  During development, directional 
mediated stretch on resident valve cells has been hypothesized, although the extent of 
anisotropic stretch in a stage dependent manner has yet to be invested.  Furthermore, the effect 
of anisotropic stretch on embryonic valve progenitor differentiation is unknown.  
 
Therefore, as a preliminary study, we sought to measure the in-vivo deformation of avian valve 
leaflets.  Identification of the mechanical environment of developing valves is particularly 
challenging because of their small size, complex geometries, and rapid movements. We have 
developed ultrasound techniques using combined imaging modalities to characterize strain 
profiles on developing valve surfaces for approximating developing cushion tissue deformations 
[43].  
 
Briefly, time dependent cushion specific time, 2D long axis videos (55 fps) of AV cushion/leaflet 
motions were digitized using NIH Image, traced, and finite strain equations were solved at each 
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time point across the cardiac cycle.  Strain tensors were then converted into the principal 
strains.  Strain profiles were generated from HH23-32 septal mitral leaflets and deformation was 
found to exceed in both magnitude over development.  Furthermore, at later stages HH30-32, 
strain was found anisotropic (20% in the XX and 40% in the YY direction), suggesting that strain 
directionality is important during leaflet formation (Figure 9.3).    
 
 
 
 
 
 
 
 
 
 
 
To examine the extent of fiber anisotropy during valve development in correlation with the 
estimated strain fields, we excised AV valves from day 5, day 8, and day 12 chicks.  We stained 
each valve with 5-DTAF, a molecule capable of staining the entire extracellular matrix.  From 
our results, it was found that the degree of fiber orientation and complexity of remodeling 
increased dramatically from day 5 to day 12 day.  Day 5 was found to be isotropic with little 
alignment, while day 8 was found to have a fiber network of ECM proteins occurring 
perpendicular to the long axis of the AV valve.   Day 12 was heavily aligned with a large network 
of ECM proteins occurring perpendicular to the long axis of the AV valve.  We suspect that this 
fiber anisotropy within the developing valve is a function of anisotropic strain profiles.  In 
Figure 9.3 – Estimated in-vivo stain profiles of avian AV leaflets suggest a significant increase in 
strain anisotropy within the AV valve during development. 
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Chapter 3, we found that increasing anisotropy of biaxial strain resulted in increased cellular 
orientation and collagen fiber alignment along the principal directions of strain and cell 
orientation was found to precede fiber reorganization.  However, this matrix remodeling has yet 
to be confirmed in embryonic valves.     
 
As a last preliminary experiment to understand how anisotropic fibers develop in the embryonic 
leaflet, we subjected multi-axial strain profiles at 2.1 Hz, while maintaining a 20% area strain.  
HH36 AV cells (Day 10) were shown to increase their degree of cellular orientation and align 
perpendicular to the applied strain field (Figure 9.4).  Therefore, we are confident that strain 
directionality proves a potent inducer of valve cellular orientation and also suggests similarities 
between the global remodeling process in embryonic AVC and adult VIC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.4 – Fibers increase in anisotropy from day 5 to day 12.  Likewise, AV cells subjected to 
anisotropic strain profiles orient into a network that closely resembles that of underlying native 
tissue architecture.   
 
 
 
214 
 
 
Lastly, while we have yet to determine the exact mechanism by which VIC orient and 
remodeling the underlying matrix architecture, our previous results in Chapter 3 suggest that 
directionality controls gene expression of resident cells in a spatial manner.  During anisotropic 
strain, VIC aligning perpendicular to the major strain field axis exhibit higher amounts of alpha-
SMA when compared to VIC in parallel alignment.  Therefore, investigation into the specific 
spatial localization of proteins (i.e. RhoA, Rac, pSmad) may prove as an effective means 
towards understanding the ability of VIC to orient and differentiation with respect to 
directionality. 
 
9.3: Recapitulation of Embryonic Process in Adult Disease States 
Developmental biologists are now beginning to connect the balance between signaling proteins, 
transcription factors, and the environment. The orchestrations of these factors are critical for 
determining the formation and homeostasis of tissue with its associated structure and function 
[44].  Interestingly, with the abundance of data now gathered at the embryonic and adult level, it 
is becoming evident that developmental process can be re-capitulated during pathological 
conditions (at least some aspect) [45].   
 
9.3.1: Epithelial to Mesenchymal Transition 
Among the key discoveries in the embryonic heart valve development with relevance to adult 
cardiovascular disease is the process called epithelial to mesenchymal transition.  This 
phenomenon is associated with a loss of epithelial traits, such as E-cadherin expression, and 
the acquisition of mesenchymal characteristics, such as Vimentin, and Fibronectin expression 
[46]. TGFβ is an important inducer of this process as seen by the initiating the formation of 
endocardial cushions in the atrioventricular valves and mediating palate fusion of medial 
epithelial cells [47-49]. In this context, EMT terminates and has been suggested as a highly 
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controlled process [50]. EMT is also important under pathological conditions, prominently in 
fibrosis and in invasion and metastasis of carcinomas [51]. Recent work by Medici et al. has 
revealed a key molecular framework through which sequential activation of TGFβ isoforms 
induces EMT, culminating decades of work within the field [52].  In Chapter 6, we sought to 
synergize the EMT data generated by Medici et al by generating a family of mechanistic ODE 
models.  After analyzing this ensemble, three main predications were found.  In the following 
paragraphs, we will discuss these hypothesis, and there potential importance in embryonic 
development. 
 
1. NFAT Hypothesis 
While much investigation has been focused on determining the molecular factors associated 
with mesenchymal transformation, equally important is determining the molecular cues which 
regulate epithelial quiescence.  Based on our simulations and experimental data, NFATs were 
found as major contributors for maintaining an epithelial phenotype.  Specifically, we correlated 
the NFATc1 isoform with nuclear localization during VEGFA treatment and knockdown of 
NFATs resulted in a significant decrease in ecadherin protein levels.  Interestingly, these results 
complement many processes found during embryonic EMT.  For example, in developing 
endocardial cells, Wu et al. found that loss of NFATc1 function leads to enhanced EMT and 
decreased proliferation of valve endocardium and mesenchyme. Using blastocyst 
complementation assays they showed that NFATc1 inhibits EMT in a cell-autonomous manner. 
It was proposed that NFATc1 suppresses transcription of Snail and Slug, the key transcriptional 
factors for initiation of EMT [53]. Furthermore, Bmp7 expression through NFATc1 transcription 
plays an important role in embryonic kidney branching morphogenesis and recently, BMP-7 
expression has been shown to reverse TGFβ1 EMT by re-induction of ecadherin [54, 55].   
Although the direct mechanism has yet to be identified and/or confirmed through targeted 
perturbation studies, these findings suggest the importance of NFATc1 in maintaining epithelial 
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phenotype (ecadherin expression).  Hence, future modeling and experimental studies 
surrounding NFAT biology may reveal critical therapeutic targets for controlling pathological 
EMT. 
 
 
2. MAPK Phophotase Hypothesis 
 The ERK-MAPK pathway has been shown to modify TGFβ signaling at multiple levels. One 
such way is that the activated Ras pathway inhibits the TGFβ induced nuclear accumulation of 
Smad2/3, as seen in epithelial cells [56]. ERK kinases have been shown to phosphorylate 
Smad2 and Smad3 at specific sites in the region linking the MH1 and MH2 domains. These 
sites are separate from the TGFβ receptor phosphorylation sites which activate Smad nuclear 
translocation [57]. The effect of interaction between ERKs and Smads is the subject of some 
controversy, with data suggesting that such an interaction either enhances or inhibits 
downstream events.  A hyperactive Ras pathway has been shown to effectively counteract the 
antiproliferative activity of TGFβ through attenuation of Smad accumulation in the nucleus [56]. 
In contrast, Ras signals strongly cooperated with Smads for invasion of human carcinoma cells 
[58]. The regulation of MAPK phosphatase is highly specific and tightly controlled through dual 
specificity. Four unique sub-groups have been shown to regulate specific complexes within 
ERK, JNK, and p38 cascades. It has been speculated that a role of an additional N-terminal 
domain within the type III subgroup could provide a cross-talk between MAPK and other 
signaling pathways [59].  Interestingly, our model suggests that upon TGFβ stimulation, high 
levels of MAPK do not affect the TGFβ3 response and inhibition of pSmads is limited. A 
possibility is through selective dephosphorylation of the MAPK/ERK complexes targeting 
pSmads. This may prove as a positive feedback mechanism, which allows the TGFβ3 autocrine 
response to ensue.  Why and how this happens may prove important for understanding 
differences between pathological and controlled EMT. 
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3. Dual Inhibition of Snail and pSMAD Hypothesis 
Recent evidence has suggested the sequential role of Snail and LEF1 for stimulation of EMT. 
Both transcription factors are expressed in tissues that undergo EMT during embryogenesis [48, 
60] and have been described to promote the invasive phenotype in cancer cells [61]. Snail 
repression of E-cadherin has been well established and directly correlated with EMT. However, 
upon blocking LEF1, epithelial cells fail to undergo mesenchymal transition. The role of LEF1 
has become increasingly complex as it can bind with b-catenin to regulate mesenchymal 
markers, form transcriptional complexes with pSmad2/4 to directly repress the E-cadherin gene, 
and negatively regulated by the Groucho/TLE complex [62, 63]. Our model is capable of 
capturing the necessary role of both Snail and pSmad2/4LEF1 E-cadherin repression.  We 
found that during TGFβ2 stimulated computer stimulation, E-cadherin reduces substrate affinity 
for beta-catenin and accumulation of free cytosolic beta-catenin ensues. When blocking TGFβ3, 
low levels of free cytosolic beta-catenin still accumulate. This suggests that Snail acts as a 
primer to release membrane bound beta-catenin. However, the pSmad2/4/LEF1 complex is 
needed to fully repress E-cadherin for complete mesenchymal phenotype shift, suggesting that 
the pSmad2/4/LEF1 complex is very robust to the negative feedback.  Hence, a dual block of 
the Snail and pSmad2 may be needed to terminate EMT.  
 
9.3.2: Myofibroblastic activation during mitral valve degeneration 
VICs continuously remodel their environment in response to mechanical cues by secreting and 
degrading ECM, releasing growth factors and cytokines, and reorganizing adhesive interactions. 
As shown in Chapter 3, embryonic AVC transition from a highly contractile myofibroblast 
phenotype during cushion development to a quiescent phenotype at later stages of maturation.  
Underlying this phenotype, transition RhoA-GTP levels dramatically decrease causing a direct 
reduction in alpha smooth muscle actin.  Without this transition, leaflet maturation would not 
ensue, and a thick fibrous tissue would form.  Interestingly, this thick fibrous leaflet and 
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consequent valve dysfunction is found in a number of mitral valve diseases such as Marfan 
syndrome and Myxomatus degeneration [64].  In these conditions, the diseased mitral VIC 
express contractile filaments like αSMA, matrix metalloproteinases, and exhibit increased 
traction for matrix remodeling, all features of activated myofibroblasts [65, 66].  This prompts the 
question, what are the contributing factors to this mitral valve degeneration and can we apply 
any of the molecular blue-print found during the myofibroblastic transition during embryonic 
development? 
 
Over the last decade, significant progress has been made on understanding the functional 
consequences of mitral valve degeneration [67].  The bulk of these studies have established the 
critical contribution of ECM deficiency through altered cell–matrix interactions and dysregulated 
TGFβ signaling [64, 68].   For example, in Chapter 6 we showed those cell-matrix deformation 
kinematics are decoupled in Marfan mutated valves.  This “decoupling” in cell-matrix 
deformation kinematics suggests that they are unable to sense or respond appropriately to their 
local microenvironment.  While we have yet to fully investigate the mechanism, one possible 
explanation is that TGFβ upregulation is altering adhesive and contractile elements in the VICs, 
which leads to this phenotype transition pathological remodeling of their microenvironment [69].  
From our previous results in Chapter 3 and 4, both embryonic and aortic valve interstitial cells  
seeded in unstressed hydrogels remain quiescent while when free floating in hydrogels.  
However, during mechanically anchored conditions, the cells develop tension and upregulate 
contractile expression, TGFβ, and matrix remodeling.  We found that mechanical strain 
regulates this process by regulating αSMA and vimentin expression.  Interestingly, strain 
directionality was found to potentiate this process by elevating αSMA and vimentin expression.  
Furthermore, we determined that both TGFΒ1 expression and smad2 phosphorylation were 
specifically activated by biaxial strain patterns.  Coupled with the known dysregulation of TGFβ1 
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in mitral valve degeneration, these findings may indicate that dysregulation in TGFβ signaling in 
MVIC may be controlled by altered mechanobiological signaling in cell-matrix interaction.   
 
Hence, further investigation into how strain controls fibroblast-myofibroblast transition in VICs 
through adhesive TGF-β signaling should be considered.  As revealed in Chapter 4, potential 
downstream targets effecting embryonic phenotype transition and matrix remodeling include the 
mechano-sensitive small GTP proteins RhoA and Rac1.  RhoA regulates actin cytoskeleton and 
stress fiber formation, while Rac1 regulates cell-cell adhesion, actin polymerization, and 
cytoskeletal polarity [70].  These proteins may be the mechanobiological mechanisms of 
myofibroblast activation and remodeling in the mitral valve.  Advances in our understanding of 
mechanobiological processes may lead to mechanics based treatments to attenuate 
pathological signaling and future uses of our dynamic bioreactor may be to screen for diseases 
mechanically at a cellular level. 
 
 9.4 Sustained Cyclic Deformation a Key for Tissue Homeostasis? 
During development, a constant barrage of hemodynamic occurs concomitantly with increasing 
mechanical force.  It is speculated that heart valve interstitial cells (VICs) maintain valvular 
tissue homeostasis through mechnoregulated extracellular matrix (primarily collagen) 
biosynthesis.  In mice, both blood pressure and myocardial contraction have been shown to 
significantly increase at 2 weeks, 3 weeks, and 4months, implying that the stresses on the 
valves are also increasing [71].  Our work has shown that the effective modulus of AV valves 
increase significantly during this period.  This is complemented by the histochemical sections 
revealing collagen compaction and a significant increase in the collagen to GAG fractional ratio 
during this period.  Previous studies in chick, have found that both AV cushions increased in 
effective modulus between HH17 and HH25, which correlated with increased blood velocity and 
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myocardial contraction. Enzymatic digestion of major structural constituent collagens or 
glycosaminoglycans resulted in distinctly different stress-strain curves suggestive of their 
individual contributions [36].  In mice, extracellular matrix remodeling and production of mature 
collagen between N11.5 and 8 weeks supports the notion of that matrix composition and fiber 
alignment/compaction is critical to the growth and function of heart valves [72].  Further work by 
Aikawa et al., visualized the extent of collagen remodeling during human development.  It was 
found that during early fetal, late fetal, child, and adult, both collagen fiber thickness and 
alignment increase in the valves, while in diseased state reverted back to an immature form 
[73]. 
 
The precise mechanisms by which macroscopic stress effects cell to ECM interactions remains 
under investigation.  Our work has shown that in post-natal development and diseased states, 
tissue stiffness correlates with cellular deformation.  We speculate that ECM composition, fiber 
alignment, and compaction, play a key role in regulating the degree of cellular deformation.  As 
collagen fibers are recruited, alignment and compaction results in tissue stiffness and cell 
lengthening [74].  In the heterozygous C1039G mice, we found tissue stiffness to be almost 
identical to that of a 3 week wild-type valve, suggesting an immature leaflet undergoing 
extensive remodeling.  Our histochemical analysis revealed a large abundance of GAGs, which 
was not unexpected as myxomatous valves have been shown to contain more GAGs and PGs 
than normal [65, 75].  Previous work using the C1039G mice had also found that the mitral 
valves were much thicker than C57/B6J, which could possibly be contributed to the swelling 
nature of GAGs [68].  This lack of collagen organization and increased GAG content may prove 
to limit the overall amount of cellular deformation under mechanical load.  Furthermore, the 
reduction in tissue stiffness may also play a role in traction force generation.  Numerous studies 
have shown that the degree of traction force is proportional to substrate stiffness, via integrins 
[76].  Recent work by Bax et al., reported an RGD sequence of fibrillin-1 has been reported to 
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support cellular adhesion in vitro via integrin avb3 [77].  Therefore, the increased GAG content 
and disorganized extracellular matrix may prove to regulate traction force generation, and hence 
the ability to deform during mechanical load. 
 
9.4.1: Hypothetical Scheme of Conserved Deformation 
To understand the physiological relevance of these findings, we computationally simulated the 
in-vivo macro-scale valve mechanics to predict an overall amount of micro-scale cellular 
deformation.  Valve stress states were estimated using a spherical pressure vessel model (hoop 
stress) as suggested by Thubrikar et al.  Membrane stress in the circumferential direction is 
defined by σm = ((Pv -Pa)*Rd)/T, where Pv -Pa is the transvalular pressure, Rd is the radius of 
deformation, and T is the thickness at the mid-zone. [78].  Previous literature values were used 
to estimate blood pressure and diameter of mitral annulus (1/2 annulus diameter annulus was 
used for radius of deformation) [71, 79, 80].  Valve thickness was determined through 
histological morphometery and confocal z-stacks (Table 9.1).   
 
 
Table 9.1 – Supplement Table 1. In-vivo physiological parameters used for estimated stress states 
of mitral valves.  Systolic blood pressure and mitral valve annulus measurements were gathered from 
various literature sources while, mitral valve thickness was estimated using histological  morphometry and 
confocal z-stack measurements.   
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According to our stress-strain curves, hypothetical stretch ratios were found to converge upon a 
stretch ratio of 1.3 during maturation in the C57/B6J mitral valve leaflets (Figure 9.5A).  
Likewise, transposing these stretch ratios onto cellular deformation curves, we found that the 
circularity index converged upon a deformation of 0.71 (Figure 9.5B).  
 
 
Figure 9.5 –Microscale deformation under macroscale stretch.  (A) In-vivo train states for different 
aged valves were estimated using physiological stress states (Table S1).  Upon maturation, the marfan 
mitral valve leaflet converges to a stretch ratio of 1.3.  (B)  Strain states for each valve were mapped 
against respective circularity index curves for estimating overall deformation.  Upon maturation, cell 
deformation converges upon a circularity index of 0.7. 
 
 In the case of the mutant valves, hypothetical tissue stretch ratios were λ=1.25 and λ=1.37 in 
the +/+Fbn1 and C1039G/+Fbn1, respectively (Figure 9.6A).  Transposing these stretch ratios onto 
the cellular deformation curves, we found that the projected cellular deformations between the 
two cases are identically CI=0.71 (Figure 9.6B).  This suggests that mechanisms of remodeling 
could stem from intrinsic cell properties governed by a specific strain.  Depending on the stress-
state observed on the mitral valve, the valvular interstitial cells will remodel the matrix to 
maintain a desired level of deformation (or strain) (Figure 9.6C). 
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Figure 9.6 – Microscale deformation under macroscale stretch.  (A) In-vivo strain states for both 
wildtype and mutant mitral valves were estimated using physiological stress states (Table S1).  At 
physiological loading states (115mmHg), the marfan mitral valve leaflet will stretch significantly more than 
wild-type (λ = 1.37 vs. λ = 1.25).  (B) Mapping stretch states for each valve to circularity index suggests 
that cell deformation is identical in wildtype and marfan valve despite the elevated stretch.  (C)  We 
hypothesize that indigenous valve fibroblasts may remodel their matrix microenvironment to to maintain a 
homeostatic morphology (in this case CI = 0.71).  
 
 
In the case of the Fbn1 mutation, VIC may therefore pathologically degenerate the matrix in 
order to achieve the homeostatic deformation state, which in turn weakens the tissue further in a 
vicious cycle leading to structural failure.  Due to loss of mechanical competence and increased 
surface area of the mitral valve leaflets, this disease leads to regurgitation and cardiac 
dysfunction.  There is a strong clinical need for percutaneous treatment of patients with mitral 
valve disease and regurgitation as an alternative to open-chest surgery [81]. This raises the 
possibility that matrix stabilization such as collagen crosslinking or radiofrequency ablation could 
be used to maintain mechanical performance and thereby delay remodeling [82]. 
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Few studies have investigated the mechano-regulation of VIC in response to altered pressure or 
strain.  Work by Merryman et al., used micropipette aspiration to assess VIC cellular stiffness 
and cytoskeleton composition from 4 different heart valves.  It was found that the VICs from the 
aortic and mitral valves were significantly stiffer than those from the pulmonary and tricuspid 
valves and left-side isolated VICs and correlated with the different transvalvular pressures [83].  
VIC isolated in vitro and mechanically strained were found to increase collagen synthesis upon 
the degree and duration of stretch.  Furthermore, when pulmonary VICs were exposed to aortic 
pressure levels, as occurs following the Ross operation, collagen and sulfated 
glycosaminoglycan synthesis were increased significantly [84]. This demonstrates that VICs are 
capable of remodeling the ECM in response to changes in the mechanical environment.  We 
speculate that mechanobiolgical consequences of hemodynamic load may play in important part 
in regulating matrix remodeling such that VIC will remodel accordingly to maintain a desired 
level of deformation.  In the case of pathological conditions, this may lead to altered ECM 
production and hence, dysfunction tissue biomechanics.   
 
In summary, elucidating the specific roles of mechanical force and extracellular matrix cues on 
valvular cells may potentially lead to an effective protocol for clinically applicable strategies.  
Understanding the embryonic pathway focuses on the “controlled” and direct process through 
which progenitor cells become mature quiescent valve cells.  To our advantage, homeostatic 
baselines during development rapidly transition (epithelial-mesencymal-fibroblast), and in many 
cases recapitulate partial events that in adult diseases’, such as valvular calcification.  
Additionally, by mapping the molecular blueprint “roadmap” during development, we may begin 
to solidify biological thresholds for normal vs. pathogenic cellular events during the valve 
development and aging process.  My hope is that these newly generated hypotheses and 
findings will bring use one step closer to developing novel regenerative agents.  
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CHAPTER 10 
 
CONCLUSIONS AND FUTURE RECCOMMENDATIONS  
 
 
 
Over 200,000 years of productive life before the age of 55 are lost due to CHD in the US each 
year and the annual direct cost for valve disease in the US is $1 billion (Nkomo et al., 2006).  
While failure to initiate the formation of valves is uniformly lethal in early gestation, clinically 
serious malformations arise from improper structural maturation of the valvuloseptal apparatus 
and outflow tract, including tetralogy of fallot, left heart hypoplasia, bicuspid aortic valve, and 
ventricular septal defects (Srivastava, 2006).  Nearly all study of mechanical action on cellular 
function focuses on the “normal and pathological” adult age. This neglects key s tages in the 
functional life cycle of tissues where remodeling is most active yet, controlled, early 
development. Until the basic interactions between cells and their microenvironment are 
understood in this context, our ability to understand congenital malformation and manipulate 
these phenomena remains limited.  By using a developmentally inspired approach, I hope that 
my work eventually lead to efficient strategies for control tissue adaptation and remodeling as 
well as accelerate the construction of cardiovascular tissue replacements.  
 
Pure populations of progenitor endocardial cells and valve mesenchyme were isolated using the 
protocols developed in Chapter 2.  Eventually, we expanded these protocols to isolate cells later 
stage AV valves ranging from HH29-HH42.  While the protocols were generally suitable for 
these cells, we did find that two important factors were critical during this isolation process. Both 
the concentration of chick serum and seeding technique dramatically regulated cell survival and 
growth.  We initially found that 1% chick serum from passage HH14- was sufficient to culture the 
endocardial progenitor cells.  This was of optimal concentration since higher amounts are 
thought to potentially shift the native phenotype.  However, during initial experimentation, 1% 
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was not sufficient for culturing HH25 mesenchymal progenitor cells.  In this case, we needed to 
increase the concentration to 5%.  We believe this was due to the fact that HH25 cells were 
embedded within a 1.5mg/ml collagen hydrogel, while the HH14 were seeded on top of the gel.  
While there may be multiple explanations for this observation, we feel that embedding of valve 
progenitor cells at HH25 into collagen gels was too harsh due to either 1) lack of cell-cell 
contacts needed for cell survival, 2) collagen gel stuffiness was much higher than native tissue 
at that stage, or 3) collagen itself (cell-ECM) lacked the necessary binding potential for these 
cells.  Hence, further investigation into how and why tissue stiffness or ECM components affect 
this progenitor cell phenotype/homeostasis should be considered.  Possibly adding a certain 
percentage of HA (Hylurounic Acid) may help with cell binding, or changing collagen 
concentration (to a lower amount) may be useful.           
 
In Chapter 3, it was shown that directionally of mechanical stretch can mediate the proliferation, 
differentiation, and remodeling process of aortic valve interstitial cells in a collagen construct.  
While we established an important model of cellular remodeling with respect to phenotype 
(mechanically anchored vs. free floating conditions), this was of no means exhaustive.  Further 
investigation into the remodeling processes associated with stretch directionality should be 
considered.  For example, how do the resident valve cells actually remodeling the collagen 
constructs?  Possibilities include 1) secretion of MMPs (MMP2, MMP9), 2) cell contractility to 
compact fibers, 3) cell polarization to organize fibers or, 4) secretion of new ECM (mature vs. 
immature fibrils, collagen, elastin, GAGs, etc.).  Concurrently, understanding the time course in 
which this happens is important.  Do the cells align first and then orient the underlying matrix 
second, or do the cells align and then degrade/secrete new matrix.  By using this this 
established model, an informative study would be useful for understand the possibly 
mechanisms by which normal and abnormal remodeling occurs during directionally mediated 
mechanical stretch.      
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Using the previously developed bioreactor and mechanically anchored vs. stress free gel 
models, in Chapter 4 we sought to understand how matrix condensation occurs simultaneously 
with phenotype quiescence typically seen in mature valves.  We found both in-vitro and in-vivo 
that RhoA/Rac1 divergence driven by mechanical stretch is central to this process.  While this 
study was fairly in-depth and comprehensive, there are still areas that could be improved and/or 
investigated.  First, understanding the myofibroblastic differentiation of valve interstitial cells by 
expanding the RhoA-SRF signaling pathway.  Recent evidence implicates serum response 
factor (SRF) and the myocardin-related transcription factors (MRTFs) as key mediators of the 
contractile gene program in response to TGF-β1 or RhoA signaling.  It has been suggested that 
a signaling axis between MRTF and SRF can regulate ACTA2 transcription through various 
levels of F-actin and G-actin.  Mechanical stretch and directionality most likely plays a large role 
in regulating these different types actin polymerization and is likely a good place to investigate.  
Second, at later stages of development Rac1 (HH40) was localized to the endothelial layer of 
the fibrosis valve layer.  At later stages of the adult life, this layer is prone to calcification.  It 
would be interesting to observe whether Rac1 is altered in any diseased conditions, compared 
to normal conditions within these endothelial cells.  Rac1 could possibly serve as a protective of 
the endothelial layer as it recently has been found to regulate ROS expression.  Third, the 
dynamics between RhoA and Rac1 are important for regulating myofibriblastic vs. quiescent 
activity.  However, the full phenotype of a valve progenitor cells has not yet fully been 
established.  I suspect that controlling the transcription factors Sox9 and Scx will be equally 
important, shown to be driven by FGF and BMP growth factors.  Recent evidence has also 
shown that Sox9-bcatenin pathway is regulated by actin polymerization and mechanical 
stimulation, possibly connecting the role of Small GTPases with Sox9.  
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In Chapter 4, we investigated the post-natal AV valve multi-scale interactions between tissue 
stretch and underlying cell-matrix deformations.  We found that tissue stretch correlates strongly 
with bulk stiffness, cell deformation, and alignment.  However, in diseased conditions such as 
Marfan syndrome, the underlying tissue deformation and tissue stretch becomes decoupled 
leading to dysfunctional mechanobiology and biomechanics.  An important question previously 
unidentified and revealed by this study is whether these alterations in local cell-matrix 
interactions with stretch are a cause or consequence of valve tissue remodeling.  Three 
possible hypotheses into the mechanical etiologies of valve dysfunction include 1) the interstitial 
cells experience a reduced mechanical force distribution, 2) cells experience the normal loading 
but, the interstitial cell is unable to sense it correctly (e.g. its mechanotransduction processes 
are tuned improperly), or 3) the cells sense the normal loading but can’t respond appropriately, 
hence pathologically remodeling the matrix instead of augmenting/maintaining its mature 
organization.  Further investigation systematically testing these different hypotheses should be 
considered.  
 
The complexity of cellular signaling is overwhelming due to the large numbers of interacting 
protein complexes, complicated feedback mechanisms, and cross-talk between multiple 
signaling pathways. As a result, even predicting the fundamental regulation of cellular fate 
processes remains difficult.  Hence, systems biology has been suggested as an essential tool.  
In Chapter 6, we sought to model the epithelial-mesenchyme transition (EMT) phenomenon, the 
first step of valve formation.  Using a systems approach, we established a predictive 
mechanistic model of EMT susceptibility, and revealed a novel signaling axis between phospho-
Sp1/NFAT for possibly regulating a normal mesenchymal invasion potential of endocardial cells 
vs. metastatic carcinoma.  In addition to the possible hypothesis discussed in Chapter 7, we 
have also developed a second generation model of valve differentiation (included in the 
supplement).  Within this model, we have included the small GTPases RhoA, Rac1, and FGF 
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signaling pathways.  Together these factors represent the entire differentiation spectrum 
associated with interstitial valve progenitors.  For future studies, I suggest training this model on 
our preliminary data captured in Chapter 4.  Once trained this model can then be used as a 
model to analyze molecular pathways, or apply towards multi-scale finite element analysis.   
 
In the final chapter 8, we developed a hands-on lesson to investigate the effects of an 
angiogenesis factor (prostaglandin E1) on the morphogenesis of chick vasculature.  The student 
activities mirror the scientific research process, including review of the scientific literature, 
hypothesis formation, experimental design, interpretation of data, and re-evaluation of initial 
hypothesis.  The exercise supports instruction on developmental biology, biophysics, animal 
research, and experimental design, and is motivated by a clinically relevant health issue.  While 
this lesson was inquiry and comprehensive, the application of using engineering technologies to 
teach students is not limited.  A few other ideas include growing zebrafish to understand 
congential defects (i.e. aquarium with zebra which can be spiked with chemical mutation at any 
time), pacing an avian embryo to understand the role cardiac rhythm in humans (i.e. hooking up 
electrodes within the ex-ovo culture and applying a certain voltage/frequency), development of 
pressure devices to understand the purpose of valves in the heart (i.e. using tubing and other 
materials, fabricate a homemade valve that can withstand the large pressures and maintain 
unidirectional flow), or teaching students about the role of mechano-transduction (i.e. create a 
computer program which can push and pull cell membrane, then cell has certain decision to 
make).  By developing these outreach activities, we hope to inspire and teach students about 
the engineering process (or science) so that they become interested in science, and maybe one 
day pursue such a career.             
 
 
In summary, a more developed understanding of valvular cell interactions in developmental 
conditions will help map a “blueprint” for developing targeted diagnostic and therapeutic 
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strategies.  Eventually we may be able alleviate congenital valve dysfunction before it 
progresses to tissue failure, potentially removing the need for valvular replacement or repair 
entirely.  
 
 
 
235 
 
APPENDIX A  
 
Relevant Protocols 
 
 
 
Protocol 1.1 - 3D Culture assay protocols for embryonic chick AV cushion mesenchyme 
 
1. Preparation 
a. Incubate 5 dozen fertilized chick eggs at 37 C and 40-50% humidity for 4.5 days. 
b. Autoclave in a covered instrument tray the following items: 
i. Serrated tissue forceps – for grabbing membranes around embryo 
ii. Tissue scissors (8 cm) – For cutting membranes around embryo 
iii. Dumont #55 forceps (2 pair) – for microdissection of tissues.  Make sure the tips are 
acceptable before autoclaving.   
c. Make sterile EBSS solution 
i. 10X liquid stock, dilute 100 ml 1:9 in milliQ water. 
ii. Add 2.2 g of sodium bicarbonate 
iii. pH to 7.0.   
iv. Sterile filter or autoclave.  If autoclaving, pH to 7.2 (filter raises pH ~0.2). 
v. Label as sterile and place in fridge until use. 
d. Make sterile 3X M199 solution 
i. Power stock, dissolve one packet in 333 ml. Use the last 33 ml to swish around the 
packet to get all powder.   
ii. Add sodium bicarbonate as indicated on package 
iii. pH to 7.0 
iv. Sterile filter (no autoclaving).   
v. Label as sterile and place in fridge until use. 
e. Make sterile 1X M199 solution 
i. Power stock, dissolve one packet in 1000 ml.  Use the last 25 ml to swish around the 
packet to get all powder.   
ii. Add sodium bicarbonate as indicated on package 
iii. pH to 7.0 
iv. Add 1% Penicillin/Streptomycin (P/S in freezer) 
v. Sterile filter (no autoclaving).   
vi. Label as sterile and place in fridge until use. 
f. Make chick cell culture medium (normally 100 ml at a time in autoclaved glass bottle) 
i. Sterile 1X M199 +P/S  
ii. + 1% Chick Serum (aliquots in freezer) 
iii. +ITS (aliquots in freezer) 
iv. Should be sterile already b/c components sterile 
 
2. AV Cushion cell isolation 
a. Clean up nasty clean bench, remove anything not being used especially for this experiment.  
Should be just the scope, an ice bucket, chick bucket, absorbent pad, some 100 mm culture 
dishes, and reagents. Wipe surfaces with ethanol before putting down pad.  Have bench 
circulating for 10+ mins before working. 
b. Wear gloves and lab coat.  Don’t be coughing/sneezing into the workspace.   
c. Take one 100mm dish and add ice cold EBSS.  Keep on ice.  No need for lid but be sterile. 
d. Take another 100mm dish and use for cracking eggs into. 
e. Spray eggs with ethanol and allow to air dry or wipe off.  Can do all eggs at once. 
f. One at a time, crack egg into dish and remove embryo.  Place embryo in EBSS on ice. 
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g. Do all 60 eggs.  You may need to empty egg bucket once.  Do it before ¾ full or you’ll have a 
big mess on your hands. 
h. Take dish with embryos and place under dissecting scope.   
i. Pull hearts from all the embryos and place in a specific location near the edge of the dish.  
You will have to move embryos around as you go through them.  
j. Using a sterile transfer pipet, transfer the hearts to a new dish with fresh cold sterile EBSS. 
k. Isolate the AV region from all hearts at once in assembly fashion.  Place the AVs in a specific 
region in the dish.  If you want, you can also isolate the ventricle and/or outflow tract and 
place them in separate places.  Ventricle cells are a nice comparison with AV and outflow 
tract cells are useful as well, especially as positive controls for Westerns.  You may want to 
gently shake each AV to get all the blood out.  Blood is bad, not fatal though.   
l. Again, sterilely transfer the AVs to a new dish with fresh cold EBSS.   
m. Sequentially isolate the cushions from the AV.  Make sure there is no myocardium present.   
n. Every 15 or so cushions, sterilely transfer them to a 15 ml conical tube that is on ice.  Be 
careful that none of them get stuck in the tube.   
o. Once all the cushions are in the tube, gently spin cushions to the bottom (300 rpm for 3 min in 
bucket centrifuge). 
p. Take a 1000 ul pipet (blue tips, sterile) and remove as much EBSS as possible without 
disturbing the cushions. 
q. Add 1 ml of prewarmed 0.25% Trypsin (freezer or fridge).  Place in water bath at 37C for 5 
min.  Pipet up and down with 1 ml tip until completely dissolved.  Add 100 ul chick serum to 
quench.   
r. Pellet cells at 1000 rpm for 5 mins.  Remove supernatant with 1000 ul tip. 
s. Resuspend in 5 ml of culture medium and mix by pipetting.  Take 10 ul of suspension and 
count on hemacytometer.  Calculate the number of cells you have. 
 
3. Invasion/migration assay.   
a. Reconstitute cells in 1000 cells/ul suspension. 
b. Pipet 20 ul boluses of this suspension in an array on a 100 mm culture lid.  Be careful to not 
get any air into the droplets (i.e. set the pipet to 22 ul and don’t push all the way down).  Also, 
place the droplets in a circle around the central region of the lid. 
c. Fill the culture dish (not the lid) with sterile EBSS. 
d. In a smooth yet quick motion, flip the lid back on the culture dish. 
e. Incubate overnight (18 hours) in the incubator (37C, 5% CO2).  The cells should aggregate by 
gravity into a small sphere inside the droplet. 
f. Next day: Make collagen gels according to the protocol in the clean bench.  Anywhere 
between 1.0 and 2.0 mg/ml can be used for different stiffnesses, but my standard is 1.5 mg/ml 
and 250 ul volume/gel.  Let solidify in the incubator for 60 mins. Do not liberate them or add 
media yet. 
g. Place the dish with the hanging drops and the collagen gels in the clean bench.  
h. Using a 20 ul pipet tip, gently suck up the drop and place down on top of a gel, slightly off 
center.  Up to 3 drops can be placed on each gel, but 2 is standard.  They should be far 
enough apart to not interact with each other. 
i. Let drops adhere for at least 1 hour (2 hours more ideal). 
j. Using 200 ul pipet, gently add culture media from the edge of the well, making sure to not 
introduce any sudden gushes.  The drop should be adhered, but be very gentle, the slightest 
nudge can wreck it.  
k. Do one 4-well at a time, and put the finished ones in the incubator.  Only have out of the 
incubator the drops you are using for that well plate. 
l. Culture for 72 hours or according to experiment. 
 
4. Collagen compaction assay 
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a. Using worksheet, determine how many gels you will make based on the number of cells you 
have isolated.  Typically 48 well plates are used for making gels with 1.5 mg/ml collagen and 
250 ul gel volume. 
b. Pellet cells and pipet off supernatant. 
c. Using protocol, add 3X M199, Water, Serum, Treatment (if any), Collagen, and NaOH in that 
order.  Mix by gentle pipetting.  
d. Inoculate 250 ul into each well.  Work quickly.   
e. Let solidify in the incubator for 1 hour. 
f. Add 400 ul of culture media.  Incubate overnight. 
g. Next day, liberate gels under dissection scope using 200 ul pipet tip.   
h. Culture until experiment ends.   
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Protocol 1.2 - Cyclic Stretch Bioreactor 
 
 
Making molds (PDMS) 
1.  Using the Sylgard 184 silicone elastomer kit, pour 66.5 grams of elastomer base into a plastic cup  
 
2.  Add 3.5 grams of elastomer curing agent into the cup, for a total of 70 grams (1:20 dilution) 
 
3.  Mix thoroughly with metal spatula (mixture should be white and bubbly) 
 
4.  Place cup in the vacuum chamber and de-gas the mixture (will take 30-45 minutes) 
 
5.  Pour one cup of mixture (70 grams) into one plastic mold.  Make sure  
to scrape off as much of the mixture from cup as possible. 
 
6.  Use leftover PDMS to re-coat the edges of the wells on previously  
made silicone molds. 
 
7.  Heat in oven at 65°C for at least 6 hours (usually leave in overnight) 
 
*Note: to make large rectangle control mold, use two cups of PDMS mixture (70 grams each) 
 
Cleaning cassettes and springs 
1.  Using tissue punch, punch out holes in PDMS mold where the screws will attach the top and bottom 
cassettes, with the PDMS sandwiched in between. 
 
2.  In warm water with soap, soak and scrub aluminum cassettes (especially the inner walls of the wells), 
bottom cassette pieces, and PDMS molds.  Make sure that the wells are very clean, then rinse with DI 
water.  Set to air dry. 
 
3.  Wash the springs by shaking in a 50ml centrifuge tube with warm water and soap.  Rinse thoroughly 
with DI water.  You may have to do this several times until completely clean.  Set out to dry. 
 
4.  Preparing springs: 
 For 1:1 strain: Fold one 1” spring into a circular shape (hook one end of the spring onto the other) 
 For 2:1 strain: Attach two 0.625” springs at the ends to form an oval shape 
 For 4:1 strain: Attach two 0.75” springs at the ends to form an oval shape  
 
 
Prepping cassettes and molds 
1.  Place PDMS mold on top of the bottom cassette piece so the open wells are facing up, and they are 
in the middle of the holes in the cassette (so the platens will hit wells in the 
middle for an even stretch) 
 
2.  Place top cassette on top of the PDMS mold, then screw tightly into place 
using an Allen wrench. 
 
3.  Make up an autoclave bag for each cassette. 
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4.  Trim off any PDMS overhanging the cassette edge with a straight edge blade, and place one spring 
into each well (to be inserted after autoclaving). 
 
5.  Seal autoclave bag, label with name and autoclave tape. 
 
 
Preparing materials for experiment 
1.  Place extra washed springs into autoclave-appropriate boxes  
2.  Place gloves into a box to be autoclaved (these will be used to insert the springs) 
3.  Place forceps into a box to be autoclaved 
4.  Prepare spring controls: 
(a)  Wash and dry squares of the control PDMS molds 
(b)  Place washed springs into each control well (it won’t matter if they crack in the autoclave 
because they are controls) 
(c)  Put these controls in a box to be autoclaved 
 
5.  Gather cassettes (in their bags), springs, gloves, controls, and forceps and place in an autoclave 
bucket 
 
6.  Put cassettes on top of boxes so the bottom of the bags won’t get wet 
 
7.  Autoclave setting: GRAVITY 25:00 min sterilize, 11:00 min dry 
 
 
Pre-experiment: Checking settings on the bioreactor 
Prepare bioreactor 
1.  Coat white plastic platens with braycote (804) rubbing on smoothly with finger 
 
2.  Use a small screwdriver to make sure that the small holes drilled into the sides of the platens are 
clear (drilled holes prevent bubbles from forming under the gel) 
 
3.  Pour lubricant into large middle screw and into all four ball bearings 
 
Check software program 
1.  Plug bioreactor into the controller 
 
2.  Plug controller into the wall 
 
3.  Plug controller into the computer  
 
4.  Open SMC60WIN (controller software) 
 
5.  Connect the unit (top right)  
*Note: This is very important: make sure unit is 
connected before you load any program to the 
controller 
 
6.  Upload program from controller 
 
7.  Send the program back to the controller (so it will 
know its starting point) 
 
This order is extremely important 
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8.  Run the program to see if motor and bioreactor is running smoothly 
 
Troubleshooting:  
1.  Make sure screws are tight on the motor (or 
else the gears won’t connect – no torque): 
tighten using hex screwdriver and attachment 
2.  For a tighter grip between gears, add 
grease to the gears 
 
9.  Set the plate manually until it is flush with 
the platens 
 
10.  Move plate up 200 steps (counter 
clockwise): this is where the cassettes will be 
loaded 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Insertion of springs into wells 
*All of these procedures should take place in the laminar flow hood 
 
1.  Open all autoclave bags with cassettes so you will be able to easily remove them later (do not touch 
cassettes yet) 
 
2.  Put on new pair of autoclaved gloves.  Touch only the very edges of the gloves (do not touch the 
fingers).  Put the right glove on first, then the left glove.  The left-hand fingers and the most important 
to keep clean (they will be touching the springs) 
 
3.  Remove the cassettes with autoclaved gloves  
 
4.  Insert the springs by pushing up on mold with your right thumb from the bottom, and carefully place 
the spring into the well with your left thumb and fingers 
9. Set to flush position 10. Up 200 steps to load cassettes 
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5.  Cover each cassette with a sterile plastic dish cover  
 
6.  Once all springs have been loaded, load each cassette into bioreactor (which should be set at 200 
steps above flush) 
 
7.  Lock in cassettes with the screw-clamps 
 
8.  Place the cassettes diagonally so the loading does not unbalance the bioreactor 
 
*Once cassettes are loaded (after springs are inserted) 
 1.  Go down 200 steps until flush 
 2.  Go down 400 steps where gels will be loaded (this will be the starting point for the experiment) 
 
 
 
 
 
 
 
 
 
 
 
 
9.  Turn on large incubator (37°C, around 3.6-3.7% CO2) 
 
10.  Place bioreactor in large incubator while making collagen gels 
 
 
 
 
1. Reset to flush position 2. Go down 400 steps to load gels 
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Making the Collagen Gel. 
 
Reagents (cell culture) 
Dulbecco’s modified eagle’s medium (DMEM)  
0.25% Trypsin-EDTA 
1X Phosphate buffered saline (PBS) 
Reagents (collagen gel) 
3X DMEM 
18 mΩ H2O 
Fetal Bovine Serum (FBS) 
Collagen type I (rat tail) 
0.1M NaOH 
Cell source 
Valve interstitial cells (use between passage 4-8) 
 
1.  Take a T75 flask of VIC out of the incubator, wash once with 10 ml of warm PBS 
 
2.  Add 4 ml of trypsin to the flask to trypsinize the cells (37°C) for 5 minutes 
 
3.  Add three times the amount of DMEM to terminate the digestion (12 ml).  Transfer to a 
centrifuge tube.  DO NOT centrifuge. 
 
4.  Count the cells using a hemocytometer. 
 
5.  Calculate the desired volume of cell suspension using collagen only disk template file. 
*Example: for VIC gels, use 400,000 cells/ml  
 
6.  Transfer the desired volume of cell suspension into a 15 ml tube; centrifuge at 1000 rpm for 5 
minutes 
 
7.  Prepare a bowl of ice.  Put collagen, 0.1M NaOH, 18 mΩ H2O, FBS, and 3X DMEM on ice  
 
8.  After centrifuge, aspirate the supernatant, add in order to the cell pellet  
3X DMEM 
18 mΩ H2O 
FBS 
Collagen 
NaOH 
 
*Mix well with each step.  Especially make sure the NaOH is well mixed with the collagen on the 
last step 
 
 
Seeding springs 
*Best to start in back and move forward 
 
1.  For 1:1 gels, add about 120µl 
d   
2.  For 2:1 gels, add about 140µl 
 
Make sure gel is completely within the coils of the springs so the 
gel will compact correctly.  Try to suck out the air from the coils, 
which will bring the collagen into the spring 
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3.  For 4:1 gels, add about 150µl 
d  
4.  After seeding bioreactor, seed controls (and if needed, the released gels ~150 µl in a 46-well 
plate, released 12 hours later) 
 
5.  Set bioreactor in incubator, let gels sit for one hour 
 
6.  Add media to gels (bioreactor and controls) 
 
7.  Let gels compact around gels for 24 hours 
 
 
Starting bioreactor 
1.  Attach water hoses to the cooling plate beneath the bioreactor 
 
2.  Plug the controller into the computer (it should already be attached to the bioreactor) 
 
3.  Connect unit 
 
4.  Upload program from controller, then send it back (this sets starting position) 
 
5.  Run the program (them remove USB connection from controller) 
 
6.  Turn on power strip where water pump in freezer is attached 
 
*Make sure incubator is at 37°C, around 3.6-3.7% C 
 
 
Materials: 
Bioreactor materials 
Sylgard 184 silicone elastomer kit (Dow Corning, 
3097358-1004) 
Castrol braycote (804) grease (SPI supplies, 05133-
AB) 
Lubricating oil  
 
Compression springs 
1” springs (Lee Spring Co., CI 010B 13 S316) 
0.75” springs (Lee Spring Co., CI 008B 11 S316) 
0.625” springs (Lee Spring Co., CI 008B 09 S316) 
 
Collagen gel and media reagents 
Dulbecco’s modified eagle’s medium, DMEM 
(Invitrogen, 12100-046) 
Fetal bovine serum, FBS (GemCell 100-500) 
Penicillin-streptomycin (Invitrogen, 15070-063) 
Collagen Type I, Rat Tail (BD, 354236) 
0.25% Trypsin-EDTA (Invitrogen, 25200072) 
 
Example bioreactor program (20%strain, 1 Hz) 
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Protocol 1.3 - Phalloidin (F-Actin) Staining 
 
 
Phalloidin stock should be prepared by dissolving in 1.5 mL methanol to yield a final 
concentration of 200 U/mL (which is about 6.6 μM) 
 
Method: 
1. Fix cells in 4% PFA overnight at 4°C 
 
2. Wash once with PBS and store at 4°C in 70% EtOH 
 
3. Wash 3 times with PBS 
 15 minutes each on rotator 
 
4. Permeabilize with 0.2% Triton-X 
 ex. 20μL per 10mL PBS 
 10 minutes on rotator 
 
5. Wash 3 times with PBS 
 15 minutes each on rotator 
 
6. Block in 1% BSA in PBS at 4°C 
 Either overnight at 4°C or for 1 hour at 37°C 
 
7. Remove 1% BSA solution 
 
8. Add 5 μL stock dye to 200 μL 1% BSA (1:40 dilution) for each gel to be stained 
 100 μL per gel sample 
 Incubate for 30 minutes at room temperature in the dark 
 
9. Wash 3 times with PBS  
 15 minutes each on rotator 
 
10. Add Draq 5 nuclear stain at 1:1000 dilution 
 100 μL per gel sample 
 Incubate 30 minutes at room temperature in the dark 
*Note: this step can be done with the phalloidin stain step to save time 
 
11. Wash once in 1X PBS 
 15 minutes on rotator 
 
12. Image with either confocal (Leica or Zeiss) 
*Note: Images are best if taken within 24 hours of staining 
 
13. Store in 18 MΩ water at 4°C covered in foil 
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Protocol 1.4 - Isolation of Endothelial Layer from Porcine Leaflet 
 
Protocol 
 
1. Preparation 
1. Autoclave in a covered instrument tray the following items:  
1. Serrated tissue forceps - For handling the leaflet tissue 
2. Tissue scissors (8 cm) - For trimming leaflet tissue and cusps 
3. Cotton Swabs - For isolating the endothelial layer from the leaflet or cusp 
2. Make sterile collagenase solution  
1. Add 4.0 grams of powdered DMEM to 250 mL of 18 MΩ water. 
2. Add 1.11 grams of sodium bicarbonate. 
3. Add (600 U/mL) 180,000 units of collagenase. 
4. Add 1% (3mL) Penicillin/Streptomycin. 
5. Adjust the pH of the solution to 7.2. 
6. Bring the solution up to 270 mL. 
7. Sterilize the solution by passing through a 0.2 μm filter. 
8. Add 10% (30mL) of sterile fetal bovine serum. 
3. Make sterile endothelial cell medium  
1. Add 6.7 grams of powdered DMEM to 400 mL of 18 MΩ water. 
2. Add 1.85 grams of sodium bicarbonate. 
3. Add (50 U/mL) 25,000 units of heparin. 
4. Add 1% (5mL) Penicillin/Streptomycin. 
5. Adjust the pH of the solution to 7.2. 
6. Bring the solution up to 450 mL. 
7. Sterilize the solution by passing through a 0.2 μm filter. 
8. Add 10% (50mL) of sterile fetal bovine serum. 
4. Make sterile interstitial cell medium  
1. Add 13.37 grams of powdered DMEM to 800 mL of 18 MΩ water. 
2. Add 3.7 grams of sodium bicarbonate. 
3. Add 1% (10mL) Penicillin/Streptomycin. 
4. Adjust the pH of the solution to 7.2. 
5. Bring the solution up to 900 mL. 
6. Sterilize the solution by passing through a 0.2 μm filter.  
7. Add 10% (100mL) of sterile bovine serum. 
 
2. Isolation of Heart Valve Leaflets 
1. Excise the aortic root immediately and aseptically from the heart after sacrifice. 
2. Thoroughly rinse the aortic root of blood with cold sterile DPBS. It is imperative to 
remove all blood components as soon as possible to limit VEC death and bacterial 
contamination. Antibiotics and antimycotics are not advised at this stage since they are 
potentially harmful to the VEC. 
3. Isolate valve leaflets (3 per valve) directly from the root and place in a sterile 15 mL 
conical tube filled with 12 mL cold DPBS. Shake several times to remove debris and refill 
with fresh DPBS. 
4. Transport back to the lab on ice. 
5. Upon arrival at the laboratory, place the container with the tissue under the sterile hood. 
 
3. Isolation of Endothelial Layer 
1. Fill a sterile 35mm dish with 3mL of cold collagenase solution per valve (3 leaflets). 
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2. Place all three leaflets from the 15 mL tube into the dish filled with the collagenase 
solution. 
3. Incubate the tissue for 5-10 minutes at 37 C. 
4. Gently remove the endothelial layer by rotating a dry sterile swab onto the surface of the 
leaflet. The direction of rotation and amount of shear applied is critical for the purity of 
your sample. The rotation of the swab should be in an opposite direction to linear motion 
of your hand creating a controlled shear. This shear is what lifts the endothelial cells 
from the tissue. The amount of force applied should be enough to feel the resistance of 
the tissue but, not penetrate the basement membrane. 
5. Occasionally, dab the swab within the collagenase solution to dislodge cells from the tip 
fibers. After swabbing is complete, the texture of the endothelial layer should feel slightly 
smoother than before. 
6. Collect the cell suspension/collagenase and transfer to a new sterile 15mL tube. 
7. Centrifuge the tubes at 1000 rpm for 5 minutes to pellet any isolated cells and aspirate 
supernatant. If isolating interstitial cells as well, perform that protocol while these cells 
are being centrifuged. 
8. Add 3 mL of endothelial porcine medium to the 15 mL tubes, centrifuge a second time, 
and aspirate media. This second centrifugation helps filter some of the unwanted 
material such as tip fibers. 
9. Re-suspend the centrifuged endothelial cells in 5 mL of endothelial porcine medium and 
plate the cells in a pre-coated T-25 flask with collagen (use 1 flask per centrifuge tube). 
10. Let the cells grow at least 2-3 days before changing the endothelial medium. This helps 
the cells recover and divide since the isolation process is fairly harsh and the cell yield 
may be low. It is critical to passage cells near confluence since contact inhibition could 
lead to cell transformation. 
 
4. Preparation of 60 mm Culture Dish for Side Specific Isolation 
1. Line the 60 mm glass petri dishes with aluminum foil (2 glass dishes per leaflet). The 
aluminum foil helps to remove the paraffin, so that the glass petri dish can be reused for 
other isolations. 
2. Place paraffin beads within the dishes, about half full, and cover for autoclaving. 
3. Once the autoclaving is complete and paraffin is melted, move the dish ensemble to a 
cool flat surface. As the paraffin cools, it will harden and create a layer that will support 
needle punctures. 
4. After 30 minutes, the sterilized dish can then be used as an isolation chamber to 
immobilize the leaflet tissue. 
 
5. Isolation of Side Specific Endothelial Layer 
1. Remove the leaflets from the 15mL tubes and place on prepared 60mm culture dish for 
side specific isolation. 
2. Manipulate the leaflet so that the ventricularis side is face down on the paraffin surface 
leaving the fibrosa side exposed. Pin the edges of the leaflet to expose the endothelial 
layer. 
3. Place a few drops of cold collagenase on each (upwards-facing) endothelial surface and 
incubate the tissue for 5-10 minutes at 37 C. 
4. As before, gently remove the endothelial layer by rotating a dry sterile swab onto the 
surface of the leaflet. The direction of rotation and amount of shear applied is critical for 
the purity of your sample. The rotation of the swab should be in an opposite direction to 
linear motion of your hand creating a controlled shear. This shear is what lifts the 
endothelial cells from the tissue and nothing else. The amount of force applied should be 
enough to feel the resistance of the tissue but, does not penetrate within the tissue. 
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5. Occasionally, dab the swab within the collagenase solution to dislodge cells from the tip 
fibers. After swabbing is complete, the texture of the endothelial layer should feel slightly 
smoother than before. 
6. Collect the cell suspension/collagenase and transfer to a new sterile 15mL tube. Indicate 
side specificity on label (leaflets from the same valve can be pooled together). 
7. Transfer the leaflets to a new culture dish so that the ventricularis side is now exposed 
and repeat steps (5.3-5.6). 
8. Once all cell suspension/collagenase is collected, centrifuge the tubes at 1000 rpm for 
5minutes to pellet any isolated cells and aspirate supernatant. If isolating interstitial cells 
as well, perform that protocol while these cells are being centrifuged. 
9. Add 3 mL of endothelial porcine medium to the tubes, centrifuge a second time, and 
aspirate media. This second centrifugation helps filter some of the unwanted material 
such as tip fibers. 
10. Re-suspend the centrifuged endothelial cells in 5 mL of endothelial porcine medium and 
plate the cells in a pre-coated T-25 flask with collage (use 1 flask per centrifuge tube). 
11. Let the cells grow at least 2-3 days before changing the endothelial medium. This helps 
the cells recover and divide since the isolation process is fairly harsh. If you notice the 
yield to be very low, consider moving to a smaller flask or well plate since cell-cell 
adhesion promotes cell growth. Remember to passage near confluence since contact 
inhibition could lead to cell transformation. 
 
6. Isolation of Interstitial Cells 
1. Fill a sterile 15 mL centrifuge tube with 10 mL of collagenase solution per valve (3 
leaflets). 
2. After swabbing the leaflets of endothelial cells, immediately place them in the 
appropriate 15mL tube with the collagenase solution. 
3. Incubate for approximately 12 to 18 hours (agitate gently if desired). 
4. Mix the degraded tissue gently with a serological pipette until cell 
suspension/collagenase becomes homogenized. This homogenization helps break up 
the tissue and release the interstitial cells. 
5. Centrifuge the digested tissue for 5 minutes at 1000 rpm and aspirate the supernatant. 
6. Add 5 mL interstitial porcine medium to the 15mL tubes, centrifuge a second time, and 
aspirate supernate. 
7. Re-suspend the centrifuged endothelial cells in 5 mL of interstitial porcine medium and 
plate the cells in a T-75 flask (use 1 flask per centrifuge tube). 
8. Let the cells grow at least 1-2 days before changing the interstitial cell medium. There 
will be much more tissue debris than with the endothelial cells but, that is expected. The 
cells should also grow to confluence faster than the endothelial cells because of the cell 
yield and their nature. 
 
 
248 
 
Protocol 1.5 - Masson’s Trichrome Stain 
 
 
Stock Solutions (all can be stored at room temperature for up to one year) 
Bouin’s Solution (Flammable cabinet). Add glacial acetic acid (to 5% just before use) ; dispose 
of in container 
25ml x 5% = 1.25 ml to 23.75 ml 
Alcoholic Hematoxylin Stock (Weigert’s) 
Hematoxylin (Sigma H9627) 5g 
95% Ethanol 500ml 
 Dissolve over gentle heat, store in corrosive cabinet 
10 % Ferric Chloride Stock 
 Ferric chloride Hexahydrate 9.67g 
 Milli-pure water 495 ml 
 Glacial acetic acid 5 ml 
  Dissolve ferric chloride in 50ml water, then dilute; store in corrosive cabinet 
Acid Fuchsin, 1% aqueous stock 
 Acid Fuchsin, 1g  [0.5g] 
 Milli-pure water 100 ml [50 ml] 
Beibrich Scarlet, 1% aqueous Stock 
 Biebrich Scarlet 10g [5 g] 
 Milli-pure water 1000 ml [50 ml] 
Aniline Blue Stock 
 Aniline Blue 1.25g 
 Glacial acetic acid 1 ml 
 Di Water 50ml 
Phosphomolybdic-Phosphotungstic Acid 
 Phosphomolybdic acid, 0.625 g 
 Phosphotungstic acid, 0.625 g 
 DI Water 50 ml 
 
 
Working Solutions 
1% Acetic Acid 
 Glacial acetic acid, 0.5 ml  [0.25 ml] 
 Di water, 49.5 ml  [24.75 ml] 
  Make fresh just before use 
Weigert’s Hematoxylin 
 Alcoholic Hematoxylin Stock, 25 ml [12.5 ml] 
 10% Ferric Chloride Stock, 25 ml [12.5 ml] 
  Prepare just before use, discard in “Hematoxylin Waste” container 
Biebrich Scarlet-Acid Fuschin Solution 
 Beibrich scarlet, 1% stock, 44.5ml [22.25 ml] 
 Acid fuschin, 1% stock, 5.0 ml  [2.5 ml] 
 Glacial acetic acid, 0.5 ml  [0.25 ml] 
  Prepare just before use, discard after 24 hours 
Aniline Blue Working Solution 
 Aniline Blue stock 50 ml [25 ml] 
 Glacial acetic acid, 1.0 ml [0.5 ml] 
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Procedure 
1. Deparaffinize and re-hydrate to H2O 
a. Xylene, 100% EtOH, 95% EtOH, 70% EtOH, ddH2O 
2. Bouin’s Solution 56 degrees (RT overnight)……………………..…1 hour 
3. Running tap water rinse until yellow clears…………………………1 min 
4. Distilled water rinse………………………………………………….1 min 
5. Weigert’s Hematoxylin ………………………………………..…….10 min 
a. Stains nuclei blue/black 
6. Running tap water rinse…………………………………..…..………10 min 
7. Distilled water rinse………………………………………….……….1 min 
8. Biebrich scarlet-acid fuchsin…………………………………………5 min 
a. Stains cytoplasm and muscle red 
9. Distilled water rinse……………………………………………….….quick dip only 
10. Phosphomolybdic-phosphotungstic acid solution……………………15-20 min 
a. Until collagen is not red, allows for uptake of aniline blue 
11. Aniline blue solution…………………………………………………15 min 
a. Stains collagen blue 
12. Distilled water rinse………………………………………………..…quick dip only 
13. 1% Acetic acid solution…………………………………………..…..4 min 
14. Dehydrate to xylene, mount with permount 
 
Collagen – blue 
Nuclei – black 
Muscle, cytoplasm, keratin - red 
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Protocol 1.6 - Russel-Movat Pentachrome Stain  
 
 
Time: ~3 hours 
Background: Performing stain with American MasterTech kit.  
Verhoeff’s Elastic  Stain expires after 24 hours, and is prepared with 6.25 mL of each of the 
following: 
1. 10% Alcoholic Hematoxylin 
2. Reagent Alcohol (not in kit, use 100% EtOH) 
3. 10% Ferric Chloride 
4.  Universal Iodine Solution 
 
Protocol: 
1. Deparaffinize slides and hydrate through alcohols 
a. 3 changes of Xylene, 3 min. each 
b. 100% ethanol  5 min., 95% ethanol 2 min., 70% ethanol 2 min. 
2. Rinse in running water for 2 min., followed by diH2O for 2 min. 
3. Place slide in Verhoeff’s Elastic Stain for 15 min. 
4. Rinse in lukewarm running water for 5 min., followed by 2 min. diH2O 
5. Differentiate in 2% Ferric Chloride for 30 sec. Looking for black fibers, gray background 
6. Rinse slide in diH2O for 2 min. and place in 5% Sodium Thiosulfate for 1 min. 
7. Rinse in lukewarm running water for 5 min. 
8. Place in 3% Acetic Acid for 3 min. 
9. Place in 1% Alcan Blue Solution for 20 min. 
10. Rinse in lukewarm running water for 1 min., then in diH2O for 2 min. 
11. Place in Crocein Scarlet-Acid Fuchsin for 2 min. 
12. Rinse through 3 changes of diH2O, 1 min. each 
13. Dip slide 5 times in 1% Acetic Acid 
14. Place in 2 changes of 5% Phosphotungstic Acid for 2 min. each. Collagen is now a pale 
pink, ground substance turns from red to bluish. Check under microscope, and stop 
differentiation when connective tissue is clear but before the elastic fibers are de-stained 
15. Dip slide 5 times in 1% Acetic Acid 
16. Dehydrate through 3 changes of 100% EtOH, 2 min. each 
17. Place in Alcoholic Saffron Solution for 15 min. collagen turns yellow 
18. Dehydrate through 3 changes of 100% EtOH, 1 min. each 
19. Clear slide through 3 changes of Xylene, 1 min. each 
20. Coverslip using permanent mounting media 
Results 
Elastic fibers, nuclei: BLACK Muscle: RED 
Collagen: YELLOW Fibrinoid: INTENSE RED 
Mucins: BLUE TO GREEN  
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Protocol 1.7 –H&E Stain (H&E) 
 
 
Paraffin sections (see back for cryostat sections)    Reviewed  7/07 
MN 
 
Station    Solution    Time (in minutes) 
   1     Xylene    4 
   2     Xylene    4 
   3     Xylene    4 
   4     100% Ethyl Alcohol (ETOH) 5 
   5     95% ETOH    2 
   6        70% ETOH   2 
   7        Deionized water   2 
   8 (Anatech, Ltd. brand cat. #842) Harris' Hematolyxin  6 
   9     running Tap water  3 
  10     0.2% Acid alcohol  20 seconds 
  11     running Tap water  1.5 
  12     1% Ammonia water   1 
  13     running Tap water  1.5 
  14      70% ETOH   1 
  15(Harleco brand, VWR cat. #15204-132) 1%  Alcoholic Eosin Y   1 
  16     95% ETOH   1 
  17     95% ETOH   1 
  18     100% ETOH   1 
  19     100% ETOH   1 
  20     Xylene    3 
 
SOLUTIONS: 
Harris' Hematoxylin (prepared) 
 Anatech, Ltd. brand -     FILTER EVERY MONDAY OR MORE OFTEN AS  
NECESSARY. 
    Change after 2 weeks (10 working days) of use.   
0.2% Acid Alcohol 
   (per Varistain container)  (4000 ml. bottle) 
 70% ETOH ---------------        680 ml.   2720 ml. 
  1% Acid alcohol --------       170 ml.    680 ml. 
 
1% Ammonia Water 
     (per Varistain container)  (4000 ml. bottle) 
 Deionized water -----------------------       800 ml.   3000 ml. 
 Ammonium Hydroxide (28%)  ---------    8 ml.    30 ml. 
 
1% Alcoholic Eosin Y (prepared) 
 Harleco brand, order from VWR Scientific (cat # 15204-132)   
Add  0.5 ml. glacial acetic acid per 750 ml. 1% Eosin Y solution before using the stain for 
the first time. 
Change after 2 weeks (10 working days) of use. 
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CHANGING SCHEDULE 
Monday:       all solutions 
Tuesday thru Friday:      rotate 100% ETOH in stations 4 & 5 
   Change: deionized water 
    1% ammonia water and 0.2% acid alcohol 
    95% ETOH in stations 17 & 18 
    100% ETOH in stations 19 & 20 (rotate last alcohol to station 19) 
CONTROLS: 
Run control slide once a week on Monday and in between whenever the Hematoxylin 
and/or  
Eosin are changed or if a problem is suspected. 
Label slide with date, your initials, and with the time in both hematoxylin and eosin 
solutions and lot number of Hematoxylin. 
Check control slide under microscope for stain quality.  Give control slide to Lab 
Supervisor for review. 
 
 
 
RAPID H&E FOR CRYOSTAT SECTIONS 
 
1. 10% neutral buffered formalin (for fresh,unfixed tissue)...............   1 min. 
If tissue is fixed start at step 2: 
2. 70% ETOH.....................................................................................   brief rinse 
3. Deionized water..............................................................................   brief rinse 
4. Harris' Hematoxylin*.....................................................................   1 min. 
5. Tap water........................................................................................   brief rinse 
6. 0.2%Acid alcohol...........................................................................   2-5 sec (1 dip) 
7. Tap water wash..............................................................................   1 min. 
8. 1% ammonia water to blue.............................................................   2-5 sec. (few dips) 
9. Tap water wash...............................................................................   1 min. 
10. 1% alcoholic Eosin Y......................................................................   10 sec. 
11. 95% ETOH (agitate slides)............................................................   few dips 
12. 100% ETOH (agitate slides)..........................................................   few dips 
13. Xylene............................................................................................   1 min. 
14. Propar............................................................................................   1 min. 
15. Mount/coverslip with Permount. 
 
 
Reference: 
 
 Preece, A., A Manual for Histologic Technicians, Third Edition, Boston 1972, 
  p. 100. 
 
 *Harris Hematoxylin time increased to 1 min from 20-30 sec. 7/25/02 (MN per 
BASummers) 
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Protocol 1.8 - Protocol for Making 4% PFA Solution 
 
 
Objective: 
Prepare 4% PFA Solutions from powder, aliquote, and store in -20C Freezer.  
 
Materials: 
1) Balance (portable) 
2) Hotplate with magnetic stirrer and thermometer 
3) Stirbar 
4) 1L Bottle 
5) 1000mL of 1X PBS 
6) 40 g of Paraformaldehyde powder (Sigma Aldrich P6 148-500 Grams) 
7) 50ml Serological pipettes 
8) Automatic pipette 
9) Orange cap 15ml centrifuge tubes 
Prepare 4% w/v PFA in 1X PBS: 
Work in the Chemical Safety Hood and wear gloves 
1)  Move balance and hot plate into Chemical Safety Hood and plug in 
2) Fill bottle with 1000mL of 1X PBS 
3) Add stir bar to bottle and place on hotplate 
4) Weigh out 40g of PFA powder 
5) Add PFA into bottle 
6) Stir and Heat at 60C until completely dissolved 
7) Use serological pipette to aliquot 10ml of 4% solution into each centrifuge tube.   
a. 1000/10 = 100 tubes of 4% PFA 
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Protocol 1.9 – Protocol: BrdU Labeling of Paraffin Sections 
 
 
 
1) Deparaffinize and re-hydrate to H2O. 
a. Heat at 60
o
 until wax melts (~15 minutes). 
b. Xylene 1…...…10-15 minutes 
c. Xylene 2…….…5-10 minutes 
d. Xylene 3…….…5 minutes 
e. 100% EtOH.….5 minutes 
f. 95% EtOH…....3-5 minutes 
g. 70% EtOH….…3 minutes 
h. Tap water 
2) HCl incubation  – put directly on slides 
a. Incubate slides in 2N HCl at 37o for 10 minutes 
b. Rinse in 0.1M Borate Buffer [pH 8.5] for 12 minutes at room temperature 
c. Rinse 3x5 min PBS 
3) Blocking- put directly on slides 
a. Incubate with 10% goat serum in 1% BSA for 30 min at room temperature. 
4) Primary Antibody – put directly on slides 
a. Incubate with 1:100 dilution of primary antibody in 1% BSA for 1 hour at room 
temperature or overnight at 4o. [mouse anti-Brdu] 
5) Wash slides 3x5 min in PBS in coplin jar 
6) Secondary Antibody – put directly on slides 
a. Incubate with 1:300 dilution of secondary antibody in PBS for 30 minutes at room 
temperature.  [goat anti-mouse] 
7) Wash slides 3x5 min in PBS in coplin jar 
a. DAB Kit (*light sensitive, do this step in the dark. Excess DAB is a biohazard.) 
b. 1 ml tap water 
c. 1 drop solution 1 (green) 
d. Vortex 
e. 1 drop solution 2 (brown) 
f. 1 drop solution 3 (white) 
g. Vortex and place on slides for 2-5 minutes; watch under microscope. 
8) Rinse slides with PBS and then tap water in coplin jar.  
9) Counter-stain in methyl green for 10-30 seconds  
10) Quickly dehydrate to Xylene and mount using Permount.  
Borate Buffer:  3.09g Boric Acid 
   500 ml ddH2O 
   Mix to dissolve. Adjust pH to 8.5 with NaOH pellets 
Store at room temperature. 
 
1% BSA is in PBS.  
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Protocol 1.10 - Immunohistochemistry (Paraffin Sections) 
 
 
 
Melt wax by placing slides in 55C oven for ~10 minutes 
 *Set slides on their side, against the wall of a box, so that wax melts down, off the 
sample 
 
Deparaffanization and Rehydration  
1. Xylene, 3 changes for 3 minutes each  
2. 100% ethanol, 1 changes, 5 minutes 
3. 95% ethanol, 1 change, 2 minutes 
4. 70% ethanol, 1 change, 2 minutes 
5. Rinse gently in de-ionized water (gently pipette and aspirate dH2O on sample) 
 
 Circle each sample with hydrophobic pen, let dry 
 Optional antigen retrieval (protocol developed by Jingjing Zhou and Caitlin Bowen, 
Summer 2012): 
o Lay slides flat in container 
o Pipet enough 2N HCl to cover samples onto each slide 
o Incubate for 70 minutes at 37C 
o Aspirate 2N HCl 
o Pipet enough 0.1M Sodium Borate (pH 8.5) to cover samples onto each slide 
o Incubate for 12 minutes at Room Temp 
o Rinse 3x in PBS for 5 minutes each 
 Alternative antigen retrieval (developed by Jingjing Zhou) 
o Tri-sodium citrate buffer:  
 Weigh out 2.94g Tri-Sodium Citrate 
 Add 1000mL distilled water 
 pH to 6.0 with 1M HCl 
 Add 0.5mL Tween-20 
o Add Sodium Citrate buffer to tip box 
o Warm buffer by heating in microwave on High for 1 min 
o Add slides to dish 
o 5 min on “warm” 
o 5 min rest 
o 5 mini on “warm” 
o 2 min rest 
o 2 min on “warm” 
o 20 min cool to RT 
o Rinse 1x in PBS 
 Apply enough 10% Goat serum (in 1X PBS) to cover sample (about 75uL per sample) 
 Incubate 60 min at 37oC or overnight at 4oC  
 
Primary antibody application: 
1. Make 100µL per sample of 1° antibody (1:500 in antibody dilution buffer) 
Antibody dilution buffer: 1% BSA in 1x PBS +0.3% Triton-X (Cell Signaling Tech) 
*Note: If in doubt of pipetting small volumes, err on the side of higher concentration 
2. Gently aspirate 1% BSA 
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3. Dry slide very carefully with a kim wipe by touching a corner of the wipe to the edge of 
the liquid on your sample 
*Do NOT touch your samples with the kim wipe 
4. Apply primary antibody 
5. Incubate overnight (at least 8 hr) at 4oC  
 
Secondary antibody application: 
Aspirate 1o ab solution 
Place slide(s) in dish (ex: pipet box lid) with enough PBS to cover 
Wash 3x in PBS on shaker, 5 minutes each 
While shaking, prepare 2o ab solution: 
 Fluorescent antibody: 1:200 
 Draq 5: 1:1000 
 In solution of 1% BSA+PBS 
  Ex: 2.5uL goat anti-rabbit 568 + .5uL Draq 5 + 497uL 1% BSA+PBS = 500uL 2o 
ab solution 
Apply 100uL 2o ab solution to each sample 
Incubate for 30 minutes at room temperature, cover with foil 
3 washes  
Wash 3x in PBS on shaker, 5 minutes each 
 
Dehydration (optional, unclear from the literature if this degrades your fluorescent signal or 
not): 
 70% ethanol, 1 change, 3 min 
 95% ethanol, 1 change, 3 min 
 100% ethanol, 2 changes, 3 min each 
 Xylene, 3 changes, 3 min each 
Rinse gently in deionized water 
 
Mounting 
Remove ProLong Gold antifade reagent (Invitrogen P36934) from freezer, allow to come to 
room temp 
 Do not apply external heat 
Remove excess liquid from specimen using kim wipe, as described above 
Apply 1 drop of medium to the sample 
 Or to the slide if sample was mounted on a coverslip 
Gently lower coverslip onto slide, avoid trapping air bubbles 
Allow slides to cure 24 hrs at room temperature. Protect from light! 
If necessary, seal the edges of the coverslip with nail polish (clear) or hot wax 
 
Long term storage: RT, fridge, or -20 freezer 
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Protocol 1.11 - Expedited IHC protocol 
 
 
 
Day 1 
Fixation & Blocking 
1. Aspirate medium 
2. Wash once with PBS (repeat until pink color is gone from solution) 
3. Add 4% PFA, incubate at least 4 hours at 4°C 
 PFA moves approximately 1 mm per hour 
4. Aspirate 4% PFA, add PBS (or 70% EtOH if you want to store them for up to 2 wks) 
5. Transfer gels from 4-well to 6-well plate (carefully, maintain up/down orientation) 
6.  Wash gels 3X in lots of PBS, 15 minutes each on rotator 
7. Permeabilize with 0.2% Triton-X 100 for 10 minutes on rotator  
(10 mL PBS, 20 μL Triton-X) 
8. Wash 3X with PBS, 15 minutes each on rotator 
9. Add blocking solution, incubate overnight at 4°C, or 1 hour at 37°C 
 1% BSA in PBS (blocking solution, 2 mL/well) 
 
Day 2 
10. Transfer gels back to 4-well plate 
11. Aspirate blocking solution and add primary antibodies in PBS, 50 μL/well 
 αSMA (spring biosciences, rabbit anti-human, 1:100) 
 QH1, for quail (mouse anti-human, 1:100) 
 ex. Have 4 x 7 gels = 28 gels 
28 x 50 μL = 1400 uL (make 1600 uL) 
16 μL QH1 antibody 
16 μL αSMA antibody 
1568 μL PBS 
12. Incubate with primary antibody overnight at 4°C in a humidified chamber (fridge) 
 
Day 3 
13. Transfer gels to 6-well plate (maintain up/down orientation) 
14. Wash 3X with PBS, 15 minutes each on rotator 
15. Transfer gels back to 4-well plate 
16. Add secondary antibody at 1:100 dilution in PBS + 1% BSA 
 100 μL per gel, 3 mL PBS, 30 μL secondary antibodies 
(QH1: goat anti-mouse 568 
  αSMA: goat anti-rabbit 488) 
17. Incubate with secondary antibody for 2 hours at RT 
18. Transfer gels to 6-well plate 
19. Wash 3X with PBS, 15 minutes each on rotator 
20. Transfer gels back to 4-well plate 
21. Add Draq 5, 1:1000, 100 μL per gel 
 3 mL PBS, 3 μL Draq 5 
22. Incubate for 30 minutes at RT 
23. Store in 2 mL PBS 
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After final Draq 5 staining, to prepare gels for imaging: 
If using Zeiss (images from bottom) 
Transfer gels to a 6-well plate, in plenty of 18 MOhm deionized water 
 Bring downstairs:  
6-well plate with gels 
squirt bottle of 18 MO water 
a few slides or coverslips 
disposable spatula 
4-well plates (with some PBS in them) for storing gels after imaging 
Flash drive 
Once downstairs, move gel carefully from well to slide, maintaining orientation 
Squirt enough water onto the gel to keep it from sliding around… will this work? Practice 
before confocal training 
Place slide carefully onto microscope stage 
After imaging, transfer gel into its well in the 4-well plate, re-use slide 
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Protocol 1.12 - Immunofluorescence of cells on slides: 
 
Cell culture: PAVEC 
Divide slide into three sections and outline outer edge with hydrophobic pen 
Sterilize under UV for > 30min 
Apply  ~100uL collagen (50ug/mL) to each section 
Incubate at 37C for >20 min 
Meanwhile, trypsinize and spin down cells 
Resuspend cells in 200uL x (# of sections) 
 Ex. For 3 slides = 9 sections = 1.8mL 
Aspirate excess collagen 
Apply cells to each section 
Let adhere for > 2 hours (until cell spreading is observed) 
Ideally, let grow overnight. 
 
Immunofluorescence: 
Rinse with PBS 
Fix in 4% PFA for 20 min at 37C or overnight at 4C 
Rinse with PBS 
Permeabilize with 0.5% Triton-X for 10 min on rotator 
 1 mL PBS + 5uL Triton-X 
Wash 3x with PBS for 5 min on rotator 
Block in 1% BSA for 30 min at room temp 
Make primary antibody solution 
 1:100 primary antibody 
 +PBS 
Aspirate BSA 
Apply 100uL primary ab to each section, at 1:100 dilution 
Incubate 1 hr at Room Temp 
Wash 2x in PBS for 5 min on rotator 
Make secondary antibody solution 
 1:100 secondary antibody 
 +1:100 Draq 5 
 +1% BSA 
Apply 100uL secondary antibody to each section, at 1:100 dilution 
Incubate 30 min at Room Temp 
Apply small drop of ProLong Gold anti-fade mounting medium 
Carefully apply coverslip 
Fix for 24 hrs 
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Protocol 1.13 - Designing primers for qPCR 
 
1. Look up desired gene (Ensembl or PubMed) 
a. Type in gene name and species (e.g. Sus Scrofa = pig) 
2. In ensemble, Click on the red box where they have identified your gene 
a. click on Transcript ID 
b. choose cDNA in the left hand menu 
c. hyperlink to FASTA sequence 
3. Copy and paste the whole FASTA sequence into Word 
4. ENSMBL gene transcript annotation to locate exon boundaries in first ~500pb and 
change the color of alternating exons between black/blue 
5. Copy and paste ~500bp of 5’ sequence into Primer3 
a. Sequence ID: animal name and gene name (e.g. Pig CDH11) 
b. Product size: 125-150 (number of base pairs) 
c. Click “pick primers” 
6. Primers are chosen, denoted by >>> and <<< 
a. Amplicon (PCR product) is the entire sequence from start of forward primer to the 
end of the reverse primer 
b. Reverse primer is backwards and complementary to the section underlined by 
<<<< 
Notes:  
* Don’t create primers near the end of the mRNA sequence 
* Avoid sequences with long repetitions of G or C –could get primer dimmers or folding 
* Ideally, have G or C clamps at the end of your primers for secure bonding 
 
7. Copy and paste chosen primer info into Word  
8. Find where primers are located in gene sequence (Ctl+F) (…reverse complement!) 
a. Amplicon should span blue/black region: this makes sure it crosses an intron-
exon boundary, which excludes genomic DNA from amplification 
b. cDNA doesn’t have introns, so spanning a boundary between two exons insures 
you’re only amplifying your cDNA 
9. BLAST the primers using NCBI primer-BLAST 
a. Select species of interest 
b. Paste forward and reverse primers in the respective fields 
c. Should see 100% match in the gene of interest 
d. Check that there are no other 100% matched 
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Protocol 1.14 - RNA Isolation 
 
Time: ~1 hour 
 
Materials (located by RNase free bench unless otherwise noted):  
RNA isolation kit (includes QIAshredders with caps, RNeasy spin columns, RW1, RPE, 1.5 mL 
collection tubes), RNase Zap, RNase free water, RNase  free 70% EtOH (Emily’s bench), 1 mL 
pipette with RNase free tips, 1 mL RNase  free centrifuge tubes, waste beaker (cabinet), 
kimwipe (Emily’s bench), tube racks 
 
Background:  
Porcine Aortic Valve Leaflets were excised from pigs and placed in vessels for disruption and 
homogenization.  Samples were flash frozen with LN2 and broken down with a mortar and 
pestle, and stored at 4C. 
 
Protocol: 
1. Retrieve samples from -80C (2nd shelf down, right hand side) 
2. Wipe down area and samples with RNase Zap 
3. Vortex samples to mix 
4. Centrifuge 30 seconds at 15,000 rpm 
5. Transfer the supernatant (lysate, ~350 uL) to a QIAshredder spin column for each 
sample 
6. Centrifuge 2 min. at 15,000 rpm 
7. Remove QIAshredder from centrifuge, remove membrane and replace it with a lid from 
the kit (label the lids) 
8. Centrifuge 3 min at 15,000 rpm to get protein/remaining contaminants to the bottom of 
the tube.  
9. Return aortic valve leaflets to the -80C freezer 
10. Transfer 300 uL of each sample to a RNase free centrifuge tubes 
11. Transfer 300 uL (1 volume) of 70% EtOH to each tube, pipette up and down until 
viscosity change is no longer visible. DO NOT CENTRIFUGE 
12. Transfer the volume (600 uL) to RNeasy spin columns  
13. Centrifuge for 30 sec at 8,000 rcf 
14. Discard flow through into a waste beaker (pour out of clear tube, tap the tube on a 
kimwipe to remove any excess) 
15. Add 700 uL RW1 to each sample, use the same tip as long as you don’t touch 
16. Centrifuge 30 sec at 8,000 rcf 
17. Remove the flow through as before 
18. Add 500 uL RPE Buffer to each sample and centrifuge 30 sec at 8,000 rcm 
19. Remove the flow through as before 
20. Add 500 uL RPE Buffer to each sample and centrifuge for 2 min at 8,000 rcf 
21. Transfer RNeasy spin column (pink membrane) into 2 mL collection tubes 
22. Centrifuge for 1 min at full speed 
23. Place RNeasy spin column into 1.5 mL collection tubes from the kit 
24. Dilute with 30 uL RNase free water by adding directly to the membrane 
25. Place tubes in centrifuge with clear lid facing inwards. Centrifuge for 1 min at 8,000 rcf 
26. Wash the waste beaker, then use RNase Zap on hands 
27. RNA solution is collected in 1.5 mL tubes after centrifugation. Add 2 uL of each sample 
to 0.5 mL tubes (black box above the RNA station) to be used with the NanoDrop 
28. Store RNA samples at -80C 
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NanoDrop Protocol: 
 
1. Put 2 uL samples on ice, take to the NanoDrop (Weill 130, LER) with gloves and RNase 
free water 
2. Open NanoDrop 2,000 softwareNucleic AcidNoOkay 
3. Change “type” to RNA, type in sample ID, load 1 uL RNase free water onto the stage 
and click blank 
4. Wipe the stage with a kimwipe, add 1 uL sample, and click measure. Repeat this step for 
all samples. When saving, use the date and nucleic acid, but add the sample name 
5. Click Report, Export, and save as a Report, Excel SML spreadsheet (*.xml). 
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Protocol 1.15 - Apoptosis Assay (APO-BrdU TUNEL Assay) 
 
Materials: 
 APO-BrdU TUNEL Assay Kit (Invitrogen A23210) 
o Positive control cells (Component A, brown cap), fixed human lymphoma cell 
line (5 ml) 
o Negative control cells (Component B, white cap), fixed human lymphoma cell 
line (5 ml) 
o Terminal deoxynucleotidyl transferase (Component C, yellow cap) (45 μl) 
o 5-Bromo-2’-deoxyuridine 5’-triphosphate (brdUTP) (Component D, violet cap) 
(480 μl) 
o Anti-BrdU mouse monoclonal antibody PRB-1, Alexa Fluor 488 conjugate 
(Component E, orange cap) (350 μl) 
o Propidium iodide/RNase A staining buffer (Component F, amber bottle) (30 
ml) 
o Reaction buffer (Componet G, green cap) (0.6 ml) 
o Wash buffer (Component H, blue cap) (120 ml) 
o Rinse bugger (Component I, red cap) (120 ml) 
 1X Phosphate Buffered Saline (PBS) 
 Draq5 (Biostatus Limited) 
 
 
Method: 
1. Wash gels once with warm PBS, then fix in 4% PFA for 24 hours (store at 4°C) 
 
2. Aspirate 4% PFA, store gels at 4°C in 70% EtOH (until staining begins) 
 
3. Aspirate EtOH, wash 3X in wash buffer (blue cap) on shaker for 5 minutes each (1X 
PBS is also ok) 
 
4. Prepare a DNA labeling solution (total volume 50 μl per gel) 
 10 μl reaction buffer (green cap) 
 0.75 μl TdT enzyme (yellow cap) 
 8.0 μl BrdUP (violet cap) 
 31.25 μl dH20 
 Note: this makes up 50 μl of labeling solution – scale up volumes as needed for 
multiple samples 
 
5. Incubate gels with 50 μl DNA labeling solution for 2 hours at 37°C (oven or incubator) 
 Note: Incubation of labeling solution can also be carried out at room temperature 
overnight 
 
6. Rinse with rinse buffer (red cap), 5 minutes on shaker 
 
7. Aspirate, rinse once more with rinse buffer (red cap), 5 minutes on shaker   
 
8. Add 100 μl antibody (1:50 dilution in rinse buffer) to each gel, incubate for 1 hour in dark 
at room temperature 
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9. Incubate samples with 1:1000 dilution Draq5 in 1X PBS for 30 minutes  
 Note: this step can be combined with the previous (add Draq5 to the BrdU 
antibody solution) 
 
10. Add 200 μl of propidium iodine (amber bottle) to each sample, incubate in dark at room 
temperature for 30 minutes 
 
11. Store in 1X PBS at 4°C until imaging 
 Note: samples are best imaged within 24 hours of staining 
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Protocol 1.16 - Proliferation Assay (BrdU Labeling) 
 
Materials: 
 BrdU Labeling Reagent (15 ml; Invitrogen 00-0103) 
 10X Phosphate Buffered Saline (PBS) 
 1.5 M Hydrochloric Acid 
 Blocking Buffer (1X PBS / 5% BSA / 0.3% Triton X-100) 
o To make 500 ml of blocking buffer: 
 50 ml 10X PBS 
 25 ml 5% BSA (1.25 g BSA in 25 ml 1X PBS) 
 420 ml dH20 
 1.5 ml Triton X-100 
o Mix well, store at 4°C 
 Antibody Dilution Buffer (1% BSA in 1X PBS) 
o To make 100 ml of buffer: 
 1 g BSA 
 100 ml 1X PBS 
o Mix well, store at 4°C 
 Anti-BrdU mouse monoclonal antibody, Alexa Fluor 488 conjugate (350 μl; 
Invitrogen B35130) 
 Draq5 (Biostatus Limited) 
 
 
Method (Part 1) – Adding BrdU to Experiment 
1. Add BrdU labeling reagent (1:100 dilution) to cell culture media 
 
2. Sterile filter BrdU media before adding to gels 
 
3. Add BrdU media to gels 12 hours prior to fixation (other cell types may need doubling 
time to be determined) 
 
4. Incubate at 37°C 
 
 
Method (Part 2) – Fixation and Staining 
12. After 12 hours incubation with BrdU, aspirate media, wash once with warm PBS, then fix 
in 4% PFA for 24 hours (store at 4°C) 
 
13. Aspirate 4% PFA, store gels at 4°C in 70% EtOH (until staining begins) 
 
14. Aspirate EtOH, wash 3X in 1X PBS on shaker for 5 minutes each. 
 
15. Add 1.5M HCl and incubate for 30 minutes at room temperature. 
 
16. Aspirate HCl and wash 2X with 1X PBS on shaker for 5 minutes each. 
 
17. Block samples in Blocking Buffer for 60 minutes at room temperature. 
 
18. Aspirate blocking buffer, add conjugated antibody (anti-BrdU 488) to each sample 
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 1:100 dilution of antibody in 1% BSA 
 Add 50 μl to each sample 
 Incubate at room temperature in the dark for 2 hours 
 
19. Incubate samples with 1:1000 dilution Draq5 in 1X PBS for 30 minutes  
 Note: this step can be combined with the previous (add Draq5 to the BrdU 
antibody solution)  
 
20. Store in 1X PBS at 4°C until imaging 
 Note: samples are best imaged within 24 hours of staining 
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Protocol 1.17 – Plasmid transfection into AVC via electroporation 
 
 
 
Transfection  
 
1. Cells should be transfected a day after passaging, when cells are still in exponential 
growth phase.  
2. Prepare biosafety hood, wipe area with 70% ethanol.  
a. Warm electroporation culture media for AVC, 1X PBS (25 mL 10X PBS in 225 
mL 18M m water, autoclaved), and trypsin in EDTA (located on middle shelf in 
large –20 C fridge) in water bath.  
b. Wipe empty beaker with ethanol, fill with 50-100 mL 100% bleach and place in 
hood. 
3. Wipe closed package of desired well-plate (located in drawer next to biosafety hood) 
and place into hood. Do not open outside of hood or sterility will be lost.  The number 
of desired experiments or predicted number of cells determines number of wells on 
plate. Refer to Neon Transfection System manual for appropriate well-plate size as a 
function of cell count. 
4. Wells must be coated with 0.500 mL collagen (125 uL stock collagen type I/10 mL 1X 
PBS) 30 minutes prior to plating to allow proper adhesion. Apply collagen to flask at 
least 10 minutes prior to beginning harvesting process. 
5. Aspirate media from current old flask and dispose into waste bleach beaker. 
6. Add 10 mL 1X PBS to flask to rinse cells. Remove PBS and dispose in waste 
beaker. 
7. Add 3 mL trypsin in EDTA to flask to remove the cells from the plate surface. Tap 
flask to aid in removal. Be mindful of time in contact with trypsin because excessive 
exposure will destroy the cells. 
8. Place in dry 37 C incubator for 3 minutes (no more than 5 minutes or cells will die). 
9. Take flask out of incubator and continue tapping. Solution should be cloudy with 
cells. Quickly check under light microscope to verify cells have been detached from 
plate bottom. 
10. Deactivate trypsin by adding 3X volume (9 mL) warm electroporation PAVEC media 
to flask. Pipette up and down to homogenize. 
11. Transfer cell suspension to 15 mL conical tube. Count cells at this stage to determine 
how much of suspension with proper number of cells must be used in electroporation 
experiment. 
12. Once required volume of suspension is determined, aliquot that amount and 
centrifuge at 1000 rpm for 5 minutes. 
13. After centrifugation, aspirate supernatant carefully without disturbing the pellet and 
dispose in waste beaker.  
 
 
*Release and pellet cells, Start here 
14. Resuspend cells in 11 uL x # rxns of Buffer R (provided in Neon Kit) and transfer 
to sterile 1.5 mL microcentrifuge tube. 
15. Obtain plasmid (located in small –20 C fridge) and thaw immediately. 
16. Slowly add 1.0 ug of plasmid per reaction to be done to cell suspension. Do not 
mix or pipette vigorously or the DNA will be lysed.   
17. Apply 10 uL Neon transfection tip (refer to Neon Transfection manual for proper 
attachment) and take up cell/DNA suspension, being careful to not take in any 
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bubbles. Place in microinjector station and run diagnostics. Troubleshoot as 
necessary. 
18. Prepare well plate by removing collagen and adding 2.5 mL warm electroporation 
PAVEC media to each well being used. 
19. Set following parameters for optimal PAVEC transfection (tested with pmaxFP-C) 
a. Parameter 15 (Database -> PAVEC -> Load) 
i. Voltage: 1650 V 
ii. Pulse width: 20 ms 
iii. Pulse number: 2 
b. Press Start 
i. Watch carefully for arcing (small orange flash) 
20. Remove microinjector from station and apply the cells in tip evenly in a single well. 
Repeat transfection for number of desired experiments. 
21. Each gold Neon tip can be used ONLY TWICE before contamination is 
unacceptable. Dispose tip after two uses.  
a. Dispose electroporation chamber after 10 uses 
22. Label plate properly with name, date, cell type, etc. 
23. Place in dry 37 C incubator. 
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Protocol 1.18 - Preparation of LB Broth 
 
 
Bacterial Transformation of Plasmid in E. coli 
 
 
1. Obtain clean and dry 500 mL glass vial (with screw-top lid). 
2. Add 500 mL 18M m water. 
3. Add 10 g LB Broth powder (located on shelf above pH meter). 
4. Prepare for autoclaving by partially sealing top with autoclave tape and labeling flask 
with name, date, solution type, etc. 
5. Choose appropriate autoclave program (20-30 minutes). Make sure lid is slightly 
loosened or pressurization will result in explosion. 
 
Preparation of LB Agar Plates (in laminar flow hood) 
 
1. Add 50 mL18M m water into a clean beaker for every plate to be poured. 
2. Add 1 LB agar tablet (located on shelf above pH meter) for every 50 mL of water. 
3. Prepare for autoclaving by partially sealing top with autoclave tape and autoclave 
using appropriate program. 
4. Thaw appropriate antibiotic.  
a. Pencillin/streptomyocin (located in mid-shelf in large –20 C freezer) 
b. 100X Kanamycin (located in door shelf in large –20 C freezer) 
c. 1000x Ampicillin  
5. After autoclaving, let LB agar solution cool to approximately 55 C. (~55C is reached 
when you can touch the beaker with gloved hands for 3 seconds before it gets too 
hot) 
6. Add appropriate amount to achieve standard final concentrations for respective 
antibiotic. 
a. Pencillin/streptomyocin – 100 ug/mL 
b. 100X Kanamycin – 0.25-0.50 ug/mL 
c. 1000x Ampicillin – 1 ul/mL 
7. Open sterile petri dishes under laminar flow hood. (be sure to reseal before putting 
back) 
8. While LB broth+agar+antibiotic mixture is still fluid and warm, pour ~40-50 mL of 
mixture into each Petri dish and let cool with cover half on to prevent condensation 
under lid. 
9. Leave in hood until solid prior to applying competent E. coli cells. For long term 
storage, store at 4 C (good for at least 6 months). 
 
Transformation in NovaBlue competent cells (protocol also provided by manufacturer) 
 
1. Create an ice bucket (ice located in autoclave room) 
2. Create 42 C water bath. Use heat block and add 18M m water to rack. 
3. For each n set of plasmids being mass-produced, [OPTIONAL] obtain n+1 number of 
tubes of competent cells from NovaBlue Singles Competent cells kit (located on third 
shelf of –80 C freezer in NovaBlue box). One tube will be used for the Test Plasmid. 
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Also take out tube of SOC medium found in the kit and warm at room temperature 
prior to starting. SOC medium can also be stored at – 20 C so it takes less time to 
thaw.  
4. Place tubes on ice and thaw for 2-5 minutes. 
5. Flick tubes 1-2 times to resuspend cells and shake once or twice with hands to get 
any liquid back to the bottom. 
6. [OPTIONAL] To one tube of competent cells, add 1 uL (0.2 ng) Test Plasmid, gently 
stir and return to ice bucket. 
7. To other tubes, add 10 uL of ligation reaction or 0.5 uL pure plasmid DNA 
(approximately 1-10 ng) and return to ice. 
8. Incubate all tubes on ice for 5-10 minutes. 
9. Without shaking, place tubes in 42 C water bath for exactly 30 seconds. 
10. Place tubes back on ice for 2 minutes. 
11. Add 250-300 uL SOC medium at room temperature to each tube. Return tube to ice. 
12. If selecting for kanamycin, streptomycin, or spectinomycin resistance, shake at 37 C 
for 30 minutes prior to next steps. If selecting for ampicillin or chloramphenicol 
resistance, continue directly to step 13. 
13. Spin down the bacteria at 1000 RPM for 1 minute in the table top centrifuge.  
14. Remove all but 50 uL of the supernatant to create a concentrated mixture and 
resuspend. 
15. Transfer the remaining 50 uL of mixture to center of cool LB agar plate prepared with 
selective media in previous steps. With blue cell spreader (under electrophoresis 
machines), spread cell mixture until dry. 
16. Place cover-side down in 37 C bacterial incubator (located in Weill B07, contact Dr 
Archer for access/permission) 12-16 hours (overnight). 
 
Selecting single colony for MiniPrep 
 
1. In the morning of the next day, warm LB broth at room temperature and transfer 5 
mL to 15 mL conical tube for every plate (done in the laminar flow hood to maintain 
sterility of the LB broth) 
2. [Optional] Add appropriate antibiotic to have final concentration listed previously. 
Make sure this concentration matches that applied to the selective media in the LB 
agar plates. 
3. Retrieve LB agar plates from incubator and with sterile pipette, transfer one single 
large colony to each conical tube (only one colony per tube) and leave 
pipette/transferring stick in the conical tube.  
4. Keep at 4 degrees until ready to place in incubator. 
5. Securely place in shaking incubator at 37 C (top incubator) and resume shaking. 
Shake overnight. Be sure to leave cap *slightly* open to allow for air to get in, without 
allowing any media to spill. 
6. Keep LB agar plates at 4 C until you are sure that you have isolated your plasmid. 
 
MiniPrep (QIAGEN)  
1. Take 1.2 ml from 5 ml of bacterial culture and place in microcentrifuge tube. Spin at 
13,000 RPM for 1 minute.  
2. Remove supernatant and resuspend in 250 uL Buffer P1. Vortex for at least 3 
minutes. If you want to pause, freeze bacterial pellet at – 80 C before resuspension. 
3. Add 250 uL Buffer P2 and mix thoroughly by inverting tube 4-6 times. Solution 
should turn blue due to LyseBlue reagent. Do not let reaction to proceed for more 
than 5 minutes 
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4. Add 350 uL Buffer N3 and mix immediately by inverting tube 4-6 times. Solution 
should turn colorless. Leave on ice for a few minutes. 
5. Centrifuge for 10 minutes at 13,000 RPM. 
6. Apply the supernatant (850 uL) to the QIAprep spin column by pipetting. Make sure 
not to get any of the white pellet into the spin column. 
7. Centrifuge for 1 minute at 13,000 RPM and discard flow-through. 
8. Wash spin column by adding 750 uL Buffer PE and centrifuge for 1 minute at 13,000 
RPM. Discard flow-through. 
9. Centrifuge for 1 minute at 13,000 RPM to dry membrane. 
10. Add column to a clean microcentrifuge tube. Add 20-30 uL ddH2O to the center of 
the spin column and let stand for 1 minute. 
11. Centrifuge for 1 minute. Expected NanoDrop reading is 90-110 ng/uL.  
 
Inoculation of colony 
 
12. Warm LB broth and transfer 100 mL to sterile Erlenmeyer flask. Use one flask for 
every colony selected/conical tube used previously. For Midi Prep, use 25 mL 
volume split into two 50 mL conical tubes (11.5 ml LB media, 1 ml cells to each). 
13. Add appropriate antibiotic to have final concentration listed previously. Make sure 
this concentration matches that applied to the selective media in the LB agar plates. 
14. Transfer 1-2 mL of bacterial cell mixture in conical in shaking incubator to 100 mL of 
newly prepared LB broth in Erlenmeyer flask. Return to shaking incubator and 
incubate at 37 C overnight. 
 
Purification of plasmid from E. coli 
 
1. Obtain two 50-mL Oak Ridge round-bottom ultracentrifuge tubes (from Dr. Reinhart-
King’s lab, ask permission or order if unobtainable) and autoclave before proceeding 
with purification. These tubes are necessary to withstand high centrifugation speeds 
used in later steps of purification. 
2. Retrieve flasks from shaking incubator and return to Weill 304. 
3. Transfer 800 uL of mixture to cryotube and add 200 uL glycerol (4:1 ratio) and place 
in –80 C freezer for later use. 
4. Use QIAGEN Endonuclease-Free MaxiPrep kit to purify. Follow manufacturer’s 
protocol. 
5. Locate appropriate centrifuges needed in purification steps (ultracentrifuge located in 
Dr. Shuler’s lab, ask Paula Miller for permission). 
6. Once purified, determine final DNA concentration (see Nanodrop analysis protocol). 
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Protocol 1.19 - Pierce 660 nm Protein Assay 
 
Time: ~30 min 
 
Materials: Protein samples, microcentrifuge tubes, 660 nm Pierce Reagent, Ionic Detergent 
Compatibility Reagent (IDCR), Laemmli Buffer, 96-well plates 
 
Background: The standard was already made (2,000 ug/mL Bovine Syrum Albumin (BSA), 
diluted 1:1 in Laemmli Buffer) and the assay performed. 
In this assay we will study the affects of TNFα, TNFα + superoxide dismutase (SOD), and 
osteogenic media (OGM) proteins. TNFα is inflammatory, and OGM allows for or induces 
calcification (not clear which). I will perform the assay on TNFα + SOD. 
 
Hypothesis: SOD mitigates the pathological affect of TNFα on Porcine Aortic Valves (PAVs). 
 
Protocol: 
 
To make reagent: 500 mg IDCR + 10 mL 660 nm protein reagent (Western blotting shelf, above 
electrophoresis equipment) 
 
1. Thaw protein samples from the -80 at room temperature 
2. Vortex the protein sample and add 5 uL to the walls of microcentrifuge tubes 
3. Wash the protein sample down with 45 uL of Laemmli Buffer 
4. Pipette up and down to mix, and add 10 uL of the solution to the wells of a 96-well plate 
(N=4) 
5. Add 150 uL of reagent (see above) to each well 
6. Cover the well plate in Parafilm, shake to mix 
7. Turn the plate reader on (Putnam Lab) 
8. Open Gen5 software 
9. Create new item: ExperimentButcher_660 nmRight click Plate1Read 
10. Plate ID: date, sample 
11. Wait for tray to come out and computer to prompt you to load the plate. Remove 
Parafilm and load, read 
12. Save experiment under DesktopButcher LabEmily660 nm Assay 
13. Export to Microsoft Excel and save the experiment the same way, email to yourself 
 
The experiment was repeated 3 times: 
1. Not enough of the protein sample was added (low results) 
2. Poor mixing of protein sample with Laemmli Buffer (wide range of results) 
3. Appropriate results 
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Protocol 1.20 - Protocol for preparing EBSS 
 
 
 
To prepare 1000 mL of 10X EBSS, the following materials will be used: 
·         Calcium chloride dihydrate (CaCl2 · 2H2O, Sigma #C7902) – 2.65 g 
·         Potassium chloride (KCl, Sigma #P5405) – 4.0 g 
·         Magnesium sulfate(MgSO4, Sigma #M2643) – 0.9767 g 
·         Sodium chloride (NaCl, Sigma #S5886) – 68.0 g 
·         Sodium phosphate monobasic (NaH2PO4· H2O, Sigma #S5011) – 1.4 g 
·         D-glucose (C6H12O6, Sigma #G7021) – 10 g 
·         ddH2O – 1000 mL 
1.)         Mix all components and 700 mL ddH2O in a 1000 mL beaker with a magnetic stirrer on 
a stir plate. 
2.)         Use a graduated cylinder to bring the volume of the solution to 1000 mL. 
3.)         Using a 0.22m bottle top filter, filter-sterilize the 10X solution into a 1000 mL bottle. 
4.)         Store the sterile salt solution at 4C. 
To prepare 1000 mL of 1X EBSS, the following materials will be used: 
·         10X EBSS liquid – 100 mL 
·         Sodium bicarbonate (NaHCO3, Sigma #S5761) – 2.2 g 
·         ddH2O – 900 mL 
1.)         In a sterile cell culture hood, pour 100 mL 10X EBSS into a graduated cylinder. 
2.)         Add 600 mL ddH2O. 
3.)         Transfer the solution to a 1000 mL beaker. 
4.)         Add 2.2 g sodium bicarbonate to the solution and mix with a magnetic stirrer on a stir 
plate. 
5.)         Adjust the pH of the solution to 7.2 using 1 M NaOH or 1 M HCl. 
6.)         Use a graduated cylinder to bring the volume of the solution to 1000 mL. 
7.)         Using a 0.22m bottle top filter, filter-sterilize the 1X solution into a 1000 mL bottle. 
8.)         Store the sterile salt solution at 4C. 
Reference 
Earl, WR. (1943) The mouse fibroblast cultures and changes seen in the living cells. J. Nat. 
Cancer Inst. 4: 165-169. 
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Protocol 1.21 - Live & Dead Assay Viability/Cytotoxicity Assay 
 
Live and Dead Viability/Cytotoxicity Kit (Molecular Probes) was used to simultaneously visualize 
live and dead cells. The cytoplasm of the live cells is stained in green by converting the calcein 
AM into green fluorescent calcein through intracellular esterases, while ethidium homodimer-1 
(EthD-1) can entered dead cells through damaged membranes to bind deoxyribonucleic acid 
(DNA) and produce a bright red fluorescence in dead cells.  
 
1. Remove the LIVE/DEAD reagent stock solutions from the freezer and allow them to warm to 
room temperature. 
 
2.  Add 10 μL of the supplied 2 mM EthD-1 stock solution to 5 mL of sterilized PBS, vortexing to 
ensure thorough mixing. This gives an approximately 4 μM EthD-1 solution.  
 
3. Add 2.5 μL of the supplied 4 mM calcein AM stock solution to the 5 mL EthD-1 solution. This 
gives an approximately 2 μM calcein AM solution. Vortex the resulting solution to ensure 
thorough mixing. The working solution is for 10 samples. 
 
4. Remove the culture medium and wash the sample with PBS. Withdraw PBS. 
 
5.  Add 0.5 ml the working solution (approximately 2 μM calcein AM and 4 μM EthD-1) directly 
to the sample.  
 
6.  Incubate the samples for 30 min in the incubator (37 C, 5% CO2). 
 
7.  Transfer the stained sample(s) to medium (if imaging process takes several hours) 
 
*Note that aqueous solutions of calcein AM are susceptible to hydrolysis (see Storage and 
Handling of Reagents). Aqueous working solutions should therefore be used within one day. 
 
EthD-1(powder form) from Invitrogen  
Dissolve 1 mg EthD-1 in DMSO/H2O (1:4 v/v, 0.117 ml DMSO and 0.468 ml H2O) to have 2 
mM stock solution (Stock solution is in Dr. Shuler lab) 
 
Calcein AM (powder form) from Invitrogen 
Dissolve 50 ug calcein AM in 12.5 ul DMSO to have 4 mM stock solution (stock solution is in 
our lab or Dr. Shuler lab) 
 
Exiction/Emmision 
•  Calcein = 494/517 nm 
•  Ethidium homodimer-1 in the presence of DNA = 528/617 nm 
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APPENDIX B 
 
SUPPLEMENTAL FIGURES FROM CHAPTER 4 
 
 
 
Figure S4.1.  Collagen to GAG ratio increases during valve maturation.  HH25, HH36, and HH40 hearts 
were isolated, fixed, and embedded.  Serial sections of the left AV left were stained using Picrosirius Red 
and Alcian blue to identify the relative amounts of collagen and glycosaminoglycans (GAGs), respectively. 
The relative contributions changed dramatically across the length of the valve, so the entire valve area 
was considered (dashed contour).  Colors were separated using an RGB or CMYK channel splitter.  
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Black and white thresholds were created in NIH ImageJ and used to determine the volume fractions of 
each contributor.  N ≥ 3, One-way ANOVA w/ Tukey’s Post Hoc. P < .05, Asterisks indicate statistical 
significance. 
 
 
 
Figure S4.2. Isotropic tension increased within the mechanically anchored collagen construct over time.  
(A) Collagen construct was seeded within fabricated well, consisting of a rigid compression spring, and a 
spring attached to a silicon deformable post.  As the collagen constructs condenses, the spring attached 
to the deformable posts bends, producing significant deformation at 12 hr., 24 hr., and 48 hr., after initial 
compaction.  To measure the force exerted by the collagen gel, the silicon posts were calibrated using a 
weight scale.  We then fit a linear curve to the amount of bending deflection (um), to force grams.   After, 
measuring the bending deflection at each time point, we converted to a gram force which was found to 
increase significantly at each time point.  Lastly, we generated a correlative graph between RhoA-GTP 
activation and tension within the hydrogel.  We found a very strong (R2=.99) correlation between RhoA-
GTP levels and tension, suggesting a relationship between the two variables.  N ≥ 6, One-way ANOVA w/ 
Tukey’s Post Hoc. P < .05, Asterisks indicate statistical significance.  
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Figure S4.3.  Mechanical stretch mitigates myofibroblastic activation in a stage dependent manner.  (A) 
HH25, HH36, and HH40 cells were isolated and seeded into the bioreactor.  Cells were allowed to 
compact for 24hrs. and stimulated at 20% area strain at 2.1hz (average frequency during development) 
for 48hrs.  After mechanical stretch, ACTA2 gene expression significantly decreased as compared to MA 
gels (HH36 and HH40 was also found significantly decrease compared to HH25).  (B) We confirmed 
ACTA2 expression levels at 48hr. via immuno-fluorescence, and ACTA2 was found significantly decrease 
in mechanically stretched gels. (C) SRF pathway was inhibited in the CTRL-MA conditions and ACTA2 
gene expression was measured at 48 hours.  Myofibroblastic activation was inhibited confirming the 
importance of the SRF pathway. Scale bars represent 100um.  N ≥ 6, One-way ANOVA w/ Tukey’s Post 
Hoc. P < .05, Different letters indicate statistical significance 
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Figure S4.4. Confirmation of RhoA and Rac1 efficiency using GLISA.   N ≥ 3, Student t-test. P < .05, 
Asterisks indicate statistical significance. 
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Figure S4.5.  Rac1 inhibits migration of HH40 AV cells..  (A)  HH40 AV cells were transfected with either 
CA-Rac1 or DN-Rac1 and seeded onto a tissue culture plastic.  At 48 hrs. a scratch was introduced into 
each well using a 200um pipette tip.  Channel width (a.u.) was measured every 24 hours for 2 days.  
Relative to the initial channel width, DN-Rac1 was found to significantly increase the migration potential, 
while CA-Rac1 mitigated this effect at 48hrs.  N ≥ 6, One-way ANOVA w/ Tukey’s Post Hoc. P < .05, 
Asterisks indicate statistical significance. 
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Figure S4.6.  In-vivo mechanical load regulates ECM content by increasing the collagen/GAG ratio.  
Hearts at D7 and D10 were isolated, fixed, and embedded.  Serial sections of the left AV left were stained 
using Picrosirius Red and Alcian blue to identify the relative amounts of collagen and glycosaminoglycans 
(GAGs), respectively. The relative contributions changed dramatically across the length of the valve, so 
the entire valve area was considered (dashed contour).  Colors were separated using an RGB or CMYK 
channel splitter.  Black and white thresholds were created in NIH ImageJ and used to determine the 
volume fractions of each contributor.  N≥ 4, One-way ANOVA w/ Tukey’s Post Hoc. P < .05, Asterisks 
indicate statistical significance. 
 
 
Extended Methods. 
 
RT-PCR.  RNA extractions were performed using a Qiagen total RNA purification kit (Qiagen, 
Valencia, CA) and RNA was reverse transcribed to cDNA using the SuperScript III RT-PCR kit 
with oligo(dT) primer (Invitrogen). Sufficient quality RNA was determined by an absorbance ratio 
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A260/A280 of 1.8-2.1, while the quantity of RNA was determined by measuring the absorbance 
at 260nm (A260). Real-time PCR experiments were conducted using the SYBR Green PCR 
system (Biorad, Hercules, CA) on a Biorad CFX96 cycler, with 40 cycles per sample. Cycling 
temperatures were as follows: denaturing, 95C; annealing, 60C; and extension, 70C. Primers 
were normalized to β-actin and 18S rRNA. A list of all primer sequences used in this study is  
included below.   
 
Gene Forward 5'-3' Reverse 5'-3' Accession 
18S CGGAGAGGGAGCCTGCGAA CGCCAGCTCGATCCCAAGA AF173612.1 
bactin ATCACAGGGGTGTGGGTGTT AATGAGAGGTTCAGGTGCCC NM_205518.1 
ACTA2 CAGTTTTCCCTTCCATCGTG TGGGGTATTTCAAGGTCAGG NM_001031229.1 
VIM TCTTAGCAGCAACGCTTTCA CGACAGGATGTTGACAATGC NM_001048076.1 
Cyclinβ2 AGGGGTGGAGAATGCCGTGA TGCCAGGTCCTTTCGTAGCCTT NM_001004369.1 
β1 Integrin TGTTTGTGGGGACCAGATTG CCAGGTGACACTTCCCATCA NM_001039254.2 
SRF 
Purchased From Qiagen Quantitect Gg_SRF_2_SG 
Catalog No QT01495872 
XM_427988 
    
 
 
Antibody Staining.  Samples were fixed in 4% PFA overnight at 4C. Samples were then 
washed for 15 minutes on a rocker 3 times with PBS, permeabilized with 0.2\% Triton-X 100 
(VWR International, Radnor, PA) for 10 minutes, and washed another 3 times with PBS. 
Samples were incubated overnight at 4C in a 1% BSA (Rockland Immunochemicals, Inc., 
Gilbertsville, PA) blocking solution followed by another 4C overnight incubation with either rabbit 
ACTA2 1:100 (Springer), rabbit SRF 1:100 (Santa Cruz, sc-13029), mouse vimentin 1:100 
(Invitrogen, V9), and mouse vinculin (Santa Cruz, sc-73614) 1:100, rabbit RhoA 1:100 (Cell 
Signaling, 67B9), rabbit Rac1 1:100 (Santa Cruz, sc-217), mouse Rac1-GTP 1:100 (NewEast 
Bioscience), mouse RhoA-GTP 1:100 (NewEast Bioscience), rabbit phospho-PAK1 1:100 (Cell 
Signaling, T402), or rabbit beta1 (Abcam, 52971). After 3 washes for 15 minutes with PBS, 
samples were exposed to Alexa Fluor 488 or 568 conjugated (Invitrogen), species specific 
secondary antibodies at 1:100 in 1% BSA for 2 hours at room temperature. Three more washes 
with PBS for 15 minutes were followed by incubation with either DRAQ5 far red nuclear stain 
(Enzo Life Sciences, Plymouth Meeting, PA) at 1:1000.  
 
FACS.  Flow cytometry for ACTA2 1:100 (Abcam) was performed. Briefly, cells were 
trypsinized, fixed with 4% PFA for 10 min and then preserved in 50% methanol/PBS. Cells were 
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kept in the -20C until antibody staining was performed. Samples were divided into multiple 
aliquots in order to stain the proteins separately and compensate for secondary antibody non-
specific binding. Cells were incubated for 24 hr at 4 C in primary antibody diluted in either PBS 
(extracellular) or 0.2% saponin-PBS (intracellular). Cells were then washed 3 times with PBS 
and incubated with appropriate secondary antibodies and imaged using a Coulter Epics XL-
MCL Flow Cytometer (Coulter). All samples were compensated using appropriate background 
subtraction and all samples were normalized using 10000 cells per flow condition. 
 
 
In-Vivo Atrial Ligation Experiments. Fertilized White Leghorn chicken eggs were incubated 
blunt end up in a 38°C forced-draft incubator to Hamburger-Hamilton (HH) stage 21 (3.5 days, 
Hamburger and Hamilton). The embryo was cultured in an ex-ovo platform previously 
described.  The egg was positioned under a nikon brightfield microscope, and the embryos 
outer membrane was removed to expose the embryo. The embryo was gently turned to the left 
side up position, and a slit-like opening was made in its thoracic wall using a pair of ﬁne forceps. 
An overhand knot of 10–0 nylon suture loop was placed across either the right or left atrium and 
tightened, partially constricting the left or right atrioventricular oriﬁce respectively. This diverted 
flow from the constricted inlet towards the untreated inlet, decreasing hemodynamic load on the 
one side and increasing it on the other. The embryo was then gently ﬂipped to its original right 
side up position and cultured for an additional 4 days.   
Three-dimensional Stereology via Microcomputed Tomography. Microcomputed 
tomography (micro-CT) analysis was performed according to described protocols (4). Brieﬂy, 50 
μm glass microneedles were used to perfuse a polymerizing CT dense contrast agent microﬁl 
(Flow-Tech, Carver, MA) at a ratio of 20:75:5 (agent, diluent, and catalyst) through the 
ventricular apex region of the chicks. Microﬁl polymerized into a cast within 15 min, after which 
the entire embryo was ﬁxed in 4% paraformaldehyde. Embryos were typically imaged within 48 
hr after ﬁxation via micro-CT (eXplore CT 120, GE Healthcare) at a 25 μm voxel resolution. 
Datasets were processed using Microview (GE Healthcare) and Osirix (Osirix). Individual 
cardiac chamber volumes were segmented and quantiﬁed as previously described (1, 2). 
ELISA.  Activation of RhoA and Rac1 were also followed using G-LISA activation assay kits 
from Cytoskeleton according to the manufacturer’s instructions with a minor modiﬁcation. Cell 
extracts were added to 96-well plate coated with GST fusion of Rho binding domain. After 
incubation with light shaking at 4°C for 30 minutes, the plate was washed 3 times with washing 
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buffer (Cytoskeleton) before addition of antigen presenting buffer (Cytoskeleton). The captured 
GTP-bound Rho GTPases were incubated with their corresponding anti-Rho GTPase 
antibodies. The GTPase-antibody conjugates were detected with horseradish peroxidase 
(HRP)–conjugated secondary antibody and quantiﬁed using the Epoch spectrophotometer 
(Biotek) . 
Scratch assay.  Freshly isolated cells were transfected and seeded into 24 well plates at 
50*104  cells/cm2.  After 24 hrs. a scratch through the central axis of the plate was gently made 
using a pipette tip. Migration of the cells into the scratch was observed at time points of 24 hr. 
and 48 hr.  Subsequent analysis and image processing was done using ImageJ.  Initial channel 
length was measured and used to normalize migration length at subsequent time intervals.  
Adhesion Assay.   Freshly isolated cells were isolated and transfected and seeded into 24 well 
plates at 50*104 cells/cm2. After 24 hours, cells were trypsinized and re-plated onto 4 well tissue 
culture dishes at 5*10
4 
cells/cm
2
.  The plates were then exposed to an orbital shaker at 500rpm 
for 15 seconds at intervals of 30 min up to 120min.  A control set of plates with each condition 
was used to quantify total cells and were not exposed to an orbital shaker.  All cells were 
counterstained using Draq5 and each condition (time interval) was analyzed via ImageJ.  Cells 
exposed to the orbital shaker were normalized to total cells, generating a percentage of 
adherent cells.  Conditions were then compared via ANOVA for statistical significance.   
Extent of Cell Alignment and Nascent Focal Complexes.  We quantified changes in cell 
alignment at 24 hrs. via multiphoton microscopy.  Hundreds of cell images (CA-Rac1, DN-Rac1, 
and control conditions) were collected and analyzed.  The angle distributions within each cell 
were determined using f-actin staining as previously described through a fiber alignment index 
(1 equals not aligned, while 5 equals highly aligned) (3, 4).   Focal complexes were quantified 
be measuring the co-localization of vinculin and F-actin along the periphery using metamorph 
software.       
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APPENDIX C 
LDATAFILE 
 
 
 
 
function DF=LDataFile(TSTART,TSTOP,Ts,INDEX) 
% Machine generated by Universal. 
 
% Load the stoichiometric matrix -- 
S=load('Network.dat'); 
[NROWS,NCOLS]=size(S); 
 
% Formulate the rate constant vector k -- 
k=zeros(NCOLS,1); 
 
% Parameter vector -- 
k=[ 
 0.5201765399659437 ; % 1 EXEXPORT_CYTOSOL + TGFB3_CYTOSOL = EXEXPORT_TGFB3_CYTOSOL
 EXEXPORT_CYTOSOL+TGFB3_CYTOSOL = EXEXPORT_TGFB3_CYTOSOL 
 0.08259715142623342 ; % 2 EXEXPORT_TGFB3_CYTOSOL = EXEXPORT_CYTOSOL + TGFB3_CYTOSOL
 EXEXPORT_TGFB3_CYTOSOL = EXEXPORT_CYTOSOL+TGFB3_CYTOSOL 
 0.3383175807457527 ; % 3 EXEXPORT_TGFB3_CYTOSOL = EXEXPORT_CYTOSOL + TGFB3_EXTRACELLULAR
 EXEXPORT_TGFB3_CYTOSOL = EXEXPORT_CYTOSOL+TGFB3_EXTRACELLULAR 
 0.4374046487299713 ; % 4 EXEXPORT_CYTOSOL + TGFB2_CYTOSOL = EXEXPORT_TGFB2_CYTOSOL
 EXEXPORT_CYTOSOL+TGFB2_CYTOSOL = EXEXPORT_TGFB2_CYTOSOL 
 0.0785125247401077 ; % 5 EXEXPORT_TGFB2_CYTOSOL = EXEXPORT_CYTOSOL + TGFB2_CYTOSOL
 EXEXPORT_TGFB2_CYTOSOL = EXEXPORT_CYTOSOL+TGFB2_CYTOSOL 
 0.9864417788655951 ; % 6 EXEXPORT_TGFB2_CYTOSOL = EXEXPORT_CYTOSOL + TGFB2_EXTRACELLULAR
 EXEXPORT_TGFB2_CYTOSOL = EXEXPORT_CYTOSOL+TGFB2_EXTRACELLULAR 
 0.9044308564376912 ; % 7 DNA_SMURF1_NUCLEAR + RNAP_NUCLEAR = DNA_SMURF1_RNAP_NUCLEAR
 DNA_SMURF1_NUCLEAR+RNAP_NUCLEAR = DNA_SMURF1_RNAP_NUCLEAR 
 0.04457378621682241 ; % 8 DNA_SMURF1_RNAP_NUCLEAR = DNA_SMURF1_NUCLEAR + RNAP_NUCLEAR
 DNA_SMURF1_RNAP_NUCLEAR = DNA_SMURF1_NUCLEAR+RNAP_NUCLEAR 
 0.9854681450664591 ; % 9 DNA_SMURF1_RNAP_NUCLEAR = DNA_SMURF1_NUCLEAR + RNAP_NUCLEAR + 
MRNA_SMURF1_NUCLEAR DNA_SMURF1_RNAP_NUCLEAR = DNA_SMURF1_NUCLEAR+RNAP_NUCLEAR+MRNA_SMURF1_NUCLEAR 
 0.17878441863520556 ; % 10 MRNA_SMURF1_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_SMURF1_NEXPORT_NUCLEAR MRNA_SMURF1_NUCLEAR+NEXPORT_NUCLEAR = MRNA_SMURF1_NEXPORT_NUCLEAR 
 0.03949756944048011 ; % 11 MRNA_SMURF1_NEXPORT_NUCLEAR = MRNA_SMURF1_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_SMURF1_NEXPORT_NUCLEAR = MRNA_SMURF1_NUCLEAR+NEXPORT_NUCLEAR 
 0.06913703105616786 ; % 12 MRNA_SMURF1_NEXPORT_NUCLEAR = MRNA_SMURF1_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_SMURF1_NEXPORT_NUCLEAR = MRNA_SMURF1_CYTOSOL+NEXPORT_NUCLEAR 
 0.46623710874896274 ; % 13 MRNA_SMURF1_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_SMURF1_RIBOSOME_CYTOSOL MRNA_SMURF1_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_SMURF1_RIBOSOME_CYTOSOL 
 0.010722949313692755 ; % 14 MRNA_SMURF1_RIBOSOME_CYTOSOL = MRNA_SMURF1_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_SMURF1_RIBOSOME_CYTOSOL = MRNA_SMURF1_CYTOSOL+RIBOSOME_CYTOSOL 
 0.3257990411263175 ; % 15 MRNA_SMURF1_RIBOSOME_CYTOSOL = 
MRNA_SMURF1_START_RIBOSOME_CYTOSOL MRNA_SMURF1_RIBOSOME_CYTOSOL = MRNA_SMURF1_START_RIBOSOME_CYTOSOL 
 0.10795192932789754 ; % 16 MRNA_SMURF1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
SMURF1_CYTOSOL + MRNA_SMURF1_CYTOSOL MRNA_SMURF1_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+SMURF1_CYTOSOL+MRNA_SMURF1_CYTOSOL 
 0.08729144081002116 ; % 17 MRNA_SMURF1_CYTOSOL = [] MRNA_SMURF1_CYTOSOL = [] 
 0.05261779092635993 ; % 18 SMURF1_CYTOSOL = [] SMURF1_CYTOSOL = [] 
 0.0026085744121078547 ; % 19 DNA_SMURF2_NUCLEAR + RNAP_NUCLEAR = DNA_SMURF2_RNAP_NUCLEAR
 DNA_SMURF2_NUCLEAR+RNAP_NUCLEAR = DNA_SMURF2_RNAP_NUCLEAR 
 0.7758758897719407 ; % 20 DNA_SMURF2_RNAP_NUCLEAR = DNA_SMURF2_NUCLEAR + RNAP_NUCLEAR
 DNA_SMURF2_RNAP_NUCLEAR = DNA_SMURF2_NUCLEAR+RNAP_NUCLEAR 
 0.7413921306133238 ; % 21 DNA_SMURF2_RNAP_NUCLEAR = DNA_SMURF2_NUCLEAR + RNAP_NUCLEAR + 
MRNA_SMURF2_NUCLEAR DNA_SMURF2_RNAP_NUCLEAR = DNA_SMURF2_NUCLEAR+RNAP_NUCLEAR+MRNA_SMURF2_NUCLEAR 
 0.5823680389491563 ; % 22 MRNA_SMURF2_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_SMURF2_NEXPORT_NUCLEAR MRNA_SMURF2_NUCLEAR+NEXPORT_NUCLEAR = MRNA_SMURF2_NEXPORT_NUCLEAR 
 0.01805033511707348 ; % 23 MRNA_SMURF2_NEXPORT_NUCLEAR = MRNA_SMURF2_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_SMURF2_NEXPORT_NUCLEAR = MRNA_SMURF2_NUCLEAR+NEXPORT_NUCLEAR 
 0.12038690090260429 ; % 24 MRNA_SMURF2_NEXPORT_NUCLEAR = MRNA_SMURF2_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_SMURF2_NEXPORT_NUCLEAR = MRNA_SMURF2_CYTOSOL+NEXPORT_NUCLEAR 
 0.3942156686103949 ; % 25 MRNA_SMURF2_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_SMURF2_RIBOSOME_CYTOSOL MRNA_SMURF2_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_SMURF2_RIBOSOME_CYTOSOL 
 0.09155943143875152 ; % 26 MRNA_SMURF2_RIBOSOME_CYTOSOL = MRNA_SMURF2_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_SMURF2_RIBOSOME_CYTOSOL = MRNA_SMURF2_CYTOSOL+RIBOSOME_CYTOSOL 
 0.2210759746367258 ; % 27 MRNA_SMURF2_RIBOSOME_CYTOSOL = 
MRNA_SMURF2_START_RIBOSOME_CYTOSOL MRNA_SMURF2_RIBOSOME_CYTOSOL = MRNA_SMURF2_START_RIBOSOME_CYTOSOL 
 0.9697132759997918 ; % 28 MRNA_SMURF2_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
SMURF2_CYTOSOL + MRNA_SMURF2_CYTOSOL MRNA_SMURF2_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+SMURF2_CYTOSOL+MRNA_SMURF2_CYTOSOL 
 0.02905293365148076 ; % 29 MRNA_SMURF2_CYTOSOL = [] MRNA_SMURF2_CYTOSOL = [] 
 0.059200472491522604 ; % 30 SMURF2_CYTOSOL = [] SMURF2_CYTOSOL = [] 
 0.90889829530306456 ; % 31 DNA_SMAD1_NUCLEAR + RNAP_NUCLEAR = DNA_SMAD1_RNAP_NUCLEAR
 DNA_SMAD1_NUCLEAR+RNAP_NUCLEAR = DNA_SMAD1_RNAP_NUCLEAR 
 0.047263836564669495 ; % 32 DNA_SMAD1_RNAP_NUCLEAR = DNA_SMAD1_NUCLEAR + RNAP_NUCLEAR
 DNA_SMAD1_RNAP_NUCLEAR = DNA_SMAD1_NUCLEAR+RNAP_NUCLEAR 
 0.3730313009057662 ; % 33 DNA_SMAD1_RNAP_NUCLEAR = DNA_SMAD1_NUCLEAR + RNAP_NUCLEAR + 
MRNA_SMAD1_NUCLEAR DNA_SMAD1_RNAP_NUCLEAR = DNA_SMAD1_NUCLEAR+RNAP_NUCLEAR+MRNA_SMAD1_NUCLEAR 
 0.18851918962290348 ; % 34 MRNA_SMAD1_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_SMAD1_NEXPORT_NUCLEAR MRNA_SMAD1_NUCLEAR+NEXPORT_NUCLEAR = MRNA_SMAD1_NEXPORT_NUCLEAR 
 0.028697769420319277 ; % 35 MRNA_SMAD1_NEXPORT_NUCLEAR = MRNA_SMAD1_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_SMAD1_NEXPORT_NUCLEAR = MRNA_SMAD1_NUCLEAR+NEXPORT_NUCLEAR 
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 0.6929672623408051 ; % 36 MRNA_SMAD1_NEXPORT_NUCLEAR = MRNA_SMAD1_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_SMAD1_NEXPORT_NUCLEAR = MRNA_SMAD1_CYTOSOL+NEXPORT_NUCLEAR 
 0.3848574589775263 ; % 37 MRNA_SMAD1_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_SMAD1_RIBOSOME_CYTOSOL MRNA_SMAD1_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_SMAD1_RIBOSOME_CYTOSOL 
 0.05086799912991296 ; % 38 MRNA_SMAD1_RIBOSOME_CYTOSOL = MRNA_SMAD1_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_SMAD1_RIBOSOME_CYTOSOL = MRNA_SMAD1_CYTOSOL+RIBOSOME_CYTOSOL 
 0.3641523397132931 ; % 39 MRNA_SMAD1_RIBOSOME_CYTOSOL = MRNA_SMAD1_START_RIBOSOME_CYTOSOL
 MRNA_SMAD1_RIBOSOME_CYTOSOL = MRNA_SMAD1_START_RIBOSOME_CYTOSOL 
 0.5222354221734035 ; % 40 MRNA_SMAD1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
SMAD1_CYTOSOL + MRNA_SMAD1_CYTOSOL MRNA_SMAD1_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+SMAD1_CYTOSOL+MRNA_SMAD1_CYTOSOL 
 0.1757259455531941 ; % 41 MRNA_SMAD1_CYTOSOL = [] MRNA_SMAD1_CYTOSOL = [] 
 0.027350417929296378 ; % 42 SMAD1_CYTOSOL = [] SMAD1_CYTOSOL = [] 
 0.9041212052161975 ; % 43 DNA_SMAD2_NUCLEAR + RNAP_NUCLEAR = DNA_SMAD2_RNAP_NUCLEAR
 DNA_SMAD2_NUCLEAR+RNAP_NUCLEAR = DNA_SMAD2_RNAP_NUCLEAR 
 0.03822475396948191 ; % 44 DNA_SMAD2_RNAP_NUCLEAR = DNA_SMAD2_NUCLEAR + RNAP_NUCLEAR
 DNA_SMAD2_RNAP_NUCLEAR = DNA_SMAD2_NUCLEAR+RNAP_NUCLEAR 
 0.44629345187005465 ; % 45 DNA_SMAD2_RNAP_NUCLEAR = DNA_SMAD2_NUCLEAR + RNAP_NUCLEAR + 
MRNA_SMAD2_NUCLEAR DNA_SMAD2_RNAP_NUCLEAR = DNA_SMAD2_NUCLEAR+RNAP_NUCLEAR+MRNA_SMAD2_NUCLEAR 
 0.4513403620669495 ; % 46 MRNA_SMAD2_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_SMAD2_NEXPORT_NUCLEAR MRNA_SMAD2_NUCLEAR+NEXPORT_NUCLEAR = MRNA_SMAD2_NEXPORT_NUCLEAR 
 0.07157408191243762 ; % 47 MRNA_SMAD2_NEXPORT_NUCLEAR = MRNA_SMAD2_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_SMAD2_NEXPORT_NUCLEAR = MRNA_SMAD2_NUCLEAR+NEXPORT_NUCLEAR 
 0.8032926823377786 ; % 48 MRNA_SMAD2_NEXPORT_NUCLEAR = MRNA_SMAD2_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_SMAD2_NEXPORT_NUCLEAR = MRNA_SMAD2_CYTOSOL+NEXPORT_NUCLEAR 
 0.1390346908996929 ; % 49 MRNA_SMAD2_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_SMAD2_RIBOSOME_CYTOSOL MRNA_SMAD2_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_SMAD2_RIBOSOME_CYTOSOL 
 0.010873960569937348 ; % 50 MRNA_SMAD2_RIBOSOME_CYTOSOL = MRNA_SMAD2_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_SMAD2_RIBOSOME_CYTOSOL = MRNA_SMAD2_CYTOSOL+RIBOSOME_CYTOSOL 
 0.10616696808269332 ; % 51 MRNA_SMAD2_RIBOSOME_CYTOSOL = MRNA_SMAD2_START_RIBOSOME_CYTOSOL
 MRNA_SMAD2_RIBOSOME_CYTOSOL = MRNA_SMAD2_START_RIBOSOME_CYTOSOL 
 0.9843890522927627 ; % 52 MRNA_SMAD2_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
SMAD2_CYTOSOL + MRNA_SMAD2_CYTOSOL MRNA_SMAD2_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+SMAD2_CYTOSOL+MRNA_SMAD2_CYTOSOL 
 0.34289372071924584 ; % 53 MRNA_SMAD2_CYTOSOL = [] MRNA_SMAD2_CYTOSOL = [] 
 0.3854504902821078 ; % 54 SMAD2_CYTOSOL = [] SMAD2_CYTOSOL = [] 
 0.914865152695174078 ; % 55 DNA_SMAD3_NUCLEAR + RNAP_NUCLEAR = DNA_SMAD3_RNAP_NUCLEAR
 DNA_SMAD3_NUCLEAR+RNAP_NUCLEAR = DNA_SMAD3_RNAP_NUCLEAR 
 0.008686705548544708 ; % 56 DNA_SMAD3_RNAP_NUCLEAR = DNA_SMAD3_NUCLEAR + RNAP_NUCLEAR
 DNA_SMAD3_RNAP_NUCLEAR = DNA_SMAD3_NUCLEAR+RNAP_NUCLEAR 
 0.47147151497316553 ; % 57 DNA_SMAD3_RNAP_NUCLEAR = DNA_SMAD3_NUCLEAR + RNAP_NUCLEAR + 
MRNA_SMAD3_NUCLEAR DNA_SMAD3_RNAP_NUCLEAR = DNA_SMAD3_NUCLEAR+RNAP_NUCLEAR+MRNA_SMAD3_NUCLEAR 
 0.8125392997761574 ; % 58 MRNA_SMAD3_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_SMAD3_NEXPORT_NUCLEAR MRNA_SMAD3_NUCLEAR+NEXPORT_NUCLEAR = MRNA_SMAD3_NEXPORT_NUCLEAR 
 0.05592088462837061 ; % 59 MRNA_SMAD3_NEXPORT_NUCLEAR = MRNA_SMAD3_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_SMAD3_NEXPORT_NUCLEAR = MRNA_SMAD3_NUCLEAR+NEXPORT_NUCLEAR 
 0.10003411121437822 ; % 60 MRNA_SMAD3_NEXPORT_NUCLEAR = MRNA_SMAD3_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_SMAD3_NEXPORT_NUCLEAR = MRNA_SMAD3_CYTOSOL+NEXPORT_NUCLEAR 
 0.9123869868761132 ; % 61 MRNA_SMAD3_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_SMAD3_RIBOSOME_CYTOSOL MRNA_SMAD3_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_SMAD3_RIBOSOME_CYTOSOL 
 0.05317720099206461 ; % 62 MRNA_SMAD3_RIBOSOME_CYTOSOL = MRNA_SMAD3_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_SMAD3_RIBOSOME_CYTOSOL = MRNA_SMAD3_CYTOSOL+RIBOSOME_CYTOSOL 
 0.6913295756938763 ; % 63 MRNA_SMAD3_RIBOSOME_CYTOSOL = MRNA_SMAD3_START_RIBOSOME_CYTOSOL
 MRNA_SMAD3_RIBOSOME_CYTOSOL = MRNA_SMAD3_START_RIBOSOME_CYTOSOL 
 0.4664249516408243 ; % 64 MRNA_SMAD3_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
SMAD3_CYTOSOL + MRNA_SMAD3_CYTOSOL MRNA_SMAD3_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+SMAD3_CYTOSOL+MRNA_SMAD3_CYTOSOL 
 0.12462045242650488 ; % 65 MRNA_SMAD3_CYTOSOL = [] MRNA_SMAD3_CYTOSOL = [] 
 0.25174914469340764 ; % 66 SMAD3_CYTOSOL = [] SMAD3_CYTOSOL = [] 
 0.9910788552173622 ; % 67 DNA_SMAD4_NUCLEAR + RNAP_NUCLEAR = DNA_SMAD4_RNAP_NUCLEAR
 DNA_SMAD4_NUCLEAR+RNAP_NUCLEAR = DNA_SMAD4_RNAP_NUCLEAR 
 0.008064508441874563 ; % 68 DNA_SMAD4_RNAP_NUCLEAR = DNA_SMAD4_NUCLEAR + RNAP_NUCLEAR
 DNA_SMAD4_RNAP_NUCLEAR = DNA_SMAD4_NUCLEAR+RNAP_NUCLEAR 
 0.8391790107174769 ; % 69 DNA_SMAD4_RNAP_NUCLEAR = DNA_SMAD4_NUCLEAR + RNAP_NUCLEAR + 
MRNA_SMAD4_NUCLEAR DNA_SMAD4_RNAP_NUCLEAR = DNA_SMAD4_NUCLEAR+RNAP_NUCLEAR+MRNA_SMAD4_NUCLEAR 
 0.7819499123822488 ; % 70 MRNA_SMAD4_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_SMAD4_NEXPORT_NUCLEAR MRNA_SMAD4_NUCLEAR+NEXPORT_NUCLEAR = MRNA_SMAD4_NEXPORT_NUCLEAR 
 0.09014065569063816 ; % 71 MRNA_SMAD4_NEXPORT_NUCLEAR = MRNA_SMAD4_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_SMAD4_NEXPORT_NUCLEAR = MRNA_SMAD4_NUCLEAR+NEXPORT_NUCLEAR 
 0.6013277866184339 ; % 72 MRNA_SMAD4_NEXPORT_NUCLEAR = MRNA_SMAD4_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_SMAD4_NEXPORT_NUCLEAR = MRNA_SMAD4_CYTOSOL+NEXPORT_NUCLEAR 
 0.48994453138996064 ; % 73 MRNA_SMAD4_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_SMAD4_RIBOSOME_CYTOSOL MRNA_SMAD4_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_SMAD4_RIBOSOME_CYTOSOL 
 0.03707791628521362 ; % 74 MRNA_SMAD4_RIBOSOME_CYTOSOL = MRNA_SMAD4_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_SMAD4_RIBOSOME_CYTOSOL = MRNA_SMAD4_CYTOSOL+RIBOSOME_CYTOSOL 
 0.950156194331962 ; % 75 MRNA_SMAD4_RIBOSOME_CYTOSOL = MRNA_SMAD4_START_RIBOSOME_CYTOSOL
 MRNA_SMAD4_RIBOSOME_CYTOSOL = MRNA_SMAD4_START_RIBOSOME_CYTOSOL 
 0.25472827492419114 ; % 76 MRNA_SMAD4_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
SMAD4_CYTOSOL + MRNA_SMAD4_CYTOSOL MRNA_SMAD4_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+SMAD4_CYTOSOL+MRNA_SMAD4_CYTOSOL 
 0.4850524206985869 ; % 77 MRNA_SMAD4_CYTOSOL = [] MRNA_SMAD4_CYTOSOL = [] 
 0.4575910513624255 ; % 78 SMAD4_CYTOSOL = [] SMAD4_CYTOSOL = [] 
 0.6962224032949356 ; % 79 DNA_SMAD5_NUCLEAR + RNAP_NUCLEAR = DNA_SMAD5_RNAP_NUCLEAR
 DNA_SMAD5_NUCLEAR+RNAP_NUCLEAR = DNA_SMAD5_RNAP_NUCLEAR 
 0.02822397745420642 ; % 80 DNA_SMAD5_RNAP_NUCLEAR = DNA_SMAD5_NUCLEAR + RNAP_NUCLEAR
 DNA_SMAD5_RNAP_NUCLEAR = DNA_SMAD5_NUCLEAR+RNAP_NUCLEAR 
 0.07635875719358298 ; % 81 DNA_SMAD5_RNAP_NUCLEAR = DNA_SMAD5_NUCLEAR + RNAP_NUCLEAR + 
MRNA_SMAD5_NUCLEAR DNA_SMAD5_RNAP_NUCLEAR = DNA_SMAD5_NUCLEAR+RNAP_NUCLEAR+MRNA_SMAD5_NUCLEAR 
 0.012938441340032969 ; % 82 MRNA_SMAD5_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_SMAD5_NEXPORT_NUCLEAR MRNA_SMAD5_NUCLEAR+NEXPORT_NUCLEAR = MRNA_SMAD5_NEXPORT_NUCLEAR 
 0.008821196161891488 ; % 83 MRNA_SMAD5_NEXPORT_NUCLEAR = MRNA_SMAD5_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_SMAD5_NEXPORT_NUCLEAR = MRNA_SMAD5_NUCLEAR+NEXPORT_NUCLEAR 
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 0.709050526371447 ; % 84 MRNA_SMAD5_NEXPORT_NUCLEAR = MRNA_SMAD5_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_SMAD5_NEXPORT_NUCLEAR = MRNA_SMAD5_CYTOSOL+NEXPORT_NUCLEAR 
 0.5422561944543943 ; % 85 MRNA_SMAD5_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_SMAD5_RIBOSOME_CYTOSOL MRNA_SMAD5_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_SMAD5_RIBOSOME_CYTOSOL 
 0.08898818046594906 ; % 86 MRNA_SMAD5_RIBOSOME_CYTOSOL = MRNA_SMAD5_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_SMAD5_RIBOSOME_CYTOSOL = MRNA_SMAD5_CYTOSOL+RIBOSOME_CYTOSOL 
 0.4301939312988523 ; % 87 MRNA_SMAD5_RIBOSOME_CYTOSOL = MRNA_SMAD5_START_RIBOSOME_CYTOSOL
 MRNA_SMAD5_RIBOSOME_CYTOSOL = MRNA_SMAD5_START_RIBOSOME_CYTOSOL 
 0.006116266289741157 ; % 88 MRNA_SMAD5_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
SMAD5_CYTOSOL + MRNA_SMAD5_CYTOSOL MRNA_SMAD5_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+SMAD5_CYTOSOL+MRNA_SMAD5_CYTOSOL 
 0.31611646239580793 ; % 89 MRNA_SMAD5_CYTOSOL = [] MRNA_SMAD5_CYTOSOL = [] 
 0.2200985768385944 ; % 90 SMAD5_CYTOSOL = [] SMAD5_CYTOSOL = [] 
 0.02118208936560032 ; % 91 DNA_SMAD6_NUCLEAR + RNAP_NUCLEAR = DNA_SMAD6_RNAP_NUCLEAR
 DNA_SMAD6_NUCLEAR+RNAP_NUCLEAR = DNA_SMAD6_RNAP_NUCLEAR 
 0.0300629815807156 ; % 92 DNA_SMAD6_RNAP_NUCLEAR = DNA_SMAD6_NUCLEAR + RNAP_NUCLEAR
 DNA_SMAD6_RNAP_NUCLEAR = DNA_SMAD6_NUCLEAR+RNAP_NUCLEAR 
 0.4806835110109028 ; % 93 DNA_SMAD6_RNAP_NUCLEAR = DNA_SMAD6_NUCLEAR + RNAP_NUCLEAR + 
MRNA_SMAD6_NUCLEAR DNA_SMAD6_RNAP_NUCLEAR = DNA_SMAD6_NUCLEAR+RNAP_NUCLEAR+MRNA_SMAD6_NUCLEAR 
 0.793074870186985 ; % 94 MRNA_SMAD6_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_SMAD6_NEXPORT_NUCLEAR MRNA_SMAD6_NUCLEAR+NEXPORT_NUCLEAR = MRNA_SMAD6_NEXPORT_NUCLEAR 
 0.06790478627548091 ; % 95 MRNA_SMAD6_NEXPORT_NUCLEAR = MRNA_SMAD6_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_SMAD6_NEXPORT_NUCLEAR = MRNA_SMAD6_NUCLEAR+NEXPORT_NUCLEAR 
 0.2794276654358169 ; % 96 MRNA_SMAD6_NEXPORT_NUCLEAR = MRNA_SMAD6_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_SMAD6_NEXPORT_NUCLEAR = MRNA_SMAD6_CYTOSOL+NEXPORT_NUCLEAR 
 0.10786537377208982 ; % 97 MRNA_SMAD6_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_SMAD6_RIBOSOME_CYTOSOL MRNA_SMAD6_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_SMAD6_RIBOSOME_CYTOSOL 
 0.06346339723634625 ; % 98 MRNA_SMAD6_RIBOSOME_CYTOSOL = MRNA_SMAD6_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_SMAD6_RIBOSOME_CYTOSOL = MRNA_SMAD6_CYTOSOL+RIBOSOME_CYTOSOL 
 0.1968710012795719 ; % 99 MRNA_SMAD6_RIBOSOME_CYTOSOL = MRNA_SMAD6_START_RIBOSOME_CYTOSOL
 MRNA_SMAD6_RIBOSOME_CYTOSOL = MRNA_SMAD6_START_RIBOSOME_CYTOSOL 
 0.8252809333373334 ; % 100 MRNA_SMAD6_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
SMAD6_CYTOSOL + MRNA_SMAD6_CYTOSOL MRNA_SMAD6_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+SMAD6_CYTOSOL+MRNA_SMAD6_CYTOSOL 
 0.2863738069696536 ; % 101 MRNA_SMAD6_CYTOSOL = [] MRNA_SMAD6_CYTOSOL = [] 
 0.2438297232078887 ; % 102 SMAD6_CYTOSOL = [] SMAD6_CYTOSOL = [] 
 0.018695377267448043 ; % 103 DNA_SMAD7_NUCLEAR + RNAP_NUCLEAR = DNA_SMAD7_RNAP_NUCLEAR
 DNA_SMAD7_NUCLEAR+RNAP_NUCLEAR = DNA_SMAD7_RNAP_NUCLEAR 
 0.07277758852471339 ; % 104 DNA_SMAD7_RNAP_NUCLEAR = DNA_SMAD7_NUCLEAR + RNAP_NUCLEAR
 DNA_SMAD7_RNAP_NUCLEAR = DNA_SMAD7_NUCLEAR+RNAP_NUCLEAR 
 0.9074885664202607 ; % 105 DNA_SMAD7_RNAP_NUCLEAR = DNA_SMAD7_NUCLEAR + RNAP_NUCLEAR + 
MRNA_SMAD7_NUCLEAR DNA_SMAD7_RNAP_NUCLEAR = DNA_SMAD7_NUCLEAR+RNAP_NUCLEAR+MRNA_SMAD7_NUCLEAR 
 0.03158187167159987 ; % 106 MRNA_SMAD7_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_SMAD7_NEXPORT_NUCLEAR MRNA_SMAD7_NUCLEAR+NEXPORT_NUCLEAR = MRNA_SMAD7_NEXPORT_NUCLEAR 
 0.031070285385804076 ; % 107 MRNA_SMAD7_NEXPORT_NUCLEAR = MRNA_SMAD7_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_SMAD7_NEXPORT_NUCLEAR = MRNA_SMAD7_NUCLEAR+NEXPORT_NUCLEAR 
 0.5184976500489137 ; % 108 MRNA_SMAD7_NEXPORT_NUCLEAR = MRNA_SMAD7_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_SMAD7_NEXPORT_NUCLEAR = MRNA_SMAD7_CYTOSOL+NEXPORT_NUCLEAR 
 0.31904601839283064 ; % 109 MRNA_SMAD7_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_SMAD7_RIBOSOME_CYTOSOL MRNA_SMAD7_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_SMAD7_RIBOSOME_CYTOSOL 
 0.033125994432657034 ; % 110 MRNA_SMAD7_RIBOSOME_CYTOSOL = MRNA_SMAD7_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_SMAD7_RIBOSOME_CYTOSOL = MRNA_SMAD7_CYTOSOL+RIBOSOME_CYTOSOL 
 0.6123023288133863 ; % 111 MRNA_SMAD7_RIBOSOME_CYTOSOL = MRNA_SMAD7_START_RIBOSOME_CYTOSOL
 MRNA_SMAD7_RIBOSOME_CYTOSOL = MRNA_SMAD7_START_RIBOSOME_CYTOSOL 
 0.594487459601517 ; % 112 MRNA_SMAD7_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
SMAD7_CYTOSOL + MRNA_SMAD7_CYTOSOL MRNA_SMAD7_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+SMAD7_CYTOSOL+MRNA_SMAD7_CYTOSOL 
 0.32024730784036487 ; % 113 MRNA_SMAD7_CYTOSOL = [] MRNA_SMAD7_CYTOSOL = [] 
 0.26775482993514105 ; % 114 SMAD7_CYTOSOL = [] SMAD7_CYTOSOL = [] 
 0.5364092853877909 ; % 115 DNA_ENDOGLIN_NUCLEAR + RNAP_NUCLEAR = DNA_ENDOGLIN_RNAP_NUCLEAR
 DNA_ENDOGLIN_NUCLEAR+RNAP_NUCLEAR = DNA_ENDOGLIN_RNAP_NUCLEAR 
 0.03144525856077001 ; % 116 DNA_ENDOGLIN_RNAP_NUCLEAR = DNA_ENDOGLIN_NUCLEAR + RNAP_NUCLEAR
 DNA_ENDOGLIN_RNAP_NUCLEAR = DNA_ENDOGLIN_NUCLEAR+RNAP_NUCLEAR 
 0.16794541590701806 ; % 117 DNA_ENDOGLIN_RNAP_NUCLEAR = DNA_ENDOGLIN_NUCLEAR + RNAP_NUCLEAR + 
MRNA_ENDOGLIN_NUCLEAR DNA_ENDOGLIN_RNAP_NUCLEAR = DNA_ENDOGLIN_NUCLEAR+RNAP_NUCLEAR+MRNA_ENDOGLIN_NUCLEAR 
 0.20495643986700485 ; % 118 MRNA_ENDOGLIN_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_ENDOGLIN_NEXPORT_NUCLEAR MRNA_ENDOGLIN_NUCLEAR+NEXPORT_NUCLEAR = MRNA_ENDOGLIN_NEXPORT_NUCLEAR 
 0.009165947890536541 ; % 119 MRNA_ENDOGLIN_NEXPORT_NUCLEAR = MRNA_ENDOGLIN_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_ENDOGLIN_NEXPORT_NUCLEAR = MRNA_ENDOGLIN_NUCLEAR+NEXPORT_NUCLEAR 
 0.6789653704657468 ; % 120 MRNA_ENDOGLIN_NEXPORT_NUCLEAR = MRNA_ENDOGLIN_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_ENDOGLIN_NEXPORT_NUCLEAR = MRNA_ENDOGLIN_CYTOSOL+NEXPORT_NUCLEAR 
 0.8285323341864742 ; % 121 MRNA_ENDOGLIN_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_ENDOGLIN_RIBOSOME_CYTOSOL MRNA_ENDOGLIN_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_ENDOGLIN_RIBOSOME_CYTOSOL 
 0.0933669607223379 ; % 122 MRNA_ENDOGLIN_RIBOSOME_CYTOSOL = MRNA_ENDOGLIN_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_ENDOGLIN_RIBOSOME_CYTOSOL = MRNA_ENDOGLIN_CYTOSOL+RIBOSOME_CYTOSOL 
 0.9438271934274336 ; % 123 MRNA_ENDOGLIN_RIBOSOME_CYTOSOL = 
MRNA_ENDOGLIN_START_RIBOSOME_CYTOSOL MRNA_ENDOGLIN_RIBOSOME_CYTOSOL = MRNA_ENDOGLIN_START_RIBOSOME_CYTOSOL 
 0.5388958714570403 ; % 124 MRNA_ENDOGLIN_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
ENDOGLIN_CYTOSOL + MRNA_ENDOGLIN_CYTOSOL MRNA_ENDOGLIN_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+ENDOGLIN_CYTOSOL+MRNA_ENDOGLIN_CYTOSOL 
 0.04537559222842208 ; % 125 MRNA_ENDOGLIN_CYTOSOL = [] MRNA_ENDOGLIN_CYTOSOL = [] 
 0.17008546230349786 ; % 126 ENDOGLIN_CYTOSOL = [] ENDOGLIN_CYTOSOL = [] 
 0.8914284372552602 ; % 127 DNA_ALK1_NUCLEAR + RNAP_NUCLEAR = DNA_ALK1_RNAP_NUCLEAR
 DNA_ALK1_NUCLEAR+RNAP_NUCLEAR = DNA_ALK1_RNAP_NUCLEAR 
 0.0015580093673532747 ; % 128 DNA_ALK1_RNAP_NUCLEAR = DNA_ALK1_NUCLEAR + RNAP_NUCLEAR
 DNA_ALK1_RNAP_NUCLEAR = DNA_ALK1_NUCLEAR+RNAP_NUCLEAR 
 0.15050700132760975 ; % 129 DNA_ALK1_RNAP_NUCLEAR = DNA_ALK1_NUCLEAR + RNAP_NUCLEAR + 
MRNA_ALK1_NUCLEAR DNA_ALK1_RNAP_NUCLEAR = DNA_ALK1_NUCLEAR+RNAP_NUCLEAR+MRNA_ALK1_NUCLEAR 
 0.8207925143528575 ; % 130 MRNA_ALK1_NUCLEAR + NEXPORT_NUCLEAR = MRNA_ALK1_NEXPORT_NUCLEAR
 MRNA_ALK1_NUCLEAR+NEXPORT_NUCLEAR = MRNA_ALK1_NEXPORT_NUCLEAR 
 1.752330751385034E-4 ; % 131 MRNA_ALK1_NEXPORT_NUCLEAR = MRNA_ALK1_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_ALK1_NEXPORT_NUCLEAR = MRNA_ALK1_NUCLEAR+NEXPORT_NUCLEAR 
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 0.9617341264993546 ; % 132 MRNA_ALK1_NEXPORT_NUCLEAR = MRNA_ALK1_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_ALK1_NEXPORT_NUCLEAR = MRNA_ALK1_CYTOSOL+NEXPORT_NUCLEAR 
 0.7045453617232692 ; % 133 MRNA_ALK1_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_ALK1_RIBOSOME_CYTOSOL
 MRNA_ALK1_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_ALK1_RIBOSOME_CYTOSOL 
 0.06819913947769468 ; % 134 MRNA_ALK1_RIBOSOME_CYTOSOL = MRNA_ALK1_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_ALK1_RIBOSOME_CYTOSOL = MRNA_ALK1_CYTOSOL+RIBOSOME_CYTOSOL 
 0.6667502681252524 ; % 135 MRNA_ALK1_RIBOSOME_CYTOSOL = MRNA_ALK1_START_RIBOSOME_CYTOSOL
 MRNA_ALK1_RIBOSOME_CYTOSOL = MRNA_ALK1_START_RIBOSOME_CYTOSOL 
 0.8438816499691592 ; % 136 MRNA_ALK1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + ALK1_CYTOSOL 
+ MRNA_ALK1_CYTOSOL MRNA_ALK1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+ALK1_CYTOSOL+MRNA_ALK1_CYTOSOL 
 0.028757248046415607 ; % 137 MRNA_ALK1_CYTOSOL = [] MRNA_ALK1_CYTOSOL = [] 
 0.19905565797917152 ; % 138 ALK1_CYTOSOL = [] ALK1_CYTOSOL = [] 
 0.9759085893754013 ; % 139 DNA_ALK2_NUCLEAR + RNAP_NUCLEAR = DNA_ALK2_RNAP_NUCLEAR
 DNA_ALK2_NUCLEAR+RNAP_NUCLEAR = DNA_ALK2_RNAP_NUCLEAR 
 0.03850708039319317 ; % 140 DNA_ALK2_RNAP_NUCLEAR = DNA_ALK2_NUCLEAR + RNAP_NUCLEAR
 DNA_ALK2_RNAP_NUCLEAR = DNA_ALK2_NUCLEAR+RNAP_NUCLEAR 
 0.3997244629439337 ; % 141 DNA_ALK2_RNAP_NUCLEAR = DNA_ALK2_NUCLEAR + RNAP_NUCLEAR + 
MRNA_ALK2_NUCLEAR DNA_ALK2_RNAP_NUCLEAR = DNA_ALK2_NUCLEAR+RNAP_NUCLEAR+MRNA_ALK2_NUCLEAR 
 0.7772152927770049 ; % 142 MRNA_ALK2_NUCLEAR + NEXPORT_NUCLEAR = MRNA_ALK2_NEXPORT_NUCLEAR
 MRNA_ALK2_NUCLEAR+NEXPORT_NUCLEAR = MRNA_ALK2_NEXPORT_NUCLEAR 
 0.009717462703479597 ; % 143 MRNA_ALK2_NEXPORT_NUCLEAR = MRNA_ALK2_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_ALK2_NEXPORT_NUCLEAR = MRNA_ALK2_NUCLEAR+NEXPORT_NUCLEAR 
 0.6709136175427387 ; % 144 MRNA_ALK2_NEXPORT_NUCLEAR = MRNA_ALK2_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_ALK2_NEXPORT_NUCLEAR = MRNA_ALK2_CYTOSOL+NEXPORT_NUCLEAR 
 0.8397405381709364 ; % 145 MRNA_ALK2_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_ALK2_RIBOSOME_CYTOSOL
 MRNA_ALK2_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_ALK2_RIBOSOME_CYTOSOL 
 0.07599945719313639 ; % 146 MRNA_ALK2_RIBOSOME_CYTOSOL = MRNA_ALK2_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_ALK2_RIBOSOME_CYTOSOL = MRNA_ALK2_CYTOSOL+RIBOSOME_CYTOSOL 
 0.8072028481983483 ; % 147 MRNA_ALK2_RIBOSOME_CYTOSOL = MRNA_ALK2_START_RIBOSOME_CYTOSOL
 MRNA_ALK2_RIBOSOME_CYTOSOL = MRNA_ALK2_START_RIBOSOME_CYTOSOL 
 0.1924892696569287 ; % 148 MRNA_ALK2_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + ALK2_CYTOSOL 
+ MRNA_ALK2_CYTOSOL MRNA_ALK2_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+ALK2_CYTOSOL+MRNA_ALK2_CYTOSOL 
 0.08963404070656744 ; % 149 MRNA_ALK2_CYTOSOL = [] MRNA_ALK2_CYTOSOL = [] 
 0.21269670831972332 ; % 150 ALK2_CYTOSOL = [] ALK2_CYTOSOL = [] 
 0.9186315393659695 ; % 151 DNA_ALK3_NUCLEAR + RNAP_NUCLEAR = DNA_ALK3_RNAP_NUCLEAR
 DNA_ALK3_NUCLEAR+RNAP_NUCLEAR = DNA_ALK3_RNAP_NUCLEAR 
 0.04764104832408128 ; % 152 DNA_ALK3_RNAP_NUCLEAR = DNA_ALK3_NUCLEAR + RNAP_NUCLEAR
 DNA_ALK3_RNAP_NUCLEAR = DNA_ALK3_NUCLEAR+RNAP_NUCLEAR 
 0.477356468978543 ; % 153 DNA_ALK3_RNAP_NUCLEAR = DNA_ALK3_NUCLEAR + RNAP_NUCLEAR + 
MRNA_ALK3_NUCLEAR DNA_ALK3_RNAP_NUCLEAR = DNA_ALK3_NUCLEAR+RNAP_NUCLEAR+MRNA_ALK3_NUCLEAR 
 0.5314710377148251 ; % 154 MRNA_ALK3_NUCLEAR + NEXPORT_NUCLEAR = MRNA_ALK3_NEXPORT_NUCLEAR
 MRNA_ALK3_NUCLEAR+NEXPORT_NUCLEAR = MRNA_ALK3_NEXPORT_NUCLEAR 
 0.011479686156112324 ; % 155 MRNA_ALK3_NEXPORT_NUCLEAR = MRNA_ALK3_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_ALK3_NEXPORT_NUCLEAR = MRNA_ALK3_NUCLEAR+NEXPORT_NUCLEAR 
 0.5353596485852495 ; % 156 MRNA_ALK3_NEXPORT_NUCLEAR = MRNA_ALK3_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_ALK3_NEXPORT_NUCLEAR = MRNA_ALK3_CYTOSOL+NEXPORT_NUCLEAR 
 0.1667698541714553 ; % 157 MRNA_ALK3_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_ALK3_RIBOSOME_CYTOSOL
 MRNA_ALK3_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_ALK3_RIBOSOME_CYTOSOL 
 0.0581155476256232 ; % 158 MRNA_ALK3_RIBOSOME_CYTOSOL = MRNA_ALK3_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_ALK3_RIBOSOME_CYTOSOL = MRNA_ALK3_CYTOSOL+RIBOSOME_CYTOSOL 
 0.6212360530656802 ; % 159 MRNA_ALK3_RIBOSOME_CYTOSOL = MRNA_ALK3_START_RIBOSOME_CYTOSOL
 MRNA_ALK3_RIBOSOME_CYTOSOL = MRNA_ALK3_START_RIBOSOME_CYTOSOL 
 0.361659504745071 ; % 160 MRNA_ALK3_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + ALK3_CYTOSOL 
+ MRNA_ALK3_CYTOSOL MRNA_ALK3_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+ALK3_CYTOSOL+MRNA_ALK3_CYTOSOL 
 0.4287215785085048 ; % 161 MRNA_ALK3_CYTOSOL = [] MRNA_ALK3_CYTOSOL = [] 
 0.48496332924758145 ; % 162 ALK3_CYTOSOL = [] ALK3_CYTOSOL = [] 
 0.21852698429551676 ; % 163 DNA_ALK5_NUCLEAR + RNAP_NUCLEAR = DNA_ALK5_RNAP_NUCLEAR
 DNA_ALK5_NUCLEAR+RNAP_NUCLEAR = DNA_ALK5_RNAP_NUCLEAR 
 0.008195100041991144 ; % 164 DNA_ALK5_RNAP_NUCLEAR = DNA_ALK5_NUCLEAR + RNAP_NUCLEAR
 DNA_ALK5_RNAP_NUCLEAR = DNA_ALK5_NUCLEAR+RNAP_NUCLEAR 
 0.9902617384007653 ; % 165 DNA_ALK5_RNAP_NUCLEAR = DNA_ALK5_NUCLEAR + RNAP_NUCLEAR + 
MRNA_ALK5_NUCLEAR DNA_ALK5_RNAP_NUCLEAR = DNA_ALK5_NUCLEAR+RNAP_NUCLEAR+MRNA_ALK5_NUCLEAR 
 0.2460988216357486 ; % 166 MRNA_ALK5_NUCLEAR + NEXPORT_NUCLEAR = MRNA_ALK5_NEXPORT_NUCLEAR
 MRNA_ALK5_NUCLEAR+NEXPORT_NUCLEAR = MRNA_ALK5_NEXPORT_NUCLEAR 
 0.03324562499557674 ; % 167 MRNA_ALK5_NEXPORT_NUCLEAR = MRNA_ALK5_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_ALK5_NEXPORT_NUCLEAR = MRNA_ALK5_NUCLEAR+NEXPORT_NUCLEAR 
 0.1928083789465429 ; % 168 MRNA_ALK5_NEXPORT_NUCLEAR = MRNA_ALK5_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_ALK5_NEXPORT_NUCLEAR = MRNA_ALK5_CYTOSOL+NEXPORT_NUCLEAR 
 0.1889736024079035 ; % 169 MRNA_ALK5_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_ALK5_RIBOSOME_CYTOSOL
 MRNA_ALK5_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_ALK5_RIBOSOME_CYTOSOL 
 0.08942552312317859 ; % 170 MRNA_ALK5_RIBOSOME_CYTOSOL = MRNA_ALK5_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_ALK5_RIBOSOME_CYTOSOL = MRNA_ALK5_CYTOSOL+RIBOSOME_CYTOSOL 
 0.32520373955515725 ; % 171 MRNA_ALK5_RIBOSOME_CYTOSOL = MRNA_ALK5_START_RIBOSOME_CYTOSOL
 MRNA_ALK5_RIBOSOME_CYTOSOL = MRNA_ALK5_START_RIBOSOME_CYTOSOL 
 0.5051299282938028 ; % 172 MRNA_ALK5_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + ALK5_CYTOSOL 
+ MRNA_ALK5_CYTOSOL MRNA_ALK5_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+ALK5_CYTOSOL+MRNA_ALK5_CYTOSOL 
 0.2494315719060336 ; % 173 MRNA_ALK5_CYTOSOL = [] MRNA_ALK5_CYTOSOL = [] 
 0.1692605933623273 ; % 174 ALK5_CYTOSOL = [] ALK5_CYTOSOL = [] 
 0.6551766834104369 ; % 175 DNA_ALK6_NUCLEAR + RNAP_NUCLEAR = DNA_ALK6_RNAP_NUCLEAR
 DNA_ALK6_NUCLEAR+RNAP_NUCLEAR = DNA_ALK6_RNAP_NUCLEAR 
 0.003940006017138765 ; % 176 DNA_ALK6_RNAP_NUCLEAR = DNA_ALK6_NUCLEAR + RNAP_NUCLEAR
 DNA_ALK6_RNAP_NUCLEAR = DNA_ALK6_NUCLEAR+RNAP_NUCLEAR 
 0.6978861900884743 ; % 177 DNA_ALK6_RNAP_NUCLEAR = DNA_ALK6_NUCLEAR + RNAP_NUCLEAR + 
MRNA_ALK6_NUCLEAR DNA_ALK6_RNAP_NUCLEAR = DNA_ALK6_NUCLEAR+RNAP_NUCLEAR+MRNA_ALK6_NUCLEAR 
 0.05474368423048548 ; % 178 MRNA_ALK6_NUCLEAR + NEXPORT_NUCLEAR = MRNA_ALK6_NEXPORT_NUCLEAR
 MRNA_ALK6_NUCLEAR+NEXPORT_NUCLEAR = MRNA_ALK6_NEXPORT_NUCLEAR 
 0.027332160031823028 ; % 179 MRNA_ALK6_NEXPORT_NUCLEAR = MRNA_ALK6_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_ALK6_NEXPORT_NUCLEAR = MRNA_ALK6_NUCLEAR+NEXPORT_NUCLEAR 
 0.13442677206550535 ; % 180 MRNA_ALK6_NEXPORT_NUCLEAR = MRNA_ALK6_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_ALK6_NEXPORT_NUCLEAR = MRNA_ALK6_CYTOSOL+NEXPORT_NUCLEAR 
 0.5192858441901614 ; % 181 MRNA_ALK6_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_ALK6_RIBOSOME_CYTOSOL
 MRNA_ALK6_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_ALK6_RIBOSOME_CYTOSOL 
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 0.07792791454221999 ; % 182 MRNA_ALK6_RIBOSOME_CYTOSOL = MRNA_ALK6_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_ALK6_RIBOSOME_CYTOSOL = MRNA_ALK6_CYTOSOL+RIBOSOME_CYTOSOL 
 0.48018771946149486 ; % 183 MRNA_ALK6_RIBOSOME_CYTOSOL = MRNA_ALK6_START_RIBOSOME_CYTOSOL
 MRNA_ALK6_RIBOSOME_CYTOSOL = MRNA_ALK6_START_RIBOSOME_CYTOSOL 
 0.45891570311066965 ; % 184 MRNA_ALK6_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + ALK6_CYTOSOL 
+ MRNA_ALK6_CYTOSOL MRNA_ALK6_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+ALK6_CYTOSOL+MRNA_ALK6_CYTOSOL 
 0.4671396689399151 ; % 185 MRNA_ALK6_CYTOSOL = [] MRNA_ALK6_CYTOSOL = [] 
 0.40348688107890374 ; % 186 ALK6_CYTOSOL = [] ALK6_CYTOSOL = [] 
 0.4807109387000512 ; % 187 DNA_SHC_NUCLEAR + RNAP_NUCLEAR = DNA_SHC_RNAP_NUCLEAR
 DNA_SHC_NUCLEAR+RNAP_NUCLEAR = DNA_SHC_RNAP_NUCLEAR 
 0.044825069081376345 ; % 188 DNA_SHC_RNAP_NUCLEAR = DNA_SHC_NUCLEAR + RNAP_NUCLEAR
 DNA_SHC_RNAP_NUCLEAR = DNA_SHC_NUCLEAR+RNAP_NUCLEAR 
 0.6092263251413107 ; % 189 DNA_SHC_RNAP_NUCLEAR = DNA_SHC_NUCLEAR + RNAP_NUCLEAR + 
MRNA_SHC_NUCLEAR DNA_SHC_RNAP_NUCLEAR = DNA_SHC_NUCLEAR+RNAP_NUCLEAR+MRNA_SHC_NUCLEAR 
 0.28205307116886635 ; % 190 MRNA_SHC_NUCLEAR + NEXPORT_NUCLEAR = MRNA_SHC_NEXPORT_NUCLEAR
 MRNA_SHC_NUCLEAR+NEXPORT_NUCLEAR = MRNA_SHC_NEXPORT_NUCLEAR 
 0.00426326926286178 ; % 191 MRNA_SHC_NEXPORT_NUCLEAR = MRNA_SHC_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_SHC_NEXPORT_NUCLEAR = MRNA_SHC_NUCLEAR+NEXPORT_NUCLEAR 
 0.9281073050782441 ; % 192 MRNA_SHC_NEXPORT_NUCLEAR = MRNA_SHC_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_SHC_NEXPORT_NUCLEAR = MRNA_SHC_CYTOSOL+NEXPORT_NUCLEAR 
 0.27375912383082757 ; % 193 MRNA_SHC_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_SHC_RIBOSOME_CYTOSOL
 MRNA_SHC_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_SHC_RIBOSOME_CYTOSOL 
 0.02030209246420305 ; % 194 MRNA_SHC_RIBOSOME_CYTOSOL = MRNA_SHC_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_SHC_RIBOSOME_CYTOSOL = MRNA_SHC_CYTOSOL+RIBOSOME_CYTOSOL 
 0.9896630727587311 ; % 195 MRNA_SHC_RIBOSOME_CYTOSOL = MRNA_SHC_START_RIBOSOME_CYTOSOL
 MRNA_SHC_RIBOSOME_CYTOSOL = MRNA_SHC_START_RIBOSOME_CYTOSOL 
 0.3320351365115597 ; % 196 MRNA_SHC_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + SHC_CYTOSOL 
+ MRNA_SHC_CYTOSOL MRNA_SHC_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+SHC_CYTOSOL+MRNA_SHC_CYTOSOL 
 0.007338159922264609 ; % 197 MRNA_SHC_CYTOSOL = [] MRNA_SHC_CYTOSOL = [] 
 0.2931501744453865 ; % 198 SHC_CYTOSOL = [] SHC_CYTOSOL = [] 
 0.7419435994042889 ; % 199 DNA_GRB2_NUCLEAR + RNAP_NUCLEAR = DNA_GRB2_RNAP_NUCLEAR
 DNA_GRB2_NUCLEAR+RNAP_NUCLEAR = DNA_GRB2_RNAP_NUCLEAR 
 0.09719010597020415 ; % 200 DNA_GRB2_RNAP_NUCLEAR = DNA_GRB2_NUCLEAR + RNAP_NUCLEAR
 DNA_GRB2_RNAP_NUCLEAR = DNA_GRB2_NUCLEAR+RNAP_NUCLEAR 
 0.44497073590791714 ; % 201 DNA_GRB2_RNAP_NUCLEAR = DNA_GRB2_NUCLEAR + RNAP_NUCLEAR + 
MRNA_GRB2_NUCLEAR DNA_GRB2_RNAP_NUCLEAR = DNA_GRB2_NUCLEAR+RNAP_NUCLEAR+MRNA_GRB2_NUCLEAR 
 0.8632318663781365 ; % 202 MRNA_GRB2_NUCLEAR + NEXPORT_NUCLEAR = MRNA_GRB2_NEXPORT_NUCLEAR
 MRNA_GRB2_NUCLEAR+NEXPORT_NUCLEAR = MRNA_GRB2_NEXPORT_NUCLEAR 
 0.0754059508115241 ; % 203 MRNA_GRB2_NEXPORT_NUCLEAR = MRNA_GRB2_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_GRB2_NEXPORT_NUCLEAR = MRNA_GRB2_NUCLEAR+NEXPORT_NUCLEAR 
 0.2780944944291569 ; % 204 MRNA_GRB2_NEXPORT_NUCLEAR = MRNA_GRB2_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_GRB2_NEXPORT_NUCLEAR = MRNA_GRB2_CYTOSOL+NEXPORT_NUCLEAR 
 0.2881833612160266 ; % 205 MRNA_GRB2_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_GRB2_RIBOSOME_CYTOSOL MRNA_GRB2_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_GRB2_RIBOSOME_CYTOSOL 
 0.012117753382413866 ; % 206 MRNA_GRB2_RIBOSOME_CYTOSOL = MRNA_GRB2_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_GRB2_RIBOSOME_CYTOSOL = MRNA_GRB2_CYTOSOL+RIBOSOME_CYTOSOL 
 0.49479703952495957 ; % 207 MRNA_GRB2_RIBOSOME_CYTOSOL = MRNA_GRB2_START_RIBOSOME_CYTOSOL
 MRNA_GRB2_RIBOSOME_CYTOSOL = MRNA_GRB2_START_RIBOSOME_CYTOSOL 
 0.7906528700130084 ; % 208 MRNA_GRB2_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
GRB2_CYTOSOL + MRNA_GRB2_CYTOSOL MRNA_GRB2_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+GRB2_CYTOSOL+MRNA_GRB2_CYTOSOL 
 0.08267280950330064 ; % 209 MRNA_GRB2_CYTOSOL = [] MRNA_GRB2_CYTOSOL = [] 
 0.12093093088159534 ; % 210 GRB2_CYTOSOL = [] GRB2_CYTOSOL = [] 
 0.5630371608878857 ; % 211 DNA_SOS_NUCLEAR + RNAP_NUCLEAR = DNA_SOS_RNAP_NUCLEAR
 DNA_SOS_NUCLEAR+RNAP_NUCLEAR = DNA_SOS_RNAP_NUCLEAR 
 0.09529736083139052 ; % 212 DNA_SOS_RNAP_NUCLEAR = DNA_SOS_NUCLEAR + RNAP_NUCLEAR
 DNA_SOS_RNAP_NUCLEAR = DNA_SOS_NUCLEAR+RNAP_NUCLEAR 
 0.27509190112175863 ; % 213 DNA_SOS_RNAP_NUCLEAR = DNA_SOS_NUCLEAR + RNAP_NUCLEAR + 
MRNA_SOS_NUCLEAR DNA_SOS_RNAP_NUCLEAR = DNA_SOS_NUCLEAR+RNAP_NUCLEAR+MRNA_SOS_NUCLEAR 
 0.3387132879576339 ; % 214 MRNA_SOS_NUCLEAR + NEXPORT_NUCLEAR = MRNA_SOS_NEXPORT_NUCLEAR
 MRNA_SOS_NUCLEAR+NEXPORT_NUCLEAR = MRNA_SOS_NEXPORT_NUCLEAR 
 0.06406211652109715 ; % 215 MRNA_SOS_NEXPORT_NUCLEAR = MRNA_SOS_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_SOS_NEXPORT_NUCLEAR = MRNA_SOS_NUCLEAR+NEXPORT_NUCLEAR 
 0.436536951080606 ; % 216 MRNA_SOS_NEXPORT_NUCLEAR = MRNA_SOS_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_SOS_NEXPORT_NUCLEAR = MRNA_SOS_CYTOSOL+NEXPORT_NUCLEAR 
 0.2170949164855861 ; % 217 MRNA_SOS_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_SOS_RIBOSOME_CYTOSOL
 MRNA_SOS_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_SOS_RIBOSOME_CYTOSOL 
 0.014985336433125596 ; % 218 MRNA_SOS_RIBOSOME_CYTOSOL = MRNA_SOS_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_SOS_RIBOSOME_CYTOSOL = MRNA_SOS_CYTOSOL+RIBOSOME_CYTOSOL 
 0.24572023457940018 ; % 219 MRNA_SOS_RIBOSOME_CYTOSOL = MRNA_SOS_START_RIBOSOME_CYTOSOL
 MRNA_SOS_RIBOSOME_CYTOSOL = MRNA_SOS_START_RIBOSOME_CYTOSOL 
 0.8080710180502351 ; % 220 MRNA_SOS_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + SOS_CYTOSOL 
+ MRNA_SOS_CYTOSOL MRNA_SOS_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+SOS_CYTOSOL+MRNA_SOS_CYTOSOL 
 0.2123985429089661 ; % 221 MRNA_SOS_CYTOSOL = [] MRNA_SOS_CYTOSOL = [] 
 0.10225640548432885 ; % 222 SOS_CYTOSOL = [] SOS_CYTOSOL = [] 
 0.669185385759699 ; % 223 DNA_BMPRII_NUCLEAR + RNAP_NUCLEAR = DNA_BMPRII_RNAP_NUCLEAR
 DNA_BMPRII_NUCLEAR+RNAP_NUCLEAR = DNA_BMPRII_RNAP_NUCLEAR 
 0.08398493054352466 ; % 224 DNA_BMPRII_RNAP_NUCLEAR = DNA_BMPRII_NUCLEAR + RNAP_NUCLEAR
 DNA_BMPRII_RNAP_NUCLEAR = DNA_BMPRII_NUCLEAR+RNAP_NUCLEAR 
 0.5454808353301231 ; % 225 DNA_BMPRII_RNAP_NUCLEAR = DNA_BMPRII_NUCLEAR + RNAP_NUCLEAR + 
MRNA_BMPRII_NUCLEAR DNA_BMPRII_RNAP_NUCLEAR = DNA_BMPRII_NUCLEAR+RNAP_NUCLEAR+MRNA_BMPRII_NUCLEAR 
 0.6480369075520682 ; % 226 MRNA_BMPRII_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_BMPRII_NEXPORT_NUCLEAR MRNA_BMPRII_NUCLEAR+NEXPORT_NUCLEAR = MRNA_BMPRII_NEXPORT_NUCLEAR 
 0.005155026174519273 ; % 227 MRNA_BMPRII_NEXPORT_NUCLEAR = MRNA_BMPRII_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_BMPRII_NEXPORT_NUCLEAR = MRNA_BMPRII_NUCLEAR+NEXPORT_NUCLEAR 
 0.659317665100542 ; % 228 MRNA_BMPRII_NEXPORT_NUCLEAR = MRNA_BMPRII_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_BMPRII_NEXPORT_NUCLEAR = MRNA_BMPRII_CYTOSOL+NEXPORT_NUCLEAR 
 0.6340416115945492 ; % 229 MRNA_BMPRII_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_BMPRII_RIBOSOME_CYTOSOL MRNA_BMPRII_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_BMPRII_RIBOSOME_CYTOSOL 
 0.058427545483033784 ; % 230 MRNA_BMPRII_RIBOSOME_CYTOSOL = MRNA_BMPRII_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_BMPRII_RIBOSOME_CYTOSOL = MRNA_BMPRII_CYTOSOL+RIBOSOME_CYTOSOL 
 0.2898037292354786 ; % 231 MRNA_BMPRII_RIBOSOME_CYTOSOL = MRNA_BMPRII_START_RIBOSOME_CYTOSOL
 MRNA_BMPRII_RIBOSOME_CYTOSOL = MRNA_BMPRII_START_RIBOSOME_CYTOSOL 
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 0.23600663634812646 ; % 232 MRNA_BMPRII_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
BMPRII_CYTOSOL + MRNA_BMPRII_CYTOSOL MRNA_BMPRII_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+BMPRII_CYTOSOL+MRNA_BMPRII_CYTOSOL 
 0.10569858272248728 ; % 233 MRNA_BMPRII_CYTOSOL = [] MRNA_BMPRII_CYTOSOL = [] 
 0.3370176935426546 ; % 234 BMPRII_CYTOSOL = [] BMPRII_CYTOSOL = [] 
 0.35074566108378613 ; % 235 DNA_TGFBRII_NUCLEAR + RNAP_NUCLEAR = DNA_TGFBRII_RNAP_NUCLEAR
 DNA_TGFBRII_NUCLEAR+RNAP_NUCLEAR = DNA_TGFBRII_RNAP_NUCLEAR 
 0.04116916773635426 ; % 236 DNA_TGFBRII_RNAP_NUCLEAR = DNA_TGFBRII_NUCLEAR + RNAP_NUCLEAR
 DNA_TGFBRII_RNAP_NUCLEAR = DNA_TGFBRII_NUCLEAR+RNAP_NUCLEAR 
 0.07928751883383911 ; % 237 DNA_TGFBRII_RNAP_NUCLEAR = DNA_TGFBRII_NUCLEAR + RNAP_NUCLEAR + 
MRNA_TGFBRII_NUCLEAR DNA_TGFBRII_RNAP_NUCLEAR = DNA_TGFBRII_NUCLEAR+RNAP_NUCLEAR+MRNA_TGFBRII_NUCLEAR 
 0.5144064252298072 ; % 238 MRNA_TGFBRII_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_TGFBRII_NEXPORT_NUCLEAR MRNA_TGFBRII_NUCLEAR+NEXPORT_NUCLEAR = MRNA_TGFBRII_NEXPORT_NUCLEAR 
 0.06116832137600162 ; % 239 MRNA_TGFBRII_NEXPORT_NUCLEAR = MRNA_TGFBRII_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_TGFBRII_NEXPORT_NUCLEAR = MRNA_TGFBRII_NUCLEAR+NEXPORT_NUCLEAR 
 0.7940226237698634 ; % 240 MRNA_TGFBRII_NEXPORT_NUCLEAR = MRNA_TGFBRII_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_TGFBRII_NEXPORT_NUCLEAR = MRNA_TGFBRII_CYTOSOL+NEXPORT_NUCLEAR 
 0.2802899339829855 ; % 241 MRNA_TGFBRII_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_TGFBRII_RIBOSOME_CYTOSOL MRNA_TGFBRII_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_TGFBRII_RIBOSOME_CYTOSOL 
 0.0016153717278438173 ; % 242 MRNA_TGFBRII_RIBOSOME_CYTOSOL = MRNA_TGFBRII_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_TGFBRII_RIBOSOME_CYTOSOL = MRNA_TGFBRII_CYTOSOL+RIBOSOME_CYTOSOL 
 0.04942176198443571 ; % 243 MRNA_TGFBRII_RIBOSOME_CYTOSOL = 
MRNA_TGFBRII_START_RIBOSOME_CYTOSOL MRNA_TGFBRII_RIBOSOME_CYTOSOL = MRNA_TGFBRII_START_RIBOSOME_CYTOSOL 
 0.3543511154106803 ; % 244 MRNA_TGFBRII_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
TGFBRII_CYTOSOL + MRNA_TGFBRII_CYTOSOL MRNA_TGFBRII_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+TGFBRII_CYTOSOL+MRNA_TGFBRII_CYTOSOL 
 0.372596879120297 ; % 245 MRNA_TGFBRII_CYTOSOL = [] MRNA_TGFBRII_CYTOSOL = [] 
 0.2975019991021161 ; % 246 TGFBRII_CYTOSOL = [] TGFBRII_CYTOSOL = [] 
 0.4549484803241236 ; % 247 DNA_TGFBRIII_NUCLEAR + RNAP_NUCLEAR = DNA_TGFBRIII_RNAP_NUCLEAR
 DNA_TGFBRIII_NUCLEAR+RNAP_NUCLEAR = DNA_TGFBRIII_RNAP_NUCLEAR 
 0.04972422993617496 ; % 248 DNA_TGFBRIII_RNAP_NUCLEAR = DNA_TGFBRIII_NUCLEAR + RNAP_NUCLEAR
 DNA_TGFBRIII_RNAP_NUCLEAR = DNA_TGFBRIII_NUCLEAR+RNAP_NUCLEAR 
 0.97944995420092 ; % 249 DNA_TGFBRIII_RNAP_NUCLEAR = DNA_TGFBRIII_NUCLEAR + RNAP_NUCLEAR + 
MRNA_TGFBRIII_NUCLEAR DNA_TGFBRIII_RNAP_NUCLEAR = DNA_TGFBRIII_NUCLEAR+RNAP_NUCLEAR+MRNA_TGFBRIII_NUCLEAR 
 0.4975339957761852 ; % 250 MRNA_TGFBRIII_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_TGFBRIII_NEXPORT_NUCLEAR MRNA_TGFBRIII_NUCLEAR+NEXPORT_NUCLEAR = MRNA_TGFBRIII_NEXPORT_NUCLEAR 
 0.03639029675479395 ; % 251 MRNA_TGFBRIII_NEXPORT_NUCLEAR = MRNA_TGFBRIII_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_TGFBRIII_NEXPORT_NUCLEAR = MRNA_TGFBRIII_NUCLEAR+NEXPORT_NUCLEAR 
 0.7021655227051585 ; % 252 MRNA_TGFBRIII_NEXPORT_NUCLEAR = MRNA_TGFBRIII_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_TGFBRIII_NEXPORT_NUCLEAR = MRNA_TGFBRIII_CYTOSOL+NEXPORT_NUCLEAR 
 0.6062312011917435 ; % 253 MRNA_TGFBRIII_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_TGFBRIII_RIBOSOME_CYTOSOL MRNA_TGFBRIII_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_TGFBRIII_RIBOSOME_CYTOSOL 
 0.09935036394228859 ; % 254 MRNA_TGFBRIII_RIBOSOME_CYTOSOL = MRNA_TGFBRIII_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_TGFBRIII_RIBOSOME_CYTOSOL = MRNA_TGFBRIII_CYTOSOL+RIBOSOME_CYTOSOL 
 0.061874091778540974 ; % 255 MRNA_TGFBRIII_RIBOSOME_CYTOSOL = 
MRNA_TGFBRIII_START_RIBOSOME_CYTOSOL MRNA_TGFBRIII_RIBOSOME_CYTOSOL = MRNA_TGFBRIII_START_RIBOSOME_CYTOSOL 
 0.5771160356390984 ; % 256 MRNA_TGFBRIII_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
TGFBRIII_CYTOSOL + MRNA_TGFBRIII_CYTOSOL MRNA_TGFBRIII_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+TGFBRIII_CYTOSOL+MRNA_TGFBRIII_CYTOSOL 
 0.3528539199833046 ; % 257 MRNA_TGFBRIII_CYTOSOL = [] MRNA_TGFBRIII_CYTOSOL = [] 
 0.2419292745046377 ; % 258 TGFBRIII_CYTOSOL = [] TGFBRIII_CYTOSOL = [] 
 0.8487577622464618 ; % 259 DNA_MSX1_NUCLEAR + RNAP_NUCLEAR = DNA_MSX1_RNAP_NUCLEAR
 DNA_MSX1_NUCLEAR+RNAP_NUCLEAR = DNA_MSX1_RNAP_NUCLEAR 
 0.030942764767411746 ; % 260 DNA_MSX1_RNAP_NUCLEAR = DNA_MSX1_NUCLEAR + RNAP_NUCLEAR
 DNA_MSX1_RNAP_NUCLEAR = DNA_MSX1_NUCLEAR+RNAP_NUCLEAR 
 0.66846587580812 ; % 261 DNA_MSX1_RNAP_NUCLEAR = DNA_MSX1_NUCLEAR + RNAP_NUCLEAR + 
MRNA_MSX1_NUCLEAR DNA_MSX1_RNAP_NUCLEAR = DNA_MSX1_NUCLEAR+RNAP_NUCLEAR+MRNA_MSX1_NUCLEAR 
 0.7972598510247131 ; % 262 MRNA_MSX1_NUCLEAR + NEXPORT_NUCLEAR = MRNA_MSX1_NEXPORT_NUCLEAR
 MRNA_MSX1_NUCLEAR+NEXPORT_NUCLEAR = MRNA_MSX1_NEXPORT_NUCLEAR 
 0.07278553699450864 ; % 263 MRNA_MSX1_NEXPORT_NUCLEAR = MRNA_MSX1_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_MSX1_NEXPORT_NUCLEAR = MRNA_MSX1_NUCLEAR+NEXPORT_NUCLEAR 
 0.0507943699482335 ; % 264 MRNA_MSX1_NEXPORT_NUCLEAR = MRNA_MSX1_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_MSX1_NEXPORT_NUCLEAR = MRNA_MSX1_CYTOSOL+NEXPORT_NUCLEAR 
 0.7155633869701031 ; % 265 MRNA_MSX1_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_MSX1_RIBOSOME_CYTOSOL MRNA_MSX1_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_MSX1_RIBOSOME_CYTOSOL 
 0.0077881268101971275 ; % 266 MRNA_MSX1_RIBOSOME_CYTOSOL = MRNA_MSX1_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_MSX1_RIBOSOME_CYTOSOL = MRNA_MSX1_CYTOSOL+RIBOSOME_CYTOSOL 
 0.8230884066017365 ; % 267 MRNA_MSX1_RIBOSOME_CYTOSOL = MRNA_MSX1_START_RIBOSOME_CYTOSOL
 MRNA_MSX1_RIBOSOME_CYTOSOL = MRNA_MSX1_START_RIBOSOME_CYTOSOL 
 0.7315265602181441 ; % 268 MRNA_MSX1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
MSX1_CYTOSOL + MRNA_MSX1_CYTOSOL MRNA_MSX1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+MSX1_CYTOSOL+MRNA_MSX1_CYTOSOL 
 0.16427100936968125 ; % 269 MRNA_MSX1_CYTOSOL = [] MRNA_MSX1_CYTOSOL = [] 
 0.3516737269073221 ; % 270 MSX1_CYTOSOL = [] MSX1_CYTOSOL = [] 
 0.12164946607853167 ; % 271 DNA_AP1_NUCLEAR + RNAP_NUCLEAR = DNA_AP1_RNAP_NUCLEAR
 DNA_AP1_NUCLEAR+RNAP_NUCLEAR = DNA_AP1_RNAP_NUCLEAR 
 0.016332488772395404 ; % 272 DNA_AP1_RNAP_NUCLEAR = DNA_AP1_NUCLEAR + RNAP_NUCLEAR
 DNA_AP1_RNAP_NUCLEAR = DNA_AP1_NUCLEAR+RNAP_NUCLEAR 
 0.5797802270389988 ; % 273 DNA_AP1_RNAP_NUCLEAR = DNA_AP1_NUCLEAR + RNAP_NUCLEAR + 
MRNA_AP1_NUCLEAR DNA_AP1_RNAP_NUCLEAR = DNA_AP1_NUCLEAR+RNAP_NUCLEAR+MRNA_AP1_NUCLEAR 
 0.6140689448643276 ; % 274 MRNA_AP1_NUCLEAR + NEXPORT_NUCLEAR = MRNA_AP1_NEXPORT_NUCLEAR
 MRNA_AP1_NUCLEAR+NEXPORT_NUCLEAR = MRNA_AP1_NEXPORT_NUCLEAR 
 0.05896060026957333 ; % 275 MRNA_AP1_NEXPORT_NUCLEAR = MRNA_AP1_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_AP1_NEXPORT_NUCLEAR = MRNA_AP1_NUCLEAR+NEXPORT_NUCLEAR 
 0.060363627386177954 ; % 276 MRNA_AP1_NEXPORT_NUCLEAR = MRNA_AP1_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_AP1_NEXPORT_NUCLEAR = MRNA_AP1_CYTOSOL+NEXPORT_NUCLEAR 
 0.7568961191456829 ; % 277 MRNA_AP1_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_AP1_RIBOSOME_CYTOSOL
 MRNA_AP1_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_AP1_RIBOSOME_CYTOSOL 
 0.028386328619030156 ; % 278 MRNA_AP1_RIBOSOME_CYTOSOL = MRNA_AP1_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_AP1_RIBOSOME_CYTOSOL = MRNA_AP1_CYTOSOL+RIBOSOME_CYTOSOL 
 0.3144174844663822 ; % 279 MRNA_AP1_RIBOSOME_CYTOSOL = MRNA_AP1_START_RIBOSOME_CYTOSOL
 MRNA_AP1_RIBOSOME_CYTOSOL = MRNA_AP1_START_RIBOSOME_CYTOSOL 
 0.7852322590891565 ; % 280 MRNA_AP1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + AP1_CYTOSOL + 
MRNA_AP1_CYTOSOL MRNA_AP1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+AP1_CYTOSOL+MRNA_AP1_CYTOSOL 
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 0.3672384371498366 ; % 281 MRNA_AP1_CYTOSOL = [] MRNA_AP1_CYTOSOL = [] 
 0.15831682535404873 ; % 282 AP1_CYTOSOL = [] AP1_CYTOSOL = [] 
 0.0910227505414073 ; % 283 DNA_GPASE_NUCLEAR + RNAP_NUCLEAR = DNA_GPASE_RNAP_NUCLEAR
 DNA_GPASE_NUCLEAR+RNAP_NUCLEAR = DNA_GPASE_RNAP_NUCLEAR 
 0.02092921163145871 ; % 284 DNA_GPASE_RNAP_NUCLEAR = DNA_GPASE_NUCLEAR + RNAP_NUCLEAR
 DNA_GPASE_RNAP_NUCLEAR = DNA_GPASE_NUCLEAR+RNAP_NUCLEAR 
 0.2622330754808647 ; % 285 DNA_GPASE_RNAP_NUCLEAR = DNA_GPASE_NUCLEAR + RNAP_NUCLEAR + 
MRNA_GPASE_NUCLEAR DNA_GPASE_RNAP_NUCLEAR = DNA_GPASE_NUCLEAR+RNAP_NUCLEAR+MRNA_GPASE_NUCLEAR 
 0.315009632721578 ; % 286 MRNA_GPASE_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_GPASE_NEXPORT_NUCLEAR MRNA_GPASE_NUCLEAR+NEXPORT_NUCLEAR = MRNA_GPASE_NEXPORT_NUCLEAR 
 0.07870993767487008 ; % 287 MRNA_GPASE_NEXPORT_NUCLEAR = MRNA_GPASE_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_GPASE_NEXPORT_NUCLEAR = MRNA_GPASE_NUCLEAR+NEXPORT_NUCLEAR 
 0.06626303322305627 ; % 288 MRNA_GPASE_NEXPORT_NUCLEAR = MRNA_GPASE_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_GPASE_NEXPORT_NUCLEAR = MRNA_GPASE_CYTOSOL+NEXPORT_NUCLEAR 
 0.7107459115002046 ; % 289 MRNA_GPASE_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_GPASE_RIBOSOME_CYTOSOL MRNA_GPASE_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_GPASE_RIBOSOME_CYTOSOL 
 0.023423759248070275 ; % 290 MRNA_GPASE_RIBOSOME_CYTOSOL = MRNA_GPASE_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_GPASE_RIBOSOME_CYTOSOL = MRNA_GPASE_CYTOSOL+RIBOSOME_CYTOSOL 
 0.8982920418747153 ; % 291 MRNA_GPASE_RIBOSOME_CYTOSOL = MRNA_GPASE_START_RIBOSOME_CYTOSOL
 MRNA_GPASE_RIBOSOME_CYTOSOL = MRNA_GPASE_START_RIBOSOME_CYTOSOL 
 0.573362254236925 ; % 292 MRNA_GPASE_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
GPASE_CYTOSOL + MRNA_GPASE_CYTOSOL MRNA_GPASE_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+GPASE_CYTOSOL+MRNA_GPASE_CYTOSOL 
 0.4221479437146893 ; % 293 MRNA_GPASE_CYTOSOL = [] MRNA_GPASE_CYTOSOL = [] 
 0.45412032716368966 ; % 294 GPASE_CYTOSOL = [] GPASE_CYTOSOL = [] 
 0.9356524043934121 ; % 295 DNA_TCF4_NUCLEAR + RNAP_NUCLEAR = DNA_TCF4_RNAP_NUCLEAR
 DNA_TCF4_NUCLEAR+RNAP_NUCLEAR = DNA_TCF4_RNAP_NUCLEAR 
 0.0896076113196335 ; % 296 DNA_TCF4_RNAP_NUCLEAR = DNA_TCF4_NUCLEAR + RNAP_NUCLEAR
 DNA_TCF4_RNAP_NUCLEAR = DNA_TCF4_NUCLEAR+RNAP_NUCLEAR 
 0.8748319509489678 ; % 297 DNA_TCF4_RNAP_NUCLEAR = DNA_TCF4_NUCLEAR + RNAP_NUCLEAR + 
MRNA_TCF4_NUCLEAR DNA_TCF4_RNAP_NUCLEAR = DNA_TCF4_NUCLEAR+RNAP_NUCLEAR+MRNA_TCF4_NUCLEAR 
 0.8146514210009796 ; % 298 MRNA_TCF4_NUCLEAR + NEXPORT_NUCLEAR = MRNA_TCF4_NEXPORT_NUCLEAR
 MRNA_TCF4_NUCLEAR+NEXPORT_NUCLEAR = MRNA_TCF4_NEXPORT_NUCLEAR 
 0.0675228203944938 ; % 299 MRNA_TCF4_NEXPORT_NUCLEAR = MRNA_TCF4_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_TCF4_NEXPORT_NUCLEAR = MRNA_TCF4_NUCLEAR+NEXPORT_NUCLEAR 
 0.24065253601488534 ; % 300 MRNA_TCF4_NEXPORT_NUCLEAR = MRNA_TCF4_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_TCF4_NEXPORT_NUCLEAR = MRNA_TCF4_CYTOSOL+NEXPORT_NUCLEAR 
 0.3919599812502418 ; % 301 MRNA_TCF4_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_TCF4_RIBOSOME_CYTOSOL
 MRNA_TCF4_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_TCF4_RIBOSOME_CYTOSOL 
 0.04317530808179448 ; % 302 MRNA_TCF4_RIBOSOME_CYTOSOL = MRNA_TCF4_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_TCF4_RIBOSOME_CYTOSOL = MRNA_TCF4_CYTOSOL+RIBOSOME_CYTOSOL 
 0.8436846857435523 ; % 303 MRNA_TCF4_RIBOSOME_CYTOSOL = MRNA_TCF4_START_RIBOSOME_CYTOSOL
 MRNA_TCF4_RIBOSOME_CYTOSOL = MRNA_TCF4_START_RIBOSOME_CYTOSOL 
 0.9726602996328213 ; % 304 MRNA_TCF4_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + TCF4_CYTOSOL 
+ MRNA_TCF4_CYTOSOL MRNA_TCF4_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+TCF4_CYTOSOL+MRNA_TCF4_CYTOSOL 
 0.38045011507169896 ; % 305 MRNA_TCF4_CYTOSOL = [] MRNA_TCF4_CYTOSOL = [] 
 0.36632379137665433 ; % 306 TCF4_CYTOSOL = [] TCF4_CYTOSOL = [] 
 0.5140366963266814 ; % 307 DNA_NOTCH1_NUCLEAR + RNAP_NUCLEAR = DNA_NOTCH1_RNAP_NUCLEAR
 DNA_NOTCH1_NUCLEAR+RNAP_NUCLEAR = DNA_NOTCH1_RNAP_NUCLEAR 
 0.01804688184243222 ; % 308 DNA_NOTCH1_RNAP_NUCLEAR = DNA_NOTCH1_NUCLEAR + RNAP_NUCLEAR
 DNA_NOTCH1_RNAP_NUCLEAR = DNA_NOTCH1_NUCLEAR+RNAP_NUCLEAR 
 0.23368361323224796 ; % 309 DNA_NOTCH1_RNAP_NUCLEAR = DNA_NOTCH1_NUCLEAR + RNAP_NUCLEAR + 
MRNA_NOTCH1_NUCLEAR DNA_NOTCH1_RNAP_NUCLEAR = DNA_NOTCH1_NUCLEAR+RNAP_NUCLEAR+MRNA_NOTCH1_NUCLEAR 
 0.4606023259883263 ; % 310 MRNA_NOTCH1_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_NOTCH1_NEXPORT_NUCLEAR MRNA_NOTCH1_NUCLEAR+NEXPORT_NUCLEAR = MRNA_NOTCH1_NEXPORT_NUCLEAR 
 0.034201503485383124 ; % 311 MRNA_NOTCH1_NEXPORT_NUCLEAR = MRNA_NOTCH1_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_NOTCH1_NEXPORT_NUCLEAR = MRNA_NOTCH1_NUCLEAR+NEXPORT_NUCLEAR 
 0.5292601015675116 ; % 312 MRNA_NOTCH1_NEXPORT_NUCLEAR = MRNA_NOTCH1_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_NOTCH1_NEXPORT_NUCLEAR = MRNA_NOTCH1_CYTOSOL+NEXPORT_NUCLEAR 
 0.32842652869697253 ; % 313 MRNA_NOTCH1_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_NOTCH1_RIBOSOME_CYTOSOL MRNA_NOTCH1_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_NOTCH1_RIBOSOME_CYTOSOL 
 0.08344095489628048 ; % 314 MRNA_NOTCH1_RIBOSOME_CYTOSOL = MRNA_NOTCH1_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_NOTCH1_RIBOSOME_CYTOSOL = MRNA_NOTCH1_CYTOSOL+RIBOSOME_CYTOSOL 
 0.7862863423626023 ; % 315 MRNA_NOTCH1_RIBOSOME_CYTOSOL = 
MRNA_NOTCH1_START_RIBOSOME_CYTOSOL MRNA_NOTCH1_RIBOSOME_CYTOSOL = MRNA_NOTCH1_START_RIBOSOME_CYTOSOL 
 0.08419219281252754 ; % 316 MRNA_NOTCH1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
NOTCH1_CYTOSOL + MRNA_NOTCH1_CYTOSOL MRNA_NOTCH1_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+NOTCH1_CYTOSOL+MRNA_NOTCH1_CYTOSOL 
 0.4986726390749206 ; % 317 MRNA_NOTCH1_CYTOSOL = [] MRNA_NOTCH1_CYTOSOL = [] 
 0.12186270634565638 ; % 318 NOTCH1_CYTOSOL = [] NOTCH1_CYTOSOL = [] 
 0.6246903477626534 ; % 319 DNA_SEL1_NUCLEAR + RNAP_NUCLEAR = DNA_SEL1_RNAP_NUCLEAR
 DNA_SEL1_NUCLEAR+RNAP_NUCLEAR = DNA_SEL1_RNAP_NUCLEAR 
 0.0020591225212280963 ; % 320 DNA_SEL1_RNAP_NUCLEAR = DNA_SEL1_NUCLEAR + RNAP_NUCLEAR
 DNA_SEL1_RNAP_NUCLEAR = DNA_SEL1_NUCLEAR+RNAP_NUCLEAR 
 0.7262400058685857 ; % 321 DNA_SEL1_RNAP_NUCLEAR = DNA_SEL1_NUCLEAR + RNAP_NUCLEAR + 
MRNA_SEL1_NUCLEAR DNA_SEL1_RNAP_NUCLEAR = DNA_SEL1_NUCLEAR+RNAP_NUCLEAR+MRNA_SEL1_NUCLEAR 
 0.3117387285750173 ; % 322 MRNA_SEL1_NUCLEAR + NEXPORT_NUCLEAR = MRNA_SEL1_NEXPORT_NUCLEAR
 MRNA_SEL1_NUCLEAR+NEXPORT_NUCLEAR = MRNA_SEL1_NEXPORT_NUCLEAR 
 0.04038546739317104 ; % 323 MRNA_SEL1_NEXPORT_NUCLEAR = MRNA_SEL1_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_SEL1_NEXPORT_NUCLEAR = MRNA_SEL1_NUCLEAR+NEXPORT_NUCLEAR 
 0.7845572573170222 ; % 324 MRNA_SEL1_NEXPORT_NUCLEAR = MRNA_SEL1_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_SEL1_NEXPORT_NUCLEAR = MRNA_SEL1_CYTOSOL+NEXPORT_NUCLEAR 
 0.9864998430957428 ; % 325 MRNA_SEL1_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_SEL1_RIBOSOME_CYTOSOL
 MRNA_SEL1_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_SEL1_RIBOSOME_CYTOSOL 
 0.04261518755259619 ; % 326 MRNA_SEL1_RIBOSOME_CYTOSOL = MRNA_SEL1_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_SEL1_RIBOSOME_CYTOSOL = MRNA_SEL1_CYTOSOL+RIBOSOME_CYTOSOL 
 0.9409916167570932 ; % 327 MRNA_SEL1_RIBOSOME_CYTOSOL = MRNA_SEL1_START_RIBOSOME_CYTOSOL
 MRNA_SEL1_RIBOSOME_CYTOSOL = MRNA_SEL1_START_RIBOSOME_CYTOSOL 
 0.3191266782287694 ; % 328 MRNA_SEL1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + SEL1_CYTOSOL 
+ MRNA_SEL1_CYTOSOL MRNA_SEL1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+SEL1_CYTOSOL+MRNA_SEL1_CYTOSOL 
 0.19762510204795392 ; % 329 MRNA_SEL1_CYTOSOL = [] MRNA_SEL1_CYTOSOL = [] 
 0.2346698267468269 ; % 330 SEL1_CYTOSOL = [] SEL1_CYTOSOL = [] 
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 0.634377546469198 ; % 331 DNA_CSL_NUCLEAR + RNAP_NUCLEAR = DNA_CSL_RNAP_NUCLEAR
 DNA_CSL_NUCLEAR+RNAP_NUCLEAR = DNA_CSL_RNAP_NUCLEAR 
 0.042914159399753495 ; % 332 DNA_CSL_RNAP_NUCLEAR = DNA_CSL_NUCLEAR + RNAP_NUCLEAR
 DNA_CSL_RNAP_NUCLEAR = DNA_CSL_NUCLEAR+RNAP_NUCLEAR 
 0.5300841324139278 ; % 333 DNA_CSL_RNAP_NUCLEAR = DNA_CSL_NUCLEAR + RNAP_NUCLEAR + 
MRNA_CSL_NUCLEAR DNA_CSL_RNAP_NUCLEAR = DNA_CSL_NUCLEAR+RNAP_NUCLEAR+MRNA_CSL_NUCLEAR 
 0.014683872107830176 ; % 334 MRNA_CSL_NUCLEAR + NEXPORT_NUCLEAR = MRNA_CSL_NEXPORT_NUCLEAR
 MRNA_CSL_NUCLEAR+NEXPORT_NUCLEAR = MRNA_CSL_NEXPORT_NUCLEAR 
 0.013296013375077487 ; % 335 MRNA_CSL_NEXPORT_NUCLEAR = MRNA_CSL_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_CSL_NEXPORT_NUCLEAR = MRNA_CSL_NUCLEAR+NEXPORT_NUCLEAR 
 0.22223507158314815 ; % 336 MRNA_CSL_NEXPORT_NUCLEAR = MRNA_CSL_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_CSL_NEXPORT_NUCLEAR = MRNA_CSL_CYTOSOL+NEXPORT_NUCLEAR 
 0.5918893335491664 ; % 337 MRNA_CSL_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_CSL_RIBOSOME_CYTOSOL
 MRNA_CSL_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_CSL_RIBOSOME_CYTOSOL 
 0.06984653096550035 ; % 338 MRNA_CSL_RIBOSOME_CYTOSOL = MRNA_CSL_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_CSL_RIBOSOME_CYTOSOL = MRNA_CSL_CYTOSOL+RIBOSOME_CYTOSOL 
 0.8657346021215516 ; % 339 MRNA_CSL_RIBOSOME_CYTOSOL = MRNA_CSL_START_RIBOSOME_CYTOSOL
 MRNA_CSL_RIBOSOME_CYTOSOL = MRNA_CSL_START_RIBOSOME_CYTOSOL 
 0.8338480348185241 ; % 340 MRNA_CSL_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + CSL_CYTOSOL + 
MRNA_CSL_CYTOSOL MRNA_CSL_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+CSL_CYTOSOL+MRNA_CSL_CYTOSOL 
 0.006301815977498182 ; % 341 MRNA_CSL_CYTOSOL = [] MRNA_CSL_CYTOSOL = [] 
 0.41266335390498404 ; % 342 CSL_CYTOSOL = [] CSL_CYTOSOL = [] 
 0.0379748813757681 ; % 343 DNA_RAS_NUCLEAR + RNAP_NUCLEAR = DNA_RAS_RNAP_NUCLEAR
 DNA_RAS_NUCLEAR+RNAP_NUCLEAR = DNA_RAS_RNAP_NUCLEAR 
 0.032095222794560375 ; % 344 DNA_RAS_RNAP_NUCLEAR = DNA_RAS_NUCLEAR + RNAP_NUCLEAR
 DNA_RAS_RNAP_NUCLEAR = DNA_RAS_NUCLEAR+RNAP_NUCLEAR 
 0.6643010011505557 ; % 345 DNA_RAS_RNAP_NUCLEAR = DNA_RAS_NUCLEAR + RNAP_NUCLEAR + 
MRNA_RAS_NUCLEAR DNA_RAS_RNAP_NUCLEAR = DNA_RAS_NUCLEAR+RNAP_NUCLEAR+MRNA_RAS_NUCLEAR 
 0.5202033885570895 ; % 346 MRNA_RAS_NUCLEAR + NEXPORT_NUCLEAR = MRNA_RAS_NEXPORT_NUCLEAR
 MRNA_RAS_NUCLEAR+NEXPORT_NUCLEAR = MRNA_RAS_NEXPORT_NUCLEAR 
 0.09641014622914124 ; % 347 MRNA_RAS_NEXPORT_NUCLEAR = MRNA_RAS_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_RAS_NEXPORT_NUCLEAR = MRNA_RAS_NUCLEAR+NEXPORT_NUCLEAR 
 0.6921609018135282 ; % 348 MRNA_RAS_NEXPORT_NUCLEAR = MRNA_RAS_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_RAS_NEXPORT_NUCLEAR = MRNA_RAS_CYTOSOL+NEXPORT_NUCLEAR 
 0.541831343851341 ; % 349 MRNA_RAS_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_RAS_RIBOSOME_CYTOSOL
 MRNA_RAS_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_RAS_RIBOSOME_CYTOSOL 
 0.09007513402168991 ; % 350 MRNA_RAS_RIBOSOME_CYTOSOL = MRNA_RAS_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_RAS_RIBOSOME_CYTOSOL = MRNA_RAS_CYTOSOL+RIBOSOME_CYTOSOL 
 0.025912427039287644 ; % 351 MRNA_RAS_RIBOSOME_CYTOSOL = MRNA_RAS_START_RIBOSOME_CYTOSOL
 MRNA_RAS_RIBOSOME_CYTOSOL = MRNA_RAS_START_RIBOSOME_CYTOSOL 
 0.531167134816863 ; % 352 MRNA_RAS_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + RAS_CYTOSOL + 
MRNA_RAS_CYTOSOL MRNA_RAS_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+RAS_CYTOSOL+MRNA_RAS_CYTOSOL 
 0.3316535214840465 ; % 353 MRNA_RAS_CYTOSOL = [] MRNA_RAS_CYTOSOL = [] 
 0.40584248387188787 ; % 354 RAS_CYTOSOL = [] RAS_CYTOSOL = [] 
 0.12010013059839253 ; % 355 DNA_RAF_NUCLEAR + RNAP_NUCLEAR = DNA_RAF_RNAP_NUCLEAR
 DNA_RAF_NUCLEAR+RNAP_NUCLEAR = DNA_RAF_RNAP_NUCLEAR 
 0.056595720187166756 ; % 356 DNA_RAF_RNAP_NUCLEAR = DNA_RAF_NUCLEAR + RNAP_NUCLEAR
 DNA_RAF_RNAP_NUCLEAR = DNA_RAF_NUCLEAR+RNAP_NUCLEAR 
 0.4610500800545444 ; % 357 DNA_RAF_RNAP_NUCLEAR = DNA_RAF_NUCLEAR + RNAP_NUCLEAR + 
MRNA_RAF_NUCLEAR DNA_RAF_RNAP_NUCLEAR = DNA_RAF_NUCLEAR+RNAP_NUCLEAR+MRNA_RAF_NUCLEAR 
 0.6360695987940695 ; % 358 MRNA_RAF_NUCLEAR + NEXPORT_NUCLEAR = MRNA_RAF_NEXPORT_NUCLEAR
 MRNA_RAF_NUCLEAR+NEXPORT_NUCLEAR = MRNA_RAF_NEXPORT_NUCLEAR 
 0.01904206240201144 ; % 359 MRNA_RAF_NEXPORT_NUCLEAR = MRNA_RAF_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_RAF_NEXPORT_NUCLEAR = MRNA_RAF_NUCLEAR+NEXPORT_NUCLEAR 
 0.8380040293474278 ; % 360 MRNA_RAF_NEXPORT_NUCLEAR = MRNA_RAF_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_RAF_NEXPORT_NUCLEAR = MRNA_RAF_CYTOSOL+NEXPORT_NUCLEAR 
 0.120183198746036 ; % 361 MRNA_RAF_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_RAF_RIBOSOME_CYTOSOL
 MRNA_RAF_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_RAF_RIBOSOME_CYTOSOL 
 0.0578496894050759 ; % 362 MRNA_RAF_RIBOSOME_CYTOSOL = MRNA_RAF_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_RAF_RIBOSOME_CYTOSOL = MRNA_RAF_CYTOSOL+RIBOSOME_CYTOSOL 
 0.3275788227864429 ; % 363 MRNA_RAF_RIBOSOME_CYTOSOL = MRNA_RAF_START_RIBOSOME_CYTOSOL
 MRNA_RAF_RIBOSOME_CYTOSOL = MRNA_RAF_START_RIBOSOME_CYTOSOL 
 0.8336545649746165 ; % 364 MRNA_RAF_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + RAF_CYTOSOL + 
MRNA_RAF_CYTOSOL MRNA_RAF_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+RAF_CYTOSOL+MRNA_RAF_CYTOSOL 
 0.08143476565310692 ; % 365 MRNA_RAF_CYTOSOL = [] MRNA_RAF_CYTOSOL = [] 
 0.300601913788011 ; % 366 RAF_CYTOSOL = [] RAF_CYTOSOL = [] 
 0.9638373379979768 ; % 367 DNA_MEK_NUCLEAR + RNAP_NUCLEAR = DNA_MEK_RNAP_NUCLEAR
 DNA_MEK_NUCLEAR+RNAP_NUCLEAR = DNA_MEK_RNAP_NUCLEAR 
 0.005418121344759053 ; % 368 DNA_MEK_RNAP_NUCLEAR = DNA_MEK_NUCLEAR + RNAP_NUCLEAR
 DNA_MEK_RNAP_NUCLEAR = DNA_MEK_NUCLEAR+RNAP_NUCLEAR 
 0.07327517572197062 ; % 369 DNA_MEK_RNAP_NUCLEAR = DNA_MEK_NUCLEAR + RNAP_NUCLEAR + 
MRNA_MEK_NUCLEAR DNA_MEK_RNAP_NUCLEAR = DNA_MEK_NUCLEAR+RNAP_NUCLEAR+MRNA_MEK_NUCLEAR 
 0.8865788640236085 ; % 370 MRNA_MEK_NUCLEAR + NEXPORT_NUCLEAR = MRNA_MEK_NEXPORT_NUCLEAR
 MRNA_MEK_NUCLEAR+NEXPORT_NUCLEAR = MRNA_MEK_NEXPORT_NUCLEAR 
 0.08895523842290107 ; % 371 MRNA_MEK_NEXPORT_NUCLEAR = MRNA_MEK_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_MEK_NEXPORT_NUCLEAR = MRNA_MEK_NUCLEAR+NEXPORT_NUCLEAR 
 0.02147663065288341 ; % 372 MRNA_MEK_NEXPORT_NUCLEAR = MRNA_MEK_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_MEK_NEXPORT_NUCLEAR = MRNA_MEK_CYTOSOL+NEXPORT_NUCLEAR 
 0.9116491837178491 ; % 373 MRNA_MEK_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_MEK_RIBOSOME_CYTOSOL
 MRNA_MEK_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_MEK_RIBOSOME_CYTOSOL 
 0.029813185773912954 ; % 374 MRNA_MEK_RIBOSOME_CYTOSOL = MRNA_MEK_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_MEK_RIBOSOME_CYTOSOL = MRNA_MEK_CYTOSOL+RIBOSOME_CYTOSOL 
 0.1752854062332635 ; % 375 MRNA_MEK_RIBOSOME_CYTOSOL = MRNA_MEK_START_RIBOSOME_CYTOSOL
 MRNA_MEK_RIBOSOME_CYTOSOL = MRNA_MEK_START_RIBOSOME_CYTOSOL 
 0.6431283489009955 ; % 376 MRNA_MEK_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + MEK_CYTOSOL 
+ MRNA_MEK_CYTOSOL MRNA_MEK_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+MEK_CYTOSOL+MRNA_MEK_CYTOSOL 
 0.3377432368960164 ; % 377 MRNA_MEK_CYTOSOL = [] MRNA_MEK_CYTOSOL = [] 
 0.40844335314139213 ; % 378 MEK_CYTOSOL = [] MEK_CYTOSOL = [] 
 0.5958345637166482 ; % 379 DNA_ERK_NUCLEAR + RNAP_NUCLEAR = DNA_ERK_RNAP_NUCLEAR
 DNA_ERK_NUCLEAR+RNAP_NUCLEAR = DNA_ERK_RNAP_NUCLEAR 
 0.01936173809170738 ; % 380 DNA_ERK_RNAP_NUCLEAR = DNA_ERK_NUCLEAR + RNAP_NUCLEAR
 DNA_ERK_RNAP_NUCLEAR = DNA_ERK_NUCLEAR+RNAP_NUCLEAR 
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 0.6315586058954646 ; % 381 DNA_ERK_RNAP_NUCLEAR = DNA_ERK_NUCLEAR + RNAP_NUCLEAR + 
MRNA_ERK_NUCLEAR DNA_ERK_RNAP_NUCLEAR = DNA_ERK_NUCLEAR+RNAP_NUCLEAR+MRNA_ERK_NUCLEAR 
 0.34128892100459995 ; % 382 MRNA_ERK_NUCLEAR + NEXPORT_NUCLEAR = MRNA_ERK_NEXPORT_NUCLEAR
 MRNA_ERK_NUCLEAR+NEXPORT_NUCLEAR = MRNA_ERK_NEXPORT_NUCLEAR 
 0.08214751297466921 ; % 383 MRNA_ERK_NEXPORT_NUCLEAR = MRNA_ERK_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_ERK_NEXPORT_NUCLEAR = MRNA_ERK_NUCLEAR+NEXPORT_NUCLEAR 
 0.9076433302687152 ; % 384 MRNA_ERK_NEXPORT_NUCLEAR = MRNA_ERK_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_ERK_NEXPORT_NUCLEAR = MRNA_ERK_CYTOSOL+NEXPORT_NUCLEAR 
 0.9646687070610893 ; % 385 MRNA_ERK_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_ERK_RIBOSOME_CYTOSOL
 MRNA_ERK_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_ERK_RIBOSOME_CYTOSOL 
 0.055610304651031076 ; % 386 MRNA_ERK_RIBOSOME_CYTOSOL = MRNA_ERK_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_ERK_RIBOSOME_CYTOSOL = MRNA_ERK_CYTOSOL+RIBOSOME_CYTOSOL 
 0.46689362455327843 ; % 387 MRNA_ERK_RIBOSOME_CYTOSOL = MRNA_ERK_START_RIBOSOME_CYTOSOL
 MRNA_ERK_RIBOSOME_CYTOSOL = MRNA_ERK_START_RIBOSOME_CYTOSOL 
 0.327085742831167 ; % 388 MRNA_ERK_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + ERK_CYTOSOL + 
MRNA_ERK_CYTOSOL MRNA_ERK_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+ERK_CYTOSOL+MRNA_ERK_CYTOSOL 
 0.4336529888094435 ; % 389 MRNA_ERK_CYTOSOL = [] MRNA_ERK_CYTOSOL = [] 
 0.3997036867423405 ; % 390 ERK_CYTOSOL = [] ERK_CYTOSOL = [] 
 0.06974555787036896 ; % 391 DNA_SPK_NUCLEAR + RNAP_NUCLEAR = DNA_SPK_RNAP_NUCLEAR
 DNA_SPK_NUCLEAR+RNAP_NUCLEAR = DNA_SPK_RNAP_NUCLEAR 
 0.009486977749145276 ; % 392 DNA_SPK_RNAP_NUCLEAR = DNA_SPK_NUCLEAR + RNAP_NUCLEAR
 DNA_SPK_RNAP_NUCLEAR = DNA_SPK_NUCLEAR+RNAP_NUCLEAR 
 0.6289463824352108 ; % 393 DNA_SPK_RNAP_NUCLEAR = DNA_SPK_NUCLEAR + RNAP_NUCLEAR + 
MRNA_SPK_NUCLEAR DNA_SPK_RNAP_NUCLEAR = DNA_SPK_NUCLEAR+RNAP_NUCLEAR+MRNA_SPK_NUCLEAR 
 0.9866766139638768 ; % 394 MRNA_SPK_NUCLEAR + NEXPORT_NUCLEAR = MRNA_SPK_NEXPORT_NUCLEAR
 MRNA_SPK_NUCLEAR+NEXPORT_NUCLEAR = MRNA_SPK_NEXPORT_NUCLEAR 
 0.020846206245687483 ; % 395 MRNA_SPK_NEXPORT_NUCLEAR = MRNA_SPK_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_SPK_NEXPORT_NUCLEAR = MRNA_SPK_NUCLEAR+NEXPORT_NUCLEAR 
 0.8470115492015456 ; % 396 MRNA_SPK_NEXPORT_NUCLEAR = MRNA_SPK_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_SPK_NEXPORT_NUCLEAR = MRNA_SPK_CYTOSOL+NEXPORT_NUCLEAR 
 0.37456649477015747 ; % 397 MRNA_SPK_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_SPK_RIBOSOME_CYTOSOL
 MRNA_SPK_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_SPK_RIBOSOME_CYTOSOL 
 0.0687075744060228 ; % 398 MRNA_SPK_RIBOSOME_CYTOSOL = MRNA_SPK_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_SPK_RIBOSOME_CYTOSOL = MRNA_SPK_CYTOSOL+RIBOSOME_CYTOSOL 
 0.26287578356347996 ; % 399 MRNA_SPK_RIBOSOME_CYTOSOL = MRNA_SPK_START_RIBOSOME_CYTOSOL
 MRNA_SPK_RIBOSOME_CYTOSOL = MRNA_SPK_START_RIBOSOME_CYTOSOL 
 0.2183768047703819 ; % 400 MRNA_SPK_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + SPK_CYTOSOL + 
MRNA_SPK_CYTOSOL MRNA_SPK_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+SPK_CYTOSOL+MRNA_SPK_CYTOSOL 
 0.4245033271132099 ; % 401 MRNA_SPK_CYTOSOL = [] MRNA_SPK_CYTOSOL = [] 
 0.194735614316004 ; % 402 SPK_CYTOSOL = [] SPK_CYTOSOL = [] 
 0.7714322465668915 ; % 403 DNA_PLCG_NUCLEAR + RNAP_NUCLEAR = DNA_PLCG_RNAP_NUCLEAR
 DNA_PLCG_NUCLEAR+RNAP_NUCLEAR = DNA_PLCG_RNAP_NUCLEAR 
 0.07481941879993896 ; % 404 DNA_PLCG_RNAP_NUCLEAR = DNA_PLCG_NUCLEAR + RNAP_NUCLEAR
 DNA_PLCG_RNAP_NUCLEAR = DNA_PLCG_NUCLEAR+RNAP_NUCLEAR 
 0.04714170778547633 ; % 405 DNA_PLCG_RNAP_NUCLEAR = DNA_PLCG_NUCLEAR + RNAP_NUCLEAR + 
MRNA_PLCG_NUCLEAR DNA_PLCG_RNAP_NUCLEAR = DNA_PLCG_NUCLEAR+RNAP_NUCLEAR+MRNA_PLCG_NUCLEAR 
 0.8442982525740508 ; % 406 MRNA_PLCG_NUCLEAR + NEXPORT_NUCLEAR = MRNA_PLCG_NEXPORT_NUCLEAR
 MRNA_PLCG_NUCLEAR+NEXPORT_NUCLEAR = MRNA_PLCG_NEXPORT_NUCLEAR 
 0.0945197471611141 ; % 407 MRNA_PLCG_NEXPORT_NUCLEAR = MRNA_PLCG_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_PLCG_NEXPORT_NUCLEAR = MRNA_PLCG_NUCLEAR+NEXPORT_NUCLEAR 
 0.6481219362708843 ; % 408 MRNA_PLCG_NEXPORT_NUCLEAR = MRNA_PLCG_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_PLCG_NEXPORT_NUCLEAR = MRNA_PLCG_CYTOSOL+NEXPORT_NUCLEAR 
 0.5493859632729868 ; % 409 MRNA_PLCG_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_PLCG_RIBOSOME_CYTOSOL MRNA_PLCG_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_PLCG_RIBOSOME_CYTOSOL 
 0.012230613771801414 ; % 410 MRNA_PLCG_RIBOSOME_CYTOSOL = MRNA_PLCG_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_PLCG_RIBOSOME_CYTOSOL = MRNA_PLCG_CYTOSOL+RIBOSOME_CYTOSOL 
 0.6615687456036196 ; % 411 MRNA_PLCG_RIBOSOME_CYTOSOL = MRNA_PLCG_START_RIBOSOME_CYTOSOL
 MRNA_PLCG_RIBOSOME_CYTOSOL = MRNA_PLCG_START_RIBOSOME_CYTOSOL 
 0.9786752152546898 ; % 412 MRNA_PLCG_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
PLCG_CYTOSOL + MRNA_PLCG_CYTOSOL MRNA_PLCG_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+PLCG_CYTOSOL+MRNA_PLCG_CYTOSOL 
 0.06894051672217255 ; % 413 MRNA_PLCG_CYTOSOL = [] MRNA_PLCG_CYTOSOL = [] 
 0.34616801812835685 ; % 414 PLCG_CYTOSOL = [] PLCG_CYTOSOL = [] 
 0.17953992005603714 ; % 415 DNA_RAF_PASE_NUCLEAR + RNAP_NUCLEAR = DNA_RAF_PASE_RNAP_NUCLEAR
 DNA_RAF_PASE_NUCLEAR+RNAP_NUCLEAR = DNA_RAF_PASE_RNAP_NUCLEAR 
 0.07690785644593728 ; % 416 DNA_RAF_PASE_RNAP_NUCLEAR = DNA_RAF_PASE_NUCLEAR + RNAP_NUCLEAR
 DNA_RAF_PASE_RNAP_NUCLEAR = DNA_RAF_PASE_NUCLEAR+RNAP_NUCLEAR 
 0.6407842658097708 ; % 417 DNA_RAF_PASE_RNAP_NUCLEAR = DNA_RAF_PASE_NUCLEAR + RNAP_NUCLEAR + 
MRNA_RAF_PASE_NUCLEAR DNA_RAF_PASE_RNAP_NUCLEAR = DNA_RAF_PASE_NUCLEAR+RNAP_NUCLEAR+MRNA_RAF_PASE_NUCLEAR 
 0.3876685692030051 ; % 418 MRNA_RAF_PASE_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_RAF_PASE_NEXPORT_NUCLEAR MRNA_RAF_PASE_NUCLEAR+NEXPORT_NUCLEAR = MRNA_RAF_PASE_NEXPORT_NUCLEAR 
 0.08935688947114832 ; % 419 MRNA_RAF_PASE_NEXPORT_NUCLEAR = MRNA_RAF_PASE_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_RAF_PASE_NEXPORT_NUCLEAR = MRNA_RAF_PASE_NUCLEAR+NEXPORT_NUCLEAR 
 0.011116016170332421 ; % 420 MRNA_RAF_PASE_NEXPORT_NUCLEAR = MRNA_RAF_PASE_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_RAF_PASE_NEXPORT_NUCLEAR = MRNA_RAF_PASE_CYTOSOL+NEXPORT_NUCLEAR 
 0.9803966537325371 ; % 421 MRNA_RAF_PASE_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_RAF_PASE_RIBOSOME_CYTOSOL MRNA_RAF_PASE_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_RAF_PASE_RIBOSOME_CYTOSOL 
 0.06041114457360476 ; % 422 MRNA_RAF_PASE_RIBOSOME_CYTOSOL = MRNA_RAF_PASE_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_RAF_PASE_RIBOSOME_CYTOSOL = MRNA_RAF_PASE_CYTOSOL+RIBOSOME_CYTOSOL 
 0.674538988740089 ; % 423 MRNA_RAF_PASE_RIBOSOME_CYTOSOL = 
MRNA_RAF_PASE_START_RIBOSOME_CYTOSOL MRNA_RAF_PASE_RIBOSOME_CYTOSOL = MRNA_RAF_PASE_START_RIBOSOME_CYTOSOL 
 0.2593093208063608 ; % 424 MRNA_RAF_PASE_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
RAF_PASE_CYTOSOL + MRNA_RAF_PASE_CYTOSOL MRNA_RAF_PASE_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+RAF_PASE_CYTOSOL+MRNA_RAF_PASE_CYTOSOL 
 0.042719294614261494 ; % 425 MRNA_RAF_PASE_CYTOSOL = [] MRNA_RAF_PASE_CYTOSOL = [] 
 0.22643998500500095 ; % 426 RAF_PASE_CYTOSOL = [] RAF_PASE_CYTOSOL = [] 
 0.7340028046157084 ; % 427 DNA_MEK_PASE_NUCLEAR + RNAP_NUCLEAR = DNA_MEK_PASE_RNAP_NUCLEAR
 DNA_MEK_PASE_NUCLEAR+RNAP_NUCLEAR = DNA_MEK_PASE_RNAP_NUCLEAR 
 0.0777762124470637 ; % 428 DNA_MEK_PASE_RNAP_NUCLEAR = DNA_MEK_PASE_NUCLEAR + RNAP_NUCLEAR
 DNA_MEK_PASE_RNAP_NUCLEAR = DNA_MEK_PASE_NUCLEAR+RNAP_NUCLEAR 
 0.6686032725605533 ; % 429 DNA_MEK_PASE_RNAP_NUCLEAR = DNA_MEK_PASE_NUCLEAR + RNAP_NUCLEAR + 
MRNA_MEK_PASE_NUCLEAR DNA_MEK_PASE_RNAP_NUCLEAR = DNA_MEK_PASE_NUCLEAR+RNAP_NUCLEAR+MRNA_MEK_PASE_NUCLEAR 
 0.8774564776836914 ; % 430 MRNA_MEK_PASE_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_MEK_PASE_NEXPORT_NUCLEAR MRNA_MEK_PASE_NUCLEAR+NEXPORT_NUCLEAR = MRNA_MEK_PASE_NEXPORT_NUCLEAR 
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 0.049184086002964526 ; % 431 MRNA_MEK_PASE_NEXPORT_NUCLEAR = MRNA_MEK_PASE_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_MEK_PASE_NEXPORT_NUCLEAR = MRNA_MEK_PASE_NUCLEAR+NEXPORT_NUCLEAR 
 0.7882664640933238 ; % 432 MRNA_MEK_PASE_NEXPORT_NUCLEAR = MRNA_MEK_PASE_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_MEK_PASE_NEXPORT_NUCLEAR = MRNA_MEK_PASE_CYTOSOL+NEXPORT_NUCLEAR 
 0.8675866423143938 ; % 433 MRNA_MEK_PASE_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_MEK_PASE_RIBOSOME_CYTOSOL MRNA_MEK_PASE_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_MEK_PASE_RIBOSOME_CYTOSOL 
 0.09359969976851115 ; % 434 MRNA_MEK_PASE_RIBOSOME_CYTOSOL = MRNA_MEK_PASE_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_MEK_PASE_RIBOSOME_CYTOSOL = MRNA_MEK_PASE_CYTOSOL+RIBOSOME_CYTOSOL 
 0.6276638992378004 ; % 435 MRNA_MEK_PASE_RIBOSOME_CYTOSOL = 
MRNA_MEK_PASE_START_RIBOSOME_CYTOSOL MRNA_MEK_PASE_RIBOSOME_CYTOSOL = MRNA_MEK_PASE_START_RIBOSOME_CYTOSOL 
 0.3947749345555097 ; % 436 MRNA_MEK_PASE_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
MEK_PASE_CYTOSOL + MRNA_MEK_PASE_CYTOSOL MRNA_MEK_PASE_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+MEK_PASE_CYTOSOL+MRNA_MEK_PASE_CYTOSOL 
 0.20055688635541719 ; % 437 MRNA_MEK_PASE_CYTOSOL = [] MRNA_MEK_PASE_CYTOSOL = [] 
 0.2747433862525737 ; % 438 MEK_PASE_CYTOSOL = [] MEK_PASE_CYTOSOL = [] 
 0.35273225617408466 ; % 439 DNA_ERK_PASE_NUCLEAR + RNAP_NUCLEAR = DNA_ERK_PASE_RNAP_NUCLEAR
 DNA_ERK_PASE_NUCLEAR+RNAP_NUCLEAR = DNA_ERK_PASE_RNAP_NUCLEAR 
 0.018610043998967575 ; % 440 DNA_ERK_PASE_RNAP_NUCLEAR = DNA_ERK_PASE_NUCLEAR + RNAP_NUCLEAR
 DNA_ERK_PASE_RNAP_NUCLEAR = DNA_ERK_PASE_NUCLEAR+RNAP_NUCLEAR 
 0.20105220964797732 ; % 441 DNA_ERK_PASE_RNAP_NUCLEAR = DNA_ERK_PASE_NUCLEAR + RNAP_NUCLEAR + 
MRNA_ERK_PASE_NUCLEAR DNA_ERK_PASE_RNAP_NUCLEAR = DNA_ERK_PASE_NUCLEAR+RNAP_NUCLEAR+MRNA_ERK_PASE_NUCLEAR 
 0.02072878527185662 ; % 442 MRNA_ERK_PASE_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_ERK_PASE_NEXPORT_NUCLEAR MRNA_ERK_PASE_NUCLEAR+NEXPORT_NUCLEAR = MRNA_ERK_PASE_NEXPORT_NUCLEAR 
 0.095186141436726 ; % 443 MRNA_ERK_PASE_NEXPORT_NUCLEAR = MRNA_ERK_PASE_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_ERK_PASE_NEXPORT_NUCLEAR = MRNA_ERK_PASE_NUCLEAR+NEXPORT_NUCLEAR 
 0.3517126027391111 ; % 444 MRNA_ERK_PASE_NEXPORT_NUCLEAR = MRNA_ERK_PASE_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_ERK_PASE_NEXPORT_NUCLEAR = MRNA_ERK_PASE_CYTOSOL+NEXPORT_NUCLEAR 
 0.4475219532227488 ; % 445 MRNA_ERK_PASE_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_ERK_PASE_RIBOSOME_CYTOSOL MRNA_ERK_PASE_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_ERK_PASE_RIBOSOME_CYTOSOL 
 0.054038232608305675 ; % 446 MRNA_ERK_PASE_RIBOSOME_CYTOSOL = MRNA_ERK_PASE_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_ERK_PASE_RIBOSOME_CYTOSOL = MRNA_ERK_PASE_CYTOSOL+RIBOSOME_CYTOSOL 
 0.8137280411184259 ; % 447 MRNA_ERK_PASE_RIBOSOME_CYTOSOL = 
MRNA_ERK_PASE_START_RIBOSOME_CYTOSOL MRNA_ERK_PASE_RIBOSOME_CYTOSOL = MRNA_ERK_PASE_START_RIBOSOME_CYTOSOL 
 0.3847582461286283 ; % 448 MRNA_ERK_PASE_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
ERK_PASE_CYTOSOL + MRNA_ERK_PASE_CYTOSOL MRNA_ERK_PASE_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+ERK_PASE_CYTOSOL+MRNA_ERK_PASE_CYTOSOL 
 0.2779916890670523 ; % 449 MRNA_ERK_PASE_CYTOSOL = [] MRNA_ERK_PASE_CYTOSOL = [] 
 0.3568257331691212 ; % 450 ERK_PASE_CYTOSOL = [] ERK_PASE_CYTOSOL = [] 
 0.4931860403925228 ; % 451 DNA_SP1_NUCLEAR + RNAP_NUCLEAR = DNA_SP1_RNAP_NUCLEAR
 DNA_SP1_NUCLEAR+RNAP_NUCLEAR = DNA_SP1_RNAP_NUCLEAR 
 0.009194092429826361 ; % 452 DNA_SP1_RNAP_NUCLEAR = DNA_SP1_NUCLEAR + RNAP_NUCLEAR
 DNA_SP1_RNAP_NUCLEAR = DNA_SP1_NUCLEAR+RNAP_NUCLEAR 
 0.9436038887775245 ; % 453 DNA_SP1_RNAP_NUCLEAR = DNA_SP1_NUCLEAR + RNAP_NUCLEAR + 
MRNA_SP1_NUCLEAR DNA_SP1_RNAP_NUCLEAR = DNA_SP1_NUCLEAR+RNAP_NUCLEAR+MRNA_SP1_NUCLEAR 
 0.8648561577156606 ; % 454 MRNA_SP1_NUCLEAR + NEXPORT_NUCLEAR = MRNA_SP1_NEXPORT_NUCLEAR
 MRNA_SP1_NUCLEAR+NEXPORT_NUCLEAR = MRNA_SP1_NEXPORT_NUCLEAR 
 0.08306476598564705 ; % 455 MRNA_SP1_NEXPORT_NUCLEAR = MRNA_SP1_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_SP1_NEXPORT_NUCLEAR = MRNA_SP1_NUCLEAR+NEXPORT_NUCLEAR 
 0.6816522571593553 ; % 456 MRNA_SP1_NEXPORT_NUCLEAR = MRNA_SP1_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_SP1_NEXPORT_NUCLEAR = MRNA_SP1_CYTOSOL+NEXPORT_NUCLEAR 
 0.33677466224504204 ; % 457 MRNA_SP1_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_SP1_RIBOSOME_CYTOSOL
 MRNA_SP1_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_SP1_RIBOSOME_CYTOSOL 
 0.05070013084692987 ; % 458 MRNA_SP1_RIBOSOME_CYTOSOL = MRNA_SP1_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_SP1_RIBOSOME_CYTOSOL = MRNA_SP1_CYTOSOL+RIBOSOME_CYTOSOL 
 0.7912798958193928 ; % 459 MRNA_SP1_RIBOSOME_CYTOSOL = MRNA_SP1_START_RIBOSOME_CYTOSOL
 MRNA_SP1_RIBOSOME_CYTOSOL = MRNA_SP1_START_RIBOSOME_CYTOSOL 
 0.15975572183917663 ; % 460 MRNA_SP1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + SP1_CYTOSOL + 
MRNA_SP1_CYTOSOL MRNA_SP1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+SP1_CYTOSOL+MRNA_SP1_CYTOSOL 
 0.48623451956903985 ; % 461 MRNA_SP1_CYTOSOL = [] MRNA_SP1_CYTOSOL = [] 
 0.4497961347623364 ; % 462 SP1_CYTOSOL = [] SP1_CYTOSOL = [] 
 0.4807115890142398 ; % 463 DNA_CJUN_NUCLEAR + RNAP_NUCLEAR = DNA_CJUN_RNAP_NUCLEAR
 DNA_CJUN_NUCLEAR+RNAP_NUCLEAR = DNA_CJUN_RNAP_NUCLEAR 
 0.012668144947803628 ; % 464 DNA_CJUN_RNAP_NUCLEAR = DNA_CJUN_NUCLEAR + RNAP_NUCLEAR
 DNA_CJUN_RNAP_NUCLEAR = DNA_CJUN_NUCLEAR+RNAP_NUCLEAR 
 0.293204739040981 ; % 465 DNA_CJUN_RNAP_NUCLEAR = DNA_CJUN_NUCLEAR + RNAP_NUCLEAR + 
MRNA_CJUN_NUCLEAR DNA_CJUN_RNAP_NUCLEAR = DNA_CJUN_NUCLEAR+RNAP_NUCLEAR+MRNA_CJUN_NUCLEAR 
 0.060327747658482256 ; % 466 MRNA_CJUN_NUCLEAR + NEXPORT_NUCLEAR = MRNA_CJUN_NEXPORT_NUCLEAR
 MRNA_CJUN_NUCLEAR+NEXPORT_NUCLEAR = MRNA_CJUN_NEXPORT_NUCLEAR 
 0.07441423051525971 ; % 467 MRNA_CJUN_NEXPORT_NUCLEAR = MRNA_CJUN_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_CJUN_NEXPORT_NUCLEAR = MRNA_CJUN_NUCLEAR+NEXPORT_NUCLEAR 
 0.3399980159954541 ; % 468 MRNA_CJUN_NEXPORT_NUCLEAR = MRNA_CJUN_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_CJUN_NEXPORT_NUCLEAR = MRNA_CJUN_CYTOSOL+NEXPORT_NUCLEAR 
 0.6386920318077327 ; % 469 MRNA_CJUN_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_CJUN_RIBOSOME_CYTOSOL
 MRNA_CJUN_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_CJUN_RIBOSOME_CYTOSOL 
 0.0944934042616978 ; % 470 MRNA_CJUN_RIBOSOME_CYTOSOL = MRNA_CJUN_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_CJUN_RIBOSOME_CYTOSOL = MRNA_CJUN_CYTOSOL+RIBOSOME_CYTOSOL 
 0.862189050584555 ; % 471 MRNA_CJUN_RIBOSOME_CYTOSOL = MRNA_CJUN_START_RIBOSOME_CYTOSOL
 MRNA_CJUN_RIBOSOME_CYTOSOL = MRNA_CJUN_START_RIBOSOME_CYTOSOL 
 0.08338570246694132 ; % 472 MRNA_CJUN_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
CJUN_CYTOSOL + MRNA_CJUN_CYTOSOL MRNA_CJUN_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+CJUN_CYTOSOL+MRNA_CJUN_CYTOSOL 
 0.4984102174361913 ; % 473 MRNA_CJUN_CYTOSOL = [] MRNA_CJUN_CYTOSOL = [] 
 0.3821437651748239 ; % 474 CJUN_CYTOSOL = [] CJUN_CYTOSOL = [] 
 0.11950229219725061 ; % 475 DNA_CPLA2_NUCLEAR + RNAP_NUCLEAR = DNA_CPLA2_RNAP_NUCLEAR
 DNA_CPLA2_NUCLEAR+RNAP_NUCLEAR = DNA_CPLA2_RNAP_NUCLEAR 
 0.04659427912596445 ; % 476 DNA_CPLA2_RNAP_NUCLEAR = DNA_CPLA2_NUCLEAR + RNAP_NUCLEAR
 DNA_CPLA2_RNAP_NUCLEAR = DNA_CPLA2_NUCLEAR+RNAP_NUCLEAR 
 0.09245693886674011 ; % 477 DNA_CPLA2_RNAP_NUCLEAR = DNA_CPLA2_NUCLEAR + RNAP_NUCLEAR + 
MRNA_CPLA2_NUCLEAR DNA_CPLA2_RNAP_NUCLEAR = DNA_CPLA2_NUCLEAR+RNAP_NUCLEAR+MRNA_CPLA2_NUCLEAR 
 0.5691044872307691 ; % 478 MRNA_CPLA2_NUCLEAR + NEXPORT_NUCLEAR = MRNA_CPLA2_NEXPORT_NUCLEAR
 MRNA_CPLA2_NUCLEAR+NEXPORT_NUCLEAR = MRNA_CPLA2_NEXPORT_NUCLEAR 
 0.04411282295577443 ; % 479 MRNA_CPLA2_NEXPORT_NUCLEAR = MRNA_CPLA2_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_CPLA2_NEXPORT_NUCLEAR = MRNA_CPLA2_NUCLEAR+NEXPORT_NUCLEAR 
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 0.2650146912610394 ; % 480 MRNA_CPLA2_NEXPORT_NUCLEAR = MRNA_CPLA2_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_CPLA2_NEXPORT_NUCLEAR = MRNA_CPLA2_CYTOSOL+NEXPORT_NUCLEAR 
 0.9645988610915756 ; % 481 MRNA_CPLA2_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_CPLA2_RIBOSOME_CYTOSOL MRNA_CPLA2_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_CPLA2_RIBOSOME_CYTOSOL 
 0.02998612332112296 ; % 482 MRNA_CPLA2_RIBOSOME_CYTOSOL = MRNA_CPLA2_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_CPLA2_RIBOSOME_CYTOSOL = MRNA_CPLA2_CYTOSOL+RIBOSOME_CYTOSOL 
 0.8667892847075997 ; % 483 MRNA_CPLA2_RIBOSOME_CYTOSOL = MRNA_CPLA2_START_RIBOSOME_CYTOSOL
 MRNA_CPLA2_RIBOSOME_CYTOSOL = MRNA_CPLA2_START_RIBOSOME_CYTOSOL 
 0.8212433953710983 ; % 484 MRNA_CPLA2_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
CPLA2_CYTOSOL + MRNA_CPLA2_CYTOSOL MRNA_CPLA2_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+CPLA2_CYTOSOL+MRNA_CPLA2_CYTOSOL 
 0.35537245949829016 ; % 485 MRNA_CPLA2_CYTOSOL = [] MRNA_CPLA2_CYTOSOL = [] 
 0.23661960823952843 ; % 486 CPLA2_CYTOSOL = [] CPLA2_CYTOSOL = [] 
 0.3647003144245555 ; % 487 DNA_GSK3B_NUCLEAR + RNAP_NUCLEAR = DNA_GSK3B_RNAP_NUCLEAR
 DNA_GSK3B_NUCLEAR+RNAP_NUCLEAR = DNA_GSK3B_RNAP_NUCLEAR 
 0.07962926662694797 ; % 488 DNA_GSK3B_RNAP_NUCLEAR = DNA_GSK3B_NUCLEAR + RNAP_NUCLEAR
 DNA_GSK3B_RNAP_NUCLEAR = DNA_GSK3B_NUCLEAR+RNAP_NUCLEAR 
 0.2619184226345602 ; % 489 DNA_GSK3B_RNAP_NUCLEAR = DNA_GSK3B_NUCLEAR + RNAP_NUCLEAR + 
MRNA_GSK3B_NUCLEAR DNA_GSK3B_RNAP_NUCLEAR = DNA_GSK3B_NUCLEAR+RNAP_NUCLEAR+MRNA_GSK3B_NUCLEAR 
 0.5562733301414404 ; % 490 MRNA_GSK3B_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_GSK3B_NEXPORT_NUCLEAR MRNA_GSK3B_NUCLEAR+NEXPORT_NUCLEAR = MRNA_GSK3B_NEXPORT_NUCLEAR 
 0.03742332469136391 ; % 491 MRNA_GSK3B_NEXPORT_NUCLEAR = MRNA_GSK3B_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_GSK3B_NEXPORT_NUCLEAR = MRNA_GSK3B_NUCLEAR+NEXPORT_NUCLEAR 
 0.31171196037930027 ; % 492 MRNA_GSK3B_NEXPORT_NUCLEAR = MRNA_GSK3B_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_GSK3B_NEXPORT_NUCLEAR = MRNA_GSK3B_CYTOSOL+NEXPORT_NUCLEAR 
 0.8925965166597075 ; % 493 MRNA_GSK3B_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_GSK3B_RIBOSOME_CYTOSOL MRNA_GSK3B_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_GSK3B_RIBOSOME_CYTOSOL 
 0.0865514045208902 ; % 494 MRNA_GSK3B_RIBOSOME_CYTOSOL = MRNA_GSK3B_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_GSK3B_RIBOSOME_CYTOSOL = MRNA_GSK3B_CYTOSOL+RIBOSOME_CYTOSOL 
 0.5106884150317391 ; % 495 MRNA_GSK3B_RIBOSOME_CYTOSOL = MRNA_GSK3B_START_RIBOSOME_CYTOSOL
 MRNA_GSK3B_RIBOSOME_CYTOSOL = MRNA_GSK3B_START_RIBOSOME_CYTOSOL 
 0.10166015018369057 ; % 496 MRNA_GSK3B_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
GSK3B_CYTOSOL + MRNA_GSK3B_CYTOSOL MRNA_GSK3B_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+GSK3B_CYTOSOL+MRNA_GSK3B_CYTOSOL 
 0.3334351233115636 ; % 497 MRNA_GSK3B_CYTOSOL = [] MRNA_GSK3B_CYTOSOL = [] 
 0.26044860907358003 ; % 498 GSK3B_CYTOSOL = [] GSK3B_CYTOSOL = [] 
 0.06562544528032555 ; % 499 DNA_CK1_NUCLEAR + RNAP_NUCLEAR = DNA_CK1_RNAP_NUCLEAR
 DNA_CK1_NUCLEAR+RNAP_NUCLEAR = DNA_CK1_RNAP_NUCLEAR 
 0.08327177422444106 ; % 500 DNA_CK1_RNAP_NUCLEAR = DNA_CK1_NUCLEAR + RNAP_NUCLEAR
 DNA_CK1_RNAP_NUCLEAR = DNA_CK1_NUCLEAR+RNAP_NUCLEAR 
 0.17547994393011201 ; % 501 DNA_CK1_RNAP_NUCLEAR = DNA_CK1_NUCLEAR + RNAP_NUCLEAR + 
MRNA_CK1_NUCLEAR DNA_CK1_RNAP_NUCLEAR = DNA_CK1_NUCLEAR+RNAP_NUCLEAR+MRNA_CK1_NUCLEAR 
 0.5826477036096949 ; % 502 MRNA_CK1_NUCLEAR + NEXPORT_NUCLEAR = MRNA_CK1_NEXPORT_NUCLEAR
 MRNA_CK1_NUCLEAR+NEXPORT_NUCLEAR = MRNA_CK1_NEXPORT_NUCLEAR 
 0.029265302694367036 ; % 503 MRNA_CK1_NEXPORT_NUCLEAR = MRNA_CK1_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_CK1_NEXPORT_NUCLEAR = MRNA_CK1_NUCLEAR+NEXPORT_NUCLEAR 
 0.6707741084697666 ; % 504 MRNA_CK1_NEXPORT_NUCLEAR = MRNA_CK1_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_CK1_NEXPORT_NUCLEAR = MRNA_CK1_CYTOSOL+NEXPORT_NUCLEAR 
 0.7279411795313381 ; % 505 MRNA_CK1_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_CK1_RIBOSOME_CYTOSOL
 MRNA_CK1_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_CK1_RIBOSOME_CYTOSOL 
 4.4262449354500746E-4 ; % 506 MRNA_CK1_RIBOSOME_CYTOSOL = MRNA_CK1_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_CK1_RIBOSOME_CYTOSOL = MRNA_CK1_CYTOSOL+RIBOSOME_CYTOSOL 
 0.9812710416782421 ; % 507 MRNA_CK1_RIBOSOME_CYTOSOL = MRNA_CK1_START_RIBOSOME_CYTOSOL
 MRNA_CK1_RIBOSOME_CYTOSOL = MRNA_CK1_START_RIBOSOME_CYTOSOL 
 0.507984281184241 ; % 508 MRNA_CK1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + CK1_CYTOSOL + 
MRNA_CK1_CYTOSOL MRNA_CK1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+CK1_CYTOSOL+MRNA_CK1_CYTOSOL 
 0.31489832219649555 ; % 509 MRNA_CK1_CYTOSOL = [] MRNA_CK1_CYTOSOL = [] 
 0.2235307574673836 ; % 510 CK1_CYTOSOL = [] CK1_CYTOSOL = [] 
 0.49030465720622074 ; % 511 DNA_APC_NUCLEAR + RNAP_NUCLEAR = DNA_APC_RNAP_NUCLEAR
 DNA_APC_NUCLEAR+RNAP_NUCLEAR = DNA_APC_RNAP_NUCLEAR 
 2.0474080100499892E-4 ; % 512 DNA_APC_RNAP_NUCLEAR = DNA_APC_NUCLEAR + RNAP_NUCLEAR
 DNA_APC_RNAP_NUCLEAR = DNA_APC_NUCLEAR+RNAP_NUCLEAR 
 0.29709960949383385 ; % 513 DNA_APC_RNAP_NUCLEAR = DNA_APC_NUCLEAR + RNAP_NUCLEAR + 
MRNA_APC_NUCLEAR DNA_APC_RNAP_NUCLEAR = DNA_APC_NUCLEAR+RNAP_NUCLEAR+MRNA_APC_NUCLEAR 
 0.314592216915593 ; % 514 MRNA_APC_NUCLEAR + NEXPORT_NUCLEAR = MRNA_APC_NEXPORT_NUCLEAR
 MRNA_APC_NUCLEAR+NEXPORT_NUCLEAR = MRNA_APC_NEXPORT_NUCLEAR 
 0.02376649055849528 ; % 515 MRNA_APC_NEXPORT_NUCLEAR = MRNA_APC_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_APC_NEXPORT_NUCLEAR = MRNA_APC_NUCLEAR+NEXPORT_NUCLEAR 
 0.7255667655393416 ; % 516 MRNA_APC_NEXPORT_NUCLEAR = MRNA_APC_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_APC_NEXPORT_NUCLEAR = MRNA_APC_CYTOSOL+NEXPORT_NUCLEAR 
 0.7385551591350612 ; % 517 MRNA_APC_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_APC_RIBOSOME_CYTOSOL
 MRNA_APC_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_APC_RIBOSOME_CYTOSOL 
 0.059797702615856055 ; % 518 MRNA_APC_RIBOSOME_CYTOSOL = MRNA_APC_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_APC_RIBOSOME_CYTOSOL = MRNA_APC_CYTOSOL+RIBOSOME_CYTOSOL 
 0.6246155414365662 ; % 519 MRNA_APC_RIBOSOME_CYTOSOL = MRNA_APC_START_RIBOSOME_CYTOSOL
 MRNA_APC_RIBOSOME_CYTOSOL = MRNA_APC_START_RIBOSOME_CYTOSOL 
 0.27500941046422145 ; % 520 MRNA_APC_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + APC_CYTOSOL + 
MRNA_APC_CYTOSOL MRNA_APC_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+APC_CYTOSOL+MRNA_APC_CYTOSOL 
 0.18515766467762163 ; % 521 MRNA_APC_CYTOSOL = [] MRNA_APC_CYTOSOL = [] 
 0.12085623385174765 ; % 522 APC_CYTOSOL = [] APC_CYTOSOL = [] 
 0.510421802242996 ; % 523 DNA_LRP_NUCLEAR + RNAP_NUCLEAR = DNA_LRP_RNAP_NUCLEAR
 DNA_LRP_NUCLEAR+RNAP_NUCLEAR = DNA_LRP_RNAP_NUCLEAR 
 0.014679083664155025 ; % 524 DNA_LRP_RNAP_NUCLEAR = DNA_LRP_NUCLEAR + RNAP_NUCLEAR
 DNA_LRP_RNAP_NUCLEAR = DNA_LRP_NUCLEAR+RNAP_NUCLEAR 
 0.21924488481646065 ; % 525 DNA_LRP_RNAP_NUCLEAR = DNA_LRP_NUCLEAR + RNAP_NUCLEAR + 
MRNA_LRP_NUCLEAR DNA_LRP_RNAP_NUCLEAR = DNA_LRP_NUCLEAR+RNAP_NUCLEAR+MRNA_LRP_NUCLEAR 
 0.7847327629308031 ; % 526 MRNA_LRP_NUCLEAR + NEXPORT_NUCLEAR = MRNA_LRP_NEXPORT_NUCLEAR
 MRNA_LRP_NUCLEAR+NEXPORT_NUCLEAR = MRNA_LRP_NEXPORT_NUCLEAR 
 0.0647201149091531 ; % 527 MRNA_LRP_NEXPORT_NUCLEAR = MRNA_LRP_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_LRP_NEXPORT_NUCLEAR = MRNA_LRP_NUCLEAR+NEXPORT_NUCLEAR 
 0.5522683287502911 ; % 528 MRNA_LRP_NEXPORT_NUCLEAR = MRNA_LRP_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_LRP_NEXPORT_NUCLEAR = MRNA_LRP_CYTOSOL+NEXPORT_NUCLEAR 
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 0.31754483859918825 ; % 529 MRNA_LRP_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_LRP_RIBOSOME_CYTOSOL
 MRNA_LRP_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_LRP_RIBOSOME_CYTOSOL 
 0.09693467348583537 ; % 530 MRNA_LRP_RIBOSOME_CYTOSOL = MRNA_LRP_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_LRP_RIBOSOME_CYTOSOL = MRNA_LRP_CYTOSOL+RIBOSOME_CYTOSOL 
 0.9349922515362089 ; % 531 MRNA_LRP_RIBOSOME_CYTOSOL = MRNA_LRP_START_RIBOSOME_CYTOSOL
 MRNA_LRP_RIBOSOME_CYTOSOL = MRNA_LRP_START_RIBOSOME_CYTOSOL 
 0.11393404609432467 ; % 532 MRNA_LRP_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + LRP_CYTOSOL + 
MRNA_LRP_CYTOSOL MRNA_LRP_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+LRP_CYTOSOL+MRNA_LRP_CYTOSOL 
 0.24747033094469317 ; % 533 MRNA_LRP_CYTOSOL = [] MRNA_LRP_CYTOSOL = [] 
 0.430300843122893 ; % 534 LRP_CYTOSOL = [] LRP_CYTOSOL = [] 
 0.9635031311666712 ; % 535 DNA_AXIN_NUCLEAR + RNAP_NUCLEAR = DNA_AXIN_RNAP_NUCLEAR
 DNA_AXIN_NUCLEAR+RNAP_NUCLEAR = DNA_AXIN_RNAP_NUCLEAR 
 0.05618570665559345 ; % 536 DNA_AXIN_RNAP_NUCLEAR = DNA_AXIN_NUCLEAR + RNAP_NUCLEAR
 DNA_AXIN_RNAP_NUCLEAR = DNA_AXIN_NUCLEAR+RNAP_NUCLEAR 
 0.8342131283928055 ; % 537 DNA_AXIN_RNAP_NUCLEAR = DNA_AXIN_NUCLEAR + RNAP_NUCLEAR + 
MRNA_AXIN_NUCLEAR DNA_AXIN_RNAP_NUCLEAR = DNA_AXIN_NUCLEAR+RNAP_NUCLEAR+MRNA_AXIN_NUCLEAR 
 0.7733452453183899 ; % 538 MRNA_AXIN_NUCLEAR + NEXPORT_NUCLEAR = MRNA_AXIN_NEXPORT_NUCLEAR
 MRNA_AXIN_NUCLEAR+NEXPORT_NUCLEAR = MRNA_AXIN_NEXPORT_NUCLEAR 
 0.006969517725743069 ; % 539 MRNA_AXIN_NEXPORT_NUCLEAR = MRNA_AXIN_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_AXIN_NEXPORT_NUCLEAR = MRNA_AXIN_NUCLEAR+NEXPORT_NUCLEAR 
 0.1324312104007933 ; % 540 MRNA_AXIN_NEXPORT_NUCLEAR = MRNA_AXIN_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_AXIN_NEXPORT_NUCLEAR = MRNA_AXIN_CYTOSOL+NEXPORT_NUCLEAR 
 0.7716695072829305 ; % 541 MRNA_AXIN_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_AXIN_RIBOSOME_CYTOSOL
 MRNA_AXIN_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_AXIN_RIBOSOME_CYTOSOL 
 0.09653901273074186 ; % 542 MRNA_AXIN_RIBOSOME_CYTOSOL = MRNA_AXIN_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_AXIN_RIBOSOME_CYTOSOL = MRNA_AXIN_CYTOSOL+RIBOSOME_CYTOSOL 
 0.05930465304785759 ; % 543 MRNA_AXIN_RIBOSOME_CYTOSOL = MRNA_AXIN_START_RIBOSOME_CYTOSOL
 MRNA_AXIN_RIBOSOME_CYTOSOL = MRNA_AXIN_START_RIBOSOME_CYTOSOL 
 0.360743459853207 ; % 544 MRNA_AXIN_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + AXIN_CYTOSOL 
+ MRNA_AXIN_CYTOSOL MRNA_AXIN_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+AXIN_CYTOSOL+MRNA_AXIN_CYTOSOL 
 0.09811166276676891 ; % 545 MRNA_AXIN_CYTOSOL = [] MRNA_AXIN_CYTOSOL = [] 
 0.3112845280499388 ; % 546 AXIN_CYTOSOL = [] AXIN_CYTOSOL = [] 
 0.8155988724972729 ; % 547 DNA_PKC_NUCLEAR + RNAP_NUCLEAR = DNA_PKC_RNAP_NUCLEAR
 DNA_PKC_NUCLEAR+RNAP_NUCLEAR = DNA_PKC_RNAP_NUCLEAR 
 0.03533850904146805 ; % 548 DNA_PKC_RNAP_NUCLEAR = DNA_PKC_NUCLEAR + RNAP_NUCLEAR
 DNA_PKC_RNAP_NUCLEAR = DNA_PKC_NUCLEAR+RNAP_NUCLEAR 
 0.9290711225232582 ; % 549 DNA_PKC_RNAP_NUCLEAR = DNA_PKC_NUCLEAR + RNAP_NUCLEAR + 
MRNA_PKC_NUCLEAR DNA_PKC_RNAP_NUCLEAR = DNA_PKC_NUCLEAR+RNAP_NUCLEAR+MRNA_PKC_NUCLEAR 
 0.13509991956918632 ; % 550 MRNA_PKC_NUCLEAR + NEXPORT_NUCLEAR = MRNA_PKC_NEXPORT_NUCLEAR
 MRNA_PKC_NUCLEAR+NEXPORT_NUCLEAR = MRNA_PKC_NEXPORT_NUCLEAR 
 0.02501095805030459 ; % 551 MRNA_PKC_NEXPORT_NUCLEAR = MRNA_PKC_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_PKC_NEXPORT_NUCLEAR = MRNA_PKC_NUCLEAR+NEXPORT_NUCLEAR 
 0.4302864838648909 ; % 552 MRNA_PKC_NEXPORT_NUCLEAR = MRNA_PKC_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_PKC_NEXPORT_NUCLEAR = MRNA_PKC_CYTOSOL+NEXPORT_NUCLEAR 
 0.650525440699793 ; % 553 MRNA_PKC_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_PKC_RIBOSOME_CYTOSOL
 MRNA_PKC_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_PKC_RIBOSOME_CYTOSOL 
 0.00445642220896193 ; % 554 MRNA_PKC_RIBOSOME_CYTOSOL = MRNA_PKC_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_PKC_RIBOSOME_CYTOSOL = MRNA_PKC_CYTOSOL+RIBOSOME_CYTOSOL 
 0.4377811251555236 ; % 555 MRNA_PKC_RIBOSOME_CYTOSOL = MRNA_PKC_START_RIBOSOME_CYTOSOL
 MRNA_PKC_RIBOSOME_CYTOSOL = MRNA_PKC_START_RIBOSOME_CYTOSOL 
 0.2321632009657847 ; % 556 MRNA_PKC_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + PKC_CYTOSOL + 
MRNA_PKC_CYTOSOL MRNA_PKC_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+PKC_CYTOSOL+MRNA_PKC_CYTOSOL 
 0.34069132484649184 ; % 557 MRNA_PKC_CYTOSOL = [] MRNA_PKC_CYTOSOL = [] 
 0.16346735279768265 ; % 558 PKC_CYTOSOL = [] PKC_CYTOSOL = [] 
 0.3229166179981863 ; % 559 DNA_BTRCP_NUCLEAR + RNAP_NUCLEAR = DNA_BTRCP_RNAP_NUCLEAR
 DNA_BTRCP_NUCLEAR+RNAP_NUCLEAR = DNA_BTRCP_RNAP_NUCLEAR 
 4.4194115107316635E-4 ; % 560 DNA_BTRCP_RNAP_NUCLEAR = DNA_BTRCP_NUCLEAR + RNAP_NUCLEAR
 DNA_BTRCP_RNAP_NUCLEAR = DNA_BTRCP_NUCLEAR+RNAP_NUCLEAR 
 0.023275440330029262 ; % 561 DNA_BTRCP_RNAP_NUCLEAR = DNA_BTRCP_NUCLEAR + RNAP_NUCLEAR + 
MRNA_BTRCP_NUCLEAR DNA_BTRCP_RNAP_NUCLEAR = DNA_BTRCP_NUCLEAR+RNAP_NUCLEAR+MRNA_BTRCP_NUCLEAR 
 0.8694705171201336 ; % 562 MRNA_BTRCP_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_BTRCP_NEXPORT_NUCLEAR MRNA_BTRCP_NUCLEAR+NEXPORT_NUCLEAR = MRNA_BTRCP_NEXPORT_NUCLEAR 
 0.008250027517403325 ; % 563 MRNA_BTRCP_NEXPORT_NUCLEAR = MRNA_BTRCP_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_BTRCP_NEXPORT_NUCLEAR = MRNA_BTRCP_NUCLEAR+NEXPORT_NUCLEAR 
 0.7888626475217473 ; % 564 MRNA_BTRCP_NEXPORT_NUCLEAR = MRNA_BTRCP_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_BTRCP_NEXPORT_NUCLEAR = MRNA_BTRCP_CYTOSOL+NEXPORT_NUCLEAR 
 0.7157797308819791 ; % 565 MRNA_BTRCP_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_BTRCP_RIBOSOME_CYTOSOL MRNA_BTRCP_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_BTRCP_RIBOSOME_CYTOSOL 
 0.009793162363255815 ; % 566 MRNA_BTRCP_RIBOSOME_CYTOSOL = MRNA_BTRCP_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_BTRCP_RIBOSOME_CYTOSOL = MRNA_BTRCP_CYTOSOL+RIBOSOME_CYTOSOL 
 0.08991983007205961 ; % 567 MRNA_BTRCP_RIBOSOME_CYTOSOL = MRNA_BTRCP_START_RIBOSOME_CYTOSOL
 MRNA_BTRCP_RIBOSOME_CYTOSOL = MRNA_BTRCP_START_RIBOSOME_CYTOSOL 
 0.6813412260114982 ; % 568 MRNA_BTRCP_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
BTRCP_CYTOSOL + MRNA_BTRCP_CYTOSOL MRNA_BTRCP_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+BTRCP_CYTOSOL+MRNA_BTRCP_CYTOSOL 
 0.4388079400406425 ; % 569 MRNA_BTRCP_CYTOSOL = [] MRNA_BTRCP_CYTOSOL = [] 
 0.35772324066169153 ; % 570 BTRCP_CYTOSOL = [] BTRCP_CYTOSOL = [] 
 0.4348078910304565 ; % 571 DNA_FRIZZLED_NUCLEAR + RNAP_NUCLEAR = DNA_FRIZZLED_RNAP_NUCLEAR
 DNA_FRIZZLED_NUCLEAR+RNAP_NUCLEAR = DNA_FRIZZLED_RNAP_NUCLEAR 
 0.01464236685779179 ; % 572 DNA_FRIZZLED_RNAP_NUCLEAR = DNA_FRIZZLED_NUCLEAR + RNAP_NUCLEAR
 DNA_FRIZZLED_RNAP_NUCLEAR = DNA_FRIZZLED_NUCLEAR+RNAP_NUCLEAR 
 0.7651047235130854 ; % 573 DNA_FRIZZLED_RNAP_NUCLEAR = DNA_FRIZZLED_NUCLEAR + RNAP_NUCLEAR + 
MRNA_FRIZZLED_NUCLEAR DNA_FRIZZLED_RNAP_NUCLEAR = DNA_FRIZZLED_NUCLEAR+RNAP_NUCLEAR+MRNA_FRIZZLED_NUCLEAR 
 0.42549998483725293 ; % 574 MRNA_FRIZZLED_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_FRIZZLED_NEXPORT_NUCLEAR MRNA_FRIZZLED_NUCLEAR+NEXPORT_NUCLEAR = MRNA_FRIZZLED_NEXPORT_NUCLEAR 
 0.012366653319528098 ; % 575 MRNA_FRIZZLED_NEXPORT_NUCLEAR = MRNA_FRIZZLED_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_FRIZZLED_NEXPORT_NUCLEAR = MRNA_FRIZZLED_NUCLEAR+NEXPORT_NUCLEAR 
 0.6194977281645392 ; % 576 MRNA_FRIZZLED_NEXPORT_NUCLEAR = MRNA_FRIZZLED_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_FRIZZLED_NEXPORT_NUCLEAR = MRNA_FRIZZLED_CYTOSOL+NEXPORT_NUCLEAR 
 0.8031093564446155 ; % 577 MRNA_FRIZZLED_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_FRIZZLED_RIBOSOME_CYTOSOL MRNA_FRIZZLED_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_FRIZZLED_RIBOSOME_CYTOSOL 
 0.03288918413272725 ; % 578 MRNA_FRIZZLED_RIBOSOME_CYTOSOL = MRNA_FRIZZLED_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_FRIZZLED_RIBOSOME_CYTOSOL = MRNA_FRIZZLED_CYTOSOL+RIBOSOME_CYTOSOL 
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 0.4111347998387943 ; % 579 MRNA_FRIZZLED_RIBOSOME_CYTOSOL = 
MRNA_FRIZZLED_START_RIBOSOME_CYTOSOL MRNA_FRIZZLED_RIBOSOME_CYTOSOL = MRNA_FRIZZLED_START_RIBOSOME_CYTOSOL 
 0.27217337085512006 ; % 580 MRNA_FRIZZLED_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
FRIZZLED_CYTOSOL + MRNA_FRIZZLED_CYTOSOL MRNA_FRIZZLED_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+FRIZZLED_CYTOSOL+MRNA_FRIZZLED_CYTOSOL 
 0.4110065904856119 ; % 581 MRNA_FRIZZLED_CYTOSOL = [] MRNA_FRIZZLED_CYTOSOL = [] 
 0.20407381597920576 ; % 582 FRIZZLED_CYTOSOL = [] FRIZZLED_CYTOSOL = [] 
 0.019320407080464452 ; % 583 DNA_BCATENIN_NUCLEAR + RNAP_NUCLEAR = DNA_BCATENIN_RNAP_NUCLEAR
 DNA_BCATENIN_NUCLEAR+RNAP_NUCLEAR = DNA_BCATENIN_RNAP_NUCLEAR 
 0.08686332907914834 ; % 584 DNA_BCATENIN_RNAP_NUCLEAR = DNA_BCATENIN_NUCLEAR + RNAP_NUCLEAR
 DNA_BCATENIN_RNAP_NUCLEAR = DNA_BCATENIN_NUCLEAR+RNAP_NUCLEAR 
 0.06688561411283234 ; % 585 DNA_BCATENIN_RNAP_NUCLEAR = DNA_BCATENIN_NUCLEAR + RNAP_NUCLEAR + 
MRNA_BCATENIN_NUCLEAR DNA_BCATENIN_RNAP_NUCLEAR = DNA_BCATENIN_NUCLEAR+RNAP_NUCLEAR+MRNA_BCATENIN_NUCLEAR 
 0.14274839828791142 ; % 586 MRNA_BCATENIN_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_BCATENIN_NEXPORT_NUCLEAR MRNA_BCATENIN_NUCLEAR+NEXPORT_NUCLEAR = MRNA_BCATENIN_NEXPORT_NUCLEAR 
 0.0031381404465271826 ; % 587 MRNA_BCATENIN_NEXPORT_NUCLEAR = MRNA_BCATENIN_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_BCATENIN_NEXPORT_NUCLEAR = MRNA_BCATENIN_NUCLEAR+NEXPORT_NUCLEAR 
 0.09858092459299284 ; % 588 MRNA_BCATENIN_NEXPORT_NUCLEAR = MRNA_BCATENIN_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_BCATENIN_NEXPORT_NUCLEAR = MRNA_BCATENIN_CYTOSOL+NEXPORT_NUCLEAR 
 0.09515702779338212 ; % 589 MRNA_BCATENIN_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_BCATENIN_RIBOSOME_CYTOSOL MRNA_BCATENIN_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_BCATENIN_RIBOSOME_CYTOSOL 
 0.0834676746882981 ; % 590 MRNA_BCATENIN_RIBOSOME_CYTOSOL = MRNA_BCATENIN_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_BCATENIN_RIBOSOME_CYTOSOL = MRNA_BCATENIN_CYTOSOL+RIBOSOME_CYTOSOL 
 0.1707465706967607 ; % 591 MRNA_BCATENIN_RIBOSOME_CYTOSOL = 
MRNA_BCATENIN_START_RIBOSOME_CYTOSOL MRNA_BCATENIN_RIBOSOME_CYTOSOL = MRNA_BCATENIN_START_RIBOSOME_CYTOSOL 
 0.636694812630464 ; % 592 MRNA_BCATENIN_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
BCATENIN_CYTOSOL + MRNA_BCATENIN_CYTOSOL MRNA_BCATENIN_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+BCATENIN_CYTOSOL+MRNA_BCATENIN_CYTOSOL 
 0.5611635119092241 ; % 593 MRNA_BCATENIN_CYTOSOL = [] MRNA_BCATENIN_CYTOSOL = [] 
 0.5330804424036437 ; % 594 BCATENIN_CYTOSOL = [] BCATENIN_CYTOSOL = [] 
 0.8650435973223999 ; % 595 DNA_DISHEVELLED_NUCLEAR + RNAP_NUCLEAR = 
DNA_DISHEVELLED_RNAP_NUCLEAR DNA_DISHEVELLED_NUCLEAR+RNAP_NUCLEAR = DNA_DISHEVELLED_RNAP_NUCLEAR 
 0.044900547505071234 ; % 596 DNA_DISHEVELLED_RNAP_NUCLEAR = DNA_DISHEVELLED_NUCLEAR + 
RNAP_NUCLEAR DNA_DISHEVELLED_RNAP_NUCLEAR = DNA_DISHEVELLED_NUCLEAR+RNAP_NUCLEAR 
 0.40932804396189093 ; % 597 DNA_DISHEVELLED_RNAP_NUCLEAR = DNA_DISHEVELLED_NUCLEAR + 
RNAP_NUCLEAR + MRNA_DISHEVELLED_NUCLEAR DNA_DISHEVELLED_RNAP_NUCLEAR = 
DNA_DISHEVELLED_NUCLEAR+RNAP_NUCLEAR+MRNA_DISHEVELLED_NUCLEAR 
 0.8601301182182971 ; % 598 MRNA_DISHEVELLED_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_DISHEVELLED_NEXPORT_NUCLEAR MRNA_DISHEVELLED_NUCLEAR+NEXPORT_NUCLEAR = MRNA_DISHEVELLED_NEXPORT_NUCLEAR 
 0.0428392936701838 ; % 599 MRNA_DISHEVELLED_NEXPORT_NUCLEAR = MRNA_DISHEVELLED_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_DISHEVELLED_NEXPORT_NUCLEAR = MRNA_DISHEVELLED_NUCLEAR+NEXPORT_NUCLEAR 
 0.5433688167229335 ; % 600 MRNA_DISHEVELLED_NEXPORT_NUCLEAR = MRNA_DISHEVELLED_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_DISHEVELLED_NEXPORT_NUCLEAR = MRNA_DISHEVELLED_CYTOSOL+NEXPORT_NUCLEAR 
 0.26594276518030346 ; % 601 MRNA_DISHEVELLED_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_DISHEVELLED_RIBOSOME_CYTOSOL MRNA_DISHEVELLED_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_DISHEVELLED_RIBOSOME_CYTOSOL 
 0.05687789676857311 ; % 602 MRNA_DISHEVELLED_RIBOSOME_CYTOSOL = MRNA_DISHEVELLED_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_DISHEVELLED_RIBOSOME_CYTOSOL = MRNA_DISHEVELLED_CYTOSOL+RIBOSOME_CYTOSOL 
 0.6959057779444638 ; % 603 MRNA_DISHEVELLED_RIBOSOME_CYTOSOL = 
MRNA_DISHEVELLED_START_RIBOSOME_CYTOSOL MRNA_DISHEVELLED_RIBOSOME_CYTOSOL = 
MRNA_DISHEVELLED_START_RIBOSOME_CYTOSOL 
 0.44421795554638155 ; % 604 MRNA_DISHEVELLED_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
DISHEVELLED_CYTOSOL + MRNA_DISHEVELLED_CYTOSOL MRNA_DISHEVELLED_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+DISHEVELLED_CYTOSOL+MRNA_DISHEVELLED_CYTOSOL 
 0.010957434341422212 ; % 605 MRNA_DISHEVELLED_CYTOSOL = [] MRNA_DISHEVELLED_CYTOSOL = [] 
 0.13838453876286722 ; % 606 DISHEVELLED_CYTOSOL = [] DISHEVELLED_CYTOSOL = [] 
 0.001 ; % 607 DNA_ECADHERIN_NUCLEAR + RNAP_NUCLEAR = DNA_ECADHERIN_RNAP_NUCLEAR
 DNA_ECADHERIN_NUCLEAR+RNAP_NUCLEAR = DNA_ECADHERIN_RNAP_NUCLEAR 
 0.0016103325301803206 ; % 608 DNA_ECADHERIN_RNAP_NUCLEAR = DNA_ECADHERIN_NUCLEAR + RNAP_NUCLEAR
 DNA_ECADHERIN_RNAP_NUCLEAR = DNA_ECADHERIN_NUCLEAR+RNAP_NUCLEAR 
 0.9343147628317134 ; % 609 DNA_ECADHERIN_RNAP_NUCLEAR = DNA_ECADHERIN_NUCLEAR + RNAP_NUCLEAR 
+ MRNA_ECADHERIN_NUCLEAR DNA_ECADHERIN_RNAP_NUCLEAR = DNA_ECADHERIN_NUCLEAR+RNAP_NUCLEAR+MRNA_ECADHERIN_NUCLEAR 
 0.729815026780462 ; % 610 MRNA_ECADHERIN_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_ECADHERIN_NEXPORT_NUCLEAR MRNA_ECADHERIN_NUCLEAR+NEXPORT_NUCLEAR = MRNA_ECADHERIN_NEXPORT_NUCLEAR 
 0.0029983174011490355 ; % 611 MRNA_ECADHERIN_NEXPORT_NUCLEAR = MRNA_ECADHERIN_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_ECADHERIN_NEXPORT_NUCLEAR = MRNA_ECADHERIN_NUCLEAR+NEXPORT_NUCLEAR 
 0.71547797619050744 ; % 612 MRNA_ECADHERIN_NEXPORT_NUCLEAR = MRNA_ECADHERIN_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_ECADHERIN_NEXPORT_NUCLEAR = MRNA_ECADHERIN_CYTOSOL+NEXPORT_NUCLEAR 
 0.7168387993532837 ; % 613 MRNA_ECADHERIN_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_ECADHERIN_RIBOSOME_CYTOSOL MRNA_ECADHERIN_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_ECADHERIN_RIBOSOME_CYTOSOL 
 0.0011836445065569379 ; % 614 MRNA_ECADHERIN_RIBOSOME_CYTOSOL = MRNA_ECADHERIN_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_ECADHERIN_RIBOSOME_CYTOSOL = MRNA_ECADHERIN_CYTOSOL+RIBOSOME_CYTOSOL 
 0.9887339825831304 ; % 615 MRNA_ECADHERIN_RIBOSOME_CYTOSOL = 
MRNA_ECADHERIN_START_RIBOSOME_CYTOSOL MRNA_ECADHERIN_RIBOSOME_CYTOSOL = MRNA_ECADHERIN_START_RIBOSOME_CYTOSOL 
 0.939049427939938 ; % 616 MRNA_ECADHERIN_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
ECADHERIN_CYTOSOL + MRNA_ECADHERIN_CYTOSOL MRNA_ECADHERIN_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+ECADHERIN_CYTOSOL+MRNA_ECADHERIN_CYTOSOL 
 0.0189974731661657 ; % 617 MRNA_ECADHERIN_CYTOSOL = [] MRNA_ECADHERIN_CYTOSOL = [] 
 0.01865222458534326 ; % 618 ECADHERIN_CYTOSOL = [] ECADHERIN_CYTOSOL = [] 
 0.48018516661682487 ; % 619 DNA_VECADHERIN_NUCLEAR + RNAP_NUCLEAR = 
DNA_VECADHERIN_RNAP_NUCLEAR DNA_VECADHERIN_NUCLEAR+RNAP_NUCLEAR = DNA_VECADHERIN_RNAP_NUCLEAR 
 0.07999472940198185 ; % 620 DNA_VECADHERIN_RNAP_NUCLEAR = DNA_VECADHERIN_NUCLEAR + 
RNAP_NUCLEAR DNA_VECADHERIN_RNAP_NUCLEAR = DNA_VECADHERIN_NUCLEAR+RNAP_NUCLEAR 
 0.9008432220651773 ; % 621 DNA_VECADHERIN_RNAP_NUCLEAR = DNA_VECADHERIN_NUCLEAR + 
RNAP_NUCLEAR + MRNA_VECADHERIN_NUCLEAR DNA_VECADHERIN_RNAP_NUCLEAR = 
DNA_VECADHERIN_NUCLEAR+RNAP_NUCLEAR+MRNA_VECADHERIN_NUCLEAR 
 0.5860817849523475 ; % 622 MRNA_VECADHERIN_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_VECADHERIN_NEXPORT_NUCLEAR MRNA_VECADHERIN_NUCLEAR+NEXPORT_NUCLEAR = MRNA_VECADHERIN_NEXPORT_NUCLEAR 
 0.010685549893641856 ; % 623 MRNA_VECADHERIN_NEXPORT_NUCLEAR = MRNA_VECADHERIN_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_VECADHERIN_NEXPORT_NUCLEAR = MRNA_VECADHERIN_NUCLEAR+NEXPORT_NUCLEAR 
 0.4961642916747795 ; % 624 MRNA_VECADHERIN_NEXPORT_NUCLEAR = MRNA_VECADHERIN_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_VECADHERIN_NEXPORT_NUCLEAR = MRNA_VECADHERIN_CYTOSOL+NEXPORT_NUCLEAR 
 0.6743154062538891 ; % 625 MRNA_VECADHERIN_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_VECADHERIN_RIBOSOME_CYTOSOL MRNA_VECADHERIN_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_VECADHERIN_RIBOSOME_CYTOSOL 
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 0.020435370741104433 ; % 626 MRNA_VECADHERIN_RIBOSOME_CYTOSOL = MRNA_VECADHERIN_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_VECADHERIN_RIBOSOME_CYTOSOL = MRNA_VECADHERIN_CYTOSOL+RIBOSOME_CYTOSOL 
 0.7554106836416242 ; % 627 MRNA_VECADHERIN_RIBOSOME_CYTOSOL = 
MRNA_VECADHERIN_START_RIBOSOME_CYTOSOL MRNA_VECADHERIN_RIBOSOME_CYTOSOL = MRNA_VECADHERIN_START_RIBOSOME_CYTOSOL 
 0.5442208822246483 ; % 628 MRNA_VECADHERIN_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
VECADHERIN_CYTOSOL + MRNA_VECADHERIN_CYTOSOL MRNA_VECADHERIN_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+VECADHERIN_CYTOSOL+MRNA_VECADHERIN_CYTOSOL 
 0.3334622739594081 ; % 629 MRNA_VECADHERIN_CYTOSOL = [] MRNA_VECADHERIN_CYTOSOL = [] 
 0.26712101370744057 ; % 630 VECADHERIN_CYTOSOL = [] VECADHERIN_CYTOSOL = [] 
 0.1722294691693581 ; % 631 DNA_PECAM1_NUCLEAR + RNAP_NUCLEAR = DNA_PECAM1_RNAP_NUCLEAR
 DNA_PECAM1_NUCLEAR+RNAP_NUCLEAR = DNA_PECAM1_RNAP_NUCLEAR 
 0.07798379629722597 ; % 632 DNA_PECAM1_RNAP_NUCLEAR = DNA_PECAM1_NUCLEAR + RNAP_NUCLEAR
 DNA_PECAM1_RNAP_NUCLEAR = DNA_PECAM1_NUCLEAR+RNAP_NUCLEAR 
 0.22643374256599802 ; % 633 DNA_PECAM1_RNAP_NUCLEAR = DNA_PECAM1_NUCLEAR + RNAP_NUCLEAR + 
MRNA_PECAM1_NUCLEAR DNA_PECAM1_RNAP_NUCLEAR = DNA_PECAM1_NUCLEAR+RNAP_NUCLEAR+MRNA_PECAM1_NUCLEAR 
 0.8964840105347499 ; % 634 MRNA_PECAM1_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_PECAM1_NEXPORT_NUCLEAR MRNA_PECAM1_NUCLEAR+NEXPORT_NUCLEAR = MRNA_PECAM1_NEXPORT_NUCLEAR 
 0.03433067584415483 ; % 635 MRNA_PECAM1_NEXPORT_NUCLEAR = MRNA_PECAM1_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_PECAM1_NEXPORT_NUCLEAR = MRNA_PECAM1_NUCLEAR+NEXPORT_NUCLEAR 
 0.19175691791162586 ; % 636 MRNA_PECAM1_NEXPORT_NUCLEAR = MRNA_PECAM1_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_PECAM1_NEXPORT_NUCLEAR = MRNA_PECAM1_CYTOSOL+NEXPORT_NUCLEAR 
 0.9985788506930559 ; % 637 MRNA_PECAM1_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_PECAM1_RIBOSOME_CYTOSOL MRNA_PECAM1_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_PECAM1_RIBOSOME_CYTOSOL 
 4.2389667377137343E-4 ; % 638 MRNA_PECAM1_RIBOSOME_CYTOSOL = MRNA_PECAM1_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_PECAM1_RIBOSOME_CYTOSOL = MRNA_PECAM1_CYTOSOL+RIBOSOME_CYTOSOL 
 0.02613113753808549 ; % 639 MRNA_PECAM1_RIBOSOME_CYTOSOL = 
MRNA_PECAM1_START_RIBOSOME_CYTOSOL MRNA_PECAM1_RIBOSOME_CYTOSOL = MRNA_PECAM1_START_RIBOSOME_CYTOSOL 
 0.3132215628152324 ; % 640 MRNA_PECAM1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
PECAM1_CYTOSOL + MRNA_PECAM1_CYTOSOL MRNA_PECAM1_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+PECAM1_CYTOSOL+MRNA_PECAM1_CYTOSOL 
 0.3317653953214866 ; % 641 MRNA_PECAM1_CYTOSOL = [] MRNA_PECAM1_CYTOSOL = [] 
 0.28626257073631317 ; % 642 PECAM1_CYTOSOL = [] PECAM1_CYTOSOL = [] 
 0.3365219212523929 ; % 643 DNA_AKT_NUCLEAR + RNAP_NUCLEAR = DNA_AKT_RNAP_NUCLEAR
 DNA_AKT_NUCLEAR+RNAP_NUCLEAR = DNA_AKT_RNAP_NUCLEAR 
 0.007998689235941037 ; % 644 DNA_AKT_RNAP_NUCLEAR = DNA_AKT_NUCLEAR + RNAP_NUCLEAR
 DNA_AKT_RNAP_NUCLEAR = DNA_AKT_NUCLEAR+RNAP_NUCLEAR 
 0.9667732759570121 ; % 645 DNA_AKT_RNAP_NUCLEAR = DNA_AKT_NUCLEAR + RNAP_NUCLEAR + 
MRNA_AKT_NUCLEAR DNA_AKT_RNAP_NUCLEAR = DNA_AKT_NUCLEAR+RNAP_NUCLEAR+MRNA_AKT_NUCLEAR 
 0.544894606865856 ; % 646 MRNA_AKT_NUCLEAR + NEXPORT_NUCLEAR = MRNA_AKT_NEXPORT_NUCLEAR
 MRNA_AKT_NUCLEAR+NEXPORT_NUCLEAR = MRNA_AKT_NEXPORT_NUCLEAR 
 0.027485532884027265 ; % 647 MRNA_AKT_NEXPORT_NUCLEAR = MRNA_AKT_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_AKT_NEXPORT_NUCLEAR = MRNA_AKT_NUCLEAR+NEXPORT_NUCLEAR 
 0.16062266371714906 ; % 648 MRNA_AKT_NEXPORT_NUCLEAR = MRNA_AKT_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_AKT_NEXPORT_NUCLEAR = MRNA_AKT_CYTOSOL+NEXPORT_NUCLEAR 
 0.4156424014309258 ; % 649 MRNA_AKT_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_AKT_RIBOSOME_CYTOSOL
 MRNA_AKT_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_AKT_RIBOSOME_CYTOSOL 
 0.030883685285236186 ; % 650 MRNA_AKT_RIBOSOME_CYTOSOL = MRNA_AKT_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_AKT_RIBOSOME_CYTOSOL = MRNA_AKT_CYTOSOL+RIBOSOME_CYTOSOL 
 0.21380512568558685 ; % 651 MRNA_AKT_RIBOSOME_CYTOSOL = MRNA_AKT_START_RIBOSOME_CYTOSOL
 MRNA_AKT_RIBOSOME_CYTOSOL = MRNA_AKT_START_RIBOSOME_CYTOSOL 
 0.7228873643748891 ; % 652 MRNA_AKT_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + AKT_CYTOSOL + 
MRNA_AKT_CYTOSOL MRNA_AKT_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+AKT_CYTOSOL+MRNA_AKT_CYTOSOL 
 0.05179729595704907 ; % 653 MRNA_AKT_CYTOSOL = [] MRNA_AKT_CYTOSOL = [] 
 0.15376695582387934 ; % 654 AKT_CYTOSOL = [] AKT_CYTOSOL = [] 
 0.6636683871535423 ; % 655 DNA_PI3K_NUCLEAR + RNAP_NUCLEAR = DNA_PI3K_RNAP_NUCLEAR
 DNA_PI3K_NUCLEAR+RNAP_NUCLEAR = DNA_PI3K_RNAP_NUCLEAR 
 0.09642061807909302 ; % 656 DNA_PI3K_RNAP_NUCLEAR = DNA_PI3K_NUCLEAR + RNAP_NUCLEAR
 DNA_PI3K_RNAP_NUCLEAR = DNA_PI3K_NUCLEAR+RNAP_NUCLEAR 
 0.8713400820847678 ; % 657 DNA_PI3K_RNAP_NUCLEAR = DNA_PI3K_NUCLEAR + RNAP_NUCLEAR + 
MRNA_PI3K_NUCLEAR DNA_PI3K_RNAP_NUCLEAR = DNA_PI3K_NUCLEAR+RNAP_NUCLEAR+MRNA_PI3K_NUCLEAR 
 0.39797364821783254 ; % 658 MRNA_PI3K_NUCLEAR + NEXPORT_NUCLEAR = MRNA_PI3K_NEXPORT_NUCLEAR
 MRNA_PI3K_NUCLEAR+NEXPORT_NUCLEAR = MRNA_PI3K_NEXPORT_NUCLEAR 
 0.008154200428734538 ; % 659 MRNA_PI3K_NEXPORT_NUCLEAR = MRNA_PI3K_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_PI3K_NEXPORT_NUCLEAR = MRNA_PI3K_NUCLEAR+NEXPORT_NUCLEAR 
 0.5047940764198364 ; % 660 MRNA_PI3K_NEXPORT_NUCLEAR = MRNA_PI3K_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_PI3K_NEXPORT_NUCLEAR = MRNA_PI3K_CYTOSOL+NEXPORT_NUCLEAR 
 0.41729907209083983 ; % 661 MRNA_PI3K_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_PI3K_RIBOSOME_CYTOSOL
 MRNA_PI3K_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_PI3K_RIBOSOME_CYTOSOL 
 0.01540597827480057 ; % 662 MRNA_PI3K_RIBOSOME_CYTOSOL = MRNA_PI3K_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_PI3K_RIBOSOME_CYTOSOL = MRNA_PI3K_CYTOSOL+RIBOSOME_CYTOSOL 
 0.09706140892433335 ; % 663 MRNA_PI3K_RIBOSOME_CYTOSOL = MRNA_PI3K_START_RIBOSOME_CYTOSOL
 MRNA_PI3K_RIBOSOME_CYTOSOL = MRNA_PI3K_START_RIBOSOME_CYTOSOL 
 0.9187229860562889 ; % 664 MRNA_PI3K_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + PI3K_CYTOSOL 
+ MRNA_PI3K_CYTOSOL MRNA_PI3K_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+PI3K_CYTOSOL+MRNA_PI3K_CYTOSOL 
 0.014704045424866252 ; % 665 MRNA_PI3K_CYTOSOL = [] MRNA_PI3K_CYTOSOL = [] 
 0.0341202560542474 ; % 666 PI3K_CYTOSOL = [] PI3K_CYTOSOL = [] 
 0.2901077962112357 ; % 667 DNA_PTEN_NUCLEAR + RNAP_NUCLEAR = DNA_PTEN_RNAP_NUCLEAR
 DNA_PTEN_NUCLEAR+RNAP_NUCLEAR = DNA_PTEN_RNAP_NUCLEAR 
 0.026124027449041888 ; % 668 DNA_PTEN_RNAP_NUCLEAR = DNA_PTEN_NUCLEAR + RNAP_NUCLEAR
 DNA_PTEN_RNAP_NUCLEAR = DNA_PTEN_NUCLEAR+RNAP_NUCLEAR 
 0.32612468733598443 ; % 669 DNA_PTEN_RNAP_NUCLEAR = DNA_PTEN_NUCLEAR + RNAP_NUCLEAR + 
MRNA_PTEN_NUCLEAR DNA_PTEN_RNAP_NUCLEAR = DNA_PTEN_NUCLEAR+RNAP_NUCLEAR+MRNA_PTEN_NUCLEAR 
 0.2663101499864593 ; % 670 MRNA_PTEN_NUCLEAR + NEXPORT_NUCLEAR = MRNA_PTEN_NEXPORT_NUCLEAR
 MRNA_PTEN_NUCLEAR+NEXPORT_NUCLEAR = MRNA_PTEN_NEXPORT_NUCLEAR 
 0.057483581743710446 ; % 671 MRNA_PTEN_NEXPORT_NUCLEAR = MRNA_PTEN_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_PTEN_NEXPORT_NUCLEAR = MRNA_PTEN_NUCLEAR+NEXPORT_NUCLEAR 
 0.43990294803349783 ; % 672 MRNA_PTEN_NEXPORT_NUCLEAR = MRNA_PTEN_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_PTEN_NEXPORT_NUCLEAR = MRNA_PTEN_CYTOSOL+NEXPORT_NUCLEAR 
 0.7665484066776502 ; % 673 MRNA_PTEN_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_PTEN_RIBOSOME_CYTOSOL
 MRNA_PTEN_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_PTEN_RIBOSOME_CYTOSOL 
 0.0917421291214164 ; % 674 MRNA_PTEN_RIBOSOME_CYTOSOL = MRNA_PTEN_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_PTEN_RIBOSOME_CYTOSOL = MRNA_PTEN_CYTOSOL+RIBOSOME_CYTOSOL 
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 0.31956862174545586 ; % 675 MRNA_PTEN_RIBOSOME_CYTOSOL = MRNA_PTEN_START_RIBOSOME_CYTOSOL
 MRNA_PTEN_RIBOSOME_CYTOSOL = MRNA_PTEN_START_RIBOSOME_CYTOSOL 
 0.6726000482770923 ; % 676 MRNA_PTEN_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
PTEN_CYTOSOL + MRNA_PTEN_CYTOSOL MRNA_PTEN_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+PTEN_CYTOSOL+MRNA_PTEN_CYTOSOL 
 0.3589483582792025 ; % 677 MRNA_PTEN_CYTOSOL = [] MRNA_PTEN_CYTOSOL = [] 
 0.49748881324214 ; % 678 PTEN_CYTOSOL = [] PTEN_CYTOSOL = [] 
 0.5635529850701433 ; % 679 DNA_PDK1_NUCLEAR + RNAP_NUCLEAR = DNA_PDK1_RNAP_NUCLEAR
 DNA_PDK1_NUCLEAR+RNAP_NUCLEAR = DNA_PDK1_RNAP_NUCLEAR 
 0.007729396007185196 ; % 680 DNA_PDK1_RNAP_NUCLEAR = DNA_PDK1_NUCLEAR + RNAP_NUCLEAR
 DNA_PDK1_RNAP_NUCLEAR = DNA_PDK1_NUCLEAR+RNAP_NUCLEAR 
 0.5531447742760895 ; % 681 DNA_PDK1_RNAP_NUCLEAR = DNA_PDK1_NUCLEAR + RNAP_NUCLEAR + 
MRNA_PDK1_NUCLEAR DNA_PDK1_RNAP_NUCLEAR = DNA_PDK1_NUCLEAR+RNAP_NUCLEAR+MRNA_PDK1_NUCLEAR 
 0.42396034476102173 ; % 682 MRNA_PDK1_NUCLEAR + NEXPORT_NUCLEAR = MRNA_PDK1_NEXPORT_NUCLEAR
 MRNA_PDK1_NUCLEAR+NEXPORT_NUCLEAR = MRNA_PDK1_NEXPORT_NUCLEAR 
 0.007926199239987386 ; % 683 MRNA_PDK1_NEXPORT_NUCLEAR = MRNA_PDK1_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_PDK1_NEXPORT_NUCLEAR = MRNA_PDK1_NUCLEAR+NEXPORT_NUCLEAR 
 0.6463181079041799 ; % 684 MRNA_PDK1_NEXPORT_NUCLEAR = MRNA_PDK1_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_PDK1_NEXPORT_NUCLEAR = MRNA_PDK1_CYTOSOL+NEXPORT_NUCLEAR 
 0.5924579936657168 ; % 685 MRNA_PDK1_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_PDK1_RIBOSOME_CYTOSOL
 MRNA_PDK1_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_PDK1_RIBOSOME_CYTOSOL 
 0.09363738238502645 ; % 686 MRNA_PDK1_RIBOSOME_CYTOSOL = MRNA_PDK1_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_PDK1_RIBOSOME_CYTOSOL = MRNA_PDK1_CYTOSOL+RIBOSOME_CYTOSOL 
 0.5728786001905815 ; % 687 MRNA_PDK1_RIBOSOME_CYTOSOL = MRNA_PDK1_START_RIBOSOME_CYTOSOL
 MRNA_PDK1_RIBOSOME_CYTOSOL = MRNA_PDK1_START_RIBOSOME_CYTOSOL 
 0.4723278391329575 ; % 688 MRNA_PDK1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
PDK1_CYTOSOL + MRNA_PDK1_CYTOSOL MRNA_PDK1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+PDK1_CYTOSOL+MRNA_PDK1_CYTOSOL 
 0.3495585368586248 ; % 689 MRNA_PDK1_CYTOSOL = [] MRNA_PDK1_CYTOSOL = [] 
 0.07443972100782537 ; % 690 PDK1_CYTOSOL = [] PDK1_CYTOSOL = [] 
 0.015788089733100197 ; % 691 DNA_AKT_PASE_NUCLEAR + RNAP_NUCLEAR = DNA_AKT_PASE_RNAP_NUCLEAR
 DNA_AKT_PASE_NUCLEAR+RNAP_NUCLEAR = DNA_AKT_PASE_RNAP_NUCLEAR 
 0.01135072980644193 ; % 692 DNA_AKT_PASE_RNAP_NUCLEAR = DNA_AKT_PASE_NUCLEAR + RNAP_NUCLEAR
 DNA_AKT_PASE_RNAP_NUCLEAR = DNA_AKT_PASE_NUCLEAR+RNAP_NUCLEAR 
 0.9939551907047479 ; % 693 DNA_AKT_PASE_RNAP_NUCLEAR = DNA_AKT_PASE_NUCLEAR + RNAP_NUCLEAR + 
MRNA_AKT_PASE_NUCLEAR DNA_AKT_PASE_RNAP_NUCLEAR = DNA_AKT_PASE_NUCLEAR+RNAP_NUCLEAR+MRNA_AKT_PASE_NUCLEAR 
 0.47531877233734376 ; % 694 MRNA_AKT_PASE_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_AKT_PASE_NEXPORT_NUCLEAR MRNA_AKT_PASE_NUCLEAR+NEXPORT_NUCLEAR = MRNA_AKT_PASE_NEXPORT_NUCLEAR 
 0.09563535074466248 ; % 695 MRNA_AKT_PASE_NEXPORT_NUCLEAR = MRNA_AKT_PASE_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_AKT_PASE_NEXPORT_NUCLEAR = MRNA_AKT_PASE_NUCLEAR+NEXPORT_NUCLEAR 
 0.4123947255323268 ; % 696 MRNA_AKT_PASE_NEXPORT_NUCLEAR = MRNA_AKT_PASE_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_AKT_PASE_NEXPORT_NUCLEAR = MRNA_AKT_PASE_CYTOSOL+NEXPORT_NUCLEAR 
 0.4618973121622628 ; % 697 MRNA_AKT_PASE_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_AKT_PASE_RIBOSOME_CYTOSOL MRNA_AKT_PASE_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_AKT_PASE_RIBOSOME_CYTOSOL 
 0.0491710368600744 ; % 698 MRNA_AKT_PASE_RIBOSOME_CYTOSOL = MRNA_AKT_PASE_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_AKT_PASE_RIBOSOME_CYTOSOL = MRNA_AKT_PASE_CYTOSOL+RIBOSOME_CYTOSOL 
 0.6739427835810264 ; % 699 MRNA_AKT_PASE_RIBOSOME_CYTOSOL = 
MRNA_AKT_PASE_START_RIBOSOME_CYTOSOL MRNA_AKT_PASE_RIBOSOME_CYTOSOL = MRNA_AKT_PASE_START_RIBOSOME_CYTOSOL 
 0.9156949901762825 ; % 700 MRNA_AKT_PASE_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
AKT_PASE_CYTOSOL + MRNA_AKT_PASE_CYTOSOL MRNA_AKT_PASE_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+AKT_PASE_CYTOSOL+MRNA_AKT_PASE_CYTOSOL 
 0.09500616615701973 ; % 701 MRNA_AKT_PASE_CYTOSOL = [] MRNA_AKT_PASE_CYTOSOL = [] 
 0.14121866256792542 ; % 702 AKT_PASE_CYTOSOL = [] AKT_PASE_CYTOSOL = [] 
 0.206121934376435 ; % 703 DNA_IKB_NUCLEAR + RNAP_NUCLEAR = DNA_IKB_RNAP_NUCLEAR
 DNA_IKB_NUCLEAR+RNAP_NUCLEAR = DNA_IKB_RNAP_NUCLEAR 
 0.02817067983041819 ; % 704 DNA_IKB_RNAP_NUCLEAR = DNA_IKB_NUCLEAR + RNAP_NUCLEAR
 DNA_IKB_RNAP_NUCLEAR = DNA_IKB_NUCLEAR+RNAP_NUCLEAR 
 0.598558375069083 ; % 705 DNA_IKB_RNAP_NUCLEAR = DNA_IKB_NUCLEAR + RNAP_NUCLEAR + 
MRNA_IKB_NUCLEAR DNA_IKB_RNAP_NUCLEAR = DNA_IKB_NUCLEAR+RNAP_NUCLEAR+MRNA_IKB_NUCLEAR 
 0.11372525676219403 ; % 706 MRNA_IKB_NUCLEAR + NEXPORT_NUCLEAR = MRNA_IKB_NEXPORT_NUCLEAR
 MRNA_IKB_NUCLEAR+NEXPORT_NUCLEAR = MRNA_IKB_NEXPORT_NUCLEAR 
 0.060512398992232735 ; % 707 MRNA_IKB_NEXPORT_NUCLEAR = MRNA_IKB_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_IKB_NEXPORT_NUCLEAR = MRNA_IKB_NUCLEAR+NEXPORT_NUCLEAR 
 0.7074996608299391 ; % 708 MRNA_IKB_NEXPORT_NUCLEAR = MRNA_IKB_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_IKB_NEXPORT_NUCLEAR = MRNA_IKB_CYTOSOL+NEXPORT_NUCLEAR 
 0.30482266581803674 ; % 709 MRNA_IKB_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_IKB_RIBOSOME_CYTOSOL
 MRNA_IKB_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_IKB_RIBOSOME_CYTOSOL 
 0.05041435505269384 ; % 710 MRNA_IKB_RIBOSOME_CYTOSOL = MRNA_IKB_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_IKB_RIBOSOME_CYTOSOL = MRNA_IKB_CYTOSOL+RIBOSOME_CYTOSOL 
 0.26114855742019316 ; % 711 MRNA_IKB_RIBOSOME_CYTOSOL = MRNA_IKB_START_RIBOSOME_CYTOSOL
 MRNA_IKB_RIBOSOME_CYTOSOL = MRNA_IKB_START_RIBOSOME_CYTOSOL 
 0.4597330484516561 ; % 712 MRNA_IKB_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + IKB_CYTOSOL + 
MRNA_IKB_CYTOSOL MRNA_IKB_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+IKB_CYTOSOL+MRNA_IKB_CYTOSOL 
 0.09706347309916408 ; % 713 MRNA_IKB_CYTOSOL = [] MRNA_IKB_CYTOSOL = [] 
 0.19587262887170026 ; % 714 IKB_CYTOSOL = [] IKB_CYTOSOL = [] 
 0.7677422719871354 ; % 715 DNA_NFKB_NUCLEAR + RNAP_NUCLEAR = DNA_NFKB_RNAP_NUCLEAR
 DNA_NFKB_NUCLEAR+RNAP_NUCLEAR = DNA_NFKB_RNAP_NUCLEAR 
 0.00510189387106974 ; % 716 DNA_NFKB_RNAP_NUCLEAR = DNA_NFKB_NUCLEAR + RNAP_NUCLEAR
 DNA_NFKB_RNAP_NUCLEAR = DNA_NFKB_NUCLEAR+RNAP_NUCLEAR 
 0.8631903428434667 ; % 717 DNA_NFKB_RNAP_NUCLEAR = DNA_NFKB_NUCLEAR + RNAP_NUCLEAR + 
MRNA_NFKB_NUCLEAR DNA_NFKB_RNAP_NUCLEAR = DNA_NFKB_NUCLEAR+RNAP_NUCLEAR+MRNA_NFKB_NUCLEAR 
 0.63359410444367 ; % 718 MRNA_NFKB_NUCLEAR + NEXPORT_NUCLEAR = MRNA_NFKB_NEXPORT_NUCLEAR
 MRNA_NFKB_NUCLEAR+NEXPORT_NUCLEAR = MRNA_NFKB_NEXPORT_NUCLEAR 
 0.05984556108274203 ; % 719 MRNA_NFKB_NEXPORT_NUCLEAR = MRNA_NFKB_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_NFKB_NEXPORT_NUCLEAR = MRNA_NFKB_NUCLEAR+NEXPORT_NUCLEAR 
 0.4679857831862664 ; % 720 MRNA_NFKB_NEXPORT_NUCLEAR = MRNA_NFKB_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_NFKB_NEXPORT_NUCLEAR = MRNA_NFKB_CYTOSOL+NEXPORT_NUCLEAR 
 0.8481116369277054 ; % 721 MRNA_NFKB_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_NFKB_RIBOSOME_CYTOSOL
 MRNA_NFKB_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_NFKB_RIBOSOME_CYTOSOL 
 0.05158092957350179 ; % 722 MRNA_NFKB_RIBOSOME_CYTOSOL = MRNA_NFKB_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_NFKB_RIBOSOME_CYTOSOL = MRNA_NFKB_CYTOSOL+RIBOSOME_CYTOSOL 
 0.8141671432833532 ; % 723 MRNA_NFKB_RIBOSOME_CYTOSOL = MRNA_NFKB_START_RIBOSOME_CYTOSOL
 MRNA_NFKB_RIBOSOME_CYTOSOL = MRNA_NFKB_START_RIBOSOME_CYTOSOL 
 0.12771024200127867 ; % 724 MRNA_NFKB_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
NFKB_CYTOSOL + MRNA_NFKB_CYTOSOL MRNA_NFKB_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+NFKB_CYTOSOL+MRNA_NFKB_CYTOSOL 
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 0.4762764848661685 ; % 725 MRNA_NFKB_CYTOSOL = [] MRNA_NFKB_CYTOSOL = [] 
 0.15044625924287008 ; % 726 NFKB_CYTOSOL = [] NFKB_CYTOSOL = [] 
 0.1269111562699613 ; % 727 DNA_VEGFR2_NUCLEAR + RNAP_NUCLEAR = DNA_VEGFR2_RNAP_NUCLEAR
 DNA_VEGFR2_NUCLEAR+RNAP_NUCLEAR = DNA_VEGFR2_RNAP_NUCLEAR 
 0.09159408492880033 ; % 728 DNA_VEGFR2_RNAP_NUCLEAR = DNA_VEGFR2_NUCLEAR + RNAP_NUCLEAR
 DNA_VEGFR2_RNAP_NUCLEAR = DNA_VEGFR2_NUCLEAR+RNAP_NUCLEAR 
 0.5512778757504175 ; % 729 DNA_VEGFR2_RNAP_NUCLEAR = DNA_VEGFR2_NUCLEAR + RNAP_NUCLEAR + 
MRNA_VEGFR2_NUCLEAR DNA_VEGFR2_RNAP_NUCLEAR = DNA_VEGFR2_NUCLEAR+RNAP_NUCLEAR+MRNA_VEGFR2_NUCLEAR 
 0.09398369291933706 ; % 730 MRNA_VEGFR2_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_VEGFR2_NEXPORT_NUCLEAR MRNA_VEGFR2_NUCLEAR+NEXPORT_NUCLEAR = MRNA_VEGFR2_NEXPORT_NUCLEAR 
 0.09087402816206167 ; % 731 MRNA_VEGFR2_NEXPORT_NUCLEAR = MRNA_VEGFR2_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_VEGFR2_NEXPORT_NUCLEAR = MRNA_VEGFR2_NUCLEAR+NEXPORT_NUCLEAR 
 0.7435454002104683 ; % 732 MRNA_VEGFR2_NEXPORT_NUCLEAR = MRNA_VEGFR2_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_VEGFR2_NEXPORT_NUCLEAR = MRNA_VEGFR2_CYTOSOL+NEXPORT_NUCLEAR 
 0.9600163857745057 ; % 733 MRNA_VEGFR2_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_VEGFR2_RIBOSOME_CYTOSOL MRNA_VEGFR2_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_VEGFR2_RIBOSOME_CYTOSOL 
 0.047082479243831334 ; % 734 MRNA_VEGFR2_RIBOSOME_CYTOSOL = MRNA_VEGFR2_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_VEGFR2_RIBOSOME_CYTOSOL = MRNA_VEGFR2_CYTOSOL+RIBOSOME_CYTOSOL 
 0.15309996252186853 ; % 735 MRNA_VEGFR2_RIBOSOME_CYTOSOL = 
MRNA_VEGFR2_START_RIBOSOME_CYTOSOL MRNA_VEGFR2_RIBOSOME_CYTOSOL = MRNA_VEGFR2_START_RIBOSOME_CYTOSOL 
 0.5468719432161087 ; % 736 MRNA_VEGFR2_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
VEGFR2_CYTOSOL + MRNA_VEGFR2_CYTOSOL MRNA_VEGFR2_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+VEGFR2_CYTOSOL+MRNA_VEGFR2_CYTOSOL 
 0.41735022100299374 ; % 737 MRNA_VEGFR2_CYTOSOL = [] MRNA_VEGFR2_CYTOSOL = [] 
 0.1887972211652128 ; % 738 VEGFR2_CYTOSOL = [] VEGFR2_CYTOSOL = [] 
 0.0     ; % 739 DNA_SNAIL_NUCLEAR + RNAP_NUCLEAR = 
DNA_SNAIL_RNAP_NUCLEAR DNA_SNAIL_NUCLEAR+RNAP_NUCLEAR = DNA_SNAIL_RNAP_NUCLEAR 
 0.05532204643858868 ; % 740 DNA_SNAIL_RNAP_NUCLEAR = DNA_SNAIL_NUCLEAR + RNAP_NUCLEAR
 DNA_SNAIL_RNAP_NUCLEAR = DNA_SNAIL_NUCLEAR+RNAP_NUCLEAR 
 0.09143303200805941 ; % 741 DNA_SNAIL_RNAP_NUCLEAR = DNA_SNAIL_NUCLEAR + RNAP_NUCLEAR + 
MRNA_SNAIL_NUCLEAR DNA_SNAIL_RNAP_NUCLEAR = DNA_SNAIL_NUCLEAR+RNAP_NUCLEAR+MRNA_SNAIL_NUCLEAR 
 0.7864082337915235 ; % 742 MRNA_SNAIL_NUCLEAR + NEXPORT_NUCLEAR = MRNA_SNAIL_NEXPORT_NUCLEAR
 MRNA_SNAIL_NUCLEAR+NEXPORT_NUCLEAR = MRNA_SNAIL_NEXPORT_NUCLEAR 
 0.0938808180071812 ; % 743 MRNA_SNAIL_NEXPORT_NUCLEAR = MRNA_SNAIL_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_SNAIL_NEXPORT_NUCLEAR = MRNA_SNAIL_NUCLEAR+NEXPORT_NUCLEAR 
 0.9343811227617576 ; % 744 MRNA_SNAIL_NEXPORT_NUCLEAR = MRNA_SNAIL_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_SNAIL_NEXPORT_NUCLEAR = MRNA_SNAIL_CYTOSOL+NEXPORT_NUCLEAR 
 0.023125202169479442 ; % 745 MRNA_SNAIL_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_SNAIL_RIBOSOME_CYTOSOL MRNA_SNAIL_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_SNAIL_RIBOSOME_CYTOSOL 
 0.04701628360928337 ; % 746 MRNA_SNAIL_RIBOSOME_CYTOSOL = MRNA_SNAIL_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_SNAIL_RIBOSOME_CYTOSOL = MRNA_SNAIL_CYTOSOL+RIBOSOME_CYTOSOL 
 0.491356065745466 ; % 747 MRNA_SNAIL_RIBOSOME_CYTOSOL = MRNA_SNAIL_START_RIBOSOME_CYTOSOL
 MRNA_SNAIL_RIBOSOME_CYTOSOL = MRNA_SNAIL_START_RIBOSOME_CYTOSOL 
 0.6792018388881008 ; % 748 MRNA_SNAIL_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
SNAIL_CYTOSOL + MRNA_SNAIL_CYTOSOL MRNA_SNAIL_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+SNAIL_CYTOSOL+MRNA_SNAIL_CYTOSOL 
 0.06477737776019549 ; % 749 MRNA_SNAIL_CYTOSOL = [] MRNA_SNAIL_CYTOSOL = [] 
 0.023267268404074948 ; % 750 SNAIL_CYTOSOL = [] SNAIL_CYTOSOL = [] 
 0.0     ; % 751 DNA_SLUG_NUCLEAR + RNAP_NUCLEAR = 
DNA_SLUG_RNAP_NUCLEAR DNA_SLUG_NUCLEAR+RNAP_NUCLEAR = DNA_SLUG_RNAP_NUCLEAR 
 0.06304061486430344 ; % 752 DNA_SLUG_RNAP_NUCLEAR = DNA_SLUG_NUCLEAR + RNAP_NUCLEAR
 DNA_SLUG_RNAP_NUCLEAR = DNA_SLUG_NUCLEAR+RNAP_NUCLEAR 
 0.6746711786167137 ; % 753 DNA_SLUG_RNAP_NUCLEAR = DNA_SLUG_NUCLEAR + RNAP_NUCLEAR + 
MRNA_SLUG_NUCLEAR DNA_SLUG_RNAP_NUCLEAR = DNA_SLUG_NUCLEAR+RNAP_NUCLEAR+MRNA_SLUG_NUCLEAR 
 0.13332611400128025 ; % 754 MRNA_SLUG_NUCLEAR + NEXPORT_NUCLEAR = MRNA_SLUG_NEXPORT_NUCLEAR
 MRNA_SLUG_NUCLEAR+NEXPORT_NUCLEAR = MRNA_SLUG_NEXPORT_NUCLEAR 
 0.030562300003852228 ; % 755 MRNA_SLUG_NEXPORT_NUCLEAR = MRNA_SLUG_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_SLUG_NEXPORT_NUCLEAR = MRNA_SLUG_NUCLEAR+NEXPORT_NUCLEAR 
 0.15139031866343033 ; % 756 MRNA_SLUG_NEXPORT_NUCLEAR = MRNA_SLUG_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_SLUG_NEXPORT_NUCLEAR = MRNA_SLUG_CYTOSOL+NEXPORT_NUCLEAR 
 0.1382918366813053 ; % 757 MRNA_SLUG_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_SLUG_RIBOSOME_CYTOSOL MRNA_SLUG_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_SLUG_RIBOSOME_CYTOSOL 
 0.0055988157016919286 ; % 758 MRNA_SLUG_RIBOSOME_CYTOSOL = MRNA_SLUG_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_SLUG_RIBOSOME_CYTOSOL = MRNA_SLUG_CYTOSOL+RIBOSOME_CYTOSOL 
 0.5043881564228239 ; % 759 MRNA_SLUG_RIBOSOME_CYTOSOL = MRNA_SLUG_START_RIBOSOME_CYTOSOL
 MRNA_SLUG_RIBOSOME_CYTOSOL = MRNA_SLUG_START_RIBOSOME_CYTOSOL 
 0.815486122632909 ; % 760 MRNA_SLUG_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
SLUG_CYTOSOL + MRNA_SLUG_CYTOSOL MRNA_SLUG_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+SLUG_CYTOSOL+MRNA_SLUG_CYTOSOL 
 0.2694520497047603 ; % 761 MRNA_SLUG_CYTOSOL = [] MRNA_SLUG_CYTOSOL = [] 
 0.02651208018954665 ; % 762 SLUG_CYTOSOL = [] SLUG_CYTOSOL = [] 
 0.9864814129830222 ; % 763 DNA_YREG1_NUCLEAR + RNAP_NUCLEAR = DNA_YREG1_RNAP_NUCLEAR
 DNA_YREG1_NUCLEAR+RNAP_NUCLEAR = DNA_YREG1_RNAP_NUCLEAR 
 0.08431837554107385 ; % 764 DNA_YREG1_RNAP_NUCLEAR = DNA_YREG1_NUCLEAR + RNAP_NUCLEAR
 DNA_YREG1_RNAP_NUCLEAR = DNA_YREG1_NUCLEAR+RNAP_NUCLEAR 
 0.1701091065927868 ; % 765 DNA_YREG1_RNAP_NUCLEAR = DNA_YREG1_NUCLEAR + RNAP_NUCLEAR + 
MRNA_YREG1_NUCLEAR DNA_YREG1_RNAP_NUCLEAR = DNA_YREG1_NUCLEAR+RNAP_NUCLEAR+MRNA_YREG1_NUCLEAR 
 0.33612163678062446 ; % 766 MRNA_YREG1_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_YREG1_NEXPORT_NUCLEAR MRNA_YREG1_NUCLEAR+NEXPORT_NUCLEAR = MRNA_YREG1_NEXPORT_NUCLEAR 
 0.002441830205072793 ; % 767 MRNA_YREG1_NEXPORT_NUCLEAR = MRNA_YREG1_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_YREG1_NEXPORT_NUCLEAR = MRNA_YREG1_NUCLEAR+NEXPORT_NUCLEAR 
 0.7520668329315655 ; % 768 MRNA_YREG1_NEXPORT_NUCLEAR = MRNA_YREG1_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_YREG1_NEXPORT_NUCLEAR = MRNA_YREG1_CYTOSOL+NEXPORT_NUCLEAR 
 0.615312849591274 ; % 769 MRNA_YREG1_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_YREG1_RIBOSOME_CYTOSOL MRNA_YREG1_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_YREG1_RIBOSOME_CYTOSOL 
 0.06792336385063377 ; % 770 MRNA_YREG1_RIBOSOME_CYTOSOL = MRNA_YREG1_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_YREG1_RIBOSOME_CYTOSOL = MRNA_YREG1_CYTOSOL+RIBOSOME_CYTOSOL 
 0.7328603303654573 ; % 771 MRNA_YREG1_RIBOSOME_CYTOSOL = MRNA_YREG1_START_RIBOSOME_CYTOSOL
 MRNA_YREG1_RIBOSOME_CYTOSOL = MRNA_YREG1_START_RIBOSOME_CYTOSOL 
 0.8297200781405897 ; % 772 MRNA_YREG1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
YREG1_CYTOSOL + MRNA_YREG1_CYTOSOL MRNA_YREG1_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+YREG1_CYTOSOL+MRNA_YREG1_CYTOSOL 
 0.24179522894951005 ; % 773 MRNA_YREG1_CYTOSOL = [] MRNA_YREG1_CYTOSOL = [] 
 0.21723442793006137 ; % 774 YREG1_CYTOSOL = [] YREG1_CYTOSOL = [] 
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 0.8530502567415338 ; % 775 DNA_LOADING_NUCLEAR + RNAP_NUCLEAR = DNA_LOADING_RNAP_NUCLEAR
 DNA_LOADING_NUCLEAR+RNAP_NUCLEAR = DNA_LOADING_RNAP_NUCLEAR 
 0.05916266996790825 ; % 776 DNA_LOADING_RNAP_NUCLEAR = DNA_LOADING_NUCLEAR + RNAP_NUCLEAR
 DNA_LOADING_RNAP_NUCLEAR = DNA_LOADING_NUCLEAR+RNAP_NUCLEAR 
 0.54422008429545918 ; % 777 DNA_LOADING_RNAP_NUCLEAR = DNA_LOADING_NUCLEAR + RNAP_NUCLEAR + 
MRNA_LOADING_NUCLEAR DNA_LOADING_RNAP_NUCLEAR = DNA_LOADING_NUCLEAR+RNAP_NUCLEAR+MRNA_LOADING_NUCLEAR 
 0.0025305384013382115 ; % 778 MRNA_LOADING_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_LOADING_NEXPORT_NUCLEAR MRNA_LOADING_NUCLEAR+NEXPORT_NUCLEAR = MRNA_LOADING_NEXPORT_NUCLEAR 
 0.0909894921043891 ; % 779 MRNA_LOADING_NEXPORT_NUCLEAR = MRNA_LOADING_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_LOADING_NEXPORT_NUCLEAR = MRNA_LOADING_NUCLEAR+NEXPORT_NUCLEAR 
 0.34408180130399924 ; % 780 MRNA_LOADING_NEXPORT_NUCLEAR = MRNA_LOADING_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_LOADING_NEXPORT_NUCLEAR = MRNA_LOADING_CYTOSOL+NEXPORT_NUCLEAR 
 0.8282032197383241 ; % 781 MRNA_LOADING_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_LOADING_RIBOSOME_CYTOSOL MRNA_LOADING_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_LOADING_RIBOSOME_CYTOSOL 
 0.08215773932368264 ; % 782 MRNA_LOADING_RIBOSOME_CYTOSOL = MRNA_LOADING_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_LOADING_RIBOSOME_CYTOSOL = MRNA_LOADING_CYTOSOL+RIBOSOME_CYTOSOL 
 0.9640156814374676 ; % 783 MRNA_LOADING_RIBOSOME_CYTOSOL = 
MRNA_LOADING_START_RIBOSOME_CYTOSOL MRNA_LOADING_RIBOSOME_CYTOSOL = MRNA_LOADING_START_RIBOSOME_CYTOSOL 
 0.3364049175843329 ; % 784 MRNA_LOADING_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
LOADING_CYTOSOL + MRNA_LOADING_CYTOSOL MRNA_LOADING_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+LOADING_CYTOSOL+MRNA_LOADING_CYTOSOL 
 0.23060790146383713 ; % 785 MRNA_LOADING_CYTOSOL = [] MRNA_LOADING_CYTOSOL = [] 
 0.244038144616249064 ; % 786 LOADING_CYTOSOL = [] LOADING_CYTOSOL = [] 
 0.6312828213643952 ; % 787 MRNA_TBX20_NUCLEAR + NEXPORT_NUCLEAR = MRNA_TBX20_NEXPORT_NUCLEAR
 MRNA_TBX20_NUCLEAR+NEXPORT_NUCLEAR = MRNA_TBX20_NEXPORT_NUCLEAR 
 0.07572429636781931 ; % 788 MRNA_TBX20_NEXPORT_NUCLEAR = MRNA_TBX20_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_TBX20_NEXPORT_NUCLEAR = MRNA_TBX20_NUCLEAR+NEXPORT_NUCLEAR 
 0.0032933796056262565 ; % 789 MRNA_TBX20_NEXPORT_NUCLEAR = MRNA_TBX20_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_TBX20_NEXPORT_NUCLEAR = MRNA_TBX20_CYTOSOL+NEXPORT_NUCLEAR 
 0.6133415925129372 ; % 790 MRNA_TBX20_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_TBX20_RIBOSOME_CYTOSOL MRNA_TBX20_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_TBX20_RIBOSOME_CYTOSOL 
 0.06487945362981005 ; % 791 MRNA_TBX20_RIBOSOME_CYTOSOL = MRNA_TBX20_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_TBX20_RIBOSOME_CYTOSOL = MRNA_TBX20_CYTOSOL+RIBOSOME_CYTOSOL 
 0.006512874830618354 ; % 792 MRNA_TBX20_RIBOSOME_CYTOSOL = MRNA_TBX20_START_RIBOSOME_CYTOSOL
 MRNA_TBX20_RIBOSOME_CYTOSOL = MRNA_TBX20_START_RIBOSOME_CYTOSOL 
 0.10374090053065299 ; % 793 MRNA_TBX20_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
TBX20_CYTOSOL + MRNA_TBX20_CYTOSOL MRNA_TBX20_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+TBX20_CYTOSOL+MRNA_TBX20_CYTOSOL 
 0.3895571865105913 ; % 794 MRNA_TBX20_CYTOSOL = [] MRNA_TBX20_CYTOSOL = [] 
 0.014478797279110056 ; % 795 TBX20_CYTOSOL = [] TBX20_CYTOSOL = [] 
 0.25754033899176065 ; % 796 DNA_TBX20_NUCLEAR + TWIST_NUCLEAR = DNA_TBX20_TWIST_NUCLEAR
 DNA_TBX20_NUCLEAR+TWIST_NUCLEAR = DNA_TBX20_TWIST_NUCLEAR 
 0.014834299624726566 ; % 797 DNA_TBX20_TWIST_NUCLEAR = DNA_TBX20_NUCLEAR + TWIST_NUCLEAR
 DNA_TBX20_TWIST_NUCLEAR = DNA_TBX20_NUCLEAR+TWIST_NUCLEAR 
 0.6071171669747513 ; % 798 DNA_TBX20_TWIST_NUCLEAR + RNAP_NUCLEAR = 
DNA_TBX20_TWIST_RNAP_NUCLEAR DNA_TBX20_TWIST_NUCLEAR+RNAP_NUCLEAR = DNA_TBX20_TWIST_RNAP_NUCLEAR 
 0.07622710159964612 ; % 799 DNA_TBX20_TWIST_RNAP_NUCLEAR = DNA_TBX20_TWIST_NUCLEAR + 
RNAP_NUCLEAR DNA_TBX20_TWIST_RNAP_NUCLEAR = DNA_TBX20_TWIST_NUCLEAR+RNAP_NUCLEAR 
 0.31321006525429296 ; % 800 TWIST_CYTOSOL + NIMPORT_NUCLEAR = TWIST_NIMPORT_NUCLEAR
 TWIST_CYTOSOL+NIMPORT_NUCLEAR = TWIST_NIMPORT_NUCLEAR 
 0.058206518467817915 ; % 801 TWIST_NIMPORT_NUCLEAR = TWIST_CYTOSOL + NIMPORT_NUCLEAR
 TWIST_NIMPORT_NUCLEAR = TWIST_CYTOSOL+NIMPORT_NUCLEAR 
 0.03684031299606638 ; % 802 TWIST_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR + TWIST_NUCLEAR
 TWIST_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR+TWIST_NUCLEAR 
 0.1046101355936444 ; % 803 TWIST_NUCLEAR + NEXPORT_NUCLEAR = TWIST_NEXPORT_NUCLEAR
 TWIST_NUCLEAR+NEXPORT_NUCLEAR = TWIST_NEXPORT_NUCLEAR 
 0.015544936228771823 ; % 804 TWIST_NEXPORT_NUCLEAR = TWIST_NUCLEAR + NEXPORT_NUCLEAR
 TWIST_NEXPORT_NUCLEAR = TWIST_NUCLEAR+NEXPORT_NUCLEAR 
 0.8715211365340421 ; % 805 TWIST_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR + TWIST_CYTOSOL
 TWIST_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR+TWIST_CYTOSOL 
 0.36989895899002656 ; % 806 DNA_TBX20_TWIST_RNAP_NUCLEAR = DNA_TBX20_NUCLEAR + TWIST_NUCLEAR + 
RNAP_NUCLEAR + MRNA_TBX20_NUCLEAR DNA_TBX20_TWIST_RNAP_NUCLEAR = 
DNA_TBX20_NUCLEAR+TWIST_NUCLEAR+RNAP_NUCLEAR+MRNA_TBX20_NUCLEAR 
 0.7162533996226281 ; % 807 DNA_PTEN_NUCLEAR + ACTIVE_NCID_CSL_NUCLEAR = 
DNA_PTEN_ACTIVE_NCID_CSL_NUCLEAR DNA_PTEN_NUCLEAR+ACTIVE_NCID_CSL_NUCLEAR = DNA_PTEN_ACTIVE_NCID_CSL_NUCLEAR 
 0.03891258486283762 ; % 808 DNA_PTEN_ACTIVE_NCID_CSL_NUCLEAR = DNA_PTEN_NUCLEAR + 
ACTIVE_NCID_CSL_NUCLEAR DNA_PTEN_ACTIVE_NCID_CSL_NUCLEAR = DNA_PTEN_NUCLEAR+ACTIVE_NCID_CSL_NUCLEAR 
 0.9296691298250067 ; % 809 DNA_PTEN_ACTIVE_NCID_CSL_NUCLEAR + RNAP_NUCLEAR = 
DNA_PTEN_ACTIVE_NCID_CSL_RNAP_NUCLEAR DNA_PTEN_ACTIVE_NCID_CSL_NUCLEAR+RNAP_NUCLEAR = DNA_PTEN_ACTIVE_NCID_CSL_RNAP_NUCLEAR 
 0.0023957344136982806 ; % 810 DNA_PTEN_ACTIVE_NCID_CSL_RNAP_NUCLEAR = 
DNA_PTEN_ACTIVE_NCID_CSL_NUCLEAR + RNAP_NUCLEAR DNA_PTEN_ACTIVE_NCID_CSL_RNAP_NUCLEAR = 
DNA_PTEN_ACTIVE_NCID_CSL_NUCLEAR+RNAP_NUCLEAR 
 0.30758961054213585 ; % 811 DNA_PTEN_ACTIVE_NCID_CSL_RNAP_NUCLEAR = DNA_PTEN_NUCLEAR + 
ACTIVE_NCID_CSL_NUCLEAR + RNAP_NUCLEAR + MRNA_PTEN_NUCLEAR DNA_PTEN_ACTIVE_NCID_CSL_RNAP_NUCLEAR = 
DNA_PTEN_NUCLEAR+ACTIVE_NCID_CSL_NUCLEAR+RNAP_NUCLEAR+MRNA_PTEN_NUCLEAR 
 0.989447052591121 ; % 812 ACTIVE_NCID_CYTOSOL + CSL_CYTOSOL = ACTIVE_NCID_CSL_CYTOSOL
 ACTIVE_NCID_CYTOSOL+CSL_CYTOSOL = ACTIVE_NCID_CSL_CYTOSOL 
 0.03735595388732662 ; % 813 ACTIVE_NCID_CSL_CYTOSOL = ACTIVE_NCID_CYTOSOL + CSL_CYTOSOL
 ACTIVE_NCID_CSL_CYTOSOL = ACTIVE_NCID_CYTOSOL+CSL_CYTOSOL 
 0.36684278668228576 ; % 814 ACTIVE_NCID_CSL_CYTOSOL + NIMPORT_NUCLEAR = 
ACTIVE_NCID_CSL_NIMPORT_NUCLEAR ACTIVE_NCID_CSL_CYTOSOL+NIMPORT_NUCLEAR = ACTIVE_NCID_CSL_NIMPORT_NUCLEAR 
 0.09903888249717843 ; % 815 ACTIVE_NCID_CSL_NIMPORT_NUCLEAR = ACTIVE_NCID_CSL_CYTOSOL + 
NIMPORT_NUCLEAR ACTIVE_NCID_CSL_NIMPORT_NUCLEAR = ACTIVE_NCID_CSL_CYTOSOL+NIMPORT_NUCLEAR 
 0.3762082536956671 ; % 816 ACTIVE_NCID_CSL_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR + 
ACTIVE_NCID_CSL_NUCLEAR ACTIVE_NCID_CSL_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR+ACTIVE_NCID_CSL_NUCLEAR 
 0.8320822340862823 ; % 817 ACTIVE_NCID_CSL_NUCLEAR + NEXPORT_NUCLEAR = 
ACTIVE_NCID_CSL_NEXPORT_NUCLEAR ACTIVE_NCID_CSL_NUCLEAR+NEXPORT_NUCLEAR = ACTIVE_NCID_CSL_NEXPORT_NUCLEAR 
 0.08011679501047485 ; % 818 ACTIVE_NCID_CSL_NEXPORT_NUCLEAR = ACTIVE_NCID_CSL_NUCLEAR + 
NEXPORT_NUCLEAR ACTIVE_NCID_CSL_NEXPORT_NUCLEAR = ACTIVE_NCID_CSL_NUCLEAR+NEXPORT_NUCLEAR 
 0.23371498680193037 ; % 819 ACTIVE_NCID_CSL_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR + 
ACTIVE_NCID_CSL_CYTOSOL ACTIVE_NCID_CSL_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR+ACTIVE_NCID_CSL_CYTOSOL 
 0.8587420257024541 ; % 820 MRNA_ALPHASMA_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_ALPHASMA_NEXPORT_NUCLEAR MRNA_ALPHASMA_NUCLEAR+NEXPORT_NUCLEAR = MRNA_ALPHASMA_NEXPORT_NUCLEAR 
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 0.017398412003889197 ; % 821 MRNA_ALPHASMA_NEXPORT_NUCLEAR = MRNA_ALPHASMA_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_ALPHASMA_NEXPORT_NUCLEAR = MRNA_ALPHASMA_NUCLEAR+NEXPORT_NUCLEAR 
 0.3684129105966647 ; % 822 MRNA_ALPHASMA_NEXPORT_NUCLEAR = MRNA_ALPHASMA_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_ALPHASMA_NEXPORT_NUCLEAR = MRNA_ALPHASMA_CYTOSOL+NEXPORT_NUCLEAR 
 0.18000435834687356 ; % 823 MRNA_ALPHASMA_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_ALPHASMA_RIBOSOME_CYTOSOL MRNA_ALPHASMA_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_ALPHASMA_RIBOSOME_CYTOSOL 
 0.092218106702465 ; % 824 MRNA_ALPHASMA_RIBOSOME_CYTOSOL = MRNA_ALPHASMA_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_ALPHASMA_RIBOSOME_CYTOSOL = MRNA_ALPHASMA_CYTOSOL+RIBOSOME_CYTOSOL 
 0.8359966402801728 ; % 825 MRNA_ALPHASMA_RIBOSOME_CYTOSOL = 
MRNA_ALPHASMA_START_RIBOSOME_CYTOSOL MRNA_ALPHASMA_RIBOSOME_CYTOSOL = MRNA_ALPHASMA_START_RIBOSOME_CYTOSOL 
 0.14630104884385053 ; % 826 MRNA_ALPHASMA_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
ALPHASMA_CYTOSOL + MRNA_ALPHASMA_CYTOSOL MRNA_ALPHASMA_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+ALPHASMA_CYTOSOL+MRNA_ALPHASMA_CYTOSOL 
 0.044764211431845835 ; % 827 MRNA_ALPHASMA_CYTOSOL = [] MRNA_ALPHASMA_CYTOSOL = [] 
 0.3293269500175904 ; % 828 ALPHASMA_CYTOSOL = [] ALPHASMA_CYTOSOL = [] 
 0.3967337738496455 ; % 829 DNA_ALPHASMA_NUCLEAR + BCATENIN_LEF1_NUCLEAR = 
DNA_ALPHASMA_BCATENIN_LEF1_NUCLEAR DNA_ALPHASMA_NUCLEAR+BCATENIN_LEF1_NUCLEAR = DNA_ALPHASMA_BCATENIN_LEF1_NUCLEAR 
 0.062443613525656076 ; % 830 DNA_ALPHASMA_BCATENIN_LEF1_NUCLEAR = DNA_ALPHASMA_NUCLEAR + 
BCATENIN_LEF1_NUCLEAR DNA_ALPHASMA_BCATENIN_LEF1_NUCLEAR = DNA_ALPHASMA_NUCLEAR+BCATENIN_LEF1_NUCLEAR 
 0.8504056453243294 ; % 831 DNA_ALPHASMA_BCATENIN_LEF1_NUCLEAR + RNAP_NUCLEAR = 
DNA_ALPHASMA_BCATENIN_LEF1_RNAP_NUCLEAR DNA_ALPHASMA_BCATENIN_LEF1_NUCLEAR+RNAP_NUCLEAR = 
DNA_ALPHASMA_BCATENIN_LEF1_RNAP_NUCLEAR 
 0.08862904991902518 ; % 832 DNA_ALPHASMA_BCATENIN_LEF1_RNAP_NUCLEAR = 
DNA_ALPHASMA_BCATENIN_LEF1_NUCLEAR + RNAP_NUCLEAR DNA_ALPHASMA_BCATENIN_LEF1_RNAP_NUCLEAR = 
DNA_ALPHASMA_BCATENIN_LEF1_NUCLEAR+RNAP_NUCLEAR 
 0.1640912016293663 ; % 833 DNA_ALPHASMA_BCATENIN_LEF1_RNAP_NUCLEAR = DNA_ALPHASMA_NUCLEAR + 
BCATENIN_LEF1_NUCLEAR + RNAP_NUCLEAR + MRNA_ALPHASMA_NUCLEAR DNA_ALPHASMA_BCATENIN_LEF1_RNAP_NUCLEAR = 
DNA_ALPHASMA_NUCLEAR+BCATENIN_LEF1_NUCLEAR+RNAP_NUCLEAR+MRNA_ALPHASMA_NUCLEAR 
 0.60549994501548854 ; % 834 BCATENIN_CYTOSOL + LEF1_CYTOSOL = BCATENIN_LEF1_CYTOSOL
 BCATENIN_CYTOSOL+LEF1_CYTOSOL = BCATENIN_LEF1_CYTOSOL 
 0.001165218645340047 ; % 835 BCATENIN_LEF1_CYTOSOL = BCATENIN_CYTOSOL + LEF1_CYTOSOL
 BCATENIN_LEF1_CYTOSOL = BCATENIN_CYTOSOL+LEF1_CYTOSOL 
 0.4442267360641858 ; % 836 BCATENIN_LEF1_CYTOSOL + NIMPORT_NUCLEAR = 
BCATENIN_LEF1_NIMPORT_NUCLEAR BCATENIN_LEF1_CYTOSOL+NIMPORT_NUCLEAR = BCATENIN_LEF1_NIMPORT_NUCLEAR 
 0.008221976456294572 ; % 837 BCATENIN_LEF1_NIMPORT_NUCLEAR = BCATENIN_LEF1_CYTOSOL + 
NIMPORT_NUCLEAR BCATENIN_LEF1_NIMPORT_NUCLEAR = BCATENIN_LEF1_CYTOSOL+NIMPORT_NUCLEAR 
 0.43343951665823 ; % 838 BCATENIN_LEF1_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR + 
BCATENIN_LEF1_NUCLEAR BCATENIN_LEF1_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR+BCATENIN_LEF1_NUCLEAR 
 0.0171641038310812 ; % 839 BCATENIN_LEF1_NUCLEAR + NEXPORT_NUCLEAR = 
BCATENIN_LEF1_NEXPORT_NUCLEAR BCATENIN_LEF1_NUCLEAR+NEXPORT_NUCLEAR = BCATENIN_LEF1_NEXPORT_NUCLEAR 
 0.08051226042975167 ; % 840 BCATENIN_LEF1_NEXPORT_NUCLEAR = BCATENIN_LEF1_NUCLEAR + 
NEXPORT_NUCLEAR BCATENIN_LEF1_NEXPORT_NUCLEAR = BCATENIN_LEF1_NUCLEAR+NEXPORT_NUCLEAR 
 0.011853971719184953 ; % 841 BCATENIN_LEF1_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR + 
BCATENIN_LEF1_CYTOSOL BCATENIN_LEF1_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR+BCATENIN_LEF1_CYTOSOL 
 0.11778912355119375 ; % 842 DNA_ALPHASMA_NUCLEAR + ACTIVE_NCID_CSL_NUCLEAR = 
DNA_ALPHASMA_ACTIVE_NCID_CSL_NUCLEAR DNA_ALPHASMA_NUCLEAR+ACTIVE_NCID_CSL_NUCLEAR = DNA_ALPHASMA_ACTIVE_NCID_CSL_NUCLEAR 
 0.001986798964149339 ; % 843 DNA_ALPHASMA_ACTIVE_NCID_CSL_NUCLEAR = DNA_ALPHASMA_NUCLEAR + 
ACTIVE_NCID_CSL_NUCLEAR DNA_ALPHASMA_ACTIVE_NCID_CSL_NUCLEAR = DNA_ALPHASMA_NUCLEAR+ACTIVE_NCID_CSL_NUCLEAR 
 0.9992294288753857 ; % 844 DNA_ALPHASMA_ACTIVE_NCID_CSL_NUCLEAR + RNAP_NUCLEAR = 
DNA_ALPHASMA_ACTIVE_NCID_CSL_RNAP_NUCLEAR DNA_ALPHASMA_ACTIVE_NCID_CSL_NUCLEAR+RNAP_NUCLEAR = 
DNA_ALPHASMA_ACTIVE_NCID_CSL_RNAP_NUCLEAR 
 0.016270204030746728 ; % 845 DNA_ALPHASMA_ACTIVE_NCID_CSL_RNAP_NUCLEAR = 
DNA_ALPHASMA_ACTIVE_NCID_CSL_NUCLEAR + RNAP_NUCLEAR DNA_ALPHASMA_ACTIVE_NCID_CSL_RNAP_NUCLEAR = 
DNA_ALPHASMA_ACTIVE_NCID_CSL_NUCLEAR+RNAP_NUCLEAR 
 0.8648839666237395 ; % 846 DNA_ALPHASMA_ACTIVE_NCID_CSL_RNAP_NUCLEAR = DNA_ALPHASMA_NUCLEAR + 
ACTIVE_NCID_CSL_NUCLEAR + RNAP_NUCLEAR + MRNA_ALPHASMA_NUCLEAR DNA_ALPHASMA_ACTIVE_NCID_CSL_RNAP_NUCLEAR = 
DNA_ALPHASMA_NUCLEAR+ACTIVE_NCID_CSL_NUCLEAR+RNAP_NUCLEAR+MRNA_ALPHASMA_NUCLEAR 
 0.9219245335771723 ; % 847 DNA_VEGFR2_NUCLEAR + NFACT1_NUCLEAR = DNA_VEGFR2_NFACT1_NUCLEAR
 DNA_VEGFR2_NUCLEAR+NFACT1_NUCLEAR = DNA_VEGFR2_NFACT1_NUCLEAR 
 0.09192728412078055 ; % 848 DNA_VEGFR2_NFACT1_NUCLEAR = DNA_VEGFR2_NUCLEAR + NFACT1_NUCLEAR
 DNA_VEGFR2_NFACT1_NUCLEAR = DNA_VEGFR2_NUCLEAR+NFACT1_NUCLEAR 
 0.1552343924327515 ; % 849 DNA_VEGFR2_NFACT1_NUCLEAR + RNAP_NUCLEAR = 
DNA_VEGFR2_NFACT1_RNAP_NUCLEAR DNA_VEGFR2_NFACT1_NUCLEAR+RNAP_NUCLEAR = DNA_VEGFR2_NFACT1_RNAP_NUCLEAR 
 0.027025033126824385 ; % 850 DNA_VEGFR2_NFACT1_RNAP_NUCLEAR = DNA_VEGFR2_NFACT1_NUCLEAR + 
RNAP_NUCLEAR DNA_VEGFR2_NFACT1_RNAP_NUCLEAR = DNA_VEGFR2_NFACT1_NUCLEAR+RNAP_NUCLEAR 
 0.0961869002953819 ; % 851 NFACT1_CYTOSOL + NIMPORT_NUCLEAR = NFACT1_NIMPORT_NUCLEAR
 NFACT1_CYTOSOL+NIMPORT_NUCLEAR = NFACT1_NIMPORT_NUCLEAR 
 0.03322099046634835 ; % 852 NFACT1_NIMPORT_NUCLEAR = NFACT1_CYTOSOL + NIMPORT_NUCLEAR
 NFACT1_NIMPORT_NUCLEAR = NFACT1_CYTOSOL+NIMPORT_NUCLEAR 
 0.2684783492575904 ; % 853 NFACT1_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR + NFACT1_NUCLEAR
 NFACT1_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR+NFACT1_NUCLEAR 
 0.5645816747302705 ; % 854 NFACT1_NUCLEAR + NEXPORT_NUCLEAR = NFACT1_NEXPORT_NUCLEAR
 NFACT1_NUCLEAR+NEXPORT_NUCLEAR = NFACT1_NEXPORT_NUCLEAR 
 0.04232636040033009 ; % 855 NFACT1_NEXPORT_NUCLEAR = NFACT1_NUCLEAR + NEXPORT_NUCLEAR
 NFACT1_NEXPORT_NUCLEAR = NFACT1_NUCLEAR+NEXPORT_NUCLEAR 
 0.8116488258257147 ; % 856 NFACT1_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR + NFACT1_CYTOSOL
 NFACT1_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR+NFACT1_CYTOSOL 
 0.9607559417022024 ; % 857 DNA_VEGFR2_NFACT1_RNAP_NUCLEAR = DNA_VEGFR2_NUCLEAR + 
NFACT1_NUCLEAR + RNAP_NUCLEAR + MRNA_VEGFR2_NUCLEAR DNA_VEGFR2_NFACT1_RNAP_NUCLEAR = 
DNA_VEGFR2_NUCLEAR+NFACT1_NUCLEAR+RNAP_NUCLEAR+MRNA_VEGFR2_NUCLEAR 
 0.9738404829793373 ; % 858 DNA_VEGFR2_NUCLEAR + ACTIVE_NCID_CSL_NUCLEAR = 
DNA_VEGFR2_ACTIVE_NCID_CSL_NUCLEAR DNA_VEGFR2_NUCLEAR+ACTIVE_NCID_CSL_NUCLEAR = DNA_VEGFR2_ACTIVE_NCID_CSL_NUCLEAR 
 0.020487944395096682 ; % 859 DNA_VEGFR2_ACTIVE_NCID_CSL_NUCLEAR = DNA_VEGFR2_NUCLEAR + 
ACTIVE_NCID_CSL_NUCLEAR DNA_VEGFR2_ACTIVE_NCID_CSL_NUCLEAR = DNA_VEGFR2_NUCLEAR+ACTIVE_NCID_CSL_NUCLEAR 
 0.2822419714756935 ; % 860 DNA_VEGFR2_ACTIVE_NCID_CSL_NUCLEAR + RNAP_NUCLEAR = 
DNA_VEGFR2_ACTIVE_NCID_CSL_RNAP_NUCLEAR DNA_VEGFR2_ACTIVE_NCID_CSL_NUCLEAR+RNAP_NUCLEAR = 
DNA_VEGFR2_ACTIVE_NCID_CSL_RNAP_NUCLEAR 
 0.022114313138316334 ; % 861 DNA_VEGFR2_ACTIVE_NCID_CSL_RNAP_NUCLEAR = 
DNA_VEGFR2_ACTIVE_NCID_CSL_NUCLEAR + RNAP_NUCLEAR DNA_VEGFR2_ACTIVE_NCID_CSL_RNAP_NUCLEAR = 
DNA_VEGFR2_ACTIVE_NCID_CSL_NUCLEAR+RNAP_NUCLEAR 
 0.9782340946202698 ; % 862 DNA_VEGFR2_ACTIVE_NCID_CSL_RNAP_NUCLEAR = DNA_VEGFR2_NUCLEAR + 
ACTIVE_NCID_CSL_NUCLEAR + RNAP_NUCLEAR + MRNA_VEGFR2_NUCLEAR DNA_VEGFR2_ACTIVE_NCID_CSL_RNAP_NUCLEAR = 
DNA_VEGFR2_NUCLEAR+ACTIVE_NCID_CSL_NUCLEAR+RNAP_NUCLEAR+MRNA_VEGFR2_NUCLEAR 
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 0.7721310426335485 ; % 863 MRNA_CYCLINB2_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_CYCLINB2_NEXPORT_NUCLEAR MRNA_CYCLINB2_NUCLEAR+NEXPORT_NUCLEAR = MRNA_CYCLINB2_NEXPORT_NUCLEAR 
 0.09581876702569035 ; % 864 MRNA_CYCLINB2_NEXPORT_NUCLEAR = MRNA_CYCLINB2_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_CYCLINB2_NEXPORT_NUCLEAR = MRNA_CYCLINB2_NUCLEAR+NEXPORT_NUCLEAR 
 0.11412154449318801 ; % 865 MRNA_CYCLINB2_NEXPORT_NUCLEAR = MRNA_CYCLINB2_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_CYCLINB2_NEXPORT_NUCLEAR = MRNA_CYCLINB2_CYTOSOL+NEXPORT_NUCLEAR 
 0.746381511311346 ; % 866 MRNA_CYCLINB2_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_CYCLINB2_RIBOSOME_CYTOSOL MRNA_CYCLINB2_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_CYCLINB2_RIBOSOME_CYTOSOL 
 0.09775590764418816 ; % 867 MRNA_CYCLINB2_RIBOSOME_CYTOSOL = MRNA_CYCLINB2_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_CYCLINB2_RIBOSOME_CYTOSOL = MRNA_CYCLINB2_CYTOSOL+RIBOSOME_CYTOSOL 
 0.6532881545763847 ; % 868 MRNA_CYCLINB2_RIBOSOME_CYTOSOL = 
MRNA_CYCLINB2_START_RIBOSOME_CYTOSOL MRNA_CYCLINB2_RIBOSOME_CYTOSOL = MRNA_CYCLINB2_START_RIBOSOME_CYTOSOL 
 0.5217217260960831 ; % 869 MRNA_CYCLINB2_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
CYCLINB2_CYTOSOL + MRNA_CYCLINB2_CYTOSOL MRNA_CYCLINB2_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+CYCLINB2_CYTOSOL+MRNA_CYCLINB2_CYTOSOL 
 0.44235818872910254 ; % 870 MRNA_CYCLINB2_CYTOSOL = [] MRNA_CYCLINB2_CYTOSOL = [] 
 0.3957023468988833 ; % 871 CYCLINB2_CYTOSOL = [] CYCLINB2_CYTOSOL = [] 
 0.7417692338665055 ; % 872 DNA_CYCLINB2_NUCLEAR + TBX20_NUCLEAR = DNA_CYCLINB2_TBX20_NUCLEAR
 DNA_CYCLINB2_NUCLEAR+TBX20_NUCLEAR = DNA_CYCLINB2_TBX20_NUCLEAR 
 0.016534190088099733 ; % 873 DNA_CYCLINB2_TBX20_NUCLEAR = DNA_CYCLINB2_NUCLEAR + TBX20_NUCLEAR
 DNA_CYCLINB2_TBX20_NUCLEAR = DNA_CYCLINB2_NUCLEAR+TBX20_NUCLEAR 
 0.522053892102061 ; % 874 DNA_CYCLINB2_TBX20_NUCLEAR + RNAP_NUCLEAR = 
DNA_CYCLINB2_TBX20_RNAP_NUCLEAR DNA_CYCLINB2_TBX20_NUCLEAR+RNAP_NUCLEAR = DNA_CYCLINB2_TBX20_RNAP_NUCLEAR 
 0.011011276825401163 ; % 875 DNA_CYCLINB2_TBX20_RNAP_NUCLEAR = DNA_CYCLINB2_TBX20_NUCLEAR + 
RNAP_NUCLEAR DNA_CYCLINB2_TBX20_RNAP_NUCLEAR = DNA_CYCLINB2_TBX20_NUCLEAR+RNAP_NUCLEAR 
 0.7570746509211372 ; % 876 TBX20_CYTOSOL + NIMPORT_NUCLEAR = TBX20_NIMPORT_NUCLEAR
 TBX20_CYTOSOL+NIMPORT_NUCLEAR = TBX20_NIMPORT_NUCLEAR 
 0.08302464666407369 ; % 877 TBX20_NIMPORT_NUCLEAR = TBX20_CYTOSOL + NIMPORT_NUCLEAR
 TBX20_NIMPORT_NUCLEAR = TBX20_CYTOSOL+NIMPORT_NUCLEAR 
 0.535382633560636 ; % 878 TBX20_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR + TBX20_NUCLEAR
 TBX20_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR+TBX20_NUCLEAR 
 0.9290902637855062 ; % 879 TBX20_NUCLEAR + NEXPORT_NUCLEAR = TBX20_NEXPORT_NUCLEAR
 TBX20_NUCLEAR+NEXPORT_NUCLEAR = TBX20_NEXPORT_NUCLEAR 
 0.07301061828594169 ; % 880 TBX20_NEXPORT_NUCLEAR = TBX20_NUCLEAR + NEXPORT_NUCLEAR
 TBX20_NEXPORT_NUCLEAR = TBX20_NUCLEAR+NEXPORT_NUCLEAR 
 0.21281847135837206 ; % 881 TBX20_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR + TBX20_CYTOSOL
 TBX20_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR+TBX20_CYTOSOL 
 0.4153250000221488 ; % 882 DNA_CYCLINB2_TBX20_RNAP_NUCLEAR = DNA_CYCLINB2_NUCLEAR + 
TBX20_NUCLEAR + RNAP_NUCLEAR + MRNA_CYCLINB2_NUCLEAR DNA_CYCLINB2_TBX20_RNAP_NUCLEAR = 
DNA_CYCLINB2_NUCLEAR+TBX20_NUCLEAR+RNAP_NUCLEAR+MRNA_CYCLINB2_NUCLEAR 
 0.2319227256399079 ; % 883 DNA_CYCLINB2_NUCLEAR + TWIST_NUCLEAR = DNA_CYCLINB2_TWIST_NUCLEAR
 DNA_CYCLINB2_NUCLEAR+TWIST_NUCLEAR = DNA_CYCLINB2_TWIST_NUCLEAR 
 0.08888880662540699 ; % 884 DNA_CYCLINB2_TWIST_NUCLEAR = DNA_CYCLINB2_NUCLEAR + TWIST_NUCLEAR
 DNA_CYCLINB2_TWIST_NUCLEAR = DNA_CYCLINB2_NUCLEAR+TWIST_NUCLEAR 
 0.9639609831708342 ; % 885 DNA_CYCLINB2_TWIST_NUCLEAR + RNAP_NUCLEAR = 
DNA_CYCLINB2_TWIST_RNAP_NUCLEAR DNA_CYCLINB2_TWIST_NUCLEAR+RNAP_NUCLEAR = DNA_CYCLINB2_TWIST_RNAP_NUCLEAR 
 0.08683421969366728 ; % 886 DNA_CYCLINB2_TWIST_RNAP_NUCLEAR = DNA_CYCLINB2_TWIST_NUCLEAR + 
RNAP_NUCLEAR DNA_CYCLINB2_TWIST_RNAP_NUCLEAR = DNA_CYCLINB2_TWIST_NUCLEAR+RNAP_NUCLEAR 
 0.3046978090150483 ; % 887 DNA_CYCLINB2_TWIST_RNAP_NUCLEAR = DNA_CYCLINB2_NUCLEAR + 
TWIST_NUCLEAR + RNAP_NUCLEAR + MRNA_CYCLINB2_NUCLEAR DNA_CYCLINB2_TWIST_RNAP_NUCLEAR = 
DNA_CYCLINB2_NUCLEAR+TWIST_NUCLEAR+RNAP_NUCLEAR+MRNA_CYCLINB2_NUCLEAR 
 0.2683926229963859 ; % 888 DNA_CYCLINB2_NUCLEAR + BCATENIN_LEF1_NUCLEAR = 
DNA_CYCLINB2_BCATENIN_LEF1_NUCLEAR DNA_CYCLINB2_NUCLEAR+BCATENIN_LEF1_NUCLEAR = DNA_CYCLINB2_BCATENIN_LEF1_NUCLEAR 
 0.031161249664524427 ; % 889 DNA_CYCLINB2_BCATENIN_LEF1_NUCLEAR = DNA_CYCLINB2_NUCLEAR + 
BCATENIN_LEF1_NUCLEAR DNA_CYCLINB2_BCATENIN_LEF1_NUCLEAR = DNA_CYCLINB2_NUCLEAR+BCATENIN_LEF1_NUCLEAR 
 0.7576437145728612 ; % 890 DNA_CYCLINB2_BCATENIN_LEF1_NUCLEAR + RNAP_NUCLEAR = 
DNA_CYCLINB2_BCATENIN_LEF1_RNAP_NUCLEAR DNA_CYCLINB2_BCATENIN_LEF1_NUCLEAR+RNAP_NUCLEAR = 
DNA_CYCLINB2_BCATENIN_LEF1_RNAP_NUCLEAR 
 0.06967799568397806 ; % 891 DNA_CYCLINB2_BCATENIN_LEF1_RNAP_NUCLEAR = 
DNA_CYCLINB2_BCATENIN_LEF1_NUCLEAR + RNAP_NUCLEAR DNA_CYCLINB2_BCATENIN_LEF1_RNAP_NUCLEAR = 
DNA_CYCLINB2_BCATENIN_LEF1_NUCLEAR+RNAP_NUCLEAR 
 0.11227107260311642 ; % 892 DNA_CYCLINB2_BCATENIN_LEF1_RNAP_NUCLEAR = DNA_CYCLINB2_NUCLEAR + 
BCATENIN_LEF1_NUCLEAR + RNAP_NUCLEAR + MRNA_CYCLINB2_NUCLEAR DNA_CYCLINB2_BCATENIN_LEF1_RNAP_NUCLEAR = 
DNA_CYCLINB2_NUCLEAR+BCATENIN_LEF1_NUCLEAR+RNAP_NUCLEAR+MRNA_CYCLINB2_NUCLEAR 
 0.11116156717189962 ; % 893 DNA_PECAM1_NUCLEAR + NFATC1_NUCLEAR = DNA_PECAM1_NFATC1_NUCLEAR
 DNA_PECAM1_NUCLEAR+NFATC1_NUCLEAR = DNA_PECAM1_NFATC1_NUCLEAR 
 0.03958927151747034 ; % 894 DNA_PECAM1_NFATC1_NUCLEAR = DNA_PECAM1_NUCLEAR + NFATC1_NUCLEAR
 DNA_PECAM1_NFATC1_NUCLEAR = DNA_PECAM1_NUCLEAR+NFATC1_NUCLEAR 
 0.718325239387041 ; % 895 DNA_PECAM1_NFATC1_NUCLEAR + RNAP_NUCLEAR = 
DNA_PECAM1_NFATC1_RNAP_NUCLEAR DNA_PECAM1_NFATC1_NUCLEAR+RNAP_NUCLEAR = DNA_PECAM1_NFATC1_RNAP_NUCLEAR 
 0.06874921201108153 ; % 896 DNA_PECAM1_NFATC1_RNAP_NUCLEAR = DNA_PECAM1_NFATC1_NUCLEAR + 
RNAP_NUCLEAR DNA_PECAM1_NFATC1_RNAP_NUCLEAR = DNA_PECAM1_NFATC1_NUCLEAR+RNAP_NUCLEAR 
 0.29461671132381695 ; % 897 NFATC1_CYTOSOL + NIMPORT_NUCLEAR = NFATC1_NIMPORT_NUCLEAR
 NFATC1_CYTOSOL+NIMPORT_NUCLEAR = NFATC1_NIMPORT_NUCLEAR 
 0.05201823826283674 ; % 898 NFATC1_NIMPORT_NUCLEAR = NFATC1_CYTOSOL + NIMPORT_NUCLEAR
 NFATC1_NIMPORT_NUCLEAR = NFATC1_CYTOSOL+NIMPORT_NUCLEAR 
 0.1900210750283109 ; % 899 NFATC1_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR + NFATC1_NUCLEAR
 NFATC1_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR+NFATC1_NUCLEAR 
 0.2783981007240266 ; % 900 NFATC1_NUCLEAR + NEXPORT_NUCLEAR = NFATC1_NEXPORT_NUCLEAR
 NFATC1_NUCLEAR+NEXPORT_NUCLEAR = NFATC1_NEXPORT_NUCLEAR 
 0.0467707138791599 ; % 901 NFATC1_NEXPORT_NUCLEAR = NFATC1_NUCLEAR + NEXPORT_NUCLEAR
 NFATC1_NEXPORT_NUCLEAR = NFATC1_NUCLEAR+NEXPORT_NUCLEAR 
 0.5033911876080657 ; % 902 NFATC1_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR + NFATC1_CYTOSOL
 NFATC1_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR+NFATC1_CYTOSOL 
 0.14198099026384603 ; % 903 DNA_PECAM1_NFATC1_RNAP_NUCLEAR = DNA_PECAM1_NUCLEAR + 
NFATC1_NUCLEAR + RNAP_NUCLEAR + MRNA_PECAM1_NUCLEAR DNA_PECAM1_NFATC1_RNAP_NUCLEAR = 
DNA_PECAM1_NUCLEAR+NFATC1_NUCLEAR+RNAP_NUCLEAR+MRNA_PECAM1_NUCLEAR 
 0.9926918199265051 ; % 904 DNA_SLUG_NUCLEAR + P_AP1_NUCLEAR = DNA_SLUG_P_AP1_NUCLEAR
 DNA_SLUG_NUCLEAR+P_AP1_NUCLEAR = DNA_SLUG_P_AP1_NUCLEAR 
 0.007123050762836125 ; % 905 DNA_SLUG_P_AP1_NUCLEAR = DNA_SLUG_NUCLEAR + P_AP1_NUCLEAR
 DNA_SLUG_P_AP1_NUCLEAR = DNA_SLUG_NUCLEAR+P_AP1_NUCLEAR 
 0.9922356396172567 ; % 906 DNA_SLUG_P_AP1_NUCLEAR + RNAP_NUCLEAR = 
DNA_SLUG_P_AP1_RNAP_NUCLEAR DNA_SLUG_P_AP1_NUCLEAR+RNAP_NUCLEAR = DNA_SLUG_P_AP1_RNAP_NUCLEAR 
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 0.006909904073225447 ; % 907 DNA_SLUG_P_AP1_RNAP_NUCLEAR = DNA_SLUG_P_AP1_NUCLEAR + 
RNAP_NUCLEAR DNA_SLUG_P_AP1_RNAP_NUCLEAR = DNA_SLUG_P_AP1_NUCLEAR+RNAP_NUCLEAR 
 0.2597192319632444 ; % 908 P_AP1_CYTOSOL + NIMPORT_NUCLEAR = P_AP1_NIMPORT_NUCLEAR
 P_AP1_CYTOSOL+NIMPORT_NUCLEAR = P_AP1_NIMPORT_NUCLEAR 
 0.017490630470009216 ; % 909 P_AP1_NIMPORT_NUCLEAR = P_AP1_CYTOSOL + NIMPORT_NUCLEAR
 P_AP1_NIMPORT_NUCLEAR = P_AP1_CYTOSOL+NIMPORT_NUCLEAR 
 0.7028254979235711 ; % 910 P_AP1_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR + P_AP1_NUCLEAR
 P_AP1_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR+P_AP1_NUCLEAR 
 0.7523032287830684 ; % 911 P_AP1_NUCLEAR + NEXPORT_NUCLEAR = P_AP1_NEXPORT_NUCLEAR
 P_AP1_NUCLEAR+NEXPORT_NUCLEAR = P_AP1_NEXPORT_NUCLEAR 
 0.05829523836192474 ; % 912 P_AP1_NEXPORT_NUCLEAR = P_AP1_NUCLEAR + NEXPORT_NUCLEAR
 P_AP1_NEXPORT_NUCLEAR = P_AP1_NUCLEAR+NEXPORT_NUCLEAR 
 0.18267704853841282 ; % 913 P_AP1_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR + P_AP1_CYTOSOL
 P_AP1_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR+P_AP1_CYTOSOL 
 0.13463967103491348 ; % 914 DNA_SLUG_P_AP1_RNAP_NUCLEAR = DNA_SLUG_NUCLEAR + P_AP1_NUCLEAR + 
RNAP_NUCLEAR + MRNA_SLUG_NUCLEAR DNA_SLUG_P_AP1_RNAP_NUCLEAR = 
DNA_SLUG_NUCLEAR+P_AP1_NUCLEAR+RNAP_NUCLEAR+MRNA_SLUG_NUCLEAR 
 0.994973930290365 ; % 915 DNA_SLUG_NUCLEAR + P_SP1_NUCLEAR = DNA_SLUG_P_SP1_NUCLEAR
 DNA_SLUG_NUCLEAR+P_SP1_NUCLEAR = DNA_SLUG_P_SP1_NUCLEAR 
 0.002331303667152923 ; % 916 DNA_SLUG_P_SP1_NUCLEAR = DNA_SLUG_NUCLEAR + P_SP1_NUCLEAR
 DNA_SLUG_P_SP1_NUCLEAR = DNA_SLUG_NUCLEAR+P_SP1_NUCLEAR 
 0.9116136962923388 ; % 917 DNA_SLUG_P_SP1_NUCLEAR + RNAP_NUCLEAR = 
DNA_SLUG_P_SP1_RNAP_NUCLEAR DNA_SLUG_P_SP1_NUCLEAR+RNAP_NUCLEAR = DNA_SLUG_P_SP1_RNAP_NUCLEAR 
 0.005864601716626418 ; % 918 DNA_SLUG_P_SP1_RNAP_NUCLEAR = DNA_SLUG_P_SP1_NUCLEAR + 
RNAP_NUCLEAR DNA_SLUG_P_SP1_RNAP_NUCLEAR = DNA_SLUG_P_SP1_NUCLEAR+RNAP_NUCLEAR 
 0.10865258878649187 ; % 919 P_SP1_CYTOSOL + NIMPORT_NUCLEAR = P_SP1_NIMPORT_NUCLEAR
 P_SP1_CYTOSOL+NIMPORT_NUCLEAR = P_SP1_NIMPORT_NUCLEAR 
 0.0957786705195906 ; % 920 P_SP1_NIMPORT_NUCLEAR = P_SP1_CYTOSOL + NIMPORT_NUCLEAR
 P_SP1_NIMPORT_NUCLEAR = P_SP1_CYTOSOL+NIMPORT_NUCLEAR 
 0.03401609851811638 ; % 921 P_SP1_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR + P_SP1_NUCLEAR
 P_SP1_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR+P_SP1_NUCLEAR 
 0.363386992746613 ; % 922 P_SP1_NUCLEAR + NEXPORT_NUCLEAR = P_SP1_NEXPORT_NUCLEAR
 P_SP1_NUCLEAR+NEXPORT_NUCLEAR = P_SP1_NEXPORT_NUCLEAR 
 0.03497764464826358 ; % 923 P_SP1_NEXPORT_NUCLEAR = P_SP1_NUCLEAR + NEXPORT_NUCLEAR
 P_SP1_NEXPORT_NUCLEAR = P_SP1_NUCLEAR+NEXPORT_NUCLEAR 
 0.5682959350530288 ; % 924 P_SP1_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR + P_SP1_CYTOSOL
 P_SP1_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR+P_SP1_CYTOSOL 
 0.8567472278827303 ; % 925 DNA_SLUG_P_SP1_RNAP_NUCLEAR = DNA_SLUG_NUCLEAR + P_SP1_NUCLEAR + 
RNAP_NUCLEAR + MRNA_SLUG_NUCLEAR DNA_SLUG_P_SP1_RNAP_NUCLEAR = 
DNA_SLUG_NUCLEAR+P_SP1_NUCLEAR+RNAP_NUCLEAR+MRNA_SLUG_NUCLEAR 
 0.0001 ; % 926 DNA_SLUG_NUCLEAR + BCATENIN_TCF4_NUCLEAR = DNA_SLUG_BCATENIN_TCF4_NUCLEAR
 DNA_SLUG_NUCLEAR+BCATENIN_TCF4_NUCLEAR = DNA_SLUG_BCATENIN_TCF4_NUCLEAR 
 0.09191658543414892 ; % 927 DNA_SLUG_BCATENIN_TCF4_NUCLEAR = DNA_SLUG_NUCLEAR + 
BCATENIN_TCF4_NUCLEAR DNA_SLUG_BCATENIN_TCF4_NUCLEAR = DNA_SLUG_NUCLEAR+BCATENIN_TCF4_NUCLEAR 
 0.0001 ; % 928 DNA_SLUG_BCATENIN_TCF4_NUCLEAR + RNAP_NUCLEAR = 
DNA_SLUG_BCATENIN_TCF4_RNAP_NUCLEAR DNA_SLUG_BCATENIN_TCF4_NUCLEAR+RNAP_NUCLEAR = DNA_SLUG_BCATENIN_TCF4_RNAP_NUCLEAR 
 0.030600169187593375 ; % 929 DNA_SLUG_BCATENIN_TCF4_RNAP_NUCLEAR = 
DNA_SLUG_BCATENIN_TCF4_NUCLEAR + RNAP_NUCLEAR DNA_SLUG_BCATENIN_TCF4_RNAP_NUCLEAR = 
DNA_SLUG_BCATENIN_TCF4_NUCLEAR+RNAP_NUCLEAR 
 0.48634329702546797 ; % 930 DNA_SLUG_BCATENIN_TCF4_RNAP_NUCLEAR = DNA_SLUG_NUCLEAR + 
BCATENIN_TCF4_NUCLEAR + RNAP_NUCLEAR + MRNA_SLUG_NUCLEAR DNA_SLUG_BCATENIN_TCF4_RNAP_NUCLEAR = 
DNA_SLUG_NUCLEAR+BCATENIN_TCF4_NUCLEAR+RNAP_NUCLEAR+MRNA_SLUG_NUCLEAR 
 0.9866179073697999 ; % 931 BCATENIN_CYTOSOL + TCF4_CYTOSOL = BCATENIN_TCF4_CYTOSOL
 BCATENIN_CYTOSOL+TCF4_CYTOSOL = BCATENIN_TCF4_CYTOSOL 
 0.00056425647523732125 ; % 932 BCATENIN_TCF4_CYTOSOL = BCATENIN_CYTOSOL + TCF4_CYTOSOL
 BCATENIN_TCF4_CYTOSOL = BCATENIN_CYTOSOL+TCF4_CYTOSOL 
 0.2108842395850017 ; % 933 BCATENIN_TCF4_CYTOSOL + NIMPORT_NUCLEAR = 
BCATENIN_TCF4_NIMPORT_NUCLEAR BCATENIN_TCF4_CYTOSOL+NIMPORT_NUCLEAR = BCATENIN_TCF4_NIMPORT_NUCLEAR 
 0.018159480329432775 ; % 934 BCATENIN_TCF4_NIMPORT_NUCLEAR = BCATENIN_TCF4_CYTOSOL + 
NIMPORT_NUCLEAR BCATENIN_TCF4_NIMPORT_NUCLEAR = BCATENIN_TCF4_CYTOSOL+NIMPORT_NUCLEAR 
 0.9568593369355222 ; % 935 BCATENIN_TCF4_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR + 
BCATENIN_TCF4_NUCLEAR BCATENIN_TCF4_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR+BCATENIN_TCF4_NUCLEAR 
 0.3491443745080983 ; % 936 BCATENIN_TCF4_NUCLEAR + NEXPORT_NUCLEAR = 
BCATENIN_TCF4_NEXPORT_NUCLEAR BCATENIN_TCF4_NUCLEAR+NEXPORT_NUCLEAR = BCATENIN_TCF4_NEXPORT_NUCLEAR 
 0.027266969211490324 ; % 937 BCATENIN_TCF4_NEXPORT_NUCLEAR = BCATENIN_TCF4_NUCLEAR + 
NEXPORT_NUCLEAR BCATENIN_TCF4_NEXPORT_NUCLEAR = BCATENIN_TCF4_NUCLEAR+NEXPORT_NUCLEAR 
 0.5898200492149793 ; % 938 BCATENIN_TCF4_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR + 
BCATENIN_TCF4_CYTOSOL BCATENIN_TCF4_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR+BCATENIN_TCF4_CYTOSOL 
 0.23168796596449515 ; % 939 DNA_SLUG_NUCLEAR + ACTIVE_NCID_CSL_NUCLEAR = 
DNA_SLUG_ACTIVE_NCID_CSL_NUCLEAR DNA_SLUG_NUCLEAR+ACTIVE_NCID_CSL_NUCLEAR = DNA_SLUG_ACTIVE_NCID_CSL_NUCLEAR 
 0.015844665359885168 ; % 940 DNA_SLUG_ACTIVE_NCID_CSL_NUCLEAR = DNA_SLUG_NUCLEAR + 
ACTIVE_NCID_CSL_NUCLEAR DNA_SLUG_ACTIVE_NCID_CSL_NUCLEAR = DNA_SLUG_NUCLEAR+ACTIVE_NCID_CSL_NUCLEAR 
 0.6974357988191648 ; % 941 DNA_SLUG_ACTIVE_NCID_CSL_NUCLEAR + RNAP_NUCLEAR = 
DNA_SLUG_ACTIVE_NCID_CSL_RNAP_NUCLEAR DNA_SLUG_ACTIVE_NCID_CSL_NUCLEAR+RNAP_NUCLEAR = DNA_SLUG_ACTIVE_NCID_CSL_RNAP_NUCLEAR 
 0.03837750027455855 ; % 942 DNA_SLUG_ACTIVE_NCID_CSL_RNAP_NUCLEAR = 
DNA_SLUG_ACTIVE_NCID_CSL_NUCLEAR + RNAP_NUCLEAR DNA_SLUG_ACTIVE_NCID_CSL_RNAP_NUCLEAR = 
DNA_SLUG_ACTIVE_NCID_CSL_NUCLEAR+RNAP_NUCLEAR 
 0.07153365223971597 ; % 943 DNA_SLUG_ACTIVE_NCID_CSL_RNAP_NUCLEAR = DNA_SLUG_NUCLEAR + 
ACTIVE_NCID_CSL_NUCLEAR + RNAP_NUCLEAR + MRNA_SLUG_NUCLEAR DNA_SLUG_ACTIVE_NCID_CSL_RNAP_NUCLEAR = 
DNA_SLUG_NUCLEAR+ACTIVE_NCID_CSL_NUCLEAR+RNAP_NUCLEAR+MRNA_SLUG_NUCLEAR 
 0.96866493395302977 ; % 944 DNA_SNAIL_NUCLEAR + P_AP1_NUCLEAR = DNA_SNAIL_P_AP1_NUCLEAR
 DNA_SNAIL_NUCLEAR+P_AP1_NUCLEAR = DNA_SNAIL_P_AP1_NUCLEAR 
 0.00168311384473153 ; % 945 DNA_SNAIL_P_AP1_NUCLEAR = DNA_SNAIL_NUCLEAR + P_AP1_NUCLEAR
 DNA_SNAIL_P_AP1_NUCLEAR = DNA_SNAIL_NUCLEAR+P_AP1_NUCLEAR 
 0.96475879080509743 ; % 946 DNA_SNAIL_P_AP1_NUCLEAR + RNAP_NUCLEAR = 
DNA_SNAIL_P_AP1_RNAP_NUCLEAR DNA_SNAIL_P_AP1_NUCLEAR+RNAP_NUCLEAR = DNA_SNAIL_P_AP1_RNAP_NUCLEAR 
 0.003667940765602734 ; % 947 DNA_SNAIL_P_AP1_RNAP_NUCLEAR = DNA_SNAIL_P_AP1_NUCLEAR + 
RNAP_NUCLEAR DNA_SNAIL_P_AP1_RNAP_NUCLEAR = DNA_SNAIL_P_AP1_NUCLEAR+RNAP_NUCLEAR 
 0.24025881428390417 ; % 948 DNA_SNAIL_P_AP1_RNAP_NUCLEAR = DNA_SNAIL_NUCLEAR + P_AP1_NUCLEAR + 
RNAP_NUCLEAR + MRNA_SNAIL_NUCLEAR DNA_SNAIL_P_AP1_RNAP_NUCLEAR = 
DNA_SNAIL_NUCLEAR+P_AP1_NUCLEAR+RNAP_NUCLEAR+MRNA_SNAIL_NUCLEAR 
 0.92506006411360093 ; % 949 DNA_SNAIL_NUCLEAR + P_SP1_NUCLEAR = DNA_SNAIL_P_SP1_NUCLEAR
 DNA_SNAIL_NUCLEAR+P_SP1_NUCLEAR = DNA_SNAIL_P_SP1_NUCLEAR 
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 0.00265324056466929 ; % 950 DNA_SNAIL_P_SP1_NUCLEAR = DNA_SNAIL_NUCLEAR + P_SP1_NUCLEAR
 DNA_SNAIL_P_SP1_NUCLEAR = DNA_SNAIL_NUCLEAR+P_SP1_NUCLEAR 
 0.990202740246663 ; % 951 DNA_SNAIL_P_SP1_NUCLEAR + RNAP_NUCLEAR = 
DNA_SNAIL_P_SP1_RNAP_NUCLEAR DNA_SNAIL_P_SP1_NUCLEAR+RNAP_NUCLEAR = DNA_SNAIL_P_SP1_RNAP_NUCLEAR 
 0.004975689082538155 ; % 952 DNA_SNAIL_P_SP1_RNAP_NUCLEAR = DNA_SNAIL_P_SP1_NUCLEAR + 
RNAP_NUCLEAR DNA_SNAIL_P_SP1_RNAP_NUCLEAR = DNA_SNAIL_P_SP1_NUCLEAR+RNAP_NUCLEAR 
 0.5197376813926342 ; % 953 DNA_SNAIL_P_SP1_RNAP_NUCLEAR = DNA_SNAIL_NUCLEAR + P_SP1_NUCLEAR + 
RNAP_NUCLEAR + MRNA_SNAIL_NUCLEAR DNA_SNAIL_P_SP1_RNAP_NUCLEAR = 
DNA_SNAIL_NUCLEAR+P_SP1_NUCLEAR+RNAP_NUCLEAR+MRNA_SNAIL_NUCLEAR 
 0.0001; % 954 DNA_SNAIL_NUCLEAR + BCATENIN_TCF4_NUCLEAR = DNA_SNAIL_BCATENIN_TCF4_NUCLEAR
 DNA_SNAIL_NUCLEAR+BCATENIN_TCF4_NUCLEAR = DNA_SNAIL_BCATENIN_TCF4_NUCLEAR 
 0.02869540256626072 ; % 955 DNA_SNAIL_BCATENIN_TCF4_NUCLEAR = DNA_SNAIL_NUCLEAR + 
BCATENIN_TCF4_NUCLEAR DNA_SNAIL_BCATENIN_TCF4_NUCLEAR = DNA_SNAIL_NUCLEAR+BCATENIN_TCF4_NUCLEAR 
 0.0001; % 956 DNA_SNAIL_BCATENIN_TCF4_NUCLEAR + RNAP_NUCLEAR = DNA_SNAIL_BCATENIN_TCF4_RNAP_NUCLEAR
 DNA_SNAIL_BCATENIN_TCF4_NUCLEAR+RNAP_NUCLEAR = DNA_SNAIL_BCATENIN_TCF4_RNAP_NUCLEAR 
 0.01500874762580181 ; % 957 DNA_SNAIL_BCATENIN_TCF4_RNAP_NUCLEAR = 
DNA_SNAIL_BCATENIN_TCF4_NUCLEAR + RNAP_NUCLEAR DNA_SNAIL_BCATENIN_TCF4_RNAP_NUCLEAR = 
DNA_SNAIL_BCATENIN_TCF4_NUCLEAR+RNAP_NUCLEAR 
 0.8747034502103713 ; % 958 DNA_SNAIL_BCATENIN_TCF4_RNAP_NUCLEAR = DNA_SNAIL_NUCLEAR + 
BCATENIN_TCF4_NUCLEAR + RNAP_NUCLEAR + MRNA_SNAIL_NUCLEAR DNA_SNAIL_BCATENIN_TCF4_RNAP_NUCLEAR = 
DNA_SNAIL_NUCLEAR+BCATENIN_TCF4_NUCLEAR+RNAP_NUCLEAR+MRNA_SNAIL_NUCLEAR 
 0.21460525891919335 ; % 959 DNA_SNAIL_NUCLEAR + ACTIVE_NCID_CSL_NUCLEAR = 
DNA_SNAIL_ACTIVE_NCID_CSL_NUCLEAR DNA_SNAIL_NUCLEAR+ACTIVE_NCID_CSL_NUCLEAR = DNA_SNAIL_ACTIVE_NCID_CSL_NUCLEAR 
 0.026428411043530886 ; % 960 DNA_SNAIL_ACTIVE_NCID_CSL_NUCLEAR = DNA_SNAIL_NUCLEAR + 
ACTIVE_NCID_CSL_NUCLEAR DNA_SNAIL_ACTIVE_NCID_CSL_NUCLEAR = DNA_SNAIL_NUCLEAR+ACTIVE_NCID_CSL_NUCLEAR 
 0.1480247985809341 ; % 961 DNA_SNAIL_ACTIVE_NCID_CSL_NUCLEAR + RNAP_NUCLEAR = 
DNA_SNAIL_ACTIVE_NCID_CSL_RNAP_NUCLEAR DNA_SNAIL_ACTIVE_NCID_CSL_NUCLEAR+RNAP_NUCLEAR = 
DNA_SNAIL_ACTIVE_NCID_CSL_RNAP_NUCLEAR 
 0.07113134186296476 ; % 962 DNA_SNAIL_ACTIVE_NCID_CSL_RNAP_NUCLEAR = 
DNA_SNAIL_ACTIVE_NCID_CSL_NUCLEAR + RNAP_NUCLEAR DNA_SNAIL_ACTIVE_NCID_CSL_RNAP_NUCLEAR = 
DNA_SNAIL_ACTIVE_NCID_CSL_NUCLEAR+RNAP_NUCLEAR 
 0.5279286510021809 ; % 963 DNA_SNAIL_ACTIVE_NCID_CSL_RNAP_NUCLEAR = DNA_SNAIL_NUCLEAR + 
ACTIVE_NCID_CSL_NUCLEAR + RNAP_NUCLEAR + MRNA_SNAIL_NUCLEAR DNA_SNAIL_ACTIVE_NCID_CSL_RNAP_NUCLEAR = 
DNA_SNAIL_NUCLEAR+ACTIVE_NCID_CSL_NUCLEAR+RNAP_NUCLEAR+MRNA_SNAIL_NUCLEAR 
 0.64155574306432 ; % 964 MRNA_LEF1_NUCLEAR + NEXPORT_NUCLEAR = MRNA_LEF1_NEXPORT_NUCLEAR
 MRNA_LEF1_NUCLEAR+NEXPORT_NUCLEAR = MRNA_LEF1_NEXPORT_NUCLEAR 
 0.044598989951473156 ; % 965 MRNA_LEF1_NEXPORT_NUCLEAR = MRNA_LEF1_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_LEF1_NEXPORT_NUCLEAR = MRNA_LEF1_NUCLEAR+NEXPORT_NUCLEAR 
 0.4606824018781721 ; % 966 MRNA_LEF1_NEXPORT_NUCLEAR = MRNA_LEF1_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_LEF1_NEXPORT_NUCLEAR = MRNA_LEF1_CYTOSOL+NEXPORT_NUCLEAR 
 0.13532995344825194 ; % 967 MRNA_LEF1_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_LEF1_RIBOSOME_CYTOSOL
 MRNA_LEF1_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_LEF1_RIBOSOME_CYTOSOL 
 0.06013032058588437 ; % 968 MRNA_LEF1_RIBOSOME_CYTOSOL = MRNA_LEF1_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_LEF1_RIBOSOME_CYTOSOL = MRNA_LEF1_CYTOSOL+RIBOSOME_CYTOSOL 
 0.8699641851750547 ; % 969 MRNA_LEF1_RIBOSOME_CYTOSOL = MRNA_LEF1_START_RIBOSOME_CYTOSOL
 MRNA_LEF1_RIBOSOME_CYTOSOL = MRNA_LEF1_START_RIBOSOME_CYTOSOL 
 0.40328427740659945 ; % 970 MRNA_LEF1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + LEF1_CYTOSOL 
+ MRNA_LEF1_CYTOSOL MRNA_LEF1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+LEF1_CYTOSOL+MRNA_LEF1_CYTOSOL 
 0.020573474813859627 ; % 971 MRNA_LEF1_CYTOSOL = [] MRNA_LEF1_CYTOSOL = [] 
 0.3245253207582558 ; % 972 LEF1_CYTOSOL = [] LEF1_CYTOSOL = [] 
 0.00036924036280513 ; % 973 DNA_LEF1_NUCLEAR + P_SP1_NUCLEAR = DNA_LEF1_P_SP1_NUCLEAR
 DNA_LEF1_NUCLEAR+P_SP1_NUCLEAR = DNA_LEF1_P_SP1_NUCLEAR 
 0.659965185878266 ; % 974 DNA_LEF1_P_SP1_NUCLEAR = DNA_LEF1_NUCLEAR + P_SP1_NUCLEAR
 DNA_LEF1_P_SP1_NUCLEAR = DNA_LEF1_NUCLEAR+P_SP1_NUCLEAR 
 0.00093208578737944787 ; % 975 DNA_LEF1_P_SP1_NUCLEAR + RNAP_NUCLEAR = DNA_LEF1_P_SP1_RNAP_NUCLEAR
 DNA_LEF1_P_SP1_NUCLEAR+RNAP_NUCLEAR = DNA_LEF1_P_SP1_RNAP_NUCLEAR 
 0.56545678129179704 ; % 976 DNA_LEF1_P_SP1_RNAP_NUCLEAR = DNA_LEF1_P_SP1_NUCLEAR + RNAP_NUCLEAR
 DNA_LEF1_P_SP1_RNAP_NUCLEAR = DNA_LEF1_P_SP1_NUCLEAR+RNAP_NUCLEAR 
 0.7830563296197833 ; % 977 DNA_LEF1_P_SP1_RNAP_NUCLEAR = DNA_LEF1_NUCLEAR + P_SP1_NUCLEAR + 
RNAP_NUCLEAR + MRNA_LEF1_NUCLEAR DNA_LEF1_P_SP1_RNAP_NUCLEAR = 
DNA_LEF1_NUCLEAR+P_SP1_NUCLEAR+RNAP_NUCLEAR+MRNA_LEF1_NUCLEAR 
 0.0001543146375926685 ; % 978 DNA_LEF1_NUCLEAR + P_AP1_NUCLEAR = DNA_LEF1_P_AP1_NUCLEAR
 DNA_LEF1_NUCLEAR+P_AP1_NUCLEAR = DNA_LEF1_P_AP1_NUCLEAR 
 0.662481631069402 ; % 979 DNA_LEF1_P_AP1_NUCLEAR = DNA_LEF1_NUCLEAR + P_AP1_NUCLEAR
 DNA_LEF1_P_AP1_NUCLEAR = DNA_LEF1_NUCLEAR+P_AP1_NUCLEAR 
 0.0009017374606204481 ; % 980 DNA_LEF1_P_AP1_NUCLEAR + RNAP_NUCLEAR = DNA_LEF1_P_AP1_RNAP_NUCLEAR
 DNA_LEF1_P_AP1_NUCLEAR+RNAP_NUCLEAR = DNA_LEF1_P_AP1_RNAP_NUCLEAR 
 0.4023809622349879 ; % 981 DNA_LEF1_P_AP1_RNAP_NUCLEAR = DNA_LEF1_P_AP1_NUCLEAR + RNAP_NUCLEAR
 DNA_LEF1_P_AP1_RNAP_NUCLEAR = DNA_LEF1_P_AP1_NUCLEAR+RNAP_NUCLEAR 
 0.9183818553334551 ; % 982 DNA_LEF1_P_AP1_RNAP_NUCLEAR = DNA_LEF1_NUCLEAR + P_AP1_NUCLEAR + 
RNAP_NUCLEAR + MRNA_LEF1_NUCLEAR DNA_LEF1_P_AP1_RNAP_NUCLEAR = 
DNA_LEF1_NUCLEAR+P_AP1_NUCLEAR+RNAP_NUCLEAR+MRNA_LEF1_NUCLEAR 
 0.6796486388720944 ; % 983 DNA_LEF1_NUCLEAR + YREG1_NUCLEAR = DNA_LEF1_YREG1_NUCLEAR
 DNA_LEF1_NUCLEAR+YREG1_NUCLEAR = DNA_LEF1_YREG1_NUCLEAR 
 0.007854445931635087 ; % 984 DNA_LEF1_YREG1_NUCLEAR = DNA_LEF1_NUCLEAR + YREG1_NUCLEAR
 DNA_LEF1_YREG1_NUCLEAR = DNA_LEF1_NUCLEAR+YREG1_NUCLEAR 
 0.9849948106923009 ; % 985 YREG1_CYTOSOL + NIMPORT_NUCLEAR = YREG1_NIMPORT_NUCLEAR
 YREG1_CYTOSOL+NIMPORT_NUCLEAR = YREG1_NIMPORT_NUCLEAR 
 0.005110431898005731 ; % 986 YREG1_NIMPORT_NUCLEAR = YREG1_CYTOSOL + NIMPORT_NUCLEAR
 YREG1_NIMPORT_NUCLEAR = YREG1_CYTOSOL+NIMPORT_NUCLEAR 
 0.6378155895561209 ; % 987 YREG1_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR + YREG1_NUCLEAR
 YREG1_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR+YREG1_NUCLEAR 
 0.037459570865114933 ; % 988 YREG1_NUCLEAR + NEXPORT_NUCLEAR = YREG1_NEXPORT_NUCLEAR
 YREG1_NUCLEAR+NEXPORT_NUCLEAR = YREG1_NEXPORT_NUCLEAR 
 0.06099730366904002 ; % 989 YREG1_NEXPORT_NUCLEAR = YREG1_NUCLEAR + NEXPORT_NUCLEAR
 YREG1_NEXPORT_NUCLEAR = YREG1_NUCLEAR+NEXPORT_NUCLEAR 
 0.0507265896782332 ; % 990 YREG1_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR + YREG1_CYTOSOL
 YREG1_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR+YREG1_CYTOSOL 
 0.00001290152514927544 ; % 991 DNA_LEF1_NUCLEAR + BCATENIN_TCF4_NUCLEAR = 
DNA_LEF1_BCATENIN_TCF4_NUCLEAR DNA_LEF1_NUCLEAR+BCATENIN_TCF4_NUCLEAR = DNA_LEF1_BCATENIN_TCF4_NUCLEAR 
 0.023740649512587444 ; % 992 DNA_LEF1_BCATENIN_TCF4_NUCLEAR = DNA_LEF1_NUCLEAR + 
BCATENIN_TCF4_NUCLEAR DNA_LEF1_BCATENIN_TCF4_NUCLEAR = DNA_LEF1_NUCLEAR+BCATENIN_TCF4_NUCLEAR 
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 0.00004700333191116176 ; % 993 DNA_LEF1_BCATENIN_TCF4_NUCLEAR + RNAP_NUCLEAR = 
DNA_LEF1_BCATENIN_TCF4_RNAP_NUCLEAR DNA_LEF1_BCATENIN_TCF4_NUCLEAR+RNAP_NUCLEAR = DNA_LEF1_BCATENIN_TCF4_RNAP_NUCLEAR 
 0.08716514430037481 ; % 994 DNA_LEF1_BCATENIN_TCF4_RNAP_NUCLEAR = 
DNA_LEF1_BCATENIN_TCF4_NUCLEAR + RNAP_NUCLEAR DNA_LEF1_BCATENIN_TCF4_RNAP_NUCLEAR = 
DNA_LEF1_BCATENIN_TCF4_NUCLEAR+RNAP_NUCLEAR 
 0.2208336482279667 ; % 995 DNA_LEF1_BCATENIN_TCF4_RNAP_NUCLEAR = DNA_LEF1_NUCLEAR + 
BCATENIN_TCF4_NUCLEAR + RNAP_NUCLEAR + MRNA_LEF1_NUCLEAR DNA_LEF1_BCATENIN_TCF4_RNAP_NUCLEAR = 
DNA_LEF1_NUCLEAR+BCATENIN_TCF4_NUCLEAR+RNAP_NUCLEAR+MRNA_LEF1_NUCLEAR 
 0.9038626132762561 ; % 996 DNA_LEF1_NUCLEAR + PSMAD2_SMAD4_NUCLEAR = 
DNA_LEF1_PSMAD2_SMAD4_NUCLEAR DNA_LEF1_NUCLEAR+PSMAD2_SMAD4_NUCLEAR = DNA_LEF1_PSMAD2_SMAD4_NUCLEAR 
 0.0001833889101410521 ; % 997 DNA_LEF1_PSMAD2_SMAD4_NUCLEAR = DNA_LEF1_NUCLEAR + 
PSMAD2_SMAD4_NUCLEAR DNA_LEF1_PSMAD2_SMAD4_NUCLEAR = DNA_LEF1_NUCLEAR+PSMAD2_SMAD4_NUCLEAR 
 0.684396272214844 ; % 998 DNA_LEF1_PSMAD2_SMAD4_NUCLEAR + RNAP_NUCLEAR = 
DNA_LEF1_PSMAD2_SMAD4_RNAP_NUCLEAR DNA_LEF1_PSMAD2_SMAD4_NUCLEAR+RNAP_NUCLEAR = DNA_LEF1_PSMAD2_SMAD4_RNAP_NUCLEAR 
 0.0008832960714437582 ; % 999 DNA_LEF1_PSMAD2_SMAD4_RNAP_NUCLEAR = 
DNA_LEF1_PSMAD2_SMAD4_NUCLEAR + RNAP_NUCLEAR DNA_LEF1_PSMAD2_SMAD4_RNAP_NUCLEAR = 
DNA_LEF1_PSMAD2_SMAD4_NUCLEAR+RNAP_NUCLEAR 
 0.9993140868262271 ; % 1000 DNA_LEF1_PSMAD2_SMAD4_RNAP_NUCLEAR = DNA_LEF1_NUCLEAR + 
PSMAD2_SMAD4_NUCLEAR + RNAP_NUCLEAR + MRNA_LEF1_NUCLEAR DNA_LEF1_PSMAD2_SMAD4_RNAP_NUCLEAR = 
DNA_LEF1_NUCLEAR+PSMAD2_SMAD4_NUCLEAR+RNAP_NUCLEAR+MRNA_LEF1_NUCLEAR 
 0.5827869322306561 ; % 1001 PSMAD2_CYTOSOL + SMAD4_CYTOSOL = PSMAD2_SMAD4_CYTOSOL
 PSMAD2_CYTOSOL+SMAD4_CYTOSOL = PSMAD2_SMAD4_CYTOSOL 
 0.008659421027035985 ; % 1002 PSMAD2_SMAD4_CYTOSOL = PSMAD2_CYTOSOL + SMAD4_CYTOSOL
 PSMAD2_SMAD4_CYTOSOL = PSMAD2_CYTOSOL+SMAD4_CYTOSOL 
 0.6193994131883749 ; % 1003 PSMAD2_SMAD4_CYTOSOL + NIMPORT_NUCLEAR = 
PSMAD2_SMAD4_NIMPORT_NUCLEAR PSMAD2_SMAD4_CYTOSOL+NIMPORT_NUCLEAR = PSMAD2_SMAD4_NIMPORT_NUCLEAR 
 0.07856214474732792 ; % 1004 PSMAD2_SMAD4_NIMPORT_NUCLEAR = PSMAD2_SMAD4_CYTOSOL + 
NIMPORT_NUCLEAR PSMAD2_SMAD4_NIMPORT_NUCLEAR = PSMAD2_SMAD4_CYTOSOL+NIMPORT_NUCLEAR 
 0.6625485915323986 ; % 1005 PSMAD2_SMAD4_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR + 
PSMAD2_SMAD4_NUCLEAR PSMAD2_SMAD4_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR+PSMAD2_SMAD4_NUCLEAR 
 0.09766889561146144 ; % 1006 PSMAD2_SMAD4_NUCLEAR + NEXPORT_NUCLEAR = 
PSMAD2_SMAD4_NEXPORT_NUCLEAR PSMAD2_SMAD4_NUCLEAR+NEXPORT_NUCLEAR = PSMAD2_SMAD4_NEXPORT_NUCLEAR 
 0.013787815981760744 ; % 1007 PSMAD2_SMAD4_NEXPORT_NUCLEAR = PSMAD2_SMAD4_NUCLEAR + 
NEXPORT_NUCLEAR PSMAD2_SMAD4_NEXPORT_NUCLEAR = PSMAD2_SMAD4_NUCLEAR+NEXPORT_NUCLEAR 
 0.07849644722521144 ; % 1008 PSMAD2_SMAD4_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR + 
PSMAD2_SMAD4_CYTOSOL PSMAD2_SMAD4_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR+PSMAD2_SMAD4_CYTOSOL 
 0.8114984141007076 ; % 1009 DNA_LEF1_NUCLEAR + PSMAD3_SMAD4_NUCLEAR = 
DNA_LEF1_PSMAD3_SMAD4_NUCLEAR DNA_LEF1_NUCLEAR+PSMAD3_SMAD4_NUCLEAR = DNA_LEF1_PSMAD3_SMAD4_NUCLEAR 
 0.0004105271269438591 ; % 1010 DNA_LEF1_PSMAD3_SMAD4_NUCLEAR = DNA_LEF1_NUCLEAR + 
PSMAD3_SMAD4_NUCLEAR DNA_LEF1_PSMAD3_SMAD4_NUCLEAR = DNA_LEF1_NUCLEAR+PSMAD3_SMAD4_NUCLEAR 
 0.5532195234135988 ; % 1011 DNA_LEF1_PSMAD3_SMAD4_NUCLEAR + RNAP_NUCLEAR = 
DNA_LEF1_PSMAD3_SMAD4_RNAP_NUCLEAR DNA_LEF1_PSMAD3_SMAD4_NUCLEAR+RNAP_NUCLEAR = DNA_LEF1_PSMAD3_SMAD4_RNAP_NUCLEAR 
 0.008752776269006068 ; % 1012 DNA_LEF1_PSMAD3_SMAD4_RNAP_NUCLEAR = 
DNA_LEF1_PSMAD3_SMAD4_NUCLEAR + RNAP_NUCLEAR DNA_LEF1_PSMAD3_SMAD4_RNAP_NUCLEAR = 
DNA_LEF1_PSMAD3_SMAD4_NUCLEAR+RNAP_NUCLEAR 
 0.66298925999519784 ; % 1013 DNA_LEF1_PSMAD3_SMAD4_RNAP_NUCLEAR = DNA_LEF1_NUCLEAR + 
PSMAD3_SMAD4_NUCLEAR + RNAP_NUCLEAR + MRNA_LEF1_NUCLEAR DNA_LEF1_PSMAD3_SMAD4_RNAP_NUCLEAR = 
DNA_LEF1_NUCLEAR+PSMAD3_SMAD4_NUCLEAR+RNAP_NUCLEAR+MRNA_LEF1_NUCLEAR 
 0.8495767718676666 ; % 1014 PSMAD3_CYTOSOL + SMAD4_CYTOSOL = PSMAD3_SMAD4_CYTOSOL
 PSMAD3_CYTOSOL+SMAD4_CYTOSOL = PSMAD3_SMAD4_CYTOSOL 
 0.0020438923808302745 ; % 1015 PSMAD3_SMAD4_CYTOSOL = PSMAD3_CYTOSOL + SMAD4_CYTOSOL
 PSMAD3_SMAD4_CYTOSOL = PSMAD3_CYTOSOL+SMAD4_CYTOSOL 
 0.50835719190732747 ; % 1016 PSMAD3_SMAD4_CYTOSOL + NIMPORT_NUCLEAR = 
PSMAD3_SMAD4_NIMPORT_NUCLEAR PSMAD3_SMAD4_CYTOSOL+NIMPORT_NUCLEAR = PSMAD3_SMAD4_NIMPORT_NUCLEAR 
 0.003528014643126919 ; % 1017 PSMAD3_SMAD4_NIMPORT_NUCLEAR = PSMAD3_SMAD4_CYTOSOL + 
NIMPORT_NUCLEAR PSMAD3_SMAD4_NIMPORT_NUCLEAR = PSMAD3_SMAD4_CYTOSOL+NIMPORT_NUCLEAR 
 0.34071586620842966 ; % 1018 PSMAD3_SMAD4_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR + 
PSMAD3_SMAD4_NUCLEAR PSMAD3_SMAD4_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR+PSMAD3_SMAD4_NUCLEAR 
 0.0946424274434269 ; % 1019 PSMAD3_SMAD4_NUCLEAR + NEXPORT_NUCLEAR = 
PSMAD3_SMAD4_NEXPORT_NUCLEAR PSMAD3_SMAD4_NUCLEAR+NEXPORT_NUCLEAR = PSMAD3_SMAD4_NEXPORT_NUCLEAR 
 0.07420319971944565 ; % 1020 PSMAD3_SMAD4_NEXPORT_NUCLEAR = PSMAD3_SMAD4_NUCLEAR + 
NEXPORT_NUCLEAR PSMAD3_SMAD4_NEXPORT_NUCLEAR = PSMAD3_SMAD4_NUCLEAR+NEXPORT_NUCLEAR 
 0.06915133141781196 ; % 1021 PSMAD3_SMAD4_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR + 
PSMAD3_SMAD4_CYTOSOL PSMAD3_SMAD4_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR+PSMAD3_SMAD4_CYTOSOL 
 0.909139794615169 ; % 1022 DNA_YREG1_NUCLEAR + SNAIL_NUCLEAR = DNA_YREG1_SNAIL_NUCLEAR
 DNA_YREG1_NUCLEAR+SNAIL_NUCLEAR = DNA_YREG1_SNAIL_NUCLEAR 
 0.06879944055708677 ; % 1023 DNA_YREG1_SNAIL_NUCLEAR = DNA_YREG1_NUCLEAR + SNAIL_NUCLEAR
 DNA_YREG1_SNAIL_NUCLEAR = DNA_YREG1_NUCLEAR+SNAIL_NUCLEAR 
 0.7792358587398225 ; % 1024 SNAIL_CYTOSOL + NIMPORT_NUCLEAR = SNAIL_NIMPORT_NUCLEAR
 SNAIL_CYTOSOL+NIMPORT_NUCLEAR = SNAIL_NIMPORT_NUCLEAR 
 0.07300115165415934 ; % 1025 SNAIL_NIMPORT_NUCLEAR = SNAIL_CYTOSOL + NIMPORT_NUCLEAR
 SNAIL_NIMPORT_NUCLEAR = SNAIL_CYTOSOL+NIMPORT_NUCLEAR 
 0.4642230978204308 ; % 1026 SNAIL_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR + SNAIL_NUCLEAR
 SNAIL_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR+SNAIL_NUCLEAR 
 0.02322970200022778 ; % 1027 SNAIL_NUCLEAR + NEXPORT_NUCLEAR = SNAIL_NEXPORT_NUCLEAR
 SNAIL_NUCLEAR+NEXPORT_NUCLEAR = SNAIL_NEXPORT_NUCLEAR 
 0.07258042671074526 ; % 1028 SNAIL_NEXPORT_NUCLEAR = SNAIL_NUCLEAR + NEXPORT_NUCLEAR
 SNAIL_NEXPORT_NUCLEAR = SNAIL_NUCLEAR+NEXPORT_NUCLEAR 
 0.025129962322406052 ; % 1029 SNAIL_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR + SNAIL_CYTOSOL
 SNAIL_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR+SNAIL_CYTOSOL 
 0.812985228726991 ; % 1030 DNA_YREG1_NUCLEAR + SLUG_NUCLEAR = DNA_YREG1_SLUG_NUCLEAR
 DNA_YREG1_NUCLEAR+SLUG_NUCLEAR = DNA_YREG1_SLUG_NUCLEAR 
 0.0037556445604581268 ; % 1031 DNA_YREG1_SLUG_NUCLEAR = DNA_YREG1_NUCLEAR + SLUG_NUCLEAR
 DNA_YREG1_SLUG_NUCLEAR = DNA_YREG1_NUCLEAR+SLUG_NUCLEAR 
 0.8057558443262969 ; % 1032 SLUG_CYTOSOL + NIMPORT_NUCLEAR = SLUG_NIMPORT_NUCLEAR
 SLUG_CYTOSOL+NIMPORT_NUCLEAR = SLUG_NIMPORT_NUCLEAR 
 0.07969757345270201 ; % 1033 SLUG_NIMPORT_NUCLEAR = SLUG_CYTOSOL + NIMPORT_NUCLEAR
 SLUG_NIMPORT_NUCLEAR = SLUG_CYTOSOL+NIMPORT_NUCLEAR 
 0.80446135534356968 ; % 1034 SLUG_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR + SLUG_NUCLEAR
 SLUG_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR+SLUG_NUCLEAR 
 0.07549790829130268 ; % 1035 SLUG_NUCLEAR + NEXPORT_NUCLEAR = SLUG_NEXPORT_NUCLEAR
 SLUG_NUCLEAR+NEXPORT_NUCLEAR = SLUG_NEXPORT_NUCLEAR 
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 0.0479385015198228 ; % 1036 SLUG_NEXPORT_NUCLEAR = SLUG_NUCLEAR + NEXPORT_NUCLEAR
 SLUG_NEXPORT_NUCLEAR = SLUG_NUCLEAR+NEXPORT_NUCLEAR 
 0.011032143643005121 ; % 1037 SLUG_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR + SLUG_CYTOSOL
 SLUG_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR+SLUG_CYTOSOL 
 0.6563516012250837 ; % 1038 DNA_YREG1_NUCLEAR + TWIST_NUCLEAR = DNA_YREG1_TWIST_NUCLEAR
 DNA_YREG1_NUCLEAR+TWIST_NUCLEAR = DNA_YREG1_TWIST_NUCLEAR 
 0.023819137080219654 ; % 1039 DNA_YREG1_TWIST_NUCLEAR = DNA_YREG1_NUCLEAR + TWIST_NUCLEAR
 DNA_YREG1_TWIST_NUCLEAR = DNA_YREG1_NUCLEAR+TWIST_NUCLEAR 
 0.4287972565918152 ; % 1040 DNA_TGFBRIII_NUCLEAR + P_SP1_NUCLEAR = DNA_TGFBRIII_P_SP1_NUCLEAR
 DNA_TGFBRIII_NUCLEAR+P_SP1_NUCLEAR = DNA_TGFBRIII_P_SP1_NUCLEAR 
 0.07095133801109646 ; % 1041 DNA_TGFBRIII_P_SP1_NUCLEAR = DNA_TGFBRIII_NUCLEAR + P_SP1_NUCLEAR
 DNA_TGFBRIII_P_SP1_NUCLEAR = DNA_TGFBRIII_NUCLEAR+P_SP1_NUCLEAR 
 0.605894081297111 ; % 1042 DNA_TGFBRIII_P_SP1_NUCLEAR + PSMAD3_SMAD4_NUCLEAR = 
DNA_TGFBRIII_P_SP1_PSMAD3_SMAD4_NUCLEAR DNA_TGFBRIII_P_SP1_NUCLEAR+PSMAD3_SMAD4_NUCLEAR = 
DNA_TGFBRIII_P_SP1_PSMAD3_SMAD4_NUCLEAR 
 0.0053095088183134805 ; % 1043 DNA_TGFBRIII_P_SP1_PSMAD3_SMAD4_NUCLEAR = DNA_TGFBRIII_P_SP1_NUCLEAR 
+ PSMAD3_SMAD4_NUCLEAR DNA_TGFBRIII_P_SP1_PSMAD3_SMAD4_NUCLEAR = DNA_TGFBRIII_P_SP1_NUCLEAR+PSMAD3_SMAD4_NUCLEAR 
 0.18593148318478914 ; % 1044 DNA_TGFBRIII_P_SP1_PSMAD3_SMAD4_NUCLEAR + RNAP_NUCLEAR = 
DNA_TGFBRIII_P_SP1_PSMAD3_SMAD4_RNAP_NUCLEAR DNA_TGFBRIII_P_SP1_PSMAD3_SMAD4_NUCLEAR+RNAP_NUCLEAR = 
DNA_TGFBRIII_P_SP1_PSMAD3_SMAD4_RNAP_NUCLEAR 
 0.01896652305266401 ; % 1045 DNA_TGFBRIII_P_SP1_PSMAD3_SMAD4_RNAP_NUCLEAR = 
DNA_TGFBRIII_P_SP1_PSMAD3_SMAD4_NUCLEAR + RNAP_NUCLEAR DNA_TGFBRIII_P_SP1_PSMAD3_SMAD4_RNAP_NUCLEAR = 
DNA_TGFBRIII_P_SP1_PSMAD3_SMAD4_NUCLEAR+RNAP_NUCLEAR 
 0.7371386880382716 ; % 1046 DNA_TGFBRIII_P_SP1_PSMAD3_SMAD4_RNAP_NUCLEAR = DNA_TGFBRIII_NUCLEAR 
+ P_SP1_NUCLEAR + PSMAD3_SMAD4_NUCLEAR + RNAP_NUCLEAR + MRNA_TGFBRIII_NUCLEAR DNA_TGFBRIII_P_SP1_PSMAD3_SMAD4_RNAP_NUCLEAR = 
DNA_TGFBRIII_NUCLEAR+P_SP1_NUCLEAR+PSMAD3_SMAD4_NUCLEAR+RNAP_NUCLEAR+MRNA_TGFBRIII_NUCLEAR 
 0.665750012435797 ; % 1047 MRNA_CREB_NUCLEAR + NEXPORT_NUCLEAR = MRNA_CREB_NEXPORT_NUCLEAR
 MRNA_CREB_NUCLEAR+NEXPORT_NUCLEAR = MRNA_CREB_NEXPORT_NUCLEAR 
 0.05674904016431015 ; % 1048 MRNA_CREB_NEXPORT_NUCLEAR = MRNA_CREB_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_CREB_NEXPORT_NUCLEAR = MRNA_CREB_NUCLEAR+NEXPORT_NUCLEAR 
 0.4964775975686876 ; % 1049 MRNA_CREB_NEXPORT_NUCLEAR = MRNA_CREB_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_CREB_NEXPORT_NUCLEAR = MRNA_CREB_CYTOSOL+NEXPORT_NUCLEAR 
 0.4055352909361867 ; % 1050 MRNA_CREB_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_CREB_RIBOSOME_CYTOSOL MRNA_CREB_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_CREB_RIBOSOME_CYTOSOL 
 0.03524739018999985 ; % 1051 MRNA_CREB_RIBOSOME_CYTOSOL = MRNA_CREB_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_CREB_RIBOSOME_CYTOSOL = MRNA_CREB_CYTOSOL+RIBOSOME_CYTOSOL 
 0.30411257048958884 ; % 1052 MRNA_CREB_RIBOSOME_CYTOSOL = MRNA_CREB_START_RIBOSOME_CYTOSOL
 MRNA_CREB_RIBOSOME_CYTOSOL = MRNA_CREB_START_RIBOSOME_CYTOSOL 
 0.7128434240185748 ; % 1053 MRNA_CREB_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
CREB_CYTOSOL + MRNA_CREB_CYTOSOL MRNA_CREB_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+CREB_CYTOSOL+MRNA_CREB_CYTOSOL 
 0.43955515132567996 ; % 1054 MRNA_CREB_CYTOSOL = [] MRNA_CREB_CYTOSOL = [] 
 0.18637865591300284 ; % 1055 CREB_CYTOSOL = [] CREB_CYTOSOL = [] 
 0.7954254033985687 ; % 1056 DNA_CREB_NUCLEAR + SNAIL_NUCLEAR = DNA_CREB_SNAIL_NUCLEAR
 DNA_CREB_NUCLEAR+SNAIL_NUCLEAR = DNA_CREB_SNAIL_NUCLEAR 
 0.0712470302943861 ; % 1057 DNA_CREB_SNAIL_NUCLEAR = DNA_CREB_NUCLEAR + SNAIL_NUCLEAR
 DNA_CREB_SNAIL_NUCLEAR = DNA_CREB_NUCLEAR+SNAIL_NUCLEAR 
 0.17939456103718765 ; % 1058 DNA_CREB_NUCLEAR + SLUG_NUCLEAR = DNA_CREB_SLUG_NUCLEAR
 DNA_CREB_NUCLEAR+SLUG_NUCLEAR = DNA_CREB_SLUG_NUCLEAR 
 0.047985228020168136 ; % 1059 DNA_CREB_SLUG_NUCLEAR = DNA_CREB_NUCLEAR + SLUG_NUCLEAR
 DNA_CREB_SLUG_NUCLEAR = DNA_CREB_NUCLEAR+SLUG_NUCLEAR 
 0.7666837272945636 ; % 1060 MRNA_TGFB3_NUCLEAR + NEXPORT_NUCLEAR = MRNA_TGFB3_NEXPORT_NUCLEAR
 MRNA_TGFB3_NUCLEAR+NEXPORT_NUCLEAR = MRNA_TGFB3_NEXPORT_NUCLEAR 
 0.05390706317068598 ; % 1061 MRNA_TGFB3_NEXPORT_NUCLEAR = MRNA_TGFB3_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_TGFB3_NEXPORT_NUCLEAR = MRNA_TGFB3_NUCLEAR+NEXPORT_NUCLEAR 
 0.5605855961675164 ; % 1062 MRNA_TGFB3_NEXPORT_NUCLEAR = MRNA_TGFB3_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_TGFB3_NEXPORT_NUCLEAR = MRNA_TGFB3_CYTOSOL+NEXPORT_NUCLEAR 
 0.32534027511968344 ; % 1063 MRNA_TGFB3_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_TGFB3_RIBOSOME_CYTOSOL MRNA_TGFB3_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_TGFB3_RIBOSOME_CYTOSOL 
 0.03796365960382067 ; % 1064 MRNA_TGFB3_RIBOSOME_CYTOSOL = MRNA_TGFB3_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_TGFB3_RIBOSOME_CYTOSOL = MRNA_TGFB3_CYTOSOL+RIBOSOME_CYTOSOL 
 0.30424085754544217 ; % 1065 MRNA_TGFB3_RIBOSOME_CYTOSOL = MRNA_TGFB3_START_RIBOSOME_CYTOSOL
 MRNA_TGFB3_RIBOSOME_CYTOSOL = MRNA_TGFB3_START_RIBOSOME_CYTOSOL 
 0.295309242494041 ; % 1066 MRNA_TGFB3_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
TGFB3_CYTOSOL + MRNA_TGFB3_CYTOSOL MRNA_TGFB3_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+TGFB3_CYTOSOL+MRNA_TGFB3_CYTOSOL 
 0.275839644207659 ; % 1067 MRNA_TGFB3_CYTOSOL = [] MRNA_TGFB3_CYTOSOL = [] 
 0.2041367153131641 ; % 1068 TGFB3_CYTOSOL = [] TGFB3_CYTOSOL = [] 
 0.08879715445996236 ; % 1069 DNA_TGFB3_NUCLEAR + YREG1_NUCLEAR = DNA_TGFB3_YREG1_NUCLEAR
 DNA_TGFB3_NUCLEAR+YREG1_NUCLEAR = DNA_TGFB3_YREG1_NUCLEAR 
 0.29714793513157001 ; % 1070 DNA_TGFB3_YREG1_NUCLEAR = DNA_TGFB3_NUCLEAR + YREG1_NUCLEAR
 DNA_TGFB3_YREG1_NUCLEAR = DNA_TGFB3_NUCLEAR+YREG1_NUCLEAR 
 0.8606759737568547 ; % 1071 DNA_TGFB3_NUCLEAR + SNAIL_NUCLEAR = DNA_TGFB3_SNAIL_NUCLEAR
 DNA_TGFB3_NUCLEAR+SNAIL_NUCLEAR = DNA_TGFB3_SNAIL_NUCLEAR 
 0.055435733674386366 ; % 1072 DNA_TGFB3_SNAIL_NUCLEAR = DNA_TGFB3_NUCLEAR + SNAIL_NUCLEAR
 DNA_TGFB3_SNAIL_NUCLEAR = DNA_TGFB3_NUCLEAR+SNAIL_NUCLEAR 
 2.7728002664714843 ; % 1073 DNA_TGFB3_SNAIL_NUCLEAR + BCATENIN_TCF4_NUCLEAR = 
DNA_TGFB3_SNAIL_BCATENIN_TCF4_NUCLEAR DNA_TGFB3_SNAIL_NUCLEAR+BCATENIN_TCF4_NUCLEAR = DNA_TGFB3_SNAIL_BCATENIN_TCF4_NUCLEAR 
 0.0009471364518100901 ; % 1074 DNA_TGFB3_SNAIL_BCATENIN_TCF4_NUCLEAR = DNA_TGFB3_SNAIL_NUCLEAR + 
BCATENIN_TCF4_NUCLEAR DNA_TGFB3_SNAIL_BCATENIN_TCF4_NUCLEAR = DNA_TGFB3_SNAIL_NUCLEAR+BCATENIN_TCF4_NUCLEAR 
 0.9602340018246602 ; % 1075 DNA_TGFB3_SNAIL_BCATENIN_TCF4_NUCLEAR + RNAP_NUCLEAR = 
DNA_TGFB3_SNAIL_BCATENIN_TCF4_RNAP_NUCLEAR DNA_TGFB3_SNAIL_BCATENIN_TCF4_NUCLEAR+RNAP_NUCLEAR = 
DNA_TGFB3_SNAIL_BCATENIN_TCF4_RNAP_NUCLEAR 
 0.008481623654728794 ; % 1076 DNA_TGFB3_SNAIL_BCATENIN_TCF4_RNAP_NUCLEAR = 
DNA_TGFB3_SNAIL_BCATENIN_TCF4_NUCLEAR + RNAP_NUCLEAR DNA_TGFB3_SNAIL_BCATENIN_TCF4_RNAP_NUCLEAR = 
DNA_TGFB3_SNAIL_BCATENIN_TCF4_NUCLEAR+RNAP_NUCLEAR 
 0.9459394466233575 ; % 1077 DNA_TGFB3_SNAIL_BCATENIN_TCF4_RNAP_NUCLEAR = DNA_TGFB3_NUCLEAR + 
SNAIL_NUCLEAR + BCATENIN_TCF4_NUCLEAR + RNAP_NUCLEAR + MRNA_TGFB3_NUCLEAR DNA_TGFB3_SNAIL_BCATENIN_TCF4_RNAP_NUCLEAR = 
DNA_TGFB3_NUCLEAR+SNAIL_NUCLEAR+BCATENIN_TCF4_NUCLEAR+RNAP_NUCLEAR+MRNA_TGFB3_NUCLEAR 
 0.9587793715687574 ; % 1078 DNA_TGFB3_NUCLEAR + SLUG_NUCLEAR = DNA_TGFB3_SLUG_NUCLEAR
 DNA_TGFB3_NUCLEAR+SLUG_NUCLEAR = DNA_TGFB3_SLUG_NUCLEAR 
 0.05844908276465517 ; % 1079 DNA_TGFB3_SLUG_NUCLEAR = DNA_TGFB3_NUCLEAR + SLUG_NUCLEAR
 DNA_TGFB3_SLUG_NUCLEAR = DNA_TGFB3_NUCLEAR+SLUG_NUCLEAR 
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 2.95658850967513944 ; % 1080 DNA_TGFB3_SLUG_NUCLEAR + BCATENIN_TCF4_NUCLEAR = 
DNA_TGFB3_SLUG_BCATENIN_TCF4_NUCLEAR DNA_TGFB3_SLUG_NUCLEAR+BCATENIN_TCF4_NUCLEAR = DNA_TGFB3_SLUG_BCATENIN_TCF4_NUCLEAR 
 0.0005632819016923157 ; % 1081 DNA_TGFB3_SLUG_BCATENIN_TCF4_NUCLEAR = DNA_TGFB3_SLUG_NUCLEAR + 
BCATENIN_TCF4_NUCLEAR DNA_TGFB3_SLUG_BCATENIN_TCF4_NUCLEAR = DNA_TGFB3_SLUG_NUCLEAR+BCATENIN_TCF4_NUCLEAR 
 0.93358643566747774 ; % 1082 DNA_TGFB3_SLUG_BCATENIN_TCF4_NUCLEAR + RNAP_NUCLEAR = 
DNA_TGFB3_SLUG_BCATENIN_TCF4_RNAP_NUCLEAR DNA_TGFB3_SLUG_BCATENIN_TCF4_NUCLEAR+RNAP_NUCLEAR = 
DNA_TGFB3_SLUG_BCATENIN_TCF4_RNAP_NUCLEAR 
 0.006430467636958169 ; % 1083 DNA_TGFB3_SLUG_BCATENIN_TCF4_RNAP_NUCLEAR = 
DNA_TGFB3_SLUG_BCATENIN_TCF4_NUCLEAR + RNAP_NUCLEAR DNA_TGFB3_SLUG_BCATENIN_TCF4_RNAP_NUCLEAR = 
DNA_TGFB3_SLUG_BCATENIN_TCF4_NUCLEAR+RNAP_NUCLEAR 
 0.90383640685612883 ; % 1084 DNA_TGFB3_SLUG_BCATENIN_TCF4_RNAP_NUCLEAR = DNA_TGFB3_NUCLEAR + 
SLUG_NUCLEAR + BCATENIN_TCF4_NUCLEAR + RNAP_NUCLEAR + MRNA_TGFB3_NUCLEAR DNA_TGFB3_SLUG_BCATENIN_TCF4_RNAP_NUCLEAR = 
DNA_TGFB3_NUCLEAR+SLUG_NUCLEAR+BCATENIN_TCF4_NUCLEAR+RNAP_NUCLEAR+MRNA_TGFB3_NUCLEAR 
 0.4850069321453715 ; % 1085 MRNA_TGFB2_NUCLEAR + NEXPORT_NUCLEAR = MRNA_TGFB2_NEXPORT_NUCLEAR
 MRNA_TGFB2_NUCLEAR+NEXPORT_NUCLEAR = MRNA_TGFB2_NEXPORT_NUCLEAR 
 0.08170558704635998 ; % 1086 MRNA_TGFB2_NEXPORT_NUCLEAR = MRNA_TGFB2_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_TGFB2_NEXPORT_NUCLEAR = MRNA_TGFB2_NUCLEAR+NEXPORT_NUCLEAR 
 0.5781424117965585 ; % 1087 MRNA_TGFB2_NEXPORT_NUCLEAR = MRNA_TGFB2_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_TGFB2_NEXPORT_NUCLEAR = MRNA_TGFB2_CYTOSOL+NEXPORT_NUCLEAR 
 0.9990814845683813 ; % 1088 MRNA_TGFB2_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_TGFB2_RIBOSOME_CYTOSOL MRNA_TGFB2_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_TGFB2_RIBOSOME_CYTOSOL 
 0.0064580080776362354 ; % 1089 MRNA_TGFB2_RIBOSOME_CYTOSOL = MRNA_TGFB2_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_TGFB2_RIBOSOME_CYTOSOL = MRNA_TGFB2_CYTOSOL+RIBOSOME_CYTOSOL 
 0.6949779528069032 ; % 1090 MRNA_TGFB2_RIBOSOME_CYTOSOL = MRNA_TGFB2_START_RIBOSOME_CYTOSOL
 MRNA_TGFB2_RIBOSOME_CYTOSOL = MRNA_TGFB2_START_RIBOSOME_CYTOSOL 
 0.6785773412130911 ; % 1091 MRNA_TGFB2_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
TGFB2_CYTOSOL + MRNA_TGFB2_CYTOSOL MRNA_TGFB2_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+TGFB2_CYTOSOL+MRNA_TGFB2_CYTOSOL 
 0.43054744497003544 ; % 1092 MRNA_TGFB2_CYTOSOL = [] MRNA_TGFB2_CYTOSOL = [] 
 0.3506301009784325 ; % 1093 TGFB2_CYTOSOL = [] TGFB2_CYTOSOL = [] 
 0.6622835370213042 ; % 1094 DNA_TGFB2_NUCLEAR + PAX3_NUCLEAR = DNA_TGFB2_PAX3_NUCLEAR
 DNA_TGFB2_NUCLEAR+PAX3_NUCLEAR = DNA_TGFB2_PAX3_NUCLEAR 
 0.06348150010650078 ; % 1095 DNA_TGFB2_PAX3_NUCLEAR = DNA_TGFB2_NUCLEAR + PAX3_NUCLEAR
 DNA_TGFB2_PAX3_NUCLEAR = DNA_TGFB2_NUCLEAR+PAX3_NUCLEAR 
 0.3315168400872974 ; % 1096 DNA_TGFB2_PAX3_NUCLEAR + PSMAD1_SMAD4_NUCLEAR = 
DNA_TGFB2_PAX3_PSMAD1_SMAD4_NUCLEAR DNA_TGFB2_PAX3_NUCLEAR+PSMAD1_SMAD4_NUCLEAR = DNA_TGFB2_PAX3_PSMAD1_SMAD4_NUCLEAR 
 0.06507976572532394 ; % 1097 DNA_TGFB2_PAX3_PSMAD1_SMAD4_NUCLEAR = DNA_TGFB2_PAX3_NUCLEAR + 
PSMAD1_SMAD4_NUCLEAR DNA_TGFB2_PAX3_PSMAD1_SMAD4_NUCLEAR = DNA_TGFB2_PAX3_NUCLEAR+PSMAD1_SMAD4_NUCLEAR 
 0.771197572873458 ; % 1098 DNA_TGFB2_PAX3_PSMAD1_SMAD4_NUCLEAR + RNAP_NUCLEAR = 
DNA_TGFB2_PAX3_PSMAD1_SMAD4_RNAP_NUCLEAR DNA_TGFB2_PAX3_PSMAD1_SMAD4_NUCLEAR+RNAP_NUCLEAR = 
DNA_TGFB2_PAX3_PSMAD1_SMAD4_RNAP_NUCLEAR 
 0.010531070462283743 ; % 1099 DNA_TGFB2_PAX3_PSMAD1_SMAD4_RNAP_NUCLEAR = 
DNA_TGFB2_PAX3_PSMAD1_SMAD4_NUCLEAR + RNAP_NUCLEAR DNA_TGFB2_PAX3_PSMAD1_SMAD4_RNAP_NUCLEAR = 
DNA_TGFB2_PAX3_PSMAD1_SMAD4_NUCLEAR+RNAP_NUCLEAR 
 0.5764951821425189 ; % 1100 DNA_TGFB2_PAX3_PSMAD1_SMAD4_RNAP_NUCLEAR = DNA_TGFB2_NUCLEAR + 
PAX3_NUCLEAR + PSMAD1_SMAD4_NUCLEAR + RNAP_NUCLEAR + MRNA_TGFB2_NUCLEAR DNA_TGFB2_PAX3_PSMAD1_SMAD4_RNAP_NUCLEAR = 
DNA_TGFB2_NUCLEAR+PAX3_NUCLEAR+PSMAD1_SMAD4_NUCLEAR+RNAP_NUCLEAR+MRNA_TGFB2_NUCLEAR 
 0.7298277826495015 ; % 1101 PAX3_CYTOSOL + NIMPORT_NUCLEAR = PAX3_NIMPORT_NUCLEAR
 PAX3_CYTOSOL+NIMPORT_NUCLEAR = PAX3_NIMPORT_NUCLEAR 
 0.037725802977387195 ; % 1102 PAX3_NIMPORT_NUCLEAR = PAX3_CYTOSOL + NIMPORT_NUCLEAR
 PAX3_NIMPORT_NUCLEAR = PAX3_CYTOSOL+NIMPORT_NUCLEAR 
 0.2943601757351937 ; % 1103 PAX3_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR + PAX3_NUCLEAR
 PAX3_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR+PAX3_NUCLEAR 
 0.19066027008711983 ; % 1104 PAX3_NUCLEAR + NEXPORT_NUCLEAR = PAX3_NEXPORT_NUCLEAR
 PAX3_NUCLEAR+NEXPORT_NUCLEAR = PAX3_NEXPORT_NUCLEAR 
 0.08465340058514474 ; % 1105 PAX3_NEXPORT_NUCLEAR = PAX3_NUCLEAR + NEXPORT_NUCLEAR
 PAX3_NEXPORT_NUCLEAR = PAX3_NUCLEAR+NEXPORT_NUCLEAR 
 0.2941437227259286 ; % 1106 PAX3_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR + PAX3_CYTOSOL
 PAX3_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR+PAX3_CYTOSOL 
 0.00617221557970149 ; % 1107 PSMAD1_CYTOSOL + SMAD4_CYTOSOL = PSMAD1_SMAD4_CYTOSOL
 PSMAD1_CYTOSOL+SMAD4_CYTOSOL = PSMAD1_SMAD4_CYTOSOL 
 0.023791508158311526 ; % 1108 PSMAD1_SMAD4_CYTOSOL = PSMAD1_CYTOSOL + SMAD4_CYTOSOL
 PSMAD1_SMAD4_CYTOSOL = PSMAD1_CYTOSOL+SMAD4_CYTOSOL 
 0.14347556112494964 ; % 1109 PSMAD1_SMAD4_CYTOSOL + NIMPORT_NUCLEAR = 
PSMAD1_SMAD4_NIMPORT_NUCLEAR PSMAD1_SMAD4_CYTOSOL+NIMPORT_NUCLEAR = PSMAD1_SMAD4_NIMPORT_NUCLEAR 
 0.036688798507741927 ; % 1110 PSMAD1_SMAD4_NIMPORT_NUCLEAR = PSMAD1_SMAD4_CYTOSOL + 
NIMPORT_NUCLEAR PSMAD1_SMAD4_NIMPORT_NUCLEAR = PSMAD1_SMAD4_CYTOSOL+NIMPORT_NUCLEAR 
 0.6963136653286528 ; % 1111 PSMAD1_SMAD4_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR + 
PSMAD1_SMAD4_NUCLEAR PSMAD1_SMAD4_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR+PSMAD1_SMAD4_NUCLEAR 
 0.29027669234818865 ; % 1112 PSMAD1_SMAD4_NUCLEAR + NEXPORT_NUCLEAR = 
PSMAD1_SMAD4_NEXPORT_NUCLEAR PSMAD1_SMAD4_NUCLEAR+NEXPORT_NUCLEAR = PSMAD1_SMAD4_NEXPORT_NUCLEAR 
 0.09480446405616899 ; % 1113 PSMAD1_SMAD4_NEXPORT_NUCLEAR = PSMAD1_SMAD4_NUCLEAR + 
NEXPORT_NUCLEAR PSMAD1_SMAD4_NEXPORT_NUCLEAR = PSMAD1_SMAD4_NUCLEAR+NEXPORT_NUCLEAR 
 0.37793673166475517 ; % 1114 PSMAD1_SMAD4_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR + 
PSMAD1_SMAD4_CYTOSOL PSMAD1_SMAD4_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR+PSMAD1_SMAD4_CYTOSOL 
 0.5543713655333042 ; % 1115 MRNA_VIMENTIN_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_VIMENTIN_NEXPORT_NUCLEAR MRNA_VIMENTIN_NUCLEAR+NEXPORT_NUCLEAR = MRNA_VIMENTIN_NEXPORT_NUCLEAR 
 0.06590140632861317 ; % 1116 MRNA_VIMENTIN_NEXPORT_NUCLEAR = MRNA_VIMENTIN_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_VIMENTIN_NEXPORT_NUCLEAR = MRNA_VIMENTIN_NUCLEAR+NEXPORT_NUCLEAR 
 0.19183873330111634 ; % 1117 MRNA_VIMENTIN_NEXPORT_NUCLEAR = MRNA_VIMENTIN_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_VIMENTIN_NEXPORT_NUCLEAR = MRNA_VIMENTIN_CYTOSOL+NEXPORT_NUCLEAR 
 0.6116435695122195 ; % 1118 MRNA_VIMENTIN_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_VIMENTIN_RIBOSOME_CYTOSOL MRNA_VIMENTIN_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_VIMENTIN_RIBOSOME_CYTOSOL 
 0.03206197161049751 ; % 1119 MRNA_VIMENTIN_RIBOSOME_CYTOSOL = MRNA_VIMENTIN_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_VIMENTIN_RIBOSOME_CYTOSOL = MRNA_VIMENTIN_CYTOSOL+RIBOSOME_CYTOSOL 
 0.751583895984501 ; % 1120 MRNA_VIMENTIN_RIBOSOME_CYTOSOL = 
MRNA_VIMENTIN_START_RIBOSOME_CYTOSOL MRNA_VIMENTIN_RIBOSOME_CYTOSOL = MRNA_VIMENTIN_START_RIBOSOME_CYTOSOL 
 0.08230348368469531 ; % 1121 MRNA_VIMENTIN_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
VIMENTIN_CYTOSOL + MRNA_VIMENTIN_CYTOSOL MRNA_VIMENTIN_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+VIMENTIN_CYTOSOL+MRNA_VIMENTIN_CYTOSOL 
 0.3600881994900167 ; % 1122 MRNA_VIMENTIN_CYTOSOL = [] MRNA_VIMENTIN_CYTOSOL = [] 
 0.18233949835885782 ; % 1123 VIMENTIN_CYTOSOL = [] VIMENTIN_CYTOSOL = [] 
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 0.933746963050898 ; % 1124 DNA_VIMENTIN_NUCLEAR + BCATENIN_LEF1_NUCLEAR = 
DNA_VIMENTIN_BCATENIN_LEF1_NUCLEAR DNA_VIMENTIN_NUCLEAR+BCATENIN_LEF1_NUCLEAR = DNA_VIMENTIN_BCATENIN_LEF1_NUCLEAR 
 0.00529883223873911822 ; % 1125 DNA_VIMENTIN_BCATENIN_LEF1_NUCLEAR = DNA_VIMENTIN_NUCLEAR + 
BCATENIN_LEF1_NUCLEAR DNA_VIMENTIN_BCATENIN_LEF1_NUCLEAR = DNA_VIMENTIN_NUCLEAR+BCATENIN_LEF1_NUCLEAR 
 0.94574432804475578 ; % 1126 DNA_VIMENTIN_BCATENIN_LEF1_NUCLEAR + RNAP_NUCLEAR = 
DNA_VIMENTIN_BCATENIN_LEF1_RNAP_NUCLEAR DNA_VIMENTIN_BCATENIN_LEF1_NUCLEAR+RNAP_NUCLEAR = 
DNA_VIMENTIN_BCATENIN_LEF1_RNAP_NUCLEAR 
 0.025355941671139741 ; % 1127 DNA_VIMENTIN_BCATENIN_LEF1_RNAP_NUCLEAR = 
DNA_VIMENTIN_BCATENIN_LEF1_NUCLEAR + RNAP_NUCLEAR DNA_VIMENTIN_BCATENIN_LEF1_RNAP_NUCLEAR = 
DNA_VIMENTIN_BCATENIN_LEF1_NUCLEAR+RNAP_NUCLEAR 
 0.42502705255690143 ; % 1128 DNA_VIMENTIN_BCATENIN_LEF1_RNAP_NUCLEAR = DNA_VIMENTIN_NUCLEAR + 
BCATENIN_LEF1_NUCLEAR + RNAP_NUCLEAR + MRNA_VIMENTIN_NUCLEAR DNA_VIMENTIN_BCATENIN_LEF1_RNAP_NUCLEAR = 
DNA_VIMENTIN_NUCLEAR+BCATENIN_LEF1_NUCLEAR+RNAP_NUCLEAR+MRNA_VIMENTIN_NUCLEAR 
 0.7359994633988156 ; % 1129 DNA_VIMENTIN_NUCLEAR + LEF1_NUCLEAR = DNA_VIMENTIN_LEF1_NUCLEAR
 DNA_VIMENTIN_NUCLEAR+LEF1_NUCLEAR = DNA_VIMENTIN_LEF1_NUCLEAR 
 0.037752819371371586 ; % 1130 DNA_VIMENTIN_LEF1_NUCLEAR = DNA_VIMENTIN_NUCLEAR + LEF1_NUCLEAR
 DNA_VIMENTIN_LEF1_NUCLEAR = DNA_VIMENTIN_NUCLEAR+LEF1_NUCLEAR 
 0.4304591719750822 ; % 1131 DNA_VIMENTIN_LEF1_NUCLEAR + PSMAD2_SMAD4_NUCLEAR = 
DNA_VIMENTIN_LEF1_PSMAD2_SMAD4_NUCLEAR DNA_VIMENTIN_LEF1_NUCLEAR+PSMAD2_SMAD4_NUCLEAR = 
DNA_VIMENTIN_LEF1_PSMAD2_SMAD4_NUCLEAR 
 0.012410542455107067 ; % 1132 DNA_VIMENTIN_LEF1_PSMAD2_SMAD4_NUCLEAR = DNA_VIMENTIN_LEF1_NUCLEAR 
+ PSMAD2_SMAD4_NUCLEAR DNA_VIMENTIN_LEF1_PSMAD2_SMAD4_NUCLEAR = DNA_VIMENTIN_LEF1_NUCLEAR+PSMAD2_SMAD4_NUCLEAR 
 0.8017017007987758 ; % 1133 DNA_VIMENTIN_LEF1_PSMAD2_SMAD4_NUCLEAR + RNAP_NUCLEAR = 
DNA_VIMENTIN_LEF1_PSMAD2_SMAD4_RNAP_NUCLEAR DNA_VIMENTIN_LEF1_PSMAD2_SMAD4_NUCLEAR+RNAP_NUCLEAR = 
DNA_VIMENTIN_LEF1_PSMAD2_SMAD4_RNAP_NUCLEAR 
 0.023025974890033676 ; % 1134 DNA_VIMENTIN_LEF1_PSMAD2_SMAD4_RNAP_NUCLEAR = 
DNA_VIMENTIN_LEF1_PSMAD2_SMAD4_NUCLEAR + RNAP_NUCLEAR DNA_VIMENTIN_LEF1_PSMAD2_SMAD4_RNAP_NUCLEAR = 
DNA_VIMENTIN_LEF1_PSMAD2_SMAD4_NUCLEAR+RNAP_NUCLEAR 
 0.022657810821324564 ; % 1135 DNA_VIMENTIN_LEF1_PSMAD2_SMAD4_RNAP_NUCLEAR = DNA_VIMENTIN_NUCLEAR 
+ LEF1_NUCLEAR + PSMAD2_SMAD4_NUCLEAR + RNAP_NUCLEAR + MRNA_VIMENTIN_NUCLEAR DNA_VIMENTIN_LEF1_PSMAD2_SMAD4_RNAP_NUCLEAR = 
DNA_VIMENTIN_NUCLEAR+LEF1_NUCLEAR+PSMAD2_SMAD4_NUCLEAR+RNAP_NUCLEAR+MRNA_VIMENTIN_NUCLEAR 
 0.8041552408319446 ; % 1136 LEF1_CYTOSOL + NIMPORT_NUCLEAR = LEF1_NIMPORT_NUCLEAR
 LEF1_CYTOSOL+NIMPORT_NUCLEAR = LEF1_NIMPORT_NUCLEAR 
 0.02364981823348049 ; % 1137 LEF1_NIMPORT_NUCLEAR = LEF1_CYTOSOL + NIMPORT_NUCLEAR
 LEF1_NIMPORT_NUCLEAR = LEF1_CYTOSOL+NIMPORT_NUCLEAR 
 0.528919155551982 ; % 1138 LEF1_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR + LEF1_NUCLEAR
 LEF1_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR+LEF1_NUCLEAR 
 0.04098648153561901 ; % 1139 LEF1_NUCLEAR + NEXPORT_NUCLEAR = LEF1_NEXPORT_NUCLEAR
 LEF1_NUCLEAR+NEXPORT_NUCLEAR = LEF1_NEXPORT_NUCLEAR 
 0.09146862207562576 ; % 1140 LEF1_NEXPORT_NUCLEAR = LEF1_NUCLEAR + NEXPORT_NUCLEAR
 LEF1_NEXPORT_NUCLEAR = LEF1_NUCLEAR+NEXPORT_NUCLEAR 
 0.5594531208281086 ; % 1141 LEF1_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR + LEF1_CYTOSOL
 LEF1_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR+LEF1_CYTOSOL 
 0.6137261668090083 ; % 1142 DNA_VIMENTIN_LEF1_NUCLEAR + PSMAD3_SMAD4_NUCLEAR = 
DNA_VIMENTIN_LEF1_PSMAD3_SMAD4_NUCLEAR DNA_VIMENTIN_LEF1_NUCLEAR+PSMAD3_SMAD4_NUCLEAR = 
DNA_VIMENTIN_LEF1_PSMAD3_SMAD4_NUCLEAR 
 0.009737057497278313 ; % 1143 DNA_VIMENTIN_LEF1_PSMAD3_SMAD4_NUCLEAR = DNA_VIMENTIN_LEF1_NUCLEAR 
+ PSMAD3_SMAD4_NUCLEAR DNA_VIMENTIN_LEF1_PSMAD3_SMAD4_NUCLEAR = DNA_VIMENTIN_LEF1_NUCLEAR+PSMAD3_SMAD4_NUCLEAR 
 0.5823813176666843 ; % 1144 DNA_VIMENTIN_LEF1_PSMAD3_SMAD4_NUCLEAR + RNAP_NUCLEAR = 
DNA_VIMENTIN_LEF1_PSMAD3_SMAD4_RNAP_NUCLEAR DNA_VIMENTIN_LEF1_PSMAD3_SMAD4_NUCLEAR+RNAP_NUCLEAR = 
DNA_VIMENTIN_LEF1_PSMAD3_SMAD4_RNAP_NUCLEAR 
 0.051680041664943346 ; % 1145 DNA_VIMENTIN_LEF1_PSMAD3_SMAD4_RNAP_NUCLEAR = 
DNA_VIMENTIN_LEF1_PSMAD3_SMAD4_NUCLEAR + RNAP_NUCLEAR DNA_VIMENTIN_LEF1_PSMAD3_SMAD4_RNAP_NUCLEAR = 
DNA_VIMENTIN_LEF1_PSMAD3_SMAD4_NUCLEAR+RNAP_NUCLEAR 
 0.08962497182038665 ; % 1146 DNA_VIMENTIN_LEF1_PSMAD3_SMAD4_RNAP_NUCLEAR = DNA_VIMENTIN_NUCLEAR 
+ LEF1_NUCLEAR + PSMAD3_SMAD4_NUCLEAR + RNAP_NUCLEAR + MRNA_VIMENTIN_NUCLEAR DNA_VIMENTIN_LEF1_PSMAD3_SMAD4_RNAP_NUCLEAR = 
DNA_VIMENTIN_NUCLEAR+LEF1_NUCLEAR+PSMAD3_SMAD4_NUCLEAR+RNAP_NUCLEAR+MRNA_VIMENTIN_NUCLEAR 
 0.62358035346184966 ; % 1147 DNA_ECADHERIN_NUCLEAR + NFATC1_NUCLEAR = 
DNA_ECADHERIN_NFATC1_NUCLEAR DNA_ECADHERIN_NUCLEAR+NFATC1_NUCLEAR = DNA_ECADHERIN_NFATC1_NUCLEAR 
 0.003968379412761332 ; % 1148 DNA_ECADHERIN_NFATC1_NUCLEAR = DNA_ECADHERIN_NUCLEAR + 
NFATC1_NUCLEAR DNA_ECADHERIN_NFATC1_NUCLEAR = DNA_ECADHERIN_NUCLEAR+NFATC1_NUCLEAR 
 0.6198477541215658 ; % 1149 DNA_ECADHERIN_NFATC1_NUCLEAR + RNAP_NUCLEAR = 
DNA_ECADHERIN_NFATC1_RNAP_NUCLEAR DNA_ECADHERIN_NFATC1_NUCLEAR+RNAP_NUCLEAR = DNA_ECADHERIN_NFATC1_RNAP_NUCLEAR 
 0.07780243834244122 ; % 1150 DNA_ECADHERIN_NFATC1_RNAP_NUCLEAR = DNA_ECADHERIN_NFATC1_NUCLEAR 
+ RNAP_NUCLEAR DNA_ECADHERIN_NFATC1_RNAP_NUCLEAR = DNA_ECADHERIN_NFATC1_NUCLEAR+RNAP_NUCLEAR 
 0.629866051164546 ; % 1151 DNA_ECADHERIN_NFATC1_RNAP_NUCLEAR = DNA_ECADHERIN_NUCLEAR + 
NFATC1_NUCLEAR + RNAP_NUCLEAR + MRNA_ECADHERIN_NUCLEAR DNA_ECADHERIN_NFATC1_RNAP_NUCLEAR = 
DNA_ECADHERIN_NUCLEAR+NFATC1_NUCLEAR+RNAP_NUCLEAR+MRNA_ECADHERIN_NUCLEAR 
 0.00045340623280635812 ; % 1152 DNA_ECADHERIN_NUCLEAR + SNAIL_NUCLEAR = DNA_ECADHERIN_SNAIL_NUCLEAR
 DNA_ECADHERIN_NUCLEAR+SNAIL_NUCLEAR = DNA_ECADHERIN_SNAIL_NUCLEAR 
 0.746528240239407 ; % 1153 DNA_ECADHERIN_SNAIL_NUCLEAR = DNA_ECADHERIN_NUCLEAR + SNAIL_NUCLEAR
 DNA_ECADHERIN_SNAIL_NUCLEAR = DNA_ECADHERIN_NUCLEAR+SNAIL_NUCLEAR 
 0.00028952961987271664 ; % 1154 DNA_ECADHERIN_NUCLEAR + SLUG_NUCLEAR = DNA_ECADHERIN_SLUG_NUCLEAR
 DNA_ECADHERIN_NUCLEAR+SLUG_NUCLEAR = DNA_ECADHERIN_SLUG_NUCLEAR 
 0.30508744645194832 ; % 1155 DNA_ECADHERIN_SLUG_NUCLEAR = DNA_ECADHERIN_NUCLEAR + SLUG_NUCLEAR
 DNA_ECADHERIN_SLUG_NUCLEAR = DNA_ECADHERIN_NUCLEAR+SLUG_NUCLEAR 
 0.0004211969880194234 ; % 1156 DNA_ECADHERIN_NUCLEAR + TWIST_NUCLEAR = 
DNA_ECADHERIN_TWIST_NUCLEAR DNA_ECADHERIN_NUCLEAR+TWIST_NUCLEAR = DNA_ECADHERIN_TWIST_NUCLEAR 
 0.598382828695121 ; % 1157 DNA_ECADHERIN_TWIST_NUCLEAR = DNA_ECADHERIN_NUCLEAR + 
TWIST_NUCLEAR DNA_ECADHERIN_TWIST_NUCLEAR = DNA_ECADHERIN_NUCLEAR+TWIST_NUCLEAR 
 10.9833610667458117 ; % 1158 DNA_ECADHERIN_NUCLEAR + PSMAD2_SMAD4_LEF1_NUCLEAR = 
DNA_ECADHERIN_PSMAD2_SMAD4_LEF1_NUCLEAR DNA_ECADHERIN_NUCLEAR+PSMAD2_SMAD4_LEF1_NUCLEAR = 
DNA_ECADHERIN_PSMAD2_SMAD4_LEF1_NUCLEAR 
 0.001924519456629695 ; % 1159 DNA_ECADHERIN_PSMAD2_SMAD4_LEF1_NUCLEAR = DNA_ECADHERIN_NUCLEAR + 
PSMAD2_SMAD4_LEF1_NUCLEAR DNA_ECADHERIN_PSMAD2_SMAD4_LEF1_NUCLEAR = DNA_ECADHERIN_NUCLEAR+PSMAD2_SMAD4_LEF1_NUCLEAR 
 0.9160893063397343 ; % 1160 PSMAD2_SMAD4_CYTOSOL + LEF1_CYTOSOL = PSMAD2_SMAD4_LEF1_CYTOSOL
 PSMAD2_SMAD4_CYTOSOL+LEF1_CYTOSOL = PSMAD2_SMAD4_LEF1_CYTOSOL 
 0.006609704069273768 ; % 1161 PSMAD2_SMAD4_LEF1_CYTOSOL = PSMAD2_SMAD4_CYTOSOL + LEF1_CYTOSOL
 PSMAD2_SMAD4_LEF1_CYTOSOL = PSMAD2_SMAD4_CYTOSOL+LEF1_CYTOSOL 
 0.988381930294002 ; % 1162 PSMAD2_SMAD4_LEF1_CYTOSOL + NIMPORT_NUCLEAR = 
PSMAD2_SMAD4_LEF1_NIMPORT_NUCLEAR PSMAD2_SMAD4_LEF1_CYTOSOL+NIMPORT_NUCLEAR = PSMAD2_SMAD4_LEF1_NIMPORT_NUCLEAR 
 0.006372435799513568 ; % 1163 PSMAD2_SMAD4_LEF1_NIMPORT_NUCLEAR = PSMAD2_SMAD4_LEF1_CYTOSOL + 
NIMPORT_NUCLEAR PSMAD2_SMAD4_LEF1_NIMPORT_NUCLEAR = PSMAD2_SMAD4_LEF1_CYTOSOL+NIMPORT_NUCLEAR 
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 0.9865763957818503 ; % 1164 PSMAD2_SMAD4_LEF1_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR + 
PSMAD2_SMAD4_LEF1_NUCLEAR PSMAD2_SMAD4_LEF1_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR+PSMAD2_SMAD4_LEF1_NUCLEAR 
 0.0045577040173680894 ; % 1165 PSMAD2_SMAD4_LEF1_NUCLEAR + NEXPORT_NUCLEAR = 
PSMAD2_SMAD4_LEF1_NEXPORT_NUCLEAR PSMAD2_SMAD4_LEF1_NUCLEAR+NEXPORT_NUCLEAR = PSMAD2_SMAD4_LEF1_NEXPORT_NUCLEAR 
 0.05511382169521936 ; % 1166 PSMAD2_SMAD4_LEF1_NEXPORT_NUCLEAR = PSMAD2_SMAD4_LEF1_NUCLEAR + 
NEXPORT_NUCLEAR PSMAD2_SMAD4_LEF1_NEXPORT_NUCLEAR = PSMAD2_SMAD4_LEF1_NUCLEAR+NEXPORT_NUCLEAR 
 0.030637592982548334 ; % 1167 PSMAD2_SMAD4_LEF1_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR + 
PSMAD2_SMAD4_LEF1_CYTOSOL PSMAD2_SMAD4_LEF1_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR+PSMAD2_SMAD4_LEF1_CYTOSOL 
 0.014545335631093836 ; % 1168 DNA_VECADHERIN_NUCLEAR + NFATC1_NUCLEAR = 
DNA_VECADHERIN_NFATC1_NUCLEAR DNA_VECADHERIN_NUCLEAR+NFATC1_NUCLEAR = DNA_VECADHERIN_NFATC1_NUCLEAR 
 0.0670217867217895 ; % 1169 DNA_VECADHERIN_NFATC1_NUCLEAR = DNA_VECADHERIN_NUCLEAR + 
NFATC1_NUCLEAR DNA_VECADHERIN_NFATC1_NUCLEAR = DNA_VECADHERIN_NUCLEAR+NFATC1_NUCLEAR 
 0.4745250965685228 ; % 1170 DNA_VECADHERIN_NFATC1_NUCLEAR + RNAP_NUCLEAR = 
DNA_VECADHERIN_NFATC1_RNAP_NUCLEAR DNA_VECADHERIN_NFATC1_NUCLEAR+RNAP_NUCLEAR = DNA_VECADHERIN_NFATC1_RNAP_NUCLEAR 
 0.038044607910185546 ; % 1171 DNA_VECADHERIN_NFATC1_RNAP_NUCLEAR = 
DNA_VECADHERIN_NFATC1_NUCLEAR + RNAP_NUCLEAR DNA_VECADHERIN_NFATC1_RNAP_NUCLEAR = 
DNA_VECADHERIN_NFATC1_NUCLEAR+RNAP_NUCLEAR 
 0.9935944967873709 ; % 1172 DNA_VECADHERIN_NFATC1_RNAP_NUCLEAR = DNA_VECADHERIN_NUCLEAR + 
NFATC1_NUCLEAR + RNAP_NUCLEAR + MRNA_VECADHERIN_NUCLEAR DNA_VECADHERIN_NFATC1_RNAP_NUCLEAR = 
DNA_VECADHERIN_NUCLEAR+NFATC1_NUCLEAR+RNAP_NUCLEAR+MRNA_VECADHERIN_NUCLEAR 
 0.703950399024606 ; % 1173 DNA_VECADHERIN_NUCLEAR + SNAIL_NUCLEAR = 
DNA_VECADHERIN_SNAIL_NUCLEAR DNA_VECADHERIN_NUCLEAR+SNAIL_NUCLEAR = DNA_VECADHERIN_SNAIL_NUCLEAR 
 0.0526623517423019 ; % 1174 DNA_VECADHERIN_SNAIL_NUCLEAR = DNA_VECADHERIN_NUCLEAR + 
SNAIL_NUCLEAR DNA_VECADHERIN_SNAIL_NUCLEAR = DNA_VECADHERIN_NUCLEAR+SNAIL_NUCLEAR 
 0.6397713167279583 ; % 1175 DNA_VECADHERIN_NUCLEAR + SLUG_NUCLEAR = 
DNA_VECADHERIN_SLUG_NUCLEAR DNA_VECADHERIN_NUCLEAR+SLUG_NUCLEAR = DNA_VECADHERIN_SLUG_NUCLEAR 
 0.007425026654045075 ; % 1176 DNA_VECADHERIN_SLUG_NUCLEAR = DNA_VECADHERIN_NUCLEAR + 
SLUG_NUCLEAR DNA_VECADHERIN_SLUG_NUCLEAR = DNA_VECADHERIN_NUCLEAR+SLUG_NUCLEAR 
 0.08042107480684346 ; % 1177 DNA_VECADHERIN_NUCLEAR + TWIST_NUCLEAR = 
DNA_VECADHERIN_TWIST_NUCLEAR DNA_VECADHERIN_NUCLEAR+TWIST_NUCLEAR = DNA_VECADHERIN_TWIST_NUCLEAR 
 0.021079792645148643 ; % 1178 DNA_VECADHERIN_TWIST_NUCLEAR = DNA_VECADHERIN_NUCLEAR + 
TWIST_NUCLEAR DNA_VECADHERIN_TWIST_NUCLEAR = DNA_VECADHERIN_NUCLEAR+TWIST_NUCLEAR 
 0.49046822044526084 ; % 1179 DNA_VECADHERIN_NUCLEAR + LEF1_NUCLEAR = 
DNA_VECADHERIN_LEF1_NUCLEAR DNA_VECADHERIN_NUCLEAR+LEF1_NUCLEAR = DNA_VECADHERIN_LEF1_NUCLEAR 
 0.033845260108793074 ; % 1180 DNA_VECADHERIN_LEF1_NUCLEAR = DNA_VECADHERIN_NUCLEAR + 
LEF1_NUCLEAR DNA_VECADHERIN_LEF1_NUCLEAR = DNA_VECADHERIN_NUCLEAR+LEF1_NUCLEAR 
 0.03809992816596819 ; % 1181 MRNA_DSCR1_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_DSCR1_NEXPORT_NUCLEAR MRNA_DSCR1_NUCLEAR+NEXPORT_NUCLEAR = MRNA_DSCR1_NEXPORT_NUCLEAR 
 0.08455285168999081 ; % 1182 MRNA_DSCR1_NEXPORT_NUCLEAR = MRNA_DSCR1_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_DSCR1_NEXPORT_NUCLEAR = MRNA_DSCR1_NUCLEAR+NEXPORT_NUCLEAR 
 0.5889360252987179 ; % 1183 MRNA_DSCR1_NEXPORT_NUCLEAR = MRNA_DSCR1_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_DSCR1_NEXPORT_NUCLEAR = MRNA_DSCR1_CYTOSOL+NEXPORT_NUCLEAR 
 0.3849362137945965 ; % 1184 MRNA_DSCR1_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_DSCR1_RIBOSOME_CYTOSOL MRNA_DSCR1_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_DSCR1_RIBOSOME_CYTOSOL 
 9.199981793933444E-4 ; % 1185 MRNA_DSCR1_RIBOSOME_CYTOSOL = MRNA_DSCR1_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_DSCR1_RIBOSOME_CYTOSOL = MRNA_DSCR1_CYTOSOL+RIBOSOME_CYTOSOL 
 0.306859001219532 ; % 1186 MRNA_DSCR1_RIBOSOME_CYTOSOL = MRNA_DSCR1_START_RIBOSOME_CYTOSOL
 MRNA_DSCR1_RIBOSOME_CYTOSOL = MRNA_DSCR1_START_RIBOSOME_CYTOSOL 
 0.9026466931638294 ; % 1187 MRNA_DSCR1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
DSCR1_CYTOSOL + MRNA_DSCR1_CYTOSOL MRNA_DSCR1_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+DSCR1_CYTOSOL+MRNA_DSCR1_CYTOSOL 
 0.13632144838973648 ; % 1188 MRNA_DSCR1_CYTOSOL = [] MRNA_DSCR1_CYTOSOL = [] 
 0.12536452459075836 ; % 1189 DSCR1_CYTOSOL = [] DSCR1_CYTOSOL = [] 
 0.7186488019708738 ; % 1190 DNA_DSCR1_NUCLEAR + NFATC1_NUCLEAR = DNA_DSCR1_NFATC1_NUCLEAR
 DNA_DSCR1_NUCLEAR+NFATC1_NUCLEAR = DNA_DSCR1_NFATC1_NUCLEAR 
 0.06697971909044166 ; % 1191 DNA_DSCR1_NFATC1_NUCLEAR = DNA_DSCR1_NUCLEAR + NFATC1_NUCLEAR
 DNA_DSCR1_NFATC1_NUCLEAR = DNA_DSCR1_NUCLEAR+NFATC1_NUCLEAR 
 0.9310573641548964 ; % 1192 DNA_DSCR1_NFATC1_NUCLEAR + RNAP_NUCLEAR = 
DNA_DSCR1_NFATC1_RNAP_NUCLEAR DNA_DSCR1_NFATC1_NUCLEAR+RNAP_NUCLEAR = DNA_DSCR1_NFATC1_RNAP_NUCLEAR 
 0.08272382064184494 ; % 1193 DNA_DSCR1_NFATC1_RNAP_NUCLEAR = DNA_DSCR1_NFATC1_NUCLEAR + 
RNAP_NUCLEAR DNA_DSCR1_NFATC1_RNAP_NUCLEAR = DNA_DSCR1_NFATC1_NUCLEAR+RNAP_NUCLEAR 
 0.4152452695250941 ; % 1194 DNA_DSCR1_NFATC1_RNAP_NUCLEAR = DNA_DSCR1_NUCLEAR + 
NFATC1_NUCLEAR + RNAP_NUCLEAR + MRNA_DSCR1_NUCLEAR DNA_DSCR1_NFATC1_RNAP_NUCLEAR = 
DNA_DSCR1_NUCLEAR+NFATC1_NUCLEAR+RNAP_NUCLEAR+MRNA_DSCR1_NUCLEAR 
 0.3580735457077039 ; % 1195 MRNA_SOX9_NUCLEAR + NEXPORT_NUCLEAR = MRNA_SOX9_NEXPORT_NUCLEAR
 MRNA_SOX9_NUCLEAR+NEXPORT_NUCLEAR = MRNA_SOX9_NEXPORT_NUCLEAR 
 0.02043676138044588 ; % 1196 MRNA_SOX9_NEXPORT_NUCLEAR = MRNA_SOX9_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_SOX9_NEXPORT_NUCLEAR = MRNA_SOX9_NUCLEAR+NEXPORT_NUCLEAR 
 0.7354592492953207 ; % 1197 MRNA_SOX9_NEXPORT_NUCLEAR = MRNA_SOX9_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_SOX9_NEXPORT_NUCLEAR = MRNA_SOX9_CYTOSOL+NEXPORT_NUCLEAR 
 0.03732395950425704 ; % 1198 MRNA_SOX9_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_SOX9_RIBOSOME_CYTOSOL
 MRNA_SOX9_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_SOX9_RIBOSOME_CYTOSOL 
 0.051672282583862195 ; % 1199 MRNA_SOX9_RIBOSOME_CYTOSOL = MRNA_SOX9_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_SOX9_RIBOSOME_CYTOSOL = MRNA_SOX9_CYTOSOL+RIBOSOME_CYTOSOL 
 0.5606078974217104 ; % 1200 MRNA_SOX9_RIBOSOME_CYTOSOL = MRNA_SOX9_START_RIBOSOME_CYTOSOL
 MRNA_SOX9_RIBOSOME_CYTOSOL = MRNA_SOX9_START_RIBOSOME_CYTOSOL 
 0.20809241382886512 ; % 1201 MRNA_SOX9_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
SOX9_CYTOSOL + MRNA_SOX9_CYTOSOL MRNA_SOX9_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+SOX9_CYTOSOL+MRNA_SOX9_CYTOSOL 
 0.03201419618542595 ; % 1202 MRNA_SOX9_CYTOSOL = [] MRNA_SOX9_CYTOSOL = [] 
 0.18316182217509586 ; % 1203 SOX9_CYTOSOL = [] SOX9_CYTOSOL = [] 
 0.767450975673607 ; % 1204 DNA_SOX9_NUCLEAR + GATA_FOG2_NUCLEAR = DNA_SOX9_GATA_FOG2_NUCLEAR
 DNA_SOX9_NUCLEAR+GATA_FOG2_NUCLEAR = DNA_SOX9_GATA_FOG2_NUCLEAR 
 0.013732718706108716 ; % 1205 DNA_SOX9_GATA_FOG2_NUCLEAR = DNA_SOX9_NUCLEAR + GATA_FOG2_NUCLEAR
 DNA_SOX9_GATA_FOG2_NUCLEAR = DNA_SOX9_NUCLEAR+GATA_FOG2_NUCLEAR 
 0.4331728669898506 ; % 1206 DNA_SOX9_GATA_FOG2_NUCLEAR + PSMAD5_SMAD4_NUCLEAR = 
DNA_SOX9_GATA_FOG2_PSMAD5_SMAD4_NUCLEAR DNA_SOX9_GATA_FOG2_NUCLEAR+PSMAD5_SMAD4_NUCLEAR = 
DNA_SOX9_GATA_FOG2_PSMAD5_SMAD4_NUCLEAR 
 0.007709130593105407 ; % 1207 DNA_SOX9_GATA_FOG2_PSMAD5_SMAD4_NUCLEAR = 
DNA_SOX9_GATA_FOG2_NUCLEAR + PSMAD5_SMAD4_NUCLEAR DNA_SOX9_GATA_FOG2_PSMAD5_SMAD4_NUCLEAR = 
DNA_SOX9_GATA_FOG2_NUCLEAR+PSMAD5_SMAD4_NUCLEAR 
 0.5130732726568538 ; % 1208 DNA_SOX9_GATA_FOG2_PSMAD5_SMAD4_NUCLEAR + RNAP_NUCLEAR = 
DNA_SOX9_GATA_FOG2_PSMAD5_SMAD4_RNAP_NUCLEAR DNA_SOX9_GATA_FOG2_PSMAD5_SMAD4_NUCLEAR+RNAP_NUCLEAR = 
DNA_SOX9_GATA_FOG2_PSMAD5_SMAD4_RNAP_NUCLEAR 
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 0.01182484160582492 ; % 1209 DNA_SOX9_GATA_FOG2_PSMAD5_SMAD4_RNAP_NUCLEAR = 
DNA_SOX9_GATA_FOG2_PSMAD5_SMAD4_NUCLEAR + RNAP_NUCLEAR DNA_SOX9_GATA_FOG2_PSMAD5_SMAD4_RNAP_NUCLEAR = 
DNA_SOX9_GATA_FOG2_PSMAD5_SMAD4_NUCLEAR+RNAP_NUCLEAR 
 0.15615556605825476 ; % 1210 DNA_SOX9_GATA_FOG2_PSMAD5_SMAD4_RNAP_NUCLEAR = DNA_SOX9_NUCLEAR + 
GATA_FOG2_NUCLEAR + PSMAD5_SMAD4_NUCLEAR + RNAP_NUCLEAR + MRNA_SOX9_NUCLEAR DNA_SOX9_GATA_FOG2_PSMAD5_SMAD4_RNAP_NUCLEAR 
= DNA_SOX9_NUCLEAR+GATA_FOG2_NUCLEAR+PSMAD5_SMAD4_NUCLEAR+RNAP_NUCLEAR+MRNA_SOX9_NUCLEAR 
 0.9492492252799193 ; % 1211 GATA_FOG2_CYTOSOL + NIMPORT_NUCLEAR = GATA_FOG2_NIMPORT_NUCLEAR
 GATA_FOG2_CYTOSOL+NIMPORT_NUCLEAR = GATA_FOG2_NIMPORT_NUCLEAR 
 0.003352513933930124 ; % 1212 GATA_FOG2_NIMPORT_NUCLEAR = GATA_FOG2_CYTOSOL + NIMPORT_NUCLEAR
 GATA_FOG2_NIMPORT_NUCLEAR = GATA_FOG2_CYTOSOL+NIMPORT_NUCLEAR 
 0.8281008021436643 ; % 1213 GATA_FOG2_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR + GATA_FOG2_NUCLEAR
 GATA_FOG2_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR+GATA_FOG2_NUCLEAR 
 0.9953607083419445 ; % 1214 GATA_FOG2_NUCLEAR + NEXPORT_NUCLEAR = GATA_FOG2_NEXPORT_NUCLEAR
 GATA_FOG2_NUCLEAR+NEXPORT_NUCLEAR = GATA_FOG2_NEXPORT_NUCLEAR 
 0.012794353055366093 ; % 1215 GATA_FOG2_NEXPORT_NUCLEAR = GATA_FOG2_NUCLEAR + NEXPORT_NUCLEAR
 GATA_FOG2_NEXPORT_NUCLEAR = GATA_FOG2_NUCLEAR+NEXPORT_NUCLEAR 
 0.29729593270758115 ; % 1216 GATA_FOG2_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR + GATA_FOG2_CYTOSOL
 GATA_FOG2_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR+GATA_FOG2_CYTOSOL 
 0.32945502426550566 ; % 1217 PSMAD5_CYTOSOL + SMAD4_CYTOSOL = PSMAD5_SMAD4_CYTOSOL
 PSMAD5_CYTOSOL+SMAD4_CYTOSOL = PSMAD5_SMAD4_CYTOSOL 
 0.03392130413805796 ; % 1218 PSMAD5_SMAD4_CYTOSOL = PSMAD5_CYTOSOL + SMAD4_CYTOSOL
 PSMAD5_SMAD4_CYTOSOL = PSMAD5_CYTOSOL+SMAD4_CYTOSOL 
 0.06037245501194399 ; % 1219 PSMAD5_SMAD4_CYTOSOL + NIMPORT_NUCLEAR = 
PSMAD5_SMAD4_NIMPORT_NUCLEAR PSMAD5_SMAD4_CYTOSOL+NIMPORT_NUCLEAR = PSMAD5_SMAD4_NIMPORT_NUCLEAR 
 0.019327110366098812 ; % 1220 PSMAD5_SMAD4_NIMPORT_NUCLEAR = PSMAD5_SMAD4_CYTOSOL + 
NIMPORT_NUCLEAR PSMAD5_SMAD4_NIMPORT_NUCLEAR = PSMAD5_SMAD4_CYTOSOL+NIMPORT_NUCLEAR 
 0.413638780975064 ; % 1221 PSMAD5_SMAD4_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR + 
PSMAD5_SMAD4_NUCLEAR PSMAD5_SMAD4_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR+PSMAD5_SMAD4_NUCLEAR 
 0.38367898710858195 ; % 1222 PSMAD5_SMAD4_NUCLEAR + NEXPORT_NUCLEAR = 
PSMAD5_SMAD4_NEXPORT_NUCLEAR PSMAD5_SMAD4_NUCLEAR+NEXPORT_NUCLEAR = PSMAD5_SMAD4_NEXPORT_NUCLEAR 
 0.06342488067787042 ; % 1223 PSMAD5_SMAD4_NEXPORT_NUCLEAR = PSMAD5_SMAD4_NUCLEAR + 
NEXPORT_NUCLEAR PSMAD5_SMAD4_NEXPORT_NUCLEAR = PSMAD5_SMAD4_NUCLEAR+NEXPORT_NUCLEAR 
 0.47003700538150883 ; % 1224 PSMAD5_SMAD4_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR + 
PSMAD5_SMAD4_CYTOSOL PSMAD5_SMAD4_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR+PSMAD5_SMAD4_CYTOSOL 
 0.2853669880510131 ; % 1225 MRNA_PAX3_NUCLEAR + NEXPORT_NUCLEAR = MRNA_PAX3_NEXPORT_NUCLEAR
 MRNA_PAX3_NUCLEAR+NEXPORT_NUCLEAR = MRNA_PAX3_NEXPORT_NUCLEAR 
 0.0608893016821006 ; % 1226 MRNA_PAX3_NEXPORT_NUCLEAR = MRNA_PAX3_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_PAX3_NEXPORT_NUCLEAR = MRNA_PAX3_NUCLEAR+NEXPORT_NUCLEAR 
 0.8244073199565453 ; % 1227 MRNA_PAX3_NEXPORT_NUCLEAR = MRNA_PAX3_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_PAX3_NEXPORT_NUCLEAR = MRNA_PAX3_CYTOSOL+NEXPORT_NUCLEAR 
 0.8824962709827538 ; % 1228 MRNA_PAX3_CYTOSOL + RIBOSOME_CYTOSOL = MRNA_PAX3_RIBOSOME_CYTOSOL
 MRNA_PAX3_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_PAX3_RIBOSOME_CYTOSOL 
 0.07303247894620196 ; % 1229 MRNA_PAX3_RIBOSOME_CYTOSOL = MRNA_PAX3_CYTOSOL + RIBOSOME_CYTOSOL
 MRNA_PAX3_RIBOSOME_CYTOSOL = MRNA_PAX3_CYTOSOL+RIBOSOME_CYTOSOL 
 0.3257197829542823 ; % 1230 MRNA_PAX3_RIBOSOME_CYTOSOL = MRNA_PAX3_START_RIBOSOME_CYTOSOL
 MRNA_PAX3_RIBOSOME_CYTOSOL = MRNA_PAX3_START_RIBOSOME_CYTOSOL 
 0.7183157058844206 ; % 1231 MRNA_PAX3_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
PAX3_CYTOSOL + MRNA_PAX3_CYTOSOL MRNA_PAX3_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL+PAX3_CYTOSOL+MRNA_PAX3_CYTOSOL 
 0.058007441496302437 ; % 1232 MRNA_PAX3_CYTOSOL = [] MRNA_PAX3_CYTOSOL = [] 
 0.20226415783851553 ; % 1233 PAX3_CYTOSOL = [] PAX3_CYTOSOL = [] 
 0.7594455409157992 ; % 1234 DNA_PAX3_NUCLEAR + PSMAD1_SMAD4_NUCLEAR = 
DNA_PAX3_PSMAD1_SMAD4_NUCLEAR DNA_PAX3_NUCLEAR+PSMAD1_SMAD4_NUCLEAR = DNA_PAX3_PSMAD1_SMAD4_NUCLEAR 
 0.09914423485236457 ; % 1235 DNA_PAX3_PSMAD1_SMAD4_NUCLEAR = DNA_PAX3_NUCLEAR + 
PSMAD1_SMAD4_NUCLEAR DNA_PAX3_PSMAD1_SMAD4_NUCLEAR = DNA_PAX3_NUCLEAR+PSMAD1_SMAD4_NUCLEAR 
 0.5788295603070166 ; % 1236 DNA_PAX3_PSMAD1_SMAD4_NUCLEAR + RNAP_NUCLEAR = 
DNA_PAX3_PSMAD1_SMAD4_RNAP_NUCLEAR DNA_PAX3_PSMAD1_SMAD4_NUCLEAR+RNAP_NUCLEAR = DNA_PAX3_PSMAD1_SMAD4_RNAP_NUCLEAR 
 0.0037607619426477945 ; % 1237 DNA_PAX3_PSMAD1_SMAD4_RNAP_NUCLEAR = 
DNA_PAX3_PSMAD1_SMAD4_NUCLEAR + RNAP_NUCLEAR DNA_PAX3_PSMAD1_SMAD4_RNAP_NUCLEAR = 
DNA_PAX3_PSMAD1_SMAD4_NUCLEAR+RNAP_NUCLEAR 
 0.7364255606134201 ; % 1238 DNA_PAX3_PSMAD1_SMAD4_RNAP_NUCLEAR = DNA_PAX3_NUCLEAR + 
PSMAD1_SMAD4_NUCLEAR + RNAP_NUCLEAR + MRNA_PAX3_NUCLEAR DNA_PAX3_PSMAD1_SMAD4_RNAP_NUCLEAR = 
DNA_PAX3_NUCLEAR+PSMAD1_SMAD4_NUCLEAR+RNAP_NUCLEAR+MRNA_PAX3_NUCLEAR 
 0.2598793229430447 ; % 1239 MRNA_MMP9_NUCLEAR + NEXPORT_NUCLEAR = MRNA_MMP9_NEXPORT_NUCLEAR
 MRNA_MMP9_NUCLEAR+NEXPORT_NUCLEAR = MRNA_MMP9_NEXPORT_NUCLEAR 
 0.00802021766712764 ; % 1240 MRNA_MMP9_NEXPORT_NUCLEAR = MRNA_MMP9_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_MMP9_NEXPORT_NUCLEAR = MRNA_MMP9_NUCLEAR+NEXPORT_NUCLEAR 
 0.15172707903343563 ; % 1241 MRNA_MMP9_NEXPORT_NUCLEAR = MRNA_MMP9_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_MMP9_NEXPORT_NUCLEAR = MRNA_MMP9_CYTOSOL+NEXPORT_NUCLEAR 
 0.5443964368192185 ; % 1242 MRNA_MMP9_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_MMP9_RIBOSOME_CYTOSOL MRNA_MMP9_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_MMP9_RIBOSOME_CYTOSOL 
 0.025031512152313196 ; % 1243 MRNA_MMP9_RIBOSOME_CYTOSOL = MRNA_MMP9_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_MMP9_RIBOSOME_CYTOSOL = MRNA_MMP9_CYTOSOL+RIBOSOME_CYTOSOL 
 0.7448154362095564 ; % 1244 MRNA_MMP9_RIBOSOME_CYTOSOL = MRNA_MMP9_START_RIBOSOME_CYTOSOL
 MRNA_MMP9_RIBOSOME_CYTOSOL = MRNA_MMP9_START_RIBOSOME_CYTOSOL 
 0.36367857799965486 ; % 1245 MRNA_MMP9_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
MMP9_CYTOSOL + MRNA_MMP9_CYTOSOL MRNA_MMP9_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+MMP9_CYTOSOL+MRNA_MMP9_CYTOSOL 
 0.4741477954585023 ; % 1246 MRNA_MMP9_CYTOSOL = [] MRNA_MMP9_CYTOSOL = [] 
 0.19819791130415254 ; % 1247 MMP9_CYTOSOL = [] MMP9_CYTOSOL = [] 
 0.25316218792900247 ; % 1248 DNA_MMP9_NUCLEAR + P_AP1_NUCLEAR = DNA_MMP9_P_AP1_NUCLEAR
 DNA_MMP9_NUCLEAR+P_AP1_NUCLEAR = DNA_MMP9_P_AP1_NUCLEAR 
 0.04597531834436702 ; % 1249 DNA_MMP9_P_AP1_NUCLEAR = DNA_MMP9_NUCLEAR + P_AP1_NUCLEAR
 DNA_MMP9_P_AP1_NUCLEAR = DNA_MMP9_NUCLEAR+P_AP1_NUCLEAR 
 0.6608126681633986 ; % 1250 DNA_MMP9_P_AP1_NUCLEAR + RNAP_NUCLEAR = 
DNA_MMP9_P_AP1_RNAP_NUCLEAR DNA_MMP9_P_AP1_NUCLEAR+RNAP_NUCLEAR = DNA_MMP9_P_AP1_RNAP_NUCLEAR 
 0.029570987307335386 ; % 1251 DNA_MMP9_P_AP1_RNAP_NUCLEAR = DNA_MMP9_P_AP1_NUCLEAR + 
RNAP_NUCLEAR DNA_MMP9_P_AP1_RNAP_NUCLEAR = DNA_MMP9_P_AP1_NUCLEAR+RNAP_NUCLEAR 
 0.6431881766629125 ; % 1252 DNA_MMP9_P_AP1_RNAP_NUCLEAR = DNA_MMP9_NUCLEAR + P_AP1_NUCLEAR + 
RNAP_NUCLEAR + MRNA_MMP9_NUCLEAR DNA_MMP9_P_AP1_RNAP_NUCLEAR = 
DNA_MMP9_NUCLEAR+P_AP1_NUCLEAR+RNAP_NUCLEAR+MRNA_MMP9_NUCLEAR 
 0.21131734860744078 ; % 1253 DNA_MMP9_NUCLEAR + TBX20_NUCLEAR = DNA_MMP9_TBX20_NUCLEAR
 DNA_MMP9_NUCLEAR+TBX20_NUCLEAR = DNA_MMP9_TBX20_NUCLEAR 
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 0.07905305091568852 ; % 1254 DNA_MMP9_TBX20_NUCLEAR = DNA_MMP9_NUCLEAR + TBX20_NUCLEAR
 DNA_MMP9_TBX20_NUCLEAR = DNA_MMP9_NUCLEAR+TBX20_NUCLEAR 
 0.4430759626075055 ; % 1255 DNA_MMP9_TBX20_NUCLEAR + PSMAD5_SMAD4_NUCLEAR = 
DNA_MMP9_TBX20_PSMAD5_SMAD4_NUCLEAR DNA_MMP9_TBX20_NUCLEAR+PSMAD5_SMAD4_NUCLEAR = DNA_MMP9_TBX20_PSMAD5_SMAD4_NUCLEAR 
 0.046020625230951254 ; % 1256 DNA_MMP9_TBX20_PSMAD5_SMAD4_NUCLEAR = DNA_MMP9_TBX20_NUCLEAR + 
PSMAD5_SMAD4_NUCLEAR DNA_MMP9_TBX20_PSMAD5_SMAD4_NUCLEAR = DNA_MMP9_TBX20_NUCLEAR+PSMAD5_SMAD4_NUCLEAR 
 0.3335900943927633 ; % 1257 DNA_MMP9_TBX20_PSMAD5_SMAD4_NUCLEAR + RNAP_NUCLEAR = 
DNA_MMP9_TBX20_PSMAD5_SMAD4_RNAP_NUCLEAR DNA_MMP9_TBX20_PSMAD5_SMAD4_NUCLEAR+RNAP_NUCLEAR = 
DNA_MMP9_TBX20_PSMAD5_SMAD4_RNAP_NUCLEAR 
 0.09203962710085331 ; % 1258 DNA_MMP9_TBX20_PSMAD5_SMAD4_RNAP_NUCLEAR = 
DNA_MMP9_TBX20_PSMAD5_SMAD4_NUCLEAR + RNAP_NUCLEAR DNA_MMP9_TBX20_PSMAD5_SMAD4_RNAP_NUCLEAR = 
DNA_MMP9_TBX20_PSMAD5_SMAD4_NUCLEAR+RNAP_NUCLEAR 
 0.7935096071646445 ; % 1259 DNA_MMP9_TBX20_PSMAD5_SMAD4_RNAP_NUCLEAR = DNA_MMP9_NUCLEAR + 
TBX20_NUCLEAR + PSMAD5_SMAD4_NUCLEAR + RNAP_NUCLEAR + MRNA_MMP9_NUCLEAR DNA_MMP9_TBX20_PSMAD5_SMAD4_RNAP_NUCLEAR = 
DNA_MMP9_NUCLEAR+TBX20_NUCLEAR+PSMAD5_SMAD4_NUCLEAR+RNAP_NUCLEAR+MRNA_MMP9_NUCLEAR 
 1.07527846535449E-4 ; % 1260 MRNA_NFATC1_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_NFATC1_NEXPORT_NUCLEAR MRNA_NFATC1_NUCLEAR+NEXPORT_NUCLEAR = MRNA_NFATC1_NEXPORT_NUCLEAR 
 0.008093749630559088 ; % 1261 MRNA_NFATC1_NEXPORT_NUCLEAR = MRNA_NFATC1_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_NFATC1_NEXPORT_NUCLEAR = MRNA_NFATC1_NUCLEAR+NEXPORT_NUCLEAR 
 0.5053959288290942 ; % 1262 MRNA_NFATC1_NEXPORT_NUCLEAR = MRNA_NFATC1_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_NFATC1_NEXPORT_NUCLEAR = MRNA_NFATC1_CYTOSOL+NEXPORT_NUCLEAR 
 0.002188634517492627 ; % 1263 MRNA_NFATC1_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_NFATC1_RIBOSOME_CYTOSOL MRNA_NFATC1_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_NFATC1_RIBOSOME_CYTOSOL 
 0.07551530454628938 ; % 1264 MRNA_NFATC1_RIBOSOME_CYTOSOL = MRNA_NFATC1_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_NFATC1_RIBOSOME_CYTOSOL = MRNA_NFATC1_CYTOSOL+RIBOSOME_CYTOSOL 
 0.7190719640193961 ; % 1265 MRNA_NFATC1_RIBOSOME_CYTOSOL = 
MRNA_NFATC1_START_RIBOSOME_CYTOSOL MRNA_NFATC1_RIBOSOME_CYTOSOL = MRNA_NFATC1_START_RIBOSOME_CYTOSOL 
 0.22068814431673855 ; % 1266 MRNA_NFATC1_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
NFATC1_CYTOSOL + MRNA_NFATC1_CYTOSOL MRNA_NFATC1_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+NFATC1_CYTOSOL+MRNA_NFATC1_CYTOSOL 
 0.3194669005610719 ; % 1267 MRNA_NFATC1_CYTOSOL = [] MRNA_NFATC1_CYTOSOL = [] 
 0.4710685457312312 ; % 1268 NFATC1_CYTOSOL = [] NFATC1_CYTOSOL = [] 
 0.5178629578611977 ; % 1269 DNA_NFATC1_NUCLEAR + P_AP1_NUCLEAR = DNA_NFATC1_P_AP1_NUCLEAR
 DNA_NFATC1_NUCLEAR+P_AP1_NUCLEAR = DNA_NFATC1_P_AP1_NUCLEAR 
 0.07400867179767422 ; % 1270 DNA_NFATC1_P_AP1_NUCLEAR = DNA_NFATC1_NUCLEAR + P_AP1_NUCLEAR
 DNA_NFATC1_P_AP1_NUCLEAR = DNA_NFATC1_NUCLEAR+P_AP1_NUCLEAR 
 0.2811654800302711 ; % 1271 DNA_NFATC1_P_AP1_NUCLEAR + RNAP_NUCLEAR = 
DNA_NFATC1_P_AP1_RNAP_NUCLEAR DNA_NFATC1_P_AP1_NUCLEAR+RNAP_NUCLEAR = DNA_NFATC1_P_AP1_RNAP_NUCLEAR 
 0.016947127352985227 ; % 1272 DNA_NFATC1_P_AP1_RNAP_NUCLEAR = DNA_NFATC1_P_AP1_NUCLEAR + 
RNAP_NUCLEAR DNA_NFATC1_P_AP1_RNAP_NUCLEAR = DNA_NFATC1_P_AP1_NUCLEAR+RNAP_NUCLEAR 
 0.9680373357183878 ; % 1273 DNA_NFATC1_P_AP1_RNAP_NUCLEAR = DNA_NFATC1_NUCLEAR + P_AP1_NUCLEAR 
+ RNAP_NUCLEAR + MRNA_NFATC1_NUCLEAR DNA_NFATC1_P_AP1_RNAP_NUCLEAR = 
DNA_NFATC1_NUCLEAR+P_AP1_NUCLEAR+RNAP_NUCLEAR+MRNA_NFATC1_NUCLEAR 
 0.17966295040479507 ; % 1274 DNA_NFATC1_NUCLEAR + P_SP1_NUCLEAR = DNA_NFATC1_P_SP1_NUCLEAR
 DNA_NFATC1_NUCLEAR+P_SP1_NUCLEAR = DNA_NFATC1_P_SP1_NUCLEAR 
 0.015199294975141676 ; % 1275 DNA_NFATC1_P_SP1_NUCLEAR = DNA_NFATC1_NUCLEAR + P_SP1_NUCLEAR
 DNA_NFATC1_P_SP1_NUCLEAR = DNA_NFATC1_NUCLEAR+P_SP1_NUCLEAR 
 0.8827464659750346 ; % 1276 DNA_NFATC1_P_SP1_NUCLEAR + RNAP_NUCLEAR = 
DNA_NFATC1_P_SP1_RNAP_NUCLEAR DNA_NFATC1_P_SP1_NUCLEAR+RNAP_NUCLEAR = DNA_NFATC1_P_SP1_RNAP_NUCLEAR 
 0.06408667563941049 ; % 1277 DNA_NFATC1_P_SP1_RNAP_NUCLEAR = DNA_NFATC1_P_SP1_NUCLEAR + 
RNAP_NUCLEAR DNA_NFATC1_P_SP1_RNAP_NUCLEAR = DNA_NFATC1_P_SP1_NUCLEAR+RNAP_NUCLEAR 
 0.1023729232293995 ; % 1278 DNA_NFATC1_P_SP1_RNAP_NUCLEAR = DNA_NFATC1_NUCLEAR + P_SP1_NUCLEAR 
+ RNAP_NUCLEAR + MRNA_NFATC1_NUCLEAR DNA_NFATC1_P_SP1_RNAP_NUCLEAR = 
DNA_NFATC1_NUCLEAR+P_SP1_NUCLEAR+RNAP_NUCLEAR+MRNA_NFATC1_NUCLEAR 
 0.889038240685759 ; % 1279 DNA_NFATC1_NUCLEAR + PSMAD2_SMAD4_NUCLEAR = 
DNA_NFATC1_PSMAD2_SMAD4_NUCLEAR DNA_NFATC1_NUCLEAR+PSMAD2_SMAD4_NUCLEAR = DNA_NFATC1_PSMAD2_SMAD4_NUCLEAR 
 0.0021758680091960993 ; % 1280 DNA_NFATC1_PSMAD2_SMAD4_NUCLEAR = DNA_NFATC1_NUCLEAR + 
PSMAD2_SMAD4_NUCLEAR DNA_NFATC1_PSMAD2_SMAD4_NUCLEAR = DNA_NFATC1_NUCLEAR+PSMAD2_SMAD4_NUCLEAR 
 0.820106536287432 ; % 1281 DNA_NFATC1_PSMAD2_SMAD4_NUCLEAR + RNAP_NUCLEAR = 
DNA_NFATC1_PSMAD2_SMAD4_RNAP_NUCLEAR DNA_NFATC1_PSMAD2_SMAD4_NUCLEAR+RNAP_NUCLEAR = 
DNA_NFATC1_PSMAD2_SMAD4_RNAP_NUCLEAR 
 0.0054699646996320905 ; % 1282 DNA_NFATC1_PSMAD2_SMAD4_RNAP_NUCLEAR = 
DNA_NFATC1_PSMAD2_SMAD4_NUCLEAR + RNAP_NUCLEAR DNA_NFATC1_PSMAD2_SMAD4_RNAP_NUCLEAR = 
DNA_NFATC1_PSMAD2_SMAD4_NUCLEAR+RNAP_NUCLEAR 
 0.80479140139075349 ; % 1283 DNA_NFATC1_PSMAD2_SMAD4_RNAP_NUCLEAR = DNA_NFATC1_NUCLEAR + 
PSMAD2_SMAD4_NUCLEAR + RNAP_NUCLEAR + MRNA_NFATC1_NUCLEAR DNA_NFATC1_PSMAD2_SMAD4_RNAP_NUCLEAR = 
DNA_NFATC1_NUCLEAR+PSMAD2_SMAD4_NUCLEAR+RNAP_NUCLEAR+MRNA_NFATC1_NUCLEAR 
 0.8411885237187595 ; % 1284 DNA_NFATC1_NUCLEAR + PSMAD3_SMAD4_NUCLEAR = 
DNA_NFATC1_PSMAD3_SMAD4_NUCLEAR DNA_NFATC1_NUCLEAR+PSMAD3_SMAD4_NUCLEAR = DNA_NFATC1_PSMAD3_SMAD4_NUCLEAR 
 0.0035900318411721165 ; % 1285 DNA_NFATC1_PSMAD3_SMAD4_NUCLEAR = DNA_NFATC1_NUCLEAR + 
PSMAD3_SMAD4_NUCLEAR DNA_NFATC1_PSMAD3_SMAD4_NUCLEAR = DNA_NFATC1_NUCLEAR+PSMAD3_SMAD4_NUCLEAR 
 0.830870289022124 ; % 1286 DNA_NFATC1_PSMAD3_SMAD4_NUCLEAR + RNAP_NUCLEAR = 
DNA_NFATC1_PSMAD3_SMAD4_RNAP_NUCLEAR DNA_NFATC1_PSMAD3_SMAD4_NUCLEAR+RNAP_NUCLEAR = 
DNA_NFATC1_PSMAD3_SMAD4_RNAP_NUCLEAR 
 0.06307398024198943 ; % 1287 DNA_NFATC1_PSMAD3_SMAD4_RNAP_NUCLEAR = 
DNA_NFATC1_PSMAD3_SMAD4_NUCLEAR + RNAP_NUCLEAR DNA_NFATC1_PSMAD3_SMAD4_RNAP_NUCLEAR = 
DNA_NFATC1_PSMAD3_SMAD4_NUCLEAR+RNAP_NUCLEAR 
 0.7091357342262075 ; % 1288 DNA_NFATC1_PSMAD3_SMAD4_RNAP_NUCLEAR = DNA_NFATC1_NUCLEAR + 
PSMAD3_SMAD4_NUCLEAR + RNAP_NUCLEAR + MRNA_NFATC1_NUCLEAR DNA_NFATC1_PSMAD3_SMAD4_RNAP_NUCLEAR = 
DNA_NFATC1_NUCLEAR+PSMAD3_SMAD4_NUCLEAR+RNAP_NUCLEAR+MRNA_NFATC1_NUCLEAR 
 0.36644289691466203 ; % 1289 DNA_NFATC1_NUCLEAR + MSX1_NUCLEAR = DNA_NFATC1_MSX1_NUCLEAR
 DNA_NFATC1_NUCLEAR+MSX1_NUCLEAR = DNA_NFATC1_MSX1_NUCLEAR 
 0.07552863874253106 ; % 1290 DNA_NFATC1_MSX1_NUCLEAR = DNA_NFATC1_NUCLEAR + MSX1_NUCLEAR
 DNA_NFATC1_MSX1_NUCLEAR = DNA_NFATC1_NUCLEAR+MSX1_NUCLEAR 
 0.7252093298717156 ; % 1291 DNA_NFATC1_MSX1_NUCLEAR + PSMAD5_SMAD4_NUCLEAR = 
DNA_NFATC1_MSX1_PSMAD5_SMAD4_NUCLEAR DNA_NFATC1_MSX1_NUCLEAR+PSMAD5_SMAD4_NUCLEAR = 
DNA_NFATC1_MSX1_PSMAD5_SMAD4_NUCLEAR 
 0.047004479568735984 ; % 1292 DNA_NFATC1_MSX1_PSMAD5_SMAD4_NUCLEAR = DNA_NFATC1_MSX1_NUCLEAR + 
PSMAD5_SMAD4_NUCLEAR DNA_NFATC1_MSX1_PSMAD5_SMAD4_NUCLEAR = DNA_NFATC1_MSX1_NUCLEAR+PSMAD5_SMAD4_NUCLEAR 
 0.7337646259341032 ; % 1293 DNA_NFATC1_MSX1_PSMAD5_SMAD4_NUCLEAR + RNAP_NUCLEAR = 
DNA_NFATC1_MSX1_PSMAD5_SMAD4_RNAP_NUCLEAR DNA_NFATC1_MSX1_PSMAD5_SMAD4_NUCLEAR+RNAP_NUCLEAR = 
DNA_NFATC1_MSX1_PSMAD5_SMAD4_RNAP_NUCLEAR 
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 0.08802855000369092 ; % 1294 DNA_NFATC1_MSX1_PSMAD5_SMAD4_RNAP_NUCLEAR = 
DNA_NFATC1_MSX1_PSMAD5_SMAD4_NUCLEAR + RNAP_NUCLEAR DNA_NFATC1_MSX1_PSMAD5_SMAD4_RNAP_NUCLEAR = 
DNA_NFATC1_MSX1_PSMAD5_SMAD4_NUCLEAR+RNAP_NUCLEAR 
 0.06880015332133194 ; % 1295 DNA_NFATC1_MSX1_PSMAD5_SMAD4_RNAP_NUCLEAR = DNA_NFATC1_NUCLEAR + 
MSX1_NUCLEAR + PSMAD5_SMAD4_NUCLEAR + RNAP_NUCLEAR + MRNA_NFATC1_NUCLEAR DNA_NFATC1_MSX1_PSMAD5_SMAD4_RNAP_NUCLEAR = 
DNA_NFATC1_NUCLEAR+MSX1_NUCLEAR+PSMAD5_SMAD4_NUCLEAR+RNAP_NUCLEAR+MRNA_NFATC1_NUCLEAR 
 0.6689443738056666 ; % 1296 MSX1_CYTOSOL + NIMPORT_NUCLEAR = MSX1_NIMPORT_NUCLEAR
 MSX1_CYTOSOL+NIMPORT_NUCLEAR = MSX1_NIMPORT_NUCLEAR 
 0.017754249855942927 ; % 1297 MSX1_NIMPORT_NUCLEAR = MSX1_CYTOSOL + NIMPORT_NUCLEAR
 MSX1_NIMPORT_NUCLEAR = MSX1_CYTOSOL+NIMPORT_NUCLEAR 
 0.2245081567476357 ; % 1298 MSX1_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR + MSX1_NUCLEAR
 MSX1_NIMPORT_NUCLEAR = NIMPORT_NUCLEAR+MSX1_NUCLEAR 
 0.07149574809722836 ; % 1299 MSX1_NUCLEAR + NEXPORT_NUCLEAR = MSX1_NEXPORT_NUCLEAR
 MSX1_NUCLEAR+NEXPORT_NUCLEAR = MSX1_NEXPORT_NUCLEAR 
 0.0915683765435206 ; % 1300 MSX1_NEXPORT_NUCLEAR = MSX1_NUCLEAR + NEXPORT_NUCLEAR
 MSX1_NEXPORT_NUCLEAR = MSX1_NUCLEAR+NEXPORT_NUCLEAR 
 0.19359445369746953 ; % 1301 MSX1_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR + MSX1_CYTOSOL
 MSX1_NEXPORT_NUCLEAR = NEXPORT_NUCLEAR+MSX1_CYTOSOL 
 0.7237106754267346 ; % 1302 MRNA_CALCNCAM_NUCLEAR + NEXPORT_NUCLEAR = 
MRNA_CALCNCAM_NEXPORT_NUCLEAR MRNA_CALCNCAM_NUCLEAR+NEXPORT_NUCLEAR = MRNA_CALCNCAM_NEXPORT_NUCLEAR 
 0.08719688343431319 ; % 1303 MRNA_CALCNCAM_NEXPORT_NUCLEAR = MRNA_CALCNCAM_NUCLEAR + 
NEXPORT_NUCLEAR MRNA_CALCNCAM_NEXPORT_NUCLEAR = MRNA_CALCNCAM_NUCLEAR+NEXPORT_NUCLEAR 
 0.41551766351748876 ; % 1304 MRNA_CALCNCAM_NEXPORT_NUCLEAR = MRNA_CALCNCAM_CYTOSOL + 
NEXPORT_NUCLEAR MRNA_CALCNCAM_NEXPORT_NUCLEAR = MRNA_CALCNCAM_CYTOSOL+NEXPORT_NUCLEAR 
 0.09372786112900522 ; % 1305 MRNA_CALCNCAM_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_CALCNCAM_RIBOSOME_CYTOSOL MRNA_CALCNCAM_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_CALCNCAM_RIBOSOME_CYTOSOL 
 0.028298676692311498 ; % 1306 MRNA_CALCNCAM_RIBOSOME_CYTOSOL = MRNA_CALCNCAM_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_CALCNCAM_RIBOSOME_CYTOSOL = MRNA_CALCNCAM_CYTOSOL+RIBOSOME_CYTOSOL 
 0.42230298255569065 ; % 1307 MRNA_CALCNCAM_RIBOSOME_CYTOSOL = 
MRNA_CALCNCAM_START_RIBOSOME_CYTOSOL MRNA_CALCNCAM_RIBOSOME_CYTOSOL = MRNA_CALCNCAM_START_RIBOSOME_CYTOSOL 
 0.6899746708745279 ; % 1308 MRNA_CALCNCAM_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
CALCNCAM_CYTOSOL + MRNA_CALCNCAM_CYTOSOL MRNA_CALCNCAM_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+CALCNCAM_CYTOSOL+MRNA_CALCNCAM_CYTOSOL 
 0.2788934888111168 ; % 1309 MRNA_CALCNCAM_CYTOSOL = [] MRNA_CALCNCAM_CYTOSOL = [] 
 0.4602964714652141 ; % 1310 CALCNCAM_CYTOSOL = [] CALCNCAM_CYTOSOL = [] 
 0.2202946319760979 ; % 1311 DNA_CALCNCAM_NUCLEAR + ACTIVE_NCID_CSL_NUCLEAR = 
DNA_CALCNCAM_ACTIVE_NCID_CSL_NUCLEAR DNA_CALCNCAM_NUCLEAR+ACTIVE_NCID_CSL_NUCLEAR = DNA_CALCNCAM_ACTIVE_NCID_CSL_NUCLEAR 
 0.009881702780120218 ; % 1312 DNA_CALCNCAM_ACTIVE_NCID_CSL_NUCLEAR = DNA_CALCNCAM_NUCLEAR + 
ACTIVE_NCID_CSL_NUCLEAR DNA_CALCNCAM_ACTIVE_NCID_CSL_NUCLEAR = DNA_CALCNCAM_NUCLEAR+ACTIVE_NCID_CSL_NUCLEAR 
 0.09373274098394357 ; % 1313 DNA_CALCNCAM_ACTIVE_NCID_CSL_NUCLEAR + RNAP_NUCLEAR = 
DNA_CALCNCAM_ACTIVE_NCID_CSL_RNAP_NUCLEAR DNA_CALCNCAM_ACTIVE_NCID_CSL_NUCLEAR+RNAP_NUCLEAR = 
DNA_CALCNCAM_ACTIVE_NCID_CSL_RNAP_NUCLEAR 
 0.08181660647388961 ; % 1314 DNA_CALCNCAM_ACTIVE_NCID_CSL_RNAP_NUCLEAR = 
DNA_CALCNCAM_ACTIVE_NCID_CSL_NUCLEAR + RNAP_NUCLEAR DNA_CALCNCAM_ACTIVE_NCID_CSL_RNAP_NUCLEAR = 
DNA_CALCNCAM_ACTIVE_NCID_CSL_NUCLEAR+RNAP_NUCLEAR 
 0.5766945666344662 ; % 1315 DNA_CALCNCAM_ACTIVE_NCID_CSL_RNAP_NUCLEAR = DNA_CALCNCAM_NUCLEAR 
+ ACTIVE_NCID_CSL_NUCLEAR + RNAP_NUCLEAR + MRNA_CALCNCAM_NUCLEAR DNA_CALCNCAM_ACTIVE_NCID_CSL_RNAP_NUCLEAR = 
DNA_CALCNCAM_NUCLEAR+ACTIVE_NCID_CSL_NUCLEAR+RNAP_NUCLEAR+MRNA_CALCNCAM_NUCLEAR 
 0.9764764256601042 ; % 1316 MRNA_TWIST_NUCLEAR + NEXPORT_NUCLEAR = MRNA_TWIST_NEXPORT_NUCLEAR
 MRNA_TWIST_NUCLEAR+NEXPORT_NUCLEAR = MRNA_TWIST_NEXPORT_NUCLEAR 
 0.007680599641556152 ; % 1317 MRNA_TWIST_NEXPORT_NUCLEAR = MRNA_TWIST_NUCLEAR + NEXPORT_NUCLEAR
 MRNA_TWIST_NEXPORT_NUCLEAR = MRNA_TWIST_NUCLEAR+NEXPORT_NUCLEAR 
 0.6283157155264475 ; % 1318 MRNA_TWIST_NEXPORT_NUCLEAR = MRNA_TWIST_CYTOSOL + NEXPORT_NUCLEAR
 MRNA_TWIST_NEXPORT_NUCLEAR = MRNA_TWIST_CYTOSOL+NEXPORT_NUCLEAR 
 0.7861943534004907 ; % 1319 MRNA_TWIST_CYTOSOL + RIBOSOME_CYTOSOL = 
MRNA_TWIST_RIBOSOME_CYTOSOL MRNA_TWIST_CYTOSOL+RIBOSOME_CYTOSOL = MRNA_TWIST_RIBOSOME_CYTOSOL 
 0.024810907012924367 ; % 1320 MRNA_TWIST_RIBOSOME_CYTOSOL = MRNA_TWIST_CYTOSOL + 
RIBOSOME_CYTOSOL MRNA_TWIST_RIBOSOME_CYTOSOL = MRNA_TWIST_CYTOSOL+RIBOSOME_CYTOSOL 
 0.9733956420331028 ; % 1321 MRNA_TWIST_RIBOSOME_CYTOSOL = MRNA_TWIST_START_RIBOSOME_CYTOSOL
 MRNA_TWIST_RIBOSOME_CYTOSOL = MRNA_TWIST_START_RIBOSOME_CYTOSOL 
 0.020456595661354937 ; % 1322 MRNA_TWIST_START_RIBOSOME_CYTOSOL = RIBOSOME_CYTOSOL + 
TWIST_CYTOSOL + MRNA_TWIST_CYTOSOL MRNA_TWIST_START_RIBOSOME_CYTOSOL = 
RIBOSOME_CYTOSOL+TWIST_CYTOSOL+MRNA_TWIST_CYTOSOL 
 0.10432874307064466 ; % 1323 MRNA_TWIST_CYTOSOL = [] MRNA_TWIST_CYTOSOL = [] 
 0.4242100412421443 ; % 1324 TWIST_CYTOSOL = [] TWIST_CYTOSOL = [] 
 0.9460529549694152 ; % 1325 DNA_TWIST_NUCLEAR + PSMAD1_SMAD4_NUCLEAR = 
DNA_TWIST_PSMAD1_SMAD4_NUCLEAR DNA_TWIST_NUCLEAR+PSMAD1_SMAD4_NUCLEAR = DNA_TWIST_PSMAD1_SMAD4_NUCLEAR 
 0.0981879741833334 ; % 1326 DNA_TWIST_PSMAD1_SMAD4_NUCLEAR = DNA_TWIST_NUCLEAR + 
PSMAD1_SMAD4_NUCLEAR DNA_TWIST_PSMAD1_SMAD4_NUCLEAR = DNA_TWIST_NUCLEAR+PSMAD1_SMAD4_NUCLEAR 
 0.0610413064629044 ; % 1327 DNA_TWIST_PSMAD1_SMAD4_NUCLEAR + RNAP_NUCLEAR = 
DNA_TWIST_PSMAD1_SMAD4_RNAP_NUCLEAR DNA_TWIST_PSMAD1_SMAD4_NUCLEAR+RNAP_NUCLEAR = DNA_TWIST_PSMAD1_SMAD4_RNAP_NUCLEAR 
 0.01306663572830108 ; % 1328 DNA_TWIST_PSMAD1_SMAD4_RNAP_NUCLEAR = 
DNA_TWIST_PSMAD1_SMAD4_NUCLEAR + RNAP_NUCLEAR DNA_TWIST_PSMAD1_SMAD4_RNAP_NUCLEAR = 
DNA_TWIST_PSMAD1_SMAD4_NUCLEAR+RNAP_NUCLEAR 
 0.28316461716764874 ; % 1329 DNA_TWIST_PSMAD1_SMAD4_RNAP_NUCLEAR = DNA_TWIST_NUCLEAR + 
PSMAD1_SMAD4_NUCLEAR + RNAP_NUCLEAR + MRNA_TWIST_NUCLEAR DNA_TWIST_PSMAD1_SMAD4_RNAP_NUCLEAR = 
DNA_TWIST_NUCLEAR+PSMAD1_SMAD4_NUCLEAR+RNAP_NUCLEAR+MRNA_TWIST_NUCLEAR 
 0.833443195677032 ; % 1330 DNA_TWIST_NUCLEAR + PSMAD5_SMAD4_NUCLEAR = 
DNA_TWIST_PSMAD5_SMAD4_NUCLEAR DNA_TWIST_NUCLEAR+PSMAD5_SMAD4_NUCLEAR = DNA_TWIST_PSMAD5_SMAD4_NUCLEAR 
 0.06706499972894701 ; % 1331 DNA_TWIST_PSMAD5_SMAD4_NUCLEAR = DNA_TWIST_NUCLEAR + 
PSMAD5_SMAD4_NUCLEAR DNA_TWIST_PSMAD5_SMAD4_NUCLEAR = DNA_TWIST_NUCLEAR+PSMAD5_SMAD4_NUCLEAR 
 0.7237535405026247 ; % 1332 DNA_TWIST_PSMAD5_SMAD4_NUCLEAR + RNAP_NUCLEAR = 
DNA_TWIST_PSMAD5_SMAD4_RNAP_NUCLEAR DNA_TWIST_PSMAD5_SMAD4_NUCLEAR+RNAP_NUCLEAR = DNA_TWIST_PSMAD5_SMAD4_RNAP_NUCLEAR 
 1.1612451795217638E-5 ; % 1333 DNA_TWIST_PSMAD5_SMAD4_RNAP_NUCLEAR = 
DNA_TWIST_PSMAD5_SMAD4_NUCLEAR + RNAP_NUCLEAR DNA_TWIST_PSMAD5_SMAD4_RNAP_NUCLEAR = 
DNA_TWIST_PSMAD5_SMAD4_NUCLEAR+RNAP_NUCLEAR 
 0.26789623806921803 ; % 1334 DNA_TWIST_PSMAD5_SMAD4_RNAP_NUCLEAR = DNA_TWIST_NUCLEAR + 
PSMAD5_SMAD4_NUCLEAR + RNAP_NUCLEAR + MRNA_TWIST_NUCLEAR DNA_TWIST_PSMAD5_SMAD4_RNAP_NUCLEAR = 
DNA_TWIST_NUCLEAR+PSMAD5_SMAD4_NUCLEAR+RNAP_NUCLEAR+MRNA_TWIST_NUCLEAR 
 0.43402666222804458 ; % 1335 RIBOSOME_CYTOSOL = [] RIBOSOME_CYTOSOL = [] 
 0.5721014878218912 ; % 1336 [] = RIBOSOME_CYTOSOL [] = RIBOSOME_CYTOSOL 
 0.55917431295969734 ; % 1337 RNAP_NUCLEAR = [] RNAP_NUCLEAR = [] 
 0.7737339878760369 ; % 1338 [] = RNAP_NUCLEAR [] = RNAP_NUCLEAR 
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 0.4453581876192623 ; % 1339 NIMPORT_NUCLEAR = [] NIMPORT_NUCLEAR = [] 
 0.6759602194907085 ; % 1340 [] = NIMPORT_NUCLEAR [] = NIMPORT_NUCLEAR 
 0.37226596293207034 ; % 1341 NEXPORT_NUCLEAR = [] NEXPORT_NUCLEAR = [] 
 0.5686117240528282 ; % 1342 [] = NEXPORT_NUCLEAR [] = NEXPORT_NUCLEAR 
 0.29113754796576835 ; % 1343 EXIMPORT_CYTOSOL = [] EXIMPORT_CYTOSOL = [] 
 0.53911564684036277 ; % 1344 [] = EXIMPORT_CYTOSOL [] = EXIMPORT_CYTOSOL 
 0.47207334500989193 ; % 1345 EXEXPORT_CYTOSOL = [] EXEXPORT_CYTOSOL = [] 
 0.633731428010798 ; % 1346 [] = EXEXPORT_CYTOSOL [] = EXEXPORT_CYTOSOL 
 0.12884992534950973 ; % 1347 GDP_CYTOSOL = [] GDP_CYTOSOL = [] 
 0.2643297919584675 ; % 1348 [] = GDP_CYTOSOL [] = GDP_CYTOSOL 
 0.4660448941130764 ; % 1349 GTP_CYTOSOL = [] GTP_CYTOSOL = [] 
 0.6142457904868078 ; % 1350 [] = GTP_CYTOSOL [] = GTP_CYTOSOL 
 0.411697198887914 ; % 1351 PIP2_CYTOSOL = [] PIP2_CYTOSOL = [] 
 0.63544301674632329 ; % 1352 [] = PIP2_CYTOSOL [] = PIP2_CYTOSOL 
 0.1437430833834576 ; % 1353 PIP3_CYTOSOL = [] PIP3_CYTOSOL = [] 
 0.0     ; % 1354 [] = PIP3_CYTOSOL [] = PIP3_CYTOSOL 
 0.3195424457637901 ; % 1355 GATA_FOG2_CYTOSOL = [] GATA_FOG2_CYTOSOL = [] 
 0.8941842829502842 ; % 1356 [] = GATA_FOG2_CYTOSOL [] = GATA_FOG2_CYTOSOL 
 0.27035584332982354 ; % 1357 DELTEX_NEDD4_CYTOSOL = [] DELTEX_NEDD4_CYTOSOL = [] 
 0.8319233414138181 ; % 1358 [] = DELTEX_NEDD4_CYTOSOL [] = DELTEX_NEDD4_CYTOSOL 
 0.6472432825423382 ; % 1359 WNT9A_EXTRACELLULAR + FRIZZLED_CYTOSOL = WNT9A_FRIZZLED_CYTOSOL
 WNT9A_EXTRACELLULAR+FRIZZLED_CYTOSOL = WNT9A_FRIZZLED_CYTOSOL 
 0.07117722685074866 ; % 1360 WNT9A_FRIZZLED_CYTOSOL = WNT9A_EXTRACELLULAR + FRIZZLED_CYTOSOL
 WNT9A_FRIZZLED_CYTOSOL = WNT9A_EXTRACELLULAR+FRIZZLED_CYTOSOL 
 0.17770134462401355 ; % 1361 WNT9A_FRIZZLED_CYTOSOL + DISHEVELLED_CYTOSOL = 
WNT9A_FRIZZLED_DISHEVELLED_CYTOSOL WNT9A_FRIZZLED_CYTOSOL+DISHEVELLED_CYTOSOL = WNT9A_FRIZZLED_DISHEVELLED_CYTOSOL 
 0.08147618866296401 ; % 1362 WNT9A_FRIZZLED_DISHEVELLED_CYTOSOL = WNT9A_FRIZZLED_CYTOSOL + 
DISHEVELLED_CYTOSOL WNT9A_FRIZZLED_DISHEVELLED_CYTOSOL = WNT9A_FRIZZLED_CYTOSOL+DISHEVELLED_CYTOSOL 
 0.9260001091725943 ; % 1363 WNT9A_FRIZZLED_DISHEVELLED_CYTOSOL + LRP_CYTOSOL = 
WNT9A_FRIZZLED_DISHEVELLED_LRP_CYTOSOL WNT9A_FRIZZLED_DISHEVELLED_CYTOSOL+LRP_CYTOSOL = 
WNT9A_FRIZZLED_DISHEVELLED_LRP_CYTOSOL 
 0.06286742192856727 ; % 1364 WNT9A_FRIZZLED_DISHEVELLED_LRP_CYTOSOL = 
WNT9A_FRIZZLED_DISHEVELLED_CYTOSOL + LRP_CYTOSOL WNT9A_FRIZZLED_DISHEVELLED_LRP_CYTOSOL = 
WNT9A_FRIZZLED_DISHEVELLED_CYTOSOL+LRP_CYTOSOL 
 0.2599375494408255 ; % 1365 WNT9A_FRIZZLED_DISHEVELLED_LRP_CYTOSOL + AXIN_CYTOSOL = 
WNT9A_FRIZZLED_DISHEVELLED_LRP_AXIN_CYTOSOL WNT9A_FRIZZLED_DISHEVELLED_LRP_CYTOSOL+AXIN_CYTOSOL = 
WNT9A_FRIZZLED_DISHEVELLED_LRP_AXIN_CYTOSOL 
 0.08294819653915285 ; % 1366 WNT9A_FRIZZLED_DISHEVELLED_LRP_AXIN_CYTOSOL = 
WNT9A_FRIZZLED_DISHEVELLED_LRP_CYTOSOL + AXIN_CYTOSOL WNT9A_FRIZZLED_DISHEVELLED_LRP_AXIN_CYTOSOL = 
WNT9A_FRIZZLED_DISHEVELLED_LRP_CYTOSOL+AXIN_CYTOSOL 
 0.999195594657313 ; % 1367 VEGFA_EXTRACELLULAR + VEGFR2_CYTOSOL = VEGFA_VEGFR2_CYTOSOL
 VEGFA_EXTRACELLULAR+VEGFR2_CYTOSOL = VEGFA_VEGFR2_CYTOSOL 
 0.0040426287032167335 ; % 1368 VEGFA_VEGFR2_CYTOSOL = VEGFA_EXTRACELLULAR + VEGFR2_CYTOSOL
 VEGFA_VEGFR2_CYTOSOL = VEGFA_EXTRACELLULAR+VEGFR2_CYTOSOL 
 0.6680836437038423 ; % 1369 VEGFA_VEGFR2_CYTOSOL + SHC_CYTOSOL = VEGFA_VEGFR2_SHC_CYTOSOL
 VEGFA_VEGFR2_CYTOSOL+SHC_CYTOSOL = VEGFA_VEGFR2_SHC_CYTOSOL 
 1.050561456712451E-4 ; % 1370 VEGFA_VEGFR2_SHC_CYTOSOL = VEGFA_VEGFR2_CYTOSOL + SHC_CYTOSOL
 VEGFA_VEGFR2_SHC_CYTOSOL = VEGFA_VEGFR2_CYTOSOL+SHC_CYTOSOL 
 0.7499130884575897 ; % 1371 BMP2_EXTRACELLULAR + BMPRII_CYTOSOL = BMP2_BMPRII_CYTOSOL
 BMP2_EXTRACELLULAR+BMPRII_CYTOSOL = BMP2_BMPRII_CYTOSOL 
 0.03015373284614914 ; % 1372 BMP2_BMPRII_CYTOSOL = BMP2_EXTRACELLULAR + BMPRII_CYTOSOL
 BMP2_BMPRII_CYTOSOL = BMP2_EXTRACELLULAR+BMPRII_CYTOSOL 
 0.4430480136425038 ; % 1373 BMP2_BMPRII_CYTOSOL + ALK2_CYTOSOL = BMP2_BMPRII_ALK2_CYTOSOL
 BMP2_BMPRII_CYTOSOL+ALK2_CYTOSOL = BMP2_BMPRII_ALK2_CYTOSOL 
 0.08024363741577445 ; % 1374 BMP2_BMPRII_ALK2_CYTOSOL = BMP2_BMPRII_CYTOSOL + ALK2_CYTOSOL
 BMP2_BMPRII_ALK2_CYTOSOL = BMP2_BMPRII_CYTOSOL+ALK2_CYTOSOL 
 0.4527839260019898 ; % 1375 BMP2_BMPRII_CYTOSOL + ALK3_CYTOSOL = BMP2_BMPRII_ALK3_CYTOSOL
 BMP2_BMPRII_CYTOSOL+ALK3_CYTOSOL = BMP2_BMPRII_ALK3_CYTOSOL 
 0.07555814966923205 ; % 1376 BMP2_BMPRII_ALK3_CYTOSOL = BMP2_BMPRII_CYTOSOL + ALK3_CYTOSOL
 BMP2_BMPRII_ALK3_CYTOSOL = BMP2_BMPRII_CYTOSOL+ALK3_CYTOSOL 
 0.42033455850723433 ; % 1377 BMP2_BMPRII_CYTOSOL + ALK6_CYTOSOL = BMP2_BMPRII_ALK6_CYTOSOL
 BMP2_BMPRII_CYTOSOL+ALK6_CYTOSOL = BMP2_BMPRII_ALK6_CYTOSOL 
 0.05360561500779816 ; % 1378 BMP2_BMPRII_ALK6_CYTOSOL = BMP2_BMPRII_CYTOSOL + ALK6_CYTOSOL
 BMP2_BMPRII_ALK6_CYTOSOL = BMP2_BMPRII_CYTOSOL+ALK6_CYTOSOL 
 0.26554844291456015 ; % 1379 BMP2_BMPRII_ALK2_CYTOSOL + SHC_CYTOSOL = 
BMP2_BMPRII_ALK2_SHC_CYTOSOL BMP2_BMPRII_ALK2_CYTOSOL+SHC_CYTOSOL = BMP2_BMPRII_ALK2_SHC_CYTOSOL 
 0.0682989735888384 ; % 1380 BMP2_BMPRII_ALK2_SHC_CYTOSOL = BMP2_BMPRII_ALK2_CYTOSOL + 
SHC_CYTOSOL BMP2_BMPRII_ALK2_SHC_CYTOSOL = BMP2_BMPRII_ALK2_CYTOSOL+SHC_CYTOSOL 
 0.5318555191224043 ; % 1381 BMP2_BMPRII_ALK2_SHC_CYTOSOL + GRB2_CYTOSOL = 
BMP2_BMPRII_ALK2_SHC_GRB2_CYTOSOL BMP2_BMPRII_ALK2_SHC_CYTOSOL+GRB2_CYTOSOL = BMP2_BMPRII_ALK2_SHC_GRB2_CYTOSOL 
 0.06023806442881577 ; % 1382 BMP2_BMPRII_ALK2_SHC_GRB2_CYTOSOL = BMP2_BMPRII_ALK2_SHC_CYTOSOL + 
GRB2_CYTOSOL BMP2_BMPRII_ALK2_SHC_GRB2_CYTOSOL = BMP2_BMPRII_ALK2_SHC_CYTOSOL+GRB2_CYTOSOL 
 0.5018033633271693 ; % 1383 BMP2_BMPRII_ALK2_SHC_GRB2_CYTOSOL + SOS_CYTOSOL = 
BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL BMP2_BMPRII_ALK2_SHC_GRB2_CYTOSOL+SOS_CYTOSOL = BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL 
 0.010980796300690055 ; % 1384 BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL = 
BMP2_BMPRII_ALK2_SHC_GRB2_CYTOSOL + SOS_CYTOSOL BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL = 
BMP2_BMPRII_ALK2_SHC_GRB2_CYTOSOL+SOS_CYTOSOL 
 0.583952871439399 ; % 1385 TGFB2_EXTRACELLULAR + BMPRII_CYTOSOL = TGFB2_BMPRII_CYTOSOL
 TGFB2_EXTRACELLULAR+BMPRII_CYTOSOL = TGFB2_BMPRII_CYTOSOL 
 0.0864691167082994 ; % 1386 TGFB2_BMPRII_CYTOSOL = TGFB2_EXTRACELLULAR + BMPRII_CYTOSOL
 TGFB2_BMPRII_CYTOSOL = TGFB2_EXTRACELLULAR+BMPRII_CYTOSOL 
 0.14456008868041614 ; % 1387 TGFB2_BMPRII_CYTOSOL + ALK2_CYTOSOL = TGFB2_BMPRII_ALK2_CYTOSOL
 TGFB2_BMPRII_CYTOSOL+ALK2_CYTOSOL = TGFB2_BMPRII_ALK2_CYTOSOL 
 0.03786975170073778 ; % 1388 TGFB2_BMPRII_ALK2_CYTOSOL = TGFB2_BMPRII_CYTOSOL + ALK2_CYTOSOL
 TGFB2_BMPRII_ALK2_CYTOSOL = TGFB2_BMPRII_CYTOSOL+ALK2_CYTOSOL 
 0.4111952266064901 ; % 1389 TGFB2_BMPRII_ALK2_CYTOSOL + ENDOGLIN_CYTOSOL = 
TGFB2_BMPRII_ALK2_ENDOGLIN_CYTOSOL TGFB2_BMPRII_ALK2_CYTOSOL+ENDOGLIN_CYTOSOL = TGFB2_BMPRII_ALK2_ENDOGLIN_CYTOSOL 
 0.04551097163302329 ; % 1390 TGFB2_BMPRII_ALK2_ENDOGLIN_CYTOSOL = TGFB2_BMPRII_ALK2_CYTOSOL + 
ENDOGLIN_CYTOSOL TGFB2_BMPRII_ALK2_ENDOGLIN_CYTOSOL = TGFB2_BMPRII_ALK2_CYTOSOL+ENDOGLIN_CYTOSOL 
 0.3541853581911274 ; % 1391 TGFB2_BMPRII_ALK2_ENDOGLIN_CYTOSOL + SHC_CYTOSOL = 
TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_CYTOSOL TGFB2_BMPRII_ALK2_ENDOGLIN_CYTOSOL+SHC_CYTOSOL = 
TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_CYTOSOL 
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 0.07477115098335378 ; % 1392 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_CYTOSOL = 
TGFB2_BMPRII_ALK2_ENDOGLIN_CYTOSOL + SHC_CYTOSOL TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_CYTOSOL = 
TGFB2_BMPRII_ALK2_ENDOGLIN_CYTOSOL+SHC_CYTOSOL 
 0.05258693919605484 ; % 1393 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_CYTOSOL + GRB2_CYTOSOL = 
TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_CYTOSOL TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_CYTOSOL+GRB2_CYTOSOL = 
TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_CYTOSOL 
 0.03094091222662633 ; % 1394 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_CYTOSOL = 
TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_CYTOSOL + GRB2_CYTOSOL TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_CYTOSOL = 
TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_CYTOSOL+GRB2_CYTOSOL 
 0.17448932974147513 ; % 1395 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_CYTOSOL + SOS_CYTOSOL = 
TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_CYTOSOL TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_CYTOSOL+SOS_CYTOSOL = 
TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_CYTOSOL 
 0.005288796696930565 ; % 1396 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_CYTOSOL = 
TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_CYTOSOL + SOS_CYTOSOL TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_CYTOSOL = 
TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_CYTOSOL+SOS_CYTOSOL 
 1.4675753713122575E-4 ; % 1397 TGFB3_EXTRACELLULAR + TGFBRII_CYTOSOL = TGFB3_TGFBRII_CYTOSOL
 TGFB3_EXTRACELLULAR+TGFBRII_CYTOSOL = TGFB3_TGFBRII_CYTOSOL 
 0.05667415053139039 ; % 1398 TGFB3_TGFBRII_CYTOSOL = TGFB3_EXTRACELLULAR + TGFBRII_CYTOSOL
 TGFB3_TGFBRII_CYTOSOL = TGFB3_EXTRACELLULAR+TGFBRII_CYTOSOL 
 0.24717274782430065 ; % 1399 TGFB3_TGFBRII_CYTOSOL + ALK1_CYTOSOL = TGFB3_TGFBRII_ALK1_CYTOSOL
 TGFB3_TGFBRII_CYTOSOL+ALK1_CYTOSOL = TGFB3_TGFBRII_ALK1_CYTOSOL 
 0.06474592888569149 ; % 1400 TGFB3_TGFBRII_ALK1_CYTOSOL = TGFB3_TGFBRII_CYTOSOL + ALK1_CYTOSOL
 TGFB3_TGFBRII_ALK1_CYTOSOL = TGFB3_TGFBRII_CYTOSOL+ALK1_CYTOSOL 
 0.62938378170872 ; % 1401 TGFB3_TGFBRII_ALK1_CYTOSOL + TGFBRIII_CYTOSOL = 
TGFB3_TGFBRII_ALK1_TGFBRIII_CYTOSOL TGFB3_TGFBRII_ALK1_CYTOSOL+TGFBRIII_CYTOSOL = TGFB3_TGFBRII_ALK1_TGFBRIII_CYTOSOL 
 0.07253075276596654 ; % 1402 TGFB3_TGFBRII_ALK1_TGFBRIII_CYTOSOL = TGFB3_TGFBRII_ALK1_CYTOSOL + 
TGFBRIII_CYTOSOL TGFB3_TGFBRII_ALK1_TGFBRIII_CYTOSOL = TGFB3_TGFBRII_ALK1_CYTOSOL+TGFBRIII_CYTOSOL 
 0.10753968048394291 ; % 1403 TGFB3_TGFBRII_CYTOSOL + ALK5_CYTOSOL = TGFB3_TGFBRII_ALK5_CYTOSOL
 TGFB3_TGFBRII_CYTOSOL+ALK5_CYTOSOL = TGFB3_TGFBRII_ALK5_CYTOSOL 
 0.04134845879166874 ; % 1404 TGFB3_TGFBRII_ALK5_CYTOSOL = TGFB3_TGFBRII_CYTOSOL + ALK5_CYTOSOL
 TGFB3_TGFBRII_ALK5_CYTOSOL = TGFB3_TGFBRII_CYTOSOL+ALK5_CYTOSOL 
 0.6370182786218236 ; % 1405 TGFB3_TGFBRII_ALK5_CYTOSOL + TGFBRIII_CYTOSOL = 
TGFB3_TGFBRII_ALK5_TGFBRIII_CYTOSOL TGFB3_TGFBRII_ALK5_CYTOSOL+TGFBRIII_CYTOSOL = TGFB3_TGFBRII_ALK5_TGFBRIII_CYTOSOL 
 0.010612050342788748 ; % 1406 TGFB3_TGFBRII_ALK5_TGFBRIII_CYTOSOL = TGFB3_TGFBRII_ALK5_CYTOSOL + 
TGFBRIII_CYTOSOL TGFB3_TGFBRII_ALK5_TGFBRIII_CYTOSOL = TGFB3_TGFBRII_ALK5_CYTOSOL+TGFBRIII_CYTOSOL 
 0.5533272719738573 ; % 1407 TGFB3_TGFBRII_ALK5_TGFBRIII_CYTOSOL + ENDOGLIN_CYTOSOL = 
TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL TGFB3_TGFBRII_ALK5_TGFBRIII_CYTOSOL+ENDOGLIN_CYTOSOL = 
TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL 
 0.06309696607422316 ; % 1408 TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL = 
TGFB3_TGFBRII_ALK5_TGFBRIII_CYTOSOL + ENDOGLIN_CYTOSOL TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL = 
TGFB3_TGFBRII_ALK5_TGFBRIII_CYTOSOL+ENDOGLIN_CYTOSOL 
 0.6833659471045659 ; % 1409 TGFB2_EXTRACELLULAR + TGFBRII_CYTOSOL = TGFB2_TGFBRII_CYTOSOL
 TGFB2_EXTRACELLULAR+TGFBRII_CYTOSOL = TGFB2_TGFBRII_CYTOSOL 
 0.07444027863677731 ; % 1410 TGFB2_TGFBRII_CYTOSOL = TGFB2_EXTRACELLULAR + TGFBRII_CYTOSOL
 TGFB2_TGFBRII_CYTOSOL = TGFB2_EXTRACELLULAR+TGFBRII_CYTOSOL 
 0.6537000555882052 ; % 1411 TGFB2_TGFBRII_CYTOSOL + ALK1_CYTOSOL = TGFB2_TGFBRII_ALK1_CYTOSOL
 TGFB2_TGFBRII_CYTOSOL+ALK1_CYTOSOL = TGFB2_TGFBRII_ALK1_CYTOSOL 
 0.08850473405525189 ; % 1412 TGFB2_TGFBRII_ALK1_CYTOSOL = TGFB2_TGFBRII_CYTOSOL + ALK1_CYTOSOL
 TGFB2_TGFBRII_ALK1_CYTOSOL = TGFB2_TGFBRII_CYTOSOL+ALK1_CYTOSOL 
 0.4651239213016717 ; % 1413 TGFB2_TGFBRII_ALK1_CYTOSOL + TGFBRIII_CYTOSOL = 
TGFB2_TGFBRII_ALK1_TGFBRIII_CYTOSOL TGFB2_TGFBRII_ALK1_CYTOSOL+TGFBRIII_CYTOSOL = TGFB2_TGFBRII_ALK1_TGFBRIII_CYTOSOL 
 0.030178469814886734 ; % 1414 TGFB2_TGFBRII_ALK1_TGFBRIII_CYTOSOL = TGFB2_TGFBRII_ALK1_CYTOSOL + 
TGFBRIII_CYTOSOL TGFB2_TGFBRII_ALK1_TGFBRIII_CYTOSOL = TGFB2_TGFBRII_ALK1_CYTOSOL+TGFBRIII_CYTOSOL 
 0.19690097921003713 ; % 1415 TGFB2_TGFBRII_CYTOSOL + ALK5_CYTOSOL = TGFB2_TGFBRII_ALK5_CYTOSOL
 TGFB2_TGFBRII_CYTOSOL+ALK5_CYTOSOL = TGFB2_TGFBRII_ALK5_CYTOSOL 
 0.09935480855124648 ; % 1416 TGFB2_TGFBRII_ALK5_CYTOSOL = TGFB2_TGFBRII_CYTOSOL + ALK5_CYTOSOL
 TGFB2_TGFBRII_ALK5_CYTOSOL = TGFB2_TGFBRII_CYTOSOL+ALK5_CYTOSOL 
 0.1288673533789424 ; % 1417 TGFB2_TGFBRII_ALK5_CYTOSOL + TGFBRIII_CYTOSOL = 
TGFB2_TGFBRII_ALK5_TGFBRIII_CYTOSOL TGFB2_TGFBRII_ALK5_CYTOSOL+TGFBRIII_CYTOSOL = TGFB2_TGFBRII_ALK5_TGFBRIII_CYTOSOL 
 0.09723589820711243 ; % 1418 TGFB2_TGFBRII_ALK5_TGFBRIII_CYTOSOL = TGFB2_TGFBRII_ALK5_CYTOSOL + 
TGFBRIII_CYTOSOL TGFB2_TGFBRII_ALK5_TGFBRIII_CYTOSOL = TGFB2_TGFBRII_ALK5_CYTOSOL+TGFBRIII_CYTOSOL 
 0.762747081861526 ; % 1419 TGFB2_TGFBRII_ALK5_TGFBRIII_CYTOSOL + ENDOGLIN_CYTOSOL = 
TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL TGFB2_TGFBRII_ALK5_TGFBRIII_CYTOSOL+ENDOGLIN_CYTOSOL = 
TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL 
 0.014529944218480619 ; % 1420 TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL = 
TGFB2_TGFBRII_ALK5_TGFBRIII_CYTOSOL + ENDOGLIN_CYTOSOL TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL = 
TGFB2_TGFBRII_ALK5_TGFBRIII_CYTOSOL+ENDOGLIN_CYTOSOL 
 0.2763859473166461 ; % 1421 JAG1_EXTRACELLULAR + NOTCH1_CYTOSOL = JAG1_NOTCH1_CYTOSOL
 JAG1_EXTRACELLULAR+NOTCH1_CYTOSOL = JAG1_NOTCH1_CYTOSOL 
 0.0641776440743194 ; % 1422 JAG1_NOTCH1_CYTOSOL = JAG1_EXTRACELLULAR + NOTCH1_CYTOSOL
 JAG1_NOTCH1_CYTOSOL = JAG1_EXTRACELLULAR+NOTCH1_CYTOSOL 
 0.15010262187820933 ; % 1423 JAG1_NOTCH1_CYTOSOL + TACE_CYTOSOL = JAG1_NOTCH1_TACE_CYTOSOL
 JAG1_NOTCH1_CYTOSOL+TACE_CYTOSOL = JAG1_NOTCH1_TACE_CYTOSOL 
 0.005374996347419292 ; % 1424 JAG1_NOTCH1_TACE_CYTOSOL = JAG1_NOTCH1_CYTOSOL + TACE_CYTOSOL
 JAG1_NOTCH1_TACE_CYTOSOL = JAG1_NOTCH1_CYTOSOL+TACE_CYTOSOL 
 0.8100595496225582 ; % 1425 DELTA4_EXTRACELLULAR + NOTCH1_CYTOSOL = DELTA4_NOTCH1_CYTOSOL
 DELTA4_EXTRACELLULAR+NOTCH1_CYTOSOL = DELTA4_NOTCH1_CYTOSOL 
 0.07509514443982951 ; % 1426 DELTA4_NOTCH1_CYTOSOL = DELTA4_EXTRACELLULAR + NOTCH1_CYTOSOL
 DELTA4_NOTCH1_CYTOSOL = DELTA4_EXTRACELLULAR+NOTCH1_CYTOSOL 
 0.5896583185091641 ; % 1427 DELTA4_NOTCH1_CYTOSOL + TACE_CYTOSOL = DELTA4_NOTCH1_TACE_CYTOSOL
 DELTA4_NOTCH1_CYTOSOL+TACE_CYTOSOL = DELTA4_NOTCH1_TACE_CYTOSOL 
 0.09510215650272963 ; % 1428 DELTA4_NOTCH1_TACE_CYTOSOL = DELTA4_NOTCH1_CYTOSOL + TACE_CYTOSOL
 DELTA4_NOTCH1_TACE_CYTOSOL = DELTA4_NOTCH1_CYTOSOL+TACE_CYTOSOL 
 0.5197929560606321 ; % 1429 ACTIVE_PI3K_CYTOSOL + PIP2_CYTOSOL = ACTIVE_PI3K_PIP2_CYTOSOL
 ACTIVE_PI3K_CYTOSOL+PIP2_CYTOSOL = ACTIVE_PI3K_PIP2_CYTOSOL 
 0.041457890216383866 ; % 1430 ACTIVE_PI3K_PIP2_CYTOSOL = ACTIVE_PI3K_CYTOSOL + PIP2_CYTOSOL
 ACTIVE_PI3K_PIP2_CYTOSOL = ACTIVE_PI3K_CYTOSOL+PIP2_CYTOSOL 
 0.028790172408215353 ; % 1431 ACTIVE_PI3K_PIP2_CYTOSOL = ACTIVE_PI3K_CYTOSOL + PIP3_CYTOSOL
 ACTIVE_PI3K_PIP2_CYTOSOL = ACTIVE_PI3K_CYTOSOL+PIP3_CYTOSOL 
 0.6742517740734068 ; % 1432 PTEN_CYTOSOL + PIP3_CYTOSOL = PTEN_PIP3_CYTOSOL
 PTEN_CYTOSOL+PIP3_CYTOSOL = PTEN_PIP3_CYTOSOL 
 0.06225996347543276 ; % 1433 PTEN_PIP3_CYTOSOL = PTEN_CYTOSOL + PIP3_CYTOSOL PTEN_PIP3_CYTOSOL = 
PTEN_CYTOSOL+PIP3_CYTOSOL 
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 0.3495464459300982 ; % 1434 PTEN_PIP3_CYTOSOL = PTEN_CYTOSOL + PIP2_CYTOSOL PTEN_PIP3_CYTOSOL = 
PTEN_CYTOSOL+PIP2_CYTOSOL 
 0.78796705848212 ; % 1435 PDK1_CYTOSOL + PIP3_CYTOSOL = PDK1_PIP3_CYTOSOL
 PDK1_CYTOSOL+PIP3_CYTOSOL = PDK1_PIP3_CYTOSOL 
 0.0929095245936462 ; % 1436 PDK1_PIP3_CYTOSOL = PDK1_CYTOSOL + PIP3_CYTOSOL PDK1_PIP3_CYTOSOL = 
PDK1_CYTOSOL+PIP3_CYTOSOL 
 0.4317451947259917 ; % 1437 PDK1_PIP3_CYTOSOL + AKT_CYTOSOL = PDK1_PIP3_AKT_CYTOSOL
 PDK1_PIP3_CYTOSOL+AKT_CYTOSOL = PDK1_PIP3_AKT_CYTOSOL 
 0.00794593845616003 ; % 1438 PDK1_PIP3_AKT_CYTOSOL = PDK1_PIP3_CYTOSOL + AKT_CYTOSOL
 PDK1_PIP3_AKT_CYTOSOL = PDK1_PIP3_CYTOSOL+AKT_CYTOSOL 
 0.05712111895848748 ; % 1439 PDK1_PIP3_AKT_CYTOSOL = PDK1_PIP3_CYTOSOL + ACTIVE_AKT_CYTOSOL
 PDK1_PIP3_AKT_CYTOSOL = PDK1_PIP3_CYTOSOL+ACTIVE_AKT_CYTOSOL 
 0.05451183398568826 ; % 1440 ACTIVE_AKT_CYTOSOL + GSK3B_CYTOSOL = ACTIVE_AKT_GSK3B_CYTOSOL
 ACTIVE_AKT_CYTOSOL+GSK3B_CYTOSOL = ACTIVE_AKT_GSK3B_CYTOSOL 
 0.09544308519187727 ; % 1441 ACTIVE_AKT_GSK3B_CYTOSOL = ACTIVE_AKT_CYTOSOL + GSK3B_CYTOSOL
 ACTIVE_AKT_GSK3B_CYTOSOL = ACTIVE_AKT_CYTOSOL+GSK3B_CYTOSOL 
 0.6988781519059352 ; % 1442 ACTIVE_AKT_GSK3B_CYTOSOL = ACTIVE_AKT_CYTOSOL + P_GSK3B_CYTOSOL
 ACTIVE_AKT_GSK3B_CYTOSOL = ACTIVE_AKT_CYTOSOL+P_GSK3B_CYTOSOL 
 0.02559074327068167 ; % 1443 AKT_PASE_CYTOSOL + ACTIVE_PI3K_CYTOSOL = AKT_PASE_ACTIVE_PI3K_CYTOSOL
 AKT_PASE_CYTOSOL+ACTIVE_PI3K_CYTOSOL = AKT_PASE_ACTIVE_PI3K_CYTOSOL 
 0.0258476234705326 ; % 1444 AKT_PASE_ACTIVE_PI3K_CYTOSOL = AKT_PASE_CYTOSOL + ACTIVE_PI3K_CYTOSOL
 AKT_PASE_ACTIVE_PI3K_CYTOSOL = AKT_PASE_CYTOSOL+ACTIVE_PI3K_CYTOSOL 
 0.4953183637882027 ; % 1445 AKT_PASE_ACTIVE_PI3K_CYTOSOL = AKT_PASE_CYTOSOL + PI3K_CYTOSOL
 AKT_PASE_ACTIVE_PI3K_CYTOSOL = AKT_PASE_CYTOSOL+PI3K_CYTOSOL 
 0.20450046233162755 ; % 1446 AKT_PASE_CYTOSOL + ACTIVE_AKT_CYTOSOL = AKT_PASE_ACTIVE_AKT_CYTOSOL
 AKT_PASE_CYTOSOL+ACTIVE_AKT_CYTOSOL = AKT_PASE_ACTIVE_AKT_CYTOSOL 
 0.09206912782257391 ; % 1447 AKT_PASE_ACTIVE_AKT_CYTOSOL = AKT_PASE_CYTOSOL + ACTIVE_AKT_CYTOSOL
 AKT_PASE_ACTIVE_AKT_CYTOSOL = AKT_PASE_CYTOSOL+ACTIVE_AKT_CYTOSOL 
 0.3460017908541758 ; % 1448 AKT_PASE_ACTIVE_AKT_CYTOSOL = AKT_PASE_CYTOSOL + AKT_CYTOSOL
 AKT_PASE_ACTIVE_AKT_CYTOSOL = AKT_PASE_CYTOSOL+AKT_CYTOSOL 
 0.27776734236815326 ; % 1449 AKT_PASE_CYTOSOL + P_GSK3B_CYTOSOL = AKT_PASE_P_GSK3B_CYTOSOL
 AKT_PASE_CYTOSOL+P_GSK3B_CYTOSOL = AKT_PASE_P_GSK3B_CYTOSOL 
 0.00304044391659466 ; % 1450 AKT_PASE_P_GSK3B_CYTOSOL = AKT_PASE_CYTOSOL + P_GSK3B_CYTOSOL
 AKT_PASE_P_GSK3B_CYTOSOL = AKT_PASE_CYTOSOL+P_GSK3B_CYTOSOL 
 0.8676631943954042 ; % 1451 AKT_PASE_P_GSK3B_CYTOSOL = AKT_PASE_CYTOSOL + GSK3B_CYTOSOL
 AKT_PASE_P_GSK3B_CYTOSOL = AKT_PASE_CYTOSOL+GSK3B_CYTOSOL 
 0.4188794952366329 ; % 1452 AXIN_CYTOSOL + BCATENIN_CYTOSOL = AXIN_BCATENIN_CYTOSOL
 AXIN_CYTOSOL+BCATENIN_CYTOSOL = AXIN_BCATENIN_CYTOSOL 
 0.0685477060786686 ; % 1453 AXIN_BCATENIN_CYTOSOL = AXIN_CYTOSOL + BCATENIN_CYTOSOL
 AXIN_BCATENIN_CYTOSOL = AXIN_CYTOSOL+BCATENIN_CYTOSOL 
 0.9606003475741256 ; % 1454 AXIN_BCATENIN_CYTOSOL + APC_CYTOSOL = AXIN_BCATENIN_APC_CYTOSOL
 AXIN_BCATENIN_CYTOSOL+APC_CYTOSOL = AXIN_BCATENIN_APC_CYTOSOL 
 0.02776938057494597 ; % 1455 AXIN_BCATENIN_APC_CYTOSOL = AXIN_BCATENIN_CYTOSOL + APC_CYTOSOL
 AXIN_BCATENIN_APC_CYTOSOL = AXIN_BCATENIN_CYTOSOL+APC_CYTOSOL 
 0.8907901963314437 ; % 1456 AXIN_BCATENIN_APC_CYTOSOL + CK1_CYTOSOL = 
AXIN_BCATENIN_APC_CK1_CYTOSOL AXIN_BCATENIN_APC_CYTOSOL+CK1_CYTOSOL = AXIN_BCATENIN_APC_CK1_CYTOSOL 
 0.09742942185492434 ; % 1457 AXIN_BCATENIN_APC_CK1_CYTOSOL = AXIN_BCATENIN_APC_CYTOSOL + 
CK1_CYTOSOL AXIN_BCATENIN_APC_CK1_CYTOSOL = AXIN_BCATENIN_APC_CYTOSOL+CK1_CYTOSOL 
 0.03452231051821808 ; % 1458 AXIN_BCATENIN_APC_CYTOSOL + GSK3B_CYTOSOL = 
AXIN_BCATENIN_APC_GSK3B_CYTOSOL AXIN_BCATENIN_APC_CYTOSOL+GSK3B_CYTOSOL = AXIN_BCATENIN_APC_GSK3B_CYTOSOL 
 0.04209029696361758 ; % 1459 AXIN_BCATENIN_APC_GSK3B_CYTOSOL = AXIN_BCATENIN_APC_CYTOSOL + 
GSK3B_CYTOSOL AXIN_BCATENIN_APC_GSK3B_CYTOSOL = AXIN_BCATENIN_APC_CYTOSOL+GSK3B_CYTOSOL 
 0.4319566537711762 ; % 1460 AXIN_BCATENIN_APC_CK1_CYTOSOL = CK1_CYTOSOL + AXIN_CYTOSOL + 
APC_CYTOSOL + PP_BCATENIN_CYTOSOL AXIN_BCATENIN_APC_CK1_CYTOSOL = 
CK1_CYTOSOL+AXIN_CYTOSOL+APC_CYTOSOL+PP_BCATENIN_CYTOSOL 
 0.20726938161225128 ; % 1461 AXIN_BCATENIN_APC_GSK3B_CYTOSOL = GSK3B_CYTOSOL + AXIN_CYTOSOL + 
APC_CYTOSOL + PP_BCATENIN_CYTOSOL AXIN_BCATENIN_APC_GSK3B_CYTOSOL = 
GSK3B_CYTOSOL+AXIN_CYTOSOL+APC_CYTOSOL+PP_BCATENIN_CYTOSOL 
 0.40972393817805053 ; % 1462 PP_BCATENIN_CYTOSOL + BTRCP_CYTOSOL = PP_BCATENIN_BTRCP_CYTOSOL
 PP_BCATENIN_CYTOSOL+BTRCP_CYTOSOL = PP_BCATENIN_BTRCP_CYTOSOL 
 0.09476293725100088 ; % 1463 PP_BCATENIN_BTRCP_CYTOSOL = PP_BCATENIN_CYTOSOL + BTRCP_CYTOSOL
 PP_BCATENIN_BTRCP_CYTOSOL = PP_BCATENIN_CYTOSOL+BTRCP_CYTOSOL 
 0.13425931209161557 ; % 1464 PP_BCATENIN_BTRCP_CYTOSOL = BTRCP_CYTOSOL + UB_PP_BCATENIN_CYTOSOL
 PP_BCATENIN_BTRCP_CYTOSOL = BTRCP_CYTOSOL+UB_PP_BCATENIN_CYTOSOL 
 0.7256142986538963 ; % 1465 GSK3B_CYTOSOL + NFATC1_CYTOSOL = GSK3B_NFATC1_CYTOSOL
 GSK3B_CYTOSOL+NFATC1_CYTOSOL = GSK3B_NFATC1_CYTOSOL 
 0.04009245285152627 ; % 1466 GSK3B_NFATC1_CYTOSOL = GSK3B_CYTOSOL + NFATC1_CYTOSOL
 GSK3B_NFATC1_CYTOSOL = GSK3B_CYTOSOL+NFATC1_CYTOSOL 
 0.38404841232945275 ; % 1467 GSK3B_NFATC1_CYTOSOL = GSK3B_CYTOSOL + P_NFATC1_CYTOSOL
 GSK3B_NFATC1_CYTOSOL = GSK3B_CYTOSOL+P_NFATC1_CYTOSOL 
 0.13537378562044527 ; % 1468 UB_PP_BCATENIN_CYTOSOL = [] UB_PP_BCATENIN_CYTOSOL = [] 
 0.6840334422776655 ; % 1469 JAG1_NOTCH1_TACE_CYTOSOL = JAG1_NCED_CYTOSOL + ACTIVE_NCID_CYTOSOL
 JAG1_NOTCH1_TACE_CYTOSOL = JAG1_NCED_CYTOSOL+ACTIVE_NCID_CYTOSOL 
 0.07568538461311392 ; % 1470 DELTA4_NOTCH1_TACE_CYTOSOL = DELTA4_NCED_CYTOSOL + 
ACTIVE_NCID_CYTOSOL DELTA4_NOTCH1_TACE_CYTOSOL = DELTA4_NCED_CYTOSOL+ACTIVE_NCID_CYTOSOL 
 0.04709894228038258 ; % 1471 ACTIVE_NCID_CYTOSOL + SEL1_CYTOSOL = ACTIVE_NCID_SEL1_CYTOSOL
 ACTIVE_NCID_CYTOSOL+SEL1_CYTOSOL = ACTIVE_NCID_SEL1_CYTOSOL 
 0.05127366042275477 ; % 1472 ACTIVE_NCID_SEL1_CYTOSOL = ACTIVE_NCID_CYTOSOL + SEL1_CYTOSOL
 ACTIVE_NCID_SEL1_CYTOSOL = ACTIVE_NCID_CYTOSOL+SEL1_CYTOSOL 
 0.050972505891123676 ; % 1473 ACTIVE_NCID_SEL1_CYTOSOL = SEL1_CYTOSOL + UB_ACTIVE_NCID_CYTOSOL
 ACTIVE_NCID_SEL1_CYTOSOL = SEL1_CYTOSOL+UB_ACTIVE_NCID_CYTOSOL 
 0.8543786642156181 ; % 1474 JAG1_NCED_CYTOSOL + DELTEX_NEDD4_CYTOSOL = 
JAG1_NCED_DELTEX_NEDD4_CYTOSOL JAG1_NCED_CYTOSOL+DELTEX_NEDD4_CYTOSOL = JAG1_NCED_DELTEX_NEDD4_CYTOSOL 
 0.03988907406494192 ; % 1475 JAG1_NCED_DELTEX_NEDD4_CYTOSOL = JAG1_NCED_CYTOSOL + 
DELTEX_NEDD4_CYTOSOL JAG1_NCED_DELTEX_NEDD4_CYTOSOL = JAG1_NCED_CYTOSOL+DELTEX_NEDD4_CYTOSOL 
 0.3631869009777403 ; % 1476 JAG1_NCED_DELTEX_NEDD4_CYTOSOL = DELTEX_NEDD4_CYTOSOL + 
UB_JAG1_NCED_CYTOSOL JAG1_NCED_DELTEX_NEDD4_CYTOSOL = DELTEX_NEDD4_CYTOSOL+UB_JAG1_NCED_CYTOSOL 
 0.00264766075673728 ; % 1477 DELTA4_NCED_CYTOSOL + DELTEX_NEDD4_CYTOSOL = 
DELTA4_NCED_DELTEX_NEDD4_CYTOSOL DELTA4_NCED_CYTOSOL+DELTEX_NEDD4_CYTOSOL = DELTA4_NCED_DELTEX_NEDD4_CYTOSOL 
 0.05357437901010942 ; % 1478 DELTA4_NCED_DELTEX_NEDD4_CYTOSOL = DELTA4_NCED_CYTOSOL + 
DELTEX_NEDD4_CYTOSOL DELTA4_NCED_DELTEX_NEDD4_CYTOSOL = DELTA4_NCED_CYTOSOL+DELTEX_NEDD4_CYTOSOL 
 0.5922101855856718 ; % 1479 DELTA4_NCED_DELTEX_NEDD4_CYTOSOL = DELTEX_NEDD4_CYTOSOL + 
UB_DELTA4_NCED_CYTOSOL DELTA4_NCED_DELTEX_NEDD4_CYTOSOL = DELTEX_NEDD4_CYTOSOL+UB_DELTA4_NCED_CYTOSOL 
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 0.4334109839703474 ; % 1480 UB_JAG1_NECD_CYTOSOL = [] UB_JAG1_NECD_CYTOSOL = [] 
 0.4121447454033347 ; % 1481 UB_DELTA4_NECD_CYTOSOL = [] UB_DELTA4_NECD_CYTOSOL = [] 
 0.024604835412359582 ; % 1482 JAG1_NECD_EXTRACELLULAR = [] JAG1_NECD_EXTRACELLULAR = [] 
 0.42321842021925066 ; % 1483 UB_ACTIVE_NCID_CYTOSOL = [] UB_ACTIVE_NCID_CYTOSOL = [] 
 0.3654473162985936 ; % 1484 RAS_CYTOSOL + GDP_CYTOSOL = RAS_GDP_CYTOSOL
 RAS_CYTOSOL+GDP_CYTOSOL = RAS_GDP_CYTOSOL 
 0.027285543520855195 ; % 1485 RAS_GDP_CYTOSOL = RAS_CYTOSOL + GDP_CYTOSOL RAS_GDP_CYTOSOL = 
RAS_CYTOSOL+GDP_CYTOSOL 
 0.02129309631861409 ; % 1486 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_CYTOSOL + RAS_GDP_CYTOSOL 
= TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_RAS_GDP_CYTOSOL
 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_CYTOSOL+RAS_GDP_CYTOSOL = 
TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_RAS_GDP_CYTOSOL 
 0.033712910629131655 ; % 1487 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_RAS_GDP_CYTOSOL = 
TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_CYTOSOL + RAS_GDP_CYTOSOL TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_RAS_GDP_CYTOSOL 
= TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_CYTOSOL+RAS_GDP_CYTOSOL 
 0.1811918771681723 ; % 1488 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_RAS_GDP_CYTOSOL + 
GTP_CYTOSOL = TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_CYTOSOL + RAS_GTP_CYTOSOL + GDP_CYTOSOL
 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_RAS_GDP_CYTOSOL+GTP_CYTOSOL = 
TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_CYTOSOL+RAS_GTP_CYTOSOL+GDP_CYTOSOL 
 0.8525355618641878 ; % 1489 BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL + RAS_GDP_CYTOSOL = 
BMP2_BMPRII_ALK2_SHC_GRB2_SOS_RAS_GDP_CYTOSOL BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL+RAS_GDP_CYTOSOL = 
BMP2_BMPRII_ALK2_SHC_GRB2_SOS_RAS_GDP_CYTOSOL 
 0.09357673938577171 ; % 1490 BMP2_BMPRII_ALK2_SHC_GRB2_SOS_RAS_GDP_CYTOSOL = 
BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL + RAS_GDP_CYTOSOL BMP2_BMPRII_ALK2_SHC_GRB2_SOS_RAS_GDP_CYTOSOL = 
BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL+RAS_GDP_CYTOSOL 
 0.4827323261920309 ; % 1491 BMP2_BMPRII_ALK2_SHC_GRB2_SOS_RAS_GDP_CYTOSOL + GTP_CYTOSOL = 
BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL + RAS_GTP_CYTOSOL + GDP_CYTOSOL
 BMP2_BMPRII_ALK2_SHC_GRB2_SOS_RAS_GDP_CYTOSOL+GTP_CYTOSOL = 
BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL+RAS_GTP_CYTOSOL+GDP_CYTOSOL 
 0.6309001574384063 ; % 1492 RAS_GTP_CYTOSOL + RAF_CYTOSOL = RAS_GTP_RAF_CYTOSOL
 RAS_GTP_CYTOSOL+RAF_CYTOSOL = RAS_GTP_RAF_CYTOSOL 
 0.06076960954251556 ; % 1493 RAS_GTP_RAF_CYTOSOL = RAS_GTP_CYTOSOL + RAF_CYTOSOL
 RAS_GTP_RAF_CYTOSOL = RAS_GTP_CYTOSOL+RAF_CYTOSOL 
 0.2659273893227704 ; % 1494 RAS_GTP_RAF_CYTOSOL = ACTIVE_RAF_CYTOSOL + RAS_GTP_CYTOSOL
 RAS_GTP_RAF_CYTOSOL = ACTIVE_RAF_CYTOSOL+RAS_GTP_CYTOSOL 
 0.8683077751131456 ; % 1495 ACTIVE_RAF_CYTOSOL + MEK_CYTOSOL = ACTIVE_RAF_MEK_CYTOSOL
 ACTIVE_RAF_CYTOSOL+MEK_CYTOSOL = ACTIVE_RAF_MEK_CYTOSOL 
 0.07016621343539779 ; % 1496 ACTIVE_RAF_MEK_CYTOSOL = ACTIVE_RAF_CYTOSOL + MEK_CYTOSOL
 ACTIVE_RAF_MEK_CYTOSOL = ACTIVE_RAF_CYTOSOL+MEK_CYTOSOL 
 0.8474761324367217 ; % 1497 ACTIVE_RAF_MEK_CYTOSOL = ACTIVE_RAF_CYTOSOL + P_MEK_CYTOSOL
 ACTIVE_RAF_MEK_CYTOSOL = ACTIVE_RAF_CYTOSOL+P_MEK_CYTOSOL 
 0.4621601351689908 ; % 1498 ACTIVE_RAF_CYTOSOL + P_MEK_CYTOSOL = ACTIVE_RAF_P_MEK_CYTOSOL
 ACTIVE_RAF_CYTOSOL+P_MEK_CYTOSOL = ACTIVE_RAF_P_MEK_CYTOSOL 
 0.05588768541374525 ; % 1499 ACTIVE_RAF_P_MEK_CYTOSOL = ACTIVE_RAF_CYTOSOL + P_MEK_CYTOSOL
 ACTIVE_RAF_P_MEK_CYTOSOL = ACTIVE_RAF_CYTOSOL+P_MEK_CYTOSOL 
 0.05047513019783878 ; % 1500 ACTIVE_RAF_P_MEK_CYTOSOL = ACTIVE_RAF_CYTOSOL + PP_MEK_CYTOSOL
 ACTIVE_RAF_P_MEK_CYTOSOL = ACTIVE_RAF_CYTOSOL+PP_MEK_CYTOSOL 
 0.6820727563687394 ; % 1501 PP_MEK_CYTOSOL + ERK_CYTOSOL = PP_MEK_ERK_CYTOSOL
 PP_MEK_CYTOSOL+ERK_CYTOSOL = PP_MEK_ERK_CYTOSOL 
 0.008916316213951558 ; % 1502 PP_MEK_ERK_CYTOSOL = PP_MEK_CYTOSOL + ERK_CYTOSOL
 PP_MEK_ERK_CYTOSOL = PP_MEK_CYTOSOL+ERK_CYTOSOL 
 0.22391960450927473 ; % 1503 PP_MEK_ERK_CYTOSOL = PP_MEK_CYTOSOL + P_ERK_CYTOSOL
 PP_MEK_ERK_CYTOSOL = PP_MEK_CYTOSOL+P_ERK_CYTOSOL 
 0.7302897817095368 ; % 1504 PP_MEK_CYTOSOL + P_ERK_CYTOSOL = PP_MEK_P_ERK_CYTOSOL
 PP_MEK_CYTOSOL+P_ERK_CYTOSOL = PP_MEK_P_ERK_CYTOSOL 
 0.037282008979755435 ; % 1505 PP_MEK_P_ERK_CYTOSOL = PP_MEK_CYTOSOL + P_ERK_CYTOSOL
 PP_MEK_P_ERK_CYTOSOL = PP_MEK_CYTOSOL+P_ERK_CYTOSOL 
 0.7245356005346338 ; % 1506 PP_MEK_P_ERK_CYTOSOL = PP_MEK_CYTOSOL + PP_ERK_CYTOSOL
 PP_MEK_P_ERK_CYTOSOL = PP_MEK_CYTOSOL+PP_ERK_CYTOSOL 
 0.3197622743646096 ; % 1507 ACTIVE_RAF_CYTOSOL + RAF_PASE_CYTOSOL = ACTIVE_RAF_RAF_PASE_CYTOSOL
 ACTIVE_RAF_CYTOSOL+RAF_PASE_CYTOSOL = ACTIVE_RAF_RAF_PASE_CYTOSOL 
 0.019020023046072546 ; % 1508 ACTIVE_RAF_RAF_PASE_CYTOSOL = ACTIVE_RAF_CYTOSOL + RAF_PASE_CYTOSOL
 ACTIVE_RAF_RAF_PASE_CYTOSOL = ACTIVE_RAF_CYTOSOL+RAF_PASE_CYTOSOL 
 0.27648886868023714 ; % 1509 ACTIVE_RAF_RAF_PASE_CYTOSOL = RAF_PASE_CYTOSOL + RAF_CYTOSOL
 ACTIVE_RAF_RAF_PASE_CYTOSOL = RAF_PASE_CYTOSOL+RAF_CYTOSOL 
 0.45409923971495236 ; % 1510 PP_MEK_CYTOSOL + MEK_PASE_CYTOSOL = PP_MEK_MEK_PASE_CYTOSOL
 PP_MEK_CYTOSOL+MEK_PASE_CYTOSOL = PP_MEK_MEK_PASE_CYTOSOL 
 0.05580335435345893 ; % 1511 PP_MEK_MEK_PASE_CYTOSOL = PP_MEK_CYTOSOL + MEK_PASE_CYTOSOL
 PP_MEK_MEK_PASE_CYTOSOL = PP_MEK_CYTOSOL+MEK_PASE_CYTOSOL 
 0.6492962291501434 ; % 1512 PP_MEK_MEK_PASE_CYTOSOL = MEK_PASE_CYTOSOL + P_MEK_CYTOSOL
 PP_MEK_MEK_PASE_CYTOSOL = MEK_PASE_CYTOSOL+P_MEK_CYTOSOL 
 0.5988021377969366 ; % 1513 P_MEK_CYTOSOL + MEK_PASE_CYTOSOL = P_MEK_MEK_PASE_CYTOSOL
 P_MEK_CYTOSOL+MEK_PASE_CYTOSOL = P_MEK_MEK_PASE_CYTOSOL 
 0.09291905045948527 ; % 1514 P_MEK_MEK_PASE_CYTOSOL = P_MEK_CYTOSOL + MEK_PASE_CYTOSOL
 P_MEK_MEK_PASE_CYTOSOL = P_MEK_CYTOSOL+MEK_PASE_CYTOSOL 
 0.026065374979508893 ; % 1515 P_MEK_MEK_PASE_CYTOSOL = MEK_PASE_CYTOSOL + MEK_CYTOSOL
 P_MEK_MEK_PASE_CYTOSOL = MEK_PASE_CYTOSOL+MEK_CYTOSOL 
 0.9017029979562975 ; % 1516 PP_ERK_CYTOSOL + ERK_PASE_CYTOSOL = PP_ERK_ERK_PASE_CYTOSOL
 PP_ERK_CYTOSOL+ERK_PASE_CYTOSOL = PP_ERK_ERK_PASE_CYTOSOL 
 0.02629843855980305 ; % 1517 PP_ERK_ERK_PASE_CYTOSOL = PP_ERK_CYTOSOL + ERK_PASE_CYTOSOL
 PP_ERK_ERK_PASE_CYTOSOL = PP_ERK_CYTOSOL+ERK_PASE_CYTOSOL 
 0.9872962677478923 ; % 1518 PP_ERK_ERK_PASE_CYTOSOL = ERK_PASE_CYTOSOL + P_ERK_CYTOSOL
 PP_ERK_ERK_PASE_CYTOSOL = ERK_PASE_CYTOSOL+P_ERK_CYTOSOL 
 0.6190580534231794 ; % 1519 P_ERK_CYTOSOL + ERK_PASE_CYTOSOL = P_ERK_ERK_PASE_CYTOSOL
 P_ERK_CYTOSOL+ERK_PASE_CYTOSOL = P_ERK_ERK_PASE_CYTOSOL 
 0.09745920484937548 ; % 1520 P_ERK_ERK_PASE_CYTOSOL = P_ERK_CYTOSOL + ERK_PASE_CYTOSOL
 P_ERK_ERK_PASE_CYTOSOL = P_ERK_CYTOSOL+ERK_PASE_CYTOSOL 
 0.9462306007701528 ; % 1521 P_ERK_ERK_PASE_CYTOSOL = ERK_PASE_CYTOSOL + ERK_CYTOSOL
 P_ERK_ERK_PASE_CYTOSOL = ERK_PASE_CYTOSOL+ERK_CYTOSOL 
 0.7797899318745652 ; % 1522 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_CYTOSOL + PP_ERK_CYTOSOL = 
TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_PP_ERK_CYTOSOL TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_CYTOSOL+PP_ERK_CYTOSOL = 
TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_PP_ERK_CYTOSOL 
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 0.08940262299211886 ; % 1523 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_PP_ERK_CYTOSOL = 
TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_CYTOSOL + PP_ERK_CYTOSOL TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_PP_ERK_CYTOSOL = 
TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_CYTOSOL+PP_ERK_CYTOSOL 
 0.8314544596860927 ; % 1524 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_PP_ERK_CYTOSOL = 
PP_ERK_CYTOSOL + TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_CYTOSOL + SOS_CYTOSOL
 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_PP_ERK_CYTOSOL = 
PP_ERK_CYTOSOL+TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_CYTOSOL+SOS_CYTOSOL 
 0.7403028419797757 ; % 1525 BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL + PP_ERK_CYTOSOL = 
BMP2_BMPRII_ALK2_SHC_GRB2_SOS_PP_ERK_CYTOSOL BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL+PP_ERK_CYTOSOL = 
BMP2_BMPRII_ALK2_SHC_GRB2_SOS_PP_ERK_CYTOSOL 
 0.019915641894977444 ; % 1526 BMP2_BMPRII_ALK2_SHC_GRB2_SOS_PP_ERK_CYTOSOL = 
BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL + PP_ERK_CYTOSOL BMP2_BMPRII_ALK2_SHC_GRB2_SOS_PP_ERK_CYTOSOL = 
BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL+PP_ERK_CYTOSOL 
 0.061986533052099335 ; % 1527 BMP2_BMPRII_ALK2_SHC_GRB2_SOS_PP_ERK_CYTOSOL = PP_ERK_CYTOSOL + 
BMP2_BMPRII_ALK2_SHC_GRB2_CYTOSOL + SOS_CYTOSOL BMP2_BMPRII_ALK2_SHC_GRB2_SOS_PP_ERK_CYTOSOL = 
PP_ERK_CYTOSOL+BMP2_BMPRII_ALK2_SHC_GRB2_CYTOSOL+SOS_CYTOSOL 
 0.4896853922511609 ; % 1528 PP_ERK_CYTOSOL + AP1_CYTOSOL = PP_ERK_AP1_CYTOSOL
 PP_ERK_CYTOSOL+AP1_CYTOSOL = PP_ERK_AP1_CYTOSOL 
 0.09520316733081992 ; % 1529 PP_ERK_AP1_CYTOSOL = PP_ERK_CYTOSOL + AP1_CYTOSOL
 PP_ERK_AP1_CYTOSOL = PP_ERK_CYTOSOL+AP1_CYTOSOL 
 0.15297795865713093 ; % 1530 PP_ERK_AP1_CYTOSOL = PP_ERK_CYTOSOL + P_AP1_CYTOSOL
 PP_ERK_AP1_CYTOSOL = PP_ERK_CYTOSOL+P_AP1_CYTOSOL 
 0.5975433893240303 ; % 1531 PP_ERK_CYTOSOL + SP1_CYTOSOL = PP_ERK_SP1_CYTOSOL
 PP_ERK_CYTOSOL+SP1_CYTOSOL = PP_ERK_SP1_CYTOSOL 
 0.050453708245729104 ; % 1532 PP_ERK_SP1_CYTOSOL = PP_ERK_CYTOSOL + SP1_CYTOSOL
 PP_ERK_SP1_CYTOSOL = PP_ERK_CYTOSOL+SP1_CYTOSOL 
 0.2753206746479774 ; % 1533 PP_ERK_SP1_CYTOSOL = PP_ERK_CYTOSOL + P_SP1_CYTOSOL
 PP_ERK_SP1_CYTOSOL = PP_ERK_CYTOSOL+P_SP1_CYTOSOL 
 0.8930851064915863 ; % 1534 PP_ERK_CYTOSOL + CJUN_CYTOSOL = PP_ERK_CJUN_CYTOSOL
 PP_ERK_CYTOSOL+CJUN_CYTOSOL = PP_ERK_CJUN_CYTOSOL 
 0.08639752115140081 ; % 1535 PP_ERK_CJUN_CYTOSOL = PP_ERK_CYTOSOL + CJUN_CYTOSOL
 PP_ERK_CJUN_CYTOSOL = PP_ERK_CYTOSOL+CJUN_CYTOSOL 
 0.7607547026608246 ; % 1536 PP_ERK_CJUN_CYTOSOL = PP_ERK_CYTOSOL + P_CJUN_CYTOSOL
 PP_ERK_CJUN_CYTOSOL = PP_ERK_CYTOSOL+P_CJUN_CYTOSOL 
 0.9383216853929269 ; % 1537 PP_ERK_CYTOSOL + CPLA2_CYTOSOL = PP_ERK_CPLA2_CYTOSOL
 PP_ERK_CYTOSOL+CPLA2_CYTOSOL = PP_ERK_CPLA2_CYTOSOL 
 0.017566049286847043 ; % 1538 PP_ERK_CPLA2_CYTOSOL = PP_ERK_CYTOSOL + CPLA2_CYTOSOL
 PP_ERK_CPLA2_CYTOSOL = PP_ERK_CYTOSOL+CPLA2_CYTOSOL 
 0.22711727424242933 ; % 1539 PP_ERK_CPLA2_CYTOSOL = PP_ERK_CYTOSOL + P_CPLA2_CYTOSOL
 PP_ERK_CPLA2_CYTOSOL = PP_ERK_CYTOSOL+P_CPLA2_CYTOSOL 
 0.00908717759666282 ; % 1540 PP_ERK_CYTOSOL + SMAD2_CYTOSOL = PP_ERK_SMAD2_CYTOSOL
 PP_ERK_CYTOSOL+SMAD2_CYTOSOL = PP_ERK_SMAD2_CYTOSOL 
 0.04577700872029053 ; % 1541 PP_ERK_SMAD2_CYTOSOL = PP_ERK_CYTOSOL + SMAD2_CYTOSOL
 PP_ERK_SMAD2_CYTOSOL = PP_ERK_CYTOSOL+SMAD2_CYTOSOL 
 0.5017153656344642 ; % 1542 PP_ERK_SMAD2_CYTOSOL = PP_ERK_CYTOSOL + P_SMAD2_CYTOSOL
 PP_ERK_SMAD2_CYTOSOL = PP_ERK_CYTOSOL+P_SMAD2_CYTOSOL 
 0.0036278479697245325 ; % 1543 PP_ERK_CYTOSOL + SMAD3_CYTOSOL = PP_ERK_SMAD3_CYTOSOL
 PP_ERK_CYTOSOL+SMAD3_CYTOSOL = PP_ERK_SMAD3_CYTOSOL 
 0.05836673638236113 ; % 1544 PP_ERK_SMAD3_CYTOSOL = PP_ERK_CYTOSOL + SMAD3_CYTOSOL
 PP_ERK_SMAD3_CYTOSOL = PP_ERK_CYTOSOL+SMAD3_CYTOSOL 
 0.31703818126340566 ; % 1545 PP_ERK_SMAD3_CYTOSOL = PP_ERK_CYTOSOL + P_SMAD3_CYTOSOL
 PP_ERK_SMAD3_CYTOSOL = PP_ERK_CYTOSOL+P_SMAD3_CYTOSOL 
 0.00272418441970879 ; % 1546 P_CPLA2_CYTOSOL + PKC_CYTOSOL = P_CPLA2_PKC_CYTOSOL
 P_CPLA2_CYTOSOL+PKC_CYTOSOL = P_CPLA2_PKC_CYTOSOL 
 0.8501728879602906 ; % 1547 P_CPLA2_PKC_CYTOSOL = P_CPLA2_CYTOSOL + PKC_CYTOSOL
 P_CPLA2_PKC_CYTOSOL = P_CPLA2_CYTOSOL+PKC_CYTOSOL 
 0.7546073529398805 ; % 1548 P_CPLA2_PKC_CYTOSOL = P_CPLA2_CYTOSOL + P_PKC_CYTOSOL
 P_CPLA2_PKC_CYTOSOL = P_CPLA2_CYTOSOL+P_PKC_CYTOSOL 
 0.00022528645324735186 ; % 1549 P_PKC_CYTOSOL + SMAD2_CYTOSOL = P_PKC_SMAD2_CYTOSOL
 P_PKC_CYTOSOL+SMAD2_CYTOSOL = P_PKC_SMAD2_CYTOSOL 
 0.03384768199634832 ; % 1550 P_PKC_SMAD2_CYTOSOL = P_PKC_CYTOSOL + SMAD2_CYTOSOL
 P_PKC_SMAD2_CYTOSOL = P_PKC_CYTOSOL+SMAD2_CYTOSOL 
 0.687617189600002 ; % 1551 P_PKC_SMAD2_CYTOSOL = P_PKC_CYTOSOL + P_SMAD2_CYTOSOL
 P_PKC_SMAD2_CYTOSOL = P_PKC_CYTOSOL+P_SMAD2_CYTOSOL 
 0.00016372544687844082 ; % 1552 P_PKC_CYTOSOL + SMAD3_CYTOSOL = P_PKC_SMAD3_CYTOSOL
 P_PKC_CYTOSOL+SMAD3_CYTOSOL = P_PKC_SMAD3_CYTOSOL 
 0.06121615975821997 ; % 1553 P_PKC_SMAD3_CYTOSOL = P_PKC_CYTOSOL + SMAD3_CYTOSOL
 P_PKC_SMAD3_CYTOSOL = P_PKC_CYTOSOL+SMAD3_CYTOSOL 
 0.36009604866247824 ; % 1554 P_PKC_SMAD3_CYTOSOL = P_PKC_CYTOSOL + P_SMAD3_CYTOSOL
 P_PKC_SMAD3_CYTOSOL = P_PKC_CYTOSOL+P_SMAD3_CYTOSOL 
 0.06729324295516959 ; % 1555 P_PKC_CYTOSOL + IKB_NFKB_CYTOSOL = P_PKC_IKB_NFKB_CYTOSOL
 P_PKC_CYTOSOL+IKB_NFKB_CYTOSOL = P_PKC_IKB_NFKB_CYTOSOL 
 0.08376878808332205 ; % 1556 P_PKC_IKB_NFKB_CYTOSOL = P_PKC_CYTOSOL + IKB_NFKB_CYTOSOL
 P_PKC_IKB_NFKB_CYTOSOL = P_PKC_CYTOSOL+IKB_NFKB_CYTOSOL 
 0.6658117772336646 ; % 1557 P_PKC_IKB_NFKB_CYTOSOL = P_PKC_CYTOSOL + P_IKB_NFKB_CYTOSOL
 P_PKC_IKB_NFKB_CYTOSOL = P_PKC_CYTOSOL+P_IKB_NFKB_CYTOSOL 
 0.0027897963637703027 ; % 1558 GPASE_CYTOSOL + P_AP1_CYTOSOL = GPASE_P_AP1_CYTOSOL
 GPASE_CYTOSOL+P_AP1_CYTOSOL = GPASE_P_AP1_CYTOSOL 
 0.0601878316804977 ; % 1559 GPASE_P_AP1_CYTOSOL = GPASE_CYTOSOL + P_AP1_CYTOSOL
 GPASE_P_AP1_CYTOSOL = GPASE_CYTOSOL+P_AP1_CYTOSOL 
 0.07891956777473075 ; % 1560 GPASE_P_AP1_CYTOSOL = GPASE_CYTOSOL + AP1_CYTOSOL
 GPASE_P_AP1_CYTOSOL = GPASE_CYTOSOL+AP1_CYTOSOL 
 0.5315584063235371 ; % 1561 GPASE_CYTOSOL + P_SP1_CYTOSOL = GPASE_P_SP1_CYTOSOL
 GPASE_CYTOSOL+P_SP1_CYTOSOL = GPASE_P_SP1_CYTOSOL 
 0.03615544077033689 ; % 1562 GPASE_P_SP1_CYTOSOL = GPASE_CYTOSOL + P_SP1_CYTOSOL
 GPASE_P_SP1_CYTOSOL = GPASE_CYTOSOL+P_SP1_CYTOSOL 
 0.2088947125970736 ; % 1563 GPASE_P_SP1_CYTOSOL = GPASE_CYTOSOL + SP1_CYTOSOL
 GPASE_P_SP1_CYTOSOL = GPASE_CYTOSOL+SP1_CYTOSOL 
 0.17798855481677767 ; % 1564 GPASE_CYTOSOL + P_CJUN_CYTOSOL = GPASE_P_CJUN_CYTOSOL
 GPASE_CYTOSOL+P_CJUN_CYTOSOL = GPASE_P_CJUN_CYTOSOL 
 0.025438548254903215 ; % 1565 GPASE_P_CJUN_CYTOSOL = GPASE_CYTOSOL + P_CJUN_CYTOSOL
 GPASE_P_CJUN_CYTOSOL = GPASE_CYTOSOL+P_CJUN_CYTOSOL 
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 0.42716652751018835 ; % 1566 GPASE_P_CJUN_CYTOSOL = GPASE_CYTOSOL + CJUN_CYTOSOL
 GPASE_P_CJUN_CYTOSOL = GPASE_CYTOSOL+CJUN_CYTOSOL 
 0.02739876362545446 ; % 1567 GPASE_CYTOSOL + P_CPLA2_CYTOSOL = GPASE_P_CPLA2_CYTOSOL
 GPASE_CYTOSOL+P_CPLA2_CYTOSOL = GPASE_P_CPLA2_CYTOSOL 
 0.03274725365738842 ; % 1568 GPASE_P_CPLA2_CYTOSOL = GPASE_CYTOSOL + P_CPLA2_CYTOSOL
 GPASE_P_CPLA2_CYTOSOL = GPASE_CYTOSOL+P_CPLA2_CYTOSOL 
 0.6704769938620023 ; % 1569 GPASE_P_CPLA2_CYTOSOL = GPASE_CYTOSOL + CPLA2_CYTOSOL
 GPASE_P_CPLA2_CYTOSOL = GPASE_CYTOSOL+CPLA2_CYTOSOL 
 0.9706903628558254 ; % 1570 GPASE_CYTOSOL + P_SMAD2_CYTOSOL = GPASE_P_SMAD2_CYTOSOL
 GPASE_CYTOSOL+P_SMAD2_CYTOSOL = GPASE_P_SMAD2_CYTOSOL 
 0.006687538627677514 ; % 1571 GPASE_P_SMAD2_CYTOSOL = GPASE_CYTOSOL + P_SMAD2_CYTOSOL
 GPASE_P_SMAD2_CYTOSOL = GPASE_CYTOSOL+P_SMAD2_CYTOSOL 
 0.8631920751265187 ; % 1572 GPASE_P_SMAD2_CYTOSOL = GPASE_CYTOSOL + SMAD2_CYTOSOL
 GPASE_P_SMAD2_CYTOSOL = GPASE_CYTOSOL+SMAD2_CYTOSOL 
 0.7313532786396573 ; % 1573 GPASE_CYTOSOL + P_SMAD3_CYTOSOL = GPASE_P_SMAD3_CYTOSOL
 GPASE_CYTOSOL+P_SMAD3_CYTOSOL = GPASE_P_SMAD3_CYTOSOL 
 0.030450001346030698 ; % 1574 GPASE_P_SMAD3_CYTOSOL = GPASE_CYTOSOL + P_SMAD3_CYTOSOL
 GPASE_P_SMAD3_CYTOSOL = GPASE_CYTOSOL+P_SMAD3_CYTOSOL 
 0.7696428467143489 ; % 1575 GPASE_P_SMAD3_CYTOSOL = GPASE_CYTOSOL + SMAD3_CYTOSOL
 GPASE_P_SMAD3_CYTOSOL = GPASE_CYTOSOL+SMAD3_CYTOSOL 
 0.01045357196653407 ; % 1576 GPASE_CYTOSOL + P_NFATC1_CYTOSOL = GPASE_P_NFATC1_CYTOSOL
 GPASE_CYTOSOL+P_NFATC1_CYTOSOL = GPASE_P_NFATC1_CYTOSOL 
 0.06787278643900517 ; % 1577 GPASE_P_NFATC1_CYTOSOL = GPASE_CYTOSOL + P_NFATC1_CYTOSOL
 GPASE_P_NFATC1_CYTOSOL = GPASE_CYTOSOL+P_NFATC1_CYTOSOL 
 0.2131829053223503 ; % 1578 GPASE_P_NFATC1_CYTOSOL = GPASE_CYTOSOL + NFATC1_CYTOSOL
 GPASE_P_NFATC1_CYTOSOL = GPASE_CYTOSOL+NFATC1_CYTOSOL 
 0.30576803192442614 ; % 1579 GPASE_CYTOSOL + P_PKC_CYTOSOL = GPASE_P_PKC_CYTOSOL
 GPASE_CYTOSOL+P_PKC_CYTOSOL = GPASE_P_PKC_CYTOSOL 
 0.07709523643578828 ; % 1580 GPASE_P_PKC_CYTOSOL = GPASE_CYTOSOL + P_PKC_CYTOSOL
 GPASE_P_PKC_CYTOSOL = GPASE_CYTOSOL+P_PKC_CYTOSOL 
 0.07902624850772588 ; % 1581 GPASE_P_PKC_CYTOSOL = GPASE_CYTOSOL + PKC_CYTOSOL
 GPASE_P_PKC_CYTOSOL = GPASE_CYTOSOL+PKC_CYTOSOL 
 0.8838222948573942 ; % 1582 BMP2_BMPRII_ALK2_CYTOSOL + SMAD1_CYTOSOL = 
BMP2_BMPRII_ALK2_SMAD1_CYTOSOL BMP2_BMPRII_ALK2_CYTOSOL+SMAD1_CYTOSOL = BMP2_BMPRII_ALK2_SMAD1_CYTOSOL 
 0.021343800595991558 ; % 1583 BMP2_BMPRII_ALK2_SMAD1_CYTOSOL = BMP2_BMPRII_ALK2_CYTOSOL + 
SMAD1_CYTOSOL BMP2_BMPRII_ALK2_SMAD1_CYTOSOL = BMP2_BMPRII_ALK2_CYTOSOL+SMAD1_CYTOSOL 
 0.4502447524872155 ; % 1584 BMP2_BMPRII_ALK2_SMAD1_CYTOSOL = BMP2_BMPRII_ALK2_CYTOSOL + 
PSMAD1_CYTOSOL BMP2_BMPRII_ALK2_SMAD1_CYTOSOL = BMP2_BMPRII_ALK2_CYTOSOL+PSMAD1_CYTOSOL 
 0.9735789101517578 ; % 1585 BMP2_BMPRII_ALK2_CYTOSOL + SMAD5_CYTOSOL = 
BMP2_BMPRII_ALK2_SMAD5_CYTOSOL BMP2_BMPRII_ALK2_CYTOSOL+SMAD5_CYTOSOL = BMP2_BMPRII_ALK2_SMAD5_CYTOSOL 
 0.010753997677813088 ; % 1586 BMP2_BMPRII_ALK2_SMAD5_CYTOSOL = BMP2_BMPRII_ALK2_CYTOSOL + 
SMAD5_CYTOSOL BMP2_BMPRII_ALK2_SMAD5_CYTOSOL = BMP2_BMPRII_ALK2_CYTOSOL+SMAD5_CYTOSOL 
 0.9479284391395204 ; % 1587 BMP2_BMPRII_ALK2_SMAD5_CYTOSOL = BMP2_BMPRII_ALK2_CYTOSOL + 
PSMAD5_CYTOSOL BMP2_BMPRII_ALK2_SMAD5_CYTOSOL = BMP2_BMPRII_ALK2_CYTOSOL+PSMAD5_CYTOSOL 
 0.5962048608049514 ; % 1588 BMP2_BMPRII_ALK3_CYTOSOL + SMAD1_CYTOSOL = 
BMP2_BMPRII_ALK3_SMAD1_CYTOSOL BMP2_BMPRII_ALK3_CYTOSOL+SMAD1_CYTOSOL = BMP2_BMPRII_ALK3_SMAD1_CYTOSOL 
 0.030382040919290365 ; % 1589 BMP2_BMPRII_ALK3_SMAD1_CYTOSOL = BMP2_BMPRII_ALK3_CYTOSOL + 
SMAD1_CYTOSOL BMP2_BMPRII_ALK3_SMAD1_CYTOSOL = BMP2_BMPRII_ALK3_CYTOSOL+SMAD1_CYTOSOL 
 0.37281328302784855 ; % 1590 BMP2_BMPRII_ALK3_SMAD1_CYTOSOL = BMP2_BMPRII_ALK3_CYTOSOL + 
PSMAD1_CYTOSOL BMP2_BMPRII_ALK3_SMAD1_CYTOSOL = BMP2_BMPRII_ALK3_CYTOSOL+PSMAD1_CYTOSOL 
 0.008755229220723026 ; % 1591 BMP2_BMPRII_ALK3_CYTOSOL + SMAD5_CYTOSOL = 
BMP2_BMPRII_ALK3_SMAD5_CYTOSOL BMP2_BMPRII_ALK3_CYTOSOL+SMAD5_CYTOSOL = BMP2_BMPRII_ALK3_SMAD5_CYTOSOL 
 0.07956406494765314 ; % 1592 BMP2_BMPRII_ALK3_SMAD5_CYTOSOL = BMP2_BMPRII_ALK3_CYTOSOL + 
SMAD5_CYTOSOL BMP2_BMPRII_ALK3_SMAD5_CYTOSOL = BMP2_BMPRII_ALK3_CYTOSOL+SMAD5_CYTOSOL 
 0.3303974781821156 ; % 1593 BMP2_BMPRII_ALK3_SMAD5_CYTOSOL = BMP2_BMPRII_ALK3_CYTOSOL + 
PSMAD5_CYTOSOL BMP2_BMPRII_ALK3_SMAD5_CYTOSOL = BMP2_BMPRII_ALK3_CYTOSOL+PSMAD5_CYTOSOL 
 0.7259628744510505 ; % 1594 BMP2_BMPRII_ALK6_CYTOSOL + SMAD1_CYTOSOL = 
BMP2_BMPRII_ALK6_SMAD1_CYTOSOL BMP2_BMPRII_ALK6_CYTOSOL+SMAD1_CYTOSOL = BMP2_BMPRII_ALK6_SMAD1_CYTOSOL 
 0.057729087355286146 ; % 1595 BMP2_BMPRII_ALK6_SMAD1_CYTOSOL = BMP2_BMPRII_ALK6_CYTOSOL + 
SMAD1_CYTOSOL BMP2_BMPRII_ALK6_SMAD1_CYTOSOL = BMP2_BMPRII_ALK6_CYTOSOL+SMAD1_CYTOSOL 
 0.8592508847016416 ; % 1596 BMP2_BMPRII_ALK6_SMAD1_CYTOSOL = BMP2_BMPRII_ALK6_CYTOSOL + 
PSMAD1_CYTOSOL BMP2_BMPRII_ALK6_SMAD1_CYTOSOL = BMP2_BMPRII_ALK6_CYTOSOL+PSMAD1_CYTOSOL 
 0.9809088642205303 ; % 1597 BMP2_BMPRII_ALK6_CYTOSOL + SMAD5_CYTOSOL = 
BMP2_BMPRII_ALK6_SMAD5_CYTOSOL BMP2_BMPRII_ALK6_CYTOSOL+SMAD5_CYTOSOL = BMP2_BMPRII_ALK6_SMAD5_CYTOSOL 
 0.043534110226768286 ; % 1598 BMP2_BMPRII_ALK6_SMAD5_CYTOSOL = BMP2_BMPRII_ALK6_CYTOSOL + 
SMAD5_CYTOSOL BMP2_BMPRII_ALK6_SMAD5_CYTOSOL = BMP2_BMPRII_ALK6_CYTOSOL+SMAD5_CYTOSOL 
 0.016072153251427523 ; % 1599 BMP2_BMPRII_ALK6_SMAD5_CYTOSOL = BMP2_BMPRII_ALK6_CYTOSOL + 
PSMAD5_CYTOSOL BMP2_BMPRII_ALK6_SMAD5_CYTOSOL = BMP2_BMPRII_ALK6_CYTOSOL+PSMAD5_CYTOSOL 
 0.4143626270079682 ; % 1600 TGFB3_TGFBRII_ALK1_TGFBRIII_CYTOSOL + SMAD2_CYTOSOL = 
TGFB3_TGFBRII_ALK1_TGFBRIII_SMAD2_CYTOSOL TGFB3_TGFBRII_ALK1_TGFBRIII_CYTOSOL+SMAD2_CYTOSOL = 
TGFB3_TGFBRII_ALK1_TGFBRIII_SMAD2_CYTOSOL 
 0.093307014740267 ; % 1601 TGFB3_TGFBRII_ALK1_TGFBRIII_SMAD2_CYTOSOL = 
TGFB3_TGFBRII_ALK1_TGFBRIII_CYTOSOL + SMAD2_CYTOSOL TGFB3_TGFBRII_ALK1_TGFBRIII_SMAD2_CYTOSOL = 
TGFB3_TGFBRII_ALK1_TGFBRIII_CYTOSOL+SMAD2_CYTOSOL 
 0.5631330348652333 ; % 1602 TGFB3_TGFBRII_ALK1_TGFBRIII_SMAD2_CYTOSOL = 
TGFB3_TGFBRII_ALK1_TGFBRIII_CYTOSOL + PSMAD2_CYTOSOL TGFB3_TGFBRII_ALK1_TGFBRIII_SMAD2_CYTOSOL = 
TGFB3_TGFBRII_ALK1_TGFBRIII_CYTOSOL+PSMAD2_CYTOSOL 
 0.15622160190609957 ; % 1603 TGFB3_TGFBRII_ALK1_TGFBRIII_CYTOSOL + SMAD3_CYTOSOL = 
TGFB3_TGFBRII_ALK1_TGFBRIII_SMAD3_CYTOSOL TGFB3_TGFBRII_ALK1_TGFBRIII_CYTOSOL+SMAD3_CYTOSOL = 
TGFB3_TGFBRII_ALK1_TGFBRIII_SMAD3_CYTOSOL 
 0.0820397087607564 ; % 1604 TGFB3_TGFBRII_ALK1_TGFBRIII_SMAD3_CYTOSOL = 
TGFB3_TGFBRII_ALK1_TGFBRIII_CYTOSOL + SMAD3_CYTOSOL TGFB3_TGFBRII_ALK1_TGFBRIII_SMAD3_CYTOSOL = 
TGFB3_TGFBRII_ALK1_TGFBRIII_CYTOSOL+SMAD3_CYTOSOL 
 0.7684171061020444 ; % 1605 TGFB3_TGFBRII_ALK1_TGFBRIII_SMAD3_CYTOSOL = 
TGFB3_TGFBRII_ALK1_TGFBRIII_CYTOSOL + PSMAD3_CYTOSOL TGFB3_TGFBRII_ALK1_TGFBRIII_SMAD3_CYTOSOL = 
TGFB3_TGFBRII_ALK1_TGFBRIII_CYTOSOL+PSMAD3_CYTOSOL 
 0.5223156483960247 ; % 1606 TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL + SMAD2_CYTOSOL = 
TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD2_CYTOSOL TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL+SMAD2_CYTOSOL = 
TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD2_CYTOSOL 
 0.0030849846871043862 ; % 1607 TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD2_CYTOSOL = 
TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL + SMAD2_CYTOSOL TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD2_CYTOSOL = 
TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL+SMAD2_CYTOSOL 
320 
 
 0.6237687761811694 ; % 1608 TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD2_CYTOSOL = 
TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL + PSMAD2_CYTOSOL TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD2_CYTOSOL = 
TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL+PSMAD2_CYTOSOL 
 0.7162315359808622 ; % 1609 TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL + SMAD3_CYTOSOL = 
TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD3_CYTOSOL TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL+SMAD3_CYTOSOL = 
TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD3_CYTOSOL 
 0.057620260416550675 ; % 1610 TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD3_CYTOSOL = 
TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL + SMAD3_CYTOSOL TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD3_CYTOSOL = 
TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL+SMAD3_CYTOSOL 
 0.6000018384898842 ; % 1611 TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD3_CYTOSOL = 
TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL + PSMAD3_CYTOSOL TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD3_CYTOSOL = 
TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL+PSMAD3_CYTOSOL 
 0.000147693134163319284 ; % 1612 TGFB2_TGFBRII_ALK1_TGFBRIII_CYTOSOL + SMAD2_CYTOSOL = 
TGFB2_TGFBRII_ALK1_TGFBRIII_SMAD2_CYTOSOL TGFB2_TGFBRII_ALK1_TGFBRIII_CYTOSOL+SMAD2_CYTOSOL = 
TGFB2_TGFBRII_ALK1_TGFBRIII_SMAD2_CYTOSOL 
 0.34819331219832904 ; % 1613 TGFB2_TGFBRII_ALK1_TGFBRIII_SMAD2_CYTOSOL = 
TGFB2_TGFBRII_ALK1_TGFBRIII_CYTOSOL + SMAD2_CYTOSOL TGFB2_TGFBRII_ALK1_TGFBRIII_SMAD2_CYTOSOL = 
TGFB2_TGFBRII_ALK1_TGFBRIII_CYTOSOL+SMAD2_CYTOSOL 
 0.0024136236913857134 ; % 1614 TGFB2_TGFBRII_ALK1_TGFBRIII_SMAD2_CYTOSOL = 
TGFB2_TGFBRII_ALK1_TGFBRIII_CYTOSOL + PSMAD2_CYTOSOL TGFB2_TGFBRII_ALK1_TGFBRIII_SMAD2_CYTOSOL = 
TGFB2_TGFBRII_ALK1_TGFBRIII_CYTOSOL+PSMAD2_CYTOSOL 
 0.0001665471828437052 ; % 1615 TGFB2_TGFBRII_ALK1_TGFBRIII_CYTOSOL + SMAD3_CYTOSOL = 
TGFB2_TGFBRII_ALK1_TGFBRIII_SMAD3_CYTOSOL TGFB2_TGFBRII_ALK1_TGFBRIII_CYTOSOL+SMAD3_CYTOSOL = 
TGFB2_TGFBRII_ALK1_TGFBRIII_SMAD3_CYTOSOL 
 0.5605410211528871 ; % 1616 TGFB2_TGFBRII_ALK1_TGFBRIII_SMAD3_CYTOSOL = 
TGFB2_TGFBRII_ALK1_TGFBRIII_CYTOSOL + SMAD3_CYTOSOL TGFB2_TGFBRII_ALK1_TGFBRIII_SMAD3_CYTOSOL = 
TGFB2_TGFBRII_ALK1_TGFBRIII_CYTOSOL+SMAD3_CYTOSOL 
 0.0008133368610320912 ; % 1617 TGFB2_TGFBRII_ALK1_TGFBRIII_SMAD3_CYTOSOL = 
TGFB2_TGFBRII_ALK1_TGFBRIII_CYTOSOL + PSMAD3_CYTOSOL TGFB2_TGFBRII_ALK1_TGFBRIII_SMAD3_CYTOSOL = 
TGFB2_TGFBRII_ALK1_TGFBRIII_CYTOSOL+PSMAD3_CYTOSOL 
 0.000109269506310881 ; % 1618 TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL + SMAD2_CYTOSOL = 
TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD2_CYTOSOL TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL+SMAD2_CYTOSOL = 
TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD2_CYTOSOL 
 0.5034711841849052 ; % 1619 TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD2_CYTOSOL = 
TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL + SMAD2_CYTOSOL TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD2_CYTOSOL = 
TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL+SMAD2_CYTOSOL 
 0.0006821629481382607 ; % 1620 TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD2_CYTOSOL = 
TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL + PSMAD2_CYTOSOL TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD2_CYTOSOL = 
TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL+PSMAD2_CYTOSOL 
 0.00015001842590867364 ; % 1621 TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL + SMAD3_CYTOSOL = 
TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD3_CYTOSOL TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL+SMAD3_CYTOSOL = 
TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD3_CYTOSOL 
 0.4830148585814499 ; % 1622 TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD3_CYTOSOL = 
TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL + SMAD3_CYTOSOL TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD3_CYTOSOL = 
TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL+SMAD3_CYTOSOL 
 0.00014645645575071353 ; % 1623 TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD3_CYTOSOL = 
TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL + PSMAD3_CYTOSOL TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD3_CYTOSOL = 
TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL+PSMAD3_CYTOSOL 
 0.00024013058037425594 ; % 1624 SMURF1_CYTOSOL + PSMAD1_CYTOSOL = SMURF1_PSMAD1_CYTOSOL
 SMURF1_CYTOSOL+PSMAD1_CYTOSOL = SMURF1_PSMAD1_CYTOSOL 
 0.3185867127703606 ; % 1625 SMURF1_PSMAD1_CYTOSOL = SMURF1_CYTOSOL + PSMAD1_CYTOSOL
 SMURF1_PSMAD1_CYTOSOL = SMURF1_CYTOSOL+PSMAD1_CYTOSOL 
 0.36561905035377806 ; % 1626 SMURF1_PSMAD1_CYTOSOL = SMURF1_CYTOSOL + UB_PSMAD1_CYTOSOL
 SMURF1_PSMAD1_CYTOSOL = SMURF1_CYTOSOL+UB_PSMAD1_CYTOSOL 
 0.00006643632440229951 ; % 1627 SMURF1_CYTOSOL + PSMAD5_CYTOSOL = SMURF1_PSMAD5_CYTOSOL
 SMURF1_CYTOSOL+PSMAD5_CYTOSOL = SMURF1_PSMAD5_CYTOSOL 
 0.0764681971678722 ; % 1628 SMURF1_PSMAD5_CYTOSOL = SMURF1_CYTOSOL + PSMAD5_CYTOSOL
 SMURF1_PSMAD5_CYTOSOL = SMURF1_CYTOSOL+PSMAD5_CYTOSOL 
 0.26744885520467143 ; % 1629 SMURF1_PSMAD5_CYTOSOL = SMURF1_CYTOSOL + UB_PSMAD5_CYTOSOL
 SMURF1_PSMAD5_CYTOSOL = SMURF1_CYTOSOL+UB_PSMAD5_CYTOSOL 
 0.0003534560126102534 ; % 1630 SMURF2_CYTOSOL + PSMAD2_CYTOSOL = SMURF2_PSMAD2_CYTOSOL
 SMURF2_CYTOSOL+PSMAD2_CYTOSOL = SMURF2_PSMAD2_CYTOSOL 
 0.8163385329250107 ; % 1631 SMURF2_PSMAD2_CYTOSOL = SMURF2_CYTOSOL + PSMAD2_CYTOSOL
 SMURF2_PSMAD2_CYTOSOL = SMURF2_CYTOSOL+PSMAD2_CYTOSOL 
 0.10674279141439047 ; % 1632 SMURF2_PSMAD2_CYTOSOL = SMURF2_CYTOSOL + UB_PSMAD2_CYTOSOL
 SMURF2_PSMAD2_CYTOSOL = SMURF2_CYTOSOL+UB_PSMAD2_CYTOSOL 
 0.00091680255433678883 ; % 1633 SMURF2_CYTOSOL + PSMAD3_CYTOSOL = SMURF2_PSMAD3_CYTOSOL
 SMURF2_CYTOSOL+PSMAD3_CYTOSOL = SMURF2_PSMAD3_CYTOSOL 
 0.1410125571251133 ; % 1634 SMURF2_PSMAD3_CYTOSOL = SMURF2_CYTOSOL + PSMAD3_CYTOSOL
 SMURF2_PSMAD3_CYTOSOL = SMURF2_CYTOSOL+PSMAD3_CYTOSOL 
 0.2978641294341158 ; % 1635 SMURF2_PSMAD3_CYTOSOL = SMURF2_CYTOSOL + UB_PSMAD3_CYTOSOL
 SMURF2_PSMAD3_CYTOSOL = SMURF2_CYTOSOL+UB_PSMAD3_CYTOSOL 
 0.23324915502438331 ; % 1636 UB_PSMAD1_CYTOSOL = [] UB_PSMAD1_CYTOSOL = [] 
 0.20941986532299117 ; % 1637 UB_PSMAD2_CYTOSOL = [] UB_PSMAD2_CYTOSOL = [] 
 0.02458733626780385 ; % 1638 UB_PSMAD3_CYTOSOL = [] UB_PSMAD3_CYTOSOL = [] 
 0.20410953277974203 ; % 1639 UB_PSMAD5_CYTOSOL = [] UB_PSMAD5_CYTOSOL = [] 
 0.031232146866218136 ; % 1640 BMP2_BMPRII_ALK2_CYTOSOL = [] BMP2_BMPRII_ALK2_CYTOSOL = [] 
 0.019658629667977445 ; % 1641 BMP2_BMPRII_ALK3_CYTOSOL = [] BMP2_BMPRII_ALK3_CYTOSOL = [] 
 0.09065239288582017 ; % 1642 BMP2_BMPRII_ALK6_CYTOSOL = [] BMP2_BMPRII_ALK6_CYTOSOL = [] 
 0.04346272457000899 ; % 1643 TGFB3_TGFBRII_ALK1_TGFBRIII_CYTOSOL = []
 TGFB3_TGFBRII_ALK1_TGFBRIII_CYTOSOL = [] 
 0.04438546667420112 ; % 1644 TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL = []
 TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL = [] 
 0.033319241586448517 ; % 1645 TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL = []
 TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL = [] 
 0.013236671846121273 ; % 1646 TGFB2_TGFBRII_ALK1_TGFBRIII_CYTOSOL = []
 TGFB2_TGFBRII_ALK1_TGFBRIII_CYTOSOL = [] 
 10.5999120317824057 ; % 1647 BCATENIN_CYTOSOL + ECADHERIN_CYTOSOL = BCATENIN_ECADHERIN_CYTOSOL
 BCATENIN_CYTOSOL+ECADHERIN_CYTOSOL = BCATENIN_ECADHERIN_CYTOSOL 
 0.00001115639115582083 ; % 1648 BCATENIN_ECADHERIN_CYTOSOL = BCATENIN_CYTOSOL + ECADHERIN_CYTOSOL
 BCATENIN_ECADHERIN_CYTOSOL = BCATENIN_CYTOSOL+ECADHERIN_CYTOSOL 
 10.32501078431318176 ; % 1649 BCATENIN_CYTOSOL + VECADHERIN_CYTOSOL = 
BCATENIN_VECADHERIN_CYTOSOL BCATENIN_CYTOSOL+VECADHERIN_CYTOSOL = BCATENIN_VECADHERIN_CYTOSOL 
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 0.00005776712141603666 ; % 1650 BCATENIN_VECADHERIN_CYTOSOL = BCATENIN_CYTOSOL + 
VECADHERIN_CYTOSOL BCATENIN_VECADHERIN_CYTOSOL = BCATENIN_CYTOSOL+VECADHERIN_CYTOSOL 
 2.46286302385161693 ; % 1651 BCATENIN_CYTOSOL + PECAM1_CYTOSOL = BCATENIN_PECAM1_CYTOSOL
 BCATENIN_CYTOSOL+PECAM1_CYTOSOL = BCATENIN_PECAM1_CYTOSOL 
 0.0008516099323708987 ; % 1652 BCATENIN_PECAM1_CYTOSOL = BCATENIN_CYTOSOL + PECAM1_CYTOSOL
 BCATENIN_PECAM1_CYTOSOL = BCATENIN_CYTOSOL+PECAM1_CYTOSOL 
 0.3443997944883932 ; % 1653 IKB_CYTOSOL + NFKB_CYTOSOL = IKB_NFKB_CYTOSOL
 IKB_CYTOSOL+NFKB_CYTOSOL = IKB_NFKB_CYTOSOL 
 0.8101801890022028 ; % 1654 P_IKB_NFKB_CYTOSOL = P_IKB_CYTOSOL + NFKB_CYTOSOL P_IKB_NFKB_CYTOSOL 
= P_IKB_CYTOSOL+NFKB_CYTOSOL 
 0.0367396231330024 ; % 1655 P_IKB_CYTOSOL + NFKB_CYTOSOL = P_IKB_NFKB_CYTOSOL
 P_IKB_CYTOSOL+NFKB_CYTOSOL = P_IKB_NFKB_CYTOSOL 
 0.06499744136140728 ; % 1656 ACTIVE_AKT_CYTOSOL + IKB_NFKB_CYTOSOL = ACTIVE_AKT_IKB_NFKB_CYTOSOL
 ACTIVE_AKT_CYTOSOL+IKB_NFKB_CYTOSOL = ACTIVE_AKT_IKB_NFKB_CYTOSOL 
 0.0915493242999715 ; % 1657 ACTIVE_AKT_IKB_NFKB_CYTOSOL = ACTIVE_AKT_CYTOSOL + IKB_NFKB_CYTOSOL
 ACTIVE_AKT_IKB_NFKB_CYTOSOL = ACTIVE_AKT_CYTOSOL+IKB_NFKB_CYTOSOL 
 0.8627263202971025 ; % 1658 ACTIVE_AKT_IKB_NFKB_CYTOSOL = ACTIVE_AKT_CYTOSOL + P_IKB_NFKB_CYTOSOL
 ACTIVE_AKT_IKB_NFKB_CYTOSOL = ACTIVE_AKT_CYTOSOL+P_IKB_NFKB_CYTOSOL 
 0.7607723103326829 ; % 1659 VEGFA_VEGFR2_SHC_CYTOSOL + PI3K_CYTOSOL = 
VEGFA_VEGFR2_SHC_PI3K_CYTOSOL VEGFA_VEGFR2_SHC_CYTOSOL+PI3K_CYTOSOL = VEGFA_VEGFR2_SHC_PI3K_CYTOSOL 
 0.09731465879918465 ; % 1660 VEGFA_VEGFR2_SHC_PI3K_CYTOSOL = VEGFA_VEGFR2_SHC_CYTOSOL + 
PI3K_CYTOSOL VEGFA_VEGFR2_SHC_PI3K_CYTOSOL = VEGFA_VEGFR2_SHC_CYTOSOL+PI3K_CYTOSOL 
 0.5073625455213779 ; % 1661 VEGFA_VEGFR2_SHC_PI3K_CYTOSOL = VEGFA_VEGFR2_SHC_CYTOSOL + 
ACTIVE_PI3K_CYTOSOL VEGFA_VEGFR2_SHC_PI3K_CYTOSOL = VEGFA_VEGFR2_SHC_CYTOSOL+ACTIVE_PI3K_CYTOSOL 
 0.44696745895454926 ; % 1662 BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL + PI3K_CYTOSOL = 
BMP2_BMPRII_ALK2_SHC_GRB2_SOS_PI3K_CYTOSOL BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL+PI3K_CYTOSOL = 
BMP2_BMPRII_ALK2_SHC_GRB2_SOS_PI3K_CYTOSOL 
 0.0383486817899375 ; % 1663 BMP2_BMPRII_ALK2_SHC_GRB2_SOS_PI3K_CYTOSOL = 
BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL + PI3K_CYTOSOL BMP2_BMPRII_ALK2_SHC_GRB2_SOS_PI3K_CYTOSOL = 
BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL+PI3K_CYTOSOL 
 0.6821496097859371 ; % 1664 BMP2_BMPRII_ALK2_SHC_GRB2_SOS_PI3K_CYTOSOL = 
BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL + ACTIVE_PI3K_CYTOSOL BMP2_BMPRII_ALK2_SHC_GRB2_SOS_PI3K_CYTOSOL = 
BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL+ACTIVE_PI3K_CYTOSOL 
 0.67542573304516 ; % 1665 AKT_PASE_CYTOSOL + P_PLCG_CYTOSOL = AKT_PASE_P_PLCG_CYTOSOL
 AKT_PASE_CYTOSOL+P_PLCG_CYTOSOL = AKT_PASE_P_PLCG_CYTOSOL 
 0.09208143434570443 ; % 1666 AKT_PASE_P_PLCG_CYTOSOL = AKT_PASE_CYTOSOL + P_PLCG_CYTOSOL
 AKT_PASE_P_PLCG_CYTOSOL = AKT_PASE_CYTOSOL+P_PLCG_CYTOSOL 
 0.14429222447230905 ; % 1667 AKT_PASE_P_PLCG_CYTOSOL = AKT_PASE_CYTOSOL + PLCG_CYTOSOL
 AKT_PASE_P_PLCG_CYTOSOL = AKT_PASE_CYTOSOL+PLCG_CYTOSOL 
 0.15412321373299387 ; % 1668 AKT_PASE_CYTOSOL + P_PKC_CYTOSOL = AKT_PASE_P_PKC_CYTOSOL
 AKT_PASE_CYTOSOL+P_PKC_CYTOSOL = AKT_PASE_P_PKC_CYTOSOL 
 0.06535815972436103 ; % 1669 AKT_PASE_P_PKC_CYTOSOL = AKT_PASE_CYTOSOL + P_PKC_CYTOSOL
 AKT_PASE_P_PKC_CYTOSOL = AKT_PASE_CYTOSOL+P_PKC_CYTOSOL 
 0.46343474587636324 ; % 1670 AKT_PASE_P_PKC_CYTOSOL = AKT_PASE_CYTOSOL + PKC_CYTOSOL
 AKT_PASE_P_PKC_CYTOSOL = AKT_PASE_CYTOSOL+PKC_CYTOSOL 
 0.9436425854258056 ; % 1671 AKT_PASE_CYTOSOL + P_SPK_CYTOSOL = AKT_PASE_P_SPK_CYTOSOL
 AKT_PASE_CYTOSOL+P_SPK_CYTOSOL = AKT_PASE_P_SPK_CYTOSOL 
 0.01243423887917633 ; % 1672 AKT_PASE_P_SPK_CYTOSOL = AKT_PASE_CYTOSOL + P_SPK_CYTOSOL
 AKT_PASE_P_SPK_CYTOSOL = AKT_PASE_CYTOSOL+P_SPK_CYTOSOL 
 0.4530701756748112 ; % 1673 AKT_PASE_P_SPK_CYTOSOL = AKT_PASE_CYTOSOL + SPK_CYTOSOL
 AKT_PASE_P_SPK_CYTOSOL = AKT_PASE_CYTOSOL+SPK_CYTOSOL 
 0.47575363492154865 ; % 1674 AKT_PASE_CYTOSOL + P_SP1_CYTOSOL = AKT_PASE_P_SP1_CYTOSOL
 AKT_PASE_CYTOSOL+P_SP1_CYTOSOL = AKT_PASE_P_SP1_CYTOSOL 
 0.044424808815843125 ; % 1675 AKT_PASE_P_SP1_CYTOSOL = AKT_PASE_CYTOSOL + P_SP1_CYTOSOL
 AKT_PASE_P_SP1_CYTOSOL = AKT_PASE_CYTOSOL+P_SP1_CYTOSOL 
 0.5669934105197201 ; % 1676 AKT_PASE_P_SP1_CYTOSOL = AKT_PASE_CYTOSOL + SP1_CYTOSOL
 AKT_PASE_P_SP1_CYTOSOL = AKT_PASE_CYTOSOL+SP1_CYTOSOL 
 0.5316885546631417 ; % 1677 VEGFA_VEGFR2_CYTOSOL + PLCG_CYTOSOL = VEGFA_VEGFR2_PLCG_CYTOSOL
 VEGFA_VEGFR2_CYTOSOL+PLCG_CYTOSOL = VEGFA_VEGFR2_PLCG_CYTOSOL 
 0.09781352390210057 ; % 1678 VEGFA_VEGFR2_PLCG_CYTOSOL = VEGFA_VEGFR2_CYTOSOL + PLCG_CYTOSOL
 VEGFA_VEGFR2_PLCG_CYTOSOL = VEGFA_VEGFR2_CYTOSOL+PLCG_CYTOSOL 
 0.3313730288094986 ; % 1679 VEGFA_VEGFR2_PLCG_CYTOSOL = VEGFA_VEGFR2_CYTOSOL + P_PLCG_CYTOSOL
 VEGFA_VEGFR2_PLCG_CYTOSOL = VEGFA_VEGFR2_CYTOSOL+P_PLCG_CYTOSOL 
 0.32664200555025447 ; % 1680 P_PLCG_CYTOSOL + PIP2_CYTOSOL = P_PLCG_PIP2_CYTOSOL
 P_PLCG_CYTOSOL+PIP2_CYTOSOL = P_PLCG_PIP2_CYTOSOL 
 0.009406156600468209 ; % 1681 P_PLCG_PIP2_CYTOSOL = P_PLCG_CYTOSOL + PIP2_CYTOSOL
 P_PLCG_PIP2_CYTOSOL = P_PLCG_CYTOSOL+PIP2_CYTOSOL 
 0.7693157566440377 ; % 1682 P_PLCG_PIP2_CYTOSOL = P_PLCG_CYTOSOL + ACTIVE_PIP2_CYTOSOL
 P_PLCG_PIP2_CYTOSOL = P_PLCG_CYTOSOL+ACTIVE_PIP2_CYTOSOL 
 0.3057053821442832 ; % 1683 ACTIVE_PI3K_CYTOSOL + PKC_CYTOSOL = ACTIVE_PI3K_PKC_CYTOSOL
 ACTIVE_PI3K_CYTOSOL+PKC_CYTOSOL = ACTIVE_PI3K_PKC_CYTOSOL 
 0.005302057140590732 ; % 1684 ACTIVE_PI3K_PKC_CYTOSOL = ACTIVE_PI3K_CYTOSOL + PKC_CYTOSOL
 ACTIVE_PI3K_PKC_CYTOSOL = ACTIVE_PI3K_CYTOSOL+PKC_CYTOSOL 
 0.7369871426437897 ; % 1685 ACTIVE_PI3K_PKC_CYTOSOL = ACTIVE_PI3K_CYTOSOL + ACTIVE_PKC_CYTOSOL
 ACTIVE_PI3K_PKC_CYTOSOL = ACTIVE_PI3K_CYTOSOL+ACTIVE_PKC_CYTOSOL 
 0.20928778556866567 ; % 1686 ACTIVE_PIP2_CYTOSOL + PKC_CYTOSOL = ACTIVE_PIP2_PKC_CYTOSOL
 ACTIVE_PIP2_CYTOSOL+PKC_CYTOSOL = ACTIVE_PIP2_PKC_CYTOSOL 
 0.09080715278619261 ; % 1687 ACTIVE_PIP2_PKC_CYTOSOL = ACTIVE_PIP2_CYTOSOL + PKC_CYTOSOL
 ACTIVE_PIP2_PKC_CYTOSOL = ACTIVE_PIP2_CYTOSOL+PKC_CYTOSOL 
 0.0034958618599655322 ; % 1688 ACTIVE_PIP2_PKC_CYTOSOL = ACTIVE_PIP2_CYTOSOL + P_PKC_CYTOSOL
 ACTIVE_PIP2_PKC_CYTOSOL = ACTIVE_PIP2_CYTOSOL+P_PKC_CYTOSOL 
 0.4634464145908038 ; % 1689 P_PKC_CYTOSOL + SPK_CYTOSOL = P_PKC_SPK_CYTOSOL
 P_PKC_CYTOSOL+SPK_CYTOSOL = P_PKC_SPK_CYTOSOL 
 0.049372093692808865 ; % 1690 P_PKC_SPK_CYTOSOL = P_PKC_CYTOSOL + SPK_CYTOSOL P_PKC_SPK_CYTOSOL 
= P_PKC_CYTOSOL+SPK_CYTOSOL 
 0.28796540967967277 ; % 1691 P_PKC_SPK_CYTOSOL = P_PKC_CYTOSOL + P_SPK_CYTOSOL
 P_PKC_SPK_CYTOSOL = P_PKC_CYTOSOL+P_SPK_CYTOSOL 
 0.11058669282261258 ; % 1692 P_PKC_CYTOSOL + SP1_CYTOSOL = P_PKC_SP1_CYTOSOL
 P_PKC_CYTOSOL+SP1_CYTOSOL = P_PKC_SP1_CYTOSOL 
 0.005468900999515258 ; % 1693 P_PKC_SP1_CYTOSOL = P_PKC_CYTOSOL + SP1_CYTOSOL P_PKC_SP1_CYTOSOL = 
P_PKC_CYTOSOL+SP1_CYTOSOL 
 0.1986357903794277 ; % 1694 P_PKC_SP1_CYTOSOL = P_PKC_CYTOSOL + P_SP1_CYTOSOL
 P_PKC_SP1_CYTOSOL = P_PKC_CYTOSOL+P_SP1_CYTOSOL 
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 0.19680616343811408 ; % 1695 P_SPK_CYTOSOL + RAF_CYTOSOL = P_SPK_RAF_CYTOSOL
 P_SPK_CYTOSOL+RAF_CYTOSOL = P_SPK_RAF_CYTOSOL 
 0.0951158761735051 ; % 1696 P_SPK_RAF_CYTOSOL = P_SPK_CYTOSOL + RAF_CYTOSOL P_SPK_RAF_CYTOSOL = 
P_SPK_CYTOSOL+RAF_CYTOSOL 
 0.4118740602208194 ; % 1697 P_SPK_RAF_CYTOSOL = P_SPK_CYTOSOL + ACTIVE_RAF_CYTOSOL
 P_SPK_RAF_CYTOSOL = P_SPK_CYTOSOL+ACTIVE_RAF_CYTOSOL 
 0.3457153158293569 ; % 1698 ACTIVE_PIP2_CYTOSOL = [] ACTIVE_PIP2_CYTOSOL = [] 
 0.4060170046032885 ; % 1699 VEGFA_VEGFR2_SHC_CYTOSOL = [] VEGFA_VEGFR2_SHC_CYTOSOL = [] 
 0.4497157568382065 ; % 1700 BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL = []
 BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL = [] 
]; 
 
% Initial conditions -- 
IC=[ 
 0.0 ;% 1 TGFB3_CYTOSOL TGFB3_CYTOSOL 
 0.0 ;% 2 EXEXPORT_TGFB3_CYTOSOL EXEXPORT_TGFB3_CYTOSOL 
 0.0 ;% 3 TGFB2_CYTOSOL TGFB2_CYTOSOL 
 0.0 ;% 4 EXEXPORT_TGFB2_CYTOSOL EXEXPORT_TGFB2_CYTOSOL 
 0.0 ;% 5 DNA_SMURF1_RNAP_NUCLEAR DNA_SMURF1_RNAP_NUCLEAR 
 0.0 ;% 6 MRNA_SMURF1_NUCLEAR MRNA_SMURF1_NUCLEAR 
 0.0 ;% 7 MRNA_SMURF1_NEXPORT_NUCLEAR MRNA_SMURF1_NEXPORT_NUCLEAR 
 0.0 ;% 8 MRNA_SMURF1_CYTOSOL MRNA_SMURF1_CYTOSOL 
 0.0 ;% 9 MRNA_SMURF1_RIBOSOME_CYTOSOL MRNA_SMURF1_RIBOSOME_CYTOSOL 
 0.0 ;% 10 MRNA_SMURF1_START_RIBOSOME_CYTOSOL MRNA_SMURF1_START_RIBOSOME_CYTOSOL 
 0.0 ;% 11 SMURF1_CYTOSOL SMURF1_CYTOSOL 
 0.0 ;% 12 DNA_SMURF2_RNAP_NUCLEAR DNA_SMURF2_RNAP_NUCLEAR 
 0.0 ;% 13 MRNA_SMURF2_NUCLEAR MRNA_SMURF2_NUCLEAR 
 0.0 ;% 14 MRNA_SMURF2_NEXPORT_NUCLEAR MRNA_SMURF2_NEXPORT_NUCLEAR 
 0.0 ;% 15 MRNA_SMURF2_CYTOSOL MRNA_SMURF2_CYTOSOL 
 0.0 ;% 16 MRNA_SMURF2_RIBOSOME_CYTOSOL MRNA_SMURF2_RIBOSOME_CYTOSOL 
 0.0 ;% 17 MRNA_SMURF2_START_RIBOSOME_CYTOSOL MRNA_SMURF2_START_RIBOSOME_CYTOSOL 
 0.0 ;% 18 SMURF2_CYTOSOL SMURF2_CYTOSOL 
 0.0 ;% 19 DNA_SMAD1_RNAP_NUCLEAR DNA_SMAD1_RNAP_NUCLEAR 
 0.0 ;% 20 MRNA_SMAD1_NUCLEAR MRNA_SMAD1_NUCLEAR 
 0.0 ;% 21 MRNA_SMAD1_NEXPORT_NUCLEAR MRNA_SMAD1_NEXPORT_NUCLEAR 
 0.0 ;% 22 MRNA_SMAD1_CYTOSOL MRNA_SMAD1_CYTOSOL 
 0.0 ;% 23 MRNA_SMAD1_RIBOSOME_CYTOSOL MRNA_SMAD1_RIBOSOME_CYTOSOL 
 0.0 ;% 24 MRNA_SMAD1_START_RIBOSOME_CYTOSOL MRNA_SMAD1_START_RIBOSOME_CYTOSOL 
 0.0 ;% 25 SMAD1_CYTOSOL SMAD1_CYTOSOL 
 0.0 ;% 26 DNA_SMAD2_RNAP_NUCLEAR DNA_SMAD2_RNAP_NUCLEAR 
 0.0 ;% 27 MRNA_SMAD2_NUCLEAR MRNA_SMAD2_NUCLEAR 
 0.0 ;% 28 MRNA_SMAD2_NEXPORT_NUCLEAR MRNA_SMAD2_NEXPORT_NUCLEAR 
 0.0 ;% 29 MRNA_SMAD2_CYTOSOL MRNA_SMAD2_CYTOSOL 
 0.0 ;% 30 MRNA_SMAD2_RIBOSOME_CYTOSOL MRNA_SMAD2_RIBOSOME_CYTOSOL 
 0.0 ;% 31 MRNA_SMAD2_START_RIBOSOME_CYTOSOL MRNA_SMAD2_START_RIBOSOME_CYTOSOL 
 0.0 ;% 32 SMAD2_CYTOSOL SMAD2_CYTOSOL 
 0.0 ;% 33 DNA_SMAD3_RNAP_NUCLEAR DNA_SMAD3_RNAP_NUCLEAR 
 0.0 ;% 34 MRNA_SMAD3_NUCLEAR MRNA_SMAD3_NUCLEAR 
 0.0 ;% 35 MRNA_SMAD3_NEXPORT_NUCLEAR MRNA_SMAD3_NEXPORT_NUCLEAR 
 0.0 ;% 36 MRNA_SMAD3_CYTOSOL MRNA_SMAD3_CYTOSOL 
 0.0 ;% 37 MRNA_SMAD3_RIBOSOME_CYTOSOL MRNA_SMAD3_RIBOSOME_CYTOSOL 
 0.0 ;% 38 MRNA_SMAD3_START_RIBOSOME_CYTOSOL MRNA_SMAD3_START_RIBOSOME_CYTOSOL 
 0.0 ;% 39 SMAD3_CYTOSOL SMAD3_CYTOSOL 
 0.0 ;% 40 DNA_SMAD4_RNAP_NUCLEAR DNA_SMAD4_RNAP_NUCLEAR 
 0.0 ;% 41 MRNA_SMAD4_NUCLEAR MRNA_SMAD4_NUCLEAR 
 0.0 ;% 42 MRNA_SMAD4_NEXPORT_NUCLEAR MRNA_SMAD4_NEXPORT_NUCLEAR 
 0.0 ;% 43 MRNA_SMAD4_CYTOSOL MRNA_SMAD4_CYTOSOL 
 0.0 ;% 44 MRNA_SMAD4_RIBOSOME_CYTOSOL MRNA_SMAD4_RIBOSOME_CYTOSOL 
 0.0 ;% 45 MRNA_SMAD4_START_RIBOSOME_CYTOSOL MRNA_SMAD4_START_RIBOSOME_CYTOSOL 
 0.0 ;% 46 SMAD4_CYTOSOL SMAD4_CYTOSOL 
 0.0 ;% 47 DNA_SMAD5_RNAP_NUCLEAR DNA_SMAD5_RNAP_NUCLEAR 
 0.0 ;% 48 MRNA_SMAD5_NUCLEAR MRNA_SMAD5_NUCLEAR 
 0.0 ;% 49 MRNA_SMAD5_NEXPORT_NUCLEAR MRNA_SMAD5_NEXPORT_NUCLEAR 
 0.0 ;% 50 MRNA_SMAD5_CYTOSOL MRNA_SMAD5_CYTOSOL 
 0.0 ;% 51 MRNA_SMAD5_RIBOSOME_CYTOSOL MRNA_SMAD5_RIBOSOME_CYTOSOL 
 0.0 ;% 52 MRNA_SMAD5_START_RIBOSOME_CYTOSOL MRNA_SMAD5_START_RIBOSOME_CYTOSOL 
 0.0 ;% 53 SMAD5_CYTOSOL SMAD5_CYTOSOL 
 0.0 ;% 54 DNA_SMAD6_RNAP_NUCLEAR DNA_SMAD6_RNAP_NUCLEAR 
 0.0 ;% 55 MRNA_SMAD6_NUCLEAR MRNA_SMAD6_NUCLEAR 
 0.0 ;% 56 MRNA_SMAD6_NEXPORT_NUCLEAR MRNA_SMAD6_NEXPORT_NUCLEAR 
 0.0 ;% 57 MRNA_SMAD6_CYTOSOL MRNA_SMAD6_CYTOSOL 
 0.0 ;% 58 MRNA_SMAD6_RIBOSOME_CYTOSOL MRNA_SMAD6_RIBOSOME_CYTOSOL 
 0.0 ;% 59 MRNA_SMAD6_START_RIBOSOME_CYTOSOL MRNA_SMAD6_START_RIBOSOME_CYTOSOL 
 0.0 ;% 60 SMAD6_CYTOSOL SMAD6_CYTOSOL 
 0.0 ;% 61 DNA_SMAD7_RNAP_NUCLEAR DNA_SMAD7_RNAP_NUCLEAR 
 0.0 ;% 62 MRNA_SMAD7_NUCLEAR MRNA_SMAD7_NUCLEAR 
 0.0 ;% 63 MRNA_SMAD7_NEXPORT_NUCLEAR MRNA_SMAD7_NEXPORT_NUCLEAR 
 0.0 ;% 64 MRNA_SMAD7_CYTOSOL MRNA_SMAD7_CYTOSOL 
 0.0 ;% 65 MRNA_SMAD7_RIBOSOME_CYTOSOL MRNA_SMAD7_RIBOSOME_CYTOSOL 
 0.0 ;% 66 MRNA_SMAD7_START_RIBOSOME_CYTOSOL MRNA_SMAD7_START_RIBOSOME_CYTOSOL 
 0.0 ;% 67 SMAD7_CYTOSOL SMAD7_CYTOSOL 
 0.0 ;% 68 DNA_ENDOGLIN_RNAP_NUCLEAR DNA_ENDOGLIN_RNAP_NUCLEAR 
 0.0 ;% 69 MRNA_ENDOGLIN_NUCLEAR MRNA_ENDOGLIN_NUCLEAR 
 0.0 ;% 70 MRNA_ENDOGLIN_NEXPORT_NUCLEAR MRNA_ENDOGLIN_NEXPORT_NUCLEAR 
 0.0 ;% 71 MRNA_ENDOGLIN_CYTOSOL MRNA_ENDOGLIN_CYTOSOL 
 0.0 ;% 72 MRNA_ENDOGLIN_RIBOSOME_CYTOSOL MRNA_ENDOGLIN_RIBOSOME_CYTOSOL 
 0.0 ;% 73 MRNA_ENDOGLIN_START_RIBOSOME_CYTOSOL MRNA_ENDOGLIN_START_RIBOSOME_CYTOSOL 
 0.0 ;% 74 ENDOGLIN_CYTOSOL ENDOGLIN_CYTOSOL 
 0.0 ;% 75 DNA_ALK1_RNAP_NUCLEAR DNA_ALK1_RNAP_NUCLEAR 
 0.0 ;% 76 MRNA_ALK1_NUCLEAR MRNA_ALK1_NUCLEAR 
 0.0 ;% 77 MRNA_ALK1_NEXPORT_NUCLEAR MRNA_ALK1_NEXPORT_NUCLEAR 
 0.0 ;% 78 MRNA_ALK1_CYTOSOL MRNA_ALK1_CYTOSOL 
 0.0 ;% 79 MRNA_ALK1_RIBOSOME_CYTOSOL MRNA_ALK1_RIBOSOME_CYTOSOL 
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 0.0 ;% 80 MRNA_ALK1_START_RIBOSOME_CYTOSOL MRNA_ALK1_START_RIBOSOME_CYTOSOL 
 0.0 ;% 81 ALK1_CYTOSOL ALK1_CYTOSOL 
 0.0 ;% 82 DNA_ALK2_RNAP_NUCLEAR DNA_ALK2_RNAP_NUCLEAR 
 0.0 ;% 83 MRNA_ALK2_NUCLEAR MRNA_ALK2_NUCLEAR 
 0.0 ;% 84 MRNA_ALK2_NEXPORT_NUCLEAR MRNA_ALK2_NEXPORT_NUCLEAR 
 0.0 ;% 85 MRNA_ALK2_CYTOSOL MRNA_ALK2_CYTOSOL 
 0.0 ;% 86 MRNA_ALK2_RIBOSOME_CYTOSOL MRNA_ALK2_RIBOSOME_CYTOSOL 
 0.0 ;% 87 MRNA_ALK2_START_RIBOSOME_CYTOSOL MRNA_ALK2_START_RIBOSOME_CYTOSOL 
 0.0 ;% 88 ALK2_CYTOSOL ALK2_CYTOSOL 
 0.0 ;% 89 DNA_ALK3_RNAP_NUCLEAR DNA_ALK3_RNAP_NUCLEAR 
 0.0 ;% 90 MRNA_ALK3_NUCLEAR MRNA_ALK3_NUCLEAR 
 0.0 ;% 91 MRNA_ALK3_NEXPORT_NUCLEAR MRNA_ALK3_NEXPORT_NUCLEAR 
 0.0 ;% 92 MRNA_ALK3_CYTOSOL MRNA_ALK3_CYTOSOL 
 0.0 ;% 93 MRNA_ALK3_RIBOSOME_CYTOSOL MRNA_ALK3_RIBOSOME_CYTOSOL 
 0.0 ;% 94 MRNA_ALK3_START_RIBOSOME_CYTOSOL MRNA_ALK3_START_RIBOSOME_CYTOSOL 
 0.0 ;% 95 ALK3_CYTOSOL ALK3_CYTOSOL 
 0.0 ;% 96 DNA_ALK5_RNAP_NUCLEAR DNA_ALK5_RNAP_NUCLEAR 
 0.0 ;% 97 MRNA_ALK5_NUCLEAR MRNA_ALK5_NUCLEAR 
 0.0 ;% 98 MRNA_ALK5_NEXPORT_NUCLEAR MRNA_ALK5_NEXPORT_NUCLEAR 
 0.0 ;% 99 MRNA_ALK5_CYTOSOL MRNA_ALK5_CYTOSOL 
 0.0 ;% 100 MRNA_ALK5_RIBOSOME_CYTOSOL MRNA_ALK5_RIBOSOME_CYTOSOL 
 0.0 ;% 101 MRNA_ALK5_START_RIBOSOME_CYTOSOL MRNA_ALK5_START_RIBOSOME_CYTOSOL 
 0.0 ;% 102 ALK5_CYTOSOL ALK5_CYTOSOL 
 0.0 ;% 103 DNA_ALK6_RNAP_NUCLEAR DNA_ALK6_RNAP_NUCLEAR 
 0.0 ;% 104 MRNA_ALK6_NUCLEAR MRNA_ALK6_NUCLEAR 
 0.0 ;% 105 MRNA_ALK6_NEXPORT_NUCLEAR MRNA_ALK6_NEXPORT_NUCLEAR 
 0.0 ;% 106 MRNA_ALK6_CYTOSOL MRNA_ALK6_CYTOSOL 
 0.0 ;% 107 MRNA_ALK6_RIBOSOME_CYTOSOL MRNA_ALK6_RIBOSOME_CYTOSOL 
 0.0 ;% 108 MRNA_ALK6_START_RIBOSOME_CYTOSOL MRNA_ALK6_START_RIBOSOME_CYTOSOL 
 0.0 ;% 109 ALK6_CYTOSOL ALK6_CYTOSOL 
 0.0 ;% 110 DNA_SHC_RNAP_NUCLEAR DNA_SHC_RNAP_NUCLEAR 
 0.0 ;% 111 MRNA_SHC_NUCLEAR MRNA_SHC_NUCLEAR 
 0.0 ;% 112 MRNA_SHC_NEXPORT_NUCLEAR MRNA_SHC_NEXPORT_NUCLEAR 
 0.0 ;% 113 MRNA_SHC_CYTOSOL MRNA_SHC_CYTOSOL 
 0.0 ;% 114 MRNA_SHC_RIBOSOME_CYTOSOL MRNA_SHC_RIBOSOME_CYTOSOL 
 0.0 ;% 115 MRNA_SHC_START_RIBOSOME_CYTOSOL MRNA_SHC_START_RIBOSOME_CYTOSOL 
 0.0 ;% 116 SHC_CYTOSOL SHC_CYTOSOL 
 0.0 ;% 117 DNA_GRB2_RNAP_NUCLEAR DNA_GRB2_RNAP_NUCLEAR 
 0.0 ;% 118 MRNA_GRB2_NUCLEAR MRNA_GRB2_NUCLEAR 
 0.0 ;% 119 MRNA_GRB2_NEXPORT_NUCLEAR MRNA_GRB2_NEXPORT_NUCLEAR 
 0.0 ;% 120 MRNA_GRB2_CYTOSOL MRNA_GRB2_CYTOSOL 
 0.0 ;% 121 MRNA_GRB2_RIBOSOME_CYTOSOL MRNA_GRB2_RIBOSOME_CYTOSOL 
 0.0 ;% 122 MRNA_GRB2_START_RIBOSOME_CYTOSOL MRNA_GRB2_START_RIBOSOME_CYTOSOL 
 0.0 ;% 123 GRB2_CYTOSOL GRB2_CYTOSOL 
 0.0 ;% 124 DNA_SOS_RNAP_NUCLEAR DNA_SOS_RNAP_NUCLEAR 
 0.0 ;% 125 MRNA_SOS_NUCLEAR MRNA_SOS_NUCLEAR 
 0.0 ;% 126 MRNA_SOS_NEXPORT_NUCLEAR MRNA_SOS_NEXPORT_NUCLEAR 
 0.0 ;% 127 MRNA_SOS_CYTOSOL MRNA_SOS_CYTOSOL 
 0.0 ;% 128 MRNA_SOS_RIBOSOME_CYTOSOL MRNA_SOS_RIBOSOME_CYTOSOL 
 0.0 ;% 129 MRNA_SOS_START_RIBOSOME_CYTOSOL MRNA_SOS_START_RIBOSOME_CYTOSOL 
 0.0 ;% 130 SOS_CYTOSOL SOS_CYTOSOL 
 0.0 ;% 131 DNA_BMPRII_RNAP_NUCLEAR DNA_BMPRII_RNAP_NUCLEAR 
 0.0 ;% 132 MRNA_BMPRII_NUCLEAR MRNA_BMPRII_NUCLEAR 
 0.0 ;% 133 MRNA_BMPRII_NEXPORT_NUCLEAR MRNA_BMPRII_NEXPORT_NUCLEAR 
 0.0 ;% 134 MRNA_BMPRII_CYTOSOL MRNA_BMPRII_CYTOSOL 
 0.0 ;% 135 MRNA_BMPRII_RIBOSOME_CYTOSOL MRNA_BMPRII_RIBOSOME_CYTOSOL 
 0.0 ;% 136 MRNA_BMPRII_START_RIBOSOME_CYTOSOL MRNA_BMPRII_START_RIBOSOME_CYTOSOL 
 0.0 ;% 137 BMPRII_CYTOSOL BMPRII_CYTOSOL 
 0.0 ;% 138 DNA_TGFBRII_RNAP_NUCLEAR DNA_TGFBRII_RNAP_NUCLEAR 
 0.0 ;% 139 MRNA_TGFBRII_NUCLEAR MRNA_TGFBRII_NUCLEAR 
 0.0 ;% 140 MRNA_TGFBRII_NEXPORT_NUCLEAR MRNA_TGFBRII_NEXPORT_NUCLEAR 
 0.0 ;% 141 MRNA_TGFBRII_CYTOSOL MRNA_TGFBRII_CYTOSOL 
 0.0 ;% 142 MRNA_TGFBRII_RIBOSOME_CYTOSOL MRNA_TGFBRII_RIBOSOME_CYTOSOL 
 0.0 ;% 143 MRNA_TGFBRII_START_RIBOSOME_CYTOSOL MRNA_TGFBRII_START_RIBOSOME_CYTOSOL 
 0.0 ;% 144 TGFBRII_CYTOSOL TGFBRII_CYTOSOL 
 0.0 ;% 145 DNA_TGFBRIII_RNAP_NUCLEAR DNA_TGFBRIII_RNAP_NUCLEAR 
 0.0 ;% 146 MRNA_TGFBRIII_NUCLEAR MRNA_TGFBRIII_NUCLEAR 
 0.0 ;% 147 MRNA_TGFBRIII_NEXPORT_NUCLEAR MRNA_TGFBRIII_NEXPORT_NUCLEAR 
 0.0 ;% 148 MRNA_TGFBRIII_CYTOSOL MRNA_TGFBRIII_CYTOSOL 
 0.0 ;% 149 MRNA_TGFBRIII_RIBOSOME_CYTOSOL MRNA_TGFBRIII_RIBOSOME_CYTOSOL 
 0.0 ;% 150 MRNA_TGFBRIII_START_RIBOSOME_CYTOSOL MRNA_TGFBRIII_START_RIBOSOME_CYTOSOL 
 0.0 ;% 151 TGFBRIII_CYTOSOL TGFBRIII_CYTOSOL 
 0.0 ;% 152 DNA_MSX1_RNAP_NUCLEAR DNA_MSX1_RNAP_NUCLEAR 
 0.0 ;% 153 MRNA_MSX1_NUCLEAR MRNA_MSX1_NUCLEAR 
 0.0 ;% 154 MRNA_MSX1_NEXPORT_NUCLEAR MRNA_MSX1_NEXPORT_NUCLEAR 
 0.0 ;% 155 MRNA_MSX1_CYTOSOL MRNA_MSX1_CYTOSOL 
 0.0 ;% 156 MRNA_MSX1_RIBOSOME_CYTOSOL MRNA_MSX1_RIBOSOME_CYTOSOL 
 0.0 ;% 157 MRNA_MSX1_START_RIBOSOME_CYTOSOL MRNA_MSX1_START_RIBOSOME_CYTOSOL 
 0.0 ;% 158 MSX1_CYTOSOL MSX1_CYTOSOL 
 0.0 ;% 159 DNA_AP1_RNAP_NUCLEAR DNA_AP1_RNAP_NUCLEAR 
 0.0 ;% 160 MRNA_AP1_NUCLEAR MRNA_AP1_NUCLEAR 
 0.0 ;% 161 MRNA_AP1_NEXPORT_NUCLEAR MRNA_AP1_NEXPORT_NUCLEAR 
 0.0 ;% 162 MRNA_AP1_CYTOSOL MRNA_AP1_CYTOSOL 
 0.0 ;% 163 MRNA_AP1_RIBOSOME_CYTOSOL MRNA_AP1_RIBOSOME_CYTOSOL 
 0.0 ;% 164 MRNA_AP1_START_RIBOSOME_CYTOSOL MRNA_AP1_START_RIBOSOME_CYTOSOL 
 0.0 ;% 165 AP1_CYTOSOL AP1_CYTOSOL 
 0.0 ;% 166 DNA_GPASE_RNAP_NUCLEAR DNA_GPASE_RNAP_NUCLEAR 
 0.0 ;% 167 MRNA_GPASE_NUCLEAR MRNA_GPASE_NUCLEAR 
 0.0 ;% 168 MRNA_GPASE_NEXPORT_NUCLEAR MRNA_GPASE_NEXPORT_NUCLEAR 
 0.0 ;% 169 MRNA_GPASE_CYTOSOL MRNA_GPASE_CYTOSOL 
 0.0 ;% 170 MRNA_GPASE_RIBOSOME_CYTOSOL MRNA_GPASE_RIBOSOME_CYTOSOL 
 0.0 ;% 171 MRNA_GPASE_START_RIBOSOME_CYTOSOL MRNA_GPASE_START_RIBOSOME_CYTOSOL 
 0.0 ;% 172 GPASE_CYTOSOL GPASE_CYTOSOL 
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 0.0 ;% 173 DNA_TCF4_RNAP_NUCLEAR DNA_TCF4_RNAP_NUCLEAR 
 0.0 ;% 174 MRNA_TCF4_NUCLEAR MRNA_TCF4_NUCLEAR 
 0.0 ;% 175 MRNA_TCF4_NEXPORT_NUCLEAR MRNA_TCF4_NEXPORT_NUCLEAR 
 0.0 ;% 176 MRNA_TCF4_CYTOSOL MRNA_TCF4_CYTOSOL 
 0.0 ;% 177 MRNA_TCF4_RIBOSOME_CYTOSOL MRNA_TCF4_RIBOSOME_CYTOSOL 
 0.0 ;% 178 MRNA_TCF4_START_RIBOSOME_CYTOSOL MRNA_TCF4_START_RIBOSOME_CYTOSOL 
 0.0 ;% 179 TCF4_CYTOSOL TCF4_CYTOSOL 
 0.0 ;% 180 DNA_NOTCH1_RNAP_NUCLEAR DNA_NOTCH1_RNAP_NUCLEAR 
 0.0 ;% 181 MRNA_NOTCH1_NUCLEAR MRNA_NOTCH1_NUCLEAR 
 0.0 ;% 182 MRNA_NOTCH1_NEXPORT_NUCLEAR MRNA_NOTCH1_NEXPORT_NUCLEAR 
 0.0 ;% 183 MRNA_NOTCH1_CYTOSOL MRNA_NOTCH1_CYTOSOL 
 0.0 ;% 184 MRNA_NOTCH1_RIBOSOME_CYTOSOL MRNA_NOTCH1_RIBOSOME_CYTOSOL 
 0.0 ;% 185 MRNA_NOTCH1_START_RIBOSOME_CYTOSOL MRNA_NOTCH1_START_RIBOSOME_CYTOSOL 
 0.0 ;% 186 NOTCH1_CYTOSOL NOTCH1_CYTOSOL 
 0.0 ;% 187 DNA_SEL1_RNAP_NUCLEAR DNA_SEL1_RNAP_NUCLEAR 
 0.0 ;% 188 MRNA_SEL1_NUCLEAR MRNA_SEL1_NUCLEAR 
 0.0 ;% 189 MRNA_SEL1_NEXPORT_NUCLEAR MRNA_SEL1_NEXPORT_NUCLEAR 
 0.0 ;% 190 MRNA_SEL1_CYTOSOL MRNA_SEL1_CYTOSOL 
 0.0 ;% 191 MRNA_SEL1_RIBOSOME_CYTOSOL MRNA_SEL1_RIBOSOME_CYTOSOL 
 0.0 ;% 192 MRNA_SEL1_START_RIBOSOME_CYTOSOL MRNA_SEL1_START_RIBOSOME_CYTOSOL 
 0.0 ;% 193 SEL1_CYTOSOL SEL1_CYTOSOL 
 0.0 ;% 194 DNA_CSL_RNAP_NUCLEAR DNA_CSL_RNAP_NUCLEAR 
 0.0 ;% 195 MRNA_CSL_NUCLEAR MRNA_CSL_NUCLEAR 
 0.0 ;% 196 MRNA_CSL_NEXPORT_NUCLEAR MRNA_CSL_NEXPORT_NUCLEAR 
 0.0 ;% 197 MRNA_CSL_CYTOSOL MRNA_CSL_CYTOSOL 
 0.0 ;% 198 MRNA_CSL_RIBOSOME_CYTOSOL MRNA_CSL_RIBOSOME_CYTOSOL 
 0.0 ;% 199 MRNA_CSL_START_RIBOSOME_CYTOSOL MRNA_CSL_START_RIBOSOME_CYTOSOL 
 0.0 ;% 200 CSL_CYTOSOL CSL_CYTOSOL 
 0.0 ;% 201 DNA_RAS_RNAP_NUCLEAR DNA_RAS_RNAP_NUCLEAR 
 0.0 ;% 202 MRNA_RAS_NUCLEAR MRNA_RAS_NUCLEAR 
 0.0 ;% 203 MRNA_RAS_NEXPORT_NUCLEAR MRNA_RAS_NEXPORT_NUCLEAR 
 0.0 ;% 204 MRNA_RAS_CYTOSOL MRNA_RAS_CYTOSOL 
 0.0 ;% 205 MRNA_RAS_RIBOSOME_CYTOSOL MRNA_RAS_RIBOSOME_CYTOSOL 
 0.0 ;% 206 MRNA_RAS_START_RIBOSOME_CYTOSOL MRNA_RAS_START_RIBOSOME_CYTOSOL 
 0.0 ;% 207 RAS_CYTOSOL RAS_CYTOSOL 
 0.0 ;% 208 DNA_RAF_RNAP_NUCLEAR DNA_RAF_RNAP_NUCLEAR 
 0.0 ;% 209 MRNA_RAF_NUCLEAR MRNA_RAF_NUCLEAR 
 0.0 ;% 210 MRNA_RAF_NEXPORT_NUCLEAR MRNA_RAF_NEXPORT_NUCLEAR 
 0.0 ;% 211 MRNA_RAF_CYTOSOL MRNA_RAF_CYTOSOL 
 0.0 ;% 212 MRNA_RAF_RIBOSOME_CYTOSOL MRNA_RAF_RIBOSOME_CYTOSOL 
 0.0 ;% 213 MRNA_RAF_START_RIBOSOME_CYTOSOL MRNA_RAF_START_RIBOSOME_CYTOSOL 
 0.0 ;% 214 RAF_CYTOSOL RAF_CYTOSOL 
 0.0 ;% 215 DNA_MEK_RNAP_NUCLEAR DNA_MEK_RNAP_NUCLEAR 
 0.0 ;% 216 MRNA_MEK_NUCLEAR MRNA_MEK_NUCLEAR 
 0.0 ;% 217 MRNA_MEK_NEXPORT_NUCLEAR MRNA_MEK_NEXPORT_NUCLEAR 
 0.0 ;% 218 MRNA_MEK_CYTOSOL MRNA_MEK_CYTOSOL 
 0.0 ;% 219 MRNA_MEK_RIBOSOME_CYTOSOL MRNA_MEK_RIBOSOME_CYTOSOL 
 0.0 ;% 220 MRNA_MEK_START_RIBOSOME_CYTOSOL MRNA_MEK_START_RIBOSOME_CYTOSOL 
 0.0 ;% 221 MEK_CYTOSOL MEK_CYTOSOL 
 0.0 ;% 222 DNA_ERK_RNAP_NUCLEAR DNA_ERK_RNAP_NUCLEAR 
 0.0 ;% 223 MRNA_ERK_NUCLEAR MRNA_ERK_NUCLEAR 
 0.0 ;% 224 MRNA_ERK_NEXPORT_NUCLEAR MRNA_ERK_NEXPORT_NUCLEAR 
 0.0 ;% 225 MRNA_ERK_CYTOSOL MRNA_ERK_CYTOSOL 
 0.0 ;% 226 MRNA_ERK_RIBOSOME_CYTOSOL MRNA_ERK_RIBOSOME_CYTOSOL 
 0.0 ;% 227 MRNA_ERK_START_RIBOSOME_CYTOSOL MRNA_ERK_START_RIBOSOME_CYTOSOL 
 0.0 ;% 228 ERK_CYTOSOL ERK_CYTOSOL 
 0.0 ;% 229 DNA_SPK_RNAP_NUCLEAR DNA_SPK_RNAP_NUCLEAR 
 0.0 ;% 230 MRNA_SPK_NUCLEAR MRNA_SPK_NUCLEAR 
 0.0 ;% 231 MRNA_SPK_NEXPORT_NUCLEAR MRNA_SPK_NEXPORT_NUCLEAR 
 0.0 ;% 232 MRNA_SPK_CYTOSOL MRNA_SPK_CYTOSOL 
 0.0 ;% 233 MRNA_SPK_RIBOSOME_CYTOSOL MRNA_SPK_RIBOSOME_CYTOSOL 
 0.0 ;% 234 MRNA_SPK_START_RIBOSOME_CYTOSOL MRNA_SPK_START_RIBOSOME_CYTOSOL 
 0.0 ;% 235 SPK_CYTOSOL SPK_CYTOSOL 
 0.0 ;% 236 DNA_PLCG_RNAP_NUCLEAR DNA_PLCG_RNAP_NUCLEAR 
 0.0 ;% 237 MRNA_PLCG_NUCLEAR MRNA_PLCG_NUCLEAR 
 0.0 ;% 238 MRNA_PLCG_NEXPORT_NUCLEAR MRNA_PLCG_NEXPORT_NUCLEAR 
 0.0 ;% 239 MRNA_PLCG_CYTOSOL MRNA_PLCG_CYTOSOL 
 0.0 ;% 240 MRNA_PLCG_RIBOSOME_CYTOSOL MRNA_PLCG_RIBOSOME_CYTOSOL 
 0.0 ;% 241 MRNA_PLCG_START_RIBOSOME_CYTOSOL MRNA_PLCG_START_RIBOSOME_CYTOSOL 
 0.0 ;% 242 PLCG_CYTOSOL PLCG_CYTOSOL 
 0.0 ;% 243 DNA_RAF_PASE_RNAP_NUCLEAR DNA_RAF_PASE_RNAP_NUCLEAR 
 0.0 ;% 244 MRNA_RAF_PASE_NUCLEAR MRNA_RAF_PASE_NUCLEAR 
 0.0 ;% 245 MRNA_RAF_PASE_NEXPORT_NUCLEAR MRNA_RAF_PASE_NEXPORT_NUCLEAR 
 0.0 ;% 246 MRNA_RAF_PASE_CYTOSOL MRNA_RAF_PASE_CYTOSOL 
 0.0 ;% 247 MRNA_RAF_PASE_RIBOSOME_CYTOSOL MRNA_RAF_PASE_RIBOSOME_CYTOSOL 
 0.0 ;% 248 MRNA_RAF_PASE_START_RIBOSOME_CYTOSOL MRNA_RAF_PASE_START_RIBOSOME_CYTOSOL 
 0.0 ;% 249 RAF_PASE_CYTOSOL RAF_PASE_CYTOSOL 
 0.0 ;% 250 DNA_MEK_PASE_RNAP_NUCLEAR DNA_MEK_PASE_RNAP_NUCLEAR 
 0.0 ;% 251 MRNA_MEK_PASE_NUCLEAR MRNA_MEK_PASE_NUCLEAR 
 0.0 ;% 252 MRNA_MEK_PASE_NEXPORT_NUCLEAR MRNA_MEK_PASE_NEXPORT_NUCLEAR 
 0.0 ;% 253 MRNA_MEK_PASE_CYTOSOL MRNA_MEK_PASE_CYTOSOL 
 0.0 ;% 254 MRNA_MEK_PASE_RIBOSOME_CYTOSOL MRNA_MEK_PASE_RIBOSOME_CYTOSOL 
 0.0 ;% 255 MRNA_MEK_PASE_START_RIBOSOME_CYTOSOL
 MRNA_MEK_PASE_START_RIBOSOME_CYTOSOL 
 0.0 ;% 256 MEK_PASE_CYTOSOL MEK_PASE_CYTOSOL 
 0.0 ;% 257 DNA_ERK_PASE_RNAP_NUCLEAR DNA_ERK_PASE_RNAP_NUCLEAR 
 0.0 ;% 258 MRNA_ERK_PASE_NUCLEAR MRNA_ERK_PASE_NUCLEAR 
 0.0 ;% 259 MRNA_ERK_PASE_NEXPORT_NUCLEAR MRNA_ERK_PASE_NEXPORT_NUCLEAR 
 0.0 ;% 260 MRNA_ERK_PASE_CYTOSOL MRNA_ERK_PASE_CYTOSOL 
 0.0 ;% 261 MRNA_ERK_PASE_RIBOSOME_CYTOSOL MRNA_ERK_PASE_RIBOSOME_CYTOSOL 
 0.0 ;% 262 MRNA_ERK_PASE_START_RIBOSOME_CYTOSOL MRNA_ERK_PASE_START_RIBOSOME_CYTOSOL 
 0.0 ;% 263 ERK_PASE_CYTOSOL ERK_PASE_CYTOSOL 
 0.0 ;% 264 DNA_SP1_RNAP_NUCLEAR DNA_SP1_RNAP_NUCLEAR 
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 0.0 ;% 265 MRNA_SP1_NUCLEAR MRNA_SP1_NUCLEAR 
 0.0 ;% 266 MRNA_SP1_NEXPORT_NUCLEAR MRNA_SP1_NEXPORT_NUCLEAR 
 0.0 ;% 267 MRNA_SP1_CYTOSOL MRNA_SP1_CYTOSOL 
 0.0 ;% 268 MRNA_SP1_RIBOSOME_CYTOSOL MRNA_SP1_RIBOSOME_CYTOSOL 
 0.0 ;% 269 MRNA_SP1_START_RIBOSOME_CYTOSOL MRNA_SP1_START_RIBOSOME_CYTOSOL 
 0.0 ;% 270 SP1_CYTOSOL SP1_CYTOSOL 
 0.0 ;% 271 DNA_CJUN_RNAP_NUCLEAR DNA_CJUN_RNAP_NUCLEAR 
 0.0 ;% 272 MRNA_CJUN_NUCLEAR MRNA_CJUN_NUCLEAR 
 0.0 ;% 273 MRNA_CJUN_NEXPORT_NUCLEAR MRNA_CJUN_NEXPORT_NUCLEAR 
 0.0 ;% 274 MRNA_CJUN_CYTOSOL MRNA_CJUN_CYTOSOL 
 0.0 ;% 275 MRNA_CJUN_RIBOSOME_CYTOSOL MRNA_CJUN_RIBOSOME_CYTOSOL 
 0.0 ;% 276 MRNA_CJUN_START_RIBOSOME_CYTOSOL MRNA_CJUN_START_RIBOSOME_CYTOSOL 
 0.0 ;% 277 CJUN_CYTOSOL CJUN_CYTOSOL 
 0.0 ;% 278 DNA_CPLA2_RNAP_NUCLEAR DNA_CPLA2_RNAP_NUCLEAR 
 0.0 ;% 279 MRNA_CPLA2_NUCLEAR MRNA_CPLA2_NUCLEAR 
 0.0 ;% 280 MRNA_CPLA2_NEXPORT_NUCLEAR MRNA_CPLA2_NEXPORT_NUCLEAR 
 0.0 ;% 281 MRNA_CPLA2_CYTOSOL MRNA_CPLA2_CYTOSOL 
 0.0 ;% 282 MRNA_CPLA2_RIBOSOME_CYTOSOL MRNA_CPLA2_RIBOSOME_CYTOSOL 
 0.0 ;% 283 MRNA_CPLA2_START_RIBOSOME_CYTOSOL MRNA_CPLA2_START_RIBOSOME_CYTOSOL 
 0.0 ;% 284 CPLA2_CYTOSOL CPLA2_CYTOSOL 
 0.0 ;% 285 DNA_GSK3B_RNAP_NUCLEAR DNA_GSK3B_RNAP_NUCLEAR 
 0.0 ;% 286 MRNA_GSK3B_NUCLEAR MRNA_GSK3B_NUCLEAR 
 0.0 ;% 287 MRNA_GSK3B_NEXPORT_NUCLEAR MRNA_GSK3B_NEXPORT_NUCLEAR 
 0.0 ;% 288 MRNA_GSK3B_CYTOSOL MRNA_GSK3B_CYTOSOL 
 0.0 ;% 289 MRNA_GSK3B_RIBOSOME_CYTOSOL MRNA_GSK3B_RIBOSOME_CYTOSOL 
 0.0 ;% 290 MRNA_GSK3B_START_RIBOSOME_CYTOSOL MRNA_GSK3B_START_RIBOSOME_CYTOSOL 
 0.0 ;% 291 GSK3B_CYTOSOL GSK3B_CYTOSOL 
 0.0 ;% 292 DNA_CK1_RNAP_NUCLEAR DNA_CK1_RNAP_NUCLEAR 
 0.0 ;% 293 MRNA_CK1_NUCLEAR MRNA_CK1_NUCLEAR 
 0.0 ;% 294 MRNA_CK1_NEXPORT_NUCLEAR MRNA_CK1_NEXPORT_NUCLEAR 
 0.0 ;% 295 MRNA_CK1_CYTOSOL MRNA_CK1_CYTOSOL 
 0.0 ;% 296 MRNA_CK1_RIBOSOME_CYTOSOL MRNA_CK1_RIBOSOME_CYTOSOL 
 0.0 ;% 297 MRNA_CK1_START_RIBOSOME_CYTOSOL MRNA_CK1_START_RIBOSOME_CYTOSOL 
 0.0 ;% 298 CK1_CYTOSOL CK1_CYTOSOL 
 0.0 ;% 299 DNA_APC_RNAP_NUCLEAR DNA_APC_RNAP_NUCLEAR 
 0.0 ;% 300 MRNA_APC_NUCLEAR MRNA_APC_NUCLEAR 
 0.0 ;% 301 MRNA_APC_NEXPORT_NUCLEAR MRNA_APC_NEXPORT_NUCLEAR 
 0.0 ;% 302 MRNA_APC_CYTOSOL MRNA_APC_CYTOSOL 
 0.0 ;% 303 MRNA_APC_RIBOSOME_CYTOSOL MRNA_APC_RIBOSOME_CYTOSOL 
 0.0 ;% 304 MRNA_APC_START_RIBOSOME_CYTOSOL MRNA_APC_START_RIBOSOME_CYTOSOL 
 0.0 ;% 305 APC_CYTOSOL APC_CYTOSOL 
 0.0 ;% 306 DNA_LRP_RNAP_NUCLEAR DNA_LRP_RNAP_NUCLEAR 
 0.0 ;% 307 MRNA_LRP_NUCLEAR MRNA_LRP_NUCLEAR 
 0.0 ;% 308 MRNA_LRP_NEXPORT_NUCLEAR MRNA_LRP_NEXPORT_NUCLEAR 
 0.0 ;% 309 MRNA_LRP_CYTOSOL MRNA_LRP_CYTOSOL 
 0.0 ;% 310 MRNA_LRP_RIBOSOME_CYTOSOL MRNA_LRP_RIBOSOME_CYTOSOL 
 0.0 ;% 311 MRNA_LRP_START_RIBOSOME_CYTOSOL MRNA_LRP_START_RIBOSOME_CYTOSOL 
 0.0 ;% 312 LRP_CYTOSOL LRP_CYTOSOL 
 0.0 ;% 313 DNA_AXIN_RNAP_NUCLEAR DNA_AXIN_RNAP_NUCLEAR 
 0.0 ;% 314 MRNA_AXIN_NUCLEAR MRNA_AXIN_NUCLEAR 
 0.0 ;% 315 MRNA_AXIN_NEXPORT_NUCLEAR MRNA_AXIN_NEXPORT_NUCLEAR 
 0.0 ;% 316 MRNA_AXIN_CYTOSOL MRNA_AXIN_CYTOSOL 
 0.0 ;% 317 MRNA_AXIN_RIBOSOME_CYTOSOL MRNA_AXIN_RIBOSOME_CYTOSOL 
 0.0 ;% 318 MRNA_AXIN_START_RIBOSOME_CYTOSOL MRNA_AXIN_START_RIBOSOME_CYTOSOL 
 0.0 ;% 319 AXIN_CYTOSOL AXIN_CYTOSOL 
 0.0 ;% 320 DNA_PKC_RNAP_NUCLEAR DNA_PKC_RNAP_NUCLEAR 
 0.0 ;% 321 MRNA_PKC_NUCLEAR MRNA_PKC_NUCLEAR 
 0.0 ;% 322 MRNA_PKC_NEXPORT_NUCLEAR MRNA_PKC_NEXPORT_NUCLEAR 
 0.0 ;% 323 MRNA_PKC_CYTOSOL MRNA_PKC_CYTOSOL 
 0.0 ;% 324 MRNA_PKC_RIBOSOME_CYTOSOL MRNA_PKC_RIBOSOME_CYTOSOL 
 0.0 ;% 325 MRNA_PKC_START_RIBOSOME_CYTOSOL MRNA_PKC_START_RIBOSOME_CYTOSOL 
 0.0 ;% 326 PKC_CYTOSOL PKC_CYTOSOL 
 0.0 ;% 327 DNA_BTRCP_RNAP_NUCLEAR DNA_BTRCP_RNAP_NUCLEAR 
 0.0 ;% 328 MRNA_BTRCP_NUCLEAR MRNA_BTRCP_NUCLEAR 
 0.0 ;% 329 MRNA_BTRCP_NEXPORT_NUCLEAR MRNA_BTRCP_NEXPORT_NUCLEAR 
 0.0 ;% 330 MRNA_BTRCP_CYTOSOL MRNA_BTRCP_CYTOSOL 
 0.0 ;% 331 MRNA_BTRCP_RIBOSOME_CYTOSOL MRNA_BTRCP_RIBOSOME_CYTOSOL 
 0.0 ;% 332 MRNA_BTRCP_START_RIBOSOME_CYTOSOL MRNA_BTRCP_START_RIBOSOME_CYTOSOL 
 0.0 ;% 333 BTRCP_CYTOSOL BTRCP_CYTOSOL 
 0.0 ;% 334 DNA_FRIZZLED_RNAP_NUCLEAR DNA_FRIZZLED_RNAP_NUCLEAR 
 0.0 ;% 335 MRNA_FRIZZLED_NUCLEAR MRNA_FRIZZLED_NUCLEAR 
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 0.0 ;% 387 MRNA_PI3K_RIBOSOME_CYTOSOL MRNA_PI3K_RIBOSOME_CYTOSOL 
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 0.0 ;% 389 PI3K_CYTOSOL PI3K_CYTOSOL 
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 0.0 ;% 571 PSMAD2_SMAD4_NEXPORT_NUCLEAR PSMAD2_SMAD4_NEXPORT_NUCLEAR 
 0.0 ;% 572 PSMAD3_SMAD4_NUCLEAR PSMAD3_SMAD4_NUCLEAR 
 0.0 ;% 573 DNA_LEF1_PSMAD3_SMAD4_NUCLEAR DNA_LEF1_PSMAD3_SMAD4_NUCLEAR 
 0.0 ;% 574 DNA_LEF1_PSMAD3_SMAD4_RNAP_NUCLEAR DNA_LEF1_PSMAD3_SMAD4_RNAP_NUCLEAR 
 0.0 ;% 575 PSMAD3_CYTOSOL PSMAD3_CYTOSOL 
 0.0 ;% 576 PSMAD3_SMAD4_CYTOSOL PSMAD3_SMAD4_CYTOSOL 
 0.0 ;% 577 PSMAD3_SMAD4_NIMPORT_NUCLEAR PSMAD3_SMAD4_NIMPORT_NUCLEAR 
 0.0 ;% 578 PSMAD3_SMAD4_NEXPORT_NUCLEAR PSMAD3_SMAD4_NEXPORT_NUCLEAR 
 0.0 ;% 579 SNAIL_NUCLEAR SNAIL_NUCLEAR 
 0.0 ;% 580 DNA_YREG1_SNAIL_NUCLEAR DNA_YREG1_SNAIL_NUCLEAR 
 0.0 ;% 581 SNAIL_NIMPORT_NUCLEAR SNAIL_NIMPORT_NUCLEAR 
 0.0 ;% 582 SNAIL_NEXPORT_NUCLEAR SNAIL_NEXPORT_NUCLEAR 
 0.0 ;% 583 SLUG_NUCLEAR SLUG_NUCLEAR 
 0.0 ;% 584 DNA_YREG1_SLUG_NUCLEAR DNA_YREG1_SLUG_NUCLEAR 
 0.0 ;% 585 SLUG_NIMPORT_NUCLEAR SLUG_NIMPORT_NUCLEAR 
 0.0 ;% 586 SLUG_NEXPORT_NUCLEAR SLUG_NEXPORT_NUCLEAR 
 0.0 ;% 587 DNA_YREG1_TWIST_NUCLEAR DNA_YREG1_TWIST_NUCLEAR 
 0.0 ;% 588 DNA_TGFBRIII_P_SP1_NUCLEAR DNA_TGFBRIII_P_SP1_NUCLEAR 
 0.0 ;% 589 DNA_TGFBRIII_P_SP1_PSMAD3_SMAD4_NUCLEAR
 DNA_TGFBRIII_P_SP1_PSMAD3_SMAD4_NUCLEAR 
 0.0 ;% 590 DNA_TGFBRIII_P_SP1_PSMAD3_SMAD4_RNAP_NUCLEAR
 DNA_TGFBRIII_P_SP1_PSMAD3_SMAD4_RNAP_NUCLEAR 
 0.0 ;% 591 MRNA_CREB_NUCLEAR MRNA_CREB_NUCLEAR 
 0.0 ;% 592 MRNA_CREB_NEXPORT_NUCLEAR MRNA_CREB_NEXPORT_NUCLEAR 
 0.0 ;% 593 MRNA_CREB_CYTOSOL MRNA_CREB_CYTOSOL 
 0.0 ;% 594 MRNA_CREB_RIBOSOME_CYTOSOL MRNA_CREB_RIBOSOME_CYTOSOL 
 0.0 ;% 595 MRNA_CREB_START_RIBOSOME_CYTOSOL MRNA_CREB_START_RIBOSOME_CYTOSOL 
 0.0 ;% 596 CREB_CYTOSOL CREB_CYTOSOL 
 0.0 ;% 597 DNA_CREB_SNAIL_NUCLEAR DNA_CREB_SNAIL_NUCLEAR 
 0.0 ;% 598 DNA_CREB_SLUG_NUCLEAR DNA_CREB_SLUG_NUCLEAR 
 0.0 ;% 599 MRNA_TGFB3_NUCLEAR MRNA_TGFB3_NUCLEAR 
 0.0 ;% 600 MRNA_TGFB3_NEXPORT_NUCLEAR MRNA_TGFB3_NEXPORT_NUCLEAR 
 0.0 ;% 601 MRNA_TGFB3_CYTOSOL MRNA_TGFB3_CYTOSOL 
 0.0 ;% 602 MRNA_TGFB3_RIBOSOME_CYTOSOL MRNA_TGFB3_RIBOSOME_CYTOSOL 
 0.0 ;% 603 MRNA_TGFB3_START_RIBOSOME_CYTOSOL MRNA_TGFB3_START_RIBOSOME_CYTOSOL 
 0.0 ;% 604 DNA_TGFB3_YREG1_NUCLEAR DNA_TGFB3_YREG1_NUCLEAR 
 0.0 ;% 605 DNA_TGFB3_SNAIL_NUCLEAR DNA_TGFB3_SNAIL_NUCLEAR 
 0.0 ;% 606 DNA_TGFB3_SNAIL_BCATENIN_TCF4_NUCLEAR DNA_TGFB3_SNAIL_BCATENIN_TCF4_NUCLEAR 
 0.0 ;% 607 DNA_TGFB3_SNAIL_BCATENIN_TCF4_RNAP_NUCLEAR
 DNA_TGFB3_SNAIL_BCATENIN_TCF4_RNAP_NUCLEAR 
 0.0 ;% 608 DNA_TGFB3_SLUG_NUCLEAR DNA_TGFB3_SLUG_NUCLEAR 
 0.0 ;% 609 DNA_TGFB3_SLUG_BCATENIN_TCF4_NUCLEAR DNA_TGFB3_SLUG_BCATENIN_TCF4_NUCLEAR 
 0.0 ;% 610 DNA_TGFB3_SLUG_BCATENIN_TCF4_RNAP_NUCLEAR
 DNA_TGFB3_SLUG_BCATENIN_TCF4_RNAP_NUCLEAR 
 0.0 ;% 611 MRNA_TGFB2_NUCLEAR MRNA_TGFB2_NUCLEAR 
 0.0 ;% 612 MRNA_TGFB2_NEXPORT_NUCLEAR MRNA_TGFB2_NEXPORT_NUCLEAR 
 0.0 ;% 613 MRNA_TGFB2_CYTOSOL MRNA_TGFB2_CYTOSOL 
 0.0 ;% 614 MRNA_TGFB2_RIBOSOME_CYTOSOL MRNA_TGFB2_RIBOSOME_CYTOSOL 
 0.0 ;% 615 MRNA_TGFB2_START_RIBOSOME_CYTOSOL MRNA_TGFB2_START_RIBOSOME_CYTOSOL 
 0.0 ;% 616 PAX3_NUCLEAR PAX3_NUCLEAR 
 0.0 ;% 617 DNA_TGFB2_PAX3_NUCLEAR DNA_TGFB2_PAX3_NUCLEAR 
 0.0 ;% 618 PSMAD1_SMAD4_NUCLEAR PSMAD1_SMAD4_NUCLEAR 
 0.0 ;% 619 DNA_TGFB2_PAX3_PSMAD1_SMAD4_NUCLEAR DNA_TGFB2_PAX3_PSMAD1_SMAD4_NUCLEAR 
 0.0 ;% 620 DNA_TGFB2_PAX3_PSMAD1_SMAD4_RNAP_NUCLEAR
 DNA_TGFB2_PAX3_PSMAD1_SMAD4_RNAP_NUCLEAR 
 0.0 ;% 621 PAX3_CYTOSOL PAX3_CYTOSOL 
 0.0 ;% 622 PAX3_NIMPORT_NUCLEAR PAX3_NIMPORT_NUCLEAR 
 0.0 ;% 623 PAX3_NEXPORT_NUCLEAR PAX3_NEXPORT_NUCLEAR 
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 0.0 ;% 624 PSMAD1_CYTOSOL PSMAD1_CYTOSOL 
 0.0 ;% 625 PSMAD1_SMAD4_CYTOSOL PSMAD1_SMAD4_CYTOSOL 
 0.0 ;% 626 PSMAD1_SMAD4_NIMPORT_NUCLEAR PSMAD1_SMAD4_NIMPORT_NUCLEAR 
 0.0 ;% 627 PSMAD1_SMAD4_NEXPORT_NUCLEAR PSMAD1_SMAD4_NEXPORT_NUCLEAR 
 0.0 ;% 628 MRNA_VIMENTIN_NUCLEAR MRNA_VIMENTIN_NUCLEAR 
 0.0 ;% 629 MRNA_VIMENTIN_NEXPORT_NUCLEAR MRNA_VIMENTIN_NEXPORT_NUCLEAR 
 0.0 ;% 630 MRNA_VIMENTIN_CYTOSOL MRNA_VIMENTIN_CYTOSOL 
 0.0 ;% 631 MRNA_VIMENTIN_RIBOSOME_CYTOSOL MRNA_VIMENTIN_RIBOSOME_CYTOSOL 
 0.0 ;% 632 MRNA_VIMENTIN_START_RIBOSOME_CYTOSOL MRNA_VIMENTIN_START_RIBOSOME_CYTOSOL 
 0.0 ;% 633 VIMENTIN_CYTOSOL VIMENTIN_CYTOSOL 
 0.0 ;% 634 DNA_VIMENTIN_BCATENIN_LEF1_NUCLEAR DNA_VIMENTIN_BCATENIN_LEF1_NUCLEAR 
 0.0 ;% 635 DNA_VIMENTIN_BCATENIN_LEF1_RNAP_NUCLEAR
 DNA_VIMENTIN_BCATENIN_LEF1_RNAP_NUCLEAR 
 0.0 ;% 636 LEF1_NUCLEAR LEF1_NUCLEAR 
 0.0 ;% 637 DNA_VIMENTIN_LEF1_NUCLEAR DNA_VIMENTIN_LEF1_NUCLEAR 
 0.0 ;% 638 DNA_VIMENTIN_LEF1_PSMAD2_SMAD4_NUCLEAR
 DNA_VIMENTIN_LEF1_PSMAD2_SMAD4_NUCLEAR 
 0.0 ;% 639 DNA_VIMENTIN_LEF1_PSMAD2_SMAD4_RNAP_NUCLEAR
 DNA_VIMENTIN_LEF1_PSMAD2_SMAD4_RNAP_NUCLEAR 
 0.0 ;% 640 LEF1_NIMPORT_NUCLEAR LEF1_NIMPORT_NUCLEAR 
 0.0 ;% 641 LEF1_NEXPORT_NUCLEAR LEF1_NEXPORT_NUCLEAR 
 0.0 ;% 642 DNA_VIMENTIN_LEF1_PSMAD3_SMAD4_NUCLEAR
 DNA_VIMENTIN_LEF1_PSMAD3_SMAD4_NUCLEAR 
 0.0 ;% 643 DNA_VIMENTIN_LEF1_PSMAD3_SMAD4_RNAP_NUCLEAR
 DNA_VIMENTIN_LEF1_PSMAD3_SMAD4_RNAP_NUCLEAR 
 0.0 ;% 644 DNA_ECADHERIN_NFATC1_NUCLEAR DNA_ECADHERIN_NFATC1_NUCLEAR 
 0.0 ;% 645 DNA_ECADHERIN_NFATC1_RNAP_NUCLEAR DNA_ECADHERIN_NFATC1_RNAP_NUCLEAR 
 0.0 ;% 646 DNA_ECADHERIN_SNAIL_NUCLEAR DNA_ECADHERIN_SNAIL_NUCLEAR 
 0.0 ;% 647 DNA_ECADHERIN_SLUG_NUCLEAR DNA_ECADHERIN_SLUG_NUCLEAR 
 0.0 ;% 648 DNA_ECADHERIN_TWIST_NUCLEAR DNA_ECADHERIN_TWIST_NUCLEAR 
 0.0 ;% 649 PSMAD2_SMAD4_LEF1_NUCLEAR PSMAD2_SMAD4_LEF1_NUCLEAR 
 0.0 ;% 650 DNA_ECADHERIN_PSMAD2_SMAD4_LEF1_NUCLEAR
 DNA_ECADHERIN_PSMAD2_SMAD4_LEF1_NUCLEAR 
 0.0 ;% 651 PSMAD2_SMAD4_LEF1_CYTOSOL PSMAD2_SMAD4_LEF1_CYTOSOL 
 0.0 ;% 652 PSMAD2_SMAD4_LEF1_NIMPORT_NUCLEAR PSMAD2_SMAD4_LEF1_NIMPORT_NUCLEAR 
 0.0 ;% 653 PSMAD2_SMAD4_LEF1_NEXPORT_NUCLEAR PSMAD2_SMAD4_LEF1_NEXPORT_NUCLEAR 
 0.0 ;% 654 DNA_VECADHERIN_NFATC1_NUCLEAR DNA_VECADHERIN_NFATC1_NUCLEAR 
 0.0 ;% 655 DNA_VECADHERIN_NFATC1_RNAP_NUCLEAR DNA_VECADHERIN_NFATC1_RNAP_NUCLEAR 
 0.0 ;% 656 DNA_VECADHERIN_SNAIL_NUCLEAR DNA_VECADHERIN_SNAIL_NUCLEAR 
 0.0 ;% 657 DNA_VECADHERIN_SLUG_NUCLEAR DNA_VECADHERIN_SLUG_NUCLEAR 
 0.0 ;% 658 DNA_VECADHERIN_TWIST_NUCLEAR DNA_VECADHERIN_TWIST_NUCLEAR 
 0.0 ;% 659 DNA_VECADHERIN_LEF1_NUCLEAR DNA_VECADHERIN_LEF1_NUCLEAR 
 0.0 ;% 660 MRNA_DSCR1_NUCLEAR MRNA_DSCR1_NUCLEAR 
 0.0 ;% 661 MRNA_DSCR1_NEXPORT_NUCLEAR MRNA_DSCR1_NEXPORT_NUCLEAR 
 0.0 ;% 662 MRNA_DSCR1_CYTOSOL MRNA_DSCR1_CYTOSOL 
 0.0 ;% 663 MRNA_DSCR1_RIBOSOME_CYTOSOL MRNA_DSCR1_RIBOSOME_CYTOSOL 
 0.0 ;% 664 MRNA_DSCR1_START_RIBOSOME_CYTOSOL MRNA_DSCR1_START_RIBOSOME_CYTOSOL 
 0.0 ;% 665 _CYTOSOL DSCR1_CYTOSOL 
 0.0 ;% 666 DNA_DSCR1_NFATC1_NUCLEAR DNA_DSCR1_NFATC1_NUCLEAR 
 0.0 ;% 667 DNA_DSCR1_NFATC1_RNAP_NUCLEAR DNA_DSCR1_NFATC1_RNAP_NUCLEAR 
 0.0 ;% 668 MRNA_SOX9_NUCLEAR MRNA_SOX9_NUCLEAR 
 0.0 ;% 669 MRNA_SOX9_NEXPORT_NUCLEAR MRNA_SOX9_NEXPORT_NUCLEAR 
 0.0 ;% 670 MRNA_SOX9_CYTOSOL MRNA_SOX9_CYTOSOL 
 0.0 ;% 671 MRNA_SOX9_RIBOSOME_CYTOSOL MRNA_SOX9_RIBOSOME_CYTOSOL 
 0.0 ;% 672 MRNA_SOX9_START_RIBOSOME_CYTOSOL MRNA_SOX9_START_RIBOSOME_CYTOSOL 
 0.0 ;% 673 SOX9_CYTOSOL SOX9_CYTOSOL 
 0.0 ;% 674 GATA_FOG2_NUCLEAR GATA_FOG2_NUCLEAR 
 0.0 ;% 675 DNA_SOX9_GATA_FOG2_NUCLEAR DNA_SOX9_GATA_FOG2_NUCLEAR 
 0.0 ;% 676 PSMAD5_SMAD4_NUCLEAR PSMAD5_SMAD4_NUCLEAR 
 0.0 ;% 677 DNA_SOX9_GATA_FOG2_PSMAD5_SMAD4_NUCLEAR
 DNA_SOX9_GATA_FOG2_PSMAD5_SMAD4_NUCLEAR 
 0.0 ;% 678 DNA_SOX9_GATA_FOG2_PSMAD5_SMAD4_RNAP_NUCLEAR
 DNA_SOX9_GATA_FOG2_PSMAD5_SMAD4_RNAP_NUCLEAR 
 0.0 ;% 679 GATA_FOG2_NIMPORT_NUCLEAR GATA_FOG2_NIMPORT_NUCLEAR 
 0.0 ;% 680 GATA_FOG2_NEXPORT_NUCLEAR GATA_FOG2_NEXPORT_NUCLEAR 
 0.0 ;% 681 PSMAD5_CYTOSOL PSMAD5_CYTOSOL 
 0.0 ;% 682 PSMAD5_SMAD4_CYTOSOL PSMAD5_SMAD4_CYTOSOL 
 0.0 ;% 683 PSMAD5_SMAD4_NIMPORT_NUCLEAR PSMAD5_SMAD4_NIMPORT_NUCLEAR 
 0.0 ;% 684 PSMAD5_SMAD4_NEXPORT_NUCLEAR PSMAD5_SMAD4_NEXPORT_NUCLEAR 
 0.0 ;% 685 MRNA_PAX3_NUCLEAR MRNA_PAX3_NUCLEAR 
 0.0 ;% 686 MRNA_PAX3_NEXPORT_NUCLEAR MRNA_PAX3_NEXPORT_NUCLEAR 
 0.0 ;% 687 MRNA_PAX3_CYTOSOL MRNA_PAX3_CYTOSOL 
 0.0 ;% 688 MRNA_PAX3_RIBOSOME_CYTOSOL MRNA_PAX3_RIBOSOME_CYTOSOL 
 0.0 ;% 689 MRNA_PAX3_START_RIBOSOME_CYTOSOL MRNA_PAX3_START_RIBOSOME_CYTOSOL 
 0.0 ;% 690 DNA_PAX3_PSMAD1_SMAD4_NUCLEAR DNA_PAX3_PSMAD1_SMAD4_NUCLEAR 
 0.0 ;% 691 DNA_PAX3_PSMAD1_SMAD4_RNAP_NUCLEAR DNA_PAX3_PSMAD1_SMAD4_RNAP_NUCLEAR 
 0.0 ;% 692 MRNA_MMP9_NUCLEAR MRNA_MMP9_NUCLEAR 
 0.0 ;% 693 MRNA_MMP9_NEXPORT_NUCLEAR MRNA_MMP9_NEXPORT_NUCLEAR 
 0.0 ;% 694 MRNA_MMP9_CYTOSOL MRNA_MMP9_CYTOSOL 
 0.0 ;% 695 MRNA_MMP9_RIBOSOME_CYTOSOL MRNA_MMP9_RIBOSOME_CYTOSOL 
 0.0 ;% 696 MRNA_MMP9_START_RIBOSOME_CYTOSOL MRNA_MMP9_START_RIBOSOME_CYTOSOL 
 0.0 ;% 697 MMP9_CYTOSOL MMP9_CYTOSOL 
 0.0 ;% 698 DNA_MMP9_P_AP1_NUCLEAR DNA_MMP9_P_AP1_NUCLEAR 
 0.0 ;% 699 DNA_MMP9_P_AP1_RNAP_NUCLEAR DNA_MMP9_P_AP1_RNAP_NUCLEAR 
 0.0 ;% 700 DNA_MMP9_TBX20_NUCLEAR DNA_MMP9_TBX20_NUCLEAR 
 0.0 ;% 701 DNA_MMP9_TBX20_PSMAD5_SMAD4_NUCLEAR DNA_MMP9_TBX20_PSMAD5_SMAD4_NUCLEAR 
 0.0 ;% 702 DNA_MMP9_TBX20_PSMAD5_SMAD4_RNAP_NUCLEAR
 DNA_MMP9_TBX20_PSMAD5_SMAD4_RNAP_NUCLEAR 
 0.0 ;% 703 MRNA_NFATC1_NUCLEAR MRNA_NFATC1_NUCLEAR 
 0.0 ;% 704 MRNA_NFATC1_NEXPORT_NUCLEAR MRNA_NFATC1_NEXPORT_NUCLEAR 
 0.0 ;% 705 MRNA_NFATC1_CYTOSOL MRNA_NFATC1_CYTOSOL 
 0.0 ;% 706 MRNA_NFATC1_RIBOSOME_CYTOSOL MRNA_NFATC1_RIBOSOME_CYTOSOL 
 0.0 ;% 707 MRNA_NFATC1_START_RIBOSOME_CYTOSOL MRNA_NFATC1_START_RIBOSOME_CYTOSOL 
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 0.0 ;% 708 DNA_NFATC1_P_AP1_NUCLEAR DNA_NFATC1_P_AP1_NUCLEAR 
 0.0 ;% 709 DNA_NFATC1_P_AP1_RNAP_NUCLEAR DNA_NFATC1_P_AP1_RNAP_NUCLEAR 
 0.0 ;% 710 DNA_NFATC1_P_SP1_NUCLEAR DNA_NFATC1_P_SP1_NUCLEAR 
 0.0 ;% 711 DNA_NFATC1_P_SP1_RNAP_NUCLEAR DNA_NFATC1_P_SP1_RNAP_NUCLEAR 
 0.0 ;% 712 DNA_NFATC1_PSMAD2_SMAD4_NUCLEAR DNA_NFATC1_PSMAD2_SMAD4_NUCLEAR 
 0.0 ;% 713 DNA_NFATC1_PSMAD2_SMAD4_RNAP_NUCLEAR DNA_NFATC1_PSMAD2_SMAD4_RNAP_NUCLEAR 
 0.0 ;% 714 DNA_NFATC1_PSMAD3_SMAD4_NUCLEAR DNA_NFATC1_PSMAD3_SMAD4_NUCLEAR 
 0.0 ;% 715 DNA_NFATC1_PSMAD3_SMAD4_RNAP_NUCLEAR DNA_NFATC1_PSMAD3_SMAD4_RNAP_NUCLEAR 
 0.0 ;% 716 MSX1_NUCLEAR MSX1_NUCLEAR 
 0.0 ;% 717 DNA_NFATC1_MSX1_NUCLEAR DNA_NFATC1_MSX1_NUCLEAR 
 0.0 ;% 718 DNA_NFATC1_MSX1_PSMAD5_SMAD4_NUCLEAR DNA_NFATC1_MSX1_PSMAD5_SMAD4_NUCLEAR 
 0.0 ;% 719 DNA_NFATC1_MSX1_PSMAD5_SMAD4_RNAP_NUCLEAR
 DNA_NFATC1_MSX1_PSMAD5_SMAD4_RNAP_NUCLEAR 
 0.0 ;% 720 MSX1_NIMPORT_NUCLEAR MSX1_NIMPORT_NUCLEAR 
 0.0 ;% 721 MSX1_NEXPORT_NUCLEAR MSX1_NEXPORT_NUCLEAR 
 0.0 ;% 722 MRNA_CALCNCAM_NUCLEAR MRNA_CALCNCAM_NUCLEAR 
 0.0 ;% 723 MRNA_CALCNCAM_NEXPORT_NUCLEAR MRNA_CALCNCAM_NEXPORT_NUCLEAR 
 0.0 ;% 724 MRNA_CALCNCAM_CYTOSOL MRNA_CALCNCAM_CYTOSOL 
 0.0 ;% 725 MRNA_CALCNCAM_RIBOSOME_CYTOSOL MRNA_CALCNCAM_RIBOSOME_CYTOSOL 
 0.0 ;% 726 MRNA_CALCNCAM_START_RIBOSOME_CYTOSOL
 MRNA_CALCNCAM_START_RIBOSOME_CYTOSOL 
 0.0 ;% 727 CALCNCAM_CYTOSOL CALCNCAM_CYTOSOL 
 0.0 ;% 728 DNA_CALCNCAM_ACTIVE_NCID_CSL_NUCLEAR DNA_CALCNCAM_ACTIVE_NCID_CSL_NUCLEAR 
 0.0 ;% 729 DNA_CALCNCAM_ACTIVE_NCID_CSL_RNAP_NUCLEAR
 DNA_CALCNCAM_ACTIVE_NCID_CSL_RNAP_NUCLEAR 
 0.0 ;% 730 MRNA_TWIST_NUCLEAR MRNA_TWIST_NUCLEAR 
 0.0 ;% 731 MRNA_TWIST_NEXPORT_NUCLEAR MRNA_TWIST_NEXPORT_NUCLEAR 
 0.0 ;% 732 MRNA_TWIST_CYTOSOL MRNA_TWIST_CYTOSOL 
 0.0 ;% 733 MRNA_TWIST_RIBOSOME_CYTOSOL MRNA_TWIST_RIBOSOME_CYTOSOL 
 0.0 ;% 734 MRNA_TWIST_START_RIBOSOME_CYTOSOL MRNA_TWIST_START_RIBOSOME_CYTOSOL 
 0.0 ;% 735 DNA_TWIST_PSMAD1_SMAD4_NUCLEAR DNA_TWIST_PSMAD1_SMAD4_NUCLEAR 
 0.0 ;% 736 DNA_TWIST_PSMAD1_SMAD4_RNAP_NUCLEAR DNA_TWIST_PSMAD1_SMAD4_RNAP_NUCLEAR 
 0.0 ;% 737 DNA_TWIST_PSMAD5_SMAD4_NUCLEAR DNA_TWIST_PSMAD5_SMAD4_NUCLEAR 
 0.0 ;% 738 DNA_TWIST_PSMAD5_SMAD4_RNAP_NUCLEAR DNA_TWIST_PSMAD5_SMAD4_RNAP_NUCLEAR 
 0.0 ;% 739 WNT9A_FRIZZLED_CYTOSOL WNT9A_FRIZZLED_CYTOSOL 
 0.0 ;% 740 WNT9A_FRIZZLED_DISHEVELLED_CYTOSOL WNT9A_FRIZZLED_DISHEVELLED_CYTOSOL 
 0.0 ;% 741 WNT9A_FRIZZLED_DISHEVELLED_LRP_CYTOSOL
 WNT9A_FRIZZLED_DISHEVELLED_LRP_CYTOSOL 
 0.0 ;% 742 WNT9A_FRIZZLED_DISHEVELLED_LRP_AXIN_CYTOSOL
 WNT9A_FRIZZLED_DISHEVELLED_LRP_AXIN_CYTOSOL 
 0.0 ;% 743 VEGFA_VEGFR2_CYTOSOL VEGFA_VEGFR2_CYTOSOL 
 0.0 ;% 744 VEGFA_VEGFR2_SHC_CYTOSOL VEGFA_VEGFR2_SHC_CYTOSOL 
 0.0 ;% 745 BMP2_BMPRII_CYTOSOL BMP2_BMPRII_CYTOSOL 
 0.0 ;% 746 BMP2_BMPRII_ALK2_CYTOSOL BMP2_BMPRII_ALK2_CYTOSOL 
 0.0 ;% 747 BMP2_BMPRII_ALK3_CYTOSOL BMP2_BMPRII_ALK3_CYTOSOL 
 0.0 ;% 748 BMP2_BMPRII_ALK6_CYTOSOL BMP2_BMPRII_ALK6_CYTOSOL 
 0.0 ;% 749 BMP2_BMPRII_ALK2_SHC_CYTOSOL BMP2_BMPRII_ALK2_SHC_CYTOSOL 
 0.0 ;% 750 BMP2_BMPRII_ALK2_SHC_GRB2_CYTOSOL BMP2_BMPRII_ALK2_SHC_GRB2_CYTOSOL 
 0.0 ;% 751 BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL BMP2_BMPRII_ALK2_SHC_GRB2_SOS_CYTOSOL 
 0.0 ;% 752 TGFB2_BMPRII_CYTOSOL TGFB2_BMPRII_CYTOSOL 
 0.0 ;% 753 TGFB2_BMPRII_ALK2_CYTOSOL TGFB2_BMPRII_ALK2_CYTOSOL 
 0.0 ;% 754 TGFB2_BMPRII_ALK2_ENDOGLIN_CYTOSOL TGFB2_BMPRII_ALK2_ENDOGLIN_CYTOSOL 
 0.0 ;% 755 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_CYTOSOL
 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_CYTOSOL 
 0.0 ;% 756 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_CYTOSOL
 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_CYTOSOL 
 0.0 ;% 757 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_CYTOSOL
 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_CYTOSOL 
 0.0 ;% 758 TGFB3_TGFBRII_CYTOSOL TGFB3_TGFBRII_CYTOSOL 
 0.0 ;% 759 TGFB3_TGFBRII_ALK1_CYTOSOL TGFB3_TGFBRII_ALK1_CYTOSOL 
 0.0 ;% 760 TGFB3_TGFBRII_ALK1_TGFBRIII_CYTOSOL TGFB3_TGFBRII_ALK1_TGFBRIII_CYTOSOL 
 0.0 ;% 761 TGFB3_TGFBRII_ALK5_CYTOSOL TGFB3_TGFBRII_ALK5_CYTOSOL 
 0.0 ;% 762 TGFB3_TGFBRII_ALK5_TGFBRIII_CYTOSOL TGFB3_TGFBRII_ALK5_TGFBRIII_CYTOSOL 
 0.0 ;% 763 TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL
 TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL 
 0.0 ;% 764 TGFB2_TGFBRII_CYTOSOL TGFB2_TGFBRII_CYTOSOL 
 0.0 ;% 765 TGFB2_TGFBRII_ALK1_CYTOSOL TGFB2_TGFBRII_ALK1_CYTOSOL 
 0.0 ;% 766 TGFB2_TGFBRII_ALK1_TGFBRIII_CYTOSOL TGFB2_TGFBRII_ALK1_TGFBRIII_CYTOSOL 
 0.0 ;% 767 TGFB2_TGFBRII_ALK5_CYTOSOL TGFB2_TGFBRII_ALK5_CYTOSOL 
 0.0 ;% 768 TGFB2_TGFBRII_ALK5_TGFBRIII_CYTOSOL TGFB2_TGFBRII_ALK5_TGFBRIII_CYTOSOL 
 0.0 ;% 769 TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL
 TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_CYTOSOL 
 0.0 ;% 770 JAG1_NOTCH1_CYTOSOL JAG1_NOTCH1_CYTOSOL 
 0.0 ;% 771 TACE_CYTOSOL TACE_CYTOSOL 
 0.0 ;% 772 JAG1_NOTCH1_TACE_CYTOSOL JAG1_NOTCH1_TACE_CYTOSOL 
 0.0 ;% 773 DELTA4_NOTCH1_CYTOSOL DELTA4_NOTCH1_CYTOSOL 
 0.0 ;% 774 DELTA4_NOTCH1_TACE_CYTOSOL DELTA4_NOTCH1_TACE_CYTOSOL 
 0.0 ;% 775 ACTIVE_PI3K_CYTOSOL ACTIVE_PI3K_CYTOSOL 
 0.0 ;% 776 ACTIVE_PI3K_PIP2_CYTOSOL ACTIVE_PI3K_PIP2_CYTOSOL 
 0.0 ;% 777 PTEN_PIP3_CYTOSOL PTEN_PIP3_CYTOSOL 
 0.0 ;% 778 PDK1_PIP3_CYTOSOL PDK1_PIP3_CYTOSOL 
 0.0 ;% 779 PDK1_PIP3_AKT_CYTOSOL PDK1_PIP3_AKT_CYTOSOL 
 0.0 ;% 780 ACTIVE_AKT_CYTOSOL ACTIVE_AKT_CYTOSOL 
 0.0 ;% 781 ACTIVE_AKT_GSK3B_CYTOSOL ACTIVE_AKT_GSK3B_CYTOSOL 
 0.0 ;% 782 P_GSK3B_CYTOSOL P_GSK3B_CYTOSOL 
 0.0 ;% 783 AKT_PASE_ACTIVE_PI3K_CYTOSOL AKT_PASE_ACTIVE_PI3K_CYTOSOL 
 0.0 ;% 784 AKT_PASE_ACTIVE_AKT_CYTOSOL AKT_PASE_ACTIVE_AKT_CYTOSOL 
 0.0 ;% 785 AKT_PASE_P_GSK3B_CYTOSOL AKT_PASE_P_GSK3B_CYTOSOL 
 0.0 ;% 786 AXIN_BCATENIN_CYTOSOL AXIN_BCATENIN_CYTOSOL 
 0.0 ;% 787 AXIN_BCATENIN_APC_CYTOSOL AXIN_BCATENIN_APC_CYTOSOL 
 0.0 ;% 788 AXIN_BCATENIN_APC_CK1_CYTOSOL AXIN_BCATENIN_APC_CK1_CYTOSOL 
 0.0 ;% 789 AXIN_BCATENIN_APC_GSK3B_CYTOSOL AXIN_BCATENIN_APC_GSK3B_CYTOSOL 
 0.0 ;% 790 PP_BCATENIN_CYTOSOL PP_BCATENIN_CYTOSOL 
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 0.0 ;% 791 PP_BCATENIN_BTRCP_CYTOSOL PP_BCATENIN_BTRCP_CYTOSOL 
 0.0 ;% 792 UB_PP_BCATENIN_CYTOSOL UB_PP_BCATENIN_CYTOSOL 
 0.0 ;% 793 GSK3B_NFATC1_CYTOSOL GSK3B_NFATC1_CYTOSOL 
 0.0 ;% 794 P_NFATC1_CYTOSOL P_NFATC1_CYTOSOL 
 0.0 ;% 795 JAG1_NCED_CYTOSOL JAG1_NCED_CYTOSOL 
 0.0 ;% 796 DELTA4_NCED_CYTOSOL DELTA4_NCED_CYTOSOL 
 0.0 ;% 797 ACTIVE_NCID_SEL1_CYTOSOL ACTIVE_NCID_SEL1_CYTOSOL 
 0.0 ;% 798 UB_ACTIVE_NCID_CYTOSOL UB_ACTIVE_NCID_CYTOSOL 
 0.0 ;% 799 JAG1_NCED_DELTEX_NEDD4_CYTOSOL JAG1_NCED_DELTEX_NEDD4_CYTOSOL 
 0.0 ;% 800 UB_JAG1_NCED_CYTOSOL UB_JAG1_NCED_CYTOSOL 
 0.0 ;% 801 DELTA4_NCED_DELTEX_NEDD4_CYTOSOL DELTA4_NCED_DELTEX_NEDD4_CYTOSOL 
 0.0 ;% 802 UB_DELTA4_NCED_CYTOSOL UB_DELTA4_NCED_CYTOSOL 
 0.0 ;% 803 UB_JAG1_NECD_CYTOSOL UB_JAG1_NECD_CYTOSOL 
 0.0 ;% 804 UB_DELTA4_NECD_CYTOSOL UB_DELTA4_NECD_CYTOSOL 
 0.0 ;% 805 JAG1_NECD_EXTRACELLULAR JAG1_NECD_EXTRACELLULAR 
 0.0 ;% 806 RAS_GDP_CYTOSOL RAS_GDP_CYTOSOL 
 0.0 ;% 807 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_RAS_GDP_CYTOSOL
 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_RAS_GDP_CYTOSOL 
 0.0 ;% 808 RAS_GTP_CYTOSOL RAS_GTP_CYTOSOL 
 0.0 ;% 809 BMP2_BMPRII_ALK2_SHC_GRB2_SOS_RAS_GDP_CYTOSOL
 BMP2_BMPRII_ALK2_SHC_GRB2_SOS_RAS_GDP_CYTOSOL 
 0.0 ;% 810 RAS_GTP_RAF_CYTOSOL RAS_GTP_RAF_CYTOSOL 
 0.0 ;% 811 ACTIVE_RAF_CYTOSOL ACTIVE_RAF_CYTOSOL 
 0.0 ;% 812 ACTIVE_RAF_MEK_CYTOSOL ACTIVE_RAF_MEK_CYTOSOL 
 0.0 ;% 813 P_MEK_CYTOSOL P_MEK_CYTOSOL 
 0.0 ;% 814 ACTIVE_RAF_P_MEK_CYTOSOL ACTIVE_RAF_P_MEK_CYTOSOL 
 0.0 ;% 815 PP_MEK_CYTOSOL PP_MEK_CYTOSOL 
 0.0 ;% 816 PP_MEK_ERK_CYTOSOL PP_MEK_ERK_CYTOSOL 
 0.0 ;% 817 P_ERK_CYTOSOL P_ERK_CYTOSOL 
 0.0 ;% 818 PP_MEK_P_ERK_CYTOSOL PP_MEK_P_ERK_CYTOSOL 
 0.0 ;% 819 PP_ERK_CYTOSOL PP_ERK_CYTOSOL 
 0.0 ;% 820 ACTIVE_RAF_RAF_PASE_CYTOSOL ACTIVE_RAF_RAF_PASE_CYTOSOL 
 0.0 ;% 821 PP_MEK_MEK_PASE_CYTOSOL PP_MEK_MEK_PASE_CYTOSOL 
 0.0 ;% 822 P_MEK_MEK_PASE_CYTOSOL P_MEK_MEK_PASE_CYTOSOL 
 0.0 ;% 823 PP_ERK_ERK_PASE_CYTOSOL PP_ERK_ERK_PASE_CYTOSOL 
 0.0 ;% 824 P_ERK_ERK_PASE_CYTOSOL P_ERK_ERK_PASE_CYTOSOL 
 0.0 ;% 825 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_PP_ERK_CYTOSOL
 TGFB2_BMPRII_ALK2_ENDOGLIN_SHC_GRB2_SOS_PP_ERK_CYTOSOL 
 0.0 ;% 826 BMP2_BMPRII_ALK2_SHC_GRB2_SOS_PP_ERK_CYTOSOL
 BMP2_BMPRII_ALK2_SHC_GRB2_SOS_PP_ERK_CYTOSOL 
 0.0 ;% 827 PP_ERK_AP1_CYTOSOL PP_ERK_AP1_CYTOSOL 
 0.0 ;% 828 PP_ERK_SP1_CYTOSOL PP_ERK_SP1_CYTOSOL 
 0.0 ;% 829 PP_ERK_CJUN_CYTOSOL PP_ERK_CJUN_CYTOSOL 
 0.0 ;% 830 P_CJUN_CYTOSOL P_CJUN_CYTOSOL 
 0.0 ;% 831 PP_ERK_CPLA2_CYTOSOL PP_ERK_CPLA2_CYTOSOL 
 0.0 ;% 832 P_CPLA2_CYTOSOL P_CPLA2_CYTOSOL 
 0.0 ;% 833 PP_ERK_SMAD2_CYTOSOL PP_ERK_SMAD2_CYTOSOL 
 0.0 ;% 834 P_SMAD2_CYTOSOL P_SMAD2_CYTOSOL 
 0.0 ;% 835 PP_ERK_SMAD3_CYTOSOL PP_ERK_SMAD3_CYTOSOL 
 0.0 ;% 836 P_SMAD3_CYTOSOL P_SMAD3_CYTOSOL 
 0.0 ;% 837 P_CPLA2_PKC_CYTOSOL P_CPLA2_PKC_CYTOSOL 
 0.0 ;% 838 P_PKC_CYTOSOL P_PKC_CYTOSOL 
 0.0 ;% 839 P_PKC_SMAD2_CYTOSOL P_PKC_SMAD2_CYTOSOL 
 0.0 ;% 840 P_PKC_SMAD3_CYTOSOL P_PKC_SMAD3_CYTOSOL 
 0.0 ;% 841 IKB_NFKB_CYTOSOL IKB_NFKB_CYTOSOL 
 0.0 ;% 842 P_PKC_IKB_NFKB_CYTOSOL P_PKC_IKB_NFKB_CYTOSOL 
 0.0 ;% 843 P_IKB_NFKB_CYTOSOL P_IKB_NFKB_CYTOSOL 
 0.0 ;% 844 GPASE_P_AP1_CYTOSOL GPASE_P_AP1_CYTOSOL 
 0.0 ;% 845 GPASE_P_SP1_CYTOSOL GPASE_P_SP1_CYTOSOL 
 0.0 ;% 846 GPASE_P_CJUN_CYTOSOL GPASE_P_CJUN_CYTOSOL 
 0.0 ;% 847 GPASE_P_CPLA2_CYTOSOL GPASE_P_CPLA2_CYTOSOL 
 0.0 ;% 848 GPASE_P_SMAD2_CYTOSOL GPASE_P_SMAD2_CYTOSOL 
 0.0 ;% 849 GPASE_P_SMAD3_CYTOSOL GPASE_P_SMAD3_CYTOSOL 
 0.0 ;% 850 GPASE_P_NFATC1_CYTOSOL GPASE_P_NFATC1_CYTOSOL 
 0.0 ;% 851 GPASE_P_PKC_CYTOSOL GPASE_P_PKC_CYTOSOL 
 0.0 ;% 852 BMP2_BMPRII_ALK2_SMAD1_CYTOSOL BMP2_BMPRII_ALK2_SMAD1_CYTOSOL 
 0.0 ;% 853 BMP2_BMPRII_ALK2_SMAD5_CYTOSOL BMP2_BMPRII_ALK2_SMAD5_CYTOSOL 
 0.0 ;% 854 BMP2_BMPRII_ALK3_SMAD1_CYTOSOL BMP2_BMPRII_ALK3_SMAD1_CYTOSOL 
 0.0 ;% 855 BMP2_BMPRII_ALK3_SMAD5_CYTOSOL BMP2_BMPRII_ALK3_SMAD5_CYTOSOL 
 0.0 ;% 856 BMP2_BMPRII_ALK6_SMAD1_CYTOSOL BMP2_BMPRII_ALK6_SMAD1_CYTOSOL 
 0.0 ;% 857 BMP2_BMPRII_ALK6_SMAD5_CYTOSOL BMP2_BMPRII_ALK6_SMAD5_CYTOSOL 
 0.0 ;% 858 TGFB3_TGFBRII_ALK1_TGFBRIII_SMAD2_CYTOSOL
 TGFB3_TGFBRII_ALK1_TGFBRIII_SMAD2_CYTOSOL 
 0.0 ;% 859 TGFB3_TGFBRII_ALK1_TGFBRIII_SMAD3_CYTOSOL
 TGFB3_TGFBRII_ALK1_TGFBRIII_SMAD3_CYTOSOL 
 0.0 ;% 860 TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD2_CYTOSOL
 TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD2_CYTOSOL 
 0.0 ;% 861 TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD3_CYTOSOL
 TGFB3_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD3_CYTOSOL 
 0.0 ;% 862 TGFB2_TGFBRII_ALK1_TGFBRIII_SMAD2_CYTOSOL
 TGFB2_TGFBRII_ALK1_TGFBRIII_SMAD2_CYTOSOL 
 0.0 ;% 863 TGFB2_TGFBRII_ALK1_TGFBRIII_SMAD3_CYTOSOL
 TGFB2_TGFBRII_ALK1_TGFBRIII_SMAD3_CYTOSOL 
 0.0 ;% 864 TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD2_CYTOSOL
 TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD2_CYTOSOL 
 0.0 ;% 865 TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD3_CYTOSOL
 TGFB2_TGFBRII_ALK5_TGFBRIII_ENDOGLIN_SMAD3_CYTOSOL 
 0.0 ;% 866 SMURF1_PSMAD1_CYTOSOL SMURF1_PSMAD1_CYTOSOL 
 0.0 ;% 867 UB_PSMAD1_CYTOSOL UB_PSMAD1_CYTOSOL 
 0.0 ;% 868 SMURF1_PSMAD5_CYTOSOL SMURF1_PSMAD5_CYTOSOL 
 0.0 ;% 869 UB_PSMAD5_CYTOSOL UB_PSMAD5_CYTOSOL 
 0.0 ;% 870 SMURF2_PSMAD2_CYTOSOL SMURF2_PSMAD2_CYTOSOL 
 0.0 ;% 871 UB_PSMAD2_CYTOSOL UB_PSMAD2_CYTOSOL 
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 0.0 ;% 872 SMURF2_PSMAD3_CYTOSOL SMURF2_PSMAD3_CYTOSOL 
 0.0 ;% 873 UB_PSMAD3_CYTOSOL UB_PSMAD3_CYTOSOL 
 0.0 ;% 874 BCATENIN_ECADHERIN_CYTOSOL BCATENIN_ECADHERIN_CYTOSOL 
 0.0 ;% 875 BCATENIN_VECADHERIN_CYTOSOL BCATENIN_VECADHERIN_CYTOSOL 
 0.0 ;% 876 BCATENIN_PECAM1_CYTOSOL BCATENIN_PECAM1_CYTOSOL 
 0.0 ;% 877 P_IKB_CYTOSOL P_IKB_CYTOSOL 
 0.0 ;% 878 ACTIVE_AKT_IKB_NFKB_CYTOSOL ACTIVE_AKT_IKB_NFKB_CYTOSOL 
 0.0 ;% 879 VEGFA_VEGFR2_SHC_PI3K_CYTOSOL VEGFA_VEGFR2_SHC_PI3K_CYTOSOL 
 0.0 ;% 880 BMP2_BMPRII_ALK2_SHC_GRB2_SOS_PI3K_CYTOSOL
 BMP2_BMPRII_ALK2_SHC_GRB2_SOS_PI3K_CYTOSOL 
 0.0 ;% 881 P_PLCG_CYTOSOL P_PLCG_CYTOSOL 
 0.0 ;% 882 AKT_PASE_P_PLCG_CYTOSOL AKT_PASE_P_PLCG_CYTOSOL 
 0.0 ;% 883 AKT_PASE_P_PKC_CYTOSOL AKT_PASE_P_PKC_CYTOSOL 
 0.0 ;% 884 P_SPK_CYTOSOL P_SPK_CYTOSOL 
 0.0 ;% 885 AKT_PASE_P_SPK_CYTOSOL AKT_PASE_P_SPK_CYTOSOL 
 0.0 ;% 886 AKT_PASE_P_SP1_CYTOSOL AKT_PASE_P_SP1_CYTOSOL 
 0.0 ;% 887 VEGFA_VEGFR2_PLCG_CYTOSOL VEGFA_VEGFR2_PLCG_CYTOSOL 
 0.0 ;% 888 P_PLCG_PIP2_CYTOSOL P_PLCG_PIP2_CYTOSOL 
 0.0 ;% 889 ACTIVE_PIP2_CYTOSOL ACTIVE_PIP2_CYTOSOL 
 0.0 ;% 890 ACTIVE_PI3K_PKC_CYTOSOL ACTIVE_PI3K_PKC_CYTOSOL 
 0.0 ;% 891 ACTIVE_PKC_CYTOSOL ACTIVE_PKC_CYTOSOL 
 0.0 ;% 892 ACTIVE_PIP2_PKC_CYTOSOL ACTIVE_PIP2_PKC_CYTOSOL 
 0.0 ;% 893 P_PKC_SPK_CYTOSOL P_PKC_SPK_CYTOSOL 
 0.0 ;% 894 P_PKC_SP1_CYTOSOL P_PKC_SP1_CYTOSOL 
 0.0 ;% 895 P_SPK_RAF_CYTOSOL P_SPK_RAF_CYTOSOL 
 100.0 ;% 896 RNAP_NUCLEAR RNAP_NUCLEAR 
 100.0 ;% 897 RIBOSOME_CYTOSOL RIBOSOME_CYTOSOL 
 100.0 ;% 898 NIMPORT_NUCLEAR NIMPORT_NUCLEAR 
 100.0 ;% 899 NEXPORT_NUCLEAR NEXPORT_NUCLEAR 
 100.0 ;% 900 EXIMPORT_CYTOSOL EXIMPORT_CYTOSOL 
 100.0 ;% 901 EXEXPORT_CYTOSOL EXEXPORT_CYTOSOL 
 100.0 ;% 902 GDP_CYTOSOL GDP_CYTOSOL 
 100.0 ;% 903 GTP_CYTOSOL GTP_CYTOSOL 
 100.0 ;% 904 PIP2_CYTOSOL PIP2_CYTOSOL 
 0.0 ;% 905 PIP3_CYTOSOL PIP3_CYTOSOL 
 0.0 ;% 906 GATA_FOG2_CYTOSOL GATA_FOG2_CYTOSOL 
 0.0 ;% 907 DELTEX_NEDD4_CYTOSOL DELTEX_NEDD4_CYTOSOL 
 1.0 ;% 908 DNA_SMURF1_NUCLEAR DNA_SMURF1_NUCLEAR 
 1.0 ;% 909 DNA_SMURF2_NUCLEAR DNA_SMURF2_NUCLEAR 
 5.0 ;% 910 DNA_SMAD1_NUCLEAR DNA_SMAD1_NUCLEAR 
 10.0 ;% 911 DNA_SMAD2_NUCLEAR DNA_SMAD2_NUCLEAR 
 10.0 ;% 912 DNA_SMAD3_NUCLEAR DNA_SMAD3_NUCLEAR 
 20.0 ;% 913 DNA_SMAD4_NUCLEAR DNA_SMAD4_NUCLEAR 
 5.0 ;% 914 DNA_SMAD5_NUCLEAR DNA_SMAD5_NUCLEAR 
 1.0 ;% 915 DNA_SMAD6_NUCLEAR DNA_SMAD6_NUCLEAR 
 1.0 ;% 916 DNA_SMAD7_NUCLEAR DNA_SMAD7_NUCLEAR 
 1.0 ;% 917 DNA_ENDOGLIN_NUCLEAR DNA_ENDOGLIN_NUCLEAR 
 1.0 ;% 918 DNA_ALK1_NUCLEAR DNA_ALK1_NUCLEAR 
 1.0 ;% 919 DNA_ALK2_NUCLEAR DNA_ALK2_NUCLEAR 
 1.0 ;% 920 DNA_ALK3_NUCLEAR DNA_ALK3_NUCLEAR 
 1.0 ;% 921 DNA_ALK5_NUCLEAR DNA_ALK5_NUCLEAR 
 1.0 ;% 922 DNA_ALK6_NUCLEAR DNA_ALK6_NUCLEAR 
 1.0 ;% 923 DNA_SHC_NUCLEAR DNA_SHC_NUCLEAR 
 1.0 ;% 924 DNA_GRB2_NUCLEAR DNA_GRB2_NUCLEAR 
 1.0 ;% 925 DNA_SOS_NUCLEAR DNA_SOS_NUCLEAR 
 1.0 ;% 926 DNA_BMPRII_NUCLEAR DNA_BMPRII_NUCLEAR 
 1.0 ;% 927 DNA_MSX1_NUCLEAR DNA_MSX1_NUCLEAR 
 1.0 ;% 928 DNA_AP1_NUCLEAR DNA_AP1_NUCLEAR 
 2.0 ;% 929 DNA_GPASE_NUCLEAR DNA_GPASE_NUCLEAR 
 1.0 ;% 930 DNA_TCF4_NUCLEAR DNA_TCF4_NUCLEAR 
 0.0 ;% 931 DNA_NOTCH1_NUCLEAR DNA_NOTCH1_NUCLEAR 
 0.0 ;% 932 DNA_SEL1_NUCLEAR DNA_SEL1_NUCLEAR 
 0.0 ;% 933 DNA_CSL_NUCLEAR DNA_CSL_NUCLEAR 
 1.0 ;% 934 DNA_RAS_NUCLEAR DNA_RAS_NUCLEAR 
 1.0 ;% 935 DNA_RAF_NUCLEAR DNA_RAF_NUCLEAR 
 1.0 ;% 936 DNA_MEK_NUCLEAR DNA_MEK_NUCLEAR 
 1.0 ;% 937 DNA_ERK_NUCLEAR DNA_ERK_NUCLEAR 
 1.0 ;% 938 DNA_RAF_PASE_NUCLEAR DNA_RAF_PASE_NUCLEAR 
 1.0 ;% 939 DNA_MEK_PASE_NUCLEAR DNA_MEK_PASE_NUCLEAR 
 1.0 ;% 940 DNA_ERK_PASE_NUCLEAR DNA_ERK_PASE_NUCLEAR 
 1.0 ;% 941 DNA_SP1_NUCLEAR DNA_SP1_NUCLEAR 
 0.0 ;% 942 DNA_CJUN_NUCLEAR DNA_CJUN_NUCLEAR 
 0.0 ;% 943 DNA_CPLA2_NUCLEAR DNA_CPLA2_NUCLEAR 
 0.0 ;% 944 DNA_GSK3B_NUCLEAR DNA_GSK3B_NUCLEAR 
 0.0 ;% 945 DNA_CK1_NUCLEAR DNA_CK1_NUCLEAR 
 0.0 ;% 946 DNA_APC_NUCLEAR DNA_APC_NUCLEAR 
 0.0 ;% 947 DNA_LRP_NUCLEAR DNA_LRP_NUCLEAR 
 0.0 ;% 948 DNA_AXIN_NUCLEAR DNA_AXIN_NUCLEAR 
 1.0 ;% 949 DNA_PKC_NUCLEAR DNA_PKC_NUCLEAR 
 0.0 ;% 950 DNA_BTRCP_NUCLEAR DNA_BTRCP_NUCLEAR 
 0.0 ;% 951 DNA_FRIZZLED_NUCLEAR DNA_FRIZZLED_NUCLEAR 
 1.0 ;% 952 DNA_BCATENIN_NUCLEAR DNA_BCATENIN_NUCLEAR 
 0.0 ;% 953 DNA_DISHEVELLED_NUCLEAR DNA_DISHEVELLED_NUCLEAR 
 1.0 ;% 954 DNA_AKT_NUCLEAR DNA_AKT_NUCLEAR 
 1.0 ;% 955 DNA_PI3K_NUCLEAR DNA_PI3K_NUCLEAR 
 1.0 ;% 956 DNA_PTEN_NUCLEAR DNA_PTEN_NUCLEAR 
 1.0 ;% 957 DNA_PDK1_NUCLEAR DNA_PDK1_NUCLEAR 
 1.0 ;% 958 DNA_AKT_PASE_NUCLEAR DNA_AKT_PASE_NUCLEAR 
 0.0 ;% 959 DNA_IKB_NUCLEAR DNA_IKB_NUCLEAR 
 0.0 ;% 960 DNA_NFKB_NUCLEAR DNA_NFKB_NUCLEAR 
 1.0 ;% 961 DNA_VEGFR2_NUCLEAR DNA_VEGFR2_NUCLEAR 
 0.0 ;% 962 DNA_TBX20_NUCLEAR DNA_TBX20_NUCLEAR 
 0.0 ;% 963 DNA_ALPHASMA_NUCLEAR DNA_ALPHASMA_NUCLEAR 
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 0.0 ;% 964 DNA_CYCLINB2_NUCLEAR DNA_CYCLINB2_NUCLEAR 
 0.0 ;% 965 DNA_PECAM1_NUCLEAR DNA_PECAM1_NUCLEAR 
 0.0 ;% 966 DNA_SLUG_NUCLEAR DNA_SLUG_NUCLEAR 
 0.0 ;% 967 DNA_SNAIL_NUCLEAR DNA_SNAIL_NUCLEAR 
 0.0 ;% 968 DNA_LEF1_NUCLEAR DNA_LEF1_NUCLEAR 
 1.0 ;% 969 DNA_TGFBRII_NUCLEAR DNA_TGFBRII_NUCLEAR 
 1.0 ;% 970 DNA_TGFBRIII_NUCLEAR DNA_TGFBRIII_NUCLEAR 
 0.0 ;% 971 DNA_TGFB3_NUCLEAR DNA_TGFB3_NUCLEAR 
 0.0 ;% 972 DNA_TGFB2_NUCLEAR DNA_TGFB2_NUCLEAR 
 1.0 ;% 973 DNA_VIMENTIN_NUCLEAR DNA_VIMENTIN_NUCLEAR 
 1.0 ;% 974 DNA_ECADHERIN_NUCLEAR DNA_ECADHERIN_NUCLEAR 
 1.0 ;% 975 DNA_VECADHERIN_NUCLEAR DNA_VECADHERIN_NUCLEAR 
 0.0 ;% 976 DNA_DSCR1_NUCLEAR DNA_DSCR1_NUCLEAR 
 0.0 ;% 977 DNA_SOX9_NUCLEAR DNA_SOX9_NUCLEAR 
 0.0 ;% 978 DNA_PAX3_NUCLEAR DNA_PAX3_NUCLEAR 
 0.0 ;% 979 DNA_MMP9_NUCLEAR DNA_MMP9_NUCLEAR 
 1.0 ;% 980 DNA_NFATC1_NUCLEAR DNA_NFATC1_NUCLEAR 
 0.0 ;% 981 DNA_CALCNCAM_NUCLEAR DNA_CALCNCAM_NUCLEAR 
 0.0 ;% 982 DNA_TWIST_NUCLEAR DNA_TWIST_NUCLEAR 
 0.0 ;% 983 DNA_SPK_NUCLEAR DNA_SPK_NUCLEAR 
 0.0 ;% 984 DNA_PLCG_NUCLEAR DNA_PLCG_NUCLEAR 
 0.0 ;% 985 DNA_CREB_NUCLEAR DNA_CREB_NUCLEAR 
 1.0 ;% 986 DNA_YREG1_NUCLEAR DNA_YREG1_NUCLEAR 
 1.0 ;% 987 DNA_LOADING_NUCLEAR DNA_LOADING_NUCLEAR 
 0.0 ;% 988 WNT9A_EXTRACELLULAR WNT9A_EXTRACELLULAR 
 0.0 ;% 989 VEGFA_EXTRACELLULAR VEGFA_EXTRACELLULAR 
 0.0 ;% 990 BMP2_EXTRACELLULAR BMP2_EXTRACELLULAR 
 0.0 ;% 991 TGFB2_EXTRACELLULAR TGFB2_EXTRACELLULAR 
 0.0 ;% 992 TGFB3_EXTRACELLULAR TGFB3_EXTRACELLULAR 
 0.0 ;% 993 JAG1_EXTRACELLULAR JAG1_EXTRACELLULAR 
 0.0 ;% 994 DELTA4_EXTRACELLULAR DELTA4_EXTRACELLULAR 
 0.0 ;% 995 ACTIVE_NCID_CYTOSOL ACTIVE_NCID_CYTOSOL 
]; 
 
% Load parameter sets from disk - 
NPARAMETERS=length(k); 
NSTATES=length(IC); 
kV = [k ; IC]; 
% Ok, override the choice of parameters above, load from disk - 
if (~isempty(INDEX)) 
 cmd=['load PSET_',num2str(INDEX),'.mat']; 
 eval(cmd); 
 kV = kP; 
 % get k and IC - 
 k=kV(1:NPARAMETERS); 
 IC=kV((NPARAMETERS+1):end); 
end; 
 
% =========== DO NOT EDIT BELOW THIS LINE ============== 
DF.STOICHIOMETRIC_MATRIX=S; 
DF.RATE_CONSTANT_VECTOR=k; 
DF.INITIAL_CONDITIONS=IC; 
DF.NUMBER_PARAMETERS=NPARAMETERS; 
DF.NUMBER_OF_STATES=NSTATES; 
DF.PARAMETER_VECTOR=kV; 
% ====================================================== 
return; 
Appendix - D
Supplementary Methods and Figures
Formulation and Solution of the Model Equations. The EMT model was formulated as a set
of coupled non-linear ordinary differential equations (ODEs):
dx
dt
= S · r (x,p) x (to) = xo (S1)
The symbol S denotes the stoichiometric matrix (995× 1700). The quantity x denotes the concen-
tration vector of proteins or protein complexes (995 × 1). The term r (x,p) denotes the vector of
reaction rates (1700 × 1), where p denotes the vector of kinetic parameters. The (i, j) element of
the matrix S, denoted by σij , described how protein i was involved in rate j. If σij < 0, protein
i was consumed by rj . Conversely, if σij > 0, protein i was produced by rj . Lastly, if σij = 0,
protein i was not involved in rate j. We assumed mass-action kinetics for each interaction in the
network. All reversible interactions were split into two irreversible steps, and complex processes
such as transcription or translations were broken into elementary mass-action steps. Thus, the
rate expression for interaction q was given by:
rq (x, kq) = kq
∏
j∈{Rq}
x
−σjq
j (S2)
The set {Rq} denotes reactants for reaction q, while σjq denotes the stoichiometric coefficient
(element of the matrix S) governing species j in reaction q. The quantity kq denotes the rate
constant (unknown) governing reaction q.
Model equations were generated using UNIVERSAL from an SBML input file (available in the
supplemental materials). UNIVERSAL is an open source Objective-C/Java code generator, avail-
able at Google Code (http://code.google.com/p/universal-code-generator/). The model equations
were solved using the LSODE routine in OCTAVE (v 3.0.5; www.octave.org) on an Apple worksta-
tion (Apple, Cupertino, CA; OS X v10.6.4).
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Estimation and Cross-Validation of a Population of EMT models. We used the Pareto Op-
timal Ensemble Technique (POETs) multiobjective optimization framework in combination with
leave-one-out cross-validation to estimate an ensemble of TGFβ/EMT models. Cross-validation
was used to calculate both training and prediction error during the parameter estimation procedure
(35). The 41 intracellular protein and mRNA data-sets used for identification were organized into
11 objective functions. These 11 objective functions were then partitioned, where each partition
contained ten training objectives and one validation objective. POETs integrates standard search
strategies e.g., Simulated Annealing (SA) or Pattern Search (PS) with a Pareto-rank fitness as-
signment (9). Denote a candidate parameter set at iteration i + 1 as ki+1. The squared error for
ki+1 for training set j was defined as:
Ej(k) =
Tj∑
i=1
(
Mˆij − yˆij(k)
)2
(S3)
The symbol Mˆij denotes scaled experimental observations (from training set j) while yˆij denotes
the scaled simulation output (from training set j). The quantity i denotes the sampled time-index
and Tj denotes the number of time points for experiment j. In this study, the experimental data
used for model training was typically the band intensity from Western or Northern blots. Band
intensity was estimated using the ImageJ software package (36). The scaled measurement for
species x at time i = {t1, t2, .., tn} in condition j is given by:
Mˆij = Mij −miniMij
maxiMij −miniMij (S4)
Under this scaling, the lowest intensity band equaled zero while the highest intensity band equaled
one. A similar scaling was defined for the simulation output. By doing this scaling, we trained
the model on the relative change in blot intensity, over conditions or time (depending upon the
experiment). Thus, when using multiple data sets (possibly from different sources) that were
qualitatively similar but quantitatively different e.g., slightly different blot intensities over time or
condition, we captured the underlying trends in the scaled data.
We computed the Pareto rank of ki+1 by comparing the simulation error at iteration i+1 against
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an archive of accepted parameter sets Ki. We used the Fonseca and Fleming ranking scheme
(37) to estimate the number of parameter sets in the archive that dominate ki+1. Parameter
sets with increasing rank were progressively further away from the optimal trade-off surface. The
parameter set ki+1 was accepted or rejected by POETs with probability P (ki+1):
P(ki+1) ≡ exp {−rank (ki+1 | Ki) /T} (S5)
where T is the annealing temperature and rank (ki+1 | Ki) denotes the Pareto rank for ki+1. The
annealing temperature was discretized into 10 quanta between To and Tf and adjusted according
to the schedule Tk = βkT0 where β was defined as (Tf/To)
1/10. The initial temperature was
To = n/log(2), where n = 4 in this study and the final temperature was Tf = 0.1. The epoch-
counter k was incremented after the addition of 100 members to the ensemble. Thus, as the
ensemble grew, the likelihood of accepting parameter sets with a large Pareto rank decreased. To
generate parameter diversity, we randomly perturbed each parameter by≤ ±25% at iteration of the
search. In addition, we performed a local pattern search every q-iterations to minimize the residual
for a single random or the worst performing objective function. The local pattern-search algorithm
has been described previously (38). From the 15,000 probable EMT models, we selected N =
1093 models with Pareto rank ≤ 1 for subsequent analysis.
Robustness Analysis of the EMT Model Population. Robustness coefficients were calculated
for 55 models selected from the ensemble (rank-zero, low-correlation, minimum error selection).
We surveyed only this subset of models (instead of the entire population of low rank models) be-
cause of the computational cost of the robustness analysis. The selected models were all rank
≤ 1 and were largely uncorrelated; 67% of the selected models had a correlation less that 0.28,
where the mean correlation was 0.28 ± 0.04. For each of the 55 models, coefficients were calcu-
lated as shown previously (13). Briefly, Robustness coefficients (denoted by α (i, j, to, tf )) are the
ratio of the integrated concentration of a network marker in the presence (numerator) and absence
(denominator) of a structural or operational perturbation. The quantities t0 and tf denote the initial
and final simulation time, respectively, while i and j denote the indices for the marker and the
perturbation respectively. If α (i, j, to, tf ) > 1, then the perturbation increased the marker con-
336
centration. Conversely, if α (i, j, to, tf ) < 1 the perturbation decreased the marker concentration.
Lastly, if α (i, j, to, tf ) ∼ 1 the perturbation did not influence the marker concentration.
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Figure 7. S1: Flux-analysis describing flow through the four distinct regions.
O# Species (cystolic protein) Cell Type Training Prediction Random Source
O1 LEF1 DLD1 CC, MDCKII, A375 MC 0.73 ±  0.22  0.66 ±  0.18  0.87 ±  0.02  Medici et al., 2008
O2 Vimenin DLD1 CC, MDCKII, A375 MC 0.96 ±  0.11  1.00 ±  0.15  0.23 ±  0.04  "
O3 TGFbeta3 DLD1 CC, MDCKII, A375 MC 1 00 ±  0.13  0.77 ±  0.22  0.61 ±  0.04  "
O4 E-Caderin DLD1 CC, MDCKII, A375 MC 0 54 ±  0.16  0.00 ±  0.00  0.15 ±  0.03  "
O5  
-beta-Catenin
DLD1 CC, MDCKII, A375 MC 0.99 ±  0.25  0.00 ±  0.00  0.00 ±  0.00  "
O6 DLD1 CC, MDCKII, A375 MC 0.89 ±  0.14  0.71 ±  0.12  0.58 ±  0.04  "
O7 Snail DLD1 CC, MDCKII, A375 MC 0.00 ±  0.00  0.00 ±  0.00  0.00 ±  0.00  "
O8 LEF1 DLD1 CC, MDCKII, A375 MC 1.00 ±  0.14  1.00 ±  0.25  0.61 ±  0.05 "
O9 E-Caderin DLD1 CC, MDCKII, A375 MC 0.96 ±  0.20 0.86 ±  0.19 0.00 ±  0.00  "
O10 Slug DLD1 CC, MDCKII, A375 MC 1.00 ±  0.20  1.00 ±  0.12  0.00 ±  0.00  "
O11 LEF1 DLD1 CC, MDCKII, A375 MC 1.00 ±  0.15  1.00 ±  0.25  0.86 ±  0.03 "
P# Species Simulated Experimental Random Source
P1 E-caderin (mRNA) MDCKII 0.10 ±  0.01  0.13 ±  0.02  0.27 ±  0.03 Medici et al., 2006
P2 pSmad2 MDCKII 0.58 ±  0.12  0.80 ±  0.04  0.13 ±  0.03 "
P3 LEF1 (mRNA) MDCKII 0.76 ±  0.05  0.65 ±  0.04  0.18 ±  0.03 "
beta-catenin
TGFbeta3
Table T1: Our model was able to effectively predict the simulated experiments 78 percent of the time. The high pre-
dictability can be contributed to the leave-one-out cross validation scheme, objective functions with overlapping data,
and multi-objective optimization (POETs). The residuals between the EMT model, intracellular protein, and mRNA
data sets (organized into 11 objective functions) were simultaneously minimized using the POETs multi-objective op-
timization algorithm (9). Because the parameter identification problem was under-determined, we used an iterative
leave-one-out cross-validation strategy to independently estimate both the prediction and training error during the pa-
rameter estimation process. At each iteration of the cross-validation, a single objective was reserved for validation while
the remaining ten were used for training. Thus, eleven different model families consisting of more than 15,000 probable
models, were generated by the optimization procedure. Of the 15,000 probable models, we selected N∼1100 models
with Pareto rank one or less for further study. These models were largely uncorrelated; the mean model correlation was
0.23±0.03, as 71% of the models had a correlation less than 0.23. Approximately 78% of the training objectives were
statistically significantly better (at a 95% confidence interval) than randomized parameter sets generated from the best-
fit nominal set (starting point for the optimization). The most tightly constrained parameters governed LEF1 expression,
Snail transcription, and TGFβ3 regulation, while the least constrained parameters involved crosstalk between MAPK
and ERK mediated AP1 activation.
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Figure 7. S2: Simulated TGFβ2 and VEGFA (known inducer of NFAT) combination re-creates phenotype heterogeneity
through NFAT and phospho-Sp1. Bar graphs represent the raw simulated values at 48 hr. (A-C) These simulations
were further quantified by plotting concentrations at 48 hrs for downstream targets (ecadherin, vimentin, phospho-Sp1,
nuclear NFAT, alpha-SMA, and Slug). In whole, high levels of phospho-Sp1 correlated with vimentin expression, while
NFAT was found largely responsible for maintaining ecadherin expression, although neither mutually exclusive.
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Figure 7. S3: VEGFA attentuates TGFβ2 to induce phenotype heterogeneity in DLD1. (A) In DLD1, we found that
5ng/ml of VEGFA increased NFATc1 and ecadherin gene expression via qPCR and 50ng/ml potentiated this effect
at 48 hrs. (B-C) These findings were confirmed at the protein level via immunofluorescence, as ecadherin levels and
nuclear localization of NFATc1 increased. (D) Treatment with (10ng/ml) TGFβ2 resulted in mesenchymal transformation
as measured via qPCR against target genes Slug, ecadherin, vimentin, Sp1, and NFATc1. (E-F) Immunofluorescence
and nuclear localization revealed a strong presence of phospho-Sp1. (D) Combination of VEGFA (50ng/ml) and TGFβ2
(10ng/ml) treatment resulted in increased Slug, NFATc1, and vimentin expression, while also increaseing ecadherin
levels compared to control. (E) Immunofluorescence confirmed these results, as both ecadherin and vimentin levels
were elevated. (F) A signficant increase in nuclear localization of both NFATc1 and phospho-Sp1 were also found.
Magnification, 40x. Scale bars: 50µm. C=Control, T=TGFβ2 , V=VEGFA, VI=NFAT inhibitor (VIVIT). Asterisks signify
statistical differences from each other according to a one-way ANOVA with Tukey’s post hoc (p≺0.05).
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Figure 7. S4: Ecadherin expression is dependent upon NFAT activity in DLD1. (A) Treatment with VEGFA (50ng/ml)
and NFAT inhibitory peptide VIVIT (10µM) resulted in significantly reduced ecadherin expression via qPCR at 48hrs.
Addition of TGFβ2 (10ng/ml) and VIVIT resulted in increased Slug and vimentin expression, while inhibiting ecadherin
levels. Combined TGFβ2, VEGFA, and VIVIT treatment resulted in target genes Slug and vimentin expression in-
creased, while inhibiting ecadherin levels. No change in Sp1 or NFATc1 expression was found. (B) These findings were
confirmed via immunofluorescence as the VIVIT inhibitors was shown to inhibit ecadherin levels in all three cases. We
also found no change in gene or nuclear localization of NFATc1 in all three cases, while phospho-Sp1 was found to
increase in both TGFβ conditions. (C) Quantitative flow cytometry also confirmed this trend. (D,E) TGFβ2, VEGFA
and VIVIT treatment in DLD1 and MCF10A resulted in no change of Sp1 expression or NFATc1 expression. (G) Like-
wise, no change in nuclear localization of NFAT in all three cases, however phospho-Sp1 was found to increase in both
TGFβ conditions. Magnification, 40x. Scale bars: 50µm. C=Control, T=TGFβ2 , V=VEGFA, VI= NFAT inhibitor (VIVIT).
Asterisks signify statistical differences from each other according to a one-way ANOVA with Tukey’s post hoc (p≺0.05).
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